<SEC-DOCUMENT>0001628280-26-050803.txt : 20260730
<SEC-HEADER>0001628280-26-050803.hdr.sgml : 20260730
<ACCEPTANCE-DATETIME>20260730073409
ACCESSION NUMBER:		0001628280-26-050803
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260730
DATE AS OF CHANGE:		20260730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		261220209

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sny-20260630.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ef965-bc7d-7da2-bb2f-04e26164615a,g:d543d692-5b77-4127-b010-746b44ca828b,d:edf5524db6df45a291b3626dfdf1bc22-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:sny="http://www.sanofi.com/20260630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sny-20260630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-3">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-4">0001121404</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-5">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-6">6/30/2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-7">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-8">Q2</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1826">one</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sny-20260630.xsd"/></ix:references><ix:resources><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="categorie"><xbrli:measure>sny:categorie</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>sny:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="bond"><xbrli:measure>sny:bond</xbrli:measure></xbrli:unit><xbrli:unit id="credit_facility"><xbrli:measure>sny:credit_facility</xbrli:measure></xbrli:unit><xbrli:unit id="extension"><xbrli:measure>sny:extension</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>sny:program</xbrli:measure></xbrli:unit><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:unit id="swaps"><xbrli:measure>sny:swaps</xbrli:measure></xbrli:unit><xbrli:unit id="proceeding"><xbrli:measure>sny:proceeding</xbrli:measure></xbrli:unit><xbrli:unit id="case"><xbrli:measure>sny:case</xbrli:measure></xbrli:unit><xbrli:unit id="defendant"><xbrli:measure>sny:defendant</xbrli:measure></xbrli:unit><xbrli:unit id="aspects"><xbrli:measure>sny:aspects</xbrli:measure></xbrli:unit><xbrli:unit id="customer"><xbrli:measure>sny:customer</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>sny:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-10</xbrli:startDate><xbrli:endDate>2026-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-10</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:MedleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-06</xbrli:startDate><xbrli:endDate>2026-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AmlitelimabAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:CDRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-30</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LOrealMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LOrealMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-02</xbrli:startDate><xbrli:endDate>2025-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2026ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-29</xbrli:startDate><xbrli:endDate>2026-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfVestingConditionsAxisAxis">sny:ThreeYearServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfVestingConditionsAxisAxis">sny:FiveYearServicePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:NetInvestmentHedgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:TwoBillionThreeHundredMillionBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMay2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMay2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondIssueFromMarch2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingOnMarch2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:MedleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInPoundSterlingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInPoundSterlingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealExpiringIn2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealExpiringIn2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:CTTQMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CTTQRovidicitinibLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:KaliTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:KaliTherapeuticsLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:TalcProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:DupixentProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:UniversityOfWashingtonAndHarborviewMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:A340BDrugPricingProgramInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:HudsonHeadwatersHealthNetworkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:A340BDrugPricingProgramInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:MosaicHealthInTheUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:A340BDrugPricingProgramInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AmvuttraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:AdditionalProfitShareForDevelopmentCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:AdditionalProfitShareForDevelopmentCostMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CertainWholesalersInTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-208 f-209 f-210 f-263 f-264 f-265 f-325 f-326 f-327 f-328 f-329 f-330 f-331 f-332 f-339 f-340 f-341 f-342 f-343 f-344" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-216 f-217 f-218 f-272 f-273 f-274 f-333 f-334 f-335" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-233 f-234 f-235 f-351 f-352 f-353" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-236 f-237 f-285 f-286" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="4"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-373 f-374" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-5" order="5"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-377 f-378" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-6" order="6"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-383 f-384" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-7" order="7"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-399 f-400" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-8" order="8"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-403 f-404" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-9" order="9"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-407 f-408" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-10" order="10"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-417 f-418" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-11" order="11"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-433 f-434" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-12" order="12"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-449 f-450" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-13" order="13"/></ix:resources></ix:header></div><div id="iedf5524db6df45a291b3626dfdf1bc22_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE&#160;13a-16&#160;OR&#160;15d-16</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the month of July 2026</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;001-31368</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">SANOFI</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">46 avenue de la Grande Arm&#233;e &#8211; 75017 Paris</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2026, Sanofi issued the financial statements and half year management report attached hereto as Exhibit 99.1 and 99.2 which are incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="iedf5524db6df45a291b3626dfdf1bc22_4"></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</span></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed half-year consolidated financial statements for 2026</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.2</span></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 Half-year management report, Statutory Auditors&#8217; Report and Responsibility Statement</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.635%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: July&#160;30, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANOFI</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Alexandra Roger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandra Roger</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Head of Securities Law and Capital Markets</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sny-20260630_d2.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ef965-bc7d-7da2-bb2f-04e26164615a,g:d543d692-5b77-4127-b010-746b44ca828b,d:f717a7f2fb424028954e92929e21ed21-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:sny="http://www.sanofi.com/20260630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sny-20260630_d2</title></head><body><div id="if717a7f2fb424028954e92929e21ed21_4"></div><div style="min-height:56.69pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:0 1pt"/></tr></table></div></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div><div style="margin-bottom:5pt;margin-top:70pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"><tr><td style="width:1.0%"/><td style="width:3.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.997%"><tr><td style="width:1.0%"/><td style="width:88.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i2689e482f9204b75bc89906e0429bf7c">1. Condensed half-year consolidated financial statements</a></span></div></td><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i2689e482f9204b75bc89906e0429bf7c">2</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c8b1613735942cf807f70034f343d7a">Consolidated balance sheets - assets</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c8b1613735942cf807f70034f343d7a">2</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib94ad90b534e46aea1b10bf8d69c112b">Consolidated balance sheets - equity and liabilities</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib94ad90b534e46aea1b10bf8d69c112b">3</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i215c65a5cefd430ea59d9dfb07343813">Consolidated income statements</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i215c65a5cefd430ea59d9dfb07343813">4</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd90c38769814877a62ee2b8aeb4e26e">Consolidated statements of comprehensive income</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#icd90c38769814877a62ee2b8aeb4e26e">5</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5b36264aed884419b2ee0b9356889d79">Consolidated statements of changes in equity</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5b36264aed884419b2ee0b9356889d79">6</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0e4bca7cce494f4ebe3fae564fb287ce">Consolidated statement of cash flows</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0e4bca7cce494f4ebe3fae564fb287ce">8</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i698c53f875644dfcb566c7de18a29143">Notes to the condensed half-year consolidated financial statements as of June 30, 2026 </a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i698c53f875644dfcb566c7de18a29143">10</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#if01b92328be14713b8ccdb292d93bd83">Introduction</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#if01b92328be14713b8ccdb292d93bd83">10</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4f7c6c891c2b4d6d95f7e8f036bb2556">A/ Basis of preparation of the half-year financial statements and accounting policies</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4f7c6c891c2b4d6d95f7e8f036bb2556">10</a></span></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic779306accf2451ea7bfae75d61cb0c8">B/ Significant information for the first half of 2026</a></span></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic779306accf2451ea7bfae75d61cb0c8">13</a></span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_7"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:15pt"><span id="i2689e482f9204b75bc89906e0429bf7c"></span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div><div id="if717a7f2fb424028954e92929e21ed21_10"></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i8c8b1613735942cf807f70034f343d7a"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated balance sheets - assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment owned</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.2.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-9">10,364</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-10">10,052</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-11">1,590</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-12">1,459</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-13">41,954</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-14">41,300</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-15">26,359</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-16">26,261</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.5.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-17">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-18">3,259</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-19">4,732</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-20">4,364</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-21">569</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-22">550</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-23">8,763</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-24">8,608</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-25">97,538</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-26">95,853</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-27">11,127</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-28">10,214</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-29">8,714</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-30">8,410</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-31">4,282</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-32">4,066</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-33">492</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-34">397</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-35">6,350</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-36">7,657</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets held for sale</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-37">557</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-38">208</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-39">31,522</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-40">30,952</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-41">129,060</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-42">126,805</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_109">33</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi&#8217;s audited full-year consolidated financial statements as of December&#160;31, 2025.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_13"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="ib94ad90b534e46aea1b10bf8d69c112b"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated balance sheets - equity and liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-43">69,207</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-44">71,376</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-45">360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-46">334</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-47">69,567</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-48">71,710</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-49">14,646</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-50">14,248</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current lease liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-51">1,677</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-52">1,467</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-53">652</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-54">585</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.12.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-55">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-56">6,703</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-57">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-58">2,081</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-59">1,553</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-60">1,666</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-61">27,563</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-62">26,750</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-63">7,150</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-64">7,361</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-66">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-67">16,446</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-68">15,565</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-69">884</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-70">751</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current lease liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-71">227</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-72">272</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-73">7,026</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-74">4,342</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-75">197</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-76">54</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-77">31,930</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-78">28,345</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></div></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-79">129,060</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-80">126,805</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_109">33</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi&#8217;s audited full-year consolidated financial statements as of December&#160;31, 2025.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_16"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i215c65a5cefd430ea59d9dfb07343813"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated income statements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.20.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-81">22,106</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-82">19,889</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.20.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-83">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-84">1,452</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-85">6,155</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-86">5,881</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-87">17,389</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-88">15,460</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-89">3,980</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-90">3,717</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-91">4,792</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-92">4,506</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.15.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-93">800</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-94">533</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.15.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-95">3,436</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-96">2,476</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-97">1,087</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-98">777</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.4.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-99">1,031</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-100">210</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.  B.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-101">37</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-102">61</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.16.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-103">563</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-104">430</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.17.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-105">95</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-106">57</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-107">3,168</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-108">3,759</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.18.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-109">465</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-110">361</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-111">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-112">184</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-113">2,840</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-114">3,582</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.19.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-115">871</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-116">711</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the&#160;equity method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-117">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-118">85</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-119">1,971</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-120">2,956</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income from discontinued operations </span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.22.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" scale="6" id="f-121">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-122">2,881</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-123">1,997</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-124">5,837</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-125">40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-126">25</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-127">1,957</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-128">5,812</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="0" id="f-129">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="0" id="f-130">2.40</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-131">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-132">2.34</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (&#8364;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-133">1.63</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-134">4.74</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="0" id="f-135">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="0" id="f-136">2.39</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-137">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-138">2.33</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diluted earnings per share (&#8364;)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.7.</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-139">1.62</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-140">4.72</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_109">33</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi&#8217;s audited full-year consolidated financial statements as of December&#160;31, 2025.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_19"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="icd90c38769814877a62ee2b8aeb4e26e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated statements of comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-141">1,997</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-142">5,837</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-143">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-144">5,812</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-145">40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-146">25</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-147">158</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-148">111</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of equity instruments included in financial assets and financial liabilities</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-149">175</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-150">222</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-151">43</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-152">92</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subtotal: items not subsequently reclassifiable to profit or loss from continuing operations (A)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-153">290</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-154">241</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of debt instruments included in financial assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-155">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-156">3</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of cash flow hedges</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-157">14</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-158">23</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in currency translation differences</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-159">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-160">5,203</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.8.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-161">5</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-162">95</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subtotal: items subsequently reclassifiable to profit or loss from continuing operations (B)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-163">1,327</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-164">5,318</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income/(loss) from continuing operations  for the period, net of taxes (A+B)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherComprehensiveIncomeFromContinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-165">1,617</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherComprehensiveIncomeFromContinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-166">5,077</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income/(loss) for the period from discontinued operations, net of taxes (C)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherComprehensiveIncomeFromDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-167">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OtherComprehensiveIncomeFromDiscontinuedOperations" scale="6" id="f-168">303</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-169">3,614</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-170">1,063</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-171">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-172">1,076</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Continuing operations</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-173">3,536</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-174">2,097</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Discontinued operations</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" scale="6" id="f-175">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-176">3,173</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #200f45;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-177">52</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-178">13</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_109">33</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi&#8217;s audited full-year consolidated financial statements as of  December&#160;31, 2025.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_22"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i5b36264aed884419b2ee0b9356889d79"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated statements of changes in equity</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:21.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.299%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.299%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Share capital</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury shares</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock options and other share-based payments</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other compre-hensive income</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to equity holders of Sanofi</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to non-controlling interests</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2025</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-179">2,526</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-6" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="6" id="f-180">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-181">840</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-182">68,185</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-183">5,260</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-184">2,376</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-185">77,507</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-186">350</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-187">77,857</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-188">243</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-189">4,979</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-190">4,736</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-191">38</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-192">4,774</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-193">5,812</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-194">5,812</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-195">25</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-196">5,837</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-197">6,055</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-198">4,979</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-199">1,076</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-200">13</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-201">1,063</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2024 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-202">3.92</ix:nonFraction> per share)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-203">4,772</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-204">4,772</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-205">4,772</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-206">32</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-207">32</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-208">3,988</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-209">3,988</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-210">3,988</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-211">74</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" sign="-" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:num-dot-decimal" scale="6" id="f-212">3,868</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:num-dot-decimal" scale="6" id="f-213">3,794</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax on share cancellations </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-216">15</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-217">15</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-218">15</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-219">1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-220">14</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-221">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-222">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and  vesting of existing restricted shares</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-223">3</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-224">3</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-227">177</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-228">177</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-229">177</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" scale="6" id="f-230">7</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" scale="6" id="f-231">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" scale="6" id="f-232">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes arising from issuance of restricted shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-233">15</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-234">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-235">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" scale="6" id="f-236">34</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" scale="6" id="f-237">34</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2025 </span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-238">2,456</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-239">11</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-240">975</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-241">65,689</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-242">5,430</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-243">2,603</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-244">70,008</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-245">271</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-246">70,279</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-247">71</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-248">160</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-249">89</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-250">5</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-251">84</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-252">2,001</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-253">2,001</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-254">13</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-255">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for the&#160;period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-256">1,930</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-257">160</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-258">2,090</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-259">8</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-260">2,098</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-261">12</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-262">12</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-263">1,027</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-264">1,027</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-265">1,027</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-266">22</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-267">170</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" sign="-" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-268">934</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-269">742</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax on share cancellations </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-272">4</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-273">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-274">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="6" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and  vesting of existing restricted shares</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Employee share ownership plan</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-277">5</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-278">160</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-279">165</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-280">165</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-281">142</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-282">142</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-283">142</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:fixed-zero" scale="6" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" scale="6" id="f-285">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" scale="6" id="f-286">68</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at&#160;December&#160;31,&#160;2025</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-287">2,439</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-288">1</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-289">1,072</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-290">66,877</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-291">5,572</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-292">2,441</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-293">71,376</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-294">334</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-295">71,710</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi&#8217;s audited full-year consolidated financial statements as of December&#160;31, 2025.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.200%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Share capital</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury shares</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock options and other share-based payments</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other compre-hensive income</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to equity holders of Sanofi</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attribut-able to non-controlling interests</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-296">2,439</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-297">1</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-298">1,072</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-299">66,877</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-300">5,572</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-301">2,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-302">71,376</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-303">334</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-304">71,710</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-305">290</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-306">1,315</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-307">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-308">12</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-309">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-310">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-311">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-312">40</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-313">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for the&#160;period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-314">2,247</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-315">1,315</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-316">3,562</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-317">52</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-318">3,614</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2025 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-319">4.12</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-320">4,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-321">4,923</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-322">4,923</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-323">26</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-324">26</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-325">1,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-326">1,003</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" format="ixt:num-dot-decimal" scale="6" id="f-327">1,003</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-328">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" sign="-" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-329">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-330">581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax on share cancellations  </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-333">3</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-334">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:TaxesOnShareCancellations" scale="6" id="f-335">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options </span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-336">3</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-337">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-338">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and vesting of existing restricted shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-339">4</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-340">4</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-341">102</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-342">102</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-345">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-346">184</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-347">184</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects of share-based payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" sign="-" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" scale="6" id="f-348">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" sign="-" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" scale="6" id="f-349">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" scale="6" id="f-350">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes arising from issuance of restricted shares </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-351">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-352">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-353">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-354">2,428</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="6" id="f-355">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-356">1,380</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-357">63,528</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-358">5,757</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-359">1,126</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-360">69,207</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-361">360</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-362">69,567</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2 and B.8.3. (for amounts relating to 2025, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2025).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-4" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.</span></ix:footnote></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accompanying notes on pages <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_34">10</a> to <a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#if717a7f2fb424028954e92929e21ed21_109">33</a> are an integral part of the condensed half-year consolidated financial statements. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_25"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i0e4bca7cce494f4ebe3fae564fb287ce"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Consolidated statement of cash flows</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.275%"><tr><td style="width:1.0%"/><td style="width:62.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.321%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-363">1,957</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-364">5,812</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (income)/loss from the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:AdjustmentsForLossesGainsOnTransferOfBusiness" scale="6" id="f-365">26</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:AdjustmentsForLossesGainsOnTransferOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-366">2,881</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-367">40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-368">25</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of undistributed earnings from investments accounted for using the equity method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-369">94</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-370">15</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-371">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-372">1,779</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains and losses on disposals of non-current assets, net of tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-373">9</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-374">266</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-375">218</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-376">539</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in non-current provisions and other non-current liabilities </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-377">195</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-378">212</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of employee benefits (stock options and other share-based payments)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-379">184</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-380">171</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of the workdown of acquired inventories remeasured at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-381">210</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" format="ixt:fixed-zero" scale="6" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other profit or loss items with no cash effect on cash flows generated</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">by operating activities </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-383">74</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-384">106</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating cash flow before changes in working capital</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-385">5,233</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-386">3,980</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in inventories</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-387">958</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-388">635</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-389">27</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-390">785</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-391">340</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-392">187</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other current assets and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" scale="6" id="f-393">735</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" scale="6" id="f-394">620</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) continuing operating activities </span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-395">4,643</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-396">3,367</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) operating activities of the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-397">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="f-398">188</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) operating activities </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-399">4,643</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-400">3,555</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and intangible assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.2. - B.3.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-401">1,296</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-402">1,420</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (e)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-403">1,408</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-404">538</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other equity investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-405">189</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-406">423</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-407">424</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-408">434</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals of consolidated undertakings and investments accounted for using the equity method, net of tax</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-409">78</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-411">32</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-412">32</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) continuing investing activities</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetCashProvidedByusedInContinuingInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-413">2,423</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetCashProvidedByusedInContinuingInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-414">1,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) investing activities of the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetCashProvidedByusedInDiscontinuingInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-415">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:NetCashProvidedByusedInDiscontinuingInvestingActivities" scale="6" id="f-416">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash inflow/(outflow) from the Opella transaction </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetCashInflowFromDiscontinuedOperations" scale="6" id="f-417">220</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetCashInflowFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-418">10,742</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-419">2,643</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-420">8,727</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.1.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-421">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-422">29</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends paid:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">to equity holders of Sanofi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-423">4,923</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-424">4,772</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">to non-controlling interests</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-425">25</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-426">27</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional long-term debt contracted</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-427">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-428">2,993</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-429">1,505</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-430">1,859</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of lease liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-431">147</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-432">124</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in short-term debt and other financial instruments </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-433">1,955</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-434">3,322</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of treasury shares and related tax effect</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.8.2</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" format="ixt:num-dot-decimal" scale="6" id="f-435">1,009</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" format="ixt:num-dot-decimal" scale="6" id="f-436">4,003</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) continuing financing activities</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-437">3,332</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-438">4,441</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) financing activities of the discontinued Opella business</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-439">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="f-440">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-441">3,332</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-442">4,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of exchange rates on cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-443">19</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-444">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.01em;line-height:100%">Cash and cash equivalents reclassified to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;letter-spacing:-0.01em;line-height:100%"> Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.01em;line-height:100%"> as of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-445">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" scale="6" id="f-446">167</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-447">1,313</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-448">7,918</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" format="ixt:num-dot-decimal" scale="6" id="f-449">7,663</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-6" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" format="ixt:num-dot-decimal" scale="6" id="f-450">7,441</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">B.9.</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" format="ixt:num-dot-decimal" scale="6" id="f-451">6,350</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-6" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" format="ixt:num-dot-decimal" scale="6" id="f-452">15,359</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi&#8217;s audited full-year consolidated financial statements as of December&#160;31, 2025.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><ix:footnote id="fn-5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes non-current financial assets and deferred taxes, amounting to <ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" format="ixt:fixed-zero" scale="0" id="f-453">zero</ix:nonFraction> as of June 30, 2026 and to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" scale="6" id="f-454">48</ix:nonFraction>&#160;million as of June 30, 2025.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><ix:footnote id="fn-6" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item includes contributions paid to pension funds (see Note B.12.).</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><ix:footnote id="fn-7" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><ix:footnote id="fn-8" continuedAt="fn-8-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Of which:</span></ix:footnote></div><ix:continuation id="fn-8-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" scale="6" id="f-455">925</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-456">1,355</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-457">260</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-458">206</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-459">111</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-460">170</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-461">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-462">5</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><ix:footnote id="fn-9" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2026, this line item includes the net cash outflow arising from the acquisition of Dynavax (see Note B.1.1.). For the six months ended June 30, 2025 it includes the net cash outflow arising from the acquisition of Dren-0201.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><ix:footnote id="fn-10" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">For the six months ended June 30, 2026 and June 30, 2025, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)</span><ix:footnote id="fn-11" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025, this amount includes &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-6" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-463">667</ix:nonFraction>)&#160;million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(h)</span><ix:footnote id="fn-12" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2026, this line item mainly comprises (i) a commercial paper program in the United States for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-464">2,388</ix:nonFraction> million and (ii) a cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-66" decimals="-6" sign="-" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" scale="6" id="f-465">249</ix:nonFraction> million arising from the settlement of the financial liabilities of Dynavax, acquired on February 10, 2026 (see Note B.1.1.). For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-466">3,353</ix:nonFraction>&#160;million.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(i)</span><ix:footnote id="fn-13" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.58pt">Includes the impact of the IFRS 9 amendment relating to the classification of financial instruments applicable from January 1, 2026.</span></ix:footnote></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_28"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span id="i698c53f875644dfcb566c7de18a29143"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Notes to the condensed half-year consolidated financial statements as of June 30, 2026 </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span></div><div id="if717a7f2fb424028954e92929e21ed21_31"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-467" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if01b92328be14713b8ccdb292d93bd83"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the six months ended June 30, 2026 were reviewed by the Sanofi Board of Directors at the Board meeting on July 29, 2026.</span></div></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_34"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-468" continuedAt="f-468-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i4f7c6c891c2b4d6d95f7e8f036bb2556"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A/ Basis of preparation of the half-year financial statements and accounting policies</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="iade2723bf556405fa760300135f156fe"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.1. International financial reporting standards (IFRS)</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-469" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2026 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2026 are available via the following web link: https://www.efrag.org/en/financial-reporting/endorsement-status.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2026 are identical to those presented in the consolidated financial statements for the year ended December 31, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable from January 1, 2026. The amendments did not have a material impact on the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026. Those improvements to various standards, which are essentially in the nature of clarifications, did not have a material impact on the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments could potentially result in an enhancement of the disclosures provided in the 2026 annual financial statements. As a reminder, renewable energy purchase contracts entered into by Sanofi as of December 31, 2025 are described in Note D.21. to the consolidated financial statements included in Sanofi&#8217;s Form 20-F for the year ended December 31, 2025 (the &#8220;2025 20-F&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In its 2026 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. As in the previous year, the effective tax rate also includes a one-off impact from the 2025 component of the exceptional surcharge in respect of French corporate income taxes (see Note B.19.).</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7eb8d7ed82b1409781780df5af14fc37"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2. Use of estimates and judgments</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-470" continuedAt="f-470-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity </span></div></ix:nonNumeric></ix:nonNumeric><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> These unaudited condensed half-year consolidated financial statements as of June 30, 2026 should be read in conjunction with Sanofi&#8217;s audited full-year consolidated financial statements as of December&#160;31, 2025.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-468-1" continuedAt="f-468-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-470-1">method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.</ix:continuation> </span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1ec2cb66eb2744b6b48188cdb25eabbf"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3. Seasonal trends</span></div><ix:nonNumeric contextRef="c-1" name="sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" id="f-471" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5f4805e586d9457eb40667dbfc3eea9d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.4. Consolidation and foreign currency translation of the financial statements of subsidiaries in hyperinflationary economies </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory" id="f-472" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2026, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears" scale="-2" id="f-473">100</ix:nonFraction>%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears" scale="-2" id="f-474">100</ix:nonFraction>%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span id="ia00b620899cb4c70a41e134ebd8334b7"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.5. Fair value of financial instruments</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="f-475" continuedAt="f-475-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="f-476" escape="true"><ix:continuation id="f-475-1"><ix:continuation id="f-468-2" continuedAt="f-468-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:3.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.996%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2025.</span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-468-3"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5c5175867eaf486690e7e1ad01ca77b2"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.6. New pronouncements issued by the IASB and applicable from 2027</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-477" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027. In terms of adapting Sanofi&#8217;s chart of accounts and financial information systems, the transition is continuing on schedule. In line with the information communicated in the 2025 financial statements as published, Sanofi&#8217;s IFRS 18 rollout project &#8211; which began in the fourth quarter of 2025 &#8211; is progressing, and the impact analysis has evolved in line with the schedule. The future structure of Sanofi&#8217;s consolidated income statement will present operating expenses by function, and will reflect presentational choices based on the &#8220;useful structured summary&#8221; principle established by IFRS 18. Those choices involve the classification of income statement items according to <ix:nonFraction unitRef="categorie" contextRef="c-1" decimals="INF" name="sny:IncomeStatementClassificationIFRS18NumberOfCategories" format="ixt-sec:numwordsen" scale="0" id="f-478">five</ix:nonFraction> categories (operating, investing, financing, income tax and discontinued operations), with the sub-totals limited solely to those specified in IFRS 18. The income statement structure will also reflect the fact that Sanofi as a whole operates a single principal activity. As regards the requirement to disclose alternative management performance measures (MPMs) that meet the IFRS 18 definition in the notes to the financial statements, Sanofi has identified the relevant MPMs. In accordance with the information communicated in Sanofi&#8217;s 2025 consolidated financial statements, the main MPMs are &#8220;Business gross profit&#8221;, &#8220;Business operating income&#8221; and &#8220;Business net income&#8221;, all of which are non-IFRS measures that Sanofi currently uses in its financial communication. No significant impact on these performance measures has been identified at this stage.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transition note intended for publication in Sanofi&#8217;s 2026 Annual Report on Form 20-F will include a reconciliation, for the comparative years 2026 and 2025, between (i) the amounts for each income statement line item presented in accordance with IFRS&#160;18 as applicable from 2027 and (ii) those presented in accordance with the currently applicable standard (IAS 1).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, the presentation of the consolidated statement of cash flows will be modified such that it starts from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> instead of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, as mentioned in Sanofi&#8217;s 2025 year-end financial communications, Sanofi is not early adopting IFRS 18.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November 13, 2025, the IASB issued &#8220;Translation to a Hyperinflationary Presentation Currency&#8221;, an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), applicable from January 1, 2027 (subject to endorsement by the European Union). Sanofi does not expect any material impact and will not early adopt this amendment.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="if717a7f2fb424028954e92929e21ed21_37"></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="ic779306accf2451ea7bfae75d61cb0c8"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B/ Significant information for the first half of 2026</span></div><div id="if717a7f2fb424028954e92929e21ed21_40"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" id="f-479" continuedAt="f-479-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ib491210deb284e268395afcc5ff6478b"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.1. Significant transactions for the first half of 2026</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i9834acbe5e0941f6b802ffcc6c644dcc"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.1. Acquisition of Dynavax Technologies Corporation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February 10, 2026, Sanofi finalized the acquisition of Dynavax Technologies Corporation (Dynavax), a vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi&#8217;s presence in adult immunization by bringing together Dynavax&#8217;s vaccines with Sanofi&#8217;s global scale, development capabilities and commercial reach.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Dynavax&#8217;s adult hepatitis B vaccine HEPLISAV-B is currently marketed in the United States and is differentiated by its two-dose regimen over one month, enabling high levels of seroprotection faster than other hepatitis B vaccines (which are given in three doses over six months).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition also includes Dynavax&#8217;s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 clinical development, and additional vaccine pipeline projects.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction involved a cash tender offer by Sanofi to acquire all outstanding shares of Dynavax for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-70" decimals="2" name="sny:BusinessCombinationEquityInterestsOfAcquirerPerShare" scale="0" id="f-480">15.50</ix:nonFraction> per share in cash, reflecting a total equity value on a fully diluted basis of approximately $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-8" name="sny:BusinessCombinationEquityValueOfAcquirer" scale="9" id="f-481">2.2</ix:nonFraction>&#160;billion, including the subsequent reimbursement of the short-term debt for $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-8" name="ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate" scale="9" id="f-482">0.3</ix:nonFraction>&#160;billion.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" id="f-483" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" scale="6" id="f-484">204</ix:nonFraction>&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.394%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-485">1,150</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="sny:OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" scale="6" id="f-486">429</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="6" id="f-487">169</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate" scale="6" id="f-488">249</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="sny:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="6" id="f-489">132</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Dynavax</span></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" format="ixt:num-dot-decimal" scale="6" id="f-490">1,367</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" scale="6" id="f-491">204</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-492">1,571</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Other intangible assets&#8221; mainly comprise Dynavax&#8217;s marketed vaccine HEPLISAV-B.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-479-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of Dynavax into the Sanofi group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Dynavax's contributions to Biopharma segment net sales and business operating income (for a definition refer to Note B.21. &#8220;Segment Information&#8221;) since the acquisition date amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-6" name="ifrs-full:RevenueOfAcquiree" scale="6" id="f-493">144</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-6" name="sny:OperatingIncomeOfAcquireeSinceAcquisitionDate" scale="6" id="f-494">89</ix:nonFraction>&#160;million, respectively. Over the same period, Dynavax made a negative contribution of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-6" sign="-" name="ifrs-full:ProfitLossOfAcquiree" scale="6" id="f-495">63</ix:nonFraction>&#160;million to consolidated net income, including amortization of intangible assets of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-6" name="sny:AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" scale="6" id="f-496">38</ix:nonFraction>&#160;million; amortization and expenses arising from the impact of acquired inventories of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-6" name="sny:AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" scale="6" id="f-497">44</ix:nonFraction>&#160;million; and restructuring costs and similar items of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-6" name="sny:RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" scale="6" id="f-498">63</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition, as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, is a net cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-66" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-499">1,403</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i33c30c05833240ffaf9267814059a54e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.2. Proposed divestment of Medley, Sanofi&#8217;s Brazilian generics business</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March 6, 2026, Sanofi and EMS Group, a major pharmaceutical conglomerate in Brazil, announced the signing of a definitive agreement for the purchase and sale of <ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="sny:PercentageOfOwnershipInterestDisposed" scale="-2" id="f-500">100</ix:nonFraction>% of Medley, one of Brazil&#8217;s leading generic drug brands.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With effect from that date, given that completion of the transaction is considered highly probable, all of the assets of Medley, and the liabilities directly associated with those assets (subsequently transferred to Medley Farmaceutica Ltda, a new legal entity formed on May 1, 2026, the equity interests in which will be divested), are presented in the consolidated balance sheet within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations); they are the main component of those line items as of June 30, 2026. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s Brazilian generics business does not meet the definition of a discontinued operation under IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2025), as a result of which the net income from this business is not presented separately in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A net gain is expected upon closing of the transaction. Consequently, no impairment was recognized on the carrying amount of the net assets of Medley Farmaceutica Ltda as of the date of reclassification as held for sale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction is expected to close no earlier than the fourth quarter of 2026 subject to the fulfilment of customary closing conditions, primarily clearance from the Brazilian Antitrust Authority (Administrative Council for Economic Defense &#8211; CADE).</span></div></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_46"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-501" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i93a93c63f0ea45e195349fc8fc299e76"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2. Property, plant and equipment</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" id="f-502" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:76.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-503">763</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-504">702</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-505">763</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-506">663</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-76" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-507">594</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-508">453</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella (discontinued operation)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-510">39</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-511">23</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-512">22</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Firm orders for property, plant and equipment stood at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:FirmOrdersOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-513">1,336</ix:nonFraction>&#160;million as of June 30, 2026.</span></div></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_49"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory" id="f-514" continuedAt="f-514-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ic132ebcff5c64c81a9061580740797ab"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3. Goodwill and other intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-515">41,954</ix:nonFraction>&#160;million as of June 30, 2026, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-516">41,300</ix:nonFraction> million as of December&#160;31, 2025. The movement during the period reflects the impact of changes in exchange rates and the recognition of the goodwill arising on the Dynavax acquisition (see note B.1.1.), partially offset by the reclassification of the goodwill relating to the Brazilian generics business to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as a result of the proposed divestment (see note B.1.2.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" id="f-517" continuedAt="f-517-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2026 were as follows:</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">14</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-514-1"><ix:continuation id="f-517-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:45.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-518">14,951</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-519">66,746</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-520">1,888</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-83" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-521">83,585</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-522">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-523">1,149</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-524">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-525">1,150</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-526">321</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-527">122</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-528">88</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-529">531</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-530">534</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-531">17</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-532">28</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-533">579</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-534">324</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-535">1,232</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-536">12</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-537">1,568</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-538">245</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-539">162</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-540">4</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-541">411</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at June 30, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-542">14,817</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-543">69,070</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-544">1,957</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-545">85,844</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-546">6,220</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-93" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-547">49,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-94" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-548">1,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-95" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-549">57,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-551">1,106</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-552">58</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-6" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-553">1,164</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-554">970</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-555">61</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-556">17</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-557">1,048</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-558">534</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-559">17</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-560">26</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-561">577</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-562">135</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-563">785</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-564">10</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-565">930</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-567">400</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-568">4</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-569">404</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-100" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-570">6,791</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-571">51,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-572">1,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-573">59,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-574">8,731</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-575">17,122</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-576">408</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-577">26,261</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2026</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-578">8,026</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-579">17,911</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-109" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-580">422</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-581">26,359</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the intangible assets recognized as part of the Dynavax  acquisition (see Note B.1.)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">See Note B.4.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other products&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">marketed products, with a carrying amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-110" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-582">17.1</ix:nonFraction> bil</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">lion as of June 30, 2026 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-111" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-583">16.2</ix:nonFraction> billion as of December 31, 2025) and a weighted average amortization period of approximately</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-112" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-584">11</ix:nonNumeric> years</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">technological platforms brought into service, with a carrying amou</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nt of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-113" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-585">0.8</ix:nonFraction> billion as</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">June 30, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (versus </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-114" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-586">0.9</ix:nonFraction> billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as of December 31, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a weighted average amortization period of approximately </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-115" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-587">18</ix:nonNumeric> years.</span></div></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_52"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" id="f-588" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i4ab9c4fdfc0e4b64a6daaec19209502e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4. Impairment of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The monitoring of impairment indicators for other intangible assets (excluding software) led to the recognition of impairment losses of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-589">1,031</ix:nonFraction>&#160;million in the first half of 2026, mainly comprising a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-116" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-590">952</ix:nonFraction>&#160;million impairment loss taken against the amlitelimab asset, corresponding to the entire carrying amount of this intangible asset.</span></div></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_55"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="f-591" continuedAt="f-591-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i2ed1b062d6704c48ae354d7c6de4df94"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5. Investments accounted for using the equity method</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" id="f-592" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2025), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:55.910%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OPAL JV Co </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-593">48.2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-594">2,965</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-595">2,934</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-596">29.6</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-121" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-597">38</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-122" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-598">64</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-599">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-124" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-600">93</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-125" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-601">112</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-602">50.0</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-127" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-603">52</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-6" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-604">59</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" format="ixt:fixed-zero" scale="-2" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-130" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-606">59</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-6" name="ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod" scale="6" id="f-607">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-608">3,207</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-609">3,259</ix:nonFraction></span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella in 2025, Sanofi holds <ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-610">48.2</ix:nonFraction>% of OPAL JV Co (CD&amp;R holds <ix:nonFraction unitRef="number" contextRef="c-133" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-611">50</ix:nonFraction>% and Bpifrance holds <ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-612">1.8</ix:nonFraction>%). As of December&#160;31, 2025 the investment included a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-6" name="sny:LoansToAssociates" scale="6" id="f-613">241</ix:nonFraction>&#160;million loan to OPAL JV Co being in substance part of the investment. In 2026, following finalization of the Opella completion accounts as of April 30, 2025, this loan was converted into ordinary shares.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-135" decimals="2" name="sny:StockPrice" scale="0" id="f-614">1.33</ix:nonFraction> as of June 30, 2026, and &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-136" decimals="2" name="sny:StockPrice" scale="0" id="f-615">2.27</ix:nonFraction> as of December&#160;31, 2025). </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. MSP Vaccine Company owns <ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-616">100</ix:nonFraction>% of MCM Vaccine BV.</span></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed net income of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-617">2</ix:nonFraction> million&#160;for the first half of 2026 (including a net loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-618">39</ix:nonFraction> million for Sanofi&#8217;s share of losses from the associate OPAL JV Co), versus net income of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-619">85</ix:nonFraction> million for the first half of 2025 (including net income of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-620">11</ix:nonFraction>&#160;million for Sanofi&#8217;s share of profits from the associate OPAL JV Co for the period from May&#160;1, 2025 through June 30, 2025). </span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-591-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-621" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:74.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-622">31</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-623">29</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-624">142</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-625">63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services (including research expenses)  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-626">548</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-627">371</ix:nonFraction></span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-628">430</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-629">588</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" scale="6" id="f-630">84</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" scale="6" id="f-631">143</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:OtherLiabilitiesRelatedPartyTransactions" scale="6" id="f-632">379</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:OtherLiabilitiesRelatedPartyTransactions" scale="6" id="f-633">710</ix:nonFraction></span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-6" name="sny:SubordinateHybridBondRelatedPartyTransactions" scale="6" id="f-634">200</ix:nonFraction>&#160;million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2026 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-144" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" scale="6" id="f-635">84</ix:nonFraction>&#160;million, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-145" decimals="-6" name="sny:OtherAssetsRelatedPartyTransactions" scale="6" id="f-636">143</ix:nonFraction>&#160;million as of December 31, 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" id="f-637" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key items from the unaudited half-year consolidated financial statements of OPAL JV Co as of June 30, 2026, as provided in accordance with Sanofi&#8217;s consolidation timelines, are presented below: </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:74.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated income statement</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net sales and other revenues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-638">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures" scale="6" id="f-639">887</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" sign="-" name="sny:NetIncomeRelatedPartyDisclosures" scale="6" id="f-640">61</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="sny:NetIncomeRelatedPartyDisclosures" scale="6" id="f-641">24</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated statement of comprehensive income</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:OtherComprehensiveIncomeRelatedPartyDisclosures" scale="6" id="f-642">83</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" sign="-" name="sny:OtherComprehensiveIncomeRelatedPartyDisclosures" scale="6" id="f-643">1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:ComprehensiveIncomeRelatedPartyDisclosures" scale="6" id="f-644">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="sny:ComprehensiveIncomeRelatedPartyDisclosures" scale="6" id="f-645">23</ix:nonFraction></span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated balance sheet</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:NonCurrentAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-646">16,673</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:NonCurrentAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-647">15,013</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:CurrentAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-648">2,925</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:CurrentAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-649">2,859</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:AssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-650">19,598</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:AssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-651">17,872</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of OPAL JV Co</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:EquityAttributableToEquityHoldersRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-652">5,958</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:EquityAttributableToEquityHoldersRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-653">5,380</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions" scale="6" id="f-654">436</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions" scale="6" id="f-655">490</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:EquityRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-656">6,394</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:EquityRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-657">5,870</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-658">11,575</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-659">9,850</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:CurrentLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-660">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:CurrentLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-661">2,152</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:LiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-662">13,204</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:LiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-663">12,002</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-6" name="sny:EquityAndLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-664">19,598</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="sny:EquityAndLiabilitiesRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-665">17,872</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_58"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory" id="f-666" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i87905fc66c7b49b89f2037c9405e25d1"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6. Other non-current assets</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" id="f-667" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-668">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-669">2,200</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-670">363</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-671">389</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-672">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-673">1,004</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-674">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-675">194</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-676">185</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-677">175</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLoansAndReceivables" scale="6" id="f-678">421</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLoansAndReceivables" scale="6" id="f-679">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" scale="6" id="f-680">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" scale="6" id="f-681">9</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-682">4,732</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-683">4,364</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">16</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_61"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfTradeReceivablesTextBlock" id="f-684" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i8a86659307ea4443ba42dfcb5d3b4e96"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.7. Accounts receivable</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfCurrentTradeReceivablesTableTextBlock" id="f-685" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-686">8,818</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-83" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-687">8,510</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-688">104</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-689">100</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-690">8,714</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-691">8,410</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in the first half of 2026 was a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" scale="6" id="f-692">6</ix:nonFraction> million (versus a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" scale="6" id="f-693">4</ix:nonFraction> million for the first half of 2025).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock" id="f-694" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:18.468%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&lt;1 month</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>1-3 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>3-6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>6-12 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-695">522</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-696">183</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-697">127</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-698">142</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-699">27</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-700">43</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-701">468</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-702">184</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-703">134</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-704">71</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-705">27</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-706">52</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amounts overdue by more than one month relate mainly to public-sector customers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2025 and hence were derecognized was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DerecognizedReceivables" scale="6" id="f-707">11</ix:nonFraction> million as of June&#160;30, 2026 (versus <ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:DerecognizedReceivables" format="ixt:fixed-zero" scale="6" id="f-708">zero</ix:nonFraction> as of December 31, 2025). The residual guarantees relating to those transfers were immaterial as of June 30, 2026.</span></div></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_64"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-709" continuedAt="f-709-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i0d5e6157a9da4039a10239b9799b7eaa"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8. Consolidated shareholders&#8217; equity</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ia7d079fa575843689ca15d686ccf06c5"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, the share capital was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="0" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="0" id="f-710">2,428,198,054</ix:nonFraction> and consisted of <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-711">1,214,099,027</ix:nonFraction> shares (the total number of shares outstanding) with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-2" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-712">2</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-713" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-714">16.03</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-715">1.320</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December&#160;31, 2025</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-716">11.96</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-717">0.981</ix:nonFraction></span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-718">10.66</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-30" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-719">0.868</ix:nonFraction></span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2025</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-720">9.53</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-721">0.755</ix:nonFraction></span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" format="ixt:num-dot-decimal" scale="0" id="f-722">30,070</ix:nonFraction> shares were issued in the first half of 2026 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-723">3,072,520</ix:nonFraction> shares vested under Sanofi restricted share plans during the first half of 2026, of which <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-724">1,886,523</ix:nonFraction>&#160;were fulfilled by issuance of new shares and <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-725">1,185,997</ix:nonFraction> by allotment of existing shares free of charge.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i91f7c2d3c7534cfd8ccaccf0cd785e5d"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.2. Repurchase of Sanofi shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2025, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of <ix:nonNumeric contextRef="c-165" name="sny:ShareRepurchaseProgramPeriod" format="ixt-sec:durmonth" id="f-726">18</ix:nonNumeric> months. Under that program, Sanofi repurchased <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-727">12,571,455</ix:nonFraction> of its own shares during the first half of 2026 for a total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-166" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" format="ixt:num-dot-decimal" scale="6" id="f-728">1,003</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding &#8364;<ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-9" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="f-729">5</ix:nonFraction>&#160;billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Or&#233;al on February&#160;2, 2025 for the acquisition of <ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="sny:PercentageOfSanofisShareCapitalAcquired" scale="-2" id="f-730">2.34</ix:nonFraction>% of Sanofi&#8217;s share capital, equivalent to <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-731">29,556,650</ix:nonFraction> shares, for a total amount of approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-169" decimals="-9" name="sny:ShareRepurchaseProgramAmountPaid" scale="9" id="f-732">3</ix:nonFraction>&#160;billion, representing a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-169" decimals="2" name="sny:PerShareValueOfSharesRepurchased" scale="0" id="f-733">101.50</ix:nonFraction> per share. The conclusion of that agreement was approved by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth in Articles L. 225-38 et seq. of the French Commercial Code.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 29, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of <ix:nonNumeric contextRef="c-170" name="sny:ShareRepurchaseProgramPeriod" format="ixt-sec:durmonth" id="f-734">18</ix:nonNumeric> months. Sanofi did n</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ot use that authorization during the first half of 2026.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="idd55326c6f4f42359cf73c8a329501bb"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.3. Reduction in share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2026, treasury shares amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CancellationOfTreasuryShares" scale="6" id="f-735">596</ix:nonFraction>&#160;million were cancelled further to decisions taken by the Sanofi Board of Directors on March 4, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those reductions have no impact on shareholders&#8217; equity, except for the impact of the tax on share cancellations.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-709-1" continuedAt="f-709-2"><div style="margin-bottom:3pt;margin-top:9pt"><span id="ie4aae90ce3ea41c0bceff57eca296b4d"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.4. Restricted share plans</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" id="f-736" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2025. The principal features of the plans awarded in 2026 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:82.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.541%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April, 29, 2026</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plans awarded to the Chief Executive Officer</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 1, 2026</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a <ix:nonNumeric contextRef="c-171" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-737">3</ix:nonNumeric>-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-738">5,087,518</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-739">3,367,862</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-172" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-740">65.86</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-741">1,719,656</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-742">1,674,656</ix:nonFraction> shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-174" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-743">57.99</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-744">45,000</ix:nonFraction> shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-175" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-745">53.46</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a <ix:nonNumeric contextRef="c-176" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-746">5</ix:nonNumeric>-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-747">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-748">180,000</ix:nonFraction> shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-177" decimals="2" name="sny:FairValuePerShareAwardedForFiveYearServicePeriod" scale="0" id="f-749">40.46</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plans at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-178" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-750">329</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of <ix:nonNumeric contextRef="c-171" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-751">3</ix:nonNumeric> years.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of <ix:nonNumeric contextRef="c-176" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-752">5</ix:nonNumeric> years.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" id="f-753" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:69.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-754">138</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-180" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-755">146</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-756">12,995,668</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-757">11,550,347</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2026 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-758">5,267,518</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-759">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2025 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-760">3,897,342</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-761">4,020,451</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-762">3,772,461</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-763">4,110,089</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-764">58,347</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-765">3,313,588</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-767">106,219</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="i77cbafef4d014f33b235e0d519481bbb"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.5. Employee stock purchase plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 28, 2026, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the opportunity to subscribe for new Sanofi shares at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-193" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-768">59.87</ix:nonFraction> per share. The subscription period was open from June&#160;9 through June&#160;29, 2026. Sanofi employees subscribed for a total of <ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="sny:NumberOfSharesSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-769">2,431,494</ix:nonFraction> shares, and the resulting capital increase was supplemented by the immediate issuance of a further <ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-770">104,327</ix:nonFraction> shares for the employer&#8217;s contribution. The total expense recognized for this plan in the first half of 2026 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-771">46</ix:nonFraction> million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 29, 2025, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the opportunity to subscribe for new Sanofi shares at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-196" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-772">72.97</ix:nonFraction> per share. The subscription period was open from June&#160;10 through June&#160;30, 2025. Sanofi employees subscribed for a total of <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="sny:NumberOfSharesSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-773">2,260,776</ix:nonFraction> shares, and the resulting capital increase was supplemented by the immediate issuance of a further <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-774">116,794</ix:nonFraction> shares for the employer&#8217;s contribution. The total expense recognized for this plan in the first half of 2025 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-775">31</ix:nonFraction> million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i1684c1a55e2d4d5280f95522eb2195d4"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.6. Stock subscription option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock subscription option plans were awarded in the first half of 2026 or in 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No further stock option plan expenses were recognized through equity in either the first half of 2026 or 2025.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-709-2" continuedAt="f-709-3"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" id="f-776" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:26.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.234%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average residual life</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-199" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-777">60.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-200" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-778">70.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-779">168,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-202" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-780">1.84</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-201" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-781">65.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-782">168,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-201" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-783">65.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-203" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-784">70.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-204" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-785">80.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-786">213,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-206" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-787">2.84</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-205" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-788">76.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-789">213,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-205" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-790">76.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-207" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-791">80.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-208" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-792">90.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-209" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-793">257,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-210" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-794">0.86</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-209" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-795">88.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-209" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-796">257,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-209" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-797">88.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-798">639,194</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-799">639,194</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="iae4940e55e3f422eb90dc30c896cfb60"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.7. Earnings per share</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-800" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net income:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.923%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-801">1,957.0</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-802">5,812.0</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which net income from continuing operations</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-803">1,931.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-5" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-804">2,941.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which net income from discontinued operations</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" scale="6" id="f-805">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-5" name="ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-806">2,871.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number of shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(number of shares in million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-807">1,200.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-808">1,225.5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" format="ixt:fixed-zero" scale="6" id="f-809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-810">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-811">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-812">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-813">1,205.5</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-814">1,230.7</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026 and June 30, 2025, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Earnings per share:</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-815" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in euros)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="0" id="f-816">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="0" id="f-817">2.40</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-818">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-819">2.34</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-820">1.63</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-821">4.74</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="0" id="f-822">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="0" id="f-823">2.39</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-824">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations" scale="0" id="f-825">2.33</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diluted earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-826">1.62</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-827">4.72</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-709-3" continuedAt="f-709-4"><div style="margin-bottom:3pt;margin-top:9pt"><span id="ia974d4d9952a48af8a624f4df1a8865a"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.8. Other comprehensive income</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" id="f-828" continuedAt="f-828-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-829">157</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-830">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-831">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-832">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" scale="6" id="f-833">20</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" scale="6" id="f-834">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-835">175</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-836">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-841">23</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-842">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-843">290</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-844">243</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-845">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-846">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" format="ixt:fixed-zero" scale="6" id="f-849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" format="ixt:fixed-zero" scale="6" id="f-850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-851">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" sign="-" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-852">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-853">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" scale="6" id="f-855">2</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" scale="6" id="f-856">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-857">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-858">5,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-859">55</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-860">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-861">489</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-862">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-863">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-864">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-865">1,327</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-866">5,017</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-867">1</ix:nonFraction>&#160;million in the first half of 2026; &#8364;<ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-868">2</ix:nonFraction>&#160;million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-828-1"><ix:continuation id="f-709-4"> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-869">146</ix:nonFraction>&#160;million loss in the first half of 2026 and a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-870">459</ix:nonFraction> million loss in the first half of 2025 relating to the deconsolidation of Opella</ix:continuation></ix:continuation>.</span></div><div id="if717a7f2fb424028954e92929e21ed21_67"></div><div style="margin-bottom:3pt;margin-top:12pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" id="f-871" continuedAt="f-871-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if3c50351e3a9496d81a572fcb437eb25"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9. Debt, cash and cash equivalents</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInFinancialPositionTableTextBlock" id="f-872" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-873">14,646</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-874">14,248</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-875">7,026</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-876">4,342</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-877">221</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-878">112</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-879">21,893</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-880">18,702</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-881">6,350</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-882">7,657</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-883">30</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-884">37</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-885">15,513</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-886">11,008</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-887">1,904</ix:nonFraction> million as of June 30, 2026 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-888">1,739</ix:nonFraction> million as of December&#160;31, 2025.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">20</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-871-1" continuedAt="f-871-2"><div style="margin-bottom:3pt;margin-top:9pt"><span id="i152be4776fb742e294ebcac319167d5e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.1. Net debt at value on redemption</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" id="f-889" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2026 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:28.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-890">14,646</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-891">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-892">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-893">14,751</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-894">14,360</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-895">7,026</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" scale="6" id="f-896">1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-898">7,027</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-899">4,344</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-900">221</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-901">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-902">131</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-903">90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-904">12</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-905">21,893</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-906">45</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" sign="-" name="ifrs-full:Borrowings" scale="6" id="f-907">70</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-908">21,868</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-909">18,716</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-910">6,350</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-911">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-913">6,350</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-914">7,657</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-915">30</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-917">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-918">30</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-919">37</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-920">15,513</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-921">45</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-922">70</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-923">15,488</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-924">11,022</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-925">1,904</ix:nonFraction> million as of June 30, 2026 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-926">1,739</ix:nonFraction> million as of December&#160;31, 2025.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" id="f-927" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-928">14,702</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-929">3,599</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-930">18,301</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-931">14,306</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-932">3,165</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-933">17,471</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-934">49</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-935">3,291</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-936">3,340</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-937">54</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-938">936</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-939">990</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-941">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-942">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-943">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-944">1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-945">1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-947">136</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-948">136</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-950">242</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-951">242</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-953">90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-954">90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-955">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-956">12</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-957">12</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-958">14,751</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-959">7,117</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-960">21,868</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-961">14,360</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-962">4,356</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-963">18,716</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-965">6,350</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-966">6,350</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-967">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-968">7,657</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-969">7,657</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-971">30</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-972">30</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-973">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-974">37</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-975">37</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-976">14,751</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-977">737</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-978">15,488</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-979">14,360</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-980">3,338</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-981">11,022</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts include $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-9" name="ifrs-full:NotionalAmount" scale="9" id="f-982">3</ix:nonFraction>&#160;billion designated  as a hedge of Sanofi&#8217;s net investment in the United States.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) As of Ju</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ne 30, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, current other bank borrowings include &#8364;<ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-983">3,217</ix:nonFraction>&#160;million related to the US commercial paper program.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span id="ib114c4f84689446085e75d598afd9d11"></span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Principal financing and debt reduction transactions during the period</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the period, Sanofi carried out a bond issue of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-8" name="ifrs-full:NotionalAmount" scale="9" id="f-984">2.3</ix:nonFraction>&#160;billion in <ix:nonFraction unitRef="tranche" contextRef="c-238" decimals="INF" name="sny:NumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-985">three</ix:nonFraction> tranches:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-986">1,000</ix:nonFraction>&#160;million of fixed-rate bonds maturing May 2029, with annual coupons and bearing interest at an annual rate of <ix:nonFraction unitRef="number" contextRef="c-239" decimals="5" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-987">3.000</ix:nonFraction>%;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-988">650</ix:nonFraction>&#160;million of fixed-rate bonds maturing May 2033, with annual coupons and bearing interest at an annual rate of <ix:nonFraction unitRef="number" contextRef="c-240" decimals="5" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-989">3.375</ix:nonFraction>%; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-990">650</ix:nonFraction>&#160;million of fixed-rate bonds maturing May 2037, with annual coupons and bearing interest at an annual rate of <ix:nonFraction unitRef="number" contextRef="c-241" decimals="5" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-991">3.750</ix:nonFraction>%.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="bond" contextRef="c-1" decimals="INF" name="sny:NumberOfBondRedeemed" format="ixt-sec:numwordsen" scale="0" id="f-992">One</ix:nonFraction> bond issue was redeemed during the period: a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-8" name="ifrs-full:NotionalAmount" scale="9" id="f-993">1.5</ix:nonFraction>&#160;billion issue from March 2018, redeemed at maturity on March 21, 2026.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, Sanofi had <ix:nonFraction unitRef="credit_facility" contextRef="c-1" decimals="INF" name="sny:NumberOfSyndicatedCreditFacilities" format="ixt-sec:numwordsen" scale="0" id="f-994">two</ix:nonFraction> syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-9" name="ifrs-full:NotionalAmount" scale="9" id="f-995">4</ix:nonFraction>&#160;billion, drawable in euros and US dollars and expiring on March 6, 2030, for which no further extension options are available; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-7" name="ifrs-full:NotionalAmount" scale="9" id="f-996">3.85</ix:nonFraction>&#160;billion, drawable in euros and US dollars and expiring on  April 23, 2031, for which <ix:nonFraction unitRef="extension" contextRef="c-245" decimals="INF" name="sny:NumberOfOneYearExtensionOptions" format="ixt-sec:numwordsen" scale="0" id="f-997">two</ix:nonFraction>  <ix:nonNumeric contextRef="c-245" name="sny:ExtensionTerm" format="ixt-sec:durwordsen" id="f-998">one-year</ix:nonNumeric> extension options are available. This facility became effective on April&#160;23, 2026, and replaced an existing &#8364;<ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-9" name="ifrs-full:NotionalAmount" scale="9" id="f-999">4</ix:nonFraction>&#160;billion facility that was cancelled on the same date and had originally been scheduled to mature on December 6, 2027.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, neither facility was drawn down.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-871-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has <ix:nonFraction unitRef="program" contextRef="c-1" decimals="INF" name="sny:NumberOfShortTermDebtProgram" format="ixt-sec:numwordsen" scale="0" id="f-1000">two</ix:nonFraction> short-term debt programs:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-9" name="ifrs-full:CommercialPapersIssued" scale="9" id="f-1001">6</ix:nonFraction> billion Negotiable European Commercial Paper program in France; and </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-9" name="ifrs-full:CommercialPapersIssued" scale="9" id="f-1002">10</ix:nonFraction>&#160;billion Commercial Paper program in the United States. </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2026:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average drawdown under the US Commercial Paper program was $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-8" name="sny:BorrowingAverageDrawdown" scale="9" id="f-1003">3.0</ix:nonFraction>&#160;billion; and </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average drawdown under the Negotiable European Commercial Paper program in France was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-8" name="sny:BorrowingAverageDrawdown" scale="9" id="f-1004">0.1</ix:nonFraction>&#160;billion.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of June 30, 2026 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i37c1361e63e94fd097254f65bc03ccbd"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.2. Market value of net debt</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfMarketValueOfNetDebtTableTextBlock" id="f-1005" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1006">14,989</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-1007">10,424</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-1008">15,488</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-1009">11,022</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_70"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="f-1010" continuedAt="f-1010-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i0dd095bcf8014bcb94796df400f45795"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10. Derivative financial instruments</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i6cb113c951b7447ab149c5d57111e97e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.1 Currency derivatives used to manage operating risk exposures</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" id="f-1011" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:26.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as&#160;cash&#160;flow hedges</span></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1012">6,536</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1013">66</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1014">221</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1015">8</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-259" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1016">8</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1017">6,315</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1018">58</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1019">2,968</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1020">38</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1021">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1022">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1023">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1024">2,968</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-268" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1025">38</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1026">555</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1027">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1030">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1031">555</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-276" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1033">530</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1034">6</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1035">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1036">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1037">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1038">530</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1039">6</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Brazilian real </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1040">422</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1041">9</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1042">221</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-286" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1043">8</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1044">8</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-288" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1045">201</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1046">1</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which  Saudi Arabian riyal</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1047">224</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1048">3</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1049">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1050">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1051">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1052">224</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1053">3</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1054">5,039</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1055">33</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1056">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1057">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1058">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1059">5,039</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-303" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1060">33</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-304" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1061">3,200</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1062">24</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1063">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1064">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1065">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1066">3,200</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1067">24</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1068">596</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1069">2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1070">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1071">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-315" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1072">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1073">596</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1074">2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1075">306</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1076">2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1077">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1078">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-322" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-323" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1080">306</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-324" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1081">2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-325" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1082">120</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-326" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1083">6</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1084">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1085">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1086">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-330" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1087">120</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1088">6</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which United Arab Emirates dirham</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1089">120</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1090">1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1091">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1092">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-336" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-337" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1094">120</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-338" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1095">1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1096">11,575</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1097">33</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1098">221</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-342" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1099">8</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1100">8</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-344" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1101">11,354</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-345" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-1102">25</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes forward sales with a notional amount of BRL <ix:nonFraction unitRef="brl" contextRef="c-346" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1103">1,300</ix:nonFraction>&#160;million expiring in 2027, designated as a cash flow hedge on the divestment of Medley in Brazil.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2026 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ib51fa0ee829f4b729dfe5c70efa6459c"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.2. Currency and interest rate derivatives used to manage financial exposure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#8217;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#8217;s debt once those instruments are taken into account.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">22</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1010-1"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" id="f-1104" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:53.599%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum expiry&#160;date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cross currency seller swaps</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-347" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1105">1,523</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1106">37</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1107">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1108">37</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1109">16,423</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1110">272</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1111">13,361</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1112">241</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Pound sterling</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1113">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1114">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Brazilian real</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1115">204</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1116">9</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1117">11,466</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1118">170</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1119">8,657</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1120">143</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1121">1,299</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1122">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1123">543</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1124">19</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-1125">29,412</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-1126">139</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises <ix:nonFraction unitRef="swaps" contextRef="c-1" decimals="INF" name="sny:NumberOfCrossCurrencySwaps" format="ixt-sec:numwordsen" scale="0" id="f-1127">two</ix:nonFraction> cross currency swaps, (i) with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-1128">870</ix:nonFraction>&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-1129">870</ix:nonFraction>&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a hedge of Sanofi&#8217;s net investment in the United States. As of June 30, 2026, the fair value of the swaps was a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-365" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1130">37</ix:nonFraction>&#160;million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-1131">33</ix:nonFraction>&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1132">4</ix:nonFraction>&#160;million debited to financial result.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1133">12,275</ix:nonFraction>&#160;million expiring in 2026 and 2027, designated as a hedge of Sanofi&#8217;s net investment in the United States.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1134">223</ix:nonFraction>&#160;million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-1135">222</ix:nonFraction>&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1136">1</ix:nonFraction>&#160;million debited to</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) &#160;Includes forward sales with a notional amount of BRL <ix:nonFraction unitRef="brl" contextRef="c-369" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1137">1,200</ix:nonFraction>&#160;million  expiring in 2027, designated as a hedge of Sanofi&#8217;s net investment in Brazil.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1138">9</ix:nonFraction>&#160;million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-1139">10</ix:nonFraction>&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-6" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1140">1</ix:nonFraction>&#160;million credited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Financial income.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1141">1,000</ix:nonFraction>&#160;million expiring in 2026, designated as a fair value hedge of the exposure of $<ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1142">1,000</ix:nonFraction>&#160;million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2026, the fair value of these contracts represented a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1143">6</ix:nonFraction>&#160;million, with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-373" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1144">6</ix:nonFraction>&#160;million&#160;debited to</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">; the impact on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> is immaterial.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" id="f-1145" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:24.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as&#160;cash&#160;flow hedges</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2030 and beyond</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 2.08% / receive Euribor 3M</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1146">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1147">850</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1148">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1149">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1150">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-379" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1151">850</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-380" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1152">2</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-381" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1153">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1154">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-383" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1155">850</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-384" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1156">2</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-385" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1157">2</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 3.77% / receive <br/>capitalized SOFR + 46bps </span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-386" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1158">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-387" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1159">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1160">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-389" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1161">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-390" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1162">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-391" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1163">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-392" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1164">4</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-393" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1165">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-394" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1166">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1167">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-396" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1168">4</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1169">4</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized SOFR USD/ <br/>receive 1.03%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-398" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1170">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-399" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1171">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-400" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1172">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-401" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1173">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-402" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1174">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-403" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1175">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-404" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1176">25</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1177">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1178">25</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-407" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1179">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1180">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1181">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/ <br/>receive 1.32%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1182">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1183">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1184">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-413" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1185"></ix:nonFraction></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1186">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1187">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-416" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1188">22</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1189">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1190">22</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-419" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1191"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-420" xsi:nil="true" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" id="f-1192"></ix:nonFraction></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1193">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 3.82% / receive <br/>capitalized SOFR USD + 54 bps </span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1194">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1195">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1196">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1197">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1198">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1199">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-428" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1200">7</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1201">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-430" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1202">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1203">438</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-432" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1204">7</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-433" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1205">7</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester/receive 0.92%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-434" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-435" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1207">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-436" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1208">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-437" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1209">650</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1210">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1211">650</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1212">28</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1213">650</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-442" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1214">28</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-443" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1215">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1216">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-445" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1217">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 2.53%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-446" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1218">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1219">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-448" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1220">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-449" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1221">750</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1222">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-451" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1223">750</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-452" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1224">2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-453" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1225">750</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-454" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1226">2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-455" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1227">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-456" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1228">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-457" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1229">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 2.71%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1230">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1231">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1232">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1233">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-462" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1234">475</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-463" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1235">475</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-464" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1236">4</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-465" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1237">475</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-466" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1238">4</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-467" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1239">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-468" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1240">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 2.91%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-470" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1242">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1243">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-472" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1244">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-473" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1245">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-474" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1246">475</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-475" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1247">475</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-476" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1248">7</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-477" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1249">475</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-478" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1250">7</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-479" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1251">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-480" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1252">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-481" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1253">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-482" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1254">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-483" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1255">1,288</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-484" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1256">1,313</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-485" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1257">1,400</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-486" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1258">950</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1259">4,951</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1260">52</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-487" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1261">3,226</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1262">62</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1263">1,726</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-342" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1264">10</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-1265">10</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_73"></div><div style="margin-bottom:3pt;margin-top:12pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" id="f-1266" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i441d86681a7946cc9b530ec9161251d5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.11. Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" id="f-1267" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2026 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"/><td style="width:45.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CVRs issued in connection with the acquisition of Blueprint</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CVRs issued in connection with the acquisition of Vigil</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2026</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1268">531</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-490" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1269">48</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-491" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1270">5</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-492" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1271">1</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1272">585</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1273">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1274">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1275">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1276">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1277">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1278">38</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1279">8</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1280">3</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-1281">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-1282">49</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1283">16</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1284">2</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1285">1</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1286">1</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" scale="6" id="f-1287">18</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-497" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1288">585</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-498" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1289">58</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-499" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1290">9</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-500" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1291">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1292">652</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Current portion</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-1293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Non-current portion</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1294">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2026, this comprised a non-current portion of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-1295">585</ix:nonFraction> million. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprised the contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-497" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1296">585</ix:nonFraction> million as of June&#160;30, 2026, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1297">531</ix:nonFraction> million as of December 31, 2025. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately <ix:nonFraction unitRef="number" contextRef="c-497" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-1298">13</ix:nonFraction>%.</span></div></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_76"></div><div style="margin-bottom:3pt;margin-top:12pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" id="f-1299" continuedAt="f-1299-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ib5e43f9013e14d0887318696ae285733"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.12. Non-current provisions and other non-current liabilities</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" id="f-1300" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.098%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.099%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1301">4,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1302">4,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1303">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1304">2,162</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1305">6,848</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1306">6,703</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-501" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1307">1,647</ix:nonFraction> million as of June 30, 2026 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States (see Note C.2. to the consolidated financial statements for the year ended December 31, 2025). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-502" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="f-1308">916</ix:nonFraction>&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-503" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1309">2,150</ix:nonFraction> million.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNonCurrentProvisionsTableTextBlock" id="f-1310" continuedAt="f-1310-1" escape="true"><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">24</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1299-1"><ix:continuation id="f-1310-1"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:29.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-504" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1311">1,440</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-505" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1312">827</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-506" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1313">654</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-507" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1314">1,620</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1315">4,541</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1316">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1317">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1318">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-1319">13</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-1320">13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="sny:IncreaseDecreaseInProvisionsAndOtherLiabilities" scale="6" id="f-1321">57</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="sny:IncreaseDecreaseInProvisionsAndOtherLiabilities" scale="6" id="f-1322">110</ix:nonFraction></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="sny:IncreaseDecreaseInProvisionsAndOtherLiabilities" scale="6" id="f-1323">180</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="sny:IncreaseDecreaseInProvisionsAndOtherLiabilities" scale="6" id="f-1324">126</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseInProvisionsAndOtherLiabilities" scale="6" id="f-1325">473</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1326">36</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1327">57</ix:nonFraction>)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1328">4</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1329">40</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-1330">137</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="6" id="f-1331">13</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="6" id="f-1332">2</ix:nonFraction>)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="6" id="f-1333">60</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="6" id="f-1334">54</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="6" id="f-1335">129</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1336">11</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1337">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1338">104</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1339">20</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-1340">113</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1341">26</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1342">1</ix:nonFraction></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1343">8</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1344">14</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" scale="6" id="f-1345">49</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1346">15</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1347">18</ix:nonFraction></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1348">2</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1349">17</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-1350">52</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" scale="6" id="f-1351">157</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1352">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1353">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-6" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-1354">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" scale="6" id="f-1355">157</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-512" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1356">1,343</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-513" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1357">897</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-514" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-1358">676</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-515" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1359">1,676</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-1360">4,592</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions and other liabilities&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:9pt"><span id="i1a226aca6ee943b898373876de7825d0"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December&#160;31, 2025, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal assumptions used (in particular, discount and inflation rates) and the market value of plan assets for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2026 to take into account changes during the first half of the year.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" id="f-1361" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:65.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.114%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-516" decimals="-6" sign="-" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-1362">71</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-517" decimals="-6" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-1363">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-518" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1364">86</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-519" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1365">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between +<ix:nonFraction unitRef="number" contextRef="c-520" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1366">0.05</ix:nonFraction>% and +<ix:nonFraction unitRef="number" contextRef="c-521" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1367">0.50</ix:nonFraction>%) and (ii) the +<ix:nonFraction unitRef="number" contextRef="c-522" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1368">0.15</ix:nonFraction>% change in the inflation rate in the United Kingdom in the first half of 2026.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between <ix:nonFraction unitRef="number" contextRef="c-523" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1369">0.00</ix:nonFraction>% and +<ix:nonFraction unitRef="number" contextRef="c-524" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-1370">0.30</ix:nonFraction>%) and (ii) the -<ix:nonFraction unitRef="number" contextRef="c-525" decimals="4" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="f-1371">0.30</ix:nonFraction>% change in the inflation rate in the United Kingdom in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes actuarial gains/ (losses) related to Opella of &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-526" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-1372">4</ix:nonFraction>)&#160;million for the first half of 2025..</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div id="if717a7f2fb424028954e92929e21ed21_79"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" id="f-1373" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if2ef66ecc61249b8827c28488e19b089"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13. Off balance sheet commitments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments to third parties as of December&#160;31, 2025 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal commitments entered into the period are described below:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">In March 2026, Sanofi entered into an exclusive license agreement to develop, manufacture, and commercialize rovadicitinib worldwide from CTTQ, a Sino Biopharmaceutical Limited subsidiary. Rovadicitinib is a global first-in-class oral small molecule dual-target JAK/ ROCK inhibitor which received its first approval in China in February 2026 as a first-line treatment for MF (myelofibrosis) indication. Under the terms of the agreement, CTTQ received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="sny:UpfrontLicensePayment" scale="6" id="f-1374">135</ix:nonFraction>&#160;million and is entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-8" name="sny:CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" scale="9" id="f-1375">1.4</ix:nonFraction>&#160;billion in development, regulatory and sales milestones, and up to double-digit tiered royalties on product sales. </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">In March 2026, Sanofi entered into a worldwide exclusive license agreement with Kali Therapeutics for a next-generation tri-specific T-cell engager for autoimmune diseases, under which Sanofi will obtain exclusive worldwide rights to KT501, a novel tri-specific antibody utilizing Kali Therapeutics&#8217; proprietary discovery and research platform. Under the terms of the agreement, Kali Therapeutics is entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-8" name="sny:CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" scale="9" id="f-1376">1.2</ix:nonFraction>&#160;billion including upfront payments (of which $<ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-8" name="sny:UpfrontLicensePayment" scale="9" id="f-1377">0.1</ix:nonFraction>&#160;billion has already been paid) plus development and sales milestones, and tiered royalties ranging from high-single to double digits on product sales.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, Sanofi has not entered into any material new long-term renewable energy contract agreements as part of its sustainability strategy. The main existing agreements are presented in Note D.21.1. to the consolidated financial statements in the 2025 Form 20-F.</span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_82"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLegalAndArbitralProceedingsTextBlock" id="f-1378" continuedAt="f-1378-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="idcc102ea9b2046cc83a259304e2abadf"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14. Litigation and arbitration proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2025.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i4c3e61ca8b9141d0b7fa8d2daa67610a"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.1. Products</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i8b1c17e995d64e019397b3fb59609de6"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zantac product litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the Multi-District Litigation (MDL) where Federal court cases were coordinated, the Eleventh Circuit held oral argument for the appeal in the fourth quarter of 2025 and a decision is expected in the second half of 2026.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In those cases pending in Delaware (State court) where the issue is to rule on defendants&#8217; Daubert motions to exclude plaintiffs&#8217; experts, in the second quarter of 2026, the Delaware Superior Court granted summary judgment and dismissed all the cases pending against Sanofi. The plaintiffs are appealing this ruling to the Delaware Supreme Court and Sanofi does not expect a decision on the appeal until the fourth quarter of 2027.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="iec0d81a85e37464bb85c5c2447256a99"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talc product litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, Sanofi was named as a defendant in approximately <ix:nonFraction unitRef="proceeding" contextRef="c-529" decimals="INF" name="sny:NumberOfClassActionLawsuits" format="ixt:num-dot-decimal" scale="0" id="f-1379">1,430</ix:nonFraction> ongoing product liability actions. To date, no cases have proceeded to trial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i97325ef9fa90480584d9004faf31c3d0"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent product litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="case" contextRef="c-530" decimals="INF" name="sny:NumberOfProductLiabilityCases" scale="0" id="f-1380">30</ix:nonFraction> product liability cases have been filed in Federal courts around the country alleging that Dupixent (dupilumab) causes or exacerbates T-Cell lymphoma. In June 2026, those cases were consolidated into a Multi-District Litigation (MDL) in New Jersey Federal court. In addition, <ix:nonFraction unitRef="case" contextRef="c-530" decimals="INF" name="sny:NumberOfCasesFiledInNewJerseyCourt" format="ixt-sec:numwordsen" scale="0" id="f-1381">eight</ix:nonFraction> cases have been filed in New Jersey State court. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess reliably the outcome of these ongoing cases.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i10d555f1b9f3459bbe1a9e0eee1c96c5"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.2. Patents</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="idee49d17dbab49a198e6d3e9dd3eeeb1"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Praluent (alirocumab)-related Amgen patent litigation in Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March 6, 2026, Sanofi, Regeneron and Amgen entered into a settlement agreement resolving these disputes. The terms of the settlement are confidential. These cases are now closed.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i0088217aa4f2473782ecce2ebc49b741"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.3. Other litigation</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="icef0d62496c244a381edef675d01510c"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel) - Attorney General Action in Texas </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the action filed by Sanofi and Bristol Myers Squibb (BMS) against the Texas Attorney General (Texas AG) in Travis County, on April 28, 2026 the Travis County court granted the Texas AG&#8217;s motion to abate the companies&#8217; suit against it; and on June 4, 2026 the companies filed a mandamus petition with the Texas Court of Appeals seeking to vacate that ruling.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i1cbe1487d6d04115b3675a499302b6f1"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B drug pricing program in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The US Health Resources and Services Administration (HRSA) withdrew its 340B Rebate Model Pilot Program in February 2026 but is expected to announce a new 340B Rebate Model Pilot Program later in 2026. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">ADR Proceedings in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the 340B Administrative Dispute Resolution (ADR) proceedings against Sanofi, <ix:nonFraction unitRef="proceeding" contextRef="c-531" decimals="INF" name="sny:NumberOfClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="f-1382">one</ix:nonFraction> filed by University of Washington/Harborview Medical Center in 2023 and <ix:nonFraction unitRef="proceeding" contextRef="c-532" decimals="INF" name="sny:NumberOfClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="f-1383">one</ix:nonFraction> filed by Hudson Headwaters Health Network in 2024 (both alleging that Sanofi&#8217;s 340B Integrity Initiative caused &#8220;overcharges&#8221; under Section 340B), on March 9, 2026 the ADR Panel determined that there was no overcharge violation by Sanofi in the proceeding involving University of Washington Medical Center/Harborview Medical Center; and on May 27, 2026 the ADR Panel determined that there was no overcharge violation by Sanofi in the proceeding involving Hudson Headwaters Network, which has requested reconsideration of the ADR Panel&#8217;s decision.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mosaic Health in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since the case was remanded by the Court of Appeal to the District Court in August 2025 following the second amended complaint filed by plaintiffs, defendants (Sanofi and <ix:nonFraction unitRef="defendant" contextRef="c-533" decimals="INF" name="sny:NumberOfOtherDefendantsInLegalProceeding" format="ixt-sec:numwordsen" scale="0" id="f-1384">three</ix:nonFraction> other manufacturers) filed a motion to dismiss certain state law claims.  Defendants also filed a petition for a writ of certiorari with the Supreme Court of the United States challenging <ix:nonFraction unitRef="aspects" contextRef="c-533" decimals="INF" name="sny:NumberOfLegalDecisionAspectsChallenged" format="ixt-sec:numwordsen" scale="0" id="f-1385">two</ix:nonFraction> aspects of the Second Circuit&#8217;s decision.  In July 2026, certain state law claims and plaintiffs&#8217; unjust enrichment claims were dismissed.  The District Court set a case schedule with fact discovery closing in November 2027.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1378-1"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Adventist Health System/West in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the appeal filed by Adventist Health System/West following the dismissal granted by the court in March 2024 in favor of the drug manufacturers including Sanofi, the Ninth Circuit Court of Appeals reversed and ordered the case to be remanded to the District Court on March 17, 2026.</span></div></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_85"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory" id="f-1386" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="icc0e2fd5b6c74cd6b05c37034b5c2038"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.15. Other operating income and expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1387">800</ix:nonFraction> million in the first half of 2026 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1388">533</ix:nonFraction> million in the first half of 2025), and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1389">3,436</ix:nonFraction> million (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">versus</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#8364; <ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1390">2,476</ix:nonFraction> million in the first half of 2025)<ix:nonNumeric contextRef="c-1" name="sny:OtherOperatingExpensesTableTextBlock" id="f-1391" continuedAt="f-1391-1" escape="true">, as shown in the table below.</ix:nonNumeric></span></div><ix:continuation id="f-1391-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net gains / (losses) on disposals of operating assets or businesses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:GainsLossOnDivestmentOfProducts" scale="6" id="f-1392">241</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:GainsLossOnDivestmentOfProducts" scale="6" id="f-1393">344</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amvuttra licensing income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-534" decimals="-6" name="sny:IncomeResultingFromOutLicensing" scale="6" id="f-1394">398</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-535" decimals="-6" name="sny:IncomeResultingFromOutLicensing" scale="6" id="f-1395">120</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-536" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1396">161</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-537" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1397">69</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherOperatingIncome" scale="6" id="f-1398">800</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OtherOperatingIncome" scale="6" id="f-1399">533</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regeneron alliance:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(i) (Profit)/loss sharing</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-538" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1400">3,486</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-539" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1401">2,475</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(ii) Additional profit share for development cost from Regeneron</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-540" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1402">594</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-541" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-1403">494</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(iii) Selling expense reimbursements to Regeneron</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1404">336</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1405">346</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-536" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1406">208</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-537" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1407">149</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1408">3,436</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-1409">2,476</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_88"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" id="f-1410" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i139e0fb357da4970a6636ccc777d86be"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16. Restructuring costs and similar items</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsDetailsTableTextBlock" id="f-1411" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-1412">284</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-1413">201</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-1414">179</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-1415">109</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-1416">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-1417">80</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1418">90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1419">40</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1420">563</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1421">430</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line includes transaction, integration and separation costs in connection with material acquisitions or divestitures amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-6" name="sny:OtherRestructuringCosts" scale="6" id="f-1422">73</ix:nonFraction> million for the first half of 2026, mainly related to the Dynavax acquisition (see note B.1.).</span></div></ix:nonNumeric></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_91"></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" id="f-1423" continuedAt="f-1423-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i20b78eca92d7471d8d4493af61426d49"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17. Other gains and losses, and litigation</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><ix:continuation id="f-1423-1" continuedAt="f-1423-2"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2026, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represents a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1424">95</ix:nonFraction> million mainly related to major litigation, compared with a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1425">57</ix:nonFraction> m</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">illion in the first half of </span></ix:continuation><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-1423-2">2025</ix:continuation>.</span></div><div id="if717a7f2fb424028954e92929e21ed21_94"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-1426" continuedAt="f-1426-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i74ae65716b9a487992160b7c640c03ed"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.18. Financial expenses and income</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" id="f-1427" continuedAt="f-1427-1" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-1428">253</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-1429">219</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:InterestIncome" scale="6" id="f-1430">118</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:InterestIncome" scale="6" id="f-1431">162</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-1432">135</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-1433">57</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-1434">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-1435">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-1436">21</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-1437">22</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-1438">27</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-1439">37</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses on financial assets, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ImpairmentLossesOnFinancialAssetsNetOfReversals" scale="6" id="f-1440">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:ImpairmentLossesOnFinancialAssetsNetOfReversals" format="ixt:fixed-zero" scale="6" id="f-1441">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-1442">26</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-1443">22</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-1444">115</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-1445">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1446">328</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-1447">177</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1448">465</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1449">361</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1450">137</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1451">184</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1426-1"><ix:continuation id="f-1427-1"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-6" name="sny:GainLossOnDerivativesUsedToManageDebt" scale="6" id="f-1452">12</ix:nonFraction> million in the first half of 2026 and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-546" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageDebt" scale="6" id="f-1453">25</ix:nonFraction>) million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-6" name="sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-1454">6</ix:nonFraction> million in the first half of 2026 and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-546" decimals="-6" sign="-" name="sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-1455">4</ix:nonFraction>)&#160;million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes a financial expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-1456">146</ix:nonFraction> million for the six months ended June 30, 2026 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-1457">50</ix:nonFraction> million for the six months ended June 30, 2025 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United States.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of the ineffective portion of hedging relationships was not material in either 2026 or 2025.</span></div></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_97"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-1458" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i629ae0ca518d4a3799c6c6b12cd80b9e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.19. Income tax expense</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" id="f-1459" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1460">1,089</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1461">1,202</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-1462">218</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-1463">491</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-1464">871</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-1465">711</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1466">2,840</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1467">3,582</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" id="f-1468" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(as a percentage)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-1469">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-1470">25.8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-1471">17.9</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-1472">7.3</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effect related to amlitelimab </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:TaxEffectRelatedToAmlitelimab" scale="-2" id="f-1473">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="sny:TaxEffectRelatedToAmlitelimab" format="ixt:fixed-zero" scale="-2" id="f-1474">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-1475">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-1476">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-1477">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-1478">1.0</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-1479">30.6</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-1480">19.8</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France, and the impact of patent-favorable tax regimes.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2025 component of the temporary exceptional corporate income tax surcharge, introduced under the 2026 French Finance Act, is included in the<br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)  This relates to the non-deductibility of the impairment loss on the amlitelimab intangible asset (see Note B.4.), and associated effects on deferred tax assets.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2026, this line includes a tax expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes" scale="6" id="f-1481">57</ix:nonFraction> million representing the estimated impact of Pillar Two based on Sanofi&#8217;s current understanding of Pillar Two rules, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes" scale="6" id="f-1482">17</ix:nonFraction> million for the six months ended June 30, 2025.</span></div></ix:nonNumeric></ix:nonNumeric><div id="if717a7f2fb424028954e92929e21ed21_100"></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueExplanatory" id="f-1483" continuedAt="f-1483-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i9da410b1c04b43f39d6815feab11f47e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20. Revenue from contracts with customers</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="if7fb0c15c7e14188b423f83b19015d10"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1. Analysis of net sales</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="f-1484" escape="true"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:7.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.690%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:4pt"><td colspan="6" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="42" style="display:none"/></tr><tr><td colspan="6" style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Group</span></div></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1485">4,304</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-548" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1486">11,633</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-549" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1487">6,169</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1488">22,106</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-550" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1489">4,144</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-551" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1490">9,535</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-552" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1491">6,210</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1492">19,889</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-553" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1493">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-554" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1494">6,922</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-555" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1495">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-556" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1496">9,324</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-557" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1497">944</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-558" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1498">5,283</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-559" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1499">1,085</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-560" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1500">7,312</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1502">576</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1503">98</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1504">674</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1505">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1506">456</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1507">86</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1508">542</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabrazyme</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1509">138</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-570" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1510">256</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1511">129</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-572" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1512">523</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-573" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1513">134</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1514">261</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-575" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1515">130</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-576" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1516">525</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme/Nexviadyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1517">152</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-578" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1518">211</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1519">63</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1520">426</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-581" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1521">132</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1522">195</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-583" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1523">60</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1524">387</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerezyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-585" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1525">126</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1526">86</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-587" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1527">140</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-588" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1528">352</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-589" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1529">119</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1530">91</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1531">153</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1532">363</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ayvakit</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1533">44</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-594" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1534">322</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-595" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1535">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1536">367</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1537">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-598" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1538">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-599" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1539">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-600" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-1540">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-601" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1541">108</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-602" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1542">132</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-603" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1543">114</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-604" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1544">354</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-605" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1545">83</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-606" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1546">119</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-607" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1547">74</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-608" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1548">276</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lantus</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-609" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1549">146</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1550">344</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-611" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1551">323</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-612" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1552">813</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-613" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1553">149</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-614" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1554">395</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-615" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1555">332</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-616" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1556">876</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Toujeo</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-617" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1557">259</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-618" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1558">134</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-619" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1559">336</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-620" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1560">729</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-621" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1561">248</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-622" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1562">126</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-623" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1563">318</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-624" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1564">692</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plavix</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-625" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1565">40</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-626" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1566">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-627" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1567">398</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-628" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1568">440</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-629" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1569">44</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-630" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1570">3</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-631" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1571">426</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-632" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1572">473</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lovenox</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-633" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1573">202</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-634" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1574">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-635" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1575">157</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-636" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1576">364</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-637" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1577">247</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-638" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1578">9</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-639" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1579">191</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-640" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1580">447</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-641" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1581">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-642" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1582">218</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-643" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1583">42</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-644" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1584">296</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-645" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1585">23</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1586">220</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-647" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1587">20</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-648" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1588">263</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-649" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1589">181</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-650" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1590">7</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-651" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1591">2</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-652" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1592">190</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-653" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1593">241</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-654" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1594">1</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-655" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1595">9</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-656" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1596">251</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-657" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1597">206</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-658" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1598">487</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1599">671</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1600">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1601">223</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1602">320</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1603">818</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1604">1,361</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-665" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1605">87</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-666" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1606">65</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-667" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1607">240</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1608">392</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1609">85</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1610">68</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-671" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1611">203</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-672" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1612">356</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-673" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1613">118</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-674" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1614">268</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-675" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1615">179</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-676" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1616">565</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-677" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1617">96</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-678" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1618">319</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-679" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1619">194</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-680" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1620">609</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">COVID-19 and Influenza vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-681" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1621">33</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-682" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1622">16</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-683" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1623">72</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-684" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1624">121</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-685" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1625">52</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-686" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1626">54</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-687" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1627">108</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-688" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1628">214</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which total launches </span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-689" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1629">546</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-690" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1630">1,891</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-691" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1631">610</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-692" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1632">3,047</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-693" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1633">423</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-694" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1634">1,204</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-695" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1635">473</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-696" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1636">2,100</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-right:0.25pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="i9915491664724057bf9655002fbed8b1"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.2. Other revenues</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOtherRevenueTextBlock" id="f-1637" continuedAt="f-1637-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:72.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.074%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe sales of non-Sanofi products</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="sny:RevenueFromVaxServeSalesOfNonSanofiProducts" scale="6" id="f-1638">746</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="sny:RevenueFromVaxServeSalesOfNonSanofiProducts" scale="6" id="f-1639">842</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales to Opella </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" scale="6" id="f-1640">60</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" scale="6" id="f-1641">61</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:RevenueFromRoyalties" scale="6" id="f-1642">91</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:RevenueFromRoyalties" scale="6" id="f-1643">68</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="sny:MiscellaneousOtherRevenue" scale="6" id="f-1644">271</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="sny:MiscellaneousOtherRevenue" scale="6" id="f-1645">275</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biopharma Other revenues</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1646">1,168</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1647">1,246</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales / Revenues from Opella products</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-698" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1648">270</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-699" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1649">206</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Other revenues</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1650">1,438</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1651">1,452</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-1637-1"><ix:continuation id="f-1483-1">(c)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily</ix:continuation></ix:continuation> (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">29</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_103"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-1652" continuedAt="f-1652-1" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i467d65866f844e78b863815e9b5709f5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21. Segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The segment information presented by Sanofi consists of a single operating segment: Biopharma.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines, and Vaccines franchises, plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella Healthcare SAS (Opella), which constitutes a related party with effect from April 30, 2025, the deconsolidation date, corresponding to the closing of Sanofi's sale of a controlling stake of approximately <ix:nonFraction unitRef="number" contextRef="c-700" decimals="2" name="sny:ProportionOfOwnershipInterestDisposedInSubsidiary" scale="-2" id="f-1653">50</ix:nonFraction>% in Opella to Clayton, Dubilier &amp; Rice (CD&amp;R). Those revenues, which before the deconsolidation date represented intragroup transactions classified within continuing operations, are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i884faad2f1f94bc3832619db02e9fdaa"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.1. Segment results</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.025em;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of the operating segment and to allocate resources.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts reported within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other gains and losses (including gains and losses on major divestments), presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other costs and provisions related to litigation, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates (i)&#160;to joint ventures or (ii) to associates with which Sanofi has entered into R&amp;D agreements and/or whose operations are managed as an integral part of Sanofi&#8217;s business activities, and;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income attributable to non-controlling interests related to continuing operations, and excluding the effects of the above reconciling items, is deducted. </span></div></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1652-1" continuedAt="f-1652-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="f-1654" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"/><td style="width:27.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026 (6 months)</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1655">22,106</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" scale="-2" id="f-1656">11.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1657">15.7</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1658">22,106</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" scale="-2" id="f-1659">11.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1660">15.7</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1661">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" sign="-" name="sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" scale="-2" id="f-1662">6.3</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" sign="-" name="sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1663">2.0</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1664">270</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" scale="-2" id="f-1665">31.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1666">31.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1667">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" sign="-" name="sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" scale="-2" id="f-1668">1.0</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1669">2.7</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1670">5,812</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1671">1.0</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" scale="-2" id="f-1672">3.8</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1673">133</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1674">3.9</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" scale="-2" id="f-1675">3.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1676">5,945</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1677">1.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" scale="-2" id="f-1678">3.8</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1679">3,979</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1680">7.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1681">9.9</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1682">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" format="ixt:fixed-zero" scale="-2" id="f-1683">&#8212;</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" format="ixt:fixed-zero" scale="-2" id="f-1684">&#8212;</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1685">3,980</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1686">7.1</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1687">9.9</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1688">4,690</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1689">5.5</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1690">9.4</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1691">102</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1692">72.9</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1693">76.3</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1694">4,792</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" scale="-2" id="f-1695">6.3</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1696">10.3</ix:nonFraction></span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1697">2,630</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1698">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1699">2,636</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1700">74</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-702" xsi:nil="true" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" id="f-1701"></ix:nonFraction></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1702">74</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1703">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-702" xsi:nil="true" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" id="f-1704"></ix:nonFraction></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1705">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1706">6,230</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" scale="-2" id="f-1707">16.5</ix:nonFraction></span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1708">22.2</ix:nonFraction></span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="sny:BusinessOperatingIncome" scale="6" id="f-1709">28</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" scale="-2" id="f-1710">75.0</ix:nonFraction></span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-702" decimals="3" name="sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1711">68.8</ix:nonFraction></span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1712">6,258</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" scale="-2" id="f-1713">16.7</ix:nonFraction></span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" scale="-2" id="f-1714">22.3</ix:nonFraction></span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sny:BusinessOperatingIncomeAsPercentOfNetSales" scale="-2" id="f-1715">28.2</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-701" decimals="3" name="sny:BusinessOperatingIncomeAsPercentOfNetSales" scale="-2" id="f-1716">28.3</ix:nonFraction></span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:50.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6 months)</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1717">19,889</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="c-703" xsi:nil="true" name="ifrs-full:RevenueFromSaleOfGoods" id="f-1718"></ix:nonFraction></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1719">19,889</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1720">1,246</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-1721">206</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1722">1,452</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1723">5,753</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1724">128</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-1725">5,881</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1726">3,716</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1727">1</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1728">3,717</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1729">4,447</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1730">59</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1731">4,506</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1732">1,941</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-1733">2</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1734">1,943</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1735">77</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-1736">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1737">77</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1738">8</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-1739">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1740">8</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1741">5,347</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="sny:BusinessOperatingIncome" scale="6" id="f-1742">16</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1743">5,363</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" id="f-1744" escape="true"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:70.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-705" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1745">6,258</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-706" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-1746">5,363</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1747">74</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1748">77</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1749">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-1750">8</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1751">1,087</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1752">777</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1753">1,031</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1754">210</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-1755">37</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-1756">61</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-1757">210</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" format="ixt:fixed-zero" scale="6" id="f-1758">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1759">563</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-1760">430</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1761">95</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-1762">57</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1763">3,168</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1764">3,759</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1765">465</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-1766">361</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1767">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-1768">184</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1769">2,840</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1770">3,582</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Mainly joint ventures.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1771">1,031</ix:nonFraction>&#160;million in the first half of 2026 mainly comprising a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-116" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1772">952</ix:nonFraction> million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly comprises impairment losses of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1773">210</ix:nonFraction>  million linked to research and development projects.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026 relate to the Blueprint Medicines and Dynavax acquisitions.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">See Note B.16.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.17.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:continuation id="f-1652-2" continuedAt="f-1652-3"><div style="margin-bottom:3pt;margin-top:9pt"><span id="i17f4673892234e26865e7dfa66a30da2"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.2. Other segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method related (a) to joint ventures or (b) to associates with which Sanofi has entered into R&amp;D agreements and/or whose operations are managed as an integral part of Sanofi&#8217;s business activities; (ii) acquisitions of property, plant and equipment; and (iii) acquisitions of intangible assets. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method mainly comprise MSP Vaccine Company and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note B.5.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" id="f-1774" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:61.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.699%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-709" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1775">204</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-710" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-1776">483</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1777">882</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-1778">845</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1779">414</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-1780">575</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span id="ic5ce3e905560415e91636d287653d938"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.3. Information by geographical region</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" id="f-1781" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:60.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.853%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1782">4,304</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-550" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1783">4,144</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-711" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1784">725</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-712" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-1785">835</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-548" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1786">11,633</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-551" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1787">9,535</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-713" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1788">6,169</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-714" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1789">6,210</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-715" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1790">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-716" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1791">1,388</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1792">22,106</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-1793">19,889</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:53.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.149%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-717" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1794">5,998</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-717" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1795">3,951</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-718" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1796">5,760</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-718" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1797">5,094</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-719" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1798">3,161</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-719" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-720" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1800">3,123</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-720" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1801">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-721" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1802">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-721" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1803">21,972</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-722" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1804">2,229</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-722" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1805">20,694</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-723" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1806">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-723" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1807">436</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-724" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1808">2,063</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-724" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1809">473</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-725" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1810">167</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-725" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-726" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1812">122</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-726" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1813">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1814">10,364</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1815">26,359</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1816">10,052</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1817">26,261</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2025, goodwill is not allocated by geographical region.</span></div></ix:continuation><div id="if717a7f2fb424028954e92929e21ed21_106"></div><ix:continuation id="f-1652-3"><div style="margin-bottom:3pt;margin-top:9pt"><span id="i6ee48613616140ac9120c037d6917ecb"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.4. Disclosures about major customers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented <ix:nonFraction unitRef="number" contextRef="c-727" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1818">42</ix:nonFraction>% of net sales in the first half of 2026. Sanofi&#8217;s <ix:nonFraction unitRef="customer" contextRef="c-1" decimals="INF" name="sny:NumberOfLargestCustomers" format="ixt-sec:numwordsen" scale="0" id="f-1819">three</ix:nonFraction> largest customers respectively accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-728" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1820">22</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-729" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1821">14</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-730" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1822">6</ix:nonFraction>% of consolidated net sales in the first half of 2026 (versus approximately <ix:nonFraction unitRef="number" contextRef="c-731" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1823">18</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-732" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1824">12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-733" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-1825">5</ix:nonFraction>% in the first half of 2025).</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td></tr></table></div></div></div><div id="if717a7f2fb424028954e92929e21ed21_109"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.803%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.1</span></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1. Condensed half-year consolidated financial statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" id="f-1827" escape="true"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ia9eff4859f124b0d914e6bab5e9a4ad8"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.22. Information related to Opella, presented within discontinued operations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2025, the Opella transaction was closed triggering loss of control, and resulting in the derecognition of all assets and liabilities of Opella subsidiaries. </span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" id="f-1828" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the main items presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:74.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.074%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales and other revenues </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-6" name="sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-1829">&#8212;</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-735" decimals="-6" name="sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1830">1,736</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-6" name="sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-1831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-735" decimals="-6" name="sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1832">266</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-6" name="sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1833">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-735" decimals="-6" name="sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1834">2,781</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1835">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-735" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1836">3,039</ix:nonFraction>&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-6" sign="-" name="sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1837">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-735" decimals="-6" name="sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1838">158</ix:nonFraction>)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" scale="6" id="f-1839">26</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-735" decimals="-6" name="ifrs-full:ProfitLossFromDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-1840">2,881</ix:nonFraction></span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In 2025, this line includes an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-736" decimals="-6" name="sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-1841">88</ix:nonFraction>&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:94.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit992-2026halfyearman.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i69eb17a5021444ec89d279a544806a88_1"></div><div style="min-height:56.69pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:32pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div style="margin-bottom:5pt;margin-top:70pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TABLE OF CONTENTS</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.997%"><tr><td style="width:1.0%"></td><td style="width:88.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#ie66ba927d69e49af8fe502621921acc5" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">2. Half-year management report</a></font></div></td><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#ie66ba927d69e49af8fe502621921acc5" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">35</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#if1b644586a64435bbe0bb931909187c5" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">A&#47; Significant events of the first half of 2026</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#if1b644586a64435bbe0bb931909187c5" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">35</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i4b97542e7c3a447db7283b089d134964" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">B&#47; Progress on implementation of the sustainability strategy</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i4b97542e7c3a447db7283b089d134964" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">40</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#idca12ca630ac48208d46a50dc144c981" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">C&#47; Events subsequent to June 30, 2026</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#idca12ca630ac48208d46a50dc144c981" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">41</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#if641367b54414bce9087edd77bd761e9" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">D&#47; Consolidated financial statements for the first half of 2026</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#if641367b54414bce9087edd77bd761e9" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">42</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#id795a9e34f284e22824a27b3ecef38fc" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">E&#47; Risk factors and related party transactions</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#id795a9e34f284e22824a27b3ecef38fc" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">56</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#ie3aaa86ee06445c59a6cea490ef4d002" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">F&#47; Outlook</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#ie3aaa86ee06445c59a6cea490ef4d002" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i0bc9083b9c04482192d344aa75b40dfc" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">G&#47; Appendix - research and development pipeline</a></font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><a href="#i0bc9083b9c04482192d344aa75b40dfc" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%;text-decoration:none">59</a></font></div></td></tr><tr><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i2a6932c6565c4f41af5221352bdff07a" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">3. Statutory auditors&#8217; review report on the half-yearly financial information</a></font></div></td><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i2a6932c6565c4f41af5221352bdff07a" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">61</a></font></div></td></tr><tr><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="padding-left:28.35pt;text-indent:-28.35pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i10f407047ef54a8fbd98b943a08ae70a" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">4. Responsibility statement of the certifying officer&#58; half-year financial report</a></font></div></td><td colspan="3" style="padding:7.37pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i10f407047ef54a8fbd98b943a08ae70a" style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">62</a></font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">34</font></div></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_4"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:15pt"><font id="ie66ba927d69e49af8fe502621921acc5"></font><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">2. Half-year management report</font></div><div id="i69eb17a5021444ec89d279a544806a88_7"></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="if1b644586a64435bbe0bb931909187c5"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">A&#47; Significant events of the first half of 2026</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib80bfcc4741a472f931501935938df6f"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. First-half overview</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2026, Sanofi continued to implement its growth and innovation strategy, focused on launching major innovations, reallocating resources and developing cutting-edge innovative R&#38;D. Significant events connected with the implementation of this strategy are described below (for additional information on developments related to Research and Development see also section &#34;A.2. Research and Development&#34;).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 29, 2026, Sanofi announced its intention to execute a &#8364;1 billion share buyback program in 2026, and on February 2, 2026, it entered into a mandate with an investment services provider for this program. Under the terms of this mandate, Sanofi was to repurchase its own shares for a maximum amount of &#8364;1 billion. The program ended at the end of April 2026.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February 10, 2026, Sanofi announced that it had completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax&#8217;s adult hepatitis B vaccine, HEPLISAV-B, currently marketed in the United States, which is distinguished by its two-dose, one-monthly vaccination schedule. It also includes Dynavax&#8217;s shingles vaccine candidate (Z-1018), currently in phase 1&#47;2 clinical trials, as well as other vaccine projects in development.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 24, 2026, Sanofi announced the successful placement of a &#8364;2.3 billion bond issue under the Euro Medium Term Note program. Sanofi will allocate the net proceeds from the issuance of these bonds to general corporate purposes.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales for the first half of 2026 amounted to &#8364;22,106&#160;million, 11.1% higher than in the first half of 2025. At constant exchange rates (CER)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net sales rose by 15.7%, driven mainly by strong performances for Dupixent, Ayvakit and ALTUVIIIO.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:112%">Net income attributable to equity holders of Sanofi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">amounted to &#8364;1,957&#160;million in the first half of 2026, versus &#8364;5,812 million in the first half of 2025. Earnings per share was &#8364;1.63 for the first half of 2026, versus &#8364;4.74 for the first half of 2025. Business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:112%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%"> was &#8364;4,765 million, up 14.8% versus the first half of 2025, while business earnings per share (business EPS</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:112%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">) was &#8364;3.97, 17.1% up versus the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i69eb17a5021444ec89d279a544806a88_10"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i5fe2a8dea82d4944b8b5d9248b160095"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. Research and development</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s research and development (R&#38;D) is focused on developing and delivering life-changing medicines and vaccines that change the lives of patients for many of the world&#8217;s most complex diseases. Progress made in R&#38;D during the first half of 2026 is described in detail below, and an update on the R&#38;D pipeline is presented in Section G&#47; of this half-year management report.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ia69318b58dd14131830dae21a82b53fa"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Immunology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i9b8957f243bd4decbf735195a665c56c"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dupixent (dupilumab)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After evaluation under priority review, the US Food and Drug Administration (FDA) approved Dupixent for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. This approval expands the coverage of sino-nasal diseases with Dupixent to now include AFRS, alongside chronic rhinosinusitis with nasal polyps (CRSwNP).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA and the European Commission (EC) approved Dupixent for the treatment of children aged two to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 antihistamine (H1AH) treatment. These approvals expand the previous authorizations for Dupixent in adults and adolescents aged 12 years and older with CSU.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Ministry of Health, Labour and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid (BP). When publishing its first-quarter 2025 results, Sanofi announced that the European Medicines Agency (EMA) had accepted its Marketing Authorisation Application for Dupixent in the treatment of BP. Following comments from the EMA during its ongoing review of Dupixent for this indication, Sanofi has decided to withdraw the application.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The two phase 3 studies of Dupixent in the LIBERTY-LSC clinical program (STYLE 1 and STYLE 2&#59; clinical study identifiers&#58; NCT06687967 and NCT06687980, respectively) in lichen simplex chronicus (LSC) did not meet their primary endpoints of itch reduction compared to placebo. The safety data from these studies were generally consistent with the known safety profile of Dupixent. As a result of this outcome, Sanofi and Regeneron will conduct a thorough analysis of the data and plan to present them at a forthcoming medical meeting. </font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-IFRS financial measure&#58; see definition in D.3., &#8220;Net sales&#8221;.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-IFRS financial measure&#58; see definition in D.2., &#8220;Business net income&#8221;.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ib07281cf29a546e69b0174f0d6d6dc44"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rezurock (belumosudil) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The EC granted a conditional marketing authorization for Rezurock for the treatment of chronic graft-versus-host disease (cGVHD) in adults and children aged 12 years and older with a body weight of at least 40 kg. The medicine is to be used when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted. This conditional marketing authorization followed the positive opinion issued by the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) in January, and is contingent on completion of a confirmatory, randomised, controlled study.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i381ea184bf2b4b7ea2b6e983300643aa"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tzield&#47;Teizeild (teplizumab) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April, the FDA approved the supplemental biologic license application for Tzield, expanding the indication to patients as young as one year old, compared to a minimum of eight years previously, to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. In June, the FDA approved Tzield to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. Both approvals were granted under a priority review process. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the EU, teplizumab was approved (under the name Teizeild) to delay the onset of stage 3 T1D in adults and pediatric patients aged eight years and older diagnosed with stage 2 T1D. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="icde7dd0b42ed4adb8dda75c61f7dbaa4"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">amlitelimab (OX40L monoclonal antibody)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 24, 2026, a decision was made as part of the ongoing strategic assessment of the pipeline that amlitelimab would not progress to regulatory submission. Sanofi determined that the totality of efficacy and safety evidence generated to date does not support further development of amlitelimab in atopic dermatitis (AD). While the ESTUARY phase 3 long-term extension study (clinical study identifier&#58; NCT06407934) showed long-term maintenance of clinical response without relapse in patients aged 12 years and older with moderate-to-severe AD and an emerging safety profile that builds on previous data (including phase 3 studies COAST 1, SHORE and COAST 2&#59; clinical study identifiers&#58; NCT06130566, NCT06224348 and NCT06181435, respectively), amlitelimab would not represent a meaningful improvement to the standard of care for patients with AD. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i0b58c79386494a03a3c0bf06744834d3"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">itepekimab (IL33 monoclonal antibody) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After complete assessment of the results from AERIFY&#160;1 (clinical study identifier&#58; NCT04701983) and AERIFY 2 (clinical study identifier&#58; NCT04751487), the two phase 3 studies in chronic obstructive pulmonary disease (COPD) that read out in May 2025, and after considering the competitive landscape, Sanofi and its collaboration partner Regeneron have decided not to proceed with development of itepekimab in COPD. As a result, the development programme will be discontinued, including all studies in chronic rhinosinusitis.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i013ec6ce49444e08bae67035519c6420"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">duvakitug (TL1A monoclonal antibody) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Positive results from the RELIEVE UCCD long-term extension (LTE) study of duvakitug (clinical study identifier&#58; NCT05668013) showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis (UC) and Crohn&#8217;s disease (CD) that initially responded to the induction phase. RELIEVE UCCD LTE is a double-blind randomised study evaluating the long-term efficacy, safety, and tolerability of duvakitug in UC and CD. The efficacy data from the LTE study and from the previous RELIEVE UCCD phase 2b induction study (clinical study identifier&#58; NCT05499130) reinforce the therapeutic potential of duvakitug in UC and CD, which is under evaluation in phase 3 clinical studies. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i2b89cd564d0a430385a29245691cdcff"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">lunsekimig (IL13xTSLP Nanobody&#174; VHH) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Phase 2 studies of lunsekimig in two chronic respiratory diseases, moderate-to-severe asthma (AIRCULES phase 2b study&#59; clinical study identifier&#58; NCT06102005) and CRSwNP (DUET phase 2a proof-of-concept study&#59; clinical study identifier&#58; NCT06454240), met their primary and key secondary endpoints compared to placebo. The exploratory VELVET phase 2b study (clinical study identifier&#58; NCT06790121) did not meet its primary endpoint in moderate-to-severe atopic dermatitis. In all studies, lunsekimig was well tolerated. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i98f9fc2851c34b889b10fa7ca74bc290"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">frexalimab (CD40L monoclonal antibody) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FREXERA phase 2&#47;3 study of frexalimab in kidney transplantation (clinical study identifier&#58; NCT07412470) commenced dosing the first patient in March 2026. The study is testing whether frexalimab dosed subcutaneously (after an initial intravenous dose) combined with standard-of-care treatment can reduce the risk of rejection of the new kidney, help it last longer, and improve kidney function. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i49a50877d9ed480ba6003873fad3a1d8"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Rare diseases</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i3a1549c9d8f745cf8aeb915ce53fbaa2"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexviazyme (avalglucosidase alfa)  </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nexviazyme met its primary endpoint (participants alive and free of invasive ventilation) in treatment-naive infants aged zero to six months in the Baby-COMET phase 3 study (clinical study identifier&#58; NCT04910776).</font><font style="background-color:#ffffff;color:#171717;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, the study met all secondary endpoints. Sanofi intends to submit the data to support a regulatory application in the US for the treatment of infantile-onset Pompe disease. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ide46223086884130a7132887360abb8e"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wayrilz (rilzabrutinib)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June, the MHLW in Japan granted marketing and manufacturing authorization to Wayrilz for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is </font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">36</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">problematic. The approval is based on the LUNA 3 phase 3 study (clinical study identifier&#58; NCT04562766) in which Wayrilz met the primary and secondary endpoints, showing a positive impact on sustained platelet counts and other symptoms. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i7707c776cf064a38a73f129ce8134210"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Myqorzo (aficamten) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May, Cytokinetics, Sanofi&#8217;s licensor of Myqorzo in China, announced positive topline results from the ACACIA-HCM phase 3 study of Myqorzo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. In the study, all primary endpoints were met, statistically significant improvements in key secondary endpoints were obtained, and no new safety signals were identified. The results are expected to form the basis for a regulatory submission in China in 2027. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i0bdba2d803544c27bc81f99ffa28e66e"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Redemplo (plozasiran) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In China, Redemplo was granted a breakthrough designation in severe hypertriglyceridemia. Redemplo will be marketed in Greater China by Sanofi under an agreement with Arrowhead. In 2025, Sanofi purchased those rights from Visirna, a majority owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead&#8217;s cardiometabolic pipeline medicines in Greater China. Sanofi plans to initiate launch of Redemplo in the near future for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), a severe and rare disease leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i9428351cfc344eac98a6df16811c0f75"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">venglustat (oral glucosylceramide synthase inhibitor)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May, the FDA granted priority review to the new drug application (NDA) for venglustat for the treatment of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder. If approved, venglustat would become the first treatment available in the US to address the progressive neurological manifestations associated with GD3 and expand Sanofi&#8217;s portfolio of treatment options for patients living with lysosomal storage diseases. The target action date for the FDA decision is November 25, 2026. In Fabry disease, venglustat did not meet the primary endpoint in the PERIDOT and CARAT phase 3 studies (clinical study identifiers&#58; NCT05206773 and NCT05280548, respectively). The long-term extensions of the PERIDOT and CARAT studies are both continuing.  </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i55ae1dce56204102bdcbb39a3f71b732"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">efdoralprin alfa (alpha-1 antitrypsin fusion protein) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Data from the global ElevAATe phase 2 study (clinical study identifier&#58; NCT05856331) demonstrated superiority of efdoralprin alfa over standard-of-care therapy in achieving and maintaining normalized functional alpha-1 antitrypsin levels in adult patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema. Additional long-term safety and efficacy outcomes are being evaluated in the ElevAATe OLE phase&#160;2 study (clinical study identifier&#58; NCT05897424). Efdoralprin alfa is a recombinant protein distinct from plasma-derived therapy, which has been the standard-of-care for nearly 40 years. It has been granted fast track designation and orphan drug designation in the US and orphan designation in the EU. A first regulatory submission in the US is expected in the second half of 2026, depending on final regulatory feedback. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i28c59ddcd8ca450d84b45da19403a416"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Neurology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i9474e2f2df7b4e8f8c61f7f2820fa929"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cenrifki (tolebrutinib)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June, the EC approved Cenrifki for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. This approval followed the positive opinion by the EMA's CHMP and was based on the HERCULES phase 3 study (clinical study identifier&#58; NCT04411641) in non-relapsing SPMS (nrSPMS), with supporting data from GEMINI 1 and GEMINI 2 phase 3 studies in relapsing multiple sclerosis (clinical study identifiers&#58; NCT04410978 and NCT04410991, respectively). The HERCULES study demonstrated that Cenrifki significantly delayed the onset of disability progression in nrSPMS. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i21a9382d6aca47d595ff4becef48f143"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">riliprubart (C1s monoclonal antibody) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June, Sanofi announced discontinuation of the MOBILIZE phase 3 study (clinical study identifier&#58; NCT06290128) of riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment. This decision followed an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study was unlikely to provide sufficient efficacy. No safety signals related to riliprubart were identified as part of this interim analysis. The continuation of other ongoing studies with riliprubart, including the VITALIZE phase 3 study (clinical study identifier&#58; NCT06290141) in IVIg-treated patients with CIDP, has been evaluated accordingly. The VITALIZE study continues as planned.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i37eb7464275645ce81a4e0f23306768d"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Oncology</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ie1ff7495f1fa4f7f9e6d2e7bef335cfe"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarclisa (isatuximab)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The EC (in June) and the FDA (in July) approved subcutaneous (SC) Sarclisa &#47; Sarclisa Escena (the US product name) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications for Sarclisa intravenous (IV) formulation. Sarclisa&#47; Sarclisa Escena is the first anticancer therapy to be administered through an on-body injector (OBI) and the first MM treatment available by both SC OBI and manual administration in the EU and the US, thereby providing flexibility of administration at patients&#8217; homes and in an outpatient setting.</font><font style="background-color:#ffffff;color:#171717;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sarclisa &#47; Sarclisa Escena can be used in conjunction with Enable Injections&#8217; CirCLIQ OBI, enabling it to be delivered subcutaneously with the push of a button using a shorter, thinner retractable needle.  Sarclisa SC formulation in combination with approved standard-of-care regimens for the treatment of MM was also approved by the MHLW in Japan. A regulatory submission for Enable Injections&#8217; </font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">37</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CirCLIQ OBI is under review in Japan. An application for Sarclisa SC administered via manual injection is currently under review in China.  </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i48021e73c3b946008d729f59df3e307d"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="if2dc3554f3bf4fc68cb51c01db653e9a"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nuvaxovid (COVID-19)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi's protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV2705) demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE (mRNA-1283), Moderna's latest mRNA COVID-19 vaccine, across all pre-specified endpoints in the COMPARE study (clinical study identifier&#58; NCT07051031), which enrolled 1,000 adults in the US. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i7949c19fcf874195b1ec86fde732ccfa"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fluzone HD&#47;Efluelda (influenza) </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA and EMA accepted for review the regulatory submission of Fluzone high dose (HD)&#47;Efluelda for use in adults aged 50 years and above to prevent influenza. The regulatory submission follows positive results in the QHD00042 phase 3 study (clinical study identifier&#58; NCT06641180) reported in October 2025.  </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i69eb17a5021444ec89d279a544806a88_13"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i36a4b763c04c4844bc47ec5d3002ef69"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. Other significant events</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ie0cc2def74a449fd85207437705a2937"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.1 Corporate governance</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Combined General Shareholders&#8217; Meeting of Sanofi was held on April 29, 2026 at the Palais des Congr&#232;s in Paris, and was chaired by Fr&#233;d&#233;ric Oud&#233;a. All resolutions submitted to the vote were adopted by the shareholders. Decisions taken by the General Meeting included approving the individual company and consolidated financial statements for the year ended December 31, 2025, and distributing an ordinary annual dividend of &#8364;4.12 per share.</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font id="i0fba01269d704218b61c0737922821b6"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board of Directors</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s Board of Directors met on February 11, 2026, and decided not to renew Paul Hudson&#8217;s term of office as a director. Consequently, on February 18, 2026, Paul Hudson resigned from his position as a director, with immediate effect.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Combined General Shareholders&#8217; Meeting of Sanofi held on April 29, 2026 approved the reappointments of Jean-Paul Kress as an independent director and Christophe Babule as a director, and the appointments of Bel&#233;n Garijo as a director and Christel Heydemann as an independent director. Following the expiry of Patrick Kron&#8217;s term of office at the close of the Annual General Meeting of April 29, 2026, the Board of Directors now comprises 16 members, of whom eight are women and two are directors representing employees. The Board of Directors retains a large majority of independent directors.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Following the departure of Paul Hudson and Patrick Kron from the board of directors, and on the proposal of the Appointments, Governance and CSR Committee, the Board of Directors appointed Fr&#233;d&#233;ric Oud&#233;a as Chairman of the Appointments, Governance and CSR Committee&#59; Bel&#233;n Garijo as a member of the Strategy Committee&#59; and Christel Heydemann as a member of the Appointments, Governance and CSR Committee and the Compensation Committee.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ic658f269237a487ebf063699dd13494b"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Chief Executive Officer</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors relieved Paul Hudson of his duties as Chief Executive Officer effective end-of-day on February 17, 2026. Olivier Charmeil (Executive Vice-President, General Medicine), served as Interim Chief Executive Officer from February 18 until April 30, 2026.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board meeting held on April 29, 2026 confirmed the appointment of Bel&#233;n Garijo as Chief Executive Officer of Sanofi with effect from May 1, 2026.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i338ea7e6d1b04bbbbc527254e08dc522"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Committee</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2026, the Executive Committee's composition changed with&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the departure of Paul Hudson as Chief Executive Officer effective end-of-day on February 17, 2026, and the appointment of Bel&#233;n Garijo to succeed him, effective May 1, 2026&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the appointment of Manuela Buxo as Executive Vice President, Specialty Care, effective March 1, 2026. Manuela Buxo succeeded Brian Foard, who decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the departure of Natalie Bickford from her position as Executive Vice President, Chief People Officer on May 31, 2026. V&#233;ronique Jaillet is currently serving as interim Chief People Officer with effect from June 1, 2026.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 21, 2026 Sanofi announced an evolution of its Executive Committee, which effective September 1, 2026 will comprise&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Fran&#231;ois Roger, Executive Vice President, Finance&#59;</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">38</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Paulo Fontoura, Executive Vice President, Head of Research &#38; Development&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Manuela Buxo, Executive Vice President, Specialty Care&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Thomas Triomphe, Executive Vice President, Vaccines&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Thomas Grenier, Executive Vice President, General Medicines&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Brendan O&#8217;Callaghan, Executive Vice President, Manufacturing &#38; Supply&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Jamie Haney, Executive Vice President, General Counsel&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">V&#233;ronique Jaillet, Executive Vice President, Interim Chief People Officer.</font></div><div id="i69eb17a5021444ec89d279a544806a88_16"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i6718e738507544e3ac15e77eacbf881b"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.2. Legal and arbitration proceedings</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the most significant developments in legal and arbitration proceedings since publication of the financial statements for the year ended December 31, 2025, refer to Note B.14. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ib9d7fe1bac1649a98969750d5b53723a"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Investigations and Related Litigation</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the insulin-related antitrust suit brought on behalf of direct purchasers in Massachusetts Federal Court, trial is scheduled to begin in January 2027.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the complaint filed in 2024 by the Texas state court alleging violations of the Texas Medicaid Fraud Prevention Act (TMFPA), o</font><font style="color:#333333;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n February 13, 2026, the State of Texas filed its Petition in Intervention asserting a false certification theory of liability. Sanofi moved to disqualify one of relator's law firms with a hearing expected in August 2026. Discovery closes on January 15, 2027&#59; trial is scheduled for July 19, 2027 &#8212; both dates are subject to continuance pending the court's ruling on the disqualification motion.</font></div><div id="i69eb17a5021444ec89d279a544806a88_19"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i91298e52db2249b6bfb653265997c421"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3.3. Other events</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June 4, 2026, Sanofi announced the launch of Action 2026, a global employee share ownership plan open to around 75,000  employees in 52 countries. Now in its twelfth year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to ensuring that employees benefit from the company&#8217;s growth and success.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The shares were offered at a subscription price of &#8364;59.87, representing a 20% discount to the average of the 20 opening prices of Sanofi shares from May 6 to June 2, 2026. For every five shares subscribed, employees were entitled to receive one free share (up to a maximum of four free shares per employee). Every eligible employee was able to purchase up to 1,500 Sanofi shares, subject to the maximum legal limit set at 25% of their gross annual salary, minus any voluntary deductions already made under employee savings schemes such as the Company Savings Plan and&#47;or Group Savings Plan and&#47;or Group Retirement Savings Plan (PERCO) during 2026&#59; the above limit does not apply to voluntary contributions to the &#8220;PERCOL&#8221; retirement savings plan.</font></div><div id="i69eb17a5021444ec89d279a544806a88_22"></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">39</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="i4b97542e7c3a447db7283b089d134964"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">B&#47; Progress on implementation of the sustainability strategy</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ib880464b5135478c8cdedf3e752db713"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acoziborole positive opinion marks major step forward in sleeping sickness elimination</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The CHMP granted a positive opinion on acoziborole, a single-dose oral medicine administered as three tablets,</font><font style="color:#171717;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> positioning it as a significant advance in supporting the WHO goal of eliminating the disease by 2030</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s commitment &#8211; alongside its long-term partner Drugs for Neglected Diseases initiative, the WHO, and other global health players &#8211; has resulted in a 98% reduction in sleeping sickness cases since 2001. Sanofi will donate acoziborole to the WHO through its philanthropic arm, Sanofi Foundation, ensuring patients receive the treatment at no cost.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ia4ba0371416f46adaad9dd469185d627"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sanofi-supported study quantifies environmental and socio-economic factors exacerbating respiratory diseases</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s sustainability strategy is built on the ambition to tackle the link between environmental challenges, health, and healthcare. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A study supported by Sanofi, in partnership with Regeneron, analysed health data from over 710,000 asthma and COPD patients</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in France between 2018 and 2022, incorporating environmental and socio-economic indicators to identify risk and protective factors associated with respiratory disease exacerbation.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The study results show that the setting and living conditions directly influence the severity of respiratory diseases. Urban living increases the risk of exacerbations by 40% in people with asthma, by 53% in asthmatic children, and by 8% in people with COPD.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Conversely, certain natural environments, such as proximity to a forest or other green areas or bodies of water, reduce risk by 5% and 20%, respectively. The study also confirmed the central role of air pollution in the worsening of respiratory diseases. Other factors, such as tobacco use and extreme temperatures (increasingly frequent in the context of climate change), also increase the risk of exacerbations. Additionally, socio-economic inequalities compound environmental risks, with patients in high-poverty areas facing up to 36% higher exacerbation risk. </font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="id38e592b500d4c74825a3d22d8e0925a"></font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GHU progress on access and healthcare system strengthening</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s Global Health Unit (GHU) aims to provide access to a broad portfolio of medicines in countries with the highest unmet medical needs. To that end, the GHU offers Impact&#58; a not-for-profit brand of WHO-essential, standard-of-care medicines produced by Sanofi.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Impact medicines portfolio is now available in 30 countries</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and marks a significant step in expanding access to quality medicines in underserved regions globally. This milestone reflects the GHU's operational progress and supports the trajectory toward reaching two million patients with non-communicable diseases (NCDs) treatments by 2030.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The GHU is also strengthening healthcare systems across 40 underserved countries through strategic partnerships, reaching 6.6 million beneficiaries &#8211; of whom 6.5 million were screened for NCDs, 1.1 million diagnosed, and nearly 500,000 linked to care (medical tre</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">atment, monitoring, support services, etc.). In parallel, over 40,000 healthcare professionals and community health workers have been trained, and</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> more than 1,000 pharmacies, distributors, and clinics supported to improve supply chain efficiency.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i1d20c430b5bf4b81b5401bfeb49215da"></font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AccesS diabetes programme expands to South Africa and India</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi's AccesS Diabetes programme addresses potential barriers to diabetes care by providing patient support initiatives, capacity and capability building, and high-quality analogue insulin through partnerships with governments and stakeholders tailored to country-specific needs.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi signed two new memoranda of understanding in South Africa and India (State of Madhya Pradesh), marking a significant expansion of its diabetes access initiatives in regions with substantial unmet medical needs. In Madhya Pradesh, the program also aims to strengthen the infrastructure for diagnosis and treatment of rare diseases.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The AccesS Diabetes program has now been rolled out in Ghana, Nigeria (States of Delta and Kano), South Africa and India (State of Madhya Pradesh).</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i7878502bd92e4b4e88d8aa6704e4c7d0"></font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Democratic Republic of the Congo approves acoziborole&#58; the first single-dose treatment for sleeping sickness</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Building on the positive EMA opinion in the first quarter of 2026, the Democratic Republic of the Congo has approved acoziborole, a breakthrough single-dose oral treatment. Following successful clinical studies in the DRC and Guinea, this registration marks an important step forward in the fight against gambiense human African trypanosomiasis.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i44d5caecc25946368092a00b351e6240"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sustainability dashboard for the second quarter of 2026 </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Please refer to the sustainability dashboard provided as an appendix to the Sanofi second-quarter 2026 results press release. </font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Study conducted using data from the National Health Data System, specifically hospital data.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Through registration or import licenses.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">40</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_25"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="idca12ca630ac48208d46a50dc144c981"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">C&#47; Events subsequent to June 30, 2026</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main events related to research and development that occurred between the end of the reporting period and the date on which the condensed consolidated financial statements were reviewed by the Board of Directors are described in section 'A.2. Research and Development'.  No other significant events occurred during this period.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">41</font></div></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_28"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="if641367b54414bce9087edd77bd761e9"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">D&#47; Consolidated financial statements for the first half of 2026</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unless otherwise indicated, all financial data in this report are presented in accordance with international financial reporting standards (IFRS), including international accounting standards and interpretations (see Note A.1. to our condensed half-year consolidated financial statements). </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i46a36cba8fce46bb935f4d239da8fb83"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated income statements for the six months ended June 30, 2025 and&#160;June&#160;30,&#160;2026</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:46.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026    (6 months)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">as % of net sales</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025      (6 months)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">as % of net sales</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,438&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.5</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,452&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.3</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,155)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-27.8&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,881)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-29.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,389</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78.7</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,460</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">77.7</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,980)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.0&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,717)</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.7&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,792)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-21.7&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,506)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-22.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">800&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">533&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,436)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,476)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,087)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(777)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,031)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(563)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(430)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,168</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.3</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,759</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18.9</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(465)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,840</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12.8</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18.0</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(871)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(711)</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) from investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from continuing operations</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,971</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8.9</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,956</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.9</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income from discontinued operations</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,881&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.5</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,997</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9.0</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,837</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29.3</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,957</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8.9</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,812</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29.2</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,200.4&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205.5&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,230.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from continuing operations (&#8364;)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.61&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.40&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from discontinued operations (&#8364;) </font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.34&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.63&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.74&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from continuing operations (&#8364;)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.60&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.39&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from discontinued operations (&#8364;) </font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.33&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diluted earnings per share (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.62&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.72&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">42</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_31"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i47ade2376d62412daf8ace22184f9a17"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.1. Segment information</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ica91603d433848a0a6394eef8c79436e"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.1.1. Operating segments</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of the single operating segment is monitored individually using internal reports and common indicators. The operating segment disclosures required under IFRS 8 are provided in Note B.21. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The segment information presented by Sanofi consists of a single operating segment&#58; Biopharma.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines, and Vaccines franchises, plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella Healthcare SAS (Opella), which constitutes a related party with effect from April 30, 2025, the deconsolidation date, corresponding to the closing of Sanofi's sale of a controlling stake of approximately 50% in Opella to Clayton, Dubilier &#38; Rice (CD&#38;R). Those revenues, which before the deconsolidation date represented intragroup transactions classified within continuing operations, are presented within </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028&#59; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement)&#59; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i0201d59e7a4d4d0ca6c1d3737a50fdf9"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.1.2. Business operating income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We report segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of the operating segment and to allocate resources. For a definition of &#8220;Business operating income&#8221; refer to Note B.21.1. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is a non-IFRS financial measure and is reconciled with IFRS </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income.</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">  In the first half of 2026, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;3,168&#160;million, versus &#8364;3,759&#160;million in the first half of 2025, and our &#8220;Business operating income&#8221; amounted to &#8364;6,258&#160;million, versus &#8364;5,363&#160;million in the first half of 2025. The reconciliation between these two measures is presented in the table below.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business operating income&#8221; is not a standardized measure, it may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Although management uses this non-IFRS measure to set goals and measure performance, it has no standardized meaning prescribed by IFRS. This non-IFRS measure is presented solely to permit investors to more fully understand how Sanofi&#8217;s management assesses underlying performance. This non-IFRS measure is not, and should not be viewed as, a substitute for IFRS measures, and should be viewed in conjunction with IFRS measures of our performance and financial position. Consequently, there may be limitations on the usefulness of this measure to investors.</font></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:72.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8364; million</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026    (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025      (6 months)</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,168</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,759</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(563)</font></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(430)</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses resulting from acquisition-related impacts on inventories&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</font></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,031)</font></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,087)</font></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(777)</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;(e)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) from investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;(f)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(74)</font></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</font></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,258</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) See Note B.17. (&#8220;Other gains and losses, and litigation&#8221;) to the condensed half-year consolidated financial statements.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) See Note B.16. (&#8220;Restructuring costs and similar items&#8221;) to the condensed half-year consolidated financial statements.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026 relate to the Blueprint Medicines and Dynavax acquisitions.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;1,031&#160;million in the first half of 2026 mainly comprising a &#8364;952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly comprises impairment losses of &#8364;210 million linked to research and development projects.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e) Excluding restructuring costs and other adjusted items attributable to non-controlling interests.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f) Primarily joint ventures.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">43</font></div></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_34"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib25857fa92f84b67a5986ce630bb6243"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.2. Business net income (non-IFRS financial measure)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also presents &#8220;Business net income&#8221;, a non-IFRS financial measure which is not defined by accounting standards and is not included in the primary financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The IFRS measure most directly comparable to &#8220;Business net income&#8221; is </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which amounted to &#8364;1,957 million in the first half of 2026, versus &#8364;5,812&#160;million in the first half of 2025, representing a decrease of 66.3%. &#8220;Business net income&#8221; amounted to &#8364;4,765&#160;million in the first half of 2026, versus &#8364;4,152&#160;million in the first half of  2025, representing an increase of 14.8%. &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business net income&#8221; </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the first half of 2026 represents</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">21.6%</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of our net sales, compared with </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">20.9% of our net sales in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also report &#8220;Business earnings per share&#8221; (business EPS), a non-IFRS financial measure which we define as business net income divided by the weighted average number of shares outstanding. Business EPS was &#8364;3.97 for the first half of 2026 (up 17.1%) compared with the 2025 first-half figure of &#8364;3.39, based on an average number of shares outstanding of &#8364;1,200 million for the first half of 2026 and &#8364;1,225&#160;million for the first half of 2025. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We define &#8220;Business net income&#8221; as </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">determined under IFRS, excluding the following items&#58; </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income from discontinued operations, including Opella&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3), or to divestments of operations meeting the definition of a business&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">restructuring costs and similar items (presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other gains and losses (including gains and losses on major divestments), presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other costs and provisions related to litigation (presented within the line item </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">(income)&#47;expenses related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph&#160;B5.4.6 of IFRS&#160;9 (Financial Instruments)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits&#47;losses from investments accounted for using the equity method, except </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">to the extent that this relates (i)&#160;to joint ventures or (ii) to associates with which Sanofi has entered into R&#38;D agreements and&#47;or whose operations are managed as an integral part of Sanofi&#8217;s business activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the portion attributable to non-controlling interests of the items listed above.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to our &#8220;Business net income&#8221; &#58;</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">44</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi (IFRS)</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,957</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,812</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (income)&#47;loss from the discontinued Opella business </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,881)</font></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets </font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,087&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,031&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial (income)&#47;expenses relating to financial liabilities accounted for at amortized cost and subject to periodic remeasurement</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effects of the items listed above&#58;</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(423)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(384)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">amortization and impairment of intangible assets</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(198)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(173)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">expenses arising from the impact of acquisitions on inventories</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">tax effects of restructuring costs and similar items</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(89)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">other items</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(83)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other tax effects</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business net income (non-IFRS)</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="background-color:#e7e7e8;color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,765</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,152</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,200.4&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</font></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic earnings per share (IFRS) (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.63&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.74&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reconciling items per share (in euros) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.34&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.35)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business earnings per share (non-IFRS) (in euros)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.97&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.39&#160;</font></td><td style="border-bottom:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In 2026, this line mainly comprises the impact of the finalization of the Opella completion accounts as of April 30, 2025. In 2025, this line item includes &#8364;2,693&#160;million related to the net gain resulting from the sale of Opella at the date of loss of control (see Note B.1. to the 2025 consolidated financial statements as presented in Sanofi&#8217;s 2025 Half year report).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;1,031&#160;million in the first half of 2026 mainly comprising a &#8364;952 million impairment loss taken against the amlitelimab asset..For the six months ended June 30, 2025, this line mainly comprises impairment losses of &#8364;210 million linked to research and development projects.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) For the first half of 2026, Other gains and losses, and litigation represents a charge of &#8364;95 million mainly related to major litigation, compared with a charge of &#8364;57 m</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">illion in the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2025.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) This line item represents the financial expense arising from remeasurement of the liability recognized in the balance sheet for estimated future royalties payable on Beyfortus sales in the United States.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e) Other items include Sanofi&#8217;s share of losses from the associates EUROAPI and OPAL JV Co (Opella).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)  Represents the reconciliation between basic earnings per share (IFRS) and business earnings per share (non-IFRS)&#58; total reconciling items divided by the weighted average number of shares outstanding.</font></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The most significant reconciling items between &#8220;Business net income&#8221; and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> relate to&#160;(i)&#160;the purchase accounting effects of our acquisitions of groups of assets and business combinations, particularly the amortization and impairment of intangible assets (other than software and other rights of an industrial or operational nature)&#59; (ii)&#160;the impacts of restructuring actions or transactions regarded as non-recurring, where the amounts involved are particularly significant&#59; (iii)&#160;the remeasurements recognized through profit or loss in respect of (a)&#160;amounts receivable in respect of business divestments and accounted for at fair value, (b)&#160;liabilities arising from business combinations (IFRS&#160;3) and accounted for at fair value, (c)&#160;liabilities accounted for at amortized cost and subject to periodic remeasurement under IFRS&#160;9&#59; and (iv) the net income from discontinued operations, including Opella. We believe that excluding those impacts enhances an investor&#8217;s understanding of our underlying economic performance, because it gives a better representation of our recurring operating performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that eliminating charges related to purchase accounting effects (particularly amortization and impairment of some intangible assets) enhances comparability of our ongoing operating performance relative to our peers. Those intangible assets (principally rights relating to research and development, technology platforms and commercialization of products) are accounted for in accordance with IAS&#160;38 (Intangible Assets) and IFRS&#160;3 (Business Combinations).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also believe that eliminating the other effects of business combinations (such as the incremental cost of sales arising from the workdown of acquired inventories remeasured at fair value in business combinations) gives a better understanding of our recurring operating performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Eliminating restructuring costs and similar items enhances comparability with our peers because those costs are incurred in connection with reorganization and transformation Company&#8217;s programs, integration or separation as part of material deals.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that eliminating the effects of transactions that we regard as non-recurring and that involve particularly significant amounts (such as major gains and losses on disposals, and costs and provisions associated with major litigation and other major non-recurring items) improves comparability from one period to the next.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, remeasurements recognized in profit or loss during the period in respect of (i)&#160;assets or liabilities accounted for at fair value and recognized in the balance sheet in connection with business acquisitions or divestments or (ii)&#160;liabilities accounted for at amortized cost and subject to periodic remeasurement, generally determined on the basis of revised sales forecasts, are not reflective of our operating performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, &#8220;Business net income&#8221; excludes net income from the Opella discontinued operation, the results of which have been presented separately in the consolidated income statement since October 2024. Under IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations), a discontinued operation is defined as a component of an entity that has been disposed of or is classified as held for sale, and represents a separate major line of business. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With effect from October 2024, &#8220;Business net income&#8221; from continuing operations is used by management to measure Sanofi&#8217;s financial performance on an ongoing basis. We believe that providing a performance measure aligned with our management approach is useful for investors and analysts.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We remind investors, however, that &#8220;Business net income&#8221; should not be considered in isolation from, or as a substitute for, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reported in accordance with IFRS. In addition, we strongly encourage investors and potential investors not to rely on any single financial measure but to review our financial statements, including the notes thereto, carefully and in their entirety.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We compensate for the material limitations described above by using &#8220;Business net income&#8221; only to supplement our IFRS financial reporting and by ensuring that our disclosures provide sufficient information for a full understanding of all adjustments included in&#160;&#8220;Business net income.&#8221;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business net income&#8221; and &#8220;Business EPS&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures.</font></div><div id="i69eb17a5021444ec89d279a544806a88_37"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ieddb6518fd23417e8d60e34c8eaf41ce"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.3. Net sales</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales for the first half of 2026 amounted to &#8364;22,106&#160;million, 11.1% higher at published exchange rates than in the first half of 2025. Exchange rate fluctuations had a negative effect of 4.6 percentage points overall, due mainly to adverse trends in the euro exchange rate against the US dollar. At constant exchange rates (CER, see definition below), net sales rose by 15.7%, driven mainly by strong performances for Dupixent, Ayvakit and ALTUVIIIO. Divestments and medicines&#47;portfolio streamlining had a negative impact of 0.4 percentage points on sales growth.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="if90c924faea2483cbb9cf6fb33ad62c9"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of net sales (IFRS) to net sales at constant exchange&#160;rates (non-IFRS)</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of exchange rates</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(905)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales at constant exchange rates</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,011</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+15.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When we refer to changes in our net sales at constant exchange rates (CER), that means we have excluded the effect of exchange rates by recalculating net sales for the relevant period using the exchange rates that were used for the previous period, with the exception of countries treated as hyperinflationary economies under IAS 29 (i.e. Argentina and Turkey, see Note A.4 to our condensed half-year consolidated financial statements).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i652252f1ddf24a738edf1e1072ad8321"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.1. Net sales by segment</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our net sales comprise the net sales generated by our Biopharma segment.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.737%"><tr><td style="width:1.0%"></td><td style="width:43.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change on<br>a reported<br>basis</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change at<br>constant<br>exchange rates</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma segment</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+15.7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.1</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+15.7</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">46</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i680c5715595846179940337e6e81a9df"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.2. Net sales by medicine, vaccine and geography</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales by main product and geographical region break down as follows&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.020%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total sales</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (reported)</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of the&#160;world</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,324&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.5</font></td><td style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+34.4</font></td><td style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,922&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+39.5</font></td><td style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,146&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.9</font></td><td style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,256&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20.8</font></td><td style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kevzara</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.9</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+28.6</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+45.7</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.8</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-20.7</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALTUVIIIO (*)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">674&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+24.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+32.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">576&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+34.4&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+20.9&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fabrazyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">523&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-0.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+4.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+4.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+2.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+4.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">426&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+10.1&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+15.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+15.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Ayvakit (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">367&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">352&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-3.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-1.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+1.1&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-8.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Alprolix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">282&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-1.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">215&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+7.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Myozyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">220&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-20.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-18.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-9.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-36.1&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-6.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">183&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+10.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+21.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+7.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cablivi (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+12.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+16.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+29.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+5.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-20.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aldurazyme</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-9.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+2.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-19.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">142&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+5.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+12.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-14.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+81.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xenpozyme (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">127&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+15.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+18.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+6.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+89.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Wayrilz (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Qfitlia (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+1100.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+1200.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+1200.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Myqorzo (*)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sarclisa (*)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">354&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+28.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+33.0&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">132&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+17.6&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+30.1&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+60.8&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Jevtana</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-3.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+4.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-6.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+45.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">813&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.2&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-3.8&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">344&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-6.6&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">146&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-2.7&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">323&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-0.9&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Toujeo</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">729&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+5.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+7.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+14.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">259&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+3.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">336&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+7.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">440&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-4.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-9.1&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">398&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-4.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">364&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-18.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-19.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-44.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-19.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-17.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">317&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+18.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+18.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">265&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+25.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-8.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Rezurock (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+12.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+18.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">218&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+5.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+60.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+110.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">257&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+3.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+8.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+7.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-4.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">80&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+13.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aprovel</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">218&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+2.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+4.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-66.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-5.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+7.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Soliqua&#47;iGlarLixi</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+21.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+24.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+27.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-3.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Multaq</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">151&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-5.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+0.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+1.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-10.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Apidra</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+1.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-60.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-3.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+8.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Synvisc</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-18.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-16.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-37.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tzield (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+27.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+34.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+25.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+300.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,700&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-13.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-11.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">162&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-29.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">514&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-13.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,024&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Industrial sales</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">190&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-24.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-21.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+700.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">181&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-22.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-88.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Polio&#47;pertussis&#47;Hib primary vaccines <br>and boosters, incl. Heplisav-B (*)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,364&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+0.2&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+2.8&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">487&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+61.3&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">206&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.6&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">671&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-17.2&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Meningitis, travel, and endemic vaccines</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">565&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-7.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-3.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">268&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-11.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">118&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+22.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-5.7&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus) (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">392&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+10.1&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+13.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+2.9&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+2.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">240&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+21.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Influenza, COVID-19 vaccines (*)</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-43.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-42.1&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-64.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-34.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">-34.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.1</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+15.7</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,633</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+29.9</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,304</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+3.6</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,169</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+1.9</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which launches (*)</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,047</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45.1</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51.8</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,891</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+66.9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">546</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+29.6</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">610</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+33.2</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">47</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="idb1718764d3e489884bbafbdf8edb561"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.3. Biopharma segment </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2026, revenue from the Biopharma business (see &#8220;Chapter D.1. Segment Information&#8221; for detailed segment information) was &#8364;22,106 million, up 11.1% on a reported basis and 15.7% at constant exchange rates (CER), driven by Dupixent and new launches.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Comments on the performances of our major Biopharma segment products are provided below.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i02ec421b823e4d0e8abd3a900cac7c98"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunology</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRcNP), eosinophilic esophagitis, nodular prurigo (NP), chronic spontaneous urticaria (CSU), chronic obstructive pulmonary disease (COPD), bullous pemphigoid and allergic fungal rhinosinusitis (AFRS)) generated net sales of &#8364;9,324 million in the first half of 2026, up 27.5% on a reported basis and 34.4% CER. This growth was driven by strong volume increases across all approved indications, with Dupixent maintaining a leading market position in all its therapeutic indications. In the United States, sales of Dupixent reached &#8364;6,922 million in the first half of 2026, up 39.5% CER, driven primarily by strong demand as well as operational improvements and a favorable change in estimated gross-to-net deductions. In Europe, the product&#8217;s net sales for the first half of 2026 totaled &#8364;1,146 million, up 20.9% CER, reflecting continued momentum in all approved indications and consistent performances in the larger markets, including Germany. In the Rest of the World region, Dupixent posted net sales of &#8364;1,256 million (+20.8% CER), mainly supported by Brazil and Canada.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Kevzara</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (rheumatoid arthritis, other rheumatological indications) amounted to &#8364;301 million, representing an increase of 28.6% CER. The majority of sales (&#8364;207 million) was generated in the United States (+45.7% CER), mainly due to increased use in the treatment of polymyalgia rheumatica, an indication approved in 2024.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i3b663c615f3c4ceeade194c7022714cf"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rare diseases</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(hemophilia A) generated sales of &#8364;674 million in the first half of 2026, with 85.5% of those sales coming from the United States. This performance reflects the transition of patients away from conventional short-acting factor replacement therapies, and to a lesser extent from other non-factor medicines. Sales in the Rest of the World region totaled &#8364;98 million, benefiting from launches in Japan and Taiwan. Sales of the factor replacement drug franchise for the treatment of hemophilia A (ALTUVIIIO and Eloctate combined) reached &#8364;816 million (+28.4% CER compared with the first half of 2025), driven primarily by the sustained commercial performance of ALTUVIIIO and geographical launches. </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Eloctate</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> generated &#8364;142 million in revenue in the first half of 2026, up 12.6% CER, reflecting the transition of patients to ALTUVIIIO.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of the Fabry disease treatment </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fabrazyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;523 million in the first half of 2026 (+4.0% CER), mainly from increased patient use and price increases in the United States.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Nexviazyme&#47;Nexviadyme </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(Pompe disease) generated revenue of &#8364;426 million, up 14.5% CER, driven by 15.2% CER growth in Europe, where the transition of patients from Myozyme&#47;Lumizyme continues. In the United States, growth reached 15.4% CER, with most patients having already made this transition. Sales of the Pompe disease franchise (Nexviazyme&#47;Nexviadyme and Myozyme&#47;Lumizyme) totaled &#8364;646 million, up 0.9% CER, with Nexviazyme&#47;Nexviadyme now representing 65.9% of the franchise's revenue.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Ayvakit</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (systemic mastocytosis) totaled &#8364;367 million. These sales were mainly distributed across the United States (&#8364;322&#160;million) and Europe (&#8364;44 million), with continued growth in the number of patients treated and their duration of treatment. The integration of Blueprint into Sanofi resulted in increased rebates granted to public authorities in the United States, negatively impacting sales. Without these increased rebates in the United States, revenue growth would have been approximately nine percentage points higher. Royalties on sales by CStone Pharmaceuticals in China are recorded in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cerezyme </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">decreased by 1.7% CER to &#8364;352 million. Growth in Europe (+5.0% CER) and the United States (+1.1% CER) was offset by lower sales in the Rest of the World region (-8.5% CER). Sales for the Gaucher disease franchise (Cerezyme and Cerdelga combined) amounted to &#8364;535 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2026, sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Alprolix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;282 million, down 1.6% CER, driven by a decline in the United States (-4.2%) offset by higher sales in the Rest of the World region (which includes sales of supplies to Sanofi&#8217;s collaboration partner Sobi).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Myozyme&#47;Lumizyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> decreased by 18.2% CER in the first half of 2026 to &#8364;220 million, due to the ongoing shift to Nexviazyme&#47;Nexviadyme as mentioned above.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cablivi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(acquired thrombotic thrombocytopenic purpura) reached &#8364;153 million (+16.2% CER) in the first half of the year, driven by an increase in the number of patients treated in the United States (where sales rose by 29.6% CER) and Europe (+5.5 % CER). In the Rest of the World region, sales totaled &#8364;8 million (-20.0% CER).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Xenpozyme</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (acid sphingomyelinase deficiency) increased to &#8364;127 million in the first half, up 18.2% CER, mainly driven by the Rest of the World region (+89.5% CER).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Wayrilz</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (immune thrombocytopenia) amounted to &#8364;27 million, exclusively in the United States, following the marketing approval obtained in August 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Qfitlia </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(hemophilia A and B) reached &#8364;12 million, exclusively in the United States, the treatment having been approved in March 2025.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">48</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Myqorzo</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (hypertrophic obstructive cardiomyopathy) amounted to &#8364;3 million, entirely in China, following the marketing authorization obtained in January 2026.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">rovadicitinib</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (myelofibrosis, no brand name in English) launched in China during the second quarter with sales anticipated to be reported from Q3 2026 results.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i687c66c10eaa4bc2bd2a69ff0ff9e8fb"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other main medicines</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Lantus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;813 million (-3.8% CER) in the first half of 2026. In the United States, sales were down 6.6% CER. Revenue declined by 2.7 % CER in Europe, and by 0.9 % CER in the Rest of the World region owing to the strategy of switching to Toujeo.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Toujeo</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales rose by 7.5% CER to &#8364;729 million, driven by the United States (+14.3%) and Europe (+3.6%). Toujeo continues to benefit from strong volume growth and increasing market share worldwide.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Plavix</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were down 4.4% CER at &#8364;440 million, reflecting a decline in the Rest of the World region, which represents the bulk of sales (&#8364;398 million, -4.0 % CER).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Lovenox</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales decreased by 19.2% CER to &#8364;364 million, reflecting the sustained impact of biosimilars.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Sarclisa </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(multiple myeloma) increased to &#8364;354 million (+33.0% CER), supported by strong growth in Europe (+30.1% CER), largely fuelled by expanded use among newly diagnosed patients, and in the Rest of the World region (+60.8% CER), which benefited from reimbursement and favorable commercial contracts.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2026</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">, Praluent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales increased by 18.4% CER to &#8364;317 million, reflecting higher sales in Europe (+25.8% CER), partially offset by a decline in the Rest of the World region (-8.6% CER).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rezurock</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (chronic graft-versus-host disease, third-line) sales increased to &#8364;296 million in the first half of the year, up 18.3% CER. This growth was driven by a strong performance in the Rest of the World region (+110.0% CER, primarily in China), while the United States recorded growth of 5.5% CER and Europe 60.9% CER, benefitting from the conditional marketing authorization granted by the European Commission on March 31, 2026.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Thymoglobulin </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">sales rose by 8.5% CER to &#8364;257 million, primarily due to higher sales in the Rest of the World region, mainly in China.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Aprovel</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were relatively stable at &#8364;218 million (+4.2% CER), mainly generated in the Rest of the World region (&#8364;184 million, +7.5% CER).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Tzield&#47;Teizeild</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (type 1 diabetes) reached &#8364;37 million (+34.5% CER), of which &#8364;32 million were generated in the United States (up 25.9% CER). Launches have begun in Europe (&#8364;4 million) and the Rest of the World region (&#8364;1&#160;million). Over 1,000 patients have now received treatment with Tzield&#47;Teizeild.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i214762018fca4f59b4439d051157e427"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaccines</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2026, Vaccines sales were down 3.8% on a reported basis and down 1.1% CER at &#8364;2,443 million, due mainly  to lower sales of influenza and meningitis, travel, and endemic vaccines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Polio&#47;pertussis&#47;Hib primary vaccines and boosters, including Heplisav-B</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> rose by 2.8% CER to &#8364;1,364 million. Sales in the United States (&#8364;487 million, +61.3% CER) increased thanks to the inclusion of newly acquired Heplisav-B to the portfolio. In the Rest of the World region (&#8364;671 million), sales were down 17.2% CER, impacted by a decline in childbirths (mostly in China).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Meningitis, Travel and Endemics Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales decreased by 3.9% CER to &#8364;565 million, with a decline in sales in the United States (&#8364;268 million, -11.0% CER) partially offset by the performance achieved in Europe (&#8364;118 million, +22.9% CER).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Beyfortus</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales reached &#8364;392 million, up 13.2% CER. The moderate increase in US sales (+2.9% CER) was due to a high comparative base resulting from increased inventory levels in the first half of 2025, as well as competitive pressure. Sales in Europe (+2.4% CER ) and the Rest of the World region (+21.2% CER) benefited from ongoing geographical expansion of infant protection, with Beyfortus now protecting infants in more than 45 countries.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of</font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Influenza and COVID-19 Vaccines</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;121 million, down 42.1% CER, mainly due to one-offs from late-season immunizations in the US and Europe and lower sales in the Southern Hemisphere, with sales in the Rest of the World region down  34.3% CER at &#8364;72 million.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">49</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ie8abe044517249d49fa3d3edce207fae"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.4. Net sales by geographical region</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:41.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change on a reported basis</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change at constant exchange rates </font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,633</font></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,535</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+22.0</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+29.9</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,304</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.9</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.6</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,169</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,210</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.7</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.9</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,325</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,388</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.5</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.5</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</font></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</font></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.1</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+15.7</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2026, net sales in the </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">United States</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;11,633 million, up 22.0% on a reported basis and 29.9% at constant exchange rates, driven by strong growth for Dupixent and pharma launches. Vaccines sales also posted a substantial increase, of 16.8% CER, driven by strong growth in Polio&#47;pertussis&#47;Hib primary vaccines and boosters, including Heplisav-B.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Europe</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, 2026 first-half net sales rose by 3.9% on a reported basis and 3.6% at constant exchange rates, to &#8364;4,304&#160;million. Growth was driven by Dupixent and launches, partially offset by lower sales of other main medicines.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the </font><font style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rest of the World region</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, first-half net sales were down 0.7% on a reported basis but up 1.9% at constant exchange rates at &#8364;6,169 million. Sales were boosted by Dupixent, which returned to growth after a price adjustment in 2025, and by the three drugs launched in China (Rezurock, Sarclisa, and Myqorzo). This was more than offset by declining sales of established drugs (particularly Plavix) and a marked drop in sales of PPH vaccines due to the decrease in the birth rate in China.</font></div><div id="i69eb17a5021444ec89d279a544806a88_40"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib5862ef303244d53a51f59e36f1e0e37"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.4. Other income statement items</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i2600eb04a4fb47a9ac504a90c3540b42"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.1. Other revenues</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> decreased by 1.0% to &#8364;1,438&#160;million in the first half of 2026 (versus &#8364;1,452&#160;million in the first half of 2025).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> line item includes VaxServe sales of non-Sanofi vaccines, amounting to &#8364;746 million (versus &#8364;842&#160;million in 2025).  In addition, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> included manufacturing and other services (&#8364;271 million)&#59; sales of Opella consumer health products in certain markets (&#8364;270 million)&#59; royalties (&#8364;91 million), and sales of supplies to Opella, etc. (&#8364;60 million).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i35a4c07c3cb445a9be0c9aa923609abc"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.2. Gross profit</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Gross profit</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2026 was &#8364;17,389 million, versus &#8364;15,460 million for the first half of 2025, a rise of 12.5%. </font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This increase includes a </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;210 million</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amortization charge arising from the remeasurement of inventories relating to the Blueprint and Dynavax acquisitions and reported within </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. This was partially offset by reversals of past provisions for pre-launch inventories amounting to over &#8364;200 million, following regulatory approval of Sarclisa SC.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross margin (the ratio of gross profit to net sales) also increased, reaching 78.7% in the first half of 2026 (versus 77.7% in the first half of 2025).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the business gross profit was &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">17,599 million</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and increased by </font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">13.8%</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> from &#8364;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">15,460 million</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Business gross profit is a non-IFRS indicator that fully excludes from </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">gross profit</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> under IFRS the effect of the release of the fair value step-up to inventory that is recognised upon acquisition, amounting to &#8364;210 million for the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026</font><font style="color:#5c5c5c;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and nil for the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025 (please refer to D.2. reconciling </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">to &#8220;Business net income&#8221;).</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ie2c35714acd7466dbd7aca3f7fe4d3f6"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.3. Research and development expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (R&#38;D expenses) in the first half of 2026 totaled &#8364;3,980&#160;million, versus &#8364;3,717&#160;million in the first half of 2025, a year-on-year increase of 7.1%. The increase includes more than &#8364;200 million of wind-down costs from decisions made on the pipeline.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">R&#38;D expenses represented 18.0% of net sales, compared with 18.7% in the first half of 2025.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i7917962942a6421a83a60b60f9f8c7bc"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.4. Selling and general expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;4,792 million in the first half of 2026 (21.7%&#160;of net sales), versus &#8364;4,506&#160;million in the first half of 2025 (22.7% of net sales). The year-on-year increase of 6.3% was elevated by the consolidation of recent acquisitions&#58; Blueprint (July 2025) and Dynavax (February 2026). </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ratio of selling and general expenses to net sales was 1.0 percentage point lower than in the first half of 2025.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">50</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ia5b51e3335ab444a85e8210c11640ff0"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.5. Other operating income and expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;800 million in the first half of 2026 (versus &#8364;533 million in the first half of 2025), and </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;3,436 million (versus &#8364;2,476 million in the first half of 2025). Overall, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income and expenses</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net expense of &#8364;2,636 million in the first half of 2026, compared with a net expense of &#8364;1,943 million in the first half of 2025, as shown in the table below.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net gains &#47; (losses) on disposals of operating assets or businesses</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amvuttra licensing income</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating income</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">800</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">533</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regeneron alliance&#58;</font></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(i) (Profit)&#47;loss sharing</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,486)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,475)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(ii) Additional profit share for development cost from Regeneron</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">494&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(iii) Selling expense reimbursements to Regeneron</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(336)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(346)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(149)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #330e74;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating expenses</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,436)</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,476)</font></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ib7802990189c4810a4f0becd0723868b"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.6. Amortization of intangible assets</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization charged against intangible assets in the first half of 2026 amounted to &#8364;1,087 million, versus &#8364;777 million in the first half of 2025. The increase is mainly related to amortization of intangible assets recognized in the first half of 2026 following the Blueprint and Dynavax acquisitions. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ic06add33ef5c47e990bfe5be237f5c1b"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.7. Impairment of intangible assets</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The monitoring of impairment indicators for other intangible assets (excluding software) led to the recognition of impairment losses of &#8364;1,031&#160;million in the first half of 2026, mainly comprising a &#8364;952&#160;million impairment loss taken against the amlitelimab asset, corresponding to the entire carrying amount of this intangible asset.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ic397d5a942474b2d9595f82815500489"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.8. Fair value remeasurement of contingent consideration</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Fair value remeasurements of contingent consideration assets and liabilities relating to business combinations (recognized in accordance with IFRS 3) represented a net expense of &#8364;37 million in the first half of 2026, versus a net expense of &#8364;61 million in the first half of 2025. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i37a022b88e554407a4e5c90b354d1f75"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.9. Restructuring costs and similar items</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to a charge of &#8364;563&#160;million in the first half of 2026, compared with a charge of &#8364;430&#160;million in the first half of 2025. The charge recognized in the first half 2026 mainly includes &#8364;284 million of employee-related expenses (compared with an expense of &#8364;201 million for the first half of 2025) and &#8364;179 million of charges, gains or losses on assets (compared with an expense of &#8364;109 million for the first half of 2025).  </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i84a4cfea68424dc5aacde435b7a5bcbb"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.10. Other gains and losses, and litigation</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2026, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represents a charge of &#8364;95 million mainly related to major litigation, compared with a charge of &#8364;57 m</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">illion in the first half of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i18a9c6769982496dad6c053cf99848dd"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.11. Operating income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;3,168 million in the first half of 2026, versus &#8364;3,759 million in the first half of 2025. The year-on-year change was mainly due to the increase in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ifbcc91d7f7da466ea850d9f7d00ccf42"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.12. Financial income and expenses</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net financial expenses were &#8364;328 million in the first half of 2026, &#8364;151 million higher than the 2025 first-half figure of &#8364;177 million. The 2026 first-half figure includes a financial expense of &#8364;146 million (&#8364;50 million for the first half of 2025) arising from the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United States.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our cost of net debt (see&#160;the definition in Section D.7., &#8220;Consolidated balance sheet&#8221; below) was &#8364;135 million in the first half of 2026, compared with &#8364;57 million in the first half of 2025.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">51</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="iafbdfbf717d246948bc5cc0ad950e2b1"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.13. Income before tax and investments accounted for using the equity method</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2026 was &#8364;2,840&#160;million, versus &#8364;3,582&#160;million for the first half of 2025. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ife441c70d9b04ff2917d0740bcff7f67"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.14. Income tax expense</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> totaled &#8364;871 million in the first half of 2026, versus &#8364;711 million in the first half of 2025, giving an effective tax rate (based on consolidated net income) of 30.6%, versus 19.8% in the first half of 2025. The increase in the effective tax rate was mainly due to the non-deductibility of current year impairment losses taken against the amlitelimab intangible asset.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The effective tax rate on our &#8220;Business net income&#8221;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a non-IFRS financial measure. It is calculated on the basis of business operating income, minus net financial expenses and before (i) the share of profit&#47;loss from investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. We believe the presentation of this measure, used by our management, is also useful for investors as it provides a means of analyzing the effective tax cost of our current business activities. It should not be seen as a substitute for the effective tax rate based on consolidated net income. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When calculated on business net income, our effective tax rate was 21.8% in the first half of 2026, compared with 21.0% in the first half of 2025 and 19.9% for 2025 as a whole. The main factors include (i) movements in deferred tax assets related to the amlitelimab intangible asset and (ii) the year-on-year change arising from the full effects of the 2026 portion of the temporary exceptional surcharge in France based on 2025 taxable profits.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i5c473601087c4d658b9813e9e6b61dc3"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.15. Share of profit&#47;(loss) from investments accounted for using the equity method</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit&#47;(loss) from investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed net income of &#8364;2 million&#160;for the first half of 2026 (including a net loss of &#8364;39 million for Sanofi&#8217;s share of losses from the associate OPAL JV Co), versus net income of &#8364;85 million for the first half of 2025 (including net income of &#8364;11&#160;million for Sanofi&#8217;s share of profits from the associate OPAL JV Co for the period from May&#160;1, 2025 through June 30, 2025). </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i0ab16439afab4cea912cb07c43a1f66f"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.16. Net income from continuing operations</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from continuing operations </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;1,971&#160;million in the first half of 2026, compared with &#8364;2,956&#160;million in the first half of 2025.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ie192f461c828426ba972aa983eb89935"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.17. Net income from discontinued operations</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the first half of 2026, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;26 million, mainly comprising the impact of the finalization of the Opella completion accounts, versus &#8364;2,881&#160;million in the first half of 2025. The 2025 first-half figure included (i) the net income of Opella until the date of loss of control and (ii) a net gain of &#8364;2,693&#160;million resulting from the divestment of Opella as of the date of loss of control.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i9255c6327b754e2ab92c343fd6c97ed9"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.18. Net income</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;1,997&#160;million in the first half of 2026, versus &#8364;5,837&#160;million in the first half of 2025&#59; the 2025 first-half figure included the &#8364;2,693&#160;million gain on the divestment of Opella.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i755a28ea35e241f5987edd278a526bad"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.19. Net income attributable to non-controlling interests</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to non-controlling interests</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the first half of 2026 was &#8364;40&#160;million, against &#8364;25 million for the first half of 2025. </font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ifd2b0ed135eb44ab87f4b868a17032c7"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4.20. Net income attributable to equity holders of Sanofi</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;1,957&#160;million in the first half of 2026, versus &#8364;5,812&#160;million in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) was &#8364;1.63, compared with &#8364;4.74 for the first half of 2025, based on an average number of shares outstanding of 1,200.4&#160;million for the first half of 2026 and 1,225.5&#160;million for the first half of 2025. Diluted earnings per share was &#8364;1.62, versus &#8364;4.72 for the first half of 2025, based on an average number of shares after dilution of 1,205.5&#160;million for the first half of 2026 and 1,230.7&#160;million for the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i69eb17a5021444ec89d279a544806a88_43"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i1f754fe34d764ad78b2ed7a1322c7144"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.5. Segment results</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the Biopharma segment, business operating income (see definition and details in note B.21.1 to the condensed half-year consolidated financial statements) amounted to &#8364;6,258 million in the first half of 2026, compared with &#8364;5,363 million in the first half of 2025, an increase of 16.7%. It represents 28.3% of sales, compared with 27.0% in the first half of 2025.</font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> See definition in section D.2., &#8220;Business net income&#8221;.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">52</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_46"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ia734f362626b4ccaada9973568fea063"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.6. Consolidated statements of cash flows</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Summarized consolidated statements of cash flows&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million) </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing operating activities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,643&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,367&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) operating activities of the discontinued Opella business</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,643</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,555</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing investing activities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,423)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,979)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) investing activities of the discontinued Opella business</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash inflow&#47;(outflow) from the Opella transaction </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(220)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,742&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) investing activities</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,643)</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,727</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) continuing financing activities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,332)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,441)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) financing activities of the discontinued Opella business</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) financing activities</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,332)</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,489)</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of exchange rates on cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;letter-spacing:-0.01em;line-height:100%">Cash and cash equivalents reclassified as &#8220;Assets held for sale&#8221; as of December 31, 2024</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,313)</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,918</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,663</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,441</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,350</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,359</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Opella's cash flows are presented separately in accordance with IFRS 5 (Non-current Assets Held for Sale and Discontinued Operations).</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) For the six months ended June 30, 2025, this amount includes &#8364;(667) million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Includes the impact of the IFRS 9 amendment relating to the classification of financial instruments applicable from January 1, 2026.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) continuing operating activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash inflow of &#8364;4,643&#160;million in the first half of 2026, against &#8364;3,367&#160;million in the first half of 2025. This increase was mainly driven by a higher level of operating cash flow before changes in working capital (&#8364;5,233&#160;million in the first half of 2026 versus &#8364;3,980&#160;million in the first half of 2025).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Working capital requirements decreased by &#8364;590&#160;million in the first half of 2026, versus a decrease of &#8364;613&#160;million in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) continuing investing activities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">represented a net cash outflow of &#8364;2,423&#160;million in the first half of 2026. The principal cash outflow in the first half of 2026 was the &#8364;1,403 million arising from the acquisition of Dynavax (see Note B.1.1.). That compares with a net cash outflow of &#8364;1,979&#160;million in the first half of 2025, including the impact of the acquisition of Dren-0201, Inc. for &#8364;539 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of property, plant and equipment and intangible assets totaled &#8364;1,296 million, versus &#8364;1,420 million in the first half of 2025. There were &#8364;882 million of acquisitions of property, plant and equipment (versus &#8364;845&#160;million in the first half of 2025), corresponding primarily to investments in industrial facilities. Acquisitions of intangible assets (&#8364;414&#160;million, versus &#8364;575&#160;million in the first half of 2025) mainly comprised contractual payments for intangible rights, primarily under license and collaboration agreements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proceeds from disposals net of tax (excluding disposals of consolidated entities and investments accounted for using the equity method) amounted to &#8364;424&#160;million in the first half of 2026, compared with &#8364;434 million for the first half of 2025, and related mainly to divestments of assets and operations relating to portfolio streamlining and to disposals of equity and debt instruments.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) continuing financing activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash outflow of &#8364;3,332 million in the first half of 2026, compared with a net outflow of &#8364;4,441&#160;million in the first half of 2025. The 2026 first-half figure includes (i) the dividend payout to our shareholders of &#8364;4,923&#160;million (versus &#8364;4,772&#160;million in the first half of&#160;2025)&#59; (ii) &#8364;2,607 million of net external debt contracted (versus net external debt contracted of &#8364;4,332 million in the first half of&#160;2025)&#59; and (iii) movements in Sanofi&#8217;s share capital, including purchases of treasury shares and the related tax effects of &#8364;1,009 million, versus &#8364;4,003 million in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net cash flows from the Opella transaction represented a net cash outflow of &#8364;220 million in the first half of 2026, versus a net cash inflow of &#8364;10,742 million in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> net change in cash and cash equivalents</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the first half of 2026 was a decrease of &#8364;1,313&#160;million, compared with an increase of &#8364;7,918&#160;million in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">53</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Free cash flow&#8221; is a non-IFRS financial measure which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from the Company&#8217;s operations that is available for strategic investments</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (net of divestments</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), for debt repayment, and for payments to shareholders. &#8220;Free cash flow&#8221; is determined from business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> after adding back (in the case of expenses and losses) or deducting (in the case of income and gains) the following items&#58; depreciation, amortization and impairment, share of undistributed earnings from investments accounted for using the equity method, gains &#38; losses on disposals of non-current assets, net change in provisions (including pensions and other post-employment benefits), deferred taxes, share-based payment expense and other non-cash items. It also includes net changes in working capital, capital expenditures and other asset acquisitions</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> net of disposal proceeds</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and payments related to restructuring and similar items. &#8220;Free cash flow&#8221; is not defined by IFRS, and is not a substitute for </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) operating activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as reported under IFRS. Management recognizes that the term &#8220;Free cash flow&#8221; may be interpreted differently by other companies and under different circumstances. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth a reconciliation between</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Net cash provided by&#47;(used in) operating activities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and &#8220;Free cash flow&#8221;&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.044%"><tr><td style="width:1.0%"></td><td style="width:69.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026       (6 months)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025       (6 months)</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,643</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,555</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by&#47;(used in) operating activities of the discontinued Opella business</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(188)</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(967)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(873)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of intangible assets, equity interests and other non-current financial assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(534)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(986)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">361&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">434&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of lease liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(147)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(124)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">640&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Free cash flow (non-IFRS) </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,724</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,458</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Most directly comparable IFRS measure to free cash flow.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Not exceeding a cap of &#8364;500 million per transaction.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) This line item includes cash outflows from major litigation not included in &#8220;Free cash flow&#8221;, in particular Plavix Hawaii in 2025.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Non-IFRS financial measure (see&#160;definition above).</font></div><div id="i69eb17a5021444ec89d279a544806a88_49"></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i12a508959e4b4a61b2f8bdf364537eee"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.7. Consolidated balance sheet</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets were &#8364;129,060&#160;million as of June&#160;30, 2026, versus &#8364;126,805 million as of December 31, 2025, representing an increase of &#8364;2,255 million. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net debt</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;15,513 million as of June&#160;30, 2026, versus &#8364;11,008 million as of December&#160;31, 2025. We believe the presentation of this non-IFRS financial measure, which is reviewed by our management, provides useful information to measure our overall liquidity and capital resources. We define &#8220;net debt&#8221; as (i) the sum total of short-term debt, long-term debt, and interest rate derivatives and currency derivatives used to manage debt, minus (ii) the sum total of cash and cash equivalents and interest rate derivatives and currency derivatives used to manage cash and cash equivalents.</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2025 </font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,646&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,248&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,026&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,342&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt (IFRS)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,893</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,702</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</font></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)  </font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(non-IFRS)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,513</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,008</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69,567&#160;</font></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71,710&#160;</font></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gearing ratio (non-IFRS)</font></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22.3</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.4</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,904 million as of June 30, 2026 and &#8364;1,739 million as of December&#160;31, 2025.</font></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To assess our financing risk, we use the &#8220;gearing ratio&#8221;, another non-IFRS financial measure. This ratio (which we define as the ratio of net debt to total equity) rose from 15.4% as of December&#160;31, 2025 to 22.3% as of June 30, 2026. Analyses of our debt as of June&#160;30, 2026 and December&#160;31,&#160;2025 are provided in Note B.9. to our condensed half-year consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;net debt&#8221; and &#8220;gearing ratio&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Despite the use of non-</font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Above a cap of &#8364;500 million per transaction.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-IFRS financial measure, as defined in &#8220;Business net income&#8221; above.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding a cap of &#8364;500 million per transaction.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">54</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS measures by management in setting goals and measuring performance, these measures have no standardized meaning prescribed by IFRS.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect that the future cash flows generated by our operating activities will be sufficient to repay our debt. The financing arrangements in place as of June&#160;30, 2026 at the Sanofi parent company level are not subject to covenants regarding financial ratios and do not contain any clauses linking credit spreads or fees to Sanofi&#8217;s credit rating.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other key movements in the balance sheet are described below.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity was &#8364;69,567&#160;million as of June&#160;30, 2026, versus &#8364;71,710 million as of December&#160;31,&#160;2025. The net change reflects the following principal factors&#58; </font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">an increase representing our net income for the first half of 2026 (&#8364;1,997 million)&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">an increase of &#8364;1,802 million due to currency translation differences arising on the financial statements of foreign subsidiaries, mainly due to movements in the US dollar&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a decrease representing the dividend payout to our shareholders of &#8364;4,923 million&#59; and</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the repurchase by Sanofi of 12,571,455 of its own shares during the first half of 2026 for a total amount of &#8364;1,003 million, plus &#8364;3 million of related tax payments.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026 we held 16.03&#160;million of our own shares, recorded as a deduction from equity and representing 1.320% of our share&#160;capital.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other intangible assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;68,313&#160;million in total) increased by &#8364;752 million, due mainly to the Dynavax acquisition and the impact of exchange rates (particularly the fluctuation in the US dollar), partly offset by amortization and impairment recognized on other intangible assets during the period.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;3,207 million) decreased by &#8364;52 million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;4,732&#160;million) increased by &#8364;368&#160;million.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net deferred tax assets </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were &#8364;7,210 million as of June 30, 2026, compared with &#8364;6,942 million as of December 31, 2025, an increase of &#8364;268 million. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;6,848&#160;million) were &#8364;145&#160;million higher than at December&#160;31,&#160;2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;652&#160;million) increased by &#8364;67 million.</font></div><div id="i69eb17a5021444ec89d279a544806a88_52"></div><div style="margin-bottom:12pt;margin-top:9pt"><font><br></font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">55</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="id795a9e34f284e22824a27b3ecef38fc"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">E&#47; Risk factors and related party transactions</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="ic89bd2c306e141c483d24983cf1155e2"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.1. Risk factors</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main risk factors to which Sanofi is exposed are described in the 2025 Form 20-F for the year ended December&#160;31, 2025, filed with the US Securities and Exchange Commission on February 17, 2026</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any of those risks, and others that we may not yet have identified, could materialize during the second half of 2026 or during subsequent periods, and could cause actual results to differ materially from those described elsewhere in this report.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i8b889542e5e54def8bba2463d776c392"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.2. Related party transactions</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our principal related parties are defined in Note D.33. to our consolidated financial statements included in the 2025 Form 20-F (page F-93)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note B.5. to our condensed half-year consolidated financial statements provides a description of the main transactions and balances for the six months ended June 30, 2026 with equity-accounted entities that qualify as related parties. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi did not enter into any transactions with key management personnel during the first half of 2026. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial relations with the Group&#8217;s principal shareholders fall within the ordinary course of business and were immaterial in the first half of 2026.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i69eb17a5021444ec89d279a544806a88_55"></div><div style="margin-bottom:12pt;margin-top:9pt"><font><br></font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Available on our corporate website&#58; www.sanofi.com.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">56</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="ie3aaa86ee06445c59a6cea490ef4d002"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">F&#47; Outlook</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2026, Sanofi net sales are now expected to grow by around 10% at constant exchange rates </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (CER). Business earnings per share </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(Business EPS) is expected to grow slightly faster than sales.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Applying July 2026 average currency exchange rates, currency impacts are estimated at approximately -1% on sales and at approximately -2% on Business EPS.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Full-year business net income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for 2025 was &#8364;9,555 million,  resulting in Business earnings per share of &#8364;7.83.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This guidance was prepared on a basis comparable with that used to prepare our historical financial information, and in accordance with Sanofi accounting policies. It was also prepared on the basis of assumptions established by Sanofi and its subsidiaries, including but not limited to&#58;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">trends in the competitive environment, in terms of innovative products and launches of generics&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">respect for our intellectual property rights&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">progress on our research and development programs&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the impact of, and progress on, our operating cost containment policy&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">trends in exchange rates and interest rates&#59;</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">integration of the contribution from acquisitions&#59; and</font></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average number of shares outstanding.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some of the above information, estimates and assumptions are derived from or rely on, in full or in part, judgments and decisions made by Sanofi management which may change or be amended in future.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="border-bottom:0.5pt solid #7802e6;margin-bottom:5pt;margin-top:10pt;opacity:1;width:155.91pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure. For a definition, see Section D.3., &#8220;Net Sales&#8221; above.</font></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure. For a definition, see Section D.2., &#8220;Business net income&#8221; above.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">57</font></div></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_58"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i1d331edf44d24bc3a2925e60a8123a74"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-looking statements</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This document contains forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;can&#8221;, &#8220;contemplate&#8221;, &#8220;could&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;is designed to&#8221;, &#8220;may&#8221;, &#8220;might&#8221;, &#8220;plan&#8221;, &#8220;potential&#8221;, &#8220;objective&#8221; &#8220;target&#8221;, &#8220;estimate&#8221;, &#8220;project&#8221;, &#8220;predict&#8221;, &#8220;forecast&#8221;, &#8220;ambition&#8221;, &#8220;guideline&#8221;, &#8220;should&#8221;, &#8220;will&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221; or the negative of these and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;may&#8221;, &#8220;is considering&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;envisages&#8221;, &#8220;aims&#8221;, &#8220;plans&#8221;, &#8220;is designed to&#8221;, &#8220;could&#8221;, &#8220;forecasts&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;objective&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;is programming&#8221;, &#8220;is likely to&#8221; and &#8220;wants&#8221; or the negative thereof, and similar expressions. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete related transactions and&#47;or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crisis may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the U.S. Securities and Exchange Commission (SEC) and the French Autorit&#233; des march&#233;s financiers (AMF) made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s Annual Report on Form 20-F for the year ended December 31, 2025. For an update on litigation, refer to Note B.14. &#8220;Legal and arbitration proceedings&#8221; to our condensed half-year consolidated financial statements for the six months ended June 30, 2026, and to section &#8220;A.3.2. Legal and arbitration proceedings&#8221;, and section &#8220;E&#47; Risk factors and related party transactions&#8221;, of this half-year management report. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With respect to any sustainability or environmental, social and governance (ESG)-related information contained herein, in light of the significant uncertainties inherent in such statements and other related information contained herein, investors should not regard these statements as a representation or warranty by Sanofi or any other person that Sanofi will achieve its goals, objectives, aspirations, metrics, plans or targets in any specified time frame or at all, including with respect to ESG and sustainability matters, and such statements and other information are dependent on future market factors, such as customer demand, continued technological progress, policy support and timely rule-making or continuation of government incentives and funding, and are forward-looking statements. Sanofi&#8217;s ability to achieve goals, objectives, aspirations, metrics, plans or targets in any specified time frame or at all, including with respect to ESG and sustainability matters, is subject to other conditions and considerations, both within and outside Sanofi&#8217;s control, that may affect its ability to meet such goals, objectives, aspirations, metrics, plans or targets, and&#47;or put in place the initiatives required to meet them. Such conditions and considerations include but are not limited to the risk factors described above. In addition, historical, current, and forward-looking environmental and other ESG or sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future, including future laws and rulemaking. Sanofi plans to continue to evaluate its goals, objectives, aspirations, metrics, plans and targets and its approach to them and may make adjustments as it deems necessary in light of such considerations.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All trademarks mentioned in this document are protected and are either trademarks owned by Sanofi and&#47;or its subsidiaries, or trademarks licensed to Sanofi and&#47;or its subsidiaries, or trademarks owned by third parties (including Regeneron and Sobi).</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">58</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_61"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:right;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><font id="i0bc9083b9c04482192d344aa75b40dfc"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">G&#47; Appendix - research and development pipeline</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font id="i5bb902f58ee44c93bd98b047eddc4d20"></font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">R&#38;D Pipeline</font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Registration</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">venglustat</font></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Oral GCS inhibitor</font></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Gaucher disease type 3 (US, EU, JP)</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Sarclisa</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD38 mAb subcutaneous</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Multiple myeloma (CN)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Fluzone HD</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Multivalent inactivated vaccine</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Influenza 50 years+ (US, EU)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SP0087</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Vero cell vaccine</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Rabies (EU)</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Phase 3</font></div></td><td colspan="3" rowspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></div></td><td colspan="9" style="background-color:#b6b6b6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Dupixent</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:700;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">IL4R mAb</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Chronic pruritus of unknown origin</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Nexviazyme</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Enzyme replacement therapy</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Infantile-onset Pompe disease (US)</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">duvakitug</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:700;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">TL1A mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Crohn&#8217;s disease<br>Ulcerative colitis</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">elenestinib</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">D816V-mutated KIT inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Indolent&#47;smoldering systemic mastocytosis</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">lunsekimig</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">IL13&#215;TSLP </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Nanobody</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> VHH</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Chronic obstructive pulmonary disease</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">fitusiran</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">RNAi targeting anti-thrombin</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Hemophilia A and B (EU, JP)</font></div></td></tr><tr style="height:36pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Rezurock</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">ROCK2 inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Chronic lung allograft dysfunction</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wayrilz</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">BTK inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Sickle cell disease</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">IgG4-related disease</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Warm autoimmune hemolytic anemia</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">frexalimab</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD40L mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Kidney transplant rejection</font></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #200f45;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #200f45;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="background-color:#0f7f40;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</font></td><td colspan="9" style="background-color:#200f45;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">frexalimab </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:700;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD40L mAb </font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Relapsing MS</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Non-relapsing secondary progressive MS</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD38 mAb</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">NDMM, TE (HD7)</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">NDMM, TE (IsKia)</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Smoldering MM (ITHACA)</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">riliprubart </font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">C1s mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">IVIg-treated CIDP</font></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#faac16;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></div></td><td colspan="3" style="background-color:#faac16;padding:0 1pt"></td><td colspan="3" style="background-color:#faac16;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SP0218</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Vero cell vaccine</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Yellow fever</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0202</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">21-valent conjugate vaccine</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Pneumococcal disease (children)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;letter-spacing:-0.04em;line-height:120%">Collaborations&#58; </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Regeneron&#59; (b) Teva Pharmaceuticals&#59; (c) ImmuNext&#59; (d) SK bioscience.</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;letter-spacing:-0.04em;line-height:120%">Abbreviations&#58;</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;letter-spacing:-0.04em;line-height:120%">BTK&#58; Bruton&#8217;s tyrosine kinase &#8211; CD&#58; Cluster of differentiation &#8211; C1s&#58; Complement component 1s &#8211; CIDP&#58; Chronic inflammatory demyelinating polyneuropathy &#8211; CN&#58; China &#8211;EU&#58; Europe &#8211; GCS&#58; Glucosylceramide synthase &#8211; HD&#58; High dose &#8211; IgG4&#58; Immunoglobulin G4 &#8211; IL&#58; Interleukin &#8211; IVIg&#58; Intravenous immunoglobulin &#8211; JP&#58; Japan &#8211; mAb&#58; Monoclonal antibody - MM&#58; Multiple myeloma - MS&#58; Multiple sclerosis - NDMM&#58; Newly diagnosed multiple myeloma - RNAi&#58; RNA interference - ROCK2&#58; Rho Associated coiled-coil containing protein kinase 2 &#8211; TE&#58; Transplant eligible &#8211; TL1A&#58; Tumor necrosis factor-like cytokine 1A &#8211; TSLP&#58; Thymic stromal lymphopoietin </font></div><div style="height:39.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">59</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:11.34pt;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.431%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2. Half-year management report</font></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Phase 2</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#929292;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">brivekimig</font></td><td colspan="3" style="border-top:0.5pt solid #7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">TNFa&#215;OX40L Nanobody</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> VHH</font></div></td><td colspan="3" style="border-top:0.5pt solid #7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Crohn&#8217;s disease </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Hidradenitis suppurativa</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Ulcerative colitis</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Type 1 diabetes, stage 3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #929292;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Wayrilz</font></td><td colspan="3" style="border-top:0.5pt solid #929292;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">BTK inhibitor</font></div></td><td colspan="3" style="border-top:0.5pt solid #929292;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Graves' disease</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">frexalimab</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:700;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD40L mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Type 1 diabetes, stage 3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">efdoralprin alfa</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">AAT fusion protein</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Alpha-1 antitrypsin deficiency emphysema</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">lunsekimig</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">IL13&#215;TSLP Nanobody</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">VHH</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Asthma</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Asthma, high-risk </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Chronic rhinosinusitis with nasal polyps</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">frexalimab <br>rilzabrutinib <br>brivekimig</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD40L mAb</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">BTK inhibitor</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">TNFa&#215;OX40L Nanobody</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> VHH</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Focal segmental glomerulosclerosis&#47;<br>minimal change disease</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SAR449028</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Wild-type KIT inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Chronic urticaria</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SAR444336</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Non-beta IL2 Synthorin</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Microscopic colitis</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#200f45;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SAR445399 </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:700;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">IL1R3 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Hidradenitis suppurativa</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SAR445877</font></td><td colspan="3" style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">PD1&#215;IL15 fusion protein </font></td><td colspan="3" style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Solid tumors</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Sarclisa</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CD38 mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Relapsed&#47;refractory multiple myeloma in combination</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#0f7f40;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#faac16;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SAR402663</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">sFLT01 AAV gene therapy</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Wet age-related macular degeneration</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SP0256</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">mRNA vaccine</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">RSV+hMPV (older adults)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SP0268</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Acne</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SP0289</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Influenza H5 pandemic</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:112%">SP0335</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Inactivated adjuvanted vaccine</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Influenza H5 pandemic</font></td></tr></table><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt"><font style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Phase 1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indication</font></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</font></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446422</font></td><td colspan="3" style="border-top:0.5pt solid #7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD28&#215;OX40 bispecific Ab</font></td><td colspan="3" style="border-top:0.5pt solid #7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR445953</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</font></div></td><td colspan="3" style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CEACAM5-Topo1 ADC</font></td><td colspan="3" style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colorectal cancer</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR448501</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CD20 bispecific mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446523</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">GPRC5D mAb</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Relapsed&#47;refractory multiple myeloma</font></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR447971</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IRAK4 degrader</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR449336</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pan KRAS inhibitor</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colorectal cancer</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#0f7f40;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Neurology</font></td><td colspan="3" style="background-color:#0f7f40;padding:0 1pt"></td><td colspan="3" style="background-color:#0f7f40;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#faac16;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#faac16;padding:0 1pt"></td><td colspan="3" style="background-color:#faac16;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446597</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bb&#215;C1s AAV gene therapy</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Geographic atrophy in dry age-related macular degeneration</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #faac16;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0287</font></td><td colspan="3" style="border-top:0.5pt solid #faac16;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fluzone HD+Nuvaxovid</font></td><td colspan="3" style="border-top:0.5pt solid #faac16;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza+COVID-19</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR448851</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TREM2 agonist</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0287</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Flublok+Nuvaxovid</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza+COVID-19</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0291</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV+hMPV+PIV3 (older adults)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0269</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">mRNA vaccine</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chlamydia</font></div></td></tr><tr><td colspan="3" style="background-color:#929292;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</font></td><td colspan="3" style="background-color:#929292;padding:0 1pt"></td><td colspan="3" style="background-color:#929292;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0340</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subunit vaccine</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV+hMPV (older adults)</font></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAR446268</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">DMPK AAV gene therapy</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Myotonic dystrophy type 1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0341</font></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subunit vaccine</font></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV+hMPV+PIV3 (older adults)</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SP0342</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subunit adjuvanted vaccine</font></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shingles</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;letter-spacing:-0.04em;line-height:120%">(1) Also known as MAB212, in-licensed from MAB Discovery.</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;letter-spacing:-0.04em;line-height:120%">Collaborations&#58;  </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) ImmuNext&#59; (b) Pfizer</font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;letter-spacing:-0.04em;line-height:120%">Abbreviations&#58;</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">AAT&#58; Alpha&#8211;1 antitrypsin &#8211; AAV&#58; Adeno-associated virus &#8211; Ab&#58; Antibody &#8211; ADC&#58; Antibody-drug conjugate &#8211; Bb&#58; Factor Bb &#8211; BTK&#58; Bruton&#8217;s tyrosine kinase &#8211; C1s&#58; Complement component 1s &#8211; CD&#58; Cluster of differentiation &#8211; CEACAM5&#58; Carcinoembryonic antigen cell adhesion molecule 5 &#8211; DMPK&#58; dystrophia myotonica protein kinase 1 &#8211; GPRC5D&#58; G-protein-coupled receptor class 5 member D &#8211; H5&#58; hemagglutinin 5 - hMPV&#58; human Metapneumovirus - JAK&#58; Janus kinase &#8211; KRAS&#58; V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog - IL&#58; Interleukin &#8211; IL1R3&#58; Interleukin-1 receptor 3 &#8211; mAb&#58; Monoclonal antibody &#8211; mRNA&#58; messenger RNA &#8211; PD1&#58; Programmed death protein 1 &#8211; PIV3&#58; Parainfluenza virus type 3 &#8211; RSV&#58; Respiratory syncytial virus &#8211; TNFa&#58; Tumor necrosis factor alpha &#8211; TNFR1&#58; Tumor necrosis factor receptor 1 &#8211; Topo1&#58; Topoisomerase - TREM2&#58; triggering receptor expressed on myeloid cells 2 &#8211; TSLP&#58; Thymic stromal lymphopoietin</font></div><div style="height:39.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">60</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_64"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.803%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr style="height:17pt"><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3. Statutory auditors&#8217; review report on the half-yearly financial information</font></div></td></tr></table></div></div><div style="margin-bottom:15pt"><font id="i2a6932c6565c4f41af5221352bdff07a"></font><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">3. Statutory auditors&#8217; review report on the half-yearly financial information</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Period from January 1 to June 30, 2026</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the Shareholders,</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In compliance with the assignment entrusted to us by your Annual General Meetings and in accordance with the requirements of article L. 451-1-2 III of the French Monetary and Financial Code (&#34;Code mon&#233;taire et financier&#34;), we hereby report to you on&#58;</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the review of the accompanying (condensed) half-yearly consolidated financial statements of Sanofi, for the period from January 1, 2026 to June 30, 2026&#59;</font></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the verification of the information presented in the half-yearly management report.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These condensed half-yearly consolidated financial statements are the responsibility of the Board of Directors. Our role is to express a conclusion on these financial statements based on our review.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="ie5adf94a7b3d4eae98e2d4d7227c7a16"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;Conclusion on the financial statements</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We conducted our review in accordance with professional standards applicable in France. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed half-yearly consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 &#8211; standard of the IFRSs as adopted by the European Union applicable to interim financial information.</font></div><div style="margin-bottom:3pt;margin-top:9pt"><font id="i6f57ab9acedb44d9b01ce75ce954de4d"></font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;Specific verification</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have also verified the information presented in the half-yearly management report on the condensed half-yearly consolidated financial statements subject to our review.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have no matters to report as to its fair presentation and consistency with the condensed half-yearly consolidated financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Neuilly-sur-Seine and Levallois-Perret, July 30 2026.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The statutory auditors</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">French original signed by</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PricewaterhouseCoopers Audit </font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forvis Mazars SA</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Anne-Claire Ferri&#233;                Am&#233;lie Graffan </font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lo&#239;c Wallaert               Ariane Mignon</font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font><br></font></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This is a free translation into English of the statutory auditors&#8217; review report on the half-yearly financial information issued in French and is provided solely for the convenience of English-speaking users. This report includes information relating to the specific verification of information given in the Group&#8217;s half-yearly management report. This report should be read in conjunction with, and construed in accordance with, French law and professional standards applicable in France.</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">61</font></div></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_67"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:2pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4. Responsibility statement of the certifying officer&#58; half-year financial report</font></div></td></tr></table></div></div><div style="margin-bottom:15pt"><font id="i10f407047ef54a8fbd98b943a08ae70a"></font><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">4. Responsibility statement of the certifying officer&#58; half-year financial report</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;I hereby certify that, to the best of my knowledge, the condensed half-year consolidated financial statements have been prepared in accordance with the applicable accounting standards and give a true and fair view of the assets and liabilities, financial position and net income of the Company and the entities included in the scope of consolidation, and that the half-year management report starting on page <a href="#i69eb17a5021444ec89d279a544806a88_4" style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:none">35</a> provides an accurate overview of the significant events of the first six months of the financial year with their impact on the half-year consolidated financial statements, together with the major transactions with related parties and a description of the main risks and uncertainties for the remaining six months of the financial year.&#8221;</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paris, July 30, 2026</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bel&#233;n Garijo</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">62</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_483"></div><hr style="page-break-after:always"><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Notes</font></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</font></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI</font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160; &#160;&#160;HALF-YEAR FINANCIAL REPORT </font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2026</font></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">63</font></div></td></tr></table></div></div></div><div id="i69eb17a5021444ec89d279a544806a88_442"></div><hr style="page-break-after:always"><div style="min-height:0pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><img alt="a2026coverhalf-yearfinanci.jpg" src="a2026coverhalf-yearfinanci.jpg" style="height:1126px;margin-bottom:5pt;vertical-align:text-bottom;width:793px"></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sny-20260630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ef965-bc7d-7da2-bb2f-04e26164615a,g:d543d692-5b77-4127-b010-746b44ca828b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sny="http://www.sanofi.com/20260630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sanofi.com/20260630">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20260630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20260630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20260630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20260630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.sanofi.com/role/Coverpage">
        <link:definition>0000001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedbalancesheets" roleURI="http://www.sanofi.com/role/Consolidatedbalancesheets">
        <link:definition>9952151 - Statement - Consolidated balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedincomestatements" roleURI="http://www.sanofi.com/role/Consolidatedincomestatements">
        <link:definition>9952152 - Statement - Consolidated income statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedincomestatements_1" roleURI="http://www.sanofi.com/role/Consolidatedincomestatements_1">
        <link:definition>9952152 - Statement - Consolidated income statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofcomprehensiveincome" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome">
        <link:definition>9952153 - Statement - Consolidated statements of comprehensive income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofcomprehensiveincome_1" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1">
        <link:definition>9952153 - Statement - Consolidated statements of comprehensive income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofcomprehensiveincome_2" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_2">
        <link:definition>9952153 - Statement - Consolidated statements of comprehensive income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofchangesinequity" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity">
        <link:definition>9952154 - Statement - Consolidated statements of changes in equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofcashflows" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcashflows">
        <link:definition>9952155 - Statement - Consolidated statements of cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedstatementsofcashflowsParenthetical" roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical">
        <link:definition>9952156 - Statement - Consolidated statements of cash flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Introduction" roleURI="http://www.sanofi.com/role/Introduction">
        <link:definition>9952157 - Disclosure - Introduction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies" roleURI="http://www.sanofi.com/role/Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies">
        <link:definition>9952158 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantinformationforthefirsthalfof2026" roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026">
        <link:definition>9952159 - Disclosure - Significant information for the first half of 2026</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.sanofi.com/role/Propertyplantandequipment">
        <link:definition>9952160 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwillandotherintangibleassets" roleURI="http://www.sanofi.com/role/Goodwillandotherintangibleassets">
        <link:definition>9952161 - Disclosure - Goodwill and other intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Impairmentofintangibleassets" roleURI="http://www.sanofi.com/role/Impairmentofintangibleassets">
        <link:definition>9952162 - Disclosure - Impairment of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investmentsaccountedforusingtheequitymethod" roleURI="http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod">
        <link:definition>9952163 - Disclosure - Investments accounted for using the equity method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othernoncurrentassets" roleURI="http://www.sanofi.com/role/Othernoncurrentassets">
        <link:definition>9952164 - Disclosure - Other non-current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountsreceivable" roleURI="http://www.sanofi.com/role/Accountsreceivable">
        <link:definition>9952165 - Disclosure - Accounts receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedshareholdersequity" roleURI="http://www.sanofi.com/role/Consolidatedshareholdersequity">
        <link:definition>9952166 - Disclosure - Consolidated shareholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debtcashandcashequivalents" roleURI="http://www.sanofi.com/role/Debtcashandcashequivalents">
        <link:definition>9952167 - Disclosure - Debt, cash and cash equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativefinancialinstruments" roleURI="http://www.sanofi.com/role/Derivativefinancialinstruments">
        <link:definition>9952168 - Disclosure - Derivative financial instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests" roleURI="http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests">
        <link:definition>9952169 - Disclosure - Liabilities related to business combinations and to non-controlling interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Noncurrentprovisionsandothernoncurrentliabilities" roleURI="http://www.sanofi.com/role/Noncurrentprovisionsandothernoncurrentliabilities">
        <link:definition>9952170 - Disclosure - Non-current provisions and other non-current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Offbalancesheetcommitments" roleURI="http://www.sanofi.com/role/Offbalancesheetcommitments">
        <link:definition>9952171 - Disclosure - Off balance sheet commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigationandarbitrationproceedings" roleURI="http://www.sanofi.com/role/Litigationandarbitrationproceedings">
        <link:definition>9952172 - Disclosure - Litigation and arbitration proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otheroperatingincomeandexpenses" roleURI="http://www.sanofi.com/role/Otheroperatingincomeandexpenses">
        <link:definition>9952173 - Disclosure - Other operating income and expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuringcostsandsimilaritems" roleURI="http://www.sanofi.com/role/Restructuringcostsandsimilaritems">
        <link:definition>9952174 - Disclosure - Restructuring costs and similar items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othergainsandlossesandlitigation" roleURI="http://www.sanofi.com/role/Othergainsandlossesandlitigation">
        <link:definition>9952175 - Disclosure - Other gains and losses, and litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialexpensesandincome" roleURI="http://www.sanofi.com/role/Financialexpensesandincome">
        <link:definition>9952176 - Disclosure - Financial expenses and income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxexpense" roleURI="http://www.sanofi.com/role/Incometaxexpense">
        <link:definition>9952177 - Disclosure - Income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuefromcontractswithcustomers" roleURI="http://www.sanofi.com/role/Revenuefromcontractswithcustomers">
        <link:definition>9952178 - Disclosure - Revenue from contracts with customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentinformation" roleURI="http://www.sanofi.com/role/Segmentinformation">
        <link:definition>9952179 - Disclosure - Segment information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InformationrelatedtoOpellapresentedwithindiscontinuedoperations" roleURI="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperations">
        <link:definition>9952180 - Disclosure - Information related to Opella, presented within discontinued operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies" roleURI="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies">
        <link:definition>9955511 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables" roleURI="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables">
        <link:definition>9955512 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantinformationforthefirsthalfof2026Tables" roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026Tables">
        <link:definition>9955513 - Disclosure - Significant information for the first half of 2026 (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentTables">
        <link:definition>9955514 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsTables" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables">
        <link:definition>9955515 - Disclosure - Goodwill and other intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodTables" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables">
        <link:definition>9955516 - Disclosure - Investments accounted for using the equity method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthernoncurrentassetsTables" roleURI="http://www.sanofi.com/role/OthernoncurrentassetsTables">
        <link:definition>9955517 - Disclosure - Other non-current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableTables" roleURI="http://www.sanofi.com/role/AccountsreceivableTables">
        <link:definition>9955518 - Disclosure - Accounts receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequityTables" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityTables">
        <link:definition>9955519 - Disclosure - Consolidated shareholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsTables" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsTables">
        <link:definition>9955520 - Disclosure - Debt, cash and cash equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsTables" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsTables">
        <link:definition>9955521 - Disclosure - Derivative financial instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables" roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables">
        <link:definition>9955522 - Disclosure - Liabilities related to business combinations and to non-controlling interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentprovisionsandothernoncurrentliabilitiesTables" roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables">
        <link:definition>9955523 - Disclosure - Non-current provisions and other non-current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingincomeandexpensesTables" roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesTables">
        <link:definition>9955524 - Disclosure - Other operating income and expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsandsimilaritemsTables" roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables">
        <link:definition>9955525 - Disclosure - Restructuring costs and similar items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialexpensesandincomeTables" roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeTables">
        <link:definition>9955526 - Disclosure - Financial expenses and income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxexpenseTables" roleURI="http://www.sanofi.com/role/IncometaxexpenseTables">
        <link:definition>9955527 - Disclosure - Income tax expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromcontractswithcustomersTables" roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables">
        <link:definition>9955528 - Disclosure - Revenue from contracts with customers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationTables" roleURI="http://www.sanofi.com/role/SegmentinformationTables">
        <link:definition>9955529 - Disclosure - Segment information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables" roleURI="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables">
        <link:definition>9955530 - Disclosure - Information related to Opella, presented within discontinued operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails" roleURI="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails">
        <link:definition>9955531 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantinformationforthefirsthalfof2026AdditionalinformationDetails" roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails">
        <link:definition>9955532 - Disclosure - Significant information for the first half of 2026 - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails" roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails">
        <link:definition>9955533 - Disclosure - Significant information for the first half of 2026 - Summary of detailed information about business combination Dynavax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails">
        <link:definition>9955534 - Disclosure - Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails">
        <link:definition>9955535 - Disclosure - Property, plant and equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails">
        <link:definition>9955536 - Disclosure - Goodwill and other intangible assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails">
        <link:definition>9955537 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofintangibleassetsDetails" roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails">
        <link:definition>9955538 - Disclosure - Impairment of intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails">
        <link:definition>9955539 - Disclosure - Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails">
        <link:definition>9955540 - Disclosure - Investments accounted for using the equity method - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>9955541 - Disclosure - Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails">
        <link:definition>9955542 - Disclosure - Investments accounted for using the equity method - Summary of Key Items Which Have Not Been Audited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthernoncurrentassetsDetails" roleURI="http://www.sanofi.com/role/OthernoncurrentassetsDetails">
        <link:definition>9955543 - Disclosure - Other non-current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableSummaryofAccountsReceivableDetails" roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails">
        <link:definition>9955544 - Disclosure - Accounts receivable - Summary of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails">
        <link:definition>9955545 - Disclosure - Accounts receivable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails">
        <link:definition>9955546 - Disclosure - Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequityAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails">
        <link:definition>9955547 - Disclosure - Consolidated shareholders' equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails">
        <link:definition>9955548 - Disclosure - Consolidated shareholders' equity - Summary of Treasury Shares Held (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails">
        <link:definition>9955549 - Disclosure - Consolidated shareholders' equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails">
        <link:definition>9955550 - Disclosure - Consolidated shareholders' equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails">
        <link:definition>9955551 - Disclosure - Consolidated shareholders' equity - Summary of stock subscription option plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofearningspershareDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails">
        <link:definition>9955552 - Disclosure - Consolidated shareholders' equity - Summary of earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails">
        <link:definition>9955553 - Disclosure - Consolidated shareholders' equity - Summary of number of shares used to compute diluted earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails">
        <link:definition>9955554 - Disclosure - Consolidated shareholders' equity - Summary of Movements within Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails">
        <link:definition>9955555 - Disclosure - Debt, cash and cash equivalents - Summary of Changes in Financial Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails">
        <link:definition>9955556 - Disclosure - Debt, cash and cash equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails">
        <link:definition>9955557 - Disclosure - Debt, cash and cash equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails">
        <link:definition>9955558 - Disclosure - Debt, cash and cash equivalents - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails">
        <link:definition>9955559 - Disclosure - Debt, cash and cash equivalents - Summary of Market Value of Net Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails">
        <link:definition>9955560 - Disclosure - Derivative financial instruments - Summary of Operating Currency Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails">
        <link:definition>9955561 - Disclosure - Derivative financial instruments- Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsDisclosureofInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails">
        <link:definition>9955562 - Disclosure - Derivative financial instruments - Disclosure of Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails">
        <link:definition>9955563 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails">
        <link:definition>9955564 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails">
        <link:definition>9955565 - Disclosure - Non-current provisions and other non-current liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails">
        <link:definition>9955566 - Disclosure - Non-current provisions and other non-current liabilities - Summary of Movements in Non-Current Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails">
        <link:definition>9955567 - Disclosure - Non-current provisions and other non-current liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsDetails" roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails">
        <link:definition>9955568 - Disclosure - Off balance sheet commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationandarbitrationproceedingsDetails" roleURI="http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails">
        <link:definition>9955569 - Disclosure - Litigation and arbitration proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingincomeandexpensesAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesAdditionalInformationDetails">
        <link:definition>9955570 - Disclosure - Other operating income and expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails" roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails">
        <link:definition>9955571 - Disclosure - Other operating income and expenses - Schedule of Other Operating Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails">
        <link:definition>9955572 - Disclosure - Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthergainsandlossesandlitigationDetails" roleURI="http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails">
        <link:definition>9955573 - Disclosure - Other gains and losses, and litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialexpensesandincomeDetails" roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails">
        <link:definition>9955574 - Disclosure - Financial expenses and income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialexpensesandincomeDetails_1" roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1">
        <link:definition>9955574 - Disclosure - Financial expenses and income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails">
        <link:definition>9955575 - Disclosure - Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails">
        <link:definition>9955576 - Disclosure - Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails" roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails">
        <link:definition>9955577 - Disclosure - Revenue from contracts with customers - Disclosures about major customers and credit risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails" roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails">
        <link:definition>9955578 - Disclosure - Revenue from contracts with customers - Disclosure of other revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails">
        <link:definition>9955579 - Disclosure - Segment information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofSegmentResultsDetails" roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails">
        <link:definition>9955580 - Disclosure - Segment information - Schedule of Segment Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails">
        <link:definition>9955581 - Disclosure - Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails">
        <link:definition>9955582 - Disclosure - Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails">
        <link:definition>9955583 - Disclosure - Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationPrincipalCustomersandCreditRiskDetails" roleURI="http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails">
        <link:definition>9955584 - Disclosure - Segment information- Principal Customers and Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails" roleURI="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails">
        <link:definition>9955585 - Disclosure - Information related to Opella, presented within discontinued operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="NonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentProvisionsAndOtherCurrentLiabilities" abstract="false" name="CurrentProvisionsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherGainsLossesAndLitigation" abstract="false" name="OtherGainsLossesAndLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" abstract="false" name="IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" abstract="false" name="GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherComprehensiveIncomeFromContinuedOperations" abstract="false" name="OtherComprehensiveIncomeFromContinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherComprehensiveIncomeFromDiscontinuedOperations" abstract="false" name="OtherComprehensiveIncomeFromDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TaxesOnShareCancellations" abstract="false" name="TaxesOnShareCancellations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShareBasedPaymentPlansAbstract" abstract="true" name="ShareBasedPaymentPlansAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" abstract="false" name="IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" abstract="false" name="IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForLossesGainsOnTransferOfBusiness" abstract="false" name="AdjustmentsForLossesGainsOnTransferOfBusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" abstract="false" name="AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" abstract="false" name="ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" abstract="false" name="NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetChangeInOtherNonCurrentAssets" abstract="false" name="NetChangeInOtherNonCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetCashProvidedByusedInContinuingInvestingActivities" abstract="false" name="NetCashProvidedByusedInContinuingInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" abstract="false" name="NetCashProvidedByusedInDiscontinuingInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetCashInflowFromDiscontinuedOperations" abstract="false" name="NetCashInflowFromDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DividendsPaidAbstract" abstract="true" name="DividendsPaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" abstract="false" name="CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" abstract="false" name="CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OpellaBusinessMember" abstract="true" name="OpellaBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommercialPaperProgramInUSAMember" abstract="true" name="CommercialPaperProgramInUSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DynavaxMember" abstract="true" name="DynavaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" abstract="false" name="AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" abstract="false" name="DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GeneralInformationAboutFinancialStatementsAbstract" abstract="true" name="GeneralInformationAboutFinancialStatementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" abstract="false" name="DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_InterestsInOtherEntitiesAbstract" abstract="true" name="InterestsInOtherEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfTradeReceivablesTextBlock" abstract="false" name="DisclosureOfTradeReceivablesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="ShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" abstract="false" name="DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" abstract="false" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OffBalanceSheetCommitmentsAbstract" abstract="true" name="OffBalanceSheetCommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" abstract="true" name="OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" abstract="false" name="DisclosureOfLegalAndArbitralProceedingsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" abstract="false" name="DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" abstract="false" name="DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DiscontinuedOperationsAbstract" abstract="true" name="DiscontinuedOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" abstract="false" name="SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" abstract="false" name="DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" abstract="false" name="DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" abstract="false" name="DisclosureOfCurrentTradeReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" abstract="false" name="DisclosureOfOverdueReceivablesGrossValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" abstract="false" name="DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" abstract="false" name="DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfChangesInFinancialPositionTableTextBlock" abstract="false" name="DisclosureOfChangesInFinancialPositionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" abstract="false" name="DisclosureOfMarketValueOfNetDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" abstract="false" name="DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" abstract="false" name="DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTableTextBlock" abstract="false" name="DisclosureOfNonCurrentProvisionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" abstract="false" name="DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OtherOperatingExpensesTableTextBlock" abstract="false" name="OtherOperatingExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" abstract="false" name="DisclosureOfRestructuringCostsDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" abstract="false" name="DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOtherRevenueTextBlock" abstract="false" name="DisclosureOfOtherRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" abstract="false" name="DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" abstract="false" name="DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" abstract="false" name="CumulativeConsumerPriceInflationRateOverTheLastThreeYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncomeStatementClassificationIFRS18NumberOfCategories" abstract="false" name="IncomeStatementClassificationIFRS18NumberOfCategories" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisposalGroupAxis" abstract="true" name="DisposalGroupAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisposalGroupDomain" abstract="true" name="DisposalGroupDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MedleyMember" abstract="true" name="MedleyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BiopharmaSegmentMember" abstract="true" name="BiopharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BusinessCombinationEquityInterestsOfAcquirerPerShare" abstract="false" name="BusinessCombinationEquityInterestsOfAcquirerPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_BusinessCombinationEquityValueOfAcquirer" abstract="false" name="BusinessCombinationEquityValueOfAcquirer" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OperatingIncomeOfAcquireeSinceAcquisitionDate" abstract="false" name="OperatingIncomeOfAcquireeSinceAcquisitionDate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" abstract="false" name="AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" abstract="false" name="AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" abstract="false" name="RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageOfOwnershipInterestDisposed" abstract="false" name="PercentageOfOwnershipInterestDisposed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" abstract="false" name="OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" abstract="false" name="NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OPALJVCoMember" abstract="true" name="OPALJVCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ManufacturingAndSupplyMember" abstract="true" name="ManufacturingAndSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FirmOrdersOfPropertyPlantAndEquipment" abstract="false" name="FirmOrdersOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MarketedProductsMember" abstract="true" name="MarketedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TechnologicalPlatformsMember" abstract="true" name="TechnologicalPlatformsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AcquiredResearchAndDevelopmentMember" abstract="true" name="AcquiredResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProductsTrademarksAndOtherRightsMember" abstract="true" name="ProductsTrademarksAndOtherRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" abstract="false" name="ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AmlitelimabAssetMember" abstract="true" name="AmlitelimabAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EuroapiMember" abstract="true" name="EuroapiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InfraservGmbhAndCoHochstKGMember" abstract="true" name="InfraservGmbhAndCoHochstKGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MSPVaccineCompanyMember" abstract="true" name="MSPVaccineCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CDRMember" abstract="true" name="CDRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BPIFranceMember" abstract="true" name="BPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MCMVaccineBVMember" abstract="true" name="MCMVaccineBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LoansToAssociates" abstract="false" name="LoansToAssociates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_StockPrice" abstract="false" name="StockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_AssociatesAndJointVenturesMember" abstract="true" name="AssociatesAndJointVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" abstract="false" name="RoyaltiesAndOtherIncomeRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherAssetsRelatedPartyTransactions" abstract="false" name="OtherAssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherLiabilitiesRelatedPartyTransactions" abstract="false" name="OtherLiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SubordinateHybridBondRelatedPartyTransactions" abstract="false" name="SubordinateHybridBondRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" abstract="false" name="NetSalesAndOtherRevenuesRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetIncomeRelatedPartyDisclosures" abstract="false" name="NetIncomeRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherComprehensiveIncomeRelatedPartyDisclosures" abstract="false" name="OtherComprehensiveIncomeRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ComprehensiveIncomeRelatedPartyDisclosures" abstract="false" name="ComprehensiveIncomeRelatedPartyDisclosures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentAssetsRelatedPartyTransactions" abstract="false" name="NonCurrentAssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentAssetsRelatedPartyTransactions" abstract="false" name="CurrentAssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AssetsRelatedPartyTransactions" abstract="false" name="AssetsRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" abstract="false" name="EquityAttributableToEquityHoldersRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" abstract="false" name="EquityAttributableToNonControllingInterestRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityRelatedPartyTransactions" abstract="false" name="EquityRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesRelatedPartyTransactions" abstract="false" name="NonCurrentLiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentLiabilitiesRelatedPartyTransactions" abstract="false" name="CurrentLiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LiabilitiesRelatedPartyTransactions" abstract="false" name="LiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityAndLiabilitiesRelatedPartyTransactions" abstract="false" name="EquityAndLiabilitiesRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsTable" abstract="true" name="DisclosureOfOtherNonCurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsLineItems" abstract="true" name="DisclosureOfOtherNonCurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" abstract="false" name="OtherFinancialAssetsAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PreFundedPensionObligations" abstract="false" name="PreFundedPensionObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LongTermPrepaidExpenses" abstract="false" name="LongTermPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentLoansAndReceivables" abstract="false" name="NonCurrentLoansAndReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableTable" abstract="true" name="DisclosureOfAccountsReceivableTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableLineItems" abstract="true" name="DisclosureOfAccountsReceivableLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DerecognizedReceivables" abstract="false" name="DerecognizedReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OverdueReceivablesGrossValue" abstract="false" name="OverdueReceivablesGrossValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EmployeeShareOwnershipPlanMember" abstract="true" name="EmployeeShareOwnershipPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2025ProgramMember" abstract="true" name="ShareRepurchase2025ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2026ProgramMember" abstract="true" name="ShareRepurchase2026ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LOrealMember" abstract="true" name="LOrealMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" abstract="false" name="NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ShareRepurchaseProgramPeriod" abstract="false" name="ShareRepurchaseProgramPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_NumberOfSharesRepurchased" abstract="false" name="NumberOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PercentageOfSanofisShareCapitalAcquired" abstract="false" name="PercentageOfSanofisShareCapitalAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_ShareRepurchaseProgramAmountPaid" abstract="false" name="ShareRepurchaseProgramAmountPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PerShareValueOfSharesRepurchased" abstract="false" name="PerShareValueOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_SubscriptionPricePerShare" abstract="false" name="SubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_NumberOfSharesSubscribed" abstract="false" name="NumberOfSharesSubscribed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_IssuanceOfFurtherSharesAsAnEmployersContribution" abstract="false" name="IssuanceOfFurtherSharesAsAnEmployersContribution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_NumberOfSharesHeld" abstract="false" name="NumberOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PercentageOfShareCapitalForThePeriod" abstract="false" name="PercentageOfShareCapitalForThePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_RestrictedSharePlan2025Member" abstract="true" name="RestrictedSharePlan2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MarketConditionAxis" abstract="true" name="MarketConditionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_MarketConditionDomain" abstract="true" name="MarketConditionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WithoutMarketConditionMember" abstract="true" name="WithoutMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WithMarketConditionMember" abstract="true" name="WithMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExcludingChiefExecutiveOfficerMember" abstract="true" name="ExcludingChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TypesOfVestingConditionsAxisAxis" abstract="true" name="TypesOfVestingConditionsAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_TypesOfVestingConditionsAxisDomain" abstract="true" name="TypesOfVestingConditionsAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ThreeYearServicePeriodMember" abstract="true" name="ThreeYearServicePeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FiveYearServicePeriodMember" abstract="true" name="FiveYearServicePeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FairValuePerShareAwardedForThreeYearServicePeriod" abstract="false" name="FairValuePerShareAwardedForThreeYearServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_FairValuePerShareAwardedForFiveYearServicePeriod" abstract="false" name="FairValuePerShareAwardedForFiveYearServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_FairValueOfPlanAtDateOfGrant" abstract="false" name="FairValueOfPlanAtDateOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfYearsServicePeriod" abstract="false" name="NumberOfYearsServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_RestrictedSharesMember" abstract="true" name="RestrictedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2026Member" abstract="true" name="RestrictedSharePlan2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2024Member" abstract="true" name="RestrictedSharePlan2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2023Member" abstract="true" name="RestrictedSharePlan2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2022Member" abstract="true" name="RestrictedSharePlan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesNotYetFullyVested" abstract="false" name="NumberOfRestrictedSharesNotYetFullyVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockOptionPlanMember" abstract="true" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" abstract="false" name="DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="BasicEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="DilutedEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EquityInstrumentsIncludedInFinancialAssetsMember" abstract="true" name="EquityInstrumentsIncludedInFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentsMember" abstract="true" name="DebtInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CashFlowAndFairValueHedgeMember" abstract="true" name="CashFlowAndFairValueHedgeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForeignCurrencyTranslationMember" abstract="true" name="ForeignCurrencyTranslationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" abstract="false" name="IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" abstract="false" name="ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" abstract="false" name="EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" abstract="false" name="ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnTaxEffects" abstract="false" name="ChangeInCurrencyTranslationOnTaxEffects" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DebtNetOfCashAndCashEquivalents" abstract="false" name="DebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_AmortizedCostNettingMember" abstract="true" name="AmortizedCostNettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdjustmentToDebtMeasuredAtFairValueMember" abstract="true" name="AdjustmentToDebtMeasuredAtFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOnRedemptionMember" abstract="true" name="ValueOnRedemptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentAssetsMember" abstract="true" name="CurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NetInvestmentHedgeMember" abstract="true" name="NetInvestmentHedgeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesMember" abstract="true" name="NonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentLiabilitiesMember" abstract="true" name="CurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherBankBorrowings" abstract="false" name="OtherBankBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TwoBillionThreeHundredMillionBondsMember" abstract="true" name="TwoBillionThreeHundredMillionBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingMarch2029Member" abstract="true" name="FixedRateBondMaturingMarch2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingMay2033Member" abstract="true" name="FixedRateBondMaturingMay2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FixedRateBondMaturingMay2037Member" abstract="true" name="FixedRateBondMaturingMay2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FixedRateBondIssueFromMarch2018Member" abstract="true" name="FixedRateBondIssueFromMarch2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FourBillionFacilityMaturingOnMarch2030Member" abstract="true" name="FourBillionFacilityMaturingOnMarch2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" abstract="true" name="ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FourBillionFacilityMaturingApril2026Member" abstract="true" name="FourBillionFacilityMaturingApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommercialPaperProgramInFranceMember" abstract="true" name="CommercialPaperProgramInFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentAxis" abstract="true" name="DebtInstrumentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DebtInstrumentDomain" abstract="true" name="DebtInstrumentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiEuroMediumTermNotesMember" abstract="true" name="SanofiEuroMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfTranches" abstract="false" name="NumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfBondRedeemed" abstract="false" name="NumberOfBondRedeemed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfSyndicatedCreditFacilities" abstract="false" name="NumberOfSyndicatedCreditFacilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfOneYearExtensionOptions" abstract="false" name="NumberOfOneYearExtensionOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_ExtensionTerm" abstract="false" name="ExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_NumberOfShortTermDebtProgram" abstract="false" name="NumberOfShortTermDebtProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_BorrowingAverageDrawdown" abstract="false" name="BorrowingAverageDrawdown" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AtMarketValueMember" abstract="true" name="AtMarketValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RedemptionOfDebtInstrumentIssued" abstract="false" name="RedemptionOfDebtInstrumentIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AtNotionalAmountMember" abstract="true" name="AtNotionalAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOfHedgeRecognizedInEquityMember" abstract="true" name="ValueOfHedgeRecognizedInEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NotEligibleForHedgeAccountingMember" abstract="true" name="NotEligibleForHedgeAccountingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesMember" abstract="true" name="ForwardCurrencySalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInUSDollarMember" abstract="true" name="ForwardCurrencySalesInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInSingaporeDollarMember" abstract="true" name="ForwardCurrencySalesInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencySalesInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInBrazilianRealMember" abstract="true" name="ForwardCurrencySalesInBrazilianRealMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInSaudiArabianRiyalMember" abstract="true" name="ForwardCurrencySalesInSaudiArabianRiyalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesMember" abstract="true" name="ForwardCurrencyPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInSingaporeDollarMember" abstract="true" name="ForwardCurrencyPurchasesInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencyPurchasesInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInTurkishLiraMember" abstract="true" name="ForwardCurrencyPurchasesInTurkishLiraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" abstract="true" name="ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialInstruments" abstract="false" name="DerivativeFinancialInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CrossCurrencySellerSwapsMember" abstract="true" name="CrossCurrencySellerSwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CrossCurrencySellerSwapsInUSDollarMember" abstract="true" name="CrossCurrencySellerSwapsInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInPoundSterlingMember" abstract="true" name="ForwardCurrencySalesInPoundSterlingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInHungarianFlorintMember" abstract="true" name="ForwardCurrencyPurchasesInHungarianFlorintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CrossCurrencySwapExpiring2029Member" abstract="true" name="CrossCurrencySwapExpiring2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CrossCurrencySwapExpiring2032Member" abstract="true" name="CrossCurrencySwapExpiring2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CrossCurrencySwapMember" abstract="true" name="CrossCurrencySwapMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" abstract="true" name="ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" abstract="true" name="ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" abstract="true" name="ForwardCurrencyPurchasesInUSDollarUSBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialInstrumentsToManageFinancialExposure" abstract="false" name="DerivativeFinancialInstrumentsToManageFinancialExposure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfCrossCurrencySwaps" abstract="false" name="NumberOfCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember" abstract="true" name="InterestRateSwapsPay2.08ReceiveEuribor3MMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" abstract="true" name="InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" abstract="true" name="InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" abstract="true" name="InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" abstract="true" name="InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive092Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive2.53Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive2.71Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive2.91Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" abstract="false" name="CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" abstract="true" name="ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" abstract="true" name="CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" abstract="true" name="CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherLiabilities1Member" abstract="true" name="OtherLiabilities1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" abstract="true" name="ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageIncreaseInFairValueLiabilities" abstract="false" name="PercentageIncreaseInFairValueLiabilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTable" abstract="true" name="DisclosureOfNonCurrentProvisionsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_PrincipalAlliancesAxis" abstract="true" name="PrincipalAlliancesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_PrincipalAlliancesDomain" abstract="true" name="PrincipalAlliancesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AntibodiesCollaborationAgreementMember" abstract="true" name="AntibodiesCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SwedishOrphanBiovitrumABMember" abstract="true" name="SwedishOrphanBiovitrumABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsLineItems" abstract="true" name="DisclosureOfNonCurrentProvisionsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" abstract="true" name="ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProvisionsForOtherLongTermBenefitsMember" abstract="true" name="ProvisionsForOtherLongTermBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonCurrentRestructuringProvisionMember" abstract="true" name="NonCurrentRestructuringProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" abstract="false" name="IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseInProvisionsAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInProvisionsAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" abstract="false" name="IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" abstract="false" name="IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PensionsAndOtherPostEmploymentBenefitsMember" abstract="true" name="PensionsAndOtherPostEmploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsTable" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_CTTQMember" abstract="true" name="CTTQMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_KaliTherapeuticsMember" abstract="true" name="KaliTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TypesOfAgreementAxis" abstract="true" name="TypesOfAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_TypesOfAgreementDomain" abstract="true" name="TypesOfAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CTTQRovidicitinibLicenseAgreementMember" abstract="true" name="CTTQRovidicitinibLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_KaliTherapeuticsLicenseAgreementMember" abstract="true" name="KaliTherapeuticsLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_UpfrontLicensePayment" abstract="false" name="UpfrontLicensePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" abstract="false" name="CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTable" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsAxis" abstract="true" name="LegalAndArbitralProceedingsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsDomain" abstract="true" name="LegalAndArbitralProceedingsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember" abstract="true" name="UniversityOfWashingtonAndHarborviewMedicalCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_HudsonHeadwatersHealthNetworkMember" abstract="true" name="HudsonHeadwatersHealthNetworkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MosaicHealthInTheUSMember" abstract="true" name="MosaicHealthInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TalcProductLitigationInTheUSMember" abstract="true" name="TalcProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_A340BDrugPricingProgramInTheUSMember" abstract="true" name="A340BDrugPricingProgramInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DupixentProductLitigationInTheUSMember" abstract="true" name="DupixentProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsLineItems" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfClassActionLawsuits" abstract="false" name="NumberOfClassActionLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfProductLiabilityCases" abstract="false" name="NumberOfProductLiabilityCases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfCasesFiledInNewJerseyCourt" abstract="false" name="NumberOfCasesFiledInNewJerseyCourt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfOtherDefendantsInLegalProceeding" abstract="false" name="NumberOfOtherDefendantsInLegalProceeding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfLegalDecisionAspectsChallenged" abstract="false" name="NumberOfLegalDecisionAspectsChallenged" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesTable" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_AmvuttraMember" abstract="true" name="AmvuttraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RegeneronMember" abstract="true" name="RegeneronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" abstract="true" name="ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdditionalProfitShareForDevelopmentCostMember" abstract="true" name="AdditionalProfitShareForDevelopmentCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommercializationRelatedExpensesMember" abstract="true" name="CommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_GainsLossOnDivestmentOfProducts" abstract="false" name="GainsLossOnDivestmentOfProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeResultingFromOutLicensing" abstract="false" name="IncomeResultingFromOutLicensing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherOperatingIncome" abstract="false" name="OtherOperatingIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherOperatingExpense" abstract="false" name="OtherOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" abstract="false" name="ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" abstract="false" name="ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" abstract="false" name="ExpenseOfRestructuringActivitiesTransformationProgramsCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherRestructuringCosts" abstract="false" name="OtherRestructuringCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesMember" abstract="true" name="InterestRateAndCurrencyDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_InterestIncome" abstract="false" name="InterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CostOfDebtNet" abstract="false" name="CostOfDebtNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonOperatingForeignExchangeGainsLosses" abstract="false" name="NonOperatingForeignExchangeGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetInterestCostRelatedToEmployeeBenefits" abstract="false" name="NetInterestCostRelatedToEmployeeBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImpairmentLossesOnFinancialAssetsNetOfReversals" abstract="false" name="ImpairmentLossesOnFinancialAssetsNetOfReversals" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainLossOnDerivativesUsedToManageDebt" abstract="false" name="GainLossOnDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" abstract="false" name="GainLossOnDerivativesUsedToManageCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LiabilityRecognisedForEstimatedFutureRoyalties" abstract="false" name="LiabilityRecognisedForEstimatedFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TaxEffectRelatedToAmlitelimab" abstract="false" name="TaxEffectRelatedToAmlitelimab" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" abstract="false" name="RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_OtherCountriesInSegmentResultsMember" abstract="true" name="OtherCountriesInSegmentResultsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DupixentMember" abstract="true" name="DupixentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AltuviiioMember" abstract="true" name="AltuviiioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FabrazymeMember" abstract="true" name="FabrazymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NexviazymeNexviadymeMember" abstract="true" name="NexviazymeNexviadymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CerezymeMember" abstract="true" name="CerezymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AyvakitMember" abstract="true" name="AyvakitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SarclisaMember" abstract="true" name="SarclisaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LantusMember" abstract="true" name="LantusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ToujeoMember" abstract="true" name="ToujeoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlavixMember" abstract="true" name="PlavixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LovenoxMember" abstract="true" name="LovenoxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RezurockMember" abstract="true" name="RezurockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IndustrialSalesMember" abstract="true" name="IndustrialSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" abstract="true" name="PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RSVVaccinesBeyfortusMember" abstract="true" name="RSVVaccinesBeyfortusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MeningitisTravelAndEndemicsVaccinesMember" abstract="true" name="MeningitisTravelAndEndemicsVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_COVID19AndInfluenzaVaccinesMember" abstract="true" name="COVID19AndInfluenzaVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LaunchesMember" abstract="true" name="LaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RevenueFromVaxServeSalesOfNonSanofiProducts" abstract="false" name="RevenueFromVaxServeSalesOfNonSanofiProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" abstract="false" name="RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MiscellaneousOtherRevenue" abstract="false" name="MiscellaneousOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfOperatingSegments" abstract="false" name="NumberOfOperatingSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_ProportionOfOwnershipInterestDisposedInSubsidiary" abstract="false" name="ProportionOfOwnershipInterestDisposedInSubsidiary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" abstract="false" name="IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" abstract="false" name="IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" abstract="false" name="IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" abstract="false" name="IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" abstract="false" name="IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" abstract="false" name="IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" abstract="false" name="IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" abstract="false" name="IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_MiscellaneousOtherOperatingIncomeExpenses" abstract="false" name="MiscellaneousOtherOperatingIncomeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BusinessOperatingIncome" abstract="false" name="BusinessOperatingIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" abstract="false" name="IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" abstract="false" name="IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_BusinessOperatingIncomeAsPercentOfNetSales" abstract="false" name="BusinessOperatingIncomeAsPercentOfNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" abstract="false" name="ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" abstract="true" name="OtherCountriesExcludingEuropeAndNorthAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_CertainWholesalersInTheUnitedStatesMember" abstract="true" name="CertainWholesalersInTheUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfLargestCustomers" abstract="false" name="NumberOfLargestCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="RevenueFromDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" abstract="false" name="IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>sny-20260630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ef965-bc7d-7da2-bb2f-04e26164615a,g:d543d692-5b77-4127-b010-746b44ca828b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedbalancesheets"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019ef965-bfdf-7c94-9cd1-a7fd97b3fa71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_019ef965-bfdf-7f65-8cad-18163549b46f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_019ef965-bfdf-7c94-9cd1-a7fd97b3fa71" xlink:to="loc_ifrs-full_NoncontrollingInterests_019ef965-bfdf-7f65-8cad-18163549b46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_019ef965-bfdf-7746-af15-50fdb8f0a282" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_019ef965-bfdf-7c94-9cd1-a7fd97b3fa71" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_019ef965-bfdf-7746-af15-50fdb8f0a282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-bfdf-7021-b188-8e5078d44c67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-bfdf-7021-b188-8e5078d44c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_019ef965-bfdf-7584-b84c-deee47cb8d81" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_RightofuseAssets_019ef965-bfdf-7584-b84c-deee47cb8d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_019ef965-bfdf-7094-a91d-62b7f5a46ddc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_Goodwill_019ef965-bfdf-7094-a91d-62b7f5a46ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7816-9709-44137d3d0409" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7816-9709-44137d3d0409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-bfdf-7319-b585-9c8a8af08abe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-bfdf-7319-b585-9c8a8af08abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_019ef965-bfdf-78e0-8167-37a0e67faf15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_019ef965-bfdf-78e0-8167-37a0e67faf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_019ef965-bfdf-733c-953b-32ca57636e14" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_019ef965-bfdf-733c-953b-32ca57636e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_019ef965-bfdf-7345-a1f5-b611f3b937cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-781f-8d65-6490421efd0f" xlink:to="loc_ifrs-full_DeferredTaxAssets_019ef965-bfdf-7345-a1f5-b611f3b937cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_019ef965-bfdf-72b9-a8a2-63b8f2ec752b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_019ef965-bfdf-72b9-a8a2-63b8f2ec752b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-7ca6-be63-60fc01dc064d" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-7ca6-be63-60fc01dc064d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_019ef965-bfdf-79b8-80ad-42d6f7f7bff0" xlink:href="sny-20260630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_019ef965-bfdf-79b8-80ad-42d6f7f7bff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_019ef965-bfdf-7c1c-b222-6487d224154f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_019ef965-bfdf-7c1c-b222-6487d224154f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_019ef965-bfdf-7c68-bd12-f90bd4fba1d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_019ef965-bfdf-7c68-bd12-f90bd4fba1d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-bfdf-73ca-b13b-4b075ca6d319" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-bfdf-73ca-b13b-4b075ca6d319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7a99-953a-07aab0f1fe42" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7aa7-885c-098d5d23c4dd" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7a99-953a-07aab0f1fe42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_019ef965-bfdf-74aa-9bf5-042caacfd9b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-7c96-84ca-7e39ef6c049c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_019ef965-bfdf-74aa-9bf5-042caacfd9b5" xlink:to="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-7c96-84ca-7e39ef6c049c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_019ef965-bfdf-7ee0-a12c-20dc1bd5ffdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_019ef965-bfdf-74aa-9bf5-042caacfd9b5" xlink:to="loc_ifrs-full_CurrentAssets_019ef965-bfdf-7ee0-a12c-20dc1bd5ffdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_019ef965-bfdf-782b-a881-e5ddeddced29" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_019ef965-bfdf-71a9-afce-3b7ae46c62a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019ef965-bfdf-782b-a881-e5ddeddced29" xlink:to="loc_ifrs-full_Inventories_019ef965-bfdf-71a9-afce-3b7ae46c62a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_019ef965-bfdf-7c14-8de8-ef1ccbd9c4bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019ef965-bfdf-782b-a881-e5ddeddced29" xlink:to="loc_ifrs-full_CurrentTradeReceivables_019ef965-bfdf-7c14-8de8-ef1ccbd9c4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_019ef965-bfdf-7b25-a154-a93d7bbebffc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019ef965-bfdf-782b-a881-e5ddeddced29" xlink:to="loc_ifrs-full_OtherCurrentAssets_019ef965-bfdf-7b25-a154-a93d7bbebffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_019ef965-bfdf-7f84-a831-69b40db6e758" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019ef965-bfdf-782b-a881-e5ddeddced29" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_019ef965-bfdf-7f84-a831-69b40db6e758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfdf-7190-bf54-a54ebf4e6fc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019ef965-bfdf-782b-a881-e5ddeddced29" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfdf-7190-bf54-a54ebf4e6fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7bb4-98eb-0be9f1ecaece" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_019ef965-bfdf-782b-a881-e5ddeddced29" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7bb4-98eb-0be9f1ecaece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-764f-aa4f-a7be8a23b52c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-762f-ac12-ebc25ff48555" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-764f-aa4f-a7be8a23b52c" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-762f-ac12-ebc25ff48555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfdf-768e-88e6-33c7fbacb32c" xlink:href="sny-20260630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-764f-aa4f-a7be8a23b52c" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfdf-768e-88e6-33c7fbacb32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_019ef965-bfdf-7353-9905-29ebbf2ad33a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-764f-aa4f-a7be8a23b52c" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_019ef965-bfdf-7353-9905-29ebbf2ad33a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_019ef965-bfdf-707b-b6e2-ac4d737d6d92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-764f-aa4f-a7be8a23b52c" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_019ef965-bfdf-707b-b6e2-ac4d737d6d92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_019ef965-bfdf-7ced-8575-8ebe57eb256c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-764f-aa4f-a7be8a23b52c" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_019ef965-bfdf-7ced-8575-8ebe57eb256c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_019ef965-bfdf-7e75-b47a-c8fd6bc4f8cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-764f-aa4f-a7be8a23b52c" xlink:to="loc_ifrs-full_LongtermBorrowings_019ef965-bfdf-7e75-b47a-c8fd6bc4f8cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_019ef965-bfdf-79a6-818e-95d77d3d949e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019ef965-bfdf-77e0-9e87-2f6b168d9f41" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_019ef965-bfdf-79a6-818e-95d77d3d949e" xlink:to="loc_ifrs-full_Equity_019ef965-bfdf-77e0-9e87-2f6b168d9f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-729d-930c-154f4b6563cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_019ef965-bfdf-79a6-818e-95d77d3d949e" xlink:to="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-729d-930c-154f4b6563cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7f2c-a567-c73b24b2a73d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_019ef965-bfdf-79a6-818e-95d77d3d949e" xlink:to="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-7f2c-a567-c73b24b2a73d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedincomestatements"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019f93fe-6731-74c8-8370-e3ab682fee72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_019f93fe-6731-751c-a3f3-5c4b5b19be13" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_019f93fe-6731-74c8-8370-e3ab682fee72" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_019f93fe-6731-751c-a3f3-5c4b5b19be13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019f93fe-6731-721a-b6b3-7df88eb711a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_019f93fe-6731-74c8-8370-e3ab682fee72" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019f93fe-6731-721a-b6b3-7df88eb711a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_019f805d-7c4a-7b05-8670-847cd81f9cee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_019f805d-7c4a-7e94-96c7-6963e1c78f60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare_019f805d-7c4a-7b05-8670-847cd81f9cee" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_019f805d-7c4a-7e94-96c7-6963e1c78f60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_019f805d-7c4a-7edb-a27f-92c4ff424da5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare_019f805d-7c4a-7b05-8670-847cd81f9cee" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_019f805d-7c4a-7edb-a27f-92c4ff424da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-bfdf-7606-a8a7-700f3ed2cd3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-bfdf-7606-a8a7-700f3ed2cd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-bfdf-7176-9f91-ae3744fdd96c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-bfdf-7176-9f91-ae3744fdd96c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-bfdf-7e59-827a-df0933ff6f34" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-bfdf-7e59-827a-df0933ff6f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019ef965-bfdf-74af-ae91-b56fa286dd6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019ef965-bfdf-74af-ae91-b56fa286dd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_019ef965-bfdf-741b-afe2-02c4b1f5b120" xlink:href="sny-20260630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_sny_OtherGainsLossesAndLitigation_019ef965-bfdf-741b-afe2-02c4b1f5b120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-75e2-8328-2b8f843c3f60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-75e2-8328-2b8f843c3f60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-bfdf-7bea-8107-007510be3982" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-bfdf-7bea-8107-007510be3982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_019ef965-bfdf-763e-9dcb-ac45dc3ce50c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_GrossProfit_019ef965-bfdf-763e-9dcb-ac45dc3ce50c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-bfdf-78db-91be-47f3cba163eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-bfdf-78db-91be-47f3cba163eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7874-8be6-2f4f8f2427e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-77df-9a7d-373c3536319e" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7874-8be6-2f4f8f2427e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_019ef965-bfdf-7835-bc36-b62cbab05aad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-755f-8a3b-c949d5c91c48" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_019ef965-bfdf-7835-bc36-b62cbab05aad" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-755f-8a3b-c949d5c91c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-bfdf-7d6f-ba64-745f3a794513" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_019ef965-bfdf-7835-bc36-b62cbab05aad" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-bfdf-7d6f-ba64-745f3a794513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019ef965-bfdf-728a-9ee2-7ffb26fcbdd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_019ef965-bfdf-7835-bc36-b62cbab05aad" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019ef965-bfdf-728a-9ee2-7ffb26fcbdd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-7106-a4d4-0bff1a83b6a9" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-7b26-8f54-9a769d086b03" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-7106-a4d4-0bff1a83b6a9" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-7b26-8f54-9a769d086b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019ef965-bfdf-7c72-a615-a05bb0419aee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-7106-a4d4-0bff1a83b6a9" xlink:to="loc_ifrs-full_FinanceCosts_019ef965-bfdf-7c72-a615-a05bb0419aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019ef965-bfdf-7072-9421-efe539a31ecb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-7106-a4d4-0bff1a83b6a9" xlink:to="loc_ifrs-full_FinanceIncome_019ef965-bfdf-7072-9421-efe539a31ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_019ef965-bfdf-7881-a5e6-19093d78592e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-bfdf-775e-8ff4-cc923e77bdb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_019ef965-bfdf-7881-a5e6-19093d78592e" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-bfdf-775e-8ff4-cc923e77bdb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019ef965-bfdf-76d2-9340-4e42014b5d49" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_019ef965-bfdf-7881-a5e6-19093d78592e" xlink:to="loc_ifrs-full_OtherRevenue_019ef965-bfdf-76d2-9340-4e42014b5d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_019ef965-bfdf-7c61-aff0-6bab92f4da47" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_019ef965-bfdf-7881-a5e6-19093d78592e" xlink:to="loc_ifrs-full_CostOfSales_019ef965-bfdf-7c61-aff0-6bab92f4da47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_019f805d-637f-758c-8f67-e89ac2431fc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_019f805d-637f-7290-a78f-0f2158c1aeb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare_019f805d-637f-758c-8f67-e89ac2431fc5" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_019f805d-637f-7290-a78f-0f2158c1aeb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_019f805d-637f-781f-a057-cf38d0174b0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare_019f805d-637f-758c-8f67-e89ac2431fc5" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_019f805d-637f-781f-a057-cf38d0174b0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedincomestatements_1" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedincomestatements_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedincomestatements_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7e21-93fb-1ea085110109" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfdf-7538-a70a-e29540efeff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7e21-93fb-1ea085110109" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfdf-7538-a70a-e29540efeff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-bfdf-78b4-a73b-44a05036253b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7e21-93fb-1ea085110109" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-bfdf-78b4-a73b-44a05036253b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofcomprehensiveincome"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7b89-b75a-754c3dce5e94" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_019ef965-bfdf-704c-a28b-3ff786fe2be1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7b89-b75a-754c3dce5e94" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_019ef965-bfdf-704c-a28b-3ff786fe2be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_019ef965-bfdf-7ee9-8e98-fdb40af162e1" xlink:href="sny-20260630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7b89-b75a-754c3dce5e94" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_019ef965-bfdf-7ee9-8e98-fdb40af162e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_019ef965-bfdf-72b2-98a7-ecf9ea342b0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7b89-b75a-754c3dce5e94" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_019ef965-bfdf-72b2-98a7-ecf9ea342b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-bfdf-741a-a5cd-22ad11155f19" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7b89-b75a-754c3dce5e94" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-bfdf-741a-a5cd-22ad11155f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019f805e-667f-7335-a17d-0fa01401fa9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_019f805e-667f-751e-847c-636c22fa9f68" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019f805e-667f-7335-a17d-0fa01401fa9b" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_019f805e-667f-751e-847c-636c22fa9f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_019f805e-667f-7650-b14b-60fb0dc14376" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019f805e-667f-7335-a17d-0fa01401fa9b" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_019f805e-667f-7650-b14b-60fb0dc14376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_019f805e-667f-74d5-bfca-92ca03ac5c18" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019f805e-667f-7335-a17d-0fa01401fa9b" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_019f805e-667f-74d5-bfca-92ca03ac5c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-bfdf-7baf-b3cc-7aa15a271ccd" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7067-8ad5-faffa7e490a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-bfdf-7baf-b3cc-7aa15a271ccd" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7067-8ad5-faffa7e490a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7106-9b61-aede77921484" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-bfdf-7baf-b3cc-7aa15a271ccd" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7106-9b61-aede77921484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7190-9f11-19f2154a7512" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_019ef965-bfdf-7d8b-a980-958f73528547" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7190-9f11-19f2154a7512" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_019ef965-bfdf-7d8b-a980-958f73528547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_019ef965-bfdf-7253-96db-69849320281f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7190-9f11-19f2154a7512" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_019ef965-bfdf-7253-96db-69849320281f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_019ef965-bfdf-7bb8-a7b4-66b920f83464" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7190-9f11-19f2154a7512" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_019ef965-bfdf-7bb8-a7b4-66b920f83464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-753f-b2c8-2c08318e2053" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_019ef965-bfdf-7098-8db3-94f4ebe32ac0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-753f-b2c8-2c08318e2053" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_019ef965-bfdf-7098-8db3-94f4ebe32ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_019ef965-bfdf-7441-ad8f-374c071d1f1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-753f-b2c8-2c08318e2053" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_019ef965-bfdf-7441-ad8f-374c071d1f1b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofcomprehensiveincome_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-710e-9406-9edf308fcaf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-796b-b46c-b14eca2ef3ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-710e-9406-9edf308fcaf4" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-796b-b46c-b14eca2ef3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_019ef965-bfdf-7c15-80fa-375b29897de6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-710e-9406-9edf308fcaf4" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_019ef965-bfdf-7c15-80fa-375b29897de6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_2" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofcomprehensiveincome_2"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-707d-81c1-661ae7e2d7da" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019ef965-bfdf-76cc-8a8f-543e4fb41c88" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-707d-81c1-661ae7e2d7da" xlink:to="loc_ifrs-full_ProfitLoss_019ef965-bfdf-76cc-8a8f-543e4fb41c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-bfdf-70b2-aa3e-b3d81ae91887" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-707d-81c1-661ae7e2d7da" xlink:to="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-bfdf-70b2-aa3e-b3d81ae91887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_019ef965-bfdf-7d0e-9c52-ffd910c39f03" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeFromDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-707d-81c1-661ae7e2d7da" xlink:to="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_019ef965-bfdf-7d0e-9c52-ffd910c39f03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofcashflows"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-71a3-8525-c4bd92bbaebb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-bfe0-7d66-879f-ac68b3c46f43" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-71a3-8525-c4bd92bbaebb" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-bfe0-7d66-879f-ac68b3c46f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-73bb-b55f-5e9022b5f25d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-71a3-8525-c4bd92bbaebb" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-73bb-b55f-5e9022b5f25d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-bfe0-7bb9-bd95-b81fa60d823a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-71a3-8525-c4bd92bbaebb" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-bfe0-7bb9-bd95-b81fa60d823a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019ef965-bfe0-7b11-8731-cc00cbca91b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-71a3-8525-c4bd92bbaebb" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019ef965-bfe0-7b11-8731-cc00cbca91b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_019ef965-bfe0-7cf3-9b92-f32b7a7a38d0" xlink:href="sny-20260630.xsd#sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-71a3-8525-c4bd92bbaebb" xlink:to="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_019ef965-bfe0-7cf3-9b92-f32b7a7a38d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-bfe0-727f-9e1a-cb6c7395b783" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-73f2-8557-d40e1f140df9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-bfe0-727f-9e1a-cb6c7395b783" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-73f2-8557-d40e1f140df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_019ef965-bfe0-7f6f-8c56-25216ce567d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-bfe0-727f-9e1a-cb6c7395b783" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_019ef965-bfe0-7f6f-8c56-25216ce567d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_019ef965-bfe0-7764-a4ef-3ccfe650cd85" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_019ef965-bfe0-7764-a4ef-3ccfe650cd85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_019ef965-bfe0-72f1-bbdd-b2b67f0ba3a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_019ef965-bfe0-72f1-bbdd-b2b67f0ba3a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_019ef965-bfe0-7b9d-803e-426080eec1f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_019ef965-bfe0-7b9d-803e-426080eec1f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_019ef965-bfe0-7cda-bc7f-872e62113399" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_019ef965-bfe0-7cda-bc7f-872e62113399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_019ef965-bfe0-76f4-8a2b-60fc71396c36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_019ef965-bfe0-76f4-8a2b-60fc71396c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019ef965-bfe0-7bca-b77e-64b1d2a92f39" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019ef965-bfe0-7bca-b77e-64b1d2a92f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019ef965-bfe0-7615-818d-4d681087ed7f" xlink:href="sny-20260630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019ef965-bfe0-7615-818d-4d681087ed7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019ef965-bfe0-7b81-96b8-61a2537ad6cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7598-9e08-e623e35bdb2e" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019ef965-bfe0-7b81-96b8-61a2537ad6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-bfe0-7c56-8951-8d08d167cf37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7662-bf27-b0fc730fa5e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-bfe0-7c56-8951-8d08d167cf37" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-7662-bf27-b0fc730fa5e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_019ef965-bfe0-7e1c-9176-52dec2156e24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-bfe0-7c56-8951-8d08d167cf37" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_019ef965-bfe0-7e1c-9176-52dec2156e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-73db-9e29-6e648daae9ab" xlink:href="sny-20260630.xsd#sny_NetCashProvidedByusedInContinuingInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019f1844-8163-7b19-95a5-2de19b84f813" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-73db-9e29-6e648daae9ab" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019f1844-8163-7b19-95a5-2de19b84f813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f1844-8163-78d9-b209-d392d96ecbd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-73db-9e29-6e648daae9ab" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f1844-8163-78d9-b209-d392d96ecbd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_019f1844-8163-7e57-a81f-cae4f9ad1b5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-73db-9e29-6e648daae9ab" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_019f1844-8163-7e57-a81f-cae4f9ad1b5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019f1844-8163-7383-99cd-3b0c6f7ec6f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-73db-9e29-6e648daae9ab" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019f1844-8163-7383-99cd-3b0c6f7ec6f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f1844-8163-7dae-ad64-0bbace904639" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-73db-9e29-6e648daae9ab" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f1844-8163-7dae-ad64-0bbace904639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_019f1844-8163-79ad-adfb-80373e452ef8" xlink:href="sny-20260630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-73db-9e29-6e648daae9ab" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_019f1844-8163-79ad-adfb-80373e452ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-72ea-9d20-4a19358ca698" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7185-9871-0b08602548ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-72ea-9d20-4a19358ca698" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7185-9871-0b08602548ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019ef965-bfe0-78be-9d83-653ee2ee97f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-72ea-9d20-4a19358ca698" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019ef965-bfe0-78be-9d83-653ee2ee97f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019ef965-bfe0-7998-b137-bff21bdbfe2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-72ea-9d20-4a19358ca698" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019ef965-bfe0-7998-b137-bff21bdbfe2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_019ef965-bfe0-735d-8854-9e3cdd1a3e0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-72ea-9d20-4a19358ca698" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_019ef965-bfe0-735d-8854-9e3cdd1a3e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_019ef965-bfe0-798f-9f89-993a104fccae" xlink:href="sny-20260630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-72ea-9d20-4a19358ca698" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_019ef965-bfe0-798f-9f89-993a104fccae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-7ce8-9a5d-d38b5b11f5ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019ef965-bfe0-788d-a906-bc799a23c3a5" xlink:href="sny-20260630.xsd#sny_NetCashProvidedByusedInContinuingInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-7ce8-9a5d-d38b5b11f5ef" xlink:to="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019ef965-bfe0-788d-a906-bc799a23c3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_019ef965-bfe0-7ffc-8370-c10282a2bdf6" xlink:href="sny-20260630.xsd#sny_NetCashProvidedByusedInDiscontinuingInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-7ce8-9a5d-d38b5b11f5ef" xlink:to="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_019ef965-bfe0-7ffc-8370-c10282a2bdf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations_019ef965-bfe0-704a-8b96-8343918d4942" xlink:href="sny-20260630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-7ce8-9a5d-d38b5b11f5ef" xlink:to="loc_sny_NetCashInflowFromDiscontinuedOperations_019ef965-bfe0-704a-8b96-8343918d4942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_019ef965-bfe0-7481-b5fe-fb8c844846e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_019ef965-bfe0-7481-b5fe-fb8c844846e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_019ef965-bfe0-7573-9bad-ad71ae1031c9" xlink:href="sny-20260630.xsd#sny_AdjustmentsForLossesGainsOnTransferOfBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_019ef965-bfe0-7573-9bad-ad71ae1031c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfe0-7d1d-b336-177b8240f54b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfe0-7d1d-b336-177b8240f54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_019ef965-bfe0-77f2-bfe8-6d195c8008fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_019ef965-bfe0-77f2-bfe8-6d195c8008fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_019ef965-bfe0-7a38-b1e2-aa189562d90c" xlink:href="sny-20260630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_019ef965-bfe0-7a38-b1e2-aa189562d90c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_019ef965-bfe0-7ffb-af1f-61fd2cd1e851" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_019ef965-bfe0-7ffb-af1f-61fd2cd1e851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_019ef965-bfe0-76ee-8d89-f16c8a41c3a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_019ef965-bfe0-76ee-8d89-f16c8a41c3a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfe0-7be2-af89-bfc9e4ace15d" xlink:href="sny-20260630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfe0-7be2-af89-bfc9e4ace15d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_019ef965-bfe0-7c0c-a92b-05adf3d67639" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_019ef965-bfe0-7c0c-a92b-05adf3d67639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_019ef965-bfe0-7a73-b6fb-1de3e32ad507" xlink:href="sny-20260630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_019ef965-bfe0-7a73-b6fb-1de3e32ad507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019ef965-bfe0-7736-9450-69cd47675675" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7c1e-98fc-12845acfcb4c" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019ef965-bfe0-7736-9450-69cd47675675" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f2-31c3-7f6b-848c-fa975a9061f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_019f22f2-31c3-7d72-a68c-cb2f638f0dd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f2-31c3-7f6b-848c-fa975a9061f8" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_019f22f2-31c3-7d72-a68c-cb2f638f0dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_019f22f2-31c3-73f7-89ae-a6614379b9c2" xlink:href="sny-20260630.xsd#sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f2-31c3-7f6b-848c-fa975a9061f8" xlink:to="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_019f22f2-31c3-73f7-89ae-a6614379b9c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_019f22f2-31c3-7892-abd6-c326e978b45c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f2-31c3-7f6b-848c-fa975a9061f8" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_019f22f2-31c3-7892-abd6-c326e978b45c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f22f2-31c3-7ded-9bb9-32ab2f38fa31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f2-31c3-7f6b-848c-fa975a9061f8" xlink:to="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f22f2-31c3-7ded-9bb9-32ab2f38fa31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_019f804f-3110-7f10-ae14-e11cf4812e5e" xlink:href="sny-20260630.xsd#sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f2-31c3-7f6b-848c-fa975a9061f8" xlink:to="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_019f804f-3110-7f10-ae14-e11cf4812e5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsRelatedPartyTransactions_019f1d45-c8d4-7ba7-8524-93b28e978011" xlink:href="sny-20260630.xsd#sny_AssetsRelatedPartyTransactions"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsRelatedPartyTransactions_019f1d45-c8d4-7f62-beb3-b9b85ac1f3bd" xlink:href="sny-20260630.xsd#sny_NonCurrentAssetsRelatedPartyTransactions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_AssetsRelatedPartyTransactions_019f1d45-c8d4-7ba7-8524-93b28e978011" xlink:to="loc_sny_NonCurrentAssetsRelatedPartyTransactions_019f1d45-c8d4-7f62-beb3-b9b85ac1f3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsRelatedPartyTransactions_019f1d45-c8d4-7dd3-8404-5009f4c4a077" xlink:href="sny-20260630.xsd#sny_CurrentAssetsRelatedPartyTransactions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_AssetsRelatedPartyTransactions_019f1d45-c8d4-7ba7-8524-93b28e978011" xlink:to="loc_sny_CurrentAssetsRelatedPartyTransactions_019f1d45-c8d4-7dd3-8404-5009f4c4a077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d46-afc8-7c5e-be4e-39faeafb3011" xlink:href="sny-20260630.xsd#sny_EquityAndLiabilitiesRelatedPartyTransactions"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions_019f1d46-afc8-71a3-9884-8298efb48ad0" xlink:href="sny-20260630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d46-afc8-7c5e-be4e-39faeafb3011" xlink:to="loc_sny_EquityRelatedPartyTransactions_019f1d46-afc8-71a3-9884-8298efb48ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d46-afc8-7d78-8f57-a94b8d3e19c8" xlink:href="sny-20260630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d46-afc8-7c5e-be4e-39faeafb3011" xlink:to="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d46-afc8-7d78-8f57-a94b8d3e19c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d46-850a-7eed-bd5c-b3d08c7e1d5b" xlink:href="sny-20260630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_019f1d46-850a-778e-acc6-14f7e9165c0c" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedPartyTransactions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d46-850a-7eed-bd5c-b3d08c7e1d5b" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_019f1d46-850a-778e-acc6-14f7e9165c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_019f1d46-850a-77e1-9e63-d22d20e9e687" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedPartyTransactions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d46-850a-7eed-bd5c-b3d08c7e1d5b" xlink:to="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_019f1d46-850a-77e1-9e63-d22d20e9e687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions_019f1d45-fafd-707a-bc9a-36092fd77f5f" xlink:href="sny-20260630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_019f1d45-fafd-7ab3-a5df-9a52baf34b29" xlink:href="sny-20260630.xsd#sny_EquityAttributableToEquityHoldersRelatedPartyTransactions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_EquityRelatedPartyTransactions_019f1d45-fafd-707a-bc9a-36092fd77f5f" xlink:to="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_019f1d45-fafd-7ab3-a5df-9a52baf34b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_019f1d45-fafd-7d60-afb1-914c2864fd4a" xlink:href="sny-20260630.xsd#sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_EquityRelatedPartyTransactions_019f1d45-fafd-707a-bc9a-36092fd77f5f" xlink:to="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_019f1d45-fafd-7d60-afb1-914c2864fd4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OthernoncurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-7a33-9d8b-e22d497be3e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_019ef965-c0a1-7a85-a2f6-1e51df916e56" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-7a33-9d8b-e22d497be3e8" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_019ef965-c0a1-7a85-a2f6-1e51df916e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_019ef965-c0a1-7a46-8fa2-f379d853f072" xlink:href="sny-20260630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-7a33-9d8b-e22d497be3e8" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_019ef965-c0a1-7a46-8fa2-f379d853f072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_019ef965-c0a1-7336-a24b-4229494534c0" xlink:href="sny-20260630.xsd#sny_PreFundedPensionObligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-7a33-9d8b-e22d497be3e8" xlink:to="loc_sny_PreFundedPensionObligations_019ef965-c0a1-7336-a24b-4229494534c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_019ef965-c0a1-7f7e-b9bf-9b357d2de85e" xlink:href="sny-20260630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-7a33-9d8b-e22d497be3e8" xlink:to="loc_sny_LongTermPrepaidExpenses_019ef965-c0a1-7f7e-b9bf-9b357d2de85e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables_019ef965-c0a1-7541-b97c-4d813ecce43c" xlink:href="sny-20260630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-7a33-9d8b-e22d497be3e8" xlink:to="loc_sny_NonCurrentLoansAndReceivables_019ef965-c0a1-7541-b97c-4d813ecce43c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_019f93f2-c5e0-77d8-bc79-04ac59fc1684" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-7a33-9d8b-e22d497be3e8" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_019f93f2-c5e0-77d8-bc79-04ac59fc1684" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofearningspershareDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_019ef965-c0a1-7559-aea6-0d9b2b3720ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_019ef965-c0a1-7d85-ac18-259fa9c38bd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_019ef965-c0a1-7559-aea6-0d9b2b3720ab" xlink:to="loc_ifrs-full_WeightedAverageShares_019ef965-c0a1-7d85-ac18-259fa9c38bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_019ef965-c0a1-7bf5-9ef2-50247b81e0d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_019ef965-c0a1-7559-aea6-0d9b2b3720ab" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_019ef965-c0a1-7bf5-9ef2-50247b81e0d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_019ef965-c0a1-7a74-8e4d-1e1d99002e10" xlink:href="sny-20260630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_019ef965-c0a1-7559-aea6-0d9b2b3720ab" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_019ef965-c0a1-7a74-8e4d-1e1d99002e10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_019ef965-c0a1-7df6-8276-2f3840fc0b28" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_019ef965-c0a1-7df6-8276-2f3840fc0b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_019ef965-c0a1-7963-a06b-b1a97c0d666d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_019ef965-c0a1-7963-a06b-b1a97c0d666d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_019ef965-c0a1-76b5-a4b7-dd49a163cab6" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_019ef965-c0a1-76b5-a4b7-dd49a163cab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_019ef965-c0a1-72f9-a911-68e5f3da7745" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_019ef965-c0a1-72f9-a911-68e5f3da7745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_019ef965-c0a1-7309-adac-4cee886ed999" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_019ef965-c0a1-7309-adac-4cee886ed999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_019ef965-c0a1-7b70-a7c9-b5921683417b" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_019ef965-c0a1-7b70-a7c9-b5921683417b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-782f-8209-bfa834062e3b" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-782f-8209-bfa834062e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_019ef965-c0a1-72e2-828e-65d01827f227" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_019ef965-c0a1-72e2-828e-65d01827f227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_019ef965-c0a1-7f93-bef4-fe565f67c9ee" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_019ef965-c0a1-7f93-bef4-fe565f67c9ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7559-8067-809fdaf51734" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7661-9f93-f2957a0cb3df" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7559-8067-809fdaf51734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-79b3-81b5-da69002b476d" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-79b3-81b5-da69002b476d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_019ef965-c0a1-7d79-9b8e-7023e76f600d" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_019ef965-c0a1-7d79-9b8e-7023e76f600d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_019ef965-c0a1-743c-b759-a15cb5455f76" xlink:href="sny-20260630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_019ef965-c0a1-743c-b759-a15cb5455f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_019ef965-c0a1-7e6c-8890-f0f1fed1b1cb" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_019ef965-c0a1-7e6c-8890-f0f1fed1b1cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_019ef965-c0a1-7a91-9e01-3800fc735fba" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_019ef965-c0a1-7a91-9e01-3800fc735fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_019ef965-c0a1-7ff5-bc4a-e36cd1a05459" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_019ef965-c0a1-7ff5-bc4a-e36cd1a05459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_019ef965-c0a1-7316-8314-283c416d6bb5" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-775f-90e8-ba43616ac660" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_019ef965-c0a1-7316-8314-283c416d6bb5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7f24-937a-7f48bd49cf06" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7537-aa6d-98d092ea086a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-7f24-937a-7f48bd49cf06" xlink:to="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7537-aa6d-98d092ea086a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-7ddb-9295-757b3dbba04f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-7f24-937a-7f48bd49cf06" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-7ddb-9295-757b3dbba04f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-72cc-88eb-fb4f86c064ac" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-7f24-937a-7f48bd49cf06" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-72cc-88eb-fb4f86c064ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7321-873b-f77af1bf86f6" xlink:href="sny-20260630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-731e-9b0c-36820808e1f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7321-873b-f77af1bf86f6" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-731e-9b0c-36820808e1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-7ac8-9027-60c62a497648" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7321-873b-f77af1bf86f6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-7ac8-9027-60c62a497648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-711f-aa82-bd5c8a1fe82b" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7321-873b-f77af1bf86f6" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-711f-aa82-bd5c8a1fe82b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-745c-98d1-77abb08f32bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_019ef965-c0a1-734f-a1e8-1d8e6404ee09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-745c-98d1-77abb08f32bf" xlink:to="loc_ifrs-full_BondsIssued_019ef965-c0a1-734f-a1e8-1d8e6404ee09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_019ef965-c0a1-731f-b57f-d5996d3753ce" xlink:href="sny-20260630.xsd#sny_OtherBankBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-745c-98d1-77abb08f32bf" xlink:to="loc_sny_OtherBankBorrowings_019ef965-c0a1-731f-b57f-d5996d3753ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_019ef965-c0a1-7f9d-b6c7-1b7c5293e9c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-745c-98d1-77abb08f32bf" xlink:to="loc_ifrs-full_OtherBorrowings_019ef965-c0a1-7f9d-b6c7-1b7c5293e9c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_019ef965-c0a1-7726-9ac1-1cec3ee65405" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-745c-98d1-77abb08f32bf" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_019ef965-c0a1-7726-9ac1-1cec3ee65405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-7ae2-b856-b49ace66153d" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_019ef965-c0a1-745c-98d1-77abb08f32bf" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-7ae2-b856-b49ace66153d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019f6b12-766f-7dd9-a84b-b39aa7d0a938" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019f6b12-766f-7be6-b968-8bb1f0e18e2d" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019f6b12-766f-7dd9-a84b-b39aa7d0a938" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019f6b12-766f-7be6-b968-8bb1f0e18e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019f6b12-766f-7d6c-af6e-5dda7a6bef2b" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019f6b12-766f-7dd9-a84b-b39aa7d0a938" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019f6b12-766f-7d6c-af6e-5dda7a6bef2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c0a1-7bd7-a540-df43fa3c0de3" xlink:href="sny-20260630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7bc4-a886-4e6242731d03" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c0a1-7bd7-a540-df43fa3c0de3" xlink:to="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7bc4-a886-4e6242731d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_019ef965-c0a1-741f-9c4a-0e78a1b47fed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c0a1-7bd7-a540-df43fa3c0de3" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_019ef965-c0a1-741f-9c4a-0e78a1b47fed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpense_019f93f5-922a-7bfd-ad84-4dd67f61298a" xlink:href="sny-20260630.xsd#sny_OtherOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019f93f5-922a-72f3-a790-1cc5748d36c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_OtherOperatingExpense_019f93f5-922a-7bfd-ad84-4dd67f61298a" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019f93f5-922a-72f3-a790-1cc5748d36c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f93f5-922a-70e3-86eb-612d7316d6a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_OtherOperatingExpense_019f93f5-922a-7bfd-ad84-4dd67f61298a" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f93f5-922a-70e3-86eb-612d7316d6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncome_019f1e33-d165-7195-b9e4-c024f3222d7a" xlink:href="sny-20260630.xsd#sny_OtherOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossOnDivestmentOfProducts_019f1e33-d165-77e2-a1f1-59172abb8cce" xlink:href="sny-20260630.xsd#sny_GainsLossOnDivestmentOfProducts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_OtherOperatingIncome_019f1e33-d165-7195-b9e4-c024f3222d7a" xlink:to="loc_sny_GainsLossOnDivestmentOfProducts_019f1e33-d165-77e2-a1f1-59172abb8cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_019f1e33-d165-7a25-89fd-7dae09a030d1" xlink:href="sny-20260630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_OtherOperatingIncome_019f1e33-d165-7195-b9e4-c024f3222d7a" xlink:to="loc_sny_IncomeResultingFromOutLicensing_019f1e33-d165-7a25-89fd-7dae09a030d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f1e33-d165-7ef5-af05-fcdd04fca396" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_OtherOperatingIncome_019f1e33-d165-7195-b9e4-c024f3222d7a" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f1e33-d165-7ef5-af05-fcdd04fca396" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-73a0-99c1-a309e8ffec84" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_019ef965-c0a1-748b-a111-a623ddc36176" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-73a0-99c1-a309e8ffec84" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_019ef965-c0a1-748b-a111-a623ddc36176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts_019ef965-c168-7ef7-a972-a693dfa191dd" xlink:href="sny-20260630.xsd#sny_OtherRestructuringCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-73a0-99c1-a309e8ffec84" xlink:to="loc_sny_OtherRestructuringCosts_019ef965-c168-7ef7-a972-a693dfa191dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_019ef965-c168-7b71-84e7-b5af68a29517" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-73a0-99c1-a309e8ffec84" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_019ef965-c168-7b71-84e7-b5af68a29517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_019ef965-c168-74b0-b786-e78c974f95b7" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-73a0-99c1-a309e8ffec84" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_019ef965-c168-74b0-b786-e78c974f95b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#FinancialexpensesandincomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_019ef965-c168-7303-a7ea-bcf4c648500a" xlink:href="sny-20260630.xsd#sny_CostOfDebtNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_019ef965-c168-746b-9752-f7df9996343f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_019ef965-c168-7303-a7ea-bcf4c648500a" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_019ef965-c168-746b-9752-f7df9996343f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_019ef965-c168-749e-acc9-d7e897ad514f" xlink:href="sny-20260630.xsd#sny_InterestIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_019ef965-c168-7303-a7ea-bcf4c648500a" xlink:to="loc_sny_InterestIncome_019ef965-c168-749e-acc9-d7e897ad514f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-7611-ab0b-7dda1bcde0b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019ef965-c168-7c29-b5dd-e40012008f9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-7611-ab0b-7dda1bcde0b6" xlink:to="loc_ifrs-full_FinanceCosts_019ef965-c168-7c29-b5dd-e40012008f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019ef965-c168-7c5e-8b87-12bca4611063" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-7611-ab0b-7dda1bcde0b6" xlink:to="loc_ifrs-full_FinanceIncome_019ef965-c168-7c5e-8b87-12bca4611063" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1" xlink:type="simple" xlink:href="sny-20260630.xsd#FinancialexpensesandincomeDetails_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_019ef965-c168-791a-82fc-cb34821ea0c0" xlink:href="sny-20260630.xsd#sny_CostOfDebtNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:to="loc_sny_CostOfDebtNet_019ef965-c168-791a-82fc-cb34821ea0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_019ef965-c168-7638-8e57-8551ffdea82e" xlink:href="sny-20260630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_019ef965-c168-7638-8e57-8551ffdea82e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_019ef965-c168-7d6f-aeb1-e42686a91350" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_019ef965-c168-7d6f-aeb1-e42686a91350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_019ef965-c168-7dd0-9176-13ae7a154fec" xlink:href="sny-20260630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_019ef965-c168-7dd0-9176-13ae7a154fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_019ef965-c168-7d1c-bc37-b83325213594" xlink:href="sny-20260630.xsd#sny_ImpairmentLossesOnFinancialAssetsNetOfReversals"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:to="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_019ef965-c168-7d1c-bc37-b83325213594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_019ef965-c168-7d8b-9c35-9a8f45e63339" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_019ef965-c168-7d8b-9c35-9a8f45e63339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_019f65d2-401d-7ceb-8125-7f2863bb5764" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-753a-af59-b6dc305a02ea" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_019f65d2-401d-7ceb-8125-7f2863bb5764" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-c168-7f18-83c6-188ea328f1ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_019ef965-c168-7ee4-bf11-3f41c9034617" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-c168-7f18-83c6-188ea328f1ab" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_019ef965-c168-7ee4-bf11-3f41c9034617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_019ef965-c168-7ca9-ae8f-c9f7c1ade3cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-c168-7f18-83c6-188ea328f1ab" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_019ef965-c168-7ca9-ae8f-c9f7c1ade3cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-773d-b0a7-454237248627" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_019ef965-c168-7ced-87f2-59e0cdd253b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-773d-b0a7-454237248627" xlink:to="loc_ifrs-full_ApplicableTaxRate_019ef965-c168-7ced-87f2-59e0cdd253b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_019ef965-c168-74e6-a05a-72c6e3bfb993" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-773d-b0a7-454237248627" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_019ef965-c168-74e6-a05a-72c6e3bfb993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxEffectRelatedToAmlitelimab_019ef965-c168-798a-be30-363a419dc672" xlink:href="sny-20260630.xsd#sny_TaxEffectRelatedToAmlitelimab"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-773d-b0a7-454237248627" xlink:to="loc_sny_TaxEffectRelatedToAmlitelimab_019ef965-c168-798a-be30-363a419dc672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_019ef965-c168-75d1-96bc-469804b8a09a" xlink:href="sny-20260630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-773d-b0a7-454237248627" xlink:to="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_019ef965-c168-75d1-96bc-469804b8a09a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_019f93f6-056b-7772-968b-03b9cba4d281" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-773d-b0a7-454237248627" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_019f93f6-056b-7772-968b-03b9cba4d281" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019f6b41-0d75-7176-8969-11d04436fb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_019f6b41-0d75-7c5a-97fd-09479f456a77" xlink:href="sny-20260630.xsd#sny_RevenueFromVaxServeSalesOfNonSanofiProducts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherRevenue_019f6b41-0d75-7176-8969-11d04436fb96" xlink:to="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_019f6b41-0d75-7c5a-97fd-09479f456a77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_019f6b41-0d76-76b2-841a-513ec8e99f6e" xlink:href="sny-20260630.xsd#sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherRevenue_019f6b41-0d75-7176-8969-11d04436fb96" xlink:to="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_019f6b41-0d76-76b2-841a-513ec8e99f6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties_019f6b41-0d76-71d8-8421-afdf5e7ca710" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherRevenue_019f6b41-0d75-7176-8969-11d04436fb96" xlink:to="loc_ifrs-full_RevenueFromRoyalties_019f6b41-0d76-71d8-8421-afdf5e7ca710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherRevenue_019f6b41-0d76-7015-afa4-a150ca8e9b35" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherRevenue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherRevenue_019f6b41-0d75-7176-8969-11d04436fb96" xlink:to="loc_sny_MiscellaneousOtherRevenue_019f6b41-0d76-7015-afa4-a150ca8e9b35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofSegmentResultsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019f22b7-84c8-729c-97a1-c241953253b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019f22b7-84c8-729c-97a1-c241953253b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019f22b7-84c8-7c23-a7e7-36c1276a1510" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_ifrs-full_OtherRevenue_019f22b7-84c8-7c23-a7e7-36c1276a1510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_019f22b7-84c8-713a-b89d-63e9b60a2e4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_ifrs-full_CostOfSales_019f22b7-84c8-713a-b89d-63e9b60a2e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_019f22b7-84c8-73f0-a272-041a7fb54ee1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_019f22b7-84c8-73f0-a272-041a7fb54ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019f22b7-84c8-7421-8466-c881a1c6418e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019f22b7-84c8-7421-8466-c881a1c6418e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_019f22b7-84c8-7d71-99d0-d676135bdfda" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_019f22b7-84c8-7d71-99d0-d676135bdfda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019f22b7-84c8-7b0f-9e98-b5bec295c6c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019f22b7-84c8-7b0f-9e98-b5bec295c6c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019f22b7-84c8-7e1c-9a3c-f9f0b02d0135" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_019f22b7-84c8-7b84-a78e-a4fa41d35902" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019f22b7-84c8-7e1c-9a3c-f9f0b02d0135" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_019ef965-c168-7a47-b588-0e6c7b085abe" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_sny_BusinessOperatingIncome_019ef965-c168-7a47-b588-0e6c7b085abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-71bd-a3f1-ae8d805a4b8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-71bd-a3f1-ae8d805a4b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-787e-99c0-8794c06f380f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-787e-99c0-8794c06f380f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c168-7a43-bb58-9a020fd3db02" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c168-7a43-bb58-9a020fd3db02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-c168-76a1-83af-de3965751f2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-c168-76a1-83af-de3965751f2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-c168-7182-a0a1-6acf33c1c7f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-c168-7182-a0a1-6acf33c1c7f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_019ef965-c168-72e3-9775-8c196d710e73" xlink:href="sny-20260630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_019ef965-c168-72e3-9775-8c196d710e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c168-760e-881d-76aecaf0d5ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c168-760e-881d-76aecaf0d5ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_019f9345-35a2-718c-a32c-d84c384f430c" xlink:href="sny-20260630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-7f4f-8c06-ab4c1857aa3c" xlink:to="loc_sny_OtherGainsLossesAndLitigation_019f9345-35a2-718c-a32c-d84c384f430c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>sny-20260630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ef965-bc7d-7da2-bb2f-04e26164615a,g:d543d692-5b77-4127-b010-746b44ca828b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20260630.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_019ef965-bfdf-7090-b8b1-b59cf2c46842" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_EntitiesTable_019ef965-bfdf-7090-b8b1-b59cf2c46842" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019ef965-bfdf-7666-859c-c0eb9c2b69d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentType_019ef965-bfdf-7666-859c-c0eb9c2b69d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019ef965-bfdf-762a-b1b8-5cb2b8ae0cb1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_EntityRegistrantName_019ef965-bfdf-762a-b1b8-5cb2b8ae0cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019ef965-bfdf-7f3a-9ac6-a64f7064fcae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_AmendmentFlag_019ef965-bfdf-7f3a-9ac6-a64f7064fcae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019ef965-bfdf-734a-a0bb-1b59de139baf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_EntityCentralIndexKey_019ef965-bfdf-734a-a0bb-1b59de139baf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019ef965-bfdf-7f61-bf6d-e175b66ff305" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_CurrentFiscalYearEndDate_019ef965-bfdf-7f61-bf6d-e175b66ff305" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019ef965-bfdf-7c02-9a65-24409aee78ed" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentPeriodEndDate_019ef965-bfdf-7c02-9a65-24409aee78ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019ef965-bfdf-7c61-b12c-6092d45921ef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentFiscalYearFocus_019ef965-bfdf-7c61-b12c-6092d45921ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019ef965-bfdf-7ccc-8b84-76056889ade2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019ef965-bfdf-7ccc-8b84-76056889ade2" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofchangesinequity"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_019ef965-bfdf-78be-9d87-04119ea6bd7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_019ef965-bfdf-78be-9d87-04119ea6bd7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-bfdf-742f-9516-94e4fd46adf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_019ef965-bfdf-78be-9d87-04119ea6bd7f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-bfdf-742f-9516-94e4fd46adf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-742f-9516-94e4fd46adf4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-bfdf-742f-9516-94e4fd46adf4" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-742f-9516-94e4fd46adf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-bfdf-742f-9516-94e4fd46adf4" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019ef965-bfdf-7889-92ff-06c6e3f1dfe4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_IssuedCapitalMember_019ef965-bfdf-7889-92ff-06c6e3f1dfe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_019ef965-bfdf-76fb-a6ff-e7dba7e7024b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_019ef965-bfdf-76fb-a6ff-e7dba7e7024b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_019ef965-bfdf-7d3c-961d-fc5d361d0dbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_TreasurySharesMember_019ef965-bfdf-7d3c-961d-fc5d361d0dbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_019ef965-bfdf-7edb-a179-6add43756ddb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_RetainedEarningsMember_019ef965-bfdf-7edb-a179-6add43756ddb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019ef965-bfdf-724d-a3b6-2c1582822570" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019ef965-bfdf-724d-a3b6-2c1582822570" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-bfdf-7e55-b617-57d99c68b1af" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-bfdf-7e55-b617-57d99c68b1af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_019ef965-bfdf-7743-a5b9-e8ecf322978a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_019ef965-bfdf-7743-a5b9-e8ecf322978a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019ef965-bfdf-7f14-9c34-6dd8ec13a533" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_Equity_019ef965-bfdf-7f14-9c34-6dd8ec13a533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_019ef965-bfdf-7f6d-a114-4dc21a64d99e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_019ef965-bfdf-7f6d-a114-4dc21a64d99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7f4d-ba24-aeb52048a6fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7f4d-ba24-aeb52048a6fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-7773-9c62-8eefe2f7bd8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-7773-9c62-8eefe2f7bd8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_019ef965-bfdf-7745-8969-0dfa1e2b4137" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_019ef965-bfdf-7745-8969-0dfa1e2b4137" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_019ef965-bfe0-77cf-801f-1624ff8c52f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_019ef965-bfe0-77cf-801f-1624ff8c52f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_019ef965-bfe0-7b38-aec1-8cb308cbc60f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_019ef965-bfe0-7b38-aec1-8cb308cbc60f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_019ef965-bfe0-7df0-ae0c-b374bcba5cac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_019ef965-bfe0-7df0-ae0c-b374bcba5cac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxesOnShareCancellations_019f182d-bdba-73a0-b7a2-81c924ef954d" xlink:href="sny-20260630.xsd#sny_TaxesOnShareCancellations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_TaxesOnShareCancellations_019f182d-bdba-73a0-b7a2-81c924ef954d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:href="sny-20260630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019ef965-bfe0-7ba6-855e-a109422929e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019ef965-bfe0-7ba6-855e-a109422929e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_019ef965-bfe0-76f0-811a-032b4808af0c" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_019ef965-bfe0-76f0-811a-032b4808af0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_019ef965-bfe0-7f66-a2ab-baa71c777960" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_019ef965-bfe0-7f66-a2ab-baa71c777960" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_019ef965-bfe0-7e16-87ae-8055e12cfee9" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_019ef965-bfe0-7e16-87ae-8055e12cfee9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_019f1821-0a4d-746f-9bb2-64ed89c1c453" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_019f1821-0a4d-746f-9bb2-64ed89c1c453" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_019ef965-bfe0-7be5-80c3-a3b7db244c81" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_019ef965-bfe0-7be5-80c3-a3b7db244c81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions_019f1829-85a4-712b-9265-74174e2231e9" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions_019f1829-85a4-712b-9265-74174e2231e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019ef965-bfe0-7cd5-bdf6-2ae83aab90b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_019ef965-bfe0-77fd-9ca0-17de12eef5d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_019ef965-bfe0-77fd-9ca0-17de12eef5d1" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedstatementsofcashflowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-bfe0-79f2-9f7c-e9b8380884fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-bfe0-79f2-9f7c-e9b8380884fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-79f2-9f7c-e9b8380884fb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-bfe0-79f2-9f7c-e9b8380884fb" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-79f2-9f7c-e9b8380884fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-7746-bee6-6b08c7e78d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-bfe0-79f2-9f7c-e9b8380884fb" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-7746-bee6-6b08c7e78d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f6a38-f95c-7fbb-b32a-5a9a911e7c08" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-7746-bee6-6b08c7e78d5a" xlink:to="loc_sny_OpellaBusinessMember_019f6a38-f95c-7fbb-b32a-5a9a911e7c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019f1851-cb57-7f55-b029-087b0eeb191b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019f1851-cb57-7f55-b029-087b0eeb191b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7f55-b029-087b0eeb191b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019f1851-cb57-7f55-b029-087b0eeb191b" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7f55-b029-087b0eeb191b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7ca8-ab6b-7eed6e7d56ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019f1851-cb57-7f55-b029-087b0eeb191b" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7ca8-ab6b-7eed6e7d56ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_019f1851-eea4-7596-b269-b4bf6fdbb7fb" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7ca8-ab6b-7eed6e7d56ab" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_019f1851-eea4-7596-b269-b4bf6fdbb7fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f8a39-0919-7536-bdc2-752e2183ba71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f8a39-0919-7536-bdc2-752e2183ba71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7536-bdc2-752e2183ba71_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f8a39-0919-7536-bdc2-752e2183ba71" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7536-bdc2-752e2183ba71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7538-bc0b-d4f80d6959ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f8a39-0919-7536-bdc2-752e2183ba71" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7538-bc0b-d4f80d6959ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f8a39-710f-7a4e-95f5-b9c18e30392d" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7538-bc0b-d4f80d6959ea" xlink:to="loc_sny_DynavaxMember_019f8a39-710f-7a4e-95f5-b9c18e30392d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense_019f184e-4e54-719d-b7dc-f25daf9616ea" xlink:href="sny-20260630.xsd#sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense_019f184e-4e54-719d-b7dc-f25daf9616ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019ef965-bfe0-729c-b987-c28638ce88ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019ef965-bfe0-729c-b987-c28638ce88ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_019ef965-bfe0-7851-9904-2c325da3ffb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_019ef965-bfe0-7851-9904-2c325da3ffb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_019ef965-bfe0-776a-b5ff-4196f14fff71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_019ef965-bfe0-776a-b5ff-4196f14fff71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_019ef965-bfe0-7546-87e4-f5519bec3226" xlink:href="sny-20260630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_019ef965-bfe0-7546-87e4-f5519bec3226" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfe0-7851-b690-bfa79134be37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfe0-7851-b690-bfa79134be37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019f1851-814a-7e83-9d4a-8714928756d4" xlink:href="sny-20260630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019f1851-814a-7e83-9d4a-8714928756d4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-bfe0-70e8-a64a-5e4416991b65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-bfe0-70e8-a64a-5e4416991b65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019ef965-bfe0-71c4-bb80-7c5ca79846f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-bfe0-70e8-a64a-5e4416991b65" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019ef965-bfe0-71c4-bb80-7c5ca79846f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-71c4-bb80-7c5ca79846f4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-bfe0-71c4-bb80-7c5ca79846f4" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-71c4-bb80-7c5ca79846f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-bfe0-71c4-bb80-7c5ca79846f4" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_019ef965-bfe0-7dc1-86d1-1a4dba7c5daf" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:to="loc_country_AR_019ef965-bfe0-7dc1-86d1-1a4dba7c5daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_019ef965-bfe0-70f8-bb86-fffd83e1ec33" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:to="loc_country_TR_019ef965-bfe0-70f8-bb86-fffd83e1ec33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_019ef965-bfe0-7a12-854f-9242c2dacc3a" xlink:href="sny-20260630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:to="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_019ef965-bfe0-7a12-854f-9242c2dacc3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementClassificationIFRS18NumberOfCategories_019fa2e1-50de-7daa-89f1-b0ff18a088a0" xlink:href="sny-20260630.xsd#sny_IncomeStatementClassificationIFRS18NumberOfCategories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:to="loc_sny_IncomeStatementClassificationIFRS18NumberOfCategories_019fa2e1-50de-7daa-89f1-b0ff18a088a0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#Significantinformationforthefirsthalfof2026AdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f22f5-8d30-7a5a-a211-f654ef2dc1a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f22f5-8d30-7a5a-a211-f654ef2dc1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-7a5a-a211-f654ef2dc1a3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f22f5-8d30-7a5a-a211-f654ef2dc1a3" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-7a5a-a211-f654ef2dc1a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-76c4-90d4-13c30a4df40f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f22f5-8d30-7a5a-a211-f654ef2dc1a3" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-76c4-90d4-13c30a4df40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f22f5-8d30-7f9f-ad07-fb02b14a9978" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-76c4-90d4-13c30a4df40f" xlink:to="loc_sny_DynavaxMember_019f22f5-8d30-7f9f-ad07-fb02b14a9978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f8f32-368c-7bf5-a6f2-8f0932b7d260" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:to="loc_sny_DisposalGroupAxis_019f8f32-368c-7bf5-a6f2-8f0932b7d260" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f8f32-368c-7bf5-a6f2-8f0932b7d260_default" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DisposalGroupAxis_019f8f32-368c-7bf5-a6f2-8f0932b7d260" xlink:to="loc_sny_DisposalGroupDomain_019f8f32-368c-7bf5-a6f2-8f0932b7d260_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f8f32-368c-7125-8e1d-e44f5620a59b" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DisposalGroupAxis_019f8f32-368c-7bf5-a6f2-8f0932b7d260" xlink:to="loc_sny_DisposalGroupDomain_019f8f32-368c-7125-8e1d-e44f5620a59b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedleyMember_019f22f6-0990-7291-af2b-b7ca10c90362" xlink:href="sny-20260630.xsd#sny_MedleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisposalGroupDomain_019f8f32-368c-7125-8e1d-e44f5620a59b" xlink:to="loc_sny_MedleyMember_019f22f6-0990-7291-af2b-b7ca10c90362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019f8f33-6621-7fb5-a511-e3dc3dd9f212" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:to="loc_ifrs-full_SegmentsAxis_019f8f33-6621-7fb5-a511-e3dc3dd9f212" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7fb5-a511-e3dc3dd9f212_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_019f8f33-6621-7fb5-a511-e3dc3dd9f212" xlink:to="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7fb5-a511-e3dc3dd9f212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7bb7-99e7-e41ed89303a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_019f8f33-6621-7fb5-a511-e3dc3dd9f212" xlink:to="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7bb7-99e7-e41ed89303a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019f8f33-8ce7-72be-b888-05c6622680f0" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7bb7-99e7-e41ed89303a4" xlink:to="loc_sny_BiopharmaSegmentMember_019f8f33-8ce7-72be-b888-05c6622680f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare_019f22f5-8d30-7906-9a2c-a6e5f0f9bc58" xlink:href="sny-20260630.xsd#sny_BusinessCombinationEquityInterestsOfAcquirerPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare_019f22f5-8d30-7906-9a2c-a6e5f0f9bc58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEquityValueOfAcquirer_019f8bd1-f39c-7c09-bb1a-7f89b7705fa9" xlink:href="sny-20260630.xsd#sny_BusinessCombinationEquityValueOfAcquirer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_BusinessCombinationEquityValueOfAcquirer_019f8bd1-f39c-7c09-bb1a-7f89b7705fa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f8f2c-b043-7280-9a5f-51190e54b49a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f8f2c-b043-7280-9a5f-51190e54b49a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f5-8d30-73fd-b44c-54d9a9e8f82d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f5-8d30-73fd-b44c-54d9a9e8f82d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueOfAcquiree_019f8f33-05d2-7734-a315-365af77efce2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueOfAcquiree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_RevenueOfAcquiree_019f8f33-05d2-7734-a315-365af77efce2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate_019f8f2e-40c7-792e-9114-be6d1859ff22" xlink:href="sny-20260630.xsd#sny_OperatingIncomeOfAcquireeSinceAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate_019f8f2e-40c7-792e-9114-be6d1859ff22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossOfAcquiree_019f8f2f-1a38-72e3-96b3-3a1829f02c8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossOfAcquiree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_ProfitLossOfAcquiree_019f8f2f-1a38-72e3-96b3-3a1829f02c8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate_019f8f2f-fd66-7e17-8de9-1453e4c99e43" xlink:href="sny-20260630.xsd#sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate_019f8f2f-fd66-7e17-8de9-1453e4c99e43" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7121-8b48-e21d6d2b07e8" xlink:href="sny-20260630.xsd#sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7121-8b48-e21d6d2b07e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7be8-b7d4-9fad9c9c2a56" xlink:href="sny-20260630.xsd#sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7be8-b7d4-9fad9c9c2a56" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f22f6-74b7-7455-9519-70b6f3c62761" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f22f6-74b7-7455-9519-70b6f3c62761" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfOwnershipInterestDisposed_019f8f38-1342-7915-82fd-0f91fdaa64bf" xlink:href="sny-20260630.xsd#sny_PercentageOfOwnershipInterestDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_PercentageOfOwnershipInterestDisposed_019f8f38-1342-7915-82fd-0f91fdaa64bf" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f1-967c-7f53-88d6-0eed6a4f40e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f1-967c-7f53-88d6-0eed6a4f40e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f22f1-967c-7160-96c0-b3273b051d1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f1-967c-7f53-88d6-0eed6a4f40e6" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f22f1-967c-7160-96c0-b3273b051d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7160-96c0-b3273b051d1c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f22f1-967c-7160-96c0-b3273b051d1c" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7160-96c0-b3273b051d1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7c14-8408-4f480e4aaf0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f22f1-967c-7160-96c0-b3273b051d1c" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7c14-8408-4f480e4aaf0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f22f1-967c-7518-99e8-1721c80686ae" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7c14-8408-4f480e4aaf0b" xlink:to="loc_sny_DynavaxMember_019f22f1-967c-7518-99e8-1721c80686ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e3b-865b-bd2156476dba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e3b-865b-bd2156476dba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_019f22f1-967c-7042-a524-144553c4d7fa" xlink:href="sny-20260630.xsd#sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_019f22f1-967c-7042-a524-144553c4d7fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e16-8471-bf9c5e0e32d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e16-8471-bf9c5e0e32d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f804e-b583-7d51-9e54-7163433619c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f804e-b583-7d51-9e54-7163433619c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_019f22f1-967c-7c17-9173-852473636967" xlink:href="sny-20260630.xsd#sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_019f22f1-967c-7c17-9173-852473636967" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f1-967c-721d-a194-ad87eb51cafc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f1-967c-721d-a194-ad87eb51cafc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f1-967c-7ac9-a2db-033a5370d0fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f1-967c-7ac9-a2db-033a5370d0fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_019f22f1-967c-7993-b330-f5c504c56135" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_019f22f1-967c-7993-b330-f5c504c56135" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c0a1-70fe-8471-b37766416b2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c0a1-70fe-8471-b37766416b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-70fe-8471-b37766416b2c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c0a1-70fe-8471-b37766416b2c" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-70fe-8471-b37766416b2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c0a1-70fe-8471-b37766416b2c" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c0a1-77b6-b70e-89ee5366f982" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c0a1-77b6-b70e-89ee5366f982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OPALJVCoMember_019f932d-0f61-745c-a1f2-68ea2a0aa183" xlink:href="sny-20260630.xsd#sny_OPALJVCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:to="loc_sny_OPALJVCoMember_019f932d-0f61-745c-a1f2-68ea2a0aa183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c0a1-766f-b805-4d3bc3ab77f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c0a1-766f-b805-4d3bc3ab77f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-766f-b805-4d3bc3ab77f2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c0a1-766f-b805-4d3bc3ab77f2" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-766f-b805-4d3bc3ab77f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-7822-a4fa-588172608eb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c0a1-766f-b805-4d3bc3ab77f2" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-7822-a4fa-588172608eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_019ef965-c0a1-7e28-a7e8-20253b822a7c" xlink:href="sny-20260630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-7822-a4fa-588172608eb6" xlink:to="loc_sny_ManufacturingAndSupplyMember_019ef965-c0a1-7e28-a7e8-20253b822a7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_019ef965-c0a1-7819-929a-ba064f5ff53a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_019ef965-c0a1-7819-929a-ba064f5ff53a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_019ef965-c0a1-75f8-8e5b-8963d144fa3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:to="loc_ifrs-full_InterestCostsCapitalised_019ef965-c0a1-75f8-8e5b-8963d144fa3c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#GoodwillandotherintangibleassetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c0a1-74f6-883d-848cd26a886d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c0a1-74f6-883d-848cd26a886d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7da9-88af-233f52796252" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c0a1-74f6-883d-848cd26a886d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7da9-88af-233f52796252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-7da9-88af-233f52796252_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7da9-88af-233f52796252" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-7da9-88af-233f52796252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7da9-88af-233f52796252" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_019ef965-c0a1-7c0f-9b70-3104b3891d2f" xlink:href="sny-20260630.xsd#sny_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:to="loc_sny_MarketedProductsMember_019ef965-c0a1-7c0f-9b70-3104b3891d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_019ef965-c0a1-717f-bfc7-96321ae7790f" xlink:href="sny-20260630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:to="loc_sny_TechnologicalPlatformsMember_019ef965-c0a1-717f-bfc7-96321ae7790f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_019ef965-c0a1-7f49-a8af-8c6d64f9f489" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:to="loc_ifrs-full_Goodwill_019ef965-c0a1-7f49-a8af-8c6d64f9f489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c0a1-78c7-9730-a81ff2ed3232" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c0a1-78c7-9730-a81ff2ed3232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cde-b6c5-95d94d7aed52" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cde-b6c5-95d94d7aed52" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7c89-9083-a1dda844eb65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7c89-9083-a1dda844eb65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-7c89-9083-a1dda844eb65_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7c89-9083-a1dda844eb65" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-7c89-9083-a1dda844eb65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7c89-9083-a1dda844eb65" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember_019ef965-c0a1-7135-b06f-c77e609d4edf" xlink:href="sny-20260630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:to="loc_sny_AcquiredResearchAndDevelopmentMember_019ef965-c0a1-7135-b06f-c77e609d4edf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember_019ef965-c0a1-7c63-bbbd-96def76ab4cb" xlink:href="sny-20260630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:to="loc_sny_ProductsTrademarksAndOtherRightsMember_019ef965-c0a1-7c63-bbbd-96def76ab4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_019ef965-c0a1-7296-9146-106b81ec7d74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:to="loc_ifrs-full_ComputerSoftwareMember_019ef965-c0a1-7296-9146-106b81ec7d74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-751c-8dea-59681123d7f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-751c-8dea-59681123d7f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751c-8dea-59681123d7f5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-751c-8dea-59681123d7f5" xlink:to="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751c-8dea-59681123d7f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-751c-8dea-59681123d7f5" xlink:to="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7d4c-a60b-61c2c24c4b59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7d4c-a60b-61c2c24c4b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_019ef965-c0a1-76cc-b2fa-91a3112d8f9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_019ef965-c0a1-76cc-b2fa-91a3112d8f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019f18b6-3626-7368-bc1f-66e9a6743a09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019f18b6-3626-7368-bc1f-66e9a6743a09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cf2-a779-3ec818b3c944" xlink:href="sny-20260630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cf2-a779-3ec818b3c944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-77cf-9538-9d00173aa893" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-77cf-9538-9d00173aa893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-76d4-b734-5b24b40d0871" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-76d4-b734-5b24b40d0871" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7bca-b489-7c7393fd1ad0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7bca-b489-7c7393fd1ad0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-741a-9b75-6a9f217fb397" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-741a-9b75-6a9f217fb397" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7c55-a9b7-b0138f70c5f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7c55-a9b7-b0138f70c5f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7af9-bbad-2a8a0260c008" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7af9-bbad-2a8a0260c008" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7e99-9d7d-4615d783e196" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ImpairmentofintangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_019f8f3e-0081-7dd0-a3e5-f014731bd400" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7d62-b7a8-6404fdf811c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_019f8f3e-0081-7dd0-a3e5-f014731bd400" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7d62-b7a8-6404fdf811c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f8f3e-0081-7abe-8680-68406015dbd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7d62-b7a8-6404fdf811c7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f8f3e-0081-7abe-8680-68406015dbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7abe-8680-68406015dbd2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f8f3e-0081-7abe-8680-68406015dbd2" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7abe-8680-68406015dbd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7d87-83f6-7e5596750d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f8f3e-0081-7abe-8680-68406015dbd2" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7d87-83f6-7e5596750d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmlitelimabAssetMember_019f8f3e-c0b4-71fc-a726-c7243f937fbd" xlink:href="sny-20260630.xsd#sny_AmlitelimabAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7d87-83f6-7e5596750d91" xlink:to="loc_sny_AmlitelimabAssetMember_019f8f3e-c0b4-71fc-a726-c7243f937fbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8f3e-0081-79d6-9e0f-435a097dfe24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_019f8f3e-0081-7dd0-a3e5-f014731bd400" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8f3e-0081-79d6-9e0f-435a097dfe24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c0a1-7d75-ae84-882c2662d861" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c0a1-7d75-ae84-882c2662d861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7d75-ae84-882c2662d861_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c0a1-7d75-ae84-882c2662d861" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7d75-ae84-882c2662d861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c0a1-7d75-ae84-882c2662d861" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OPALJVCoMember_019ef965-c0a1-7a88-938f-c1084bbb5d43" xlink:href="sny-20260630.xsd#sny_OPALJVCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:to="loc_sny_OPALJVCoMember_019ef965-c0a1-7a88-938f-c1084bbb5d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_019ef965-c0a1-7323-82ad-07038bc1abb5" xlink:href="sny-20260630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:to="loc_sny_EuroapiMember_019ef965-c0a1-7323-82ad-07038bc1abb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_019ef965-c0a1-76b8-b205-00fa23595b66" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_019ef965-c0a1-76b8-b205-00fa23595b66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_019ef965-c0a1-7c0b-81c8-123282c0987f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_ifrs-full_JointVenturesAxis_019ef965-c0a1-7c0b-81c8-123282c0987f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-7c0b-81c8-123282c0987f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_019ef965-c0a1-7c0b-81c8-123282c0987f" xlink:to="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-7c0b-81c8-123282c0987f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_019ef965-c0a1-7c0b-81c8-123282c0987f" xlink:to="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_019ef965-c0a1-72ea-95f8-1707c3d96187" xlink:href="sny-20260630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_019ef965-c0a1-72ea-95f8-1707c3d96187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-7726-a00f-9da2d36f0cca" xlink:href="sny-20260630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:to="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-7726-a00f-9da2d36f0cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019ef965-c0a1-78d9-95b2-4491ee0f5bdb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_dei_LegalEntityAxis_019ef965-c0a1-78d9-95b2-4491ee0f5bdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019ef965-c0a1-78d9-95b2-4491ee0f5bdb_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019ef965-c0a1-78d9-95b2-4491ee0f5bdb" xlink:to="loc_dei_EntityDomain_019ef965-c0a1-78d9-95b2-4491ee0f5bdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019ef965-c0a1-78d9-95b2-4491ee0f5bdb" xlink:to="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CDRMember_019f7fa8-6a80-7d66-b7b0-c2e2128e4d7f" xlink:href="sny-20260630.xsd#sny_CDRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_CDRMember_019f7fa8-6a80-7d66-b7b0-c2e2128e4d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BPIFranceMember_019f7fa8-b8b9-78cc-bbdf-5f5aa1eac61f" xlink:href="sny-20260630.xsd#sny_BPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_BPIFranceMember_019f7fa8-b8b9-78cc-bbdf-5f5aa1eac61f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_019ef965-c0a1-7a9b-af15-d5c986b4fe58" xlink:href="sny-20260630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_EuroapiMember_019ef965-c0a1-7a9b-af15-d5c986b4fe58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-77f1-af50-7f7a94e04ffd" xlink:href="sny-20260630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-77f1-af50-7f7a94e04ffd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-7df9-8b8a-872fc00b52be" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-7df9-8b8a-872fc00b52be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7df9-8b8a-872fc00b52be_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-7df9-8b8a-872fc00b52be" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7df9-8b8a-872fc00b52be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7ec3-98f3-012a793b0846" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-7df9-8b8a-872fc00b52be" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7ec3-98f3-012a793b0846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_019ef965-c0a1-7280-9db6-c3033f9770e8" xlink:href="sny-20260630.xsd#sny_MCMVaccineBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7ec3-98f3-012a793b0846" xlink:to="loc_sny_MCMVaccineBVMember_019ef965-c0a1-7280-9db6-c3033f9770e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_019ef965-c0a1-75a0-8eeb-dec79b08ec36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_019ef965-c0a1-75a0-8eeb-dec79b08ec36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_019ef965-c0a1-7a29-a173-f177eb84c890" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_019ef965-c0a1-7a29-a173-f177eb84c890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_019ef965-c0a1-72ed-abd7-5583b39660a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_019ef965-c0a1-72ed-abd7-5583b39660a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_019ef965-c0a1-7d4a-99cc-3fc0162da4c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_019ef965-c0a1-7d4a-99cc-3fc0162da4c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c0a1-7ef1-98d6-84247c3b2d9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c0a1-7ef1-98d6-84247c3b2d9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LoansToAssociates_019ef965-c0a1-7cb2-851a-86f4322ee80e" xlink:href="sny-20260630.xsd#sny_LoansToAssociates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_sny_LoansToAssociates_019ef965-c0a1-7cb2-851a-86f4322ee80e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_019ef965-c0a1-764f-b12c-481062e6fddd" xlink:href="sny-20260630.xsd#sny_StockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_sny_StockPrice_019ef965-c0a1-764f-b12c-481062e6fddd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_019ef965-c0a1-7cce-8da5-b78e59c48b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_019ef965-c0a1-7cce-8da5-b78e59c48b89" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019f1d36-33cf-7c39-a565-551defd6c510" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019f1d36-33cf-77ef-a8bd-e48ec0f69441" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019f1d36-33cf-7c39-a565-551defd6c510" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019f1d36-33cf-77ef-a8bd-e48ec0f69441" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d36-33cf-7f6d-b0eb-c1c0010eed79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019f1d36-33cf-77ef-a8bd-e48ec0f69441" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d36-33cf-7f6d-b0eb-c1c0010eed79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7f6d-b0eb-c1c0010eed79_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d36-33cf-7f6d-b0eb-c1c0010eed79" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7f6d-b0eb-c1c0010eed79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7bdd-8bba-0ac782202cb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d36-33cf-7f6d-b0eb-c1c0010eed79" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7bdd-8bba-0ac782202cb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OPALJVCoMember_019f1d36-33cf-7c40-a519-4a44d18e29b3" xlink:href="sny-20260630.xsd#sny_OPALJVCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7bdd-8bba-0ac782202cb3" xlink:to="loc_sny_OPALJVCoMember_019f1d36-33cf-7c40-a519-4a44d18e29b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019f1d36-33cf-714e-a0be-e0db94d8c251" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019f1d36-33cf-7c39-a565-551defd6c510" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019f1d36-33cf-714e-a0be-e0db94d8c251" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7367-ae47-95bb9aaf6952" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7367-ae47-95bb9aaf6952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7367-ae47-95bb9aaf6952_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7367-ae47-95bb9aaf6952" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7367-ae47-95bb9aaf6952_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-742f-b4d9-14aac92354c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7367-ae47-95bb9aaf6952" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-742f-b4d9-14aac92354c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7088-b634-1638738f7c6f" xlink:href="sny-20260630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-742f-b4d9-14aac92354c5" xlink:to="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7088-b634-1638738f7c6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d40-4514-77cb-98cf-fdb1cff791f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d40-4514-77cb-98cf-fdb1cff791f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-77cb-98cf-fdb1cff791f3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d40-4514-77cb-98cf-fdb1cff791f3" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-77cb-98cf-fdb1cff791f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-7f84-8203-1358fa70e636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d40-4514-77cb-98cf-fdb1cff791f3" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-7f84-8203-1358fa70e636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_019f1d40-4514-76aa-9e93-2807fdcc6fd1" xlink:href="sny-20260630.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-7f84-8203-1358fa70e636" xlink:to="loc_sny_EuroapiMember_019f1d40-4514-76aa-9e93-2807fdcc6fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_019ef965-c0a1-7e43-a290-f97b8a8d83fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_019ef965-c0a1-7e43-a290-f97b8a8d83fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_019ef965-c0a1-700c-bf64-4f3109b70340" xlink:href="sny-20260630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_019ef965-c0a1-700c-bf64-4f3109b70340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_019ef965-c0a1-7f7c-9ec1-57b593b9fd5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_019ef965-c0a1-7f7c-9ec1-57b593b9fd5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_019ef965-c0a1-7d5e-bb43-d49bbb990255" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_019ef965-c0a1-7d5e-bb43-d49bbb990255" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsRelatedPartyTransactions_019ef965-c0a1-720f-b711-010c6c71aa7b" xlink:href="sny-20260630.xsd#sny_OtherAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_OtherAssetsRelatedPartyTransactions_019ef965-c0a1-720f-b711-010c6c71aa7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilitiesRelatedPartyTransactions_019ef965-c0a1-7618-9c1d-ca2d02d4e1e1" xlink:href="sny-20260630.xsd#sny_OtherLiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_OtherLiabilitiesRelatedPartyTransactions_019ef965-c0a1-7618-9c1d-ca2d02d4e1e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubordinateHybridBondRelatedPartyTransactions_019ef965-c0a1-76a0-b080-cf860217cdaa" xlink:href="sny-20260630.xsd#sny_SubordinateHybridBondRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_SubordinateHybridBondRelatedPartyTransactions_019ef965-c0a1-76a0-b080-cf860217cdaa" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7878-84f7-bc0447f6a6c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7878-84f7-bc0447f6a6c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7553-9c50-982be07216ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7878-84f7-bc0447f6a6c2" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7553-9c50-982be07216ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7553-9c50-982be07216ad_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7553-9c50-982be07216ad" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7553-9c50-982be07216ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7245-9c0f-75603a5d7a5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7553-9c50-982be07216ad" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7245-9c0f-75603a5d7a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7e8c-917d-06f5d41c00a1" xlink:href="sny-20260630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7245-9c0f-75603a5d7a5d" xlink:to="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7e8c-917d-06f5d41c00a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_019f1d44-34cf-7264-844c-5b35652d589e" xlink:href="sny-20260630.xsd#sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_019f1d44-34cf-7264-844c-5b35652d589e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetIncomeRelatedPartyDisclosures_019f1d44-34cf-79a1-bd4c-b52e240e428c" xlink:href="sny-20260630.xsd#sny_NetIncomeRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NetIncomeRelatedPartyDisclosures_019f1d44-34cf-79a1-bd4c-b52e240e428c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-7abf-9f32-3e644eb27b9a" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-7abf-9f32-3e644eb27b9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-773f-9ce3-4508e5bcdf83" xlink:href="sny-20260630.xsd#sny_ComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-773f-9ce3-4508e5bcdf83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsRelatedPartyTransactions_019f1d44-5afb-7290-8985-630313959174" xlink:href="sny-20260630.xsd#sny_NonCurrentAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NonCurrentAssetsRelatedPartyTransactions_019f1d44-5afb-7290-8985-630313959174" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsRelatedPartyTransactions_019f1d44-5afb-76c3-8b31-3cbbe0cc932c" xlink:href="sny-20260630.xsd#sny_CurrentAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_CurrentAssetsRelatedPartyTransactions_019f1d44-5afb-76c3-8b31-3cbbe0cc932c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsRelatedPartyTransactions_019f1d44-5afb-7c35-834a-47acd486d51c" xlink:href="sny-20260630.xsd#sny_AssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_AssetsRelatedPartyTransactions_019f1d44-5afb-7c35-834a-47acd486d51c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_019f1d44-5afb-7c32-b82a-ba9a98cba339" xlink:href="sny-20260630.xsd#sny_EquityAttributableToEquityHoldersRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_019f1d44-5afb-7c32-b82a-ba9a98cba339" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_019f1d44-5afb-790e-90be-4c60a8dcd422" xlink:href="sny-20260630.xsd#sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_019f1d44-5afb-790e-90be-4c60a8dcd422" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions_019f1d44-5afb-7385-b228-f203c2b003fe" xlink:href="sny-20260630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityRelatedPartyTransactions_019f1d44-5afb-7385-b228-f203c2b003fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7681-8085-9357e54a4d0f" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7681-8085-9357e54a4d0f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-79a1-b804-7ce58a452d7f" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-79a1-b804-7ce58a452d7f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d44-5afb-742f-8ad7-40489c708b52" xlink:href="sny-20260630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d44-5afb-742f-8ad7-40489c708b52" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7672-ad97-30f9e42569cb" xlink:href="sny-20260630.xsd#sny_EquityAndLiabilitiesRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7672-ad97-30f9e42569cb" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OthernoncurrentassetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c0a1-79e0-ab18-9f4769108a60" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c0a1-79e0-ab18-9f4769108a60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-73c3-a2db-0913cbc20c1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c0a1-79e0-ab18-9f4769108a60" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-73c3-a2db-0913cbc20c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-73c3-a2db-0913cbc20c1d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-73c3-a2db-0913cbc20c1d" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-73c3-a2db-0913cbc20c1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-73c3-a2db-0913cbc20c1d" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_019ef965-c0a1-7421-af43-e73aa097e1ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_019ef965-c0a1-7421-af43-e73aa097e1ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_019ef965-c0a1-7f88-9f55-63174bf3c36a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:to="loc_ifrs-full_DebtSecuritiesMember_019ef965-c0a1-7f88-9f55-63174bf3c36a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_019ef965-c0a1-7712-9a24-de9dc53d040d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_019ef965-c0a1-7712-9a24-de9dc53d040d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_019ef965-c0a1-7f02-ae6a-cf548c4d56e9" xlink:href="sny-20260630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_019ef965-c0a1-7f02-ae6a-cf548c4d56e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_019ef965-c0a1-744e-b9b0-3556fe2c4dec" xlink:href="sny-20260630.xsd#sny_PreFundedPensionObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_PreFundedPensionObligations_019ef965-c0a1-744e-b9b0-3556fe2c4dec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_019ef965-c0a1-73c1-96ed-cb25c10438d1" xlink:href="sny-20260630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_LongTermPrepaidExpenses_019ef965-c0a1-73c1-96ed-cb25c10438d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables_019ef965-c0a1-73c7-aa11-f270d102d81a" xlink:href="sny-20260630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_NonCurrentLoansAndReceivables_019ef965-c0a1-73c7-aa11-f270d102d81a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_019ef965-c0a1-7c43-8618-473a69eb8359" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_019ef965-c0a1-7c43-8618-473a69eb8359" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-79de-bde4-42f3dc4fcbe7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-79de-bde4-42f3dc4fcbe7" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#AccountsreceivableSummaryofAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_019ef965-c0a1-7bcc-bc88-c352a78132a7" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_019ef965-c0a1-7c11-acec-efd11d24205f" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_019ef965-c0a1-7bcc-bc88-c352a78132a7" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_019ef965-c0a1-7c11-acec-efd11d24205f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-750d-8b30-a46675310d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_019ef965-c0a1-7c11-acec-efd11d24205f" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-750d-8b30-a46675310d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-750d-8b30-a46675310d60_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-750d-8b30-a46675310d60" xlink:to="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-750d-8b30-a46675310d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-750d-8b30-a46675310d60" xlink:to="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7f5a-88a7-2a3d46fa97a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7f5a-88a7-2a3d46fa97a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_019ef965-c0a1-75e8-8d1b-dc9966977f5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_019ef965-c0a1-75e8-8d1b-dc9966977f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_019ef965-c0a1-76ef-bd8f-f634a91d7845" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_019ef965-c0a1-7bcc-bc88-c352a78132a7" xlink:to="loc_ifrs-full_CurrentTradeReceivables_019ef965-c0a1-76ef-bd8f-f634a91d7845" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_019ef965-c0a1-7561-afad-c33bcee8a1bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c0a1-7f13-97c9-1541431dedb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_019ef965-c0a1-7561-afad-c33bcee8a1bf" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c0a1-7f13-97c9-1541431dedb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-77bf-b12e-4ea949c51f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c0a1-7f13-97c9-1541431dedb2" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-77bf-b12e-4ea949c51f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-77bf-b12e-4ea949c51f18_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-77bf-b12e-4ea949c51f18" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-77bf-b12e-4ea949c51f18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-77bf-b12e-4ea949c51f18" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_019ef965-c0a1-7f0a-9d7f-5d7471c030ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_019ef965-c0a1-7f0a-9d7f-5d7471c030ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_019ef965-c0a1-70ab-ab42-973ab46e4979" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_019ef965-c0a1-70ab-ab42-973ab46e4979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_019ef965-c0a1-72d9-9882-27df3ec7e2ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_019ef965-c0a1-72d9-9882-27df3ec7e2ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_019ef965-c0a1-7c95-986c-3b4851c28835" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_019ef965-c0a1-7c95-986c-3b4851c28835" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_019ef965-c0a1-7d1f-9943-f192adb23be4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanOneYearMember_019ef965-c0a1-7d1f-9943-f192adb23be4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_019ef965-c0a1-759e-bbbe-23e09a960bba" xlink:href="sny-20260630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_019ef965-c0a1-7561-afad-c33bcee8a1bf" xlink:to="loc_sny_OverdueReceivablesGrossValue_019ef965-c0a1-759e-bbbe-23e09a960bba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019f1dab-334a-79cd-8060-df019c837186" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_dei_LegalEntityAxis_019f1dab-334a-79cd-8060-df019c837186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019f1dab-334a-79cd-8060-df019c837186_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019f1dab-334a-79cd-8060-df019c837186" xlink:to="loc_dei_EntityDomain_019f1dab-334a-79cd-8060-df019c837186_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019f1dab-334a-7849-a34c-754f57f4bf5d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019f1dab-334a-79cd-8060-df019c837186" xlink:to="loc_dei_EntityDomain_019f1dab-334a-7849-a34c-754f57f4bf5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_019f1dab-334a-7afb-8d9c-a4becff19bd9" xlink:href="sny-20260630.xsd#sny_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019f1dab-334a-7849-a34c-754f57f4bf5d" xlink:to="loc_sny_SanofiMember_019f1dab-334a-7afb-8d9c-a4becff19bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019f1dab-334a-70ce-9bbb-210363fcd672" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019f1dab-334a-70ce-9bbb-210363fcd672" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-70ce-9bbb-210363fcd672_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019f1dab-334a-70ce-9bbb-210363fcd672" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-70ce-9bbb-210363fcd672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-79c7-8c4d-57f11b553f4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019f1dab-334a-70ce-9bbb-210363fcd672" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-79c7-8c4d-57f11b553f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019f1dab-334a-783a-8ee5-73e0e03ce77d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-79c7-8c4d-57f11b553f4f" xlink:to="loc_ifrs-full_IssuedCapitalMember_019f1dab-334a-783a-8ee5-73e0e03ce77d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019f1dab-9cbe-7eec-8497-776cdb944a20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019f1dab-9cbe-7eec-8497-776cdb944a20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-7eec-8497-776cdb944a20_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019f1dab-9cbe-7eec-8497-776cdb944a20" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-7eec-8497-776cdb944a20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-74b1-aa46-bb1ed9074fa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019f1dab-9cbe-7eec-8497-776cdb944a20" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-74b1-aa46-bb1ed9074fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember_019f1dab-9cbe-780f-a45d-4609972861ed" xlink:href="sny-20260630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-74b1-aa46-bb1ed9074fa3" xlink:to="loc_sny_EmployeeShareOwnershipPlanMember_019f1dab-9cbe-780f-a45d-4609972861ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-777d-8572-023f7e060013" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-777d-8572-023f7e060013" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-777d-8572-023f7e060013_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-777d-8572-023f7e060013" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-777d-8572-023f7e060013_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-777d-8572-023f7e060013" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2025ProgramMember_019f7fb9-cbbb-76e0-9b76-3fb9a4a27ace" xlink:href="sny-20260630.xsd#sny_ShareRepurchase2025ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:to="loc_sny_ShareRepurchase2025ProgramMember_019f7fb9-cbbb-76e0-9b76-3fb9a4a27ace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2026ProgramMember_019f9374-2742-7b59-af04-a5aec656a859" xlink:href="sny-20260630.xsd#sny_ShareRepurchase2026ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:to="loc_sny_ShareRepurchase2026ProgramMember_019f9374-2742-7b59-af04-a5aec656a859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019f89cd-e857-7030-af3a-e294a539b042" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_ifrs-full_CounterpartiesAxis_019f89cd-e857-7030-af3a-e294a539b042" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7030-af3a-e294a539b042_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_019f89cd-e857-7030-af3a-e294a539b042" xlink:to="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7030-af3a-e294a539b042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7246-a65c-2e2d3cf3bfdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_019f89cd-e857-7030-af3a-e294a539b042" xlink:to="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7246-a65c-2e2d3cf3bfdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LOrealMember_019f89ce-2703-7c25-b77b-fb34e42aabc5" xlink:href="sny-20260630.xsd#sny_LOrealMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7246-a65c-2e2d3cf3bfdb" xlink:to="loc_sny_LOrealMember_019f89ce-2703-7c25-b77b-fb34e42aabc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_019f1dab-085a-7f86-8b66-9c77384a65af" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_IssuedCapital_019f1dab-085a-7f86-8b66-9c77384a65af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_019f1dab-085a-7877-9f9f-56c52e816945" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_NumberOfSharesIssued_019f1dab-085a-7877-9f9f-56c52e816945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019f1dab-085a-78b7-91e0-66e0c332c85f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_ParValuePerShare_019f1dab-085a-78b7-91e0-66e0c332c85f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_019f1dab-334a-71f5-9ef2-97e8f1f48fc8" xlink:href="sny-20260630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_019f1dab-334a-71f5-9ef2-97e8f1f48fc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_019f1dab-334a-7258-b1ed-14765f50a92f" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_019f1dab-334a-7258-b1ed-14765f50a92f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_019f1dab-334a-72d0-9afd-c16c4dfd11b6" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_019f1dab-334a-72d0-9afd-c16c4dfd11b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_019f1dab-334a-75cf-8728-3ec2710c3b8d" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_019f1dab-334a-75cf-8728-3ec2710c3b8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchaseProgramPeriod_019f1dab-5d4b-7db8-8dbb-7171a7e562f0" xlink:href="sny-20260630.xsd#sny_ShareRepurchaseProgramPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_ShareRepurchaseProgramPeriod_019f1dab-5d4b-7db8-8dbb-7171a7e562f0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_019f1dab-5d4b-7bd8-87de-e3b09f75a5b0" xlink:href="sny-20260630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfSharesRepurchased_019f1dab-5d4b-7bd8-87de-e3b09f75a5b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019f8a41-fcd2-7b12-8af8-d36d47586192" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019f8a41-fcd2-7b12-8af8-d36d47586192" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019f7fb7-d4fd-78ae-bc23-f10bedeb3811" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019f7fb7-d4fd-78ae-bc23-f10bedeb3811" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSanofisShareCapitalAcquired_019f2301-0ec8-7064-be83-dd80e28758f1" xlink:href="sny-20260630.xsd#sny_PercentageOfSanofisShareCapitalAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_PercentageOfSanofisShareCapitalAcquired_019f2301-0ec8-7064-be83-dd80e28758f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchaseProgramAmountPaid_019f8aec-4220-72d8-acfb-0c9a7ff532ad" xlink:href="sny-20260630.xsd#sny_ShareRepurchaseProgramAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_ShareRepurchaseProgramAmountPaid_019f8aec-4220-72d8-acfb-0c9a7ff532ad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerShareValueOfSharesRepurchased_019f1dab-5d4b-712e-9f80-66275a2b3c6f" xlink:href="sny-20260630.xsd#sny_PerShareValueOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_PerShareValueOfSharesRepurchased_019f1dab-5d4b-712e-9f80-66275a2b3c6f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CancellationOfTreasuryShares_019f1dab-5d4b-7e32-941a-9dfcd1a6cbac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CancellationOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_CancellationOfTreasuryShares_019f1dab-5d4b-7e32-941a-9dfcd1a6cbac" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_019f1dab-9cbe-70e2-8942-d020115041c6" xlink:href="sny-20260630.xsd#sny_SubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_SubscriptionPricePerShare_019f1dab-9cbe-70e2-8942-d020115041c6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed_019f1dab-9cbe-71cf-9813-2ce76d173f2c" xlink:href="sny-20260630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfSharesSubscribed_019f1dab-9cbe-71cf-9813-2ce76d173f2c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_019f1dab-9cbe-7d0e-b12c-17826e0fa47e" xlink:href="sny-20260630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_019f1dab-9cbe-7d0e-b12c-17826e0fa47e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019f1dab-9cbe-7e3a-b800-147d2b2bea16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019f1dab-9cbe-7e3a-b800-147d2b2bea16" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-70c9-9dd4-7e374e7b7b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-70c9-9dd4-7e374e7b7b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-70c9-9dd4-7e374e7b7b26_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-70c9-9dd4-7e374e7b7b26" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-70c9-9dd4-7e374e7b7b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7160-86cb-746b636ba0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-70c9-9dd4-7e374e7b7b26" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7160-86cb-746b636ba0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7994-b66a-9f514b4658cd" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7160-86cb-746b636ba0ae" xlink:to="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7994-b66a-9f514b4658cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_019ef965-c0a1-7c89-b0f0-6abb2d249e6d" xlink:href="sny-20260630.xsd#sny_MarketConditionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_sny_MarketConditionAxis_019ef965-c0a1-7c89-b0f0-6abb2d249e6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_019ef965-c0a1-7c89-b0f0-6abb2d249e6d_default" xlink:href="sny-20260630.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_MarketConditionAxis_019ef965-c0a1-7c89-b0f0-6abb2d249e6d" xlink:to="loc_sny_MarketConditionDomain_019ef965-c0a1-7c89-b0f0-6abb2d249e6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:href="sny-20260630.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_MarketConditionAxis_019ef965-c0a1-7c89-b0f0-6abb2d249e6d" xlink:to="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_019ef965-c0a1-7b11-868c-e493a74103aa" xlink:href="sny-20260630.xsd#sny_WithoutMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:to="loc_sny_WithoutMarketConditionMember_019ef965-c0a1-7b11-868c-e493a74103aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_019ef965-c0a1-73a8-ac18-31854040bcb6" xlink:href="sny-20260630.xsd#sny_WithMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:to="loc_sny_WithMarketConditionMember_019ef965-c0a1-73a8-ac18-31854040bcb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019ef965-c0a1-736d-b2b3-1aea163465b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_srt_TitleOfIndividualAxis_019ef965-c0a1-736d-b2b3-1aea163465b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-736d-b2b3-1aea163465b5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_019ef965-c0a1-736d-b2b3-1aea163465b5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-736d-b2b3-1aea163465b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_019ef965-c0a1-736d-b2b3-1aea163465b5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember_019ef965-c0a1-7b59-9a51-9c57de4008e7" xlink:href="sny-20260630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:to="loc_sny_ExcludingChiefExecutiveOfficerMember_019ef965-c0a1-7b59-9a51-9c57de4008e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_019ef965-c0a1-7c2a-b850-b665fb07d945" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:to="loc_srt_ChiefExecutiveOfficerMember_019ef965-c0a1-7c2a-b850-b665fb07d945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f" xlink:href="sny-20260630.xsd#sny_TypesOfVestingConditionsAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f_default" xlink:href="sny-20260630.xsd#sny_TypesOfVestingConditionsAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f" xlink:to="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:href="sny-20260630.xsd#sny_TypesOfVestingConditionsAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f" xlink:to="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ThreeYearServicePeriodMember_019f8f55-6a6b-7b90-81de-50264d84bd60" xlink:href="sny-20260630.xsd#sny_ThreeYearServicePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:to="loc_sny_ThreeYearServicePeriodMember_019f8f55-6a6b-7b90-81de-50264d84bd60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FiveYearServicePeriodMember_019f8f55-d423-7fe1-9445-f9774973d4be" xlink:href="sny-20260630.xsd#sny_FiveYearServicePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:to="loc_sny_FiveYearServicePeriodMember_019f8f55-d423-7fe1-9445-f9774973d4be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019ef965-c0a1-7507-9933-868263c9dbad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019ef965-c0a1-7507-9933-868263c9dbad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_019ef965-c0a1-71af-b98d-c0f348f3bcdd" xlink:href="sny-20260630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_019ef965-c0a1-71af-b98d-c0f348f3bcdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForFiveYearServicePeriod_019f8f4d-da66-746a-8860-4e73b1874e05" xlink:href="sny-20260630.xsd#sny_FairValuePerShareAwardedForFiveYearServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_FairValuePerShareAwardedForFiveYearServicePeriod_019f8f4d-da66-746a-8860-4e73b1874e05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_019ef965-c0a1-7735-b9d0-96fcae64de0a" xlink:href="sny-20260630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_019ef965-c0a1-7735-b9d0-96fcae64de0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_019ef965-c0a1-7bdf-862d-3e59e3b38e98" xlink:href="sny-20260630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_NumberOfYearsServicePeriod_019ef965-c0a1-7bdf-862d-3e59e3b38e98" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7bc3-a1ce-5061b7c5dbd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7bc3-a1ce-5061b7c5dbd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-73fa-bbc5-2f345560c176" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7bc3-a1ce-5061b7c5dbd6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-73fa-bbc5-2f345560c176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-73fa-bbc5-2f345560c176_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-73fa-bbc5-2f345560c176" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-73fa-bbc5-2f345560c176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7927-95fb-82944fff30e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-73fa-bbc5-2f345560c176" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7927-95fb-82944fff30e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:href="sny-20260630.xsd#sny_RestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7927-95fb-82944fff30e9" xlink:to="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2026Member_019f372f-fa4c-762c-bfa9-ac2e40792281" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2026Member_019f372f-fa4c-762c-bfa9-ac2e40792281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7f41-9dd3-8d825f95dd17" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7f41-9dd3-8d825f95dd17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_019ef965-c0a1-7150-948d-2d9ef9e868b2" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2024Member_019ef965-c0a1-7150-948d-2d9ef9e868b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_019ef965-c0a1-7cce-8c82-acea80acfa24" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2023Member_019ef965-c0a1-7cce-8c82-acea80acfa24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_019ef965-c0a1-739e-96cc-2771896b13d3" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2022Member_019ef965-c0a1-739e-96cc-2771896b13d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019ef965-c0a1-7792-b8ca-91745b399da7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019ef965-c0a1-7792-b8ca-91745b399da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_019ef965-c0a1-7443-8f10-6c4b9e814bde" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_019ef965-c0a1-7443-8f10-6c4b9e814bde" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019ef965-c0a1-7908-9601-af03111057a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:to="loc_ifrs-full_RangeAxis_019ef965-c0a1-7908-9601-af03111057a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019ef965-c0a1-7908-9601-af03111057a8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_019ef965-c0a1-7908-9601-af03111057a8" xlink:to="loc_ifrs-full_RangeDomain_019ef965-c0a1-7908-9601-af03111057a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_019ef965-c0a1-7908-9601-af03111057a8" xlink:to="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019ef965-c0a1-73bc-9040-04232ef7d19e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:to="loc_ifrs-full_BottomOfRangeMember_019ef965-c0a1-73bc-9040-04232ef7d19e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019ef965-c0a1-7ef4-a0b2-08a1e8f6262a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:to="loc_ifrs-full_TopOfRangeMember_019ef965-c0a1-7ef4-a0b2-08a1e8f6262a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_019ef965-c0a1-7fbb-a814-c1728d8d4f5e" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:to="loc_sny_ExercisePriceRangeTwoMember_019ef965-c0a1-7fbb-a814-c1728d8d4f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_019ef965-c0a1-774d-969e-e1bf5cce92e5" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:to="loc_sny_ExercisePriceRangeThreeMember_019ef965-c0a1-774d-969e-e1bf5cce92e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_019ef965-c0a1-78b8-9bca-be11c2427b4e" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:to="loc_sny_ExercisePriceRangeFourMember_019ef965-c0a1-78b8-9bca-be11c2427b4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-7bda-9e23-265f46864f5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-7bda-9e23-265f46864f5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-7bda-9e23-265f46864f5e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-7bda-9e23-265f46864f5e" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-7bda-9e23-265f46864f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-78dd-9b55-237b70ebeb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-7bda-9e23-265f46864f5e" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-78dd-9b55-237b70ebeb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_019ef965-c0a1-77e3-a324-a05913d9c3bf" xlink:href="sny-20260630.xsd#sny_StockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-78dd-9b55-237b70ebeb96" xlink:to="loc_sny_StockOptionPlanMember_019ef965-c0a1-77e3-a324-a05913d9c3bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_019ef965-c0a1-7d6a-9ee1-3572779c7dca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_019ef965-c0a1-7d6a-9ee1-3572779c7dca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_019ef965-c0a1-76ad-8eba-4304f5185e23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_019ef965-c0a1-76ad-8eba-4304f5185e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_019ef965-c0a1-77e5-b507-9fc092482e76" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_019ef965-c0a1-77e5-b507-9fc092482e76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_019ef965-c0a1-7e2f-9991-f4efc1ce61a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_019ef965-c0a1-7e2f-9991-f4efc1ce61a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_019ef965-c0a1-7d26-ae91-5aacf9c960ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_019ef965-c0a1-7d26-ae91-5aacf9c960ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_019ef965-c0a1-7b84-86cb-408103270c29" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_019ef965-c0a1-7b84-86cb-408103270c29" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-767b-aa68-2eab67a97a7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-767b-aa68-2eab67a97a7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-767b-aa68-2eab67a97a7b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-767b-aa68-2eab67a97a7b" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-767b-aa68-2eab67a97a7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-75cc-b1f3-d698a956e8ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-767b-aa68-2eab67a97a7b" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-75cc-b1f3-d698a956e8ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-c0a1-7a21-90ed-56a0a7b8e0e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-75cc-b1f3-d698a956e8ff" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-c0a1-7a21-90ed-56a0a7b8e0e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_019ef965-c0a1-7320-9b3d-a9e1c4156690" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_019ef965-c0a1-7320-9b3d-a9e1c4156690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7320-9b3d-a9e1c4156690_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_019ef965-c0a1-7320-9b3d-a9e1c4156690" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7320-9b3d-a9e1c4156690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_019ef965-c0a1-7320-9b3d-a9e1c4156690" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-76a4-9c16-ac4afb2883af" xlink:href="sny-20260630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-76a4-9c16-ac4afb2883af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-729e-be97-94e44ee22e3a" xlink:href="sny-20260630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-729e-be97-94e44ee22e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c0a1-72d9-9b7b-371d44a17cad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c0a1-72d9-9b7b-371d44a17cad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-72d9-9b7b-371d44a17cad_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c0a1-72d9-9b7b-371d44a17cad" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-72d9-9b7b-371d44a17cad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c0a1-72d9-9b7b-371d44a17cad" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_019ef965-c0a1-766c-8b74-fb9d8d6c5b25" xlink:href="sny-20260630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_019ef965-c0a1-766c-8b74-fb9d8d6c5b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_019ef965-c0a1-769e-bb73-7f7e06e718d7" xlink:href="sny-20260630.xsd#sny_DebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_DebtInstrumentsMember_019ef965-c0a1-769e-bb73-7f7e06e718d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_019ef965-c0a1-7568-b309-dfb21e7d672a" xlink:href="sny-20260630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_019ef965-c0a1-7568-b309-dfb21e7d672a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_019ef965-c0a1-73a2-9425-8b10884bf64e" xlink:href="sny-20260630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_ForeignCurrencyTranslationMember_019ef965-c0a1-73a2-9425-8b10884bf64e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_019ef965-c0a1-7974-a30d-696451241bbe" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_019ef965-c0a1-7974-a30d-696451241bbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7d29-af04-eb17fdad6e13" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7d29-af04-eb17fdad6e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_019ef965-c0a1-7726-9868-dc76ca8053fb" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_019ef965-c0a1-7726-9868-dc76ca8053fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_019ef965-c0a1-73e6-a5f0-ea91c0511359" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_019ef965-c0a1-73e6-a5f0-ea91c0511359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_019ef965-c0a1-7a56-a304-05df2d3c2e1d" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_019ef965-c0a1-7a56-a304-05df2d3c2e1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_019ef965-c0a1-7530-bfa5-f874054e78c6" xlink:href="sny-20260630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_019ef965-c0a1-7530-bfa5-f874054e78c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_019ef965-c0a1-710d-8e45-fcebb9f23ee8" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_019ef965-c0a1-710d-8e45-fcebb9f23ee8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7c2d-ba5a-430f046be715" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7c2d-ba5a-430f046be715" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_019ef965-c0a1-7a60-ad89-61095558bdf2" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_019ef965-c0a1-7a60-ad89-61095558bdf2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_019ef965-c0a1-7cc8-a620-2676d3d723da" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_019ef965-c0a1-7cc8-a620-2676d3d723da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_019ef965-c0a1-76f4-91d2-febc24015c9f" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_019ef965-c0a1-76f4-91d2-febc24015c9f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_019ef965-c0a1-7fb4-9d6f-6b48be347230" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_019ef965-c0a1-7fb4-9d6f-6b48be347230" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7717-a26e-11d36741bada" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7717-a26e-11d36741bada" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_019ef965-c0a1-7ea6-ad3f-21b0f1bc6371" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_019ef965-c0a1-7ea6-ad3f-21b0f1bc6371" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_019ef965-c0a1-7af6-bd67-9003db01c6b6" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_019ef965-c0a1-7af6-bd67-9003db01c6b6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7043-a676-3879cbf11057" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7043-a676-3879cbf11057" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_019ef965-c0a1-7a07-a7e3-ae5bdd7f3714" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_019ef965-c0a1-7a07-a7e3-ae5bdd7f3714" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_019ef965-c0a1-7437-9b51-05dac590f924" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_019ef965-c0a1-7437-9b51-05dac590f924" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-70c8-9aa3-ae223b71ec6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-70c8-9aa3-ae223b71ec6f" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7683-ac32-86162a9c46f0" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7683-ac32-86162a9c46f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7632-88f0-a76df101ad97" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7683-ac32-86162a9c46f0" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7632-88f0-a76df101ad97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7632-88f0-a76df101ad97_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7632-88f0-a76df101ad97" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7632-88f0-a76df101ad97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7632-88f0-a76df101ad97" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember_019ef965-c0a1-70f8-9e9d-6e90c4f900a4" xlink:href="sny-20260630.xsd#sny_AmortizedCostNettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:to="loc_sny_AmortizedCostNettingMember_019ef965-c0a1-70f8-9e9d-6e90c4f900a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_019ef965-c0a1-7b25-beb1-51dbf785e1f7" xlink:href="sny-20260630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_019ef965-c0a1-7b25-beb1-51dbf785e1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7f79-826b-0eb1384b51de" xlink:href="sny-20260630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:to="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7f79-826b-0eb1384b51de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7fbd-8fa0-8b153c7f093f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7fbd-8fa0-8b153c7f093f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-71bd-ba2e-1ccace50a4e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-71bd-ba2e-1ccace50a4e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-75ca-be1a-707f2c4bc3b6" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-75ca-be1a-707f2c4bc3b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7f84-befd-d3042b7fe7f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-7f84-befd-d3042b7fe7f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-7125-a425-361785faa020" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-7125-a425-361785faa020" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-77ec-89c4-c1fa2fd01c2e" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-77ec-89c4-c1fa2fd01c2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-716d-abaf-fca822b6d112" xlink:href="sny-20260630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-716d-abaf-fca822b6d112" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019ef965-c0a1-7f1a-b583-5c8bdc2864cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_LeaseLiabilities_019ef965-c0a1-7f1a-b583-5c8bdc2864cd" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7fce-9163-a28153d7350f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7fce-9163-a28153d7350f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7fce-9163-a28153d7350f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7fce-9163-a28153d7350f" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7fce-9163-a28153d7350f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7777-acc5-36dd70e474ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7fce-9163-a28153d7350f" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7777-acc5-36dd70e474ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-73e8-94bb-464d57614906" xlink:href="sny-20260630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7777-acc5-36dd70e474ee" xlink:to="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-73e8-94bb-464d57614906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-78e0-b96d-7569d9c035f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-78e0-b96d-7569d9c035f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-78e0-b96d-7569d9c035f9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-78e0-b96d-7569d9c035f9" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-78e0-b96d-7569d9c035f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-78e0-b96d-7569d9c035f9" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_019ef965-c0a1-7a94-b65e-41a5d174852b" xlink:href="sny-20260630.xsd#sny_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:to="loc_sny_NonCurrentAssetsMember_019ef965-c0a1-7a94-b65e-41a5d174852b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_019ef965-c0a1-7e00-9987-030716b229f1" xlink:href="sny-20260630.xsd#sny_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:to="loc_sny_CurrentAssetsMember_019ef965-c0a1-7e00-9987-030716b229f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7a7c-b641-5c02a9c4ac42" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7a7c-b641-5c02a9c4ac42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7a7c-b641-5c02a9c4ac42_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7a7c-b641-5c02a9c4ac42" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7a7c-b641-5c02a9c4ac42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7fc3-94c4-2b53dd8c628d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7a7c-b641-5c02a9c4ac42" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7fc3-94c4-2b53dd8c628d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_019ef965-c0a1-7f05-95ca-e85a00d72676" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7fc3-94c4-2b53dd8c628d" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_019ef965-c0a1-7f05-95ca-e85a00d72676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019f1db9-1d30-7f97-95be-969ae794aeb5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_srt_StatementGeographicalAxis_019f1db9-1d30-7f97-95be-969ae794aeb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7f97-95be-969ae794aeb5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_019f1db9-1d30-7f97-95be-969ae794aeb5" xlink:to="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7f97-95be-969ae794aeb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7c08-9dc5-2ed11b805a57" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_019f1db9-1d30-7f97-95be-969ae794aeb5" xlink:to="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7c08-9dc5-2ed11b805a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019f1db9-5899-7b7b-a066-d2ba41ddc60f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7c08-9dc5-2ed11b805a57" xlink:to="loc_country_US_019f1db9-5899-7b7b-a066-d2ba41ddc60f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_019f6afe-116b-7679-ba75-9b0ce95aad01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_HedgedItemsAxis_019f6afe-116b-7679-ba75-9b0ce95aad01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-7679-ba75-9b0ce95aad01_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_019f6afe-116b-7679-ba75-9b0ce95aad01" xlink:to="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-7679-ba75-9b0ce95aad01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-76a3-b220-ea35f391fe6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_019f6afe-116b-7679-ba75-9b0ce95aad01" xlink:to="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-76a3-b220-ea35f391fe6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInvestmentHedgeMember_019f6afe-116b-7140-9818-31b94caf0f85" xlink:href="sny-20260630.xsd#sny_NetInvestmentHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-76a3-b220-ea35f391fe6a" xlink:to="loc_sny_NetInvestmentHedgeMember_019f6afe-116b-7140-9818-31b94caf0f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-711b-8c92-099cf56612f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-711b-8c92-099cf56612f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-711b-8c92-099cf56612f2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-711b-8c92-099cf56612f2" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-711b-8c92-099cf56612f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-711b-8c92-099cf56612f2" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_019f7fc9-83a0-7073-b54e-a4169052f0bf" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:to="loc_sny_NonCurrentLiabilitiesMember_019f7fc9-83a0-7073-b54e-a4169052f0bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_019f7fc9-8b11-7e31-962c-9c88e2c19040" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:to="loc_sny_CurrentLiabilitiesMember_019f7fc9-8b11-7e31-962c-9c88e2c19040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_019ef965-c0a1-7ee8-abb8-5b1d1f1d31ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_BondsIssued_019ef965-c0a1-7ee8-abb8-5b1d1f1d31ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_019ef965-c0a1-7c1d-9e25-25d8d147fd92" xlink:href="sny-20260630.xsd#sny_OtherBankBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_OtherBankBorrowings_019ef965-c0a1-7c1d-9e25-25d8d147fd92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_019ef965-c0a1-7b99-92cc-7be803b78eda" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_OtherBorrowings_019ef965-c0a1-7b99-92cc-7be803b78eda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_019ef965-c0a1-7e56-afe4-23f100991b33" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_019ef965-c0a1-7e56-afe4-23f100991b33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-755f-bb9a-eb62eaa6e446" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-755f-bb9a-eb62eaa6e446" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7295-8aaa-d0c6405c5b4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-7295-8aaa-d0c6405c5b4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-727b-b0b8-09e6d26ba01a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-727b-b0b8-09e6d26ba01a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-724e-a5eb-da7d9f26d6dc" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-724e-a5eb-da7d9f26d6dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7702-803b-e374271077ec" xlink:href="sny-20260630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7702-803b-e374271077ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019f6afd-f1b3-7867-b01f-a6223c1b5250" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_NotionalAmount_019f6afd-f1b3-7867-b01f-a6223c1b5250" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7e61-a280-6449472ba64d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7e61-a280-6449472ba64d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7e61-a280-6449472ba64d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7e61-a280-6449472ba64d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7e61-a280-6449472ba64d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7e61-a280-6449472ba64d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TwoBillionThreeHundredMillionBondsMember_019f1dd9-c4e2-7be5-9eda-60adb2acd99d" xlink:href="sny-20260630.xsd#sny_TwoBillionThreeHundredMillionBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_TwoBillionThreeHundredMillionBondsMember_019f1dd9-c4e2-7be5-9eda-60adb2acd99d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2029Member_019f1dd9-c4e2-73cf-b862-50f901b4f1dd" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMarch2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondMaturingMarch2029Member_019f1dd9-c4e2-73cf-b862-50f901b4f1dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMay2033Member_019f1dd9-c4e2-7d92-84e0-b08c0b862fe0" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMay2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondMaturingMay2033Member_019f1dd9-c4e2-7d92-84e0-b08c0b862fe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMay2037Member_019f1dd9-c4e2-77ce-aa00-7ecb5d5d37d3" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMay2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondMaturingMay2037Member_019f1dd9-c4e2-77ce-aa00-7ecb5d5d37d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromMarch2018Member_019f1dd9-c4e2-77d8-9c5a-56eadd68bb70" xlink:href="sny-20260630.xsd#sny_FixedRateBondIssueFromMarch2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondIssueFromMarch2018Member_019f1dd9-c4e2-77d8-9c5a-56eadd68bb70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingOnMarch2030Member_019f1dd9-c4e2-79a8-bd40-ea49f7284785" xlink:href="sny-20260630.xsd#sny_FourBillionFacilityMaturingOnMarch2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FourBillionFacilityMaturingOnMarch2030Member_019f1dd9-c4e2-79a8-bd40-ea49f7284785" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member_019f1dd9-c4e2-7598-808a-0d9a2cc7b700" xlink:href="sny-20260630.xsd#sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member_019f1dd9-c4e2-7598-808a-0d9a2cc7b700" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingApril2026Member_019f1dd9-c4e2-743c-972e-9cf85dd95f49" xlink:href="sny-20260630.xsd#sny_FourBillionFacilityMaturingApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FourBillionFacilityMaturingApril2026Member_019f1dd9-c4e2-743c-972e-9cf85dd95f49" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_019f1dd9-c4e2-7d7a-ac69-48d69fdcd100" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_019f1dd9-c4e2-7d7a-ac69-48d69fdcd100" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_019f1dd9-c4e2-739a-98f6-0c4149315048" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_019f1dd9-c4e2-739a-98f6-0c4149315048" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis_019f1dd9-c4e2-713c-96fa-7ec5544573b7" xlink:href="sny-20260630.xsd#sny_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:to="loc_sny_DebtInstrumentAxis_019f1dd9-c4e2-713c-96fa-7ec5544573b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-713c-96fa-7ec5544573b7_default" xlink:href="sny-20260630.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DebtInstrumentAxis_019f1dd9-c4e2-713c-96fa-7ec5544573b7" xlink:to="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-713c-96fa-7ec5544573b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-7fb2-975d-db598b22a455" xlink:href="sny-20260630.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DebtInstrumentAxis_019f1dd9-c4e2-713c-96fa-7ec5544573b7" xlink:to="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-7fb2-975d-db598b22a455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_019f1dd9-c4e2-7afd-a27f-32f1df96d7d3" xlink:href="sny-20260630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-7fb2-975d-db598b22a455" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_019f1dd9-c4e2-7afd-a27f-32f1df96d7d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_019f6afd-50d5-7a31-9a04-b176d777483b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:to="loc_ifrs-full_HedgedItemsAxis_019f6afd-50d5-7a31-9a04-b176d777483b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7a31-9a04-b176d777483b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_019f6afd-50d5-7a31-9a04-b176d777483b" xlink:to="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7a31-9a04-b176d777483b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7222-9d08-17873c2dd01c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_019f6afd-50d5-7a31-9a04-b176d777483b" xlink:to="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7222-9d08-17873c2dd01c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInvestmentHedgeMember_019f6afd-8abd-7248-96ad-746778cb4929" xlink:href="sny-20260630.xsd#sny_NetInvestmentHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7222-9d08-17873c2dd01c" xlink:to="loc_sny_NetInvestmentHedgeMember_019f6afd-8abd-7248-96ad-746778cb4929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019f1dd9-c4e2-7f8b-b07b-36fcd10cf99e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_ifrs-full_NotionalAmount_019f1dd9-c4e2-7f8b-b07b-36fcd10cf99e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTranches_019f1dd9-c4e2-74d9-a218-6755ef1b9777" xlink:href="sny-20260630.xsd#sny_NumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfTranches_019f1dd9-c4e2-74d9-a218-6755ef1b9777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_019f1dd9-c4e2-7c7a-80da-800db3e8cfc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_ifrs-full_BorrowingsInterestRate_019f1dd9-c4e2-7c7a-80da-800db3e8cfc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondRedeemed_019f1dd9-c4e2-7560-b149-1297e9d80d25" xlink:href="sny-20260630.xsd#sny_NumberOfBondRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfBondRedeemed_019f1dd9-c4e2-7560-b149-1297e9d80d25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSyndicatedCreditFacilities_019f1dd9-c4e2-7545-8c25-5590a0a7d0b5" xlink:href="sny-20260630.xsd#sny_NumberOfSyndicatedCreditFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfSyndicatedCreditFacilities_019f1dd9-c4e2-7545-8c25-5590a0a7d0b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOneYearExtensionOptions_019f8f7c-3515-70a1-8706-47cfa0b2a7b5" xlink:href="sny-20260630.xsd#sny_NumberOfOneYearExtensionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfOneYearExtensionOptions_019f8f7c-3515-70a1-8706-47cfa0b2a7b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExtensionTerm_019f8f7d-54b0-798b-8464-c3e3d3cf524b" xlink:href="sny-20260630.xsd#sny_ExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_ExtensionTerm_019f8f7d-54b0-798b-8464-c3e3d3cf524b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShortTermDebtProgram_019f1dd9-c4e2-757d-bb1a-513468b8e776" xlink:href="sny-20260630.xsd#sny_NumberOfShortTermDebtProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfShortTermDebtProgram_019f1dd9-c4e2-757d-bb1a-513468b8e776" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_019f1dd9-c4e2-7e0f-a281-ed4a64777211" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_ifrs-full_CommercialPapersIssued_019f1dd9-c4e2-7e0f-a281-ed4a64777211" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_019f1dd9-c4e2-7b8a-adb6-5464646429bb" xlink:href="sny-20260630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_BorrowingAverageDrawdown_019f1dd9-c4e2-7b8a-adb6-5464646429bb" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-7d76-89bf-b804872ab4b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-7d76-89bf-b804872ab4b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a12-aef8-8d34d68d7dfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-7d76-89bf-b804872ab4b0" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a12-aef8-8d34d68d7dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7a12-aef8-8d34d68d7dfd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a12-aef8-8d34d68d7dfd" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7a12-aef8-8d34d68d7dfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a12-aef8-8d34d68d7dfd" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_019ef965-c0a1-7db8-b3cc-5bb7b69887f4" xlink:href="sny-20260630.xsd#sny_AtMarketValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:to="loc_sny_AtMarketValueMember_019ef965-c0a1-7db8-b3cc-5bb7b69887f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7a06-9a96-25735f898513" xlink:href="sny-20260630.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:to="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7a06-9a96-25735f898513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7c1e-b1aa-9bae37b180f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-7c1e-b1aa-9bae37b180f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_019ef965-c0a1-75cc-b21d-eee6fdbdbabf" xlink:href="sny-20260630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_019ef965-c0a1-75cc-b21d-eee6fdbdbabf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_019ef965-c0a1-7461-8e4a-c2ad3069d697" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_019ef965-c0a1-7461-8e4a-c2ad3069d697" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-71b2-b44e-9e8277183068" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-71b2-b44e-9e8277183068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-71b2-b44e-9e8277183068_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-71b2-b44e-9e8277183068" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-71b2-b44e-9e8277183068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-71b2-b44e-9e8277183068" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c13-aa14-298c5b5decb7" xlink:href="sny-20260630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:to="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c13-aa14-298c5b5decb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7fd9-9bb4-20cb2b4e48cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:to="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7fd9-9bb4-20cb2b4e48cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-75fc-8c14-d93946c4f61c" xlink:href="sny-20260630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7fd9-9bb4-20cb2b4e48cb" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-75fc-8c14-d93946c4f61c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-7250-aeec-db09ba1faaa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-7250-aeec-db09ba1faaa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7250-aeec-db09ba1faaa2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-7250-aeec-db09ba1faaa2" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7250-aeec-db09ba1faaa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-7250-aeec-db09ba1faaa2" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-75de-abd0-f057ae87666e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:to="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-75de-abd0-f057ae87666e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_019ef965-c0a1-73e9-b036-9c5e2f8ed8f4" xlink:href="sny-20260630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_019ef965-c0a1-73e9-b036-9c5e2f8ed8f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7caf-b6f3-6ba76f51394f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7caf-b6f3-6ba76f51394f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7caf-b6f3-6ba76f51394f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7caf-b6f3-6ba76f51394f" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7caf-b6f3-6ba76f51394f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7caf-b6f3-6ba76f51394f" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:to="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-7288-b60e-fec0bb5833ef" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-7288-b60e-fec0bb5833ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_019ef965-c0a1-73a3-8dce-766e4b3039a1" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_019ef965-c0a1-73a3-8dce-766e4b3039a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_019ef965-c0a1-7b68-93d0-c9a6929bae71" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_019ef965-c0a1-7b68-93d0-c9a6929bae71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65a1-0037-79df-a9a8-6f3aa76dbf00" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65a1-0037-79df-a9a8-6f3aa76dbf00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSaudiArabianRiyalMember_019f65a2-e824-794a-999b-932e9106e336" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInSaudiArabianRiyalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInSaudiArabianRiyalMember_019f65a2-e824-794a-999b-932e9106e336" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-79e4-a361-da4314ddb354" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-79e4-a361-da4314ddb354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-74fa-bb39-76dfeee2928a" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-74fa-bb39-76dfeee2928a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_019ef965-c0a1-72e4-b656-c115e6de23f7" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_019ef965-c0a1-72e4-b656-c115e6de23f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_019ef965-c0a1-74f2-b20f-855072abe252" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_019ef965-c0a1-74f2-b20f-855072abe252" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember_019f1de6-252b-7f55-9eb2-0eece2e63485" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember_019f1de6-252b-7f55-9eb2-0eece2e63485" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f65a9-e9e0-781d-ad8a-2c802b00d217" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_sny_DisposalGroupAxis_019f65a9-e9e0-781d-ad8a-2c802b00d217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f65a9-e9e0-781d-ad8a-2c802b00d217_default" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DisposalGroupAxis_019f65a9-e9e0-781d-ad8a-2c802b00d217" xlink:to="loc_sny_DisposalGroupDomain_019f65a9-e9e0-781d-ad8a-2c802b00d217_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f65a9-e9e0-7284-87c1-0548d4b197a3" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DisposalGroupAxis_019f65a9-e9e0-781d-ad8a-2c802b00d217" xlink:to="loc_sny_DisposalGroupDomain_019f65a9-e9e0-7284-87c1-0548d4b197a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedleyMember_019f65aa-28ff-761f-b94b-8c4e409ae789" xlink:href="sny-20260630.xsd#sny_MedleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisposalGroupDomain_019f65a9-e9e0-7284-87c1-0548d4b197a3" xlink:to="loc_sny_MedleyMember_019f65aa-28ff-761f-b94b-8c4e409ae789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_019ef965-c0a1-7f6a-b037-0c9b73b3edbd" xlink:href="sny-20260630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_019ef965-c0a1-7461-8e4a-c2ad3069d697" xlink:to="loc_sny_DerivativeFinancialInstruments_019ef965-c0a1-7f6a-b037-0c9b73b3edbd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a27-b8d8-199cb0e08880" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a27-b8d8-199cb0e08880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7a27-b8d8-199cb0e08880_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a27-b8d8-199cb0e08880" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7a27-b8d8-199cb0e08880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a27-b8d8-199cb0e08880" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_019ef965-c0a1-73cb-8f31-42e9072b8188" xlink:href="sny-20260630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:to="loc_sny_AtNotionalAmountMember_019ef965-c0a1-73cb-8f31-42e9072b8188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7712-9f9d-be14f9402636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:to="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7712-9f9d-be14f9402636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7805-a1b2-17ee315f762c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7805-a1b2-17ee315f762c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7805-a1b2-17ee315f762c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7805-a1b2-17ee315f762c" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7805-a1b2-17ee315f762c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7805-a1b2-17ee315f762c" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsMember_019ef965-c0a1-7c23-afd5-e07262f7760d" xlink:href="sny-20260630.xsd#sny_CrossCurrencySellerSwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySellerSwapsMember_019ef965-c0a1-7c23-afd5-e07262f7760d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_019ef965-c0a1-7b01-b8b5-69ee2ddf3e51" xlink:href="sny-20260630.xsd#sny_CrossCurrencySellerSwapsInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CrossCurrencySellerSwapsMember_019ef965-c0a1-7c23-afd5-e07262f7760d" xlink:to="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_019ef965-c0a1-7b01-b8b5-69ee2ddf3e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-77e9-897a-0f12e9a7a755" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-77e9-897a-0f12e9a7a755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember_019ef965-c0a1-7153-b095-fc6e6fec4a79" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:to="loc_sny_ForwardCurrencySalesInPoundSterlingMember_019ef965-c0a1-7153-b095-fc6e6fec4a79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65ab-68cf-71f1-a8e1-883171e4b901" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:to="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65ab-68cf-71f1-a8e1-883171e4b901" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-7743-90c6-57587c0dbfbd" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-7743-90c6-57587c0dbfbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-7106-b0fb-25915663f3cc" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-7106-b0fb-25915663f3cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_019ef965-c0a1-786d-bb1a-543a9eab22cf" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:to="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_019ef965-c0a1-786d-bb1a-543a9eab22cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2029Member_019ef965-c0a1-7d6b-8b6f-083cabf7db04" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapExpiring2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySwapExpiring2029Member_019ef965-c0a1-7d6b-8b6f-083cabf7db04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2032Member_019ef965-c0a1-7c5f-b687-00e3c42c5fc0" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapExpiring2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySwapExpiring2032Member_019ef965-c0a1-7c5f-b687-00e3c42c5fc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapMember_019ef965-c0a1-742a-a100-35fe8fa79b39" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySwapMember_019ef965-c0a1-742a-a100-35fe8fa79b39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member_019f65b0-a5e8-737f-bd08-2e3915f15884" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member_019f65b0-a5e8-737f-bd08-2e3915f15884" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member_019f65b9-2ff4-720c-9843-593325f96895" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member_019f65b9-2ff4-720c-9843-593325f96895" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_019f1df8-c3f1-7c22-8ad9-e906d6ad8a22" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_019f1df8-c3f1-7c22-8ad9-e906d6ad8a22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7dff-b996-f98498d4322b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7dff-b996-f98498d4322b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7dff-b996-f98498d4322b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7dff-b996-f98498d4322b" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7dff-b996-f98498d4322b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7dff-b996-f98498d4322b" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7a9d-b81e-07a1aed74048" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7a9d-b81e-07a1aed74048" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-7e07-9856-e77c2755f66b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-7e07-9856-e77c2755f66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_019ef965-c0a1-7e76-8aca-5f866d2a7c2a" xlink:href="sny-20260630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_019ef965-c0a1-7e76-8aca-5f866d2a7c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCrossCurrencySwaps_019f1ded-0ff0-714d-bdae-a2c698c657f7" xlink:href="sny-20260630.xsd#sny_NumberOfCrossCurrencySwaps"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_sny_NumberOfCrossCurrencySwaps_019f1ded-0ff0-714d-bdae-a2c698c657f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019ef965-c0a1-7820-8500-72bb1e387795" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_NotionalAmount_019ef965-c0a1-7820-8500-72bb1e387795" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_019f65c1-c98e-776f-bddb-1126e4ee43a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_019f65c1-c98e-776f-bddb-1126e4ee43a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-c0a1-7595-9e6e-d6e62e832671" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-c0a1-7595-9e6e-d6e62e832671" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_019f65b5-bcd4-7c15-8c1c-7a2e109e9c04" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_FinanceIncomeCost_019f65b5-bcd4-7c15-8c1c-7a2e109e9c04" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_019ef965-c0a1-72e7-a468-5573c29f8bbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_019ef965-c0a1-72e7-a468-5573c29f8bbb" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7ad2-9f01-9c5f1c760921" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7ad2-9f01-9c5f1c760921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7ad2-9f01-9c5f1c760921_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7ad2-9f01-9c5f1c760921" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7ad2-9f01-9c5f1c760921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7ad2-9f01-9c5f1c760921" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember_019f1e04-f0ae-7a2e-9669-d008309202aa" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember_019f1e04-f0ae-7a2e-9669-d008309202aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember_019f1e04-f0ae-7b80-ad91-459641b88dec" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember_019f1e04-f0ae-7b80-ad91-459641b88dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member_019f1e04-f0ae-7423-b660-e7a2004a680e" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member_019f1e04-f0ae-7423-b660-e7a2004a680e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member_019f1e04-f0ae-70dd-940b-1bbce6c2c188" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member_019f1e04-f0ae-70dd-940b-1bbce6c2c188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember_019f1e04-f0ae-7df9-a285-a5128c603c49" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember_019f1e04-f0ae-7df9-a285-a5128c603c49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_019f1e04-f0ae-7347-afb8-3c259f39bf1c" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_019f1e04-f0ae-7347-afb8-3c259f39bf1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member_019f65c3-12c8-7047-9ea5-b1f887ec3e58" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member_019f65c3-12c8-7047-9ea5-b1f887ec3e58" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member_019f65c3-65bb-724f-bf83-fbfb05e88fb6" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member_019f65c3-65bb-724f-bf83-fbfb05e88fb6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member_019f1e04-f0ae-76db-9c1f-37f2e1e37717" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member_019f1e04-f0ae-76db-9c1f-37f2e1e37717" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7caf-b773-abcafe8d2a70" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7caf-b773-abcafe8d2a70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7caf-b773-abcafe8d2a70_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7caf-b773-abcafe8d2a70" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7caf-b773-abcafe8d2a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7caf-b773-abcafe8d2a70" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c48-a693-ce36a532e656" xlink:href="sny-20260630.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:to="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c48-a693-ce36a532e656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7f2d-aa2c-5871e24deec7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:to="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7f2d-aa2c-5871e24deec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-7ed5-84e5-8b8fe5485cad" xlink:href="sny-20260630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-7ed5-84e5-8b8fe5485cad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7eb9-9697-195ac8d7f5e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7eb9-9697-195ac8d7f5e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7eb9-9697-195ac8d7f5e9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7eb9-9697-195ac8d7f5e9" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7eb9-9697-195ac8d7f5e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7eb9-9697-195ac8d7f5e9" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7949-bd38-1fbd3fcecb45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7949-bd38-1fbd3fcecb45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-766b-809c-2f426798d319" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-766b-809c-2f426798d319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_019ef965-c0a1-73d2-9bab-e1423b6a5182" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_019ef965-c0a1-73d2-9bab-e1423b6a5182" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_019ef965-c0a1-7bee-aec7-ee540e6b50a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_019ef965-c0a1-7bee-aec7-ee540e6b50a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_019ef965-c0a1-777a-b131-48a709f743f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_019ef965-c0a1-777a-b131-48a709f743f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-77a7-9041-52edb6b38428" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-77a7-9041-52edb6b38428" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-77a7-9041-52edb6b38428_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-77a7-9041-52edb6b38428" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-77a7-9041-52edb6b38428_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-77a7-9041-52edb6b38428" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_019ef965-c0a1-7ad6-ad6f-0d7e953c5736" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:to="loc_ifrs-full_FairValueHedgesMember_019ef965-c0a1-7ad6-ad6f-0d7e953c5736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-7cff-b6f7-a521deee263c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:to="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-7cff-b6f7-a521deee263c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_019ef965-c0a1-7da1-ad6e-13436f89d09a" xlink:href="sny-20260630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_019ef965-c0a1-72e7-a468-5573c29f8bbb" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_019ef965-c0a1-7da1-ad6e-13436f89d09a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-78ce-a1b3-6d6c1355e1d5" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-78ce-a1b3-6d6c1355e1d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-7025-ba49-c7928e2bc215" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-78ce-a1b3-6d6c1355e1d5" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-7025-ba49-c7928e2bc215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7025-ba49-c7928e2bc215_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-7025-ba49-c7928e2bc215" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7025-ba49-c7928e2bc215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-7025-ba49-c7928e2bc215" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-76cf-8ff9-3b84fa46ab8c" xlink:href="sny-20260630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-76cf-8ff9-3b84fa46ab8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember_019f1e09-22f8-7460-8533-04966b2023a5" xlink:href="sny-20260630.xsd#sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember_019f1e09-22f8-7460-8533-04966b2023a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember_019f1e09-5e40-7e7a-bbfd-575b90b472ce" xlink:href="sny-20260630.xsd#sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember_019f1e09-5e40-7e7a-bbfd-575b90b472ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_019ef965-c0a1-70f3-a1a1-a6eae3e1ba18" xlink:href="sny-20260630.xsd#sny_OtherLiabilities1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_OtherLiabilities1Member_019ef965-c0a1-70f3-a1a1-a6eae3e1ba18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:href="sny-20260630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:to="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-7536-be1f-0fe43c825bd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-7536-be1f-0fe43c825bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-71bf-99b1-50ea09c130e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-71bf-99b1-50ea09c130e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_019ef965-c0a1-7832-b71d-e6a1034f1b77" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_019ef965-c0a1-7832-b71d-e6a1034f1b77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_019ef965-c0a1-7fe8-8c99-994537018c34" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_019ef965-c0a1-7fe8-8c99-994537018c34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-7e07-bfd9-67a7743a0739" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-77c4-95fb-1838e5f6219c" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-77c4-95fb-1838e5f6219c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-7081-a220-6dedbe0dc2c2" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-7081-a220-6dedbe0dc2c2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-76e3-9550-23088e17476a" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-76e3-9550-23088e17476a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-70fe-939c-7236c2f91dc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-76e3-9550-23088e17476a" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-70fe-939c-7236c2f91dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-70fe-939c-7236c2f91dc6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-70fe-939c-7236c2f91dc6" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-70fe-939c-7236c2f91dc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7e19-a69f-1adf49d9eac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-70fe-939c-7236c2f91dc6" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7e19-a69f-1adf49d9eac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-7b7a-8a65-c28efd504a1a" xlink:href="sny-20260630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7e19-a69f-1adf49d9eac9" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-7b7a-8a65-c28efd504a1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-729b-ab77-cf66fe41fab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-729b-ab77-cf66fe41fab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_019ef965-c0a1-74d6-abee-81af57b153c9" xlink:href="sny-20260630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_019ef965-c0a1-74d6-abee-81af57b153c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8" xlink:href="sny-20260630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:to="loc_sny_PrincipalAlliancesAxis_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8_default" xlink:href="sny-20260630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8" xlink:to="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-7da5-b78e-1655fe03736a" xlink:href="sny-20260630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8" xlink:to="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-7da5-b78e-1655fe03736a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_019ef965-c0a1-7a2d-b19c-0691bf296d44" xlink:href="sny-20260630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-7da5-b78e-1655fe03736a" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_019ef965-c0a1-7a2d-b19c-0691bf296d44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:to="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c" xlink:to="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7f09-8445-269526cba260" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c" xlink:to="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7f09-8445-269526cba260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_019ef965-c0a1-76a6-8bd6-9ab2cf306378" xlink:href="sny-20260630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7f09-8445-269526cba260" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_019ef965-c0a1-76a6-8bd6-9ab2cf306378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7a53-a11d-e40791c89569" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7a53-a11d-e40791c89569" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7a53-a11d-e40791c89569_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7a53-a11d-e40791c89569" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7a53-a11d-e40791c89569_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7a53-a11d-e40791c89569" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_019ef965-c0a1-72f6-996b-cee19566891a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_019ef965-c0a1-72f6-996b-cee19566891a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_019ef965-c0a1-700f-a386-f6c0a915081b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_019ef965-c0a1-700f-a386-f6c0a915081b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-70af-8d9c-ec151f6fad45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:to="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-70af-8d9c-ec151f6fad45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_019ef965-c0a1-7498-be37-17ea6a2bf7df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_019ef965-c0a1-7498-be37-17ea6a2bf7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c0a1-721d-a2ae-4c6afc63ec52" xlink:href="sny-20260630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c0a1-721d-a2ae-4c6afc63ec52" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-77ac-b287-07802b41398e" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7595-8551-11e092c5160d" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-77ac-b287-07802b41398e" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7595-8551-11e092c5160d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_019ef965-c0a1-79db-987d-49eedf38a140" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7595-8551-11e092c5160d" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_019ef965-c0a1-79db-987d-49eedf38a140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-79db-987d-49eedf38a140_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_019ef965-c0a1-79db-987d-49eedf38a140" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-79db-987d-49eedf38a140_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_019ef965-c0a1-79db-987d-49eedf38a140" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_019ef965-c0a1-7989-93c2-a7765c721906" xlink:href="sny-20260630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_019ef965-c0a1-7989-93c2-a7765c721906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_019ef965-c0a1-7917-a423-38110c77ec24" xlink:href="sny-20260630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_019ef965-c0a1-7917-a423-38110c77ec24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_019ef965-c0a1-752c-9b01-735b29e21aa4" xlink:href="sny-20260630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_019ef965-c0a1-752c-9b01-735b29e21aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_019ef965-c0a1-767d-a78f-737429cdf31e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_019ef965-c0a1-767d-a78f-737429cdf31e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-77ac-b287-07802b41398e" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7c84-90d2-7a5b67b95eb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7c84-90d2-7a5b67b95eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_019f7fda-b67f-7b2f-821f-2154100e4103" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_019f7fda-b67f-7b2f-821f-2154100e4103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities_019f1e13-943c-76d7-8040-4db59185c0ea" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInProvisionsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities_019f1e13-943c-76d7-8040-4db59185c0ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_019f1e13-943c-7360-a720-cc5f8d0be80f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_019f1e13-943c-7360-a720-cc5f8d0be80f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_019f1e13-943c-7c06-9e93-419f59902f9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_019f1e13-943c-7c06-9e93-419f59902f9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_019f1e13-943c-7ee9-87ae-c19d5d5470ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_019f1e13-943c-7ee9-87ae-c19d5d5470ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_019f1e13-943c-75dc-b0ed-b987602b0517" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_019f1e13-943c-75dc-b0ed-b987602b0517" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_019f1e13-943c-77d3-b0f9-25ef6f6d48d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_019f1e13-943c-77d3-b0f9-25ef6f6d48d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_019f1e13-943c-73bb-8a6e-1df8fde3b1e6" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_019f1e13-943c-73bb-8a6e-1df8fde3b1e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7488-82bc-82b5fb323ec9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c0a1-73c4-b1a7-d5b853318dac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c0a1-73c4-b1a7-d5b853318dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-73c4-b1a7-d5b853318dac_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c0a1-73c4-b1a7-d5b853318dac" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-73c4-b1a7-d5b853318dac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c0a1-73c4-b1a7-d5b853318dac" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_019ef965-c0a1-74c9-b460-eeaa5bef98aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:to="loc_ifrs-full_PlanAssetsMember_019ef965-c0a1-74c9-b460-eeaa5bef98aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_019f7fdd-5021-78db-b28b-d2d2ce0f3605" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_019f7fdd-5021-78db-b28b-d2d2ce0f3605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_019ef965-c0a1-7fd5-98ed-4e846edc4080" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_019ef965-c0a1-7fd5-98ed-4e846edc4080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-7fd5-98ed-4e846edc4080_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_019ef965-c0a1-7fd5-98ed-4e846edc4080" xlink:to="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-7fd5-98ed-4e846edc4080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-723f-a53a-e3f633796d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_019ef965-c0a1-7fd5-98ed-4e846edc4080" xlink:to="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-723f-a53a-e3f633796d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_019ef965-c0a1-7ac3-865f-3818569f7e36" xlink:href="sny-20260630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-723f-a53a-e3f633796d60" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_019ef965-c0a1-7ac3-865f-3818569f7e36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019ef965-c0a1-79d8-84f8-9aea209f3026" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019ef965-c0a1-79d8-84f8-9aea209f3026" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-79d8-84f8-9aea209f3026_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-c0a1-79d8-84f8-9aea209f3026" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-79d8-84f8-9aea209f3026_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-7e3c-abe5-435cbab765e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-c0a1-79d8-84f8-9aea209f3026" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-7e3c-abe5-435cbab765e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019ef965-c0a1-704c-87ac-4f74e4ac6df7" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-7e3c-abe5-435cbab765e4" xlink:to="loc_country_GB_019ef965-c0a1-704c-87ac-4f74e4ac6df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_019ef965-c0a1-7a4f-9905-e36cef59fa65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_019ef965-c0a1-7a4f-9905-e36cef59fa65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7a4f-9905-e36cef59fa65_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_019ef965-c0a1-7a4f-9905-e36cef59fa65" xlink:to="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7a4f-9905-e36cef59fa65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_019ef965-c0a1-7a4f-9905-e36cef59fa65" xlink:to="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_019ef965-c0a1-7e8f-bab6-45007dbc3e19" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_019ef965-c0a1-7e8f-bab6-45007dbc3e19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_019ef965-c0a1-7fae-aab8-de9334a1928d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_019ef965-c0a1-7fae-aab8-de9334a1928d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019ef965-c0a1-77a1-b02e-2e3954f530dc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_srt_RangeAxis_019ef965-c0a1-77a1-b02e-2e3954f530dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019ef965-c0a1-77a1-b02e-2e3954f530dc_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019ef965-c0a1-77a1-b02e-2e3954f530dc" xlink:to="loc_srt_RangeMember_019ef965-c0a1-77a1-b02e-2e3954f530dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019ef965-c0a1-77a1-b02e-2e3954f530dc" xlink:to="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019ef965-c0a1-7e42-8819-5b21197ea7fa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:to="loc_srt_MinimumMember_019ef965-c0a1-7e42-8819-5b21197ea7fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019ef965-c0a1-7056-84b3-a8ba7d707899" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:to="loc_srt_MaximumMember_019ef965-c0a1-7056-84b3-a8ba7d707899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-71da-b7ac-23ddff242a31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-71da-b7ac-23ddff242a31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-71da-b7ac-23ddff242a31_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-71da-b7ac-23ddff242a31" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-71da-b7ac-23ddff242a31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7fca-bd3f-b943e848737a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-71da-b7ac-23ddff242a31" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7fca-bd3f-b943e848737a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019ef965-c0a1-7921-91ed-1e26ffec5425" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7fca-bd3f-b943e848737a" xlink:to="loc_sny_OpellaBusinessMember_019ef965-c0a1-7921-91ed-1e26ffec5425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_019ef965-c0a1-751d-a01e-327e5e8caeb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_019ef965-c0a1-751d-a01e-327e5e8caeb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_019ef965-c0a1-77d4-b78e-b58f99db141c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_019ef965-c0a1-77d4-b78e-b58f99db141c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_019ef965-c0a1-7fc3-a876-1966c9a27e85" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_019ef965-c0a1-7fc3-a876-1966c9a27e85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_019ef965-c0a1-790e-a0e9-e01622936c97" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_019ef965-c0a1-790e-a0e9-e01622936c97" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OffbalancesheetcommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7d9b-be0e-a38d5239e202" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:to="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7d9b-be0e-a38d5239e202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7d9b-be0e-a38d5239e202_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7d9b-be0e-a38d5239e202" xlink:to="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7d9b-be0e-a38d5239e202_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7d9b-be0e-a38d5239e202" xlink:to="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CTTQMember_019f937e-2bf5-778f-ad68-bd7c424bc148" xlink:href="sny-20260630.xsd#sny_CTTQMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:to="loc_sny_CTTQMember_019f937e-2bf5-778f-ad68-bd7c424bc148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KaliTherapeuticsMember_019fa2c7-bd6b-7851-a752-d1d7bb35e7b0" xlink:href="sny-20260630.xsd#sny_KaliTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:to="loc_sny_KaliTherapeuticsMember_019fa2c7-bd6b-7851-a752-d1d7bb35e7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_019f937c-a757-7aaa-a302-ff4c02e7aa39" xlink:href="sny-20260630.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:to="loc_sny_TypesOfAgreementAxis_019f937c-a757-7aaa-a302-ff4c02e7aa39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_019f937c-a757-7aaa-a302-ff4c02e7aa39_default" xlink:href="sny-20260630.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_019f937c-a757-7aaa-a302-ff4c02e7aa39" xlink:to="loc_sny_TypesOfAgreementDomain_019f937c-a757-7aaa-a302-ff4c02e7aa39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:href="sny-20260630.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_019f937c-a757-7aaa-a302-ff4c02e7aa39" xlink:to="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CTTQRovidicitinibLicenseAgreementMember_019f937c-da30-7828-b6e6-70636c3d0dff" xlink:href="sny-20260630.xsd#sny_CTTQRovidicitinibLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:to="loc_sny_CTTQRovidicitinibLicenseAgreementMember_019f937c-da30-7828-b6e6-70636c3d0dff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KaliTherapeuticsLicenseAgreementMember_019fa2c8-4e0b-78de-9931-4c1096372b0f" xlink:href="sny-20260630.xsd#sny_KaliTherapeuticsLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:to="loc_sny_KaliTherapeuticsLicenseAgreementMember_019fa2c8-4e0b-78de-9931-4c1096372b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontLicensePayment_019f937c-469d-7ade-9d33-6a106b171d27" xlink:href="sny-20260630.xsd#sny_UpfrontLicensePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:to="loc_sny_UpfrontLicensePayment_019f937c-469d-7ade-9d33-6a106b171d27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments_019f9380-96f6-712e-96f2-953f90759ddb" xlink:href="sny-20260630.xsd#sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:to="loc_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments_019f9380-96f6-712e-96f2-953f90759ddb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#LitigationandarbitrationproceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_019f9382-51b8-77d8-9584-5006197004e1" xlink:href="sny-20260630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_019f9382-51b8-77d8-9584-5006197004e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-77d8-9584-5006197004e1_default" xlink:href="sny-20260630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_019f9382-51b8-77d8-9584-5006197004e1" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-77d8-9584-5006197004e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:href="sny-20260630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_019f9382-51b8-77d8-9584-5006197004e1" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember_019f9382-51b8-7e06-9910-5376416a09a2" xlink:href="sny-20260630.xsd#sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:to="loc_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember_019f9382-51b8-7e06-9910-5376416a09a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HudsonHeadwatersHealthNetworkMember_019f9382-51b8-7be0-9276-8272188d6a1d" xlink:href="sny-20260630.xsd#sny_HudsonHeadwatersHealthNetworkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:to="loc_sny_HudsonHeadwatersHealthNetworkMember_019f9382-51b8-7be0-9276-8272188d6a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MosaicHealthInTheUSMember_019f9382-51b8-71a1-b915-2ab47581d439" xlink:href="sny-20260630.xsd#sny_MosaicHealthInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:to="loc_sny_MosaicHealthInTheUSMember_019f9382-51b8-71a1-b915-2ab47581d439" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_019f9382-51b8-721e-9615-21a6fa6d577e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_019f9382-51b8-721e-9615-21a6fa6d577e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-721e-9615-21a6fa6d577e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_019f9382-51b8-721e-9615-21a6fa6d577e" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-721e-9615-21a6fa6d577e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_019f9382-51b8-721e-9615-21a6fa6d577e" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TalcProductLitigationInTheUSMember_019f9383-a750-7110-9f0e-dfebcffc687f" xlink:href="sny-20260630.xsd#sny_TalcProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:to="loc_sny_TalcProductLitigationInTheUSMember_019f9383-a750-7110-9f0e-dfebcffc687f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A340BDrugPricingProgramInTheUSMember_019f9382-51b8-7356-9ecb-15d7f8359aa7" xlink:href="sny-20260630.xsd#sny_A340BDrugPricingProgramInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:to="loc_sny_A340BDrugPricingProgramInTheUSMember_019f9382-51b8-7356-9ecb-15d7f8359aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentProductLitigationInTheUSMember_019fa41e-81e3-7102-8901-f629c11c05b0" xlink:href="sny-20260630.xsd#sny_DupixentProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:to="loc_sny_DupixentProductLitigationInTheUSMember_019fa41e-81e3-7102-8901-f629c11c05b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_019f9382-51b8-7b46-bed3-3d0e96410b78" xlink:href="sny-20260630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfClassActionLawsuits_019f9382-51b8-7b46-bed3-3d0e96410b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfProductLiabilityCases_019f9383-a750-751e-bda4-12e07d18c178" xlink:href="sny-20260630.xsd#sny_NumberOfProductLiabilityCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfProductLiabilityCases_019f9383-a750-751e-bda4-12e07d18c178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCasesFiledInNewJerseyCourt_019fa2e4-3489-71c8-a4e1-cf0ce950dd19" xlink:href="sny-20260630.xsd#sny_NumberOfCasesFiledInNewJerseyCourt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfCasesFiledInNewJerseyCourt_019fa2e4-3489-71c8-a4e1-cf0ce950dd19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOtherDefendantsInLegalProceeding_019f9382-51b8-7e36-92b3-96199b2f9de5" xlink:href="sny-20260630.xsd#sny_NumberOfOtherDefendantsInLegalProceeding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfOtherDefendantsInLegalProceeding_019f9382-51b8-7e36-92b3-96199b2f9de5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLegalDecisionAspectsChallenged_019f9382-51b8-701c-a40b-05180bf4463b" xlink:href="sny-20260630.xsd#sny_NumberOfLegalDecisionAspectsChallenged"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfLegalDecisionAspectsChallenged_019f9382-51b8-701c-a40b-05180bf4463b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7f6a-977a-9dcb07d510d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7f6a-977a-9dcb07d510d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7f6a-977a-9dcb07d510d2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7f6a-977a-9dcb07d510d2" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7f6a-977a-9dcb07d510d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7f6a-977a-9dcb07d510d2" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmvuttraMember_019f1e32-2d1c-73da-ae0a-71069f481be1" xlink:href="sny-20260630.xsd#sny_AmvuttraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:to="loc_sny_AmvuttraMember_019f1e32-2d1c-73da-ae0a-71069f481be1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_019f1e32-2d1c-7e2d-b0d5-16c08262ce12" xlink:href="sny-20260630.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:to="loc_sny_RegeneronMember_019f1e32-2d1c-7e2d-b0d5-16c08262ce12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_019f1e32-2d1c-7c8b-9256-0e404933d3a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_019f1e32-2d1c-7c8b-9256-0e404933d3a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019f1e32-2d1c-76f3-8507-1f2f48f9024a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019f1e32-2d1c-76f3-8507-1f2f48f9024a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-76f3-8507-1f2f48f9024a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019f1e32-2d1c-76f3-8507-1f2f48f9024a" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-76f3-8507-1f2f48f9024a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019f1e32-2d1c-76f3-8507-1f2f48f9024a" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_019f1e32-2d1c-7a2a-bf34-73dc1d5fb213" xlink:href="sny-20260630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_019f1e32-2d1c-7a2a-bf34-73dc1d5fb213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalProfitShareForDevelopmentCostMember_019f801e-4b60-725a-a4fc-d22fa146c90b" xlink:href="sny-20260630.xsd#sny_AdditionalProfitShareForDevelopmentCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:to="loc_sny_AdditionalProfitShareForDevelopmentCostMember_019f801e-4b60-725a-a4fc-d22fa146c90b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_019f1e32-2d1c-78fd-93b2-61ff8beae636" xlink:href="sny-20260630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:to="loc_sny_CommercializationRelatedExpensesMember_019f1e32-2d1c-78fd-93b2-61ff8beae636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossOnDivestmentOfProducts_019f1e32-2d1c-70b5-859c-3d74faa527df" xlink:href="sny-20260630.xsd#sny_GainsLossOnDivestmentOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_GainsLossOnDivestmentOfProducts_019f1e32-2d1c-70b5-859c-3d74faa527df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_019f1e32-2d1c-7d9e-b696-bb4bf1cc9e11" xlink:href="sny-20260630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_IncomeResultingFromOutLicensing_019f1e32-2d1c-7d9e-b696-bb4bf1cc9e11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f1e32-2d1c-7614-b628-4d5268b5e704" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f1e32-2d1c-7614-b628-4d5268b5e704" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncome_019f1e32-2d1c-700f-aa6f-0584e441bc6e" xlink:href="sny-20260630.xsd#sny_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_OtherOperatingIncome_019f1e32-2d1c-700f-aa6f-0584e441bc6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019f1e32-2d1c-71af-be59-0480405d15bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019f1e32-2d1c-71af-be59-0480405d15bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpense_019f1e32-2d1c-7680-b6b9-f401792408d8" xlink:href="sny-20260630.xsd#sny_OtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_OtherOperatingExpense_019f1e32-2d1c-7680-b6b9-f401792408d8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7f83-aa41-803fe274cdc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7f83-aa41-803fe274cdc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f1e3b-2237-7359-b418-4292ea8c6471" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7f83-aa41-803fe274cdc1" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f1e3b-2237-7359-b418-4292ea8c6471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7359-b418-4292ea8c6471_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f1e3b-2237-7359-b418-4292ea8c6471" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7359-b418-4292ea8c6471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7620-bc44-f6236d21167a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f1e3b-2237-7359-b418-4292ea8c6471" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7620-bc44-f6236d21167a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f801f-c452-7fc7-9374-563a59f80682" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7620-bc44-f6236d21167a" xlink:to="loc_sny_DynavaxMember_019f801f-c452-7fc7-9374-563a59f80682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_019ef965-c0a1-74b1-ae12-c228f2d16c48" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_019ef965-c0a1-74b1-ae12-c228f2d16c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_019ef965-c0a1-709c-bc7a-143db88a82e9" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_019ef965-c0a1-709c-bc7a-143db88a82e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_019ef965-c0a1-7743-8d4b-a31c06b211a7" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_019ef965-c0a1-7743-8d4b-a31c06b211a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts_019ef965-c0a1-7a73-99ff-74db50fad79b" xlink:href="sny-20260630.xsd#sny_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_OtherRestructuringCosts_019ef965-c0a1-7a73-99ff-74db50fad79b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-7ce4-a635-1a4ff31a57d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-7ce4-a635-1a4ff31a57d1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#FinancialexpensesandincomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:href="sny-20260630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c168-79db-bd7e-583d5eaa266c" xlink:href="sny-20260630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c168-79db-bd7e-583d5eaa266c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_019ef965-c168-7a59-b297-9a9022990572" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c168-79db-bd7e-583d5eaa266c" xlink:to="loc_ifrs-full_HedgedItemsAxis_019ef965-c168-7a59-b297-9a9022990572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-7a59-b297-9a9022990572_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_019ef965-c168-7a59-b297-9a9022990572" xlink:to="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-7a59-b297-9a9022990572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-79bd-a9c1-735097591676" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_019ef965-c168-7a59-b297-9a9022990572" xlink:to="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-79bd-a9c1-735097591676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_019ef965-c168-7145-b3ec-09b40a029249" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-79bd-a9c1-735097591676" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_019ef965-c168-7145-b3ec-09b40a029249" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_019ef965-c168-7335-afbf-a42d655fc8d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_019ef965-c168-7335-afbf-a42d655fc8d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_019ef965-c168-74fe-9fe0-1b199f89ee13" xlink:href="sny-20260630.xsd#sny_InterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_InterestIncome_019ef965-c168-74fe-9fe0-1b199f89ee13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_019ef965-c168-7ac3-80d9-76659f49ecfc" xlink:href="sny-20260630.xsd#sny_CostOfDebtNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_CostOfDebtNet_019ef965-c168-7ac3-80d9-76659f49ecfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_019ef965-c168-7e44-8e51-63237834a178" xlink:href="sny-20260630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_019ef965-c168-7e44-8e51-63237834a178" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_019ef965-c168-7534-a190-4f257049fade" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_019ef965-c168-7534-a190-4f257049fade" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_019ef965-c168-7a44-a35d-c69da54480cf" xlink:href="sny-20260630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_019ef965-c168-7a44-a35d-c69da54480cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_019f65d0-e083-7923-b621-2bd5b4481d9c" xlink:href="sny-20260630.xsd#sny_ImpairmentLossesOnFinancialAssetsNetOfReversals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_019f65d0-e083-7923-b621-2bd5b4481d9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_019ef965-c168-7660-be2c-347545474dd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_019ef965-c168-7660-be2c-347545474dd7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_019ef965-c168-74b1-b581-c894055625c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_019ef965-c168-74b1-b581-c894055625c4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-7eb7-90cf-e99d1a29a329" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-7eb7-90cf-e99d1a29a329" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019ef965-c168-7ed2-ac59-014667f7daae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_FinanceCosts_019ef965-c168-7ed2-ac59-014667f7daae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019ef965-c168-7dd7-8755-e5aad0ca9d65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_FinanceIncome_019ef965-c168-7dd7-8755-e5aad0ca9d65" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt_019ef965-c168-7202-8d4a-3979db539f00" xlink:href="sny-20260630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageDebt_019ef965-c168-7202-8d4a-3979db539f00" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_019ef965-c168-7494-8606-9a34f0051392" xlink:href="sny-20260630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_019ef965-c168-7494-8606-9a34f0051392" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_019ef965-c168-7c1f-9cdb-a2d0f1bdde3a" xlink:href="sny-20260630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_019ef965-c168-7c1f-9cdb-a2d0f1bdde3a" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019f21f7-88ba-70f4-a34a-90a8c8185c67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019f21f7-88ba-70f4-a34a-90a8c8185c67" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019f21f7-88ba-75b4-88b6-42c8053c5515" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019f21f7-88ba-75b4-88b6-42c8053c5515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-75b4-88b6-42c8053c5515_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019f21f7-88ba-75b4-88b6-42c8053c5515" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-75b4-88b6-42c8053c5515_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019f21f7-88ba-75b4-88b6-42c8053c5515" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_019f21f7-88ba-7fb2-87c8-5ad2f0bfd524" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:to="loc_srt_EuropeMember_019f21f7-88ba-7fb2-87c8-5ad2f0bfd524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019f21f7-88ba-77b9-8a18-2203c73cf584" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:to="loc_country_US_019f21f7-88ba-77b9-8a18-2203c73cf584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesInSegmentResultsMember_019f21f7-88ba-7fb4-b41d-ee47f0b77ad4" xlink:href="sny-20260630.xsd#sny_OtherCountriesInSegmentResultsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:to="loc_sny_OtherCountriesInSegmentResultsMember_019f21f7-88ba-7fb4-b41d-ee47f0b77ad4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_019f21f7-88ba-741e-a454-5b55be4b3dc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_019f21f7-88ba-741e-a454-5b55be4b3dc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-741e-a454-5b55be4b3dc1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_019f21f7-88ba-741e-a454-5b55be4b3dc1" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-741e-a454-5b55be4b3dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_019f21f7-88ba-741e-a454-5b55be4b3dc1" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_019f21f7-88ba-7137-944a-8382d708961c" xlink:href="sny-20260630.xsd#sny_DupixentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_DupixentMember_019f21f7-88ba-7137-944a-8382d708961c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_019f21f7-88ba-723d-ace3-b7288267b236" xlink:href="sny-20260630.xsd#sny_AltuviiioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_AltuviiioMember_019f21f7-88ba-723d-ace3-b7288267b236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_019f65d5-ddf8-775e-bff0-277ea919742e" xlink:href="sny-20260630.xsd#sny_FabrazymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_FabrazymeMember_019f65d5-ddf8-775e-bff0-277ea919742e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeNexviadymeMember_019f21f7-88ba-7f3b-9b4d-c9a859a8fa8d" xlink:href="sny-20260630.xsd#sny_NexviazymeNexviadymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_NexviazymeNexviadymeMember_019f21f7-88ba-7f3b-9b4d-c9a859a8fa8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_019f65d6-9abc-7d68-83b0-37097b105a9e" xlink:href="sny-20260630.xsd#sny_CerezymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_CerezymeMember_019f65d6-9abc-7d68-83b0-37097b105a9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AyvakitMember_019f21f7-88ba-78f2-9099-4f94fb1ae82a" xlink:href="sny-20260630.xsd#sny_AyvakitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_AyvakitMember_019f21f7-88ba-78f2-9099-4f94fb1ae82a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember_019f21f7-88ba-70b7-8643-984faa2cea14" xlink:href="sny-20260630.xsd#sny_SarclisaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_SarclisaMember_019f21f7-88ba-70b7-8643-984faa2cea14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_019f65d4-5eb1-7d2a-bd2c-cab84abeb04f" xlink:href="sny-20260630.xsd#sny_LantusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_LantusMember_019f65d4-5eb1-7d2a-bd2c-cab84abeb04f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_019f65d4-7ed2-7149-9e52-dcaec2a8f5f4" xlink:href="sny-20260630.xsd#sny_ToujeoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_ToujeoMember_019f65d4-7ed2-7149-9e52-dcaec2a8f5f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_019f65d4-9b35-754a-9c86-eaf7013fd6c2" xlink:href="sny-20260630.xsd#sny_PlavixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_PlavixMember_019f65d4-9b35-754a-9c86-eaf7013fd6c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_019f65d4-b975-793f-ba2e-f3f29de238e5" xlink:href="sny-20260630.xsd#sny_LovenoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_LovenoxMember_019f65d4-b975-793f-ba2e-f3f29de238e5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember_019f21f7-88ba-76de-88c8-d5376fe83fc4" xlink:href="sny-20260630.xsd#sny_RezurockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_RezurockMember_019f21f7-88ba-76de-88c8-d5376fe83fc4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_019f21f7-88ba-7abc-a4fd-bf742300ed8c" xlink:href="sny-20260630.xsd#sny_IndustrialSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_IndustrialSalesMember_019f21f7-88ba-7abc-a4fd-bf742300ed8c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember_019f21f7-88ba-7bec-8862-af2451834048" xlink:href="sny-20260630.xsd#sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember_019f21f7-88ba-7bec-8862-af2451834048" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesBeyfortusMember_019f21f7-88ba-789f-966a-02c0b9bede12" xlink:href="sny-20260630.xsd#sny_RSVVaccinesBeyfortusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_RSVVaccinesBeyfortusMember_019f21f7-88ba-789f-966a-02c0b9bede12" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicsVaccinesMember_019f21f7-88ba-7298-a4d8-45fc08a6bfc7" xlink:href="sny-20260630.xsd#sny_MeningitisTravelAndEndemicsVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_MeningitisTravelAndEndemicsVaccinesMember_019f21f7-88ba-7298-a4d8-45fc08a6bfc7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_COVID19AndInfluenzaVaccinesMember_019f21f7-88ba-7da5-8aa2-6a3288af5672" xlink:href="sny-20260630.xsd#sny_COVID19AndInfluenzaVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_COVID19AndInfluenzaVaccinesMember_019f21f7-88ba-7da5-8aa2-6a3288af5672" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LaunchesMember_019f21f7-88ba-7f9f-b060-18a2aba763d9" xlink:href="sny-20260630.xsd#sny_LaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_LaunchesMember_019f21f7-88ba-7f9f-b060-18a2aba763d9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019f21f7-88ba-76b6-b2b9-186c8f1e0ae5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019f21f7-88ba-70f4-a34a-90a8c8185c67" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019f21f7-88ba-76b6-b2b9-186c8f1e0ae5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c168-7e09-be0d-24bca4f2c60f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c168-7e09-be0d-24bca4f2c60f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c168-7e28-8586-71db3e83943e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c168-7e09-be0d-24bca4f2c60f" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c168-7e28-8586-71db3e83943e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7e28-8586-71db3e83943e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7e28-8586-71db3e83943e" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7e28-8586-71db3e83943e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7e28-8586-71db3e83943e" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c168-7799-b507-fe8b46fd910b" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c168-7799-b507-fe8b46fd910b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019ef965-c168-72ae-8d8e-8fc74d82a5be" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:to="loc_sny_OpellaBusinessMember_019ef965-c168-72ae-8d8e-8fc74d82a5be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_019ef965-c168-7a76-a3e4-aae46f9885ef" xlink:href="sny-20260630.xsd#sny_RevenueFromVaxServeSalesOfNonSanofiProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_019ef965-c168-7a76-a3e4-aae46f9885ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_019ef965-c168-758b-989e-5d2587000aec" xlink:href="sny-20260630.xsd#sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_019ef965-c168-758b-989e-5d2587000aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties_019ef965-c168-769c-ac44-bfda77358e3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_ifrs-full_RevenueFromRoyalties_019ef965-c168-769c-ac44-bfda77358e3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherRevenue_019ef965-c168-7963-b23a-60e5443f510e" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_sny_MiscellaneousOtherRevenue_019ef965-c168-7963-b23a-60e5443f510e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019ef965-c168-7794-ac20-d80c3261bf5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_ifrs-full_OtherRevenue_019ef965-c168-7794-ac20-d80c3261bf5b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019f804a-5079-724e-8361-e8c5ab746722" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019f804a-5079-724e-8361-e8c5ab746722" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f804a-5079-70de-9a36-bc321c1432e0" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019f804a-5079-724e-8361-e8c5ab746722" xlink:to="loc_sny_DisposalGroupAxis_019f804a-5079-70de-9a36-bc321c1432e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f804a-5079-70de-9a36-bc321c1432e0_default" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DisposalGroupAxis_019f804a-5079-70de-9a36-bc321c1432e0" xlink:to="loc_sny_DisposalGroupDomain_019f804a-5079-70de-9a36-bc321c1432e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f804a-5079-7915-bf9a-445f3344d3c8" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DisposalGroupAxis_019f804a-5079-70de-9a36-bc321c1432e0" xlink:to="loc_sny_DisposalGroupDomain_019f804a-5079-7915-bf9a-445f3344d3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f804a-5079-7486-a7f8-ab360ac5d7ca" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisposalGroupDomain_019f804a-5079-7915-bf9a-445f3344d3c8" xlink:to="loc_sny_OpellaBusinessMember_019f804a-5079-7486-a7f8-ab360ac5d7ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_019ef965-c168-71ff-bb94-557c9082c50f" xlink:href="sny-20260630.xsd#sny_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:to="loc_sny_NumberOfOperatingSegments_019ef965-c168-71ff-bb94-557c9082c50f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProportionOfOwnershipInterestDisposedInSubsidiary_019f804a-5079-7faf-9df3-4a90e1c78e8a" xlink:href="sny-20260630.xsd#sny_ProportionOfOwnershipInterestDisposedInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:to="loc_sny_ProportionOfOwnershipInterestDisposedInSubsidiary_019f804a-5079-7faf-9df3-4a90e1c78e8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofSegmentResultsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-78e2-8fd2-82c239520869" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-78e2-8fd2-82c239520869" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c168-7121-b429-1c5a4f89158e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-78e2-8fd2-82c239520869" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c168-7121-b429-1c5a4f89158e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7121-b429-1c5a4f89158e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7121-b429-1c5a4f89158e" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7121-b429-1c5a4f89158e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7121-b429-1c5a4f89158e" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c168-7348-af06-4e3e5209a403" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c168-7348-af06-4e3e5209a403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_019ef965-c168-7af0-ad9d-17a0ba0510b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_019ef965-c168-7af0-ad9d-17a0ba0510b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_019f22b0-92f1-7d18-90d8-c6a63c305ba1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:to="loc_ifrs-full_ReportableSegmentsMember_019f22b0-92f1-7d18-90d8-c6a63c305ba1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-70eb-9823-93ae33f70344" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-70eb-9823-93ae33f70344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage_019f8032-b185-7196-8c84-ef3e53544ad1" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage_019f8032-b185-7196-8c84-ef3e53544ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage_019f802f-4568-7f27-a94a-2acf97f6c2bd" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage_019f802f-4568-7f27-a94a-2acf97f6c2bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019ef965-c168-7f0f-b279-3b4ee79a8e70" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_OtherRevenue_019ef965-c168-7f0f-b279-3b4ee79a8e70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage_019f802c-c6af-763e-8d19-5cb35abec61e" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage_019f802c-c6af-763e-8d19-5cb35abec61e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage_019f8032-5eb3-7441-9228-3d8705dd2f4b" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage_019f8032-5eb3-7441-9228-3d8705dd2f4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_019ef965-c168-72a5-b6bd-ea9075964800" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_CostOfSales_019ef965-c168-72a5-b6bd-ea9075964800" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage_019f8031-7c25-7f10-813a-7dd331d42152" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage_019f8031-7c25-7f10-813a-7dd331d42152" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS_019f802b-d17d-778c-8b0a-b32616eb4538" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS_019f802b-d17d-778c-8b0a-b32616eb4538" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-c168-7686-a87d-1be0f25982a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-c168-7686-a87d-1be0f25982a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage_019f8034-6d8b-797e-b409-c4b4ddec373f" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage_019f8034-6d8b-797e-b409-c4b4ddec373f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage_019f802e-b20e-7fde-9f1c-47fccf919049" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage_019f802e-b20e-7fde-9f1c-47fccf919049" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-c168-74c1-bbf7-58aa2029668e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-c168-74c1-bbf7-58aa2029668e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage_019f8035-2d7d-78a9-898a-b8779b14a518" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage_019f8035-2d7d-78a9-898a-b8779b14a518" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage_019f8035-bbc2-7975-bbf0-bb23338b6e71" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage_019f8035-bbc2-7975-bbf0-bb23338b6e71" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_019ef965-c168-7471-b947-030a52a5e756" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_019ef965-c168-7471-b947-030a52a5e756" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7365-8ff9-b819691dfb92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7365-8ff9-b819691dfb92" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7c5b-b16d-5ca2e76ab8a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7c5b-b16d-5ca2e76ab8a7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_019ef965-c168-7b8a-8814-257d64bc63be" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_BusinessOperatingIncome_019ef965-c168-7b8a-8814-257d64bc63be" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage_019f8039-3b5e-7c19-8b66-503c747c9dfe" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage_019f8039-3b5e-7c19-8b66-503c747c9dfe" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage_019f8039-c3d3-7b0e-aebe-007222da1c17" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage_019f8039-c3d3-7b0e-aebe-007222da1c17" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncomeAsPercentOfNetSales_019f22b6-52d0-7be2-9af0-c4972072bef5" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncomeAsPercentOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_BusinessOperatingIncomeAsPercentOfNetSales_019f22b6-52d0-7be2-9af0-c4972072bef5" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c168-7f8e-8269-e9b7b98efb1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c168-7f8e-8269-e9b7b98efb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7f8e-8269-e9b7b98efb1b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c168-7f8e-8269-e9b7b98efb1b" xlink:to="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7f8e-8269-e9b7b98efb1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c168-7f8e-8269-e9b7b98efb1b" xlink:to="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_019ef965-c168-74de-956f-c44e4856c33c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:to="loc_ifrs-full_OperatingSegmentsMember_019ef965-c168-74de-956f-c44e4856c33c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_019ef965-c168-7e91-825e-c4c8aa996fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_019ef965-c168-7e91-825e-c4c8aa996fab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f9393-085d-7f89-8778-db4697b1ab43" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f9393-085d-7f89-8778-db4697b1ab43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7f89-8778-db4697b1ab43_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f9393-085d-7f89-8778-db4697b1ab43" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7f89-8778-db4697b1ab43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7109-9355-8bc3fce4b32a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f9393-085d-7f89-8778-db4697b1ab43" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7109-9355-8bc3fce4b32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmlitelimabAssetMember_019f9393-085d-7feb-be6c-7c5ef08f5345" xlink:href="sny-20260630.xsd#sny_AmlitelimabAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7109-9355-8bc3fce4b32a" xlink:to="loc_sny_AmlitelimabAssetMember_019f9393-085d-7feb-be6c-7c5ef08f5345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_019ef965-c168-76d9-b843-b7f333584796" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_BusinessOperatingIncome_019ef965-c168-76d9-b843-b7f333584796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7882-90b1-bdddbc945935" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7882-90b1-bdddbc945935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7523-acf3-e7d00cf56af9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7523-acf3-e7d00cf56af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019f9343-7435-7c39-8bd3-7547c58f4446" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019f9343-7435-7c39-8bd3-7547c58f4446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8042-7989-75ae-ac37-4d57b265571f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8042-7989-75ae-ac37-4d57b265571f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-c168-7a75-8e43-5bcadfd99fbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-c168-7a75-8e43-5bcadfd99fbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_019ef965-c168-7b2e-8fa4-51a34d63d044" xlink:href="sny-20260630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_019ef965-c168-7b2e-8fa4-51a34d63d044" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c168-715d-8de7-ce3aca3fda7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c168-715d-8de7-ce3aca3fda7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_019ef965-c168-7d2e-acb5-a46a775631f8" xlink:href="sny-20260630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_OtherGainsLossesAndLitigation_019ef965-c168-7d2e-acb5-a46a775631f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-741c-a0f0-45f86b61ba7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-741c-a0f0-45f86b61ba7e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019ef965-c168-735b-baea-956c0561b0bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_FinanceCosts_019ef965-c168-735b-baea-956c0561b0bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019ef965-c168-7d74-8d96-3d33e65e0306" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_FinanceIncome_019ef965-c168-7d74-8d96-3d33e65e0306" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c168-7eb1-8bdc-dc0f26c99812" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c168-7eb1-8bdc-dc0f26c99812" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-7181-b222-5fbae397234f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-7181-b222-5fbae397234f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c168-7053-9d3f-749ad6026ff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-7181-b222-5fbae397234f" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c168-7053-9d3f-749ad6026ff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7053-9d3f-749ad6026ff2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7053-9d3f-749ad6026ff2" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7053-9d3f-749ad6026ff2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7906-b474-17f3db4430a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7053-9d3f-749ad6026ff2" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7906-b474-17f3db4430a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_019ef965-c168-7dcb-ab67-3f935fec2469" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7906-b474-17f3db4430a5" xlink:to="loc_ifrs-full_ReportableSegmentsMember_019ef965-c168-7dcb-ab67-3f935fec2469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c168-70db-a426-e5bd1b5587ba" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_019ef965-c168-7dcb-ab67-3f935fec2469" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c168-70db-a426-e5bd1b5587ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c168-73c8-a062-8b0e0421783f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c168-73c8-a062-8b0e0421783f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019ef965-c168-709f-88b8-78bb19f45f12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019ef965-c168-709f-88b8-78bb19f45f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019ef965-c168-79d3-8ee1-1ea70c9a3b3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019ef965-c168-79d3-8ee1-1ea70c9a3b3a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-70cd-9dad-00fcba2bd6b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-70cd-9dad-00fcba2bd6b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019ef965-c168-7c2c-ae3e-9425b68c8183" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-70cd-9dad-00fcba2bd6b6" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019ef965-c168-7c2c-ae3e-9425b68c8183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7c2c-ae3e-9425b68c8183_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-c168-7c2c-ae3e-9425b68c8183" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7c2c-ae3e-9425b68c8183_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-c168-7c2c-ae3e-9425b68c8183" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_019ef965-c168-7920-bbfd-af4350698f84" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:to="loc_srt_EuropeMember_019ef965-c168-7920-bbfd-af4350698f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_019ef965-c168-79e1-aec7-387bdea770f1" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EuropeMember_019ef965-c168-7920-bbfd-af4350698f84" xlink:to="loc_country_FR_019ef965-c168-79e1-aec7-387bdea770f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019ef965-c168-7168-ac84-7ee49f172718" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:to="loc_country_US_019ef965-c168-7168-ac84-7ee49f172718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_019ef965-c168-736f-a89b-fb95b65eba80" xlink:href="sny-20260630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:to="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_019ef965-c168-736f-a89b-fb95b65eba80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_019ef965-c168-735b-b29d-6454825a5fad" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_019ef965-c168-736f-a89b-fb95b65eba80" xlink:to="loc_country_CN_019ef965-c168-735b-b29d-6454825a5fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-793f-9de7-617635068bea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-793f-9de7-617635068bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-c168-76aa-a456-c534cfdc17fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-c168-76aa-a456-c534cfdc17fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c168-7aa9-b967-1c5ee6508174" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c168-7aa9-b967-1c5ee6508174" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationPrincipalCustomersandCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:href="sny-20260630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c168-70f9-8a3f-689a7dacd405" xlink:href="sny-20260630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c168-70f9-8a3f-689a7dacd405" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_019ef965-c168-75c2-9acf-b9544afb468e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c168-70f9-8a3f-689a7dacd405" xlink:to="loc_ifrs-full_MajorCustomersAxis_019ef965-c168-75c2-9acf-b9544afb468e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-75c2-9acf-b9544afb468e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_019ef965-c168-75c2-9acf-b9544afb468e" xlink:to="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-75c2-9acf-b9544afb468e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_019ef965-c168-75c2-9acf-b9544afb468e" xlink:to="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember_019ef965-c168-7d3d-8083-1632e4941616" xlink:href="sny-20260630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CertainWholesalersInTheUnitedStatesMember_019ef965-c168-7d3d-8083-1632e4941616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_019ef965-c168-76f1-83c0-b628d01b4f11" xlink:href="sny-20260630.xsd#sny_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CustomerOneMember_019ef965-c168-76f1-83c0-b628d01b4f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_019ef965-c168-7373-8af9-360ea2911054" xlink:href="sny-20260630.xsd#sny_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CustomerTwoMember_019ef965-c168-7373-8af9-360ea2911054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_019ef965-c168-76dd-91fd-21ef962f9e50" xlink:href="sny-20260630.xsd#sny_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CustomerThreeMember_019ef965-c168-76dd-91fd-21ef962f9e50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLargestCustomers_019f22c2-55de-7264-87f2-088ff6501b22" xlink:href="sny-20260630.xsd#sny_NumberOfLargestCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:to="loc_sny_NumberOfLargestCustomers_019f22c2-55de-7264-87f2-088ff6501b22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_019ef965-c168-75c4-95fa-42af6f3feed0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_019ef965-c168-75c4-95fa-42af6f3feed0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019f22c9-74f4-7f95-9f18-6cd963e65d87" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019f22c9-74f4-7f95-9f18-6cd963e65d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-7f95-9f18-6cd963e65d87_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019f22c9-74f4-7f95-9f18-6cd963e65d87" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-7f95-9f18-6cd963e65d87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-73eb-a8d9-9d0e621faae9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019f22c9-74f4-7f95-9f18-6cd963e65d87" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-73eb-a8d9-9d0e621faae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f22c9-74f4-7ba8-b846-af9e2f4de0a1" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-73eb-a8d9-9d0e621faae9" xlink:to="loc_sny_OpellaBusinessMember_019f22c9-74f4-7ba8-b846-af9e2f4de0a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f8044-f10f-7074-bbad-3bdbe5e9d59d" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:to="loc_sny_DisposalGroupAxis_019f8044-f10f-7074-bbad-3bdbe5e9d59d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f8044-f10f-7074-bbad-3bdbe5e9d59d_default" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DisposalGroupAxis_019f8044-f10f-7074-bbad-3bdbe5e9d59d" xlink:to="loc_sny_DisposalGroupDomain_019f8044-f10f-7074-bbad-3bdbe5e9d59d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f8044-f10f-7434-b797-6fd3395045b8" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DisposalGroupAxis_019f8044-f10f-7074-bbad-3bdbe5e9d59d" xlink:to="loc_sny_DisposalGroupDomain_019f8044-f10f-7434-b797-6fd3395045b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f8045-1eb1-7af5-b2ee-302835bef8fc" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisposalGroupDomain_019f8044-f10f-7434-b797-6fd3395045b8" xlink:to="loc_sny_OpellaBusinessMember_019f8045-1eb1-7af5-b2ee-302835bef8fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-79ef-8314-684c45d1e509" xlink:href="sny-20260630.xsd#sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-79ef-8314-684c45d1e509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7dfa-875d-7c7c9db7fb0f" xlink:href="sny-20260630.xsd#sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7dfa-875d-7c7c9db7fb0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-719c-99f8-352800ddf890" xlink:href="sny-20260630.xsd#sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-719c-99f8-352800ddf890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7f36-80b1-9ee89ece5e44" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7f36-80b1-9ee89ece5e44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-768c-b116-14c82642aa94" xlink:href="sny-20260630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-768c-b116-14c82642aa94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019f22c9-4090-76a3-80ec-6a8d32be1c63" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019f22c9-4090-76a3-80ec-6a8d32be1c63" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>sny-20260630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ef965-bc7d-7da2-bb2f-04e26164615a,g:d543d692-5b77-4127-b010-746b44ca828b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_019ef965-c2b6-722b-8ac9-919f9f540fee_terseLabel_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from non-consolidated entities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Received From Nonconsolidated Entities Classified As Operating Activities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_documentation_en-US" xlink:label="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends received from non-consolidated entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:href="sny-20260630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:to="lab_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c228-7ccf-bdd4-2cc188f5f4ef_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeStatementClassificationIFRS18NumberOfCategories_019fa2e1-50de-7775-8dfa-080f9f06f6c8_terseLabel_en-US" xlink:label="lab_sny_IncomeStatementClassificationIFRS18NumberOfCategories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of categories</link:label>
    <link:label id="lab_sny_IncomeStatementClassificationIFRS18NumberOfCategories_label_en-US" xlink:label="lab_sny_IncomeStatementClassificationIFRS18NumberOfCategories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Classification, IFRS 18, Number Of Categories</link:label>
    <link:label id="lab_sny_IncomeStatementClassificationIFRS18NumberOfCategories_documentation_en-US" xlink:label="lab_sny_IncomeStatementClassificationIFRS18NumberOfCategories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Categories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementClassificationIFRS18NumberOfCategories" xlink:href="sny-20260630.xsd#sny_IncomeStatementClassificationIFRS18NumberOfCategories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeStatementClassificationIFRS18NumberOfCategories" xlink:to="lab_sny_IncomeStatementClassificationIFRS18NumberOfCategories" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_019ef965-c2b7-783d-a30a-ee8b393aef8d_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other changes arising from issuance of restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Issuance Of Restricted Shares, Equity</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through issuance of restricted shares, equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:to="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019ef965-c228-7d36-be11-850f8142bbe7_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentAxis_019ef965-c228-7134-9a27-3a0772abc2b1_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrumentAxis_label_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrumentAxis_documentation_en-US" xlink:label="lab_sny_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis" xlink:href="sny-20260630.xsd#sny_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentAxis" xlink:to="lab_sny_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c228-7a1c-9c71-ebda69b18231_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Singapore dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Singapore Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage_019f8039-3b5e-7e9b-8b74-3ff3d23f09ff_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in business operating income, on a reported basis (IFRS), percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Business Operating Income, On A Reported Basis (IFRS), Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Business Operating Income, On A Reported Basis (IFRS), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_019ef965-c228-77a7-b29c-90df0b99217a_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester/receive 0.92%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019ef965-c2b7-7960-8460-24eae97bb95c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-c228-74fe-8da4-f376bdab2f8e_negatedLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-c228-7bdf-9fce-062e5aa0099a_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss on other intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_019ef965-c2b6-7808-88dd-aadeec824aa3_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_019f8900-3330-7fb9-be93-262b80e3abf3_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income from continuing operations, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_019ef965-c2b7-7d7f-a5c9-66c15de109fa_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c169-704c-b196-a5c73e5065f9_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [Axis]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_019ef965-c228-775e-b81e-c6465f6217d5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member_019f1e03-6493-7ff7-bf5b-29798349bd64_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized SOFR USD/ receive 1.32%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_019ef965-c2b6-7569-aedb-5aa62f32fef3_terseLabel_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedges and fair value hedges:</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_label_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow And Fair Value Hedge [Member]</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_documentation_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow And Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember" xlink:href="sny-20260630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowAndFairValueHedgeMember" xlink:to="lab_sny_CashFlowAndFairValueHedgeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_019ef965-c228-74ca-8110-3c1acb799697_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 6-12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_019ef965-c228-780d-ba18-c9007917bb3d_negatedLabel_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net interest cost related to employee benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_label_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Interest Cost Related To Employee Benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_documentation_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net interest cost related to employee benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:href="sny-20260630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:to="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_019ef965-c228-7025-875a-0306b7193e19_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance income (cost)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_019ef965-c228-73bb-9f4b-55d8ed219a39_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net financial income/(expenses)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BorrowingAverageDrawdown_019ef965-c228-7c2a-b8a1-c4396bd68eba_terseLabel_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, average drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_label_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_documentation_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown" xlink:href="sny-20260630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BorrowingAverageDrawdown" xlink:to="lab_sny_BorrowingAverageDrawdown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c2b6-7172-9dde-8454a5e18b44_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_019ef965-c169-7d3a-aa46-60f11f09d529_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of other equity investments</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c228-7c00-874d-01c5c32347ec_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_019ef965-c169-7136-b61d-eb2c218c7205_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Analysis of Financial Income and Expenses</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for financial income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-c2b7-7090-b16e-198a86680360_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_sny_DiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Abstract]</link:label>
    <link:label id="lab_sny_DiscontinuedOperationsAbstract_documentation_en-US" xlink:label="lab_sny_DiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DiscontinuedOperationsAbstract" xlink:href="sny-20260630.xsd#sny_DiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DiscontinuedOperationsAbstract" xlink:to="lab_sny_DiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-c228-7514-8f48-a8c1bd28afa9_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_019ef965-c228-73f9-a622-d97555b343d3_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share from continuing operations (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherLiabilities1Member_019ef965-c228-77f4-918d-43b7bf074ae3_terseLabel_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_label_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities1 [member]</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_documentation_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member" xlink:href="sny-20260630.xsd#sny_OtherLiabilities1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherLiabilities1Member" xlink:to="lab_sny_OtherLiabilities1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherRevenueTextBlock_019ef965-c169-7577-b2e7-fd4a02701c7c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other revenue</link:label>
    <link:label id="lab_sny_DisclosureOfOtherRevenueTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other revenue [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherRevenueTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other revenue [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherRevenueTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherRevenueTextBlock" xlink:to="lab_sny_DisclosureOfOtherRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c228-795b-bac1-09460c0d8307_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019ef965-c2b7-71ad-98b9-0c6e10149294_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in accounts receivable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IndustrialSalesMember_019ef965-c228-7f53-9870-3ddcba833982_terseLabel_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industrial sales</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_label_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industrial Sales [Member]</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_documentation_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Industrial Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember" xlink:href="sny-20260630.xsd#sny_IndustrialSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IndustrialSalesMember" xlink:to="lab_sny_IndustrialSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_019ef965-c228-71c4-a9c9-6f56c4ed7d4f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Liabilities Related To Business Combinations And To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_019ef965-c228-7b8b-b764-538fb306b5e7_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_019ef965-c2b6-74e4-a40d-35cad269f2af_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Hungarian forint</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Hungarian florint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInHungarianFlorintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_019ef965-c228-75ce-965c-67a5eb87fc13_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Remeasurement of Net Defined Benefit Liability Asset</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:to="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019ef965-c169-7cf7-9979-d920d958aef5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019ef965-c2b6-7141-9387-3ea9cfd28795_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of treasury shares and related tax effect</link:label>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019ef965-c2b6-779d-a6a1-a9a25c466e37_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_label_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AyvakitMember_019f21f4-02fc-74e4-94b7-43f72d3176b1_terseLabel_en-US" xlink:label="lab_sny_AyvakitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ayvakit</link:label>
    <link:label id="lab_sny_AyvakitMember_label_en-US" xlink:label="lab_sny_AyvakitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ayvakit [Member]</link:label>
    <link:label id="lab_sny_AyvakitMember_documentation_en-US" xlink:label="lab_sny_AyvakitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ayvakit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AyvakitMember" xlink:href="sny-20260630.xsd#sny_AyvakitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AyvakitMember" xlink:to="lab_sny_AyvakitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019ef965-c228-769e-9323-338b7a0242ad_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_019ef965-c228-70e1-92be-00c11f7f44be_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans [Axis]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TwoBillionThreeHundredMillionBondsMember_019f1dc2-9530-7e6f-bf06-7fb86deb2e2a_terseLabel_en-US" xlink:label="lab_sny_TwoBillionThreeHundredMillionBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two billion three hundred million bonds</link:label>
    <link:label id="lab_sny_TwoBillionThreeHundredMillionBondsMember_label_en-US" xlink:label="lab_sny_TwoBillionThreeHundredMillionBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Billion Three Hundred Million Bonds [Member]</link:label>
    <link:label id="lab_sny_TwoBillionThreeHundredMillionBondsMember_documentation_en-US" xlink:label="lab_sny_TwoBillionThreeHundredMillionBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Billion Three Hundred Million Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TwoBillionThreeHundredMillionBondsMember" xlink:href="sny-20260630.xsd#sny_TwoBillionThreeHundredMillionBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TwoBillionThreeHundredMillionBondsMember" xlink:to="lab_sny_TwoBillionThreeHundredMillionBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedProvisionReversedOtherProvisions_019f8f1d-74b4-73e4-961f-cd07635c2dae_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reversals of unutilized provisions</link:label>
    <link:label id="lab_ifrs-full_UnusedProvisionReversedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused provision reversed, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:to="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c2b7-7462-92a4-e20e519b8478_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-c228-76e5-bb1a-ba961b3abd23_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c2b6-7aaa-add1-ab6185aef0d4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember_019f1e02-b40e-7c4f-8ad8-852094469e6d_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay 3.77% / receive capitalized SOFR + 46bps</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember_label_en-US" xlink:label="lab_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay 3.77% / Receive Capitalized SOFR + 46bps [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay 3.77% / Receive Capitalized SOFR + 46bps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" xlink:to="lab_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7a59-ac6d-c5a237dca59d_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_019ef965-c2b7-7386-81d9-0890aa3cbf74_terseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) on benefit obligations</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_019ef965-c169-7494-be55-3e8e49fb5837_terseLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives [Member]</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7565-9040-9d0aec02d6ad_terseLabel_en-US" xlink:label="lab_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and similar costs</link:label>
    <link:label id="lab_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate_label_en-US" xlink:label="lab_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs and Other Items of Acquiree Since Acquisition Date</link:label>
    <link:label id="lab_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate_documentation_en-US" xlink:label="lab_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Costs and Other Items of Acquiree Since Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" xlink:href="sny-20260630.xsd#sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" xlink:to="lab_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_019ef965-c228-71d5-b1cf-43156c324453_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_019ef965-c228-7ba0-a703-2a6143a73b39_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_019ef965-c228-7ec4-8849-b4abc07795bb_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share from continuing operations (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOneYearExtensionOptions_019f8f7c-3515-7a91-8e7b-7d2cb2bb4f5c_terseLabel_en-US" xlink:label="lab_sny_NumberOfOneYearExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of one-year extension options</link:label>
    <link:label id="lab_sny_NumberOfOneYearExtensionOptions_label_en-US" xlink:label="lab_sny_NumberOfOneYearExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of One-Year Extension Options</link:label>
    <link:label id="lab_sny_NumberOfOneYearExtensionOptions_documentation_en-US" xlink:label="lab_sny_NumberOfOneYearExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of One-Year Extension Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOneYearExtensionOptions" xlink:href="sny-20260630.xsd#sny_NumberOfOneYearExtensionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOneYearExtensionOptions" xlink:to="lab_sny_NumberOfOneYearExtensionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_019ef965-c228-7157-80b6-5f0cefb367a7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation of the half-year financial statements and accounting policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_019ef965-c2b6-76a4-a2c9-3e7f7181feda_terseLabel_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees share ownership plan</link:label>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_label_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Share Ownership Plan [Member]</link:label>
    <link:label id="lab_sny_EmployeeShareOwnershipPlanMember_documentation_en-US" xlink:label="lab_sny_EmployeeShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees share ownership plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember" xlink:href="sny-20260630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EmployeeShareOwnershipPlanMember" xlink:to="lab_sny_EmployeeShareOwnershipPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019ef965-c169-7c01-908b-5fa3cedf077b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_019ef965-c2b6-77a8-8965-5ea5d3782df2_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossOnDivestmentOfProducts_019ef965-c2b6-74c3-8682-6a198b51294e_terseLabel_en-US" xlink:label="lab_sny_GainsLossOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains / (losses) on disposals of operating assets or businesses</link:label>
    <link:label id="lab_sny_GainsLossOnDivestmentOfProducts_label_en-US" xlink:label="lab_sny_GainsLossOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Loss) On Divestment Of Products</link:label>
    <link:label id="lab_sny_GainsLossOnDivestmentOfProducts_documentation_en-US" xlink:label="lab_sny_GainsLossOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains on divestment of products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossOnDivestmentOfProducts" xlink:href="sny-20260630.xsd#sny_GainsLossOnDivestmentOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossOnDivestmentOfProducts" xlink:to="lab_sny_GainsLossOnDivestmentOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c2b6-7191-ac76-3d53bc457763_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_019ef965-c2b6-720d-852d-4528ced56f3d_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in currency translation differences</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c169-7b15-8273-7d491b36bbc4_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates [domain]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c2b6-78ba-87cc-a1daf2dda1b6_terseLabel_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_019ef965-c169-72d0-b6c0-fd6d655392ab_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable and other receivables</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchaseProgramPeriod_019ef965-c228-734c-9104-ba59f96c2049_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchaseProgramPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of share repurchase program</link:label>
    <link:label id="lab_sny_ShareRepurchaseProgramPeriod_label_en-US" xlink:label="lab_sny_ShareRepurchaseProgramPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Period</link:label>
    <link:label id="lab_sny_ShareRepurchaseProgramPeriod_documentation_en-US" xlink:label="lab_sny_ShareRepurchaseProgramPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of share repurchase program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchaseProgramPeriod" xlink:href="sny-20260630.xsd#sny_ShareRepurchaseProgramPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchaseProgramPeriod" xlink:to="lab_sny_ShareRepurchaseProgramPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_019ef965-c228-7ca3-9d4a-b541a707a508_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation and arbitration proceedings</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22f3-0545-73cb-afcb-dcec8f39c3f1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense_019f184e-4e54-75e6-937d-09bfdb458579_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for non current financial assets and deferred tax expense</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense_label_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Non Current Financial Assets and Deferred Tax Expense</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense_documentation_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Non Current Financial Assets and Deferred Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" xlink:href="sny-20260630.xsd#sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" xlink:to="lab_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementAxis_019ef965-c228-7130-98e9-7737ee5b2ba4_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_label_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis" xlink:href="sny-20260630.xsd#sny_TypesOfAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementAxis" xlink:to="lab_sny_TypesOfAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionDomain_019ef965-c2b6-7eb4-bed6-3fcd44943480_terseLabel_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_label_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_documentation_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain" xlink:href="sny-20260630.xsd#sny_MarketConditionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionDomain" xlink:to="lab_sny_MarketConditionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_019ef965-c228-79cf-b81d-69175ac21e0c_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_019ef965-c228-7ccc-9472-a9cb1c2a0c84_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c2b7-7350-b4d6-b69069fcc320_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions [Member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c228-7a0b-990e-245e8c5aa80a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherBankBorrowings_019ef965-c228-7fec-8241-db50494dca8c_terseLabel_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other bank borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_label_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Bank Borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_documentation_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other bank borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings" xlink:href="sny-20260630.xsd#sny_OtherBankBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherBankBorrowings" xlink:to="lab_sny_OtherBankBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c2b6-70bc-83c1-d2d7126ae536_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-current Provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_019ef965-c2b7-7d28-9aae-20d87ae67f6f_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) excluding investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BiopharmaSegmentMember_019ef965-c228-7898-af96-4f4e8ff280bb_terseLabel_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharma</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_label_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_documentation_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmaceuticals segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BiopharmaSegmentMember" xlink:to="lab_sny_BiopharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestIncome_019ef965-c228-798c-9d0e-87537ef7d6b2_terseLabel_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_sny_InterestIncome_label_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_sny_InterestIncome_documentation_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome" xlink:href="sny-20260630.xsd#sny_InterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestIncome" xlink:to="lab_sny_InterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c169-7636-bf4a-ca5805db1073_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about finance income expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent detailed information about finance income expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_019ef965-c228-7e8d-b9f9-304a0ce5fcfa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Introduction</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_019ef965-c228-7e94-ae2e-245862fa1601_terseLabel_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revisions to tax exposures and settlements of tax disputes</link:label>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_label_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revisions To Tax Exposures And Settlements Of Tax Disputes</link:label>
    <link:label id="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_documentation_en-US" xlink:label="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revisions to tax exposures and settlements of tax disputes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:href="sny-20260630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:to="lab_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c2b7-75ff-8016-a333bc0676be_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2026Member_019f372f-fa4c-7f11-8663-88a259275fc5_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Under 2026 plans</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2026Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2026 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2026Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2026Member" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2026Member" xlink:to="lab_sny_RestrictedSharePlan2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_019ef965-c2b6-7883-8ee8-46db867c1e99_terseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in other current assets and other current liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Change In Other Current Assets And Other Current Liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:href="sny-20260630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:to="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxesOnShareCancellations_019f182d-d3e3-7559-8f52-821c9dd7876f_negatedTerseLabel_en-US" xlink:label="lab_sny_TaxesOnShareCancellations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax on share cancellations</link:label>
    <link:label id="lab_sny_TaxesOnShareCancellations_label_en-US" xlink:label="lab_sny_TaxesOnShareCancellations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on Share Cancellations</link:label>
    <link:label id="lab_sny_TaxesOnShareCancellations_documentation_en-US" xlink:label="lab_sny_TaxesOnShareCancellations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taxes on Share Cancellations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxesOnShareCancellations" xlink:href="sny-20260630.xsd#sny_TaxesOnShareCancellations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxesOnShareCancellations" xlink:to="lab_sny_TaxesOnShareCancellations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_019ef965-c228-7116-8a9b-580f3b313445_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief executive officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DupixentMember_019ef965-c228-77c3-91d3-64eb720552a4_terseLabel_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dupixent</link:label>
    <link:label id="lab_sny_DupixentMember_label_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dupixent [Member]</link:label>
    <link:label id="lab_sny_DupixentMember_documentation_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dupixent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember" xlink:href="sny-20260630.xsd#sny_DupixentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DupixentMember" xlink:to="lab_sny_DupixentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_019ef965-c2b6-76a5-acba-bd3eb4d2f45d_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding options (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_019ef965-c228-7b2f-9d5b-d3f3f572caa0_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TalcProductLitigationInTheUSMember_019ef965-c2b7-7315-a27b-3abe2af57e6d_terseLabel_en-US" xlink:label="lab_sny_TalcProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Talc product litigation in the US</link:label>
    <link:label id="lab_sny_TalcProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_TalcProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Talc Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_TalcProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_TalcProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Talc Product Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TalcProductLitigationInTheUSMember" xlink:href="sny-20260630.xsd#sny_TalcProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TalcProductLitigationInTheUSMember" xlink:to="lab_sny_TalcProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessOperatingIncomeAsPercentOfNetSales_019f22b6-52d0-7e8f-8a1f-8f95fd833591_terseLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncomeAsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</link:label>
    <link:label id="lab_sny_BusinessOperatingIncomeAsPercentOfNetSales_label_en-US" xlink:label="lab_sny_BusinessOperatingIncomeAsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Operating Income As Percent Of Net Sales</link:label>
    <link:label id="lab_sny_BusinessOperatingIncomeAsPercentOfNetSales_documentation_en-US" xlink:label="lab_sny_BusinessOperatingIncomeAsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Operating Income As Percent Of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncomeAsPercentOfNetSales" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncomeAsPercentOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessOperatingIncomeAsPercentOfNetSales" xlink:to="lab_sny_BusinessOperatingIncomeAsPercentOfNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019ef965-c2b6-7bea-9755-7c2e806b7037_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income (expenses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PerShareValueOfSharesRepurchased_019ef965-c228-7212-a3c3-556a07fa7d15_terseLabel_en-US" xlink:label="lab_sny_PerShareValueOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share value of shares repurchased (in euros per share)</link:label>
    <link:label id="lab_sny_PerShareValueOfSharesRepurchased_label_en-US" xlink:label="lab_sny_PerShareValueOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per Share Value of Shares Repurchased</link:label>
    <link:label id="lab_sny_PerShareValueOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_PerShareValueOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per Share Value of Shares Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerShareValueOfSharesRepurchased" xlink:href="sny-20260630.xsd#sny_PerShareValueOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PerShareValueOfSharesRepurchased" xlink:to="lab_sny_PerShareValueOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_019ef965-c228-7647-a41c-261f499bbfa6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals and other decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesSubscribed_019ef965-c228-7e3c-8db6-8999ee897414_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares subscribed (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesSubscribed_label_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Subscribed</link:label>
    <link:label id="lab_sny_NumberOfSharesSubscribed_documentation_en-US" xlink:label="lab_sny_NumberOfSharesSubscribed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares subscribed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed" xlink:href="sny-20260630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesSubscribed" xlink:to="lab_sny_NumberOfSharesSubscribed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_019f21f7-5d8b-772c-a01c-a827cb9cf9e6_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_019ef965-c228-7800-8c80-7c84240780c5_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_019ef965-c169-7e3c-9fd0-e1c498875a7b_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_019ef965-c169-796a-97c1-c08aece86204_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ToujeoMember_019ef965-c228-7535-8aa1-575f10696ff5_terseLabel_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toujeo</link:label>
    <link:label id="lab_sny_ToujeoMember_label_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toujeo [Member]</link:label>
    <link:label id="lab_sny_ToujeoMember_documentation_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toujeo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember" xlink:href="sny-20260630.xsd#sny_ToujeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ToujeoMember" xlink:to="lab_sny_ToujeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithoutMarketConditionMember_019ef965-c2b7-7242-93a7-d9242ec7570c_terseLabel_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Without market condition</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_label_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Without Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Without Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember" xlink:href="sny-20260630.xsd#sny_WithoutMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithoutMarketConditionMember" xlink:to="lab_sny_WithoutMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_019ef965-c2b6-7617-a1e8-4fcf6ed80dfa_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncomeCost" xlink:to="lab_ifrs-full_OtherFinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CDRMember_019f1d2c-f434-7d36-be47-54b2701c2d5e_terseLabel_en-US" xlink:label="lab_sny_CDRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CD&amp;R</link:label>
    <link:label id="lab_sny_CDRMember_label_en-US" xlink:label="lab_sny_CDRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CD&amp;R [Member]</link:label>
    <link:label id="lab_sny_CDRMember_documentation_en-US" xlink:label="lab_sny_CDRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CD&amp;R</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CDRMember" xlink:href="sny-20260630.xsd#sny_CDRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CDRMember" xlink:to="lab_sny_CDRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7103-93d7-c9c1d20bcc6f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaBusinessMember_019ef965-c169-7cdb-9b9b-3d4c483bc0b8_terseLabel_en-US" xlink:label="lab_sny_OpellaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opella Business</link:label>
    <link:label id="lab_sny_OpellaBusinessMember_label_en-US" xlink:label="lab_sny_OpellaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opella Business [Member]</link:label>
    <link:label id="lab_sny_OpellaBusinessMember_documentation_en-US" xlink:label="lab_sny_OpellaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opella Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaBusinessMember" xlink:to="lab_sny_OpellaBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_019ef965-c228-78b9-a5bf-48905a281c4c_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_019ef965-c2b6-7077-9e97-e738f3d71544_terseLabel_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets at fair value through profit or loss</link:label>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Assets At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Assets At Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="sny-20260630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_019f8f3e-0081-78c8-8af4-cd153afe362c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c228-744c-b1c5-004822068c4a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_019ef965-c2b7-7114-be2c-09dc8beab46e_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and other share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member_019f1e04-3dd7-7395-b30b-8bfeee3117dc_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 2.91%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 2.91% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 2.91%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-c2b6-7e18-81dc-ef8e3bb6d86b_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_019ef965-c228-7efd-8130-b66006e45c9d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in deferred taxes</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for deferred tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_019ef965-c2b7-751c-af5d-aa9829df0c6e_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Under 2022 plans</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2022 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2022Member" xlink:to="lab_sny_RestrictedSharePlan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019ef965-c228-71af-b40e-6622d1f3744e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember_019f1e02-440b-7e01-8d9a-be1dd47e679a_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay 2.08% / receive Euribor 3M</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember_label_en-US" xlink:label="lab_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay 2.08%/Receive Euribor 3M [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay 2.08%/Receive Euribor 3M</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember" xlink:to="lab_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesMember_019ef965-c228-70b0-829f-89a12b4cfddb_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesMember" xlink:to="lab_sny_ForwardCurrencySalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_019f7f50-1b0f-7236-be92-00705b88b979_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income from discontinued operations, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesHeld_019ef965-c228-798b-a06d-4493b97c3a3e_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_label_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Held</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_documentation_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld" xlink:href="sny-20260630.xsd#sny_NumberOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesHeld" xlink:to="lab_sny_NumberOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtNotionalAmountMember_019ef965-c2b6-7f8a-979a-cc927ca55e94_terseLabel_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_label_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Notional Amount [member]</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_documentation_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At notional amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember" xlink:href="sny-20260630.xsd#sny_AtNotionalAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtNotionalAmountMember" xlink:to="lab_sny_AtNotionalAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_019ef965-c2b7-783e-8219-36f14d14ebf8_terseLabel_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All other segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllOtherSegmentsMember" xlink:to="lab_ifrs-full_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_019ef965-c169-74d0-8802-00daf71e48fe_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of interest rates hedging instruments with notional amount by expiry date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_019ef965-c2b6-70aa-bd4c-2215875d8753_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share from discontinued operations (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_019ef965-c169-7b3b-af8f-b89587efa3e7_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_019ef965-c228-7de9-a127-5942dde18188_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c228-7a71-a786-ccb62400be55_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-c2b7-79ca-9bab-0139de4e5392_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) continuing operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_019f7fda-b67f-7d1a-8187-0494e6337cb3_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FabrazymeMember_019ef965-c2b6-703b-ac0d-b4db5ae74aff_terseLabel_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fabrazyme</link:label>
    <link:label id="lab_sny_FabrazymeMember_label_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:label id="lab_sny_FabrazymeMember_documentation_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember" xlink:href="sny-20260630.xsd#sny_FabrazymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FabrazymeMember" xlink:to="lab_sny_FabrazymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_019ef965-c169-7b91-9d71-84edf2850616_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of accounts receivable</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Current Trade Receivables [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of current trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:to="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_019ef965-c228-74cb-a44a-39f0edfa1950_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income (expense) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfShortTermDebtProgram_019f1dd6-34c5-7312-998b-b5ddea307fcb_terseLabel_en-US" xlink:label="lab_sny_NumberOfShortTermDebtProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of short-term debt programs</link:label>
    <link:label id="lab_sny_NumberOfShortTermDebtProgram_label_en-US" xlink:label="lab_sny_NumberOfShortTermDebtProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Short-Term Debt Program</link:label>
    <link:label id="lab_sny_NumberOfShortTermDebtProgram_documentation_en-US" xlink:label="lab_sny_NumberOfShortTermDebtProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Short-Term Debt Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShortTermDebtProgram" xlink:href="sny-20260630.xsd#sny_NumberOfShortTermDebtProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfShortTermDebtProgram" xlink:to="lab_sny_NumberOfShortTermDebtProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_019ef965-c169-70a8-86a6-4d731633c74b_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c228-7f0d-8bf6-3d98ed22331f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage_019f8031-7c25-7d26-9774-b4221966a6f2_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in research and development expenses, on a reported basis (IFRS), percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Research And Development Expenses, On A Reported Basis (IFRS), Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Research And Development Expenses, On A Reported Basis (IFRS), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCasesFiledInNewJerseyCourt_019fa2e4-3489-7665-8105-969ac7ffb36d_terseLabel_en-US" xlink:label="lab_sny_NumberOfCasesFiledInNewJerseyCourt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of cases filed in New Jersey court</link:label>
    <link:label id="lab_sny_NumberOfCasesFiledInNewJerseyCourt_label_en-US" xlink:label="lab_sny_NumberOfCasesFiledInNewJerseyCourt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Cases Filed In New Jersey Court</link:label>
    <link:label id="lab_sny_NumberOfCasesFiledInNewJerseyCourt_documentation_en-US" xlink:label="lab_sny_NumberOfCasesFiledInNewJerseyCourt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Cases Filed In New Jersey Court</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCasesFiledInNewJerseyCourt" xlink:href="sny-20260630.xsd#sny_NumberOfCasesFiledInNewJerseyCourt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCasesFiledInNewJerseyCourt" xlink:to="lab_sny_NumberOfCasesFiledInNewJerseyCourt" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c228-7f89-b689-21ab649d4c78_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsDomain_019ef965-c228-722a-808d-605646d50264_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [domain]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsDomain_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain" xlink:to="lab_ifrs-full_ActuarialAssumptionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_019ef965-c169-79de-b604-d02d8bdb6ac5_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by less than 1 month</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one month [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:to="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LaunchesMember_019f21f6-d1f0-780e-9e5d-4c3d21ef874b_terseLabel_en-US" xlink:label="lab_sny_LaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Of which total launches</link:label>
    <link:label id="lab_sny_LaunchesMember_label_en-US" xlink:label="lab_sny_LaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Launches [Member]</link:label>
    <link:label id="lab_sny_LaunchesMember_documentation_en-US" xlink:label="lab_sny_LaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Launches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LaunchesMember" xlink:href="sny-20260630.xsd#sny_LaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LaunchesMember" xlink:to="lab_sny_LaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage_019f8035-2d7d-79e4-9b3b-2e0f9376b180_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in selling and general expenses, on a reported basis (IFRS), percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Selling And General Expenses, On A Reported Basis (IFRS), Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Selling And General Expenses, On A Reported Basis (IFRS), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_019ef965-c228-78a3-8606-fc934553c536_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in joint ventures</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019ef965-c228-7c87-b053-b5fe719f948f_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfLegalDecisionAspectsChallenged_019f8015-c7f4-728c-a605-4e73105b2222_terseLabel_en-US" xlink:label="lab_sny_NumberOfLegalDecisionAspectsChallenged" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of legal decision aspects challenged</link:label>
    <link:label id="lab_sny_NumberOfLegalDecisionAspectsChallenged_label_en-US" xlink:label="lab_sny_NumberOfLegalDecisionAspectsChallenged" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Legal Decision Aspects Challenged</link:label>
    <link:label id="lab_sny_NumberOfLegalDecisionAspectsChallenged_documentation_en-US" xlink:label="lab_sny_NumberOfLegalDecisionAspectsChallenged" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Legal Decision Aspects Challenged</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLegalDecisionAspectsChallenged" xlink:href="sny-20260630.xsd#sny_NumberOfLegalDecisionAspectsChallenged"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfLegalDecisionAspectsChallenged" xlink:to="lab_sny_NumberOfLegalDecisionAspectsChallenged" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_019ef965-c2b6-75e6-bedc-be748a0baf3c_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Singapore dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Singapore Dollar [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_019ef965-c228-701f-8ec5-a0109f65d325_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;60.00 to &#8364;70.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeTwoMember" xlink:to="lab_sny_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_019ef965-c228-76f9-8d2a-357d2f7bf780_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_019ef965-c169-7d14-85d4-b36fde4860de_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of the World</link:label>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_label_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Countries, Excluding Europe And North America [Member]</link:label>
    <link:label id="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Countries, Excluding Europe And North America</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:href="sny-20260630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:to="lab_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_019ef965-c2b7-774d-9fd2-7793d6f84a0c_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-c2b7-785a-9ef0-d0c148dba06e_totalLabel_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss) from continuing operations for the period, net of taxes (A+B)</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromContinuedOperations_label_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income from continued operations</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromContinuedOperations_documentation_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other comprehensive income from continued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:to="lab_sny_OtherComprehensiveIncomeFromContinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_019ef965-c169-7ccb-9ff6-4e26123ff6ba_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) on plan assets</link:label>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_019f895d-3c2b-7d0a-8fff-e72e0207148f_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="lab_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c228-7a98-b444-36e54ff120db_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MCMVaccineBVMember_019ef965-c228-776f-9eaf-c685e41ebb37_terseLabel_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_label_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV [Member]</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_documentation_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MCM Vaccine BV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember" xlink:href="sny-20260630.xsd#sny_MCMVaccineBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MCMVaccineBVMember" xlink:to="lab_sny_MCMVaccineBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_019ef965-c228-7df6-b6a7-c742016923d0_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [Member]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasDomain" xlink:to="lab_ifrs-full_GeographicalAreasDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_019ef965-c228-7e7b-9b38-40f0eb02c70f_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains and losses on disposals of non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate_019f8f2e-40c7-7718-855b-0d3b699fbade_terseLabel_en-US" xlink:label="lab_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income of acquiree since acquisition date</link:label>
    <link:label id="lab_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate_label_en-US" xlink:label="lab_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income Of Acquiree Since Acquisition Date</link:label>
    <link:label id="lab_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate_documentation_en-US" xlink:label="lab_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Income Of Acquiree Since Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate" xlink:href="sny-20260630.xsd#sny_OperatingIncomeOfAcquireeSinceAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate" xlink:to="lab_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_019ef965-c2b7-7c56-9f97-6784dddbde48_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_019ef965-c228-7f8b-a2f1-e9e1a521527e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_019ef965-c228-7959-9727-bea73439cc1f_terseLabel_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of debt instruments included in financial assets</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_label_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_documentation_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:href="sny-20260630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:to="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MedleyMember_019f22f6-0990-7036-857b-542ce167b57f_terseLabel_en-US" xlink:label="lab_sny_MedleyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medley</link:label>
    <link:label id="lab_sny_MedleyMember_label_en-US" xlink:label="lab_sny_MedleyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medley [Member]</link:label>
    <link:label id="lab_sny_MedleyMember_documentation_en-US" xlink:label="lab_sny_MedleyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medley</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedleyMember" xlink:href="sny-20260630.xsd#sny_MedleyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MedleyMember" xlink:to="lab_sny_MedleyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-72b1-8e34-f79b15c971b6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_019ef965-c169-7e07-9eb3-03fa56ab0c36_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:to="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-c169-7b83-a1ad-a0c61aa76de7_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessOperatingIncome_019ef965-c169-78ad-b3d4-610223f47216_totalLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Business operating income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_019ef965-c169-71c3-bb99-7c5320ed70af_terseLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business operating income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_label_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Operating Income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_documentation_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessOperatingIncome" xlink:to="lab_sny_BusinessOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_019ef965-c169-71da-807b-5cbc1e963ac7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_019ef965-c169-7ce2-8289-c64f2296b435_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest related to employee benefits, and unwinding of discount</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Net Interest Related To Employees Benefits And Unwinding Of Discount, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net interest related to employees benefits and unwinding of discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_019ef965-c169-758f-bd40-e6596ed3b8d2_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (income)/loss from the discontinued Opella business</link:label>
    <link:label id="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_label_en-US" xlink:label="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on transfer of business</link:label>
    <link:label id="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_documentation_en-US" xlink:label="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on transfer of business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:href="sny-20260630.xsd#sny_AdjustmentsForLossesGainsOnTransferOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:to="lab_sny_AdjustmentsForLossesGainsOnTransferOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_019ef965-c228-7ef5-9c4e-3463671ac639_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Actuarial Gains And Losses On Defined Benefit Plans, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_019ef965-c2b6-70bc-a7c7-07d72c98cd60_terseLabel_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not eligible for hedge accounting</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_label_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Eligible For Hedge Accounting [Member]</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_documentation_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Not eligible for hedge accounting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember" xlink:href="sny-20260630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NotEligibleForHedgeAccountingMember" xlink:to="lab_sny_NotEligibleForHedgeAccountingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c2b7-70ea-93cf-e7331119ccd3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromRoyalties_019ef965-c228-70b7-b9d0-76ee0d20310f_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_ifrs-full_RevenueFromRoyalties_label_en-US" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromRoyalties" xlink:to="lab_ifrs-full_RevenueFromRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019ef965-c228-7748-9a12-622f260d6a93_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c2b6-7fb3-abaa-54076a35ec4a_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_019ef965-c169-78a1-a4af-9c72da8159a6_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of options, outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_019ef965-c2b7-7662-9d8a-b0725b4459b7_terseLabel_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excluding general director</link:label>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excluding Chief Executive Officer [Member]</link:label>
    <link:label id="lab_sny_ExcludingChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excluding Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember" xlink:href="sny-20260630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExcludingChiefExecutiveOfficerMember" xlink:to="lab_sny_ExcludingChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegeneronMember_019ef965-c169-74fb-afeb-5fe22a1aa098_terseLabel_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regeneron</link:label>
    <link:label id="lab_sny_RegeneronMember_label_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regeneron [Member]</link:label>
    <link:label id="lab_sny_RegeneronMember_documentation_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regeneron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember" xlink:href="sny-20260630.xsd#sny_RegeneronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegeneronMember" xlink:to="lab_sny_RegeneronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_019ef965-c228-796a-9b1d-37b100f6a5be_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of allocation of income tax between current and deferred taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:to="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-c228-72bf-811c-6c82c789a6c7_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_019ef965-c169-7a26-9edb-3c7b67aa64c9_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain" xlink:href="sny-20260630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain" xlink:to="lab_sny_LegalAndArbitralProceedingsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_019ef965-c2b6-784f-ad52-e4482e42a34e_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper program in USA</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper Program In USA [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial paper program in USA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInUSAMember" xlink:to="lab_sny_CommercialPaperProgramInUSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-c228-7825-8c3e-f20162694c3f_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on cash flow hedges, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_019ef965-c169-7a45-be2a-d122e415681a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for liabilities related to business combination and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_019ef965-c228-7da7-b554-89e611d64b1a_terseLabel_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_label_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB [Member]</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_documentation_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember" xlink:href="sny-20260630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SwedishOrphanBiovitrumABMember" xlink:to="lab_sny_SwedishOrphanBiovitrumABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_019ef965-c228-74cd-b9b8-29166448232e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non-Current Liabilities [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non-Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_019ef965-c2b7-7f77-b344-0079a613e33a_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted shares and vesting of existing restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CerezymeMember_019ef965-c169-7fc3-aa52-7bebb259eea2_terseLabel_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cerezyme</link:label>
    <link:label id="lab_sny_CerezymeMember_label_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cerezyme [Member]</link:label>
    <link:label id="lab_sny_CerezymeMember_documentation_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cerezyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember" xlink:href="sny-20260630.xsd#sny_CerezymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CerezymeMember" xlink:to="lab_sny_CerezymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_KaliTherapeuticsLicenseAgreementMember_019fa2c8-4e0b-78a1-a6f6-3357de611bc0_terseLabel_en-US" xlink:label="lab_sny_KaliTherapeuticsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kali Therapeutics License Agreement</link:label>
    <link:label id="lab_sny_KaliTherapeuticsLicenseAgreementMember_label_en-US" xlink:label="lab_sny_KaliTherapeuticsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kali Therapeutics License Agreement [Member]</link:label>
    <link:label id="lab_sny_KaliTherapeuticsLicenseAgreementMember_documentation_en-US" xlink:label="lab_sny_KaliTherapeuticsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kali Therapeutics License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KaliTherapeuticsLicenseAgreementMember" xlink:href="sny-20260630.xsd#sny_KaliTherapeuticsLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_KaliTherapeuticsLicenseAgreementMember" xlink:to="lab_sny_KaliTherapeuticsLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_019ef965-c228-72dd-8516-68bb115ab184_terseLabel_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract" xlink:href="sny-20260630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FinancialInstrumentsAbstract" xlink:to="lab_sny_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_019ef965-c2b6-734d-ad7d-5fb9f941c679_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember_019f1e03-b271-7acd-aea4-65b36df78f7f_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay 3.82% / receive capitalized SOFR USD + 54 bps</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember_label_en-US" xlink:label="lab_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay 3.82% / Receive Capitalized SOFR USD + 54 bps [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay 3.82% / Receive Capitalized SOFR USD + 54 bps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" xlink:to="lab_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c2b7-7918-8e05-2a9882e993cf_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_019ef965-c2b6-7b5a-bc04-b2473c464164_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Segments Reconciling Items [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of operating segments reconciling items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CostOfDebtNet_019ef965-c2b6-72c3-baf5-93530b165d86_negatedTotalLabel_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Cost of net debt</link:label>
    <link:label id="lab_sny_CostOfDebtNet_label_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of Debt Net</link:label>
    <link:label id="lab_sny_CostOfDebtNet_documentation_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of debt net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet" xlink:href="sny-20260630.xsd#sny_CostOfDebtNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CostOfDebtNet" xlink:to="lab_sny_CostOfDebtNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember_019f8010-23c8-7894-bcd5-b95da64aae3c_terseLabel_en-US" xlink:label="lab_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">University of Washington and Harborview medical center</link:label>
    <link:label id="lab_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember_label_en-US" xlink:label="lab_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University Of Washington And Harborview Medical Center [Member]</link:label>
    <link:label id="lab_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember_documentation_en-US" xlink:label="lab_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">University Of Washington And Harborview Medical Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember" xlink:href="sny-20260630.xsd#sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember" xlink:to="lab_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_KaliTherapeuticsMember_019fa2c7-bd6b-7031-8728-21ad6800bd14_terseLabel_en-US" xlink:label="lab_sny_KaliTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kali Therapeutics</link:label>
    <link:label id="lab_sny_KaliTherapeuticsMember_label_en-US" xlink:label="lab_sny_KaliTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kali Therapeutics [Member]</link:label>
    <link:label id="lab_sny_KaliTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_KaliTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kali Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KaliTherapeuticsMember" xlink:href="sny-20260630.xsd#sny_KaliTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_KaliTherapeuticsMember" xlink:to="lab_sny_KaliTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_019ef965-c169-7bfa-9cb3-bc0bc23d92d0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_019ef965-c228-780c-ace8-ad44e080f103_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_019ef965-c228-756c-af23-83a758ae0547_terseLabel_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value on redemption</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_label_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Of Debt Instrument Issued</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_documentation_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption of debt instrument issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:href="sny-20260630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:to="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019ef965-c228-79ad-bf1d-399c3eed56a6_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other profit or loss items with no cash effect on cash flows generated by operating activities</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MeningitisTravelAndEndemicsVaccinesMember_019f21f6-d1f0-7a1b-af24-dfa55f88c7f1_terseLabel_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicsVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meningitis, travel and endemics vaccines</link:label>
    <link:label id="lab_sny_MeningitisTravelAndEndemicsVaccinesMember_label_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicsVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Meningitis, Travel And Endemics Vaccines [Member]</link:label>
    <link:label id="lab_sny_MeningitisTravelAndEndemicsVaccinesMember_documentation_en-US" xlink:label="lab_sny_MeningitisTravelAndEndemicsVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Meningitis, Travel And Endemics Vaccines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicsVaccinesMember" xlink:href="sny-20260630.xsd#sny_MeningitisTravelAndEndemicsVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MeningitisTravelAndEndemicsVaccinesMember" xlink:to="lab_sny_MeningitisTravelAndEndemicsVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixMember_019ef965-c228-709a-9227-d0e8c7b58cfc_terseLabel_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plavix</link:label>
    <link:label id="lab_sny_PlavixMember_label_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plavix [Member]</link:label>
    <link:label id="lab_sny_PlavixMember_documentation_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plavix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember" xlink:href="sny-20260630.xsd#sny_PlavixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixMember" xlink:to="lab_sny_PlavixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_019ef965-c2b7-7646-ad5f-312a96585f01_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis" xlink:href="sny-20260630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis" xlink:to="lab_sny_LegalAndArbitralProceedingsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_A340BDrugPricingProgramInTheUSMember_019f89c5-2a23-7874-ab0d-37534eaf4f9e_terseLabel_en-US" xlink:label="lab_sny_A340BDrugPricingProgramInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">340B Drug Pricing Program in the US</link:label>
    <link:label id="lab_sny_A340BDrugPricingProgramInTheUSMember_label_en-US" xlink:label="lab_sny_A340BDrugPricingProgramInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">340B Drug Pricing Program in the US [Member]</link:label>
    <link:label id="lab_sny_A340BDrugPricingProgramInTheUSMember_documentation_en-US" xlink:label="lab_sny_A340BDrugPricingProgramInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">340B Drug Pricing Program in the US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A340BDrugPricingProgramInTheUSMember" xlink:href="sny-20260630.xsd#sny_A340BDrugPricingProgramInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_A340BDrugPricingProgramInTheUSMember" xlink:to="lab_sny_A340BDrugPricingProgramInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019ef965-c2b7-79a8-99d8-b1c525415980_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property, plant and equipment and intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_019ef965-c2b6-745a-a1e7-3e2d7164922e_terseLabel_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provisions and other current liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions And Other Current Liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:href="sny-20260630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:to="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_019ef965-c2b6-78c4-8ec9-807ff524cea1_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_019ef965-c228-71ce-b8cb-d9ced2a7d40e_terseLabel_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value per share awarded for three year service period (in euros per share)</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_label_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_documentation_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value per share awarded to a three year service period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:href="sny-20260630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:to="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c169-78d5-916b-0cb9b9527e79_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_019ef965-c228-757f-be16-58049d499523_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_019ef965-c2b6-7b37-981c-bac2717a6c4b_terseLabel_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_label_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes [Member]</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_documentation_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi Euro Medium Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember" xlink:href="sny-20260630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiEuroMediumTermNotesMember" xlink:to="lab_sny_SanofiEuroMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_019ef965-c2b7-79eb-a5b2-ebee92074165_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unwinding of discounting of provisions</link:label>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_label_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense arising from passage of time on other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c169-74ad-a6f9-1ebec7fb7891_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2025Member_019ef965-c2b6-7a1e-8806-cc1308b579e8_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Under 2025 plans</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2025Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2025 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2025Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2025Member" xlink:to="lab_sny_RestrictedSharePlan2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_019f65d1-1b24-7988-897a-f6e6bb0abcc5_negatedTerseLabel_en-US" xlink:label="lab_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses on financial assets, net of reversals</link:label>
    <link:label id="lab_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_label_en-US" xlink:label="lab_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Losses On Financial Assets, Net Of Reversals</link:label>
    <link:label id="lab_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_documentation_en-US" xlink:label="lab_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment Losses On Financial Assets, Net Of Reversals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals" xlink:href="sny-20260630.xsd#sny_ImpairmentLossesOnFinancialAssetsNetOfReversals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals" xlink:to="lab_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_019ef965-c2b7-7fdf-b3b0-0060e077a5f4_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Chinese yuan renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Chinese Yuan Renminbi [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Chinese Yuan Renminbi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_019ef965-c2b6-7e87-8d2e-29fb0d6599e5_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged items [Axis]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsAxis" xlink:to="lab_ifrs-full_HedgedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssetsRelatedPartyTransactions_019f1d45-c8d4-71f4-8fa2-ff8b40f452f0_totalLabel_en-US" xlink:label="lab_sny_AssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_sny_AssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_AssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_AssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_AssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_AssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssetsRelatedPartyTransactions" xlink:to="lab_sny_AssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_019ef965-c228-73cd-b6b7-d934b358a561_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of principal characteristics of restricted share plans</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member_019f65c3-12c8-78da-b99c-ce85d8030996_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 2.53%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 2.53% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 2.53%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInBrazilianRealMember_019f65a1-0037-79f1-bbbc-e57ec8fb1fed_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInBrazilianRealMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Brazilian real</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInBrazilianRealMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInBrazilianRealMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Brazilian Real [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInBrazilianRealMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInBrazilianRealMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Brazilian Real</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInBrazilianRealMember" xlink:to="lab_sny_ForwardCurrencySalesInBrazilianRealMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOnRedemptionMember_019ef965-c228-713a-8538-0757f12ab415_terseLabel_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value on redemption</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_label_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value On Redemption [Member]</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_documentation_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember" xlink:href="sny-20260630.xsd#sny_ValueOnRedemptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOnRedemptionMember" xlink:to="lab_sny_ValueOnRedemptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c169-71a7-a621-619843b0ee72_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesInSegmentResultsMember_019f21ef-5cab-7fec-890b-df3028f9513c_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesInSegmentResultsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other countries</link:label>
    <link:label id="lab_sny_OtherCountriesInSegmentResultsMember_label_en-US" xlink:label="lab_sny_OtherCountriesInSegmentResultsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Countries In Segment Results [Member]</link:label>
    <link:label id="lab_sny_OtherCountriesInSegmentResultsMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesInSegmentResultsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Countries In Segment Results</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesInSegmentResultsMember" xlink:href="sny-20260630.xsd#sny_OtherCountriesInSegmentResultsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesInSegmentResultsMember" xlink:to="lab_sny_OtherCountriesInSegmentResultsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsAbstract_label_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments [Abstract]</link:label>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsAbstract_documentation_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Off-Balance Sheet Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract" xlink:href="sny-20260630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract" xlink:to="lab_sny_OffBalanceSheetCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c228-70da-8613-d8370fdac126_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-c169-7b38-a812-08bc49db7efc_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_019ef965-c169-7795-b6a6-ddb9f59d147d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Off balance sheet commitments</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of off-balance sheet commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_019ef965-c2b6-71f4-b779-a1a4a0ad75be_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to cash flow hedges included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_019ef965-c228-7885-8705-9fc89a6a62ca_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_019ef965-c228-7012-b40f-cff1acd07772_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_019ef965-c228-7d46-b1ce-7259acf0f747_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember_019f1de6-252b-72d9-a291-a39a6cb9f651_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which United Arab Emirates dirham</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In United Emirates Dirham [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In United Emirates Dirham</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AR_019ef965-c2b7-78bb-a6cc-7fb32b30a6b6_terseLabel_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Argentina</link:label>
    <link:label id="lab_country_AR_label_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARGENTINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AR" xlink:to="lab_country_AR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain_019ef965-c228-79dd-a2b2-77675c5d5c82_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CTTQMember_019f937e-2bf5-7829-9f24-6589d1ddb6f5_terseLabel_en-US" xlink:label="lab_sny_CTTQMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CTTQ</link:label>
    <link:label id="lab_sny_CTTQMember_label_en-US" xlink:label="lab_sny_CTTQMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CTTQ [Member]</link:label>
    <link:label id="lab_sny_CTTQMember_documentation_en-US" xlink:label="lab_sny_CTTQMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CTTQ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CTTQMember" xlink:href="sny-20260630.xsd#sny_CTTQMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CTTQMember" xlink:to="lab_sny_CTTQMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TechnologicalPlatformsMember_019ef965-c2b7-70a4-8f9d-d2b776cbdf46_terseLabel_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technological platforms</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_label_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technological Platforms [Member]</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_documentation_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technological Platforms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember" xlink:href="sny-20260630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TechnologicalPlatformsMember" xlink:to="lab_sny_TechnologicalPlatformsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentAssetsMember_019ef965-c228-7fd7-9c09-702b439d6869_terseLabel_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">current</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_label_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember" xlink:href="sny-20260630.xsd#sny_CurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentAssetsMember" xlink:to="lab_sny_CurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_019ef965-c2b6-7f67-b876-8739e41f2f0b_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_019ef965-c2b6-7c03-afb1-3428d6c2ede1_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetInvestmentHedgeMember_019f6afd-8abd-72e4-b268-c307eb299484_terseLabel_en-US" xlink:label="lab_sny_NetInvestmentHedgeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedge</link:label>
    <link:label id="lab_sny_NetInvestmentHedgeMember_label_en-US" xlink:label="lab_sny_NetInvestmentHedgeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedge [Member]</link:label>
    <link:label id="lab_sny_NetInvestmentHedgeMember_documentation_en-US" xlink:label="lab_sny_NetInvestmentHedgeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Investment Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInvestmentHedgeMember" xlink:href="sny-20260630.xsd#sny_NetInvestmentHedgeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetInvestmentHedgeMember" xlink:to="lab_sny_NetInvestmentHedgeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019ef965-c2b6-74ae-8a73-340fda371fbd_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of consolidated undertakings and investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019ef965-c2b6-70cc-a094-c2acf8c016c0_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flow on acquisition</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOtherDefendantsInLegalProceeding_019f8012-e107-7e03-b947-4c14f2f22a40_terseLabel_en-US" xlink:label="lab_sny_NumberOfOtherDefendantsInLegalProceeding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other manufacturers in legal proceeding</link:label>
    <link:label id="lab_sny_NumberOfOtherDefendantsInLegalProceeding_label_en-US" xlink:label="lab_sny_NumberOfOtherDefendantsInLegalProceeding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Other Defendants In Legal Proceeding</link:label>
    <link:label id="lab_sny_NumberOfOtherDefendantsInLegalProceeding_documentation_en-US" xlink:label="lab_sny_NumberOfOtherDefendantsInLegalProceeding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Other Defendants In Legal Proceeding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOtherDefendantsInLegalProceeding" xlink:href="sny-20260630.xsd#sny_NumberOfOtherDefendantsInLegalProceeding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOtherDefendantsInLegalProceeding" xlink:to="lab_sny_NumberOfOtherDefendantsInLegalProceeding" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c2b6-750b-8268-f417ed8bf117_terseLabel_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items Not Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20260630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PlanAssetsMember_019ef965-c228-7fe2-9ef1-3a7d9d44e94e_terseLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan assets</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsMember_label_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsMember" xlink:to="lab_ifrs-full_PlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_019ef965-c2b6-7521-8e59-e197c5d8319b_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockOptionPlanMember_019ef965-c169-7b13-9e1c-2f0cc2a6959c_terseLabel_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_label_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_documentation_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember" xlink:href="sny-20260630.xsd#sny_StockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockOptionPlanMember" xlink:to="lab_sny_StockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_019ef965-c2b7-74d6-9ca3-20625af4daf0_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_019ef965-c2b7-7666-a175-3c8bf99a4a40_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_019ef965-c2b7-7a0a-9438-ea0273366d5a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_019ef965-c2b6-7a52-82e1-ab82767dcb12_terseLabel_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_label_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_documentation_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:href="sny-20260630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:to="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c228-7924-9ffb-159e60378262_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c228-74e6-9293-de8b96f5415c_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_019ef965-c2b6-789e-95ae-4c68fe629aa6_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences Business Combinations And Noncontrolling Interests</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease through net exchange differences business combinations and noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:to="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019ef965-c228-7a21-897d-5d1b18e14bc8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperations_019ef965-c2b6-7b33-ba7f-1b37af277411_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_019ef965-c2b6-7bf6-9f84-f417865c1bf3_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_019ef965-c228-7a90-afad-639186851e0f_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedges of net investments in foreign operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation On Hedges Of Net Investments In Foreign Operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation on hedges of net investments in foreign operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:to="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_019ef965-c228-7305-be48-44f6643d7f04_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Market Value of Net Debt</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Market Value Of Net Debt [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of market value of net debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:to="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_019ef965-c228-7031-9bef-08b3630f93d9_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RezurockMember_019ef965-c228-717e-9766-e6504c26086c_terseLabel_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rezurock</link:label>
    <link:label id="lab_sny_RezurockMember_label_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rezurock [Member]</link:label>
    <link:label id="lab_sny_RezurockMember_documentation_en-US" xlink:label="lab_sny_RezurockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rezurock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember" xlink:href="sny-20260630.xsd#sny_RezurockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RezurockMember" xlink:to="lab_sny_RezurockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_019ef965-c228-799e-a15f-29a1cbc8c9bd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LovenoxMember_019ef965-c228-790a-902d-3db1d7135d24_terseLabel_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lovenox</link:label>
    <link:label id="lab_sny_LovenoxMember_label_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lovenox [Member]</link:label>
    <link:label id="lab_sny_LovenoxMember_documentation_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lovenox.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember" xlink:href="sny-20260630.xsd#sny_LovenoxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LovenoxMember" xlink:to="lab_sny_LovenoxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_019ef965-c228-72aa-844b-c3c74011a6cf_verboseLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other gains and losses, and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_019ef965-c228-71b6-9095-e9ce0d2d918e_negatedNetLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Other losses and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_label_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Gains, (Losses) And Litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_documentation_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation" xlink:href="sny-20260630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherGainsLossesAndLitigation" xlink:to="lab_sny_OtherGainsLossesAndLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_019ef965-c2b6-7d3b-8cfa-b34b47291b2e_terseLabel_en-US" xlink:label="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to equity holders of OPAL JV Co</link:label>
    <link:label id="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Attributable to Equity Holders, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Attributable to Equity Holders, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_EquityAttributableToEquityHoldersRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:to="lab_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019ef965-c2b7-7b8c-81df-8d0671b73c7c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member_019f65b0-a5e8-726c-9614-5de0d6027ad3_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales In US dollar, expiring in 2026 and 2027</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In US Dollar Expiring In 2026 And 2027 [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In US Dollar Expiring In 2026 And 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" xlink:to="lab_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_019ef965-c228-7e05-8aba-5a7d75ef56de_terseLabel_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper programs</link:label>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_label_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommercialPapersIssued" xlink:to="lab_ifrs-full_CommercialPapersIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_019ef965-c228-70b2-9e8c-3e026a5fd298_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_019ef965-c228-7a55-b377-2ea2a5074f08_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FiveYearServicePeriodMember_019f8f55-d424-7111-a28b-a67e99c95fc0_terseLabel_en-US" xlink:label="lab_sny_FiveYearServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5 year service period</link:label>
    <link:label id="lab_sny_FiveYearServicePeriodMember_label_en-US" xlink:label="lab_sny_FiveYearServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Year Service Period [Member]</link:label>
    <link:label id="lab_sny_FiveYearServicePeriodMember_documentation_en-US" xlink:label="lab_sny_FiveYearServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five Year Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FiveYearServicePeriodMember" xlink:href="sny-20260630.xsd#sny_FiveYearServicePeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FiveYearServicePeriodMember" xlink:to="lab_sny_FiveYearServicePeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-c228-7e3c-8362-28393c19985b_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-c228-7cf2-af9d-4aa946e226f0_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities_019f1e13-0f95-79bd-b83d-1a9861849e3b_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases in provisions and other liabilities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Provisions And Other Liabilities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Provisions And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInProvisionsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities" xlink:to="lab_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProportionOfOwnershipInterestDisposedInSubsidiary_019f8048-95c9-7ca7-8f34-b96f678c2821_terseLabel_en-US" xlink:label="lab_sny_ProportionOfOwnershipInterestDisposedInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest disposed in subsidiary</link:label>
    <link:label id="lab_sny_ProportionOfOwnershipInterestDisposedInSubsidiary_label_en-US" xlink:label="lab_sny_ProportionOfOwnershipInterestDisposedInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion Of Ownership Interest Disposed In Subsidiary</link:label>
    <link:label id="lab_sny_ProportionOfOwnershipInterestDisposedInSubsidiary_documentation_en-US" xlink:label="lab_sny_ProportionOfOwnershipInterestDisposedInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proportion Of Ownership Interest Disposed In Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProportionOfOwnershipInterestDisposedInSubsidiary" xlink:href="sny-20260630.xsd#sny_ProportionOfOwnershipInterestDisposedInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProportionOfOwnershipInterestDisposedInSubsidiary" xlink:to="lab_sny_ProportionOfOwnershipInterestDisposedInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_019ef965-c169-722a-87d8-1a34e0c63a40_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_label_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-Of Use Assets And Intangible Asset</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_documentation_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:href="sny-20260630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:to="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-c169-7068-912c-b2393a36dfcb_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c228-70d8-9a2c-c441295a2775_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c2b6-78b8-b3f3-50eb02ffbbbc_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c2b6-73d1-8b2a-4fc4baeed0ad_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c2b6-78c5-9481-e79e77f37acd_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration payable</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cee-a9b4-0103ffd7f228_terseLabel_en-US" xlink:label="lab_sny_TypesOfVestingConditionsAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Vesting Conditions Axis [Domain]</link:label>
    <link:label id="lab_sny_TypesOfVestingConditionsAxisDomain_label_en-US" xlink:label="lab_sny_TypesOfVestingConditionsAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Vesting Conditions Axis [Domain]</link:label>
    <link:label id="lab_sny_TypesOfVestingConditionsAxisDomain_documentation_en-US" xlink:label="lab_sny_TypesOfVestingConditionsAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Vesting Conditions Axis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfVestingConditionsAxisDomain" xlink:href="sny-20260630.xsd#sny_TypesOfVestingConditionsAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfVestingConditionsAxisDomain" xlink:to="lab_sny_TypesOfVestingConditionsAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-c228-7277-9518-69cdf81012e3_negatedLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Selling and general expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-c228-7802-8598-f9a0348af2de_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling and general expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019ef965-c2b6-7ea1-82d9-105a5c7e2f5a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2032Member_019ef965-c2b7-7f2b-b227-b631436670d4_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross currency swap, expiring 2032</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2032Member_label_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2032 [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2032Member_documentation_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2032 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2032Member" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapExpiring2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySwapExpiring2032Member" xlink:to="lab_sny_CrossCurrencySwapExpiring2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c2b6-7eae-95e9-46095e641db4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ThreeYearServicePeriodMember_019f8f55-6a6b-76fc-a5d8-f7559b96b2cb_terseLabel_en-US" xlink:label="lab_sny_ThreeYearServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3 year service period</link:label>
    <link:label id="lab_sny_ThreeYearServicePeriodMember_label_en-US" xlink:label="lab_sny_ThreeYearServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Year Service Period [Member]</link:label>
    <link:label id="lab_sny_ThreeYearServicePeriodMember_documentation_en-US" xlink:label="lab_sny_ThreeYearServicePeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three Year Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ThreeYearServicePeriodMember" xlink:href="sny-20260630.xsd#sny_ThreeYearServicePeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ThreeYearServicePeriodMember" xlink:to="lab_sny_ThreeYearServicePeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_019ef965-c169-74e6-92d0-9364f5c94231_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [Axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_019ef965-c2b7-7234-83cc-6b1b3b613a4f_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income that will be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfLargestCustomers_019f22c2-55de-79d3-a5a7-40dc9af06d5e_terseLabel_en-US" xlink:label="lab_sny_NumberOfLargestCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of largest customers</link:label>
    <link:label id="lab_sny_NumberOfLargestCustomers_label_en-US" xlink:label="lab_sny_NumberOfLargestCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Largest Customers</link:label>
    <link:label id="lab_sny_NumberOfLargestCustomers_documentation_en-US" xlink:label="lab_sny_NumberOfLargestCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Largest Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLargestCustomers" xlink:href="sny-20260630.xsd#sny_NumberOfLargestCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfLargestCustomers" xlink:to="lab_sny_NumberOfLargestCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_019ef965-c228-75bd-9ede-1409a7c3b288_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_019ef965-c228-75db-a08f-c29c7ed31dbf_terseLabel_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for restricted shares (in shares)</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_label_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Effect Of Share Options On Number Of Restricted Shares</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_documentation_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on number of restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:href="sny-20260630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:to="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_019ef965-c2b6-7c2d-a1fe-921f05dd2099_terseLabel_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency and interest rate derivatives</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:href="sny-20260630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_019ef965-c2b7-71cd-91c7-ab11fe83e925_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisposalGroupAxis_019f65a9-e9e0-7dd9-b11b-703a1091a471_terseLabel_en-US" xlink:label="lab_sny_DisposalGroupAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group [Axis]</link:label>
    <link:label id="lab_sny_DisposalGroupAxis_label_en-US" xlink:label="lab_sny_DisposalGroupAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group [Axis]</link:label>
    <link:label id="lab_sny_DisposalGroupAxis_documentation_en-US" xlink:label="lab_sny_DisposalGroupAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisposalGroupAxis" xlink:to="lab_sny_DisposalGroupAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c169-7edc-9780-7edb65a4315a_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates [Axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_019ef965-c228-7621-a452-651dcc339c51_terseLabel_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_019ef965-c228-7def-b5b6-2b2e6178cf32_verboseLabel_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reportable segments [member]</link:label>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReportableSegmentsMember" xlink:to="lab_ifrs-full_ReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019ef965-c228-74fd-b0b8-322ae827d89b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c169-7d0d-841f-129db3a8b2a7_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySwapMember_019ef965-c169-7e44-ad52-2381d44ff68f_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross currency swap</link:label>
    <link:label id="lab_sny_CrossCurrencySwapMember_label_en-US" xlink:label="lab_sny_CrossCurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Swap [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySwapMember_documentation_en-US" xlink:label="lab_sny_CrossCurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapMember" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySwapMember" xlink:to="lab_sny_CrossCurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherAssetsRelatedPartyTransactions_019ef965-c228-78f1-b8b7-d413725ff1bc_terseLabel_en-US" xlink:label="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_sny_OtherAssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_OtherAssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_OtherAssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherAssetsRelatedPartyTransactions" xlink:to="lab_sny_OtherAssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_019ef965-c169-79a1-83c3-5ac6c65f9cf1_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c2b6-7842-bd0e-92ff46b9414a_terseLabel_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Items subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20260630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019ef965-c228-74e5-a605-b26b5aa8e149_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_019f7fb7-d4fd-7f04-9e88-832d44afbc1f_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, authorized, amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_019ef965-c2b6-73ca-8a2b-6e775da8d9fd_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_019ef965-c228-7a7b-80b7-0a93d81aab4c_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingSegmentsMember" xlink:to="lab_ifrs-full_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_019ef965-c2b7-71d6-9a26-06b55db14d67_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 and beyond</link:label>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c2b6-79d6-9ccb-306b583d3b67_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and other share-based payment [Member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueOfAcquiree_019f8f33-05d2-7e2d-8e35-d77ec849aa74_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
    <link:label id="lab_ifrs-full_RevenueOfAcquiree_label_en-US" xlink:label="lab_ifrs-full_RevenueOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueOfAcquiree" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueOfAcquiree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueOfAcquiree" xlink:to="lab_ifrs-full_RevenueOfAcquiree" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c228-72c2-903e-bd10630a8f71_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_019ef965-c2b6-785f-9a70-eb4080699b54_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_019ef965-c228-7148-82c5-952e806b3ef1_verboseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c2b7-7369-8119-8ab71793475b_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_019ef965-c228-780d-af59-663efd3df884_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_019ef965-c228-7fe2-8a15-57293b538c32_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondIssueFromMarch2018Member_019f1dcc-41aa-72df-9646-0bb6dac84bc1_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondIssueFromMarch2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed rate bond issue from March 2018</link:label>
    <link:label id="lab_sny_FixedRateBondIssueFromMarch2018Member_label_en-US" xlink:label="lab_sny_FixedRateBondIssueFromMarch2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from March 2018 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondIssueFromMarch2018Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondIssueFromMarch2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Issue from March 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromMarch2018Member" xlink:href="sny-20260630.xsd#sny_FixedRateBondIssueFromMarch2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondIssueFromMarch2018Member" xlink:to="lab_sny_FixedRateBondIssueFromMarch2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_019ef965-c2b6-78a1-9bf6-ea2d00d0be98_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) financing activities of the discontinued Opella business</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_019ef965-c2b6-76f1-9c59-1fe92ed0b442_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-708f-a9c7-5afd57d791ad_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c169-747a-85de-9c1f0f739c74_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019ef965-c228-7ba3-9e09-ba2793148e5b_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals of consolidated undertakings and investments accounted for using the equity method, net of tax</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsDomain_019ef965-c228-7641-b613-ccd454a2cc77_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified items [Member]</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsDomain_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassified items [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain" xlink:to="lab_ifrs-full_ReclassifiedItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CTTQRovidicitinibLicenseAgreementMember_019f937c-da30-778e-a1fd-82937c2693d8_terseLabel_en-US" xlink:label="lab_sny_CTTQRovidicitinibLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CTTQ Rovidicitinib license agreement</link:label>
    <link:label id="lab_sny_CTTQRovidicitinibLicenseAgreementMember_label_en-US" xlink:label="lab_sny_CTTQRovidicitinibLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CTTQ Rovidicitinib License Agreement [Member]</link:label>
    <link:label id="lab_sny_CTTQRovidicitinibLicenseAgreementMember_documentation_en-US" xlink:label="lab_sny_CTTQRovidicitinibLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CTTQ Rovidicitinib License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CTTQRovidicitinibLicenseAgreementMember" xlink:href="sny-20260630.xsd#sny_CTTQRovidicitinibLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CTTQRovidicitinibLicenseAgreementMember" xlink:to="lab_sny_CTTQRovidicitinibLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_019ef965-c2b6-70fe-87fd-bdff5da996a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DupixentProductLitigationInTheUSMember_019fa41e-81e3-7b90-b117-d4826f2a6f90_terseLabel_en-US" xlink:label="lab_sny_DupixentProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dupixent product litigation in the US</link:label>
    <link:label id="lab_sny_DupixentProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_DupixentProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dupixent Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_DupixentProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_DupixentProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dupixent Product Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentProductLitigationInTheUSMember" xlink:href="sny-20260630.xsd#sny_DupixentProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DupixentProductLitigationInTheUSMember" xlink:to="lab_sny_DupixentProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member_019f65b9-2ff4-77c5-8938-7735b7be0154_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency sales in BRL, expiring in 2027</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Brazilian Real Expiring In 2027 [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Brazilian Real Expiring In 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" xlink:to="lab_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OPALJVCoMember_019ef965-c169-7faa-a2a3-d7b938c7fa9a_terseLabel_en-US" xlink:label="lab_sny_OPALJVCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPAL JV Co</link:label>
    <link:label id="lab_sny_OPALJVCoMember_label_en-US" xlink:label="lab_sny_OPALJVCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OPAL JV Co [Member]</link:label>
    <link:label id="lab_sny_OPALJVCoMember_documentation_en-US" xlink:label="lab_sny_OPALJVCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OPAL JV Co</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OPALJVCoMember" xlink:href="sny-20260630.xsd#sny_OPALJVCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OPALJVCoMember" xlink:to="lab_sny_OPALJVCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c228-7219-9127-0330c18fbda2_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [domain]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_019ef965-c228-7de4-8dbd-954fd4c4ca06_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_019ef965-c2b7-7355-b402-554e68b3858b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses, net of reversals</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in other comprehensive income, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_019ef965-c2b7-765d-bfe1-0745580b64e7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c228-749b-80e0-b4a9fb40bb1b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information About Major Customers and Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_019ef965-c2b7-7253-b34d-f760bf70f307_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_019ef965-c228-779c-bcab-26338041c918_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reduction in share capital</link:label>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_label_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReductionOfIssuedCapital" xlink:to="lab_ifrs-full_ReductionOfIssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_019f934c-2350-754d-9600-06533b2aec26_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_019f934c-3af2-7ac3-abc6-4271ce0c6927_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents if different from statement of financial position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="lab_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_019ef965-c169-725e-a3dd-e1edc8d985a1_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [domain]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesDomain" xlink:to="lab_ifrs-full_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_019ef965-c228-7008-88e7-abc96995aa7a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Results</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_019ef965-c228-7899-affc-c9f6ada1e448_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LongTermPrepaidExpenses_019ef965-c2b7-7d43-8a6f-d128fe4930be_terseLabel_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term prepaid expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_label_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Prepaid Expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_documentation_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long term prepaid expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses" xlink:href="sny-20260630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LongTermPrepaidExpenses" xlink:to="lab_sny_LongTermPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_019ef965-c228-7584-a59c-7a9d0adf5e92_terseLabel_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading equity securities</link:label>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading equity securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:to="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_019ef965-c169-7f82-813a-5f3e98c8dc10_terseLabel_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_label_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Other Operating Income (Expenses)</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_documentation_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other operating income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:to="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockPrice_019ef965-c2b6-755c-b2ce-00a23e856698_terseLabel_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price (in euro per share)</link:label>
    <link:label id="lab_sny_StockPrice_label_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price</link:label>
    <link:label id="lab_sny_StockPrice_documentation_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice" xlink:href="sny-20260630.xsd#sny_StockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockPrice" xlink:to="lab_sny_StockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c169-7e0b-8b0a-068b458ad2ce_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member_019f65c3-65bb-78a2-b113-b75827ba8ead_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized Ester / receive 2.71%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 2.71% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 2.71%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_019ef965-c2b7-769a-8e9e-b2982fb86b34_totalLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_ifrs-full_Borrowings_019ef965-c2b7-7f6a-829c-b7c3a8a98ca5_verboseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill_019ef965-c228-7163-8b2f-46cc64027eb8_terseLabel_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" xlink:href="sny-20260630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfBondRedeemed_019f1dd9-c4e2-7304-9f56-916dc7ff0dfe_terseLabel_en-US" xlink:label="lab_sny_NumberOfBondRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of bonds redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondRedeemed_label_en-US" xlink:label="lab_sny_NumberOfBondRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Bond Redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondRedeemed_documentation_en-US" xlink:label="lab_sny_NumberOfBondRedeemed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Bond Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondRedeemed" xlink:href="sny-20260630.xsd#sny_NumberOfBondRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfBondRedeemed" xlink:to="lab_sny_NumberOfBondRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherBorrowings_019ef965-c169-7ae7-9e0a-b5b8460def56_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:label id="lab_ifrs-full_OtherBorrowings_label_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherBorrowings" xlink:to="lab_ifrs-full_OtherBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansDomain_019ef965-c228-745d-8a73-3286108ed2da_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plans [Member]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansDomain_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansDomain" xlink:to="lab_ifrs-full_DefinedBenefitPlansDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_019ef965-c228-7120-a184-32509f2ee9b2_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherLiabilitiesRelatedPartyTransactions_019f1d3d-5693-71e4-83f1-c712ae59a7f4_terseLabel_en-US" xlink:label="lab_sny_OtherLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_sny_OtherLiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_OtherLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_OtherLiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_OtherLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilitiesRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_OtherLiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherLiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_OtherLiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-c228-7672-b316-5388e7b469c3_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c228-73f5-b91c-e788ae8df415_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c228-7ff9-9e0e-4f4d3a81901b_verboseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersDomain_019ef965-c228-7c73-89a3-7ae2db55a669_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customers [Member]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersDomain_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersDomain" xlink:to="lab_ifrs-full_MajorCustomersDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member_019f1e03-202b-7cdd-a604-f0c7a91ec06d_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">pay capitalized SOFR USD/ receive 1.03%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-c169-7991-b68b-c572eafb25c0_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FourBillionFacilityMaturingApril2026Member_019f1dd1-73de-7934-87b8-3dfca0def476_terseLabel_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four billion facility maturing April 2026</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingApril2026Member_label_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing April 2026 [Member]</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingApril2026Member_documentation_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing April 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingApril2026Member" xlink:href="sny-20260630.xsd#sny_FourBillionFacilityMaturingApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FourBillionFacilityMaturingApril2026Member" xlink:to="lab_sny_FourBillionFacilityMaturingApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_019ef965-c169-76d8-b692-77980eccb425_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [Axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_019ef965-c228-7d67-b719-72284c648923_terseLabel_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value hedges</link:label>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_label_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FairValueHedgesMember" xlink:to="lab_ifrs-full_FairValueHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_019ef965-c228-7331-acfb-d5b4217543eb_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization and impairment</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValuePerShareAwardedForFiveYearServicePeriod_019f8f4d-da66-7be4-a0be-f955293fd701_terseLabel_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForFiveYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value per share awarded for five year service period (in euros per share)</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForFiveYearServicePeriod_label_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForFiveYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Per Share Awarded For Five Year Service Period</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForFiveYearServicePeriod_documentation_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForFiveYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Per Share Awarded For Five Year Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForFiveYearServicePeriod" xlink:href="sny-20260630.xsd#sny_FairValuePerShareAwardedForFiveYearServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValuePerShareAwardedForFiveYearServicePeriod" xlink:to="lab_sny_FairValuePerShareAwardedForFiveYearServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_019ef965-c2b7-7fba-a173-e5a9253384ae_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_019ef965-c228-7d27-930e-5c507aa81b03_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:to="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilitiesRelatedPartyTransactions_019f1d46-850a-7ed1-b11a-663078783559_totalLabel_en-US" xlink:label="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_sny_LiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_LiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_LiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLoansAndReceivables_019ef965-c2b6-7e91-ba47-26050d25622a_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loans and advances and other non-current receivables</link:label>
    <link:label id="lab_sny_NonCurrentLoansAndReceivables_label_en-US" xlink:label="lab_sny_NonCurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non current loans and receivables</link:label>
    <link:label id="lab_sny_NonCurrentLoansAndReceivables_documentation_en-US" xlink:label="lab_sny_NonCurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non current loans and receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables" xlink:href="sny-20260630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLoansAndReceivables" xlink:to="lab_sny_NonCurrentLoansAndReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_019ef965-c2b6-74cc-8dfb-149a36dab45b_negatedLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_019ef965-c2b6-7850-bde4-4e4b9aea3b13_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c228-763d-84f0-4a8f7d69931e_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt and current portion of long-term debt</link:label>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings and current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c169-75d3-bf94-e64a90628f00_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_019ef965-c228-7057-a907-fe32921fbff0_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [Member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019ef965-c169-799c-baec-20fc38c6ffc1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d46-afc8-7fe2-93a8-2e2f37a4f603_totalLabel_en-US" xlink:label="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
    <link:label id="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity and Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_EquityAndLiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_EquityAndLiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentAssetsRelatedPartyTransactions_019ef965-c2b7-70da-a483-cf6c66760f41_terseLabel_en-US" xlink:label="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_sny_CurrentAssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_CurrentAssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_CurrentAssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentAssetsRelatedPartyTransactions" xlink:to="lab_sny_CurrentAssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_019ef965-c2b7-7a53-82cf-38e5374af42e_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee share ownership plan</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee share ownership plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesDomain_019ef965-c228-7572-a63e-f5ea6ff73251_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedges [Member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of hedges [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesDomain" xlink:to="lab_ifrs-full_TypesOfHedgesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_019ef965-c228-7be1-9ce0-7af6734439cb_terseLabel_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amvuttra licensing income</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_label_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_documentation_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing" xlink:href="sny-20260630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeResultingFromOutLicensing" xlink:to="lab_sny_IncomeResultingFromOutLicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f8bcd-ee96-7b42-9c35-a683c3abc47f_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f8bce-0db1-7945-a817-566cd8b335af_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_019ef965-c2b7-7534-88bd-57569c255b93_terseLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend paid per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid, ordinary shares per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:to="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c228-7de8-aa88-47f8d9aeaf05_totalLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c228-7c0d-aef2-8453dc894487_terseLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_label_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Equity Method Investments</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_documentation_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for equity method investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:to="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2025ProgramMember_019ef965-c2b6-7695-bacb-87162e65f372_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2025ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2025 Program</link:label>
    <link:label id="lab_sny_ShareRepurchase2025ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2025ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2025 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2025ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2025ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2025 Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2025ProgramMember" xlink:href="sny-20260630.xsd#sny_ShareRepurchase2025ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2025ProgramMember" xlink:to="lab_sny_ShareRepurchase2025ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_019ef965-c2b6-70af-b974-13681b12ce3c_terseLabel_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_label_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_documentation_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:href="sny-20260630.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:to="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_019ef965-c169-715c-9188-e530a3169133_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_019ef965-c169-7d06-adb1-f151a28b5bcc_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c228-75ce-8572-4445c69ee3ad_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c228-7177-a04b-0fa23074b91b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures_019ef965-c2b6-7ecc-b700-b330ec4f143b_terseLabel_en-US" xlink:label="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Related Party Disclosures</link:label>
    <link:label id="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:href="sny-20260630.xsd#sny_ComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:to="lab_sny_ComprehensiveIncomeRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage_019f802c-c6af-7082-8340-3f4d240a7fc1_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in cost of sales, on a reported basis (IFRS), percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cost Of Sales, On A Reported Basis (IFRS), Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cost Of Sales, On A Reported Basis (IFRS), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_019ef965-c2b6-71ad-b096-595c54ea85a9_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_019ef965-c2b6-7f45-889c-79415628c06b_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentAssetsRelatedPartyTransactions_019ef965-c228-72f9-b63e-dda9e4f52b14_terseLabel_en-US" xlink:label="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_sny_NonCurrentAssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Current assets, Related Party Transactions</link:label>
    <link:label id="lab_sny_NonCurrentAssetsRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Current assets, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_NonCurrentAssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:to="lab_sny_NonCurrentAssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_019ef965-c2b6-7c51-b643-c41b422a4740_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value on cash flow hedges net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_019ef965-c228-7c2e-af4d-8017ec368439_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_019ef965-c2b6-75a0-b654-9b5064c9a806_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_019ef965-c228-7487-be1a-5b94b66f0fb3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Investments in Associates and Joint Ventures</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of investments in associates and joint ventures explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:to="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_019ef965-c228-7784-aa3c-3d3a71c58022_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DynavaxMember_019f22f1-967c-7cf1-b712-a3a68b216d6c_terseLabel_en-US" xlink:label="lab_sny_DynavaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dynavax</link:label>
    <link:label id="lab_sny_DynavaxMember_label_en-US" xlink:label="lab_sny_DynavaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dynavax [Member]</link:label>
    <link:label id="lab_sny_DynavaxMember_documentation_en-US" xlink:label="lab_sny_DynavaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dynavax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DynavaxMember" xlink:to="lab_sny_DynavaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_019ef965-c2b6-7a6a-b145-5ced2e040ddd_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves and retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_019ef965-c228-7d13-ba93-564d985e5412_terseLabel_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank credit balances</link:label>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_019ef965-c228-7a9d-a843-c949cee22319_terseLabel_en-US" xlink:label="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and other revenues</link:label>
    <link:label id="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Sales and Other Revenues, Related Party Disclosures</link:label>
    <link:label id="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Sales and Other Revenues, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:href="sny-20260630.xsd#sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:to="lab_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_019ef965-c228-7ff4-88dd-44e73fc78474_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial expenses and income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c228-7e54-9c5b-65cff217cc82_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_019f7fdd-5021-73db-be8a-994c66754d8b_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of defined benefit obligation</link:label>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_label_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of defined benefit obligation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:to="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_019ef965-c169-7910-8e1e-94d67493f28c_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividend paid out of earnings</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c2b7-776b-877d-4726b94cf20c_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_019ef965-c228-76c8-898e-12ac2826ec54_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of options outstanding and exercisable</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:to="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_019ef965-c169-7545-a75f-d4641ecc201f_terseLabel_en-US" xlink:label="lab_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and non-current assets and liabilities</link:label>
    <link:label id="lab_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_label_en-US" xlink:label="lab_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets And Non-Current Assets And Liabilities As Of Acquisition Date</link:label>
    <link:label id="lab_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other assets and non-current assets and liabilities as of acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" xlink:href="sny-20260630.xsd#sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" xlink:to="lab_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_019ef965-c228-7c47-8958-3a833b927126_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between the standard French tax rate and the rates applicable to Sanofi</link:label>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_019ef965-c2b6-77e7-ae4a-6c520d9bb8d6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in Non-Current Provisions</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of noncurrent provisions explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BondsIssued_019ef965-c228-7e1d-b1ff-fe8f19a4262f_terseLabel_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bond issues</link:label>
    <link:label id="lab_ifrs-full_BondsIssued_label_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BondsIssued" xlink:to="lab_ifrs-full_BondsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_019ef965-c2b6-7cfb-9802-da5686aeb797_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of gross value of overdue receivables</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Overdue Receivables Gross Value [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:to="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_019ef965-c169-7f5d-bd0b-63e6d0e36808_negatedLabel_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expense arising from the impact of acquisitions on inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_label_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Arising From The Impact Of Acquisitions On Inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_documentation_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses arising from the impact of acquisitions on inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:href="sny-20260630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:to="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_019ef965-c2b7-7217-a1db-fbd76d166b0d_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [Member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-c169-7dd9-82f8-f2f1bd9646dd_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) continuing financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_019ef965-c2b6-70af-b9b2-0105684e882c_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_label_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_documentation_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued in regards of capital increase by exercise of stock subscription options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:href="sny-20260630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:to="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c228-7d0b-a9aa-1b31bdf8ad27_negatedLabel_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled liabilities, contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c2b6-7ea5-b9eb-a6724b0dd7d8_terseLabel_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_label_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:label id="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_documentation_en-US" xlink:label="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:href="sny-20260630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:to="lab_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_019ef965-c228-71f0-93e9-33241bef42f2_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional long-term debt contracted</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_019ef965-c228-71a5-8979-f89d1cc9db59_terseLabel_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seasonal trends</link:label>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_label_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seasonality Or Cyclicality Of Interim Operations [Policy Text Block]</link:label>
    <link:label id="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seasonality Or Cyclicality Of Interim Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:href="sny-20260630.xsd#sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:to="lab_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CancellationOfTreasuryShares_019ef965-c2b6-7708-b5f4-1405ab08eaf8_terseLabel_en-US" xlink:label="lab_ifrs-full_CancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of treasury shares</link:label>
    <link:label id="lab_ifrs-full_CancellationOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_CancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancellation of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CancellationOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CancellationOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CancellationOfTreasuryShares" xlink:to="lab_ifrs-full_CancellationOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MiscellaneousOtherRevenue_019ef965-c228-770e-8270-4f1b4c1b5778_terseLabel_en-US" xlink:label="lab_sny_MiscellaneousOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sny_MiscellaneousOtherRevenue_label_en-US" xlink:label="lab_sny_MiscellaneousOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other revenue</link:label>
    <link:label id="lab_sny_MiscellaneousOtherRevenue_documentation_en-US" xlink:label="lab_sny_MiscellaneousOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miscellaneous other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherRevenue" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MiscellaneousOtherRevenue" xlink:to="lab_sny_MiscellaneousOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_019ef965-c228-7fae-862a-0cf06683ca95_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_019ef965-c2b7-7306-91c0-e6e70bfa527b_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:to="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember_019f1e09-22f8-7620-b52b-6db7cf3d6df0_terseLabel_en-US" xlink:label="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVRs issued in connection with the acquisition of Blueprint</link:label>
    <link:label id="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember_label_en-US" xlink:label="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CVRs issued in connection with the acquisition of Blueprint [Member]</link:label>
    <link:label id="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember_documentation_en-US" xlink:label="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CVRs issued in connection with the acquisition of Blueprint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" xlink:href="sny-20260630.xsd#sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" xlink:to="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOperatingSegments_019ef965-c2b7-77ee-8bc1-4332d879ea70_terseLabel_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments_label_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Segments</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments_documentation_en-US" xlink:label="lab_sny_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of operating segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments" xlink:href="sny-20260630.xsd#sny_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOperatingSegments" xlink:to="lab_sny_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisposalGroupDomain_019f65a9-e9e0-7fd6-b11e-e15d5711374b_terseLabel_en-US" xlink:label="lab_sny_DisposalGroupDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group [Domain]</link:label>
    <link:label id="lab_sny_DisposalGroupDomain_label_en-US" xlink:label="lab_sny_DisposalGroupDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group [Domain]</link:label>
    <link:label id="lab_sny_DisposalGroupDomain_documentation_en-US" xlink:label="lab_sny_DisposalGroupDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisposalGroupDomain" xlink:to="lab_sny_DisposalGroupDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmvuttraMember_019f1e23-3812-70f6-b3ee-f141a1fb9566_terseLabel_en-US" xlink:label="lab_sny_AmvuttraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amvuttra</link:label>
    <link:label id="lab_sny_AmvuttraMember_label_en-US" xlink:label="lab_sny_AmvuttraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amvuttra [Member]</link:label>
    <link:label id="lab_sny_AmvuttraMember_documentation_en-US" xlink:label="lab_sny_AmvuttraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amvuttra</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmvuttraMember" xlink:href="sny-20260630.xsd#sny_AmvuttraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmvuttraMember" xlink:to="lab_sny_AmvuttraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_019ef965-c228-7683-879c-c1d6e2ce8d4f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Geographical Information on Net Sales and Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019ef965-c228-799b-973e-1d48bccbbf09_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiMember_019ef965-c2b6-723d-a3f1-3705fc661929_terseLabel_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sny_SanofiMember_label_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi [member]</link:label>
    <link:label id="lab_sny_SanofiMember_documentation_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember" xlink:href="sny-20260630.xsd#sny_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiMember" xlink:to="lab_sny_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_019ef965-c228-7d21-9575-1120000c5c30_terseLabel_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Operating Expenses</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_label_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_documentation_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:href="sny-20260630.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:to="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherRestructuringCosts_019ef965-c228-75d7-8284-9199332164be_terseLabel_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
    <link:label id="lab_sny_OtherRestructuringCosts_label_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:label id="lab_sny_OtherRestructuringCosts_documentation_en-US" xlink:label="lab_sny_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other restructuring costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts" xlink:href="sny-20260630.xsd#sny_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherRestructuringCosts" xlink:to="lab_sny_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_019ef965-c228-7e86-b5bd-a6237e69a003_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Turkish lira</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In Turkish lira</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInTurkishLiraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_019ef965-c169-74d7-a747-0c2429836650_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Turkey</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">T&#220;RKIYE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_019ef965-c169-75af-b062-1e32fdf67043_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for pensions &amp; other post-employment benefits</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Pensions And Other Postemployment Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions for pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:href="sny-20260630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:to="lab_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c228-7c99-835c-e5262fa5849b_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which US dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_019ef965-c2b7-751e-8835-2678ad65b924_terseLabel_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_label_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_documentation_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod" xlink:href="sny-20260630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfYearsServicePeriod" xlink:to="lab_sny_NumberOfYearsServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare_019ef965-c2b6-71b6-9227-c48abc03e60e_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interests of acquirer (in USD per share)</link:label>
    <link:label id="lab_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare_label_en-US" xlink:label="lab_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Interests Of Acquirer, Per Share</link:label>
    <link:label id="lab_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare_documentation_en-US" xlink:label="lab_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Interests Of Acquirer, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare" xlink:href="sny-20260630.xsd#sny_BusinessCombinationEquityInterestsOfAcquirerPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare" xlink:to="lab_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_019ef965-c228-7863-9d7a-8b922552f2f8_terseLabel_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instruments included in financial assets and financial liabilities:</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_label_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Instruments Included In Financial Assets [Member]</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember_documentation_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Instruments Included In Financial Assets[member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:href="sny-20260630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:to="lab_sny_EquityInstrumentsIncludedInFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_019ef965-c2b7-7c36-8157-19cfa091ef98_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares not yet fully vested (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Not Yet Fully Vested</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:to="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_019ef965-c2b6-7b47-912e-052f88adc8d5_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_019f1828-31e8-7992-9a67-7de1a43f7738_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects of share-based payments</link:label>
    <link:label id="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) through tax on share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019ef965-c228-79cf-9365-f117deaa14b0_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the&#160;equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c228-7a73-abf8-0f8d4d716513_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationEquityValueOfAcquirer_019f8bd1-f39c-7554-9bea-ef64aa11591d_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationEquityValueOfAcquirer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity value of acquirer</link:label>
    <link:label id="lab_sny_BusinessCombinationEquityValueOfAcquirer_label_en-US" xlink:label="lab_sny_BusinessCombinationEquityValueOfAcquirer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Value Of Acquirer</link:label>
    <link:label id="lab_sny_BusinessCombinationEquityValueOfAcquirer_documentation_en-US" xlink:label="lab_sny_BusinessCombinationEquityValueOfAcquirer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Value Of Acquirer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEquityValueOfAcquirer" xlink:href="sny-20260630.xsd#sny_BusinessCombinationEquityValueOfAcquirer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationEquityValueOfAcquirer" xlink:to="lab_sny_BusinessCombinationEquityValueOfAcquirer" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c2b6-793f-8fb4-d7da2b55a34d_terseLabel_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of hedge recognized in equity</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_label_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_documentation_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:href="sny-20260630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:to="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_019ef965-c228-7ae6-b462-14a7b98a6aa1_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_019ef965-c228-7ac1-acb8-2710d04433b0_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_019ef965-c228-7bc2-8f75-ecb5b3fa8263_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchaseProgramAmountPaid_019f8aec-4220-788f-9748-6e65d20598bc_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchaseProgramAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, amount paid</link:label>
    <link:label id="lab_sny_ShareRepurchaseProgramAmountPaid_label_en-US" xlink:label="lab_sny_ShareRepurchaseProgramAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Amount Paid</link:label>
    <link:label id="lab_sny_ShareRepurchaseProgramAmountPaid_documentation_en-US" xlink:label="lab_sny_ShareRepurchaseProgramAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Amount Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchaseProgramAmountPaid" xlink:href="sny-20260630.xsd#sny_ShareRepurchaseProgramAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchaseProgramAmountPaid" xlink:to="lab_sny_ShareRepurchaseProgramAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_019ef965-c169-707a-9105-d561d5608832_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment owned</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_019ef965-c169-78e0-af89-1f1ed69ec21c_verboseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_019ef965-c228-7227-b10f-20f7cf2f6a51_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) operating activities of the discontinued Opella business</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossProfit_019ef965-c169-733a-85a5-b10b54847938_totalLabel_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_ifrs-full_GrossProfit_label_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit" xlink:to="lab_ifrs-full_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInSaudiArabianRiyalMember_019f65a2-e824-78eb-81c7-b460cb350c90_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSaudiArabianRiyalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Saudi Arabian riyal</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSaudiArabianRiyalMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSaudiArabianRiyalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Saudi Arabian Riyal [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSaudiArabianRiyalMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSaudiArabianRiyalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Saudi Arabian Riyal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSaudiArabianRiyalMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInSaudiArabianRiyalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInSaudiArabianRiyalMember" xlink:to="lab_sny_ForwardCurrencySalesInSaudiArabianRiyalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_019ef965-c169-7bfd-abc4-5e549184b907_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation Before Tax Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation before tax excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_019ef965-c228-7c0b-b5ff-9c171e71e616_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for impairment of intangible assets and property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_019ef965-c2b7-7f2f-928e-fd5abac3c04a_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesMember" xlink:to="lab_sny_ForwardCurrencyPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-c169-73ef-b901-b8854310196a_terseLabel_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c169-7cd6-974c-73e4932042fc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_019ef965-c228-7f94-8fe4-a7e315c5f2d2_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;80.00 to &#8364;90.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeFourMember" xlink:to="lab_sny_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_019ef965-c2b6-7880-a60f-1e30acfb1b4d_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of equity instruments included in financial assets and financial liabilities</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:to="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_019ef965-c2b7-74e6-8e87-3dd3f498ef1d_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage_019f8039-c3d3-722a-96c2-f4d40c19aaec_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in business operating income, at constant exchange rates non-IFRS, percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Business Operating Income, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Business Operating Income, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_019ef965-c2b6-7f61-bb9f-cb5b6b9378a7_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price per&#160;share, outstanding (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketedProductsMember_019ef965-c228-79f4-99d7-ee6a0a0f836f_terseLabel_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_sny_MarketedProductsMember_label_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketed Products [Member]</link:label>
    <link:label id="lab_sny_MarketedProductsMember_documentation_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketed products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember" xlink:href="sny-20260630.xsd#sny_MarketedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketedProductsMember" xlink:to="lab_sny_MarketedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-c228-74a6-99ea-74476e4534e7_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-c228-7bb2-9704-4df14675a83d_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_019ef965-c228-76d9-ab7a-dc8180045707_terseLabel_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss) for the period from discontinued operations, net of taxes (C)</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_label_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income from discontinued operations</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other comprehensive income from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:to="lab_sny_OtherComprehensiveIncomeFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_COVID19AndInfluenzaVaccinesMember_019f21f6-d1f0-7789-b28c-008627d6f833_terseLabel_en-US" xlink:label="lab_sny_COVID19AndInfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COVID-19 and Influenza vaccines</link:label>
    <link:label id="lab_sny_COVID19AndInfluenzaVaccinesMember_label_en-US" xlink:label="lab_sny_COVID19AndInfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 And Influenza Vaccines [Member]</link:label>
    <link:label id="lab_sny_COVID19AndInfluenzaVaccinesMember_documentation_en-US" xlink:label="lab_sny_COVID19AndInfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19 And Influenza Vaccines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_COVID19AndInfluenzaVaccinesMember" xlink:href="sny-20260630.xsd#sny_COVID19AndInfluenzaVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_COVID19AndInfluenzaVaccinesMember" xlink:to="lab_sny_COVID19AndInfluenzaVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_019ef965-c2b7-79bf-99f3-4acafcb4f3e9_terseLabel_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to debt measured at fair value</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_label_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Debt Measured At Fair Value [Member]</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_documentation_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment to debt measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:href="sny-20260630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:to="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LantusMember_019ef965-c2b7-7376-b066-aa1c0cd955ac_terseLabel_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lantus</link:label>
    <link:label id="lab_sny_LantusMember_label_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lantus [Member]</link:label>
    <link:label id="lab_sny_LantusMember_documentation_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lantus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember" xlink:href="sny-20260630.xsd#sny_LantusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LantusMember" xlink:to="lab_sny_LantusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_019ef965-c228-7abc-8fef-72f2902a1595_verboseLabel_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20260630.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_019ef965-c2b7-7773-89c3-bfe633e299b8_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs and similar items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring Costs And Similar Items [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of restructuring costs and similar items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage_019f8032-5eb3-742b-b77d-6e8806fd9474_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other revenue, at constant exchange rates non-IFRS, percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Other Revenue, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Other Revenue, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_019ef965-c2b7-75a6-bdba-1f6e406b8656_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_019ef965-c169-7dac-88be-29bdb64766c9_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customers [Axis]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersAxis" xlink:to="lab_ifrs-full_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_019ef965-c228-7202-9bb3-c53a73f1b671_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Under 2024 plans</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2024Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2024Member" xlink:to="lab_sny_RestrictedSharePlan2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_019ef965-c2b7-7959-abbf-7efe5bfdf187_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_019ef965-c229-751d-a523-4a61711ad2c5_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DividendsPaidAbstract_019ef965-c228-77a6-b8e9-59105e46c959_terseLabel_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid:</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_label_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Paid [Abstract]</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_documentation_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dividends Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract" xlink:href="sny-20260630.xsd#sny_DividendsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsPaidAbstract" xlink:to="lab_sny_DividendsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_019ef965-c228-76a9-9239-c5e1e240bce4_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_label_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flow hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowHedgesMember" xlink:to="lab_ifrs-full_CashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivablesAbstract_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other receivables [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="lab_ifrs-full_TradeAndOtherReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_019ef965-c2b7-737d-bca3-bee7d561b0be_terseLabel_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired R&amp;D</link:label>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_label_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Research And Development [Member]</link:label>
    <link:label id="lab_sny_AcquiredResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember" xlink:href="sny-20260630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AcquiredResearchAndDevelopmentMember" xlink:to="lab_sny_AcquiredResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_019ef965-c228-7803-a3f8-3a9f7d41696b_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_019ef965-c169-7830-b4c4-005b77908b24_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_019ef965-c228-7946-bcd0-e3898163c643_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to&#160;non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_019ef965-c228-7cdc-9e51-38b6a983b505_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_019ef965-c169-75a6-bc72-6f6d395fe12b_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average residual life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_019ef965-c228-7fd2-8481-1b56a11b0cff_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_label_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:to="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_019ef965-c2b6-7100-8e73-0d637087a18c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:to="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_019ef965-c2b6-7182-988e-743d4dfcbd1c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementDomain_019ef965-c2b7-727c-ae1d-64495e1c7175_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated measurement [Member]</link:label>
    <link:label id="lab_ifrs-full_MeasurementDomain_label_en-US" xlink:label="lab_ifrs-full_MeasurementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementDomain" xlink:to="lab_ifrs-full_MeasurementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_019ef965-c228-775a-9379-8c5441ffb62d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesAxis_019ef965-c169-704f-89c7-bad5aca42c93_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_label_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Alliances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis" xlink:href="sny-20260630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesAxis" xlink:to="lab_sny_PrincipalAlliancesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_019ef965-c2b7-7605-baa4-2afa931f8172_negatedLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses)</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_019ef965-c169-7169-9774-283f329d6032_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_019ef965-c169-75c0-bb12-4b18b959d9af_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of inflation</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of inflation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019ef965-c228-7c8a-8675-a3b8a1179507_terseLabel_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in short-term debt and other financial instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_label_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_documentation_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:href="sny-20260630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:to="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c228-7c27-bca3-a140355cbfa6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to details of finance income (expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019ef965-c169-7b2f-905a-1956cca52f51_netLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total number of shares awarded (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_019ef965-c2b6-73cc-beed-73232e631ab5_terseLabel_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derivatives Used To Manage Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (loss) on derivatives used to manage cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:href="sny-20260630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:to="lab_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_019ef965-c228-7b51-9473-143a0c42c429_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerTwoMember_019ef965-c228-7176-be4e-f517a6fb1d8f_terseLabel_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer two</link:label>
    <link:label id="lab_sny_CustomerTwoMember_label_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [member]</link:label>
    <link:label id="lab_sny_CustomerTwoMember_documentation_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember" xlink:href="sny-20260630.xsd#sny_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerTwoMember" xlink:to="lab_sny_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BPIFranceMember_019f1d2d-3039-7258-b7e9-137a048e80a7_terseLabel_en-US" xlink:label="lab_sny_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BPIFrance</link:label>
    <link:label id="lab_sny_BPIFranceMember_label_en-US" xlink:label="lab_sny_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BPIFrance [Member]</link:label>
    <link:label id="lab_sny_BPIFranceMember_documentation_en-US" xlink:label="lab_sny_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BPIFrance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BPIFranceMember" xlink:href="sny-20260630.xsd#sny_BPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BPIFranceMember" xlink:to="lab_sny_BPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c169-739b-b454-4e8ad03773b7_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_019ef965-c169-74c3-90df-55fa2db2727a_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_019ef965-c228-7501-bf21-8be696e15d38_terseLabel_en-US" xlink:label="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of Opella before tax</link:label>
    <link:label id="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_019ef965-c228-7772-8802-f58791b9d3f2_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_019ef965-c2b6-7eb3-9340-7302ef1fea39_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_019f1db9-1d30-7857-ad74-1d872bfb68ac_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_019ef965-c169-7213-90bd-27427b7341d4_terseLabel_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity risk hedging instruments designated as fair value hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_label_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_documentation_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:href="sny-20260630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:to="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithMarketConditionMember_019ef965-c2b6-7739-bce3-1b6441eab60e_terseLabel_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">With market condition</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_label_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">With Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">With Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember" xlink:href="sny-20260630.xsd#sny_WithMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithMarketConditionMember" xlink:to="lab_sny_WithMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_019ef965-c2b7-7f8b-a17d-d8ea2e974c08_terseLabel_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20260630.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c2b7-781a-b2ae-feba81eae1a0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets that are Either Past Due or Impaired [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_019ef965-c2b6-734a-9d2f-ed877cd408be_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [Axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c2b6-7396-883e-f4f4f1e4029e_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [Member]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_019ef965-c228-7261-97d4-8c86c4c305c6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Financial Position</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Changes In Financial Position [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of changes in financial position [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExtensionTerm_019f8f7d-54b0-794f-a313-ba2f5e55dc2b_terseLabel_en-US" xlink:label="lab_sny_ExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of option to extend lease</link:label>
    <link:label id="lab_sny_ExtensionTerm_label_en-US" xlink:label="lab_sny_ExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extension, Term</link:label>
    <link:label id="lab_sny_ExtensionTerm_documentation_en-US" xlink:label="lab_sny_ExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extension, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExtensionTerm" xlink:href="sny-20260630.xsd#sny_ExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExtensionTerm" xlink:to="lab_sny_ExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_019ef965-c228-7b92-b544-d2e4c616fa5e_terseLabel_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties and other income</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties And Other Income, Related Party Transactions</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties and other income, related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:to="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_019ef965-c228-75b3-819b-c7f48863915b_terseLabel_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">% of share capital for the period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_label_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Share Capital For The Period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_documentation_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of share capital for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:href="sny-20260630.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:to="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_019ef965-c169-7087-8bfb-962d83d30bfb_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c228-7685-b250-552fbc443d39_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for noncurrent provisions and other noncurrent liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20260630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c228-78de-be01-ad1977c26d12_verboseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c228-71f7-b77c-7042755e37b8_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_019f18b6-3626-75d2-b021-046dfcc8cb5e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill at beginning of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_019f18b6-8471-78c3-b0e1-4cf1276aa0c0_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill at end of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-c169-76d7-ab7d-4e341df2eaf1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-c169-736e-91e2-48e8539c1c9c_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-c169-774f-881f-8d20dcf232a4_verboseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsDomain_019ef965-c169-725c-8200-990bee24a3db_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Member]</link:label>
    <link:label id="lab_ifrs-full_SegmentsDomain_label_en-US" xlink:label="lab_ifrs-full_SegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsDomain" xlink:to="lab_ifrs-full_SegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_019ef965-c228-78c9-b864-c3ae917e2499_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_019ef965-c228-792e-a3e8-15fa7fb67d87_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_019ef965-c2b6-72f3-8e2c-6f401d3c5ba5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Principal Transactions and Balances with Related Parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_019ef965-c228-77ab-a7ca-32e9c46b5917_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_019ef965-c2b6-7df2-a19a-041fe57aa995_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_019ef965-c2b6-78ae-aae1-47ac1a932d87_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_019ef965-c228-7849-b04d-9a2336fa5fd2_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c228-7323-ac43-2c7d7fdb5d25_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_019ef965-c228-77c3-8e9f-2d8088189c83_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Axis]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_019ef965-c228-7435-977e-e4fad2fae57c_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward currency purchases in US dollar, US bond</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, US Bond [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar, US Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsDomain_019ef965-c169-79dd-8c63-1014cb57c538_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [Member]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsDomain_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsDomain" xlink:to="lab_ifrs-full_BusinessCombinationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_019ef965-c228-7f65-b95b-8dd74edc3c06_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">non-current</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesMember" xlink:to="lab_sny_NonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember_019f1e09-5e40-7b8b-a3df-b73866a040e8_terseLabel_en-US" xlink:label="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CVRs issued in connection with the acquisition of Vigil</link:label>
    <link:label id="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember_label_en-US" xlink:label="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CVRs issued in connection with the acquisition of Vigil [Member]</link:label>
    <link:label id="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember_documentation_en-US" xlink:label="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CVRs issued in connection with the acquisition of Vigil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" xlink:href="sny-20260630.xsd#sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" xlink:to="lab_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesMember_019ef965-c2b6-78a9-b1a6-901d9d5afcf6_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">current</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesMember" xlink:to="lab_sny_CurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_019ef965-c169-7bc2-97d5-99ebf8258a07_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares vested (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Vested In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Vested In Regards Of Capital Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerecognizedReceivables_019ef965-c228-7871-916a-1098dd386a29_terseLabel_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognized receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_label_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognized Receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_documentation_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derecognized receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables" xlink:href="sny-20260630.xsd#sny_DerecognizedReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerecognizedReceivables" xlink:to="lab_sny_DerecognizedReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_019ef965-c228-7b9b-99ef-5c62dbe5f0b9_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of number of restricted shares not yet fully vested</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of number of restricted share plans Not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:to="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfProductLiabilityCases_019f9375-2652-706b-8ca5-fd51eca0bd3d_terseLabel_en-US" xlink:label="lab_sny_NumberOfProductLiabilityCases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product liability cases</link:label>
    <link:label id="lab_sny_NumberOfProductLiabilityCases_label_en-US" xlink:label="lab_sny_NumberOfProductLiabilityCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product Liability Cases</link:label>
    <link:label id="lab_sny_NumberOfProductLiabilityCases_documentation_en-US" xlink:label="lab_sny_NumberOfProductLiabilityCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product Liability Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfProductLiabilityCases" xlink:href="sny-20260630.xsd#sny_NumberOfProductLiabilityCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfProductLiabilityCases" xlink:to="lab_sny_NumberOfProductLiabilityCases" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage_019f802f-4568-754e-a14c-143782e9af25_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in revenue, at constant exchange rates non-IFRS, percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_019ef965-c2b6-739c-8e3d-eff09bd3c486_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of movements within other comprehensive income</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information of accumulated other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7a66-a8b7-7072b990e047_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesDomain_019ef965-c228-7b0c-a2a4-7ef76fbcaeb9_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint ventures [domain]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesDomain_label_en-US" xlink:label="lab_ifrs-full_JointVenturesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint ventures [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesDomain" xlink:to="lab_ifrs-full_JointVenturesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities_019f1844-8163-7d2a-96cb-be355370e6f0_totalLabel_en-US" xlink:label="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) continuing investing activities</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities_label_en-US" xlink:label="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Continuing Investing Activities</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities_documentation_en-US" xlink:label="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Continuing Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:href="sny-20260630.xsd#sny_NetCashProvidedByusedInContinuingInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:to="lab_sny_NetCashProvidedByusedInContinuingInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesDomain_019ef965-c228-7ae6-8941-2005815c763d_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_label_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain" xlink:href="sny-20260630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesDomain" xlink:to="lab_sny_PrincipalAlliancesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_019ef965-c2b7-7a11-b802-b03007e57a4f_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper program in France</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper Program In France [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial paper program In France.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInFranceMember" xlink:to="lab_sny_CommercialPaperProgramInFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_019ef965-c228-792b-9112-c68c896f88bc_terseLabel_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan at the date of grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_label_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Plan At Date Of Grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_documentation_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of plan at the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:href="sny-20260630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:to="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c169-793f-a1fd-22bf4293ad49_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerThreeMember_019ef965-c169-724f-8534-7ab5426bc9d0_terseLabel_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer three</link:label>
    <link:label id="lab_sny_CustomerThreeMember_label_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Three [member]</link:label>
    <link:label id="lab_sny_CustomerThreeMember_documentation_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember" xlink:href="sny-20260630.xsd#sny_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerThreeMember" xlink:to="lab_sny_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_019ef965-c169-75e4-9937-57d09026bca3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_019ef965-c2b6-79f6-8c18-749f5856c731_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c228-71d5-a233-1ffffe078747_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, class [Member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_019ef965-c228-7095-9c75-a41ba5b57c93_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of other non-current assets</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Components Of Other Non-Current Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of components of other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_019ef965-c2b7-7fb8-a87a-a6a8600d9c40_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International financial reporting standards (IFRS)</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_019ef965-c2b6-7076-aa7a-b2efa450b5ce_terseLabel_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain wholesalers in the United States</link:label>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_label_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Wholesalers, In The United States [Member]</link:label>
    <link:label id="lab_sny_CertainWholesalersInTheUnitedStatesMember_documentation_en-US" xlink:label="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Wholesalers, In The United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember" xlink:href="sny-20260630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CertainWholesalersInTheUnitedStatesMember" xlink:to="lab_sny_CertainWholesalersInTheUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityRelatedPartyTransactions_019f1d45-fafd-701e-afc6-1db91d0bb7b6_totalLabel_en-US" xlink:label="lab_sny_EquityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_sny_EquityRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityRelatedPartyTransactions" xlink:to="lab_sny_EquityRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_019ef965-c2b7-7998-85f5-b2259c8029cd_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_019ef965-c2b6-78cd-8f28-bbc199e6883b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates and judgments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_019ef965-c2b6-7809-806b-4493db79ff17_negatedLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019ef965-c169-71bb-b671-33cc5479edc2_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_019ef965-c228-7e25-a540-2d3f0967044c_terseLabel_en-US" xlink:label="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities of the discontinued Opella business</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_label_en-US" xlink:label="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Discontinuing Investing Activities</link:label>
    <link:label id="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_documentation_en-US" xlink:label="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Provided by/(used in) Discontinuing Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:href="sny-20260630.xsd#sny_NetCashProvidedByusedInDiscontinuingInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:to="lab_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_019ef965-c2b7-7cd2-b18f-422aac34f9dd_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for other long-term benefits</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Other Long Term Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions for other long term benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:href="sny-20260630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:to="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_019ef965-c169-70c3-9f4d-8134aab8e06f_terseLabel_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization related expenses</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Related Expenses [Member]</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember" xlink:href="sny-20260630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercializationRelatedExpensesMember" xlink:to="lab_sny_CommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c228-7bd6-a34d-7ca486eb3230_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_019ef965-c228-719b-b086-5581e12c3607_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Under 2023 plans</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Plan 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2023Member" xlink:to="lab_sny_RestrictedSharePlan2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c169-7c1f-9671-1ba760a4b62c_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c169-7f5d-ac65-3d62e8e29ed8_totalLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20260630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfTranches_019ef965-c2b6-7993-840f-30cc4692890f_terseLabel_en-US" xlink:label="lab_sny_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_sny_NumberOfTranches_label_en-US" xlink:label="lab_sny_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:label id="lab_sny_NumberOfTranches_documentation_en-US" xlink:label="lab_sny_NumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTranches" xlink:href="sny-20260630.xsd#sny_NumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfTranches" xlink:to="lab_sny_NumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SubordinateHybridBondRelatedPartyTransactions_019ef965-c2b6-7acc-b3c5-85d611495812_terseLabel_en-US" xlink:label="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subordinate hybrid bond, related party transactions</link:label>
    <link:label id="lab_sny_SubordinateHybridBondRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subordinate Hybrid Bond, Related Party Transactions</link:label>
    <link:label id="lab_sny_SubordinateHybridBondRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subordinate Hybrid Bond, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_SubordinateHybridBondRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:to="lab_sny_SubordinateHybridBondRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c169-7301-8c37-22a2bb9d2aec_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [Member]</link:label>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsDomain_label_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain" xlink:to="lab_ifrs-full_SegmentConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c2b6-7d06-b278-21742d6e0f4d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LoansToAssociates_019ef965-c228-7de7-9323-f8ea60881b5b_terseLabel_en-US" xlink:label="lab_sny_LoansToAssociates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans to Associates</link:label>
    <link:label id="lab_sny_LoansToAssociates_label_en-US" xlink:label="lab_sny_LoansToAssociates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans to Associates</link:label>
    <link:label id="lab_sny_LoansToAssociates_documentation_en-US" xlink:label="lab_sny_LoansToAssociates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans to Associates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LoansToAssociates" xlink:href="sny-20260630.xsd#sny_LoansToAssociates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LoansToAssociates" xlink:to="lab_sny_LoansToAssociates" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7fd4-aa99-d770d1330486_terseLabel_en-US" xlink:label="lab_sny_TypesOfVestingConditionsAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Vesting Conditions Axis [Axis]</link:label>
    <link:label id="lab_sny_TypesOfVestingConditionsAxisAxis_label_en-US" xlink:label="lab_sny_TypesOfVestingConditionsAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Vesting Conditions Axis [Axis]</link:label>
    <link:label id="lab_sny_TypesOfVestingConditionsAxisAxis_documentation_en-US" xlink:label="lab_sny_TypesOfVestingConditionsAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Vesting Conditions Axis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfVestingConditionsAxisAxis" xlink:href="sny-20260630.xsd#sny_TypesOfVestingConditionsAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfVestingConditionsAxisAxis" xlink:to="lab_sny_TypesOfVestingConditionsAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage_019f802e-b20e-7b0f-b343-2e1ba8e0a091_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in research and development expenses, at constant exchange rates non-IFRS, percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Research And Development Expenses, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Research And Development Expenses, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MosaicHealthInTheUSMember_019f89ca-627d-73ef-ab6e-d4bbb098bedf_terseLabel_en-US" xlink:label="lab_sny_MosaicHealthInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mosaic Health in the US</link:label>
    <link:label id="lab_sny_MosaicHealthInTheUSMember_label_en-US" xlink:label="lab_sny_MosaicHealthInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mosaic Health in the US [Member]</link:label>
    <link:label id="lab_sny_MosaicHealthInTheUSMember_documentation_en-US" xlink:label="lab_sny_MosaicHealthInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mosaic Health in the US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MosaicHealthInTheUSMember" xlink:href="sny-20260630.xsd#sny_MosaicHealthInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MosaicHealthInTheUSMember" xlink:to="lab_sny_MosaicHealthInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesRepurchased_019ef965-c169-75f1-8c4f-79816ad49f46_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_label_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Repurchased</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares repurchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased" xlink:href="sny-20260630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesRepurchased" xlink:to="lab_sny_NumberOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentsMember_019ef965-c2b7-7d9f-8ffd-7561f651f124_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments included in financial assets:</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_label_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments [Member]</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_documentation_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember" xlink:href="sny-20260630.xsd#sny_DebtInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentsMember" xlink:to="lab_sny_DebtInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_019ef965-c2b7-77cc-ac32-45298ec4a572_terseLabel_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates and joint ventures</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_label_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates And Joint Ventures [Member]</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_documentation_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Associates and Joint Ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember" xlink:href="sny-20260630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssociatesAndJointVenturesMember" xlink:to="lab_sny_AssociatesAndJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-c228-749f-9cd7-9f8dabd87bcf_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c228-7613-8f56-50d811214be9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes_019f8023-de72-73b6-9fd0-fca9487f1298_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income), related to Pillar Two income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income), related to Pillar Two income taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_019ef965-c169-7592-a4a3-e14339424c21_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant information for the first half of 2026</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_019ef965-c228-7ba4-891a-659dc8757f37_terseLabel_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_label_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Restructuring Provision [Member]</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_documentation_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember" xlink:href="sny-20260630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentRestructuringProvisionMember" xlink:to="lab_sny_NonCurrentRestructuringProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_019ef965-c228-7e36-a76b-06f4fcf8575d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Operating Currency Hedging Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_019ef965-c228-746c-9551-fcdf389369a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information related to Opella, presented within discontinued operations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current assets held for sale and discontinued operations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_019ef965-c228-75b8-9a9e-221d1b2c8450_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_019f36fa-dd12-77d7-91b7-880c63b46105_verboseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_019ef965-c169-7ba6-87e1-59d825cd6056_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019ef965-c228-7156-9cdf-51d036e76a94_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_019ef965-c169-7db4-b241-d7ea5f9465e4_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overdue by &gt; 12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FourBillionFacilityMaturingOnMarch2030Member_019ef965-c2b7-783a-bee2-88f5e2845473_terseLabel_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingOnMarch2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four billion facility maturing on March, 2030</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingOnMarch2030Member_label_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingOnMarch2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing On March, 2030 [Member]</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingOnMarch2030Member_documentation_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingOnMarch2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Billion Facility Maturing December 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingOnMarch2030Member" xlink:href="sny-20260630.xsd#sny_FourBillionFacilityMaturingOnMarch2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FourBillionFacilityMaturingOnMarch2030Member" xlink:to="lab_sny_FourBillionFacilityMaturingOnMarch2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_019ef965-c169-7773-87cb-ce9f2047527d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Measurement Principles Applied to Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember_019f21f6-d1f0-73db-9c7a-4dc460ea11d7_terseLabel_en-US" xlink:label="lab_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</link:label>
    <link:label id="lab_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember_label_en-US" xlink:label="lab_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Polio Pertussis Hib Primary Vaccines And Boosters, incl. Heplisav-B [Member]</link:label>
    <link:label id="lab_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember_documentation_en-US" xlink:label="lab_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Polio Pertussis Hib Primary Vaccines And Boosters, incl. Heplisav-B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" xlink:href="sny-20260630.xsd#sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" xlink:to="lab_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedPartyTransactions_019ef965-c169-7e2b-ae8a-7ce0d49724d6_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_CurrentLiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_019ef965-c228-750c-91a2-a30f1d586a6a_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_019ef965-c228-7ac7-8779-dd6c2123e80b_terseLabel_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Infraserv GmbH &amp; Co. H&#246;chst KG</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_label_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Infraserv Gmbh And Co Hochst KG [member]</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_documentation_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Infraserv GmbH and Co. Hochst KG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:href="sny-20260630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:to="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_019ef965-c228-71bc-919c-a2e4b720bfe2_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New pronouncements issued by the IASB and applicable from 2027</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_019ef965-c228-7200-a98b-5fd61c0a7270_terseLabel_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material reconciling items</link:label>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material reconciling items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:to="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_019ef965-c228-7358-8386-b7337b7836fd_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentAssetsMember_019ef965-c228-7d97-9ad5-3e1b0fca0843_terseLabel_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">non-current</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_label_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Assets [Member]</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember" xlink:href="sny-20260630.xsd#sny_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentAssetsMember" xlink:to="lab_sny_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingExpense_019f933e-bd19-701d-a20b-b38353582b17_negatedTotalLabel_en-US" xlink:label="lab_sny_OtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total other operating expenses</link:label>
    <link:label id="lab_sny_OtherOperatingExpense_label_en-US" xlink:label="lab_sny_OtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Expense</link:label>
    <link:label id="lab_sny_OtherOperatingExpense_documentation_en-US" xlink:label="lab_sny_OtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpense" xlink:href="sny-20260630.xsd#sny_OtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingExpense" xlink:to="lab_sny_OtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SarclisaMember_019ef965-c228-7220-9192-f649ba9d08fb_terseLabel_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarclisa</link:label>
    <link:label id="lab_sny_SarclisaMember_label_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarclisa [Member]</link:label>
    <link:label id="lab_sny_SarclisaMember_documentation_en-US" xlink:label="lab_sny_SarclisaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarclisa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember" xlink:href="sny-20260630.xsd#sny_SarclisaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SarclisaMember" xlink:to="lab_sny_SarclisaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-c228-719a-a4a3-21ce880565d9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_019ef965-c2b7-7573-a71d-c2d33214e550_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharesMember_019ef965-c228-735d-ba2c-d42feaa60565_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember" xlink:href="sny-20260630.xsd#sny_RestrictedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharesMember" xlink:to="lab_sny_RestrictedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_019ef965-c228-7010-a60b-185f83736f90_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 3-6 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:to="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_019ef965-c169-7e2e-a72d-40b181b3b5b5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_019ef965-c2b6-73d5-aba9-5fd70540696c_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for stock options with dilutive effect (in shares)</link:label>
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on weighted average number of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_019ef965-c228-75ad-8054-894ba06076ff_terseLabel_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances</link:label>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_label_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for credit losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:to="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_019ef965-c2b6-7d01-ae51-57c7bdc99d33_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities related to assets held for sale</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_019f1d52-2d6e-7dce-bbd5-bf4512d686ae_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of earnings per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_019ef965-c228-707d-9d44-5cd7d5a80315_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross value</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_019ef965-c228-704a-b7dd-ffb62ea41535_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard tax rate applicable in France</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_019ef965-c169-79cd-8b56-7526c078da6e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetCashInflowFromDiscontinuedOperations_019ef965-c228-7e9d-b644-bc83c1c50e3e_terseLabel_en-US" xlink:label="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash inflow/(outflow) from the Opella transaction</link:label>
    <link:label id="lab_sny_NetCashInflowFromDiscontinuedOperations_label_en-US" xlink:label="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Inflow from Discontinued Operations</link:label>
    <link:label id="lab_sny_NetCashInflowFromDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Inflow from Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetCashInflowFromDiscontinuedOperations" xlink:to="lab_sny_NetCashInflowFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_019ef965-c169-7961-953f-6d9abc736705_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Sanofi shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_019ef965-c169-763a-a124-bff69eeb0aac_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_019ef965-c169-71b9-b595-fd3ccb54231d_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_019ef965-c228-79cb-bed2-5dd6b59fc1cd_terseLabel_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Firm orders of property, plant and equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Firm Orders Of Property Plant And Equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Firm orders of property plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:href="sny-20260630.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:to="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_019ef965-c228-7292-b304-f296925a7432_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts Receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts receivable Table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable" xlink:to="lab_sny_DisclosureOfAccountsReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_019ef965-c228-79f9-a217-c7d169e6b2f8_terseLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_019ef965-c228-74f2-9852-fbaa11addb54_terseLabel_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_label_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_documentation_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:href="sny-20260630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:to="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_019ef965-c2b7-7197-94c3-8936bcbfc55e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of average effective tax rate and applicable tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_019ef965-c228-7501-9e06-b7f7efc52820_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_019ef965-c228-78d3-a1c3-01039f3382b3_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019ef965-c2b7-7c42-9df8-14bf6241caf4_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_019ef965-c228-7c83-9ec7-27e714939532_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019ef965-c169-701e-8655-978a67bf2ca8_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_019ef965-c2b6-7812-a3dd-8b1007b33287_negatedLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share of undistributed earnings from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for undistributed profits of investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_019ef965-c228-7236-9034-1baa44bc1503_terseLabel_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating foreign exchange gains/(losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_label_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Operating Foreign Exchange Gains/(Losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_documentation_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-operating foreign exchange gains/(losses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:href="sny-20260630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:to="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_019ef965-c2b7-793b-a7f1-3034741df4f1_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of acquisitions and capitalized interest by operating segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_019ef965-c169-72be-8552-d9f9ce72d638_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_019ef965-c228-7486-9a42-7ed795a7cd9f_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in fair value on cash flow hedges excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019ef965-c228-76ec-878b-394ddefa5825_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_019f805d-637f-763e-b84f-4bab6f2004a7_totalLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementAxis_019ef965-c228-74d5-82a0-b609dc224747_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [Axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_019ef965-c2b7-741e-9acb-9c8c1955f1e1_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of dividends to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member_019f1dcf-f6b5-7db0-ad28-3a2c5e241da8_terseLabel_en-US" xlink:label="lab_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three billion eight hundred fifty million facility maturing April 2031</link:label>
    <link:label id="lab_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member_label_en-US" xlink:label="lab_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Billion Eight Hundred Fifty Million Facility Maturing April 2031 [Member]</link:label>
    <link:label id="lab_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member_documentation_en-US" xlink:label="lab_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three Billion Eight Hundred Fifty Million Facility Maturing April 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" xlink:href="sny-20260630.xsd#sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" xlink:to="lab_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_019ef965-c169-7c65-8cbb-d9dc359353e0_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2029Member_019f1dc4-c974-76f6-92ff-45dd23bfba0b_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed rate bond maturing march 2029</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2029Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2029 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMarch2029Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing March 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2029Member" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMarch2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingMarch2029Member" xlink:to="lab_sny_FixedRateBondMaturingMarch2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_019ef965-c2b7-71c6-8697-3b47ef978d27_totalLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Average number of shares used to compute diluted earnings per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c169-7ec3-87b3-7f884426aa75_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c228-748f-ab44-0d2427f9b66c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate_019f8f2f-fd66-7d25-8a92-66c826068b79_terseLabel_en-US" xlink:label="lab_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets of acquiree since acquisition date</link:label>
    <link:label id="lab_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate_label_en-US" xlink:label="lab_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets of Acquiree Since Acquisition Date</link:label>
    <link:label id="lab_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate_documentation_en-US" xlink:label="lab_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets of Acquiree Since Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" xlink:href="sny-20260630.xsd#sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" xlink:to="lab_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_019ef965-c2b6-72a6-8a03-765cdbb10ded_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of employee benefits (stock options and other share-based payments)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_019ef965-c228-74c2-bc56-dd1a2bd67b6e_terseLabel_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment plans:</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_label_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Payment Plans [abstract]</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_documentation_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based payment plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract" xlink:href="sny-20260630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract" xlink:to="lab_sny_ShareBasedPaymentPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_019ef965-c228-7797-90d5-cfce20a30d4d_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation differences (investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_019ef965-c2b6-7d06-b6bf-949aacb1ae32_terseLabel_en-US" xlink:label="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and other revenues</link:label>
    <link:label id="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySellerSwapsMember_019ef965-c2b7-7eaf-86af-4de81cc24de3_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross currency seller swaps</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsMember_label_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsMember_documentation_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsMember" xlink:href="sny-20260630.xsd#sny_CrossCurrencySellerSwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySellerSwapsMember" xlink:to="lab_sny_CrossCurrencySellerSwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_019ef965-c228-785b-8d21-3cb3451339bd_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of movements in other intangible assets</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in other intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_019ef965-c228-7b85-af4b-ebe83c069045_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Debt by Type Valuation of Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of debt net of cash and cash equivalents by type at value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_019ef965-c2b6-76e6-a00b-72a79214cc84_terseLabel_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued immediately for employer's contribution (in shares)</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_label_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Further Shares As An Employers Contribution</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_documentation_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Further shares as an employers contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:href="sny-20260630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:to="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_019ef965-c169-7f3b-8222-6dec71de90df_terseLabel_en-US" xlink:label="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VaxServe sales of non-Sanofi products</link:label>
    <link:label id="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_label_en-US" xlink:label="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from VaxServe sales of non-Sanofi products</link:label>
    <link:label id="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_documentation_en-US" xlink:label="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from VaxServe sales of non-Sanofi products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:href="sny-20260630.xsd#sny_RevenueFromVaxServeSalesOfNonSanofiProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:to="lab_sny_RevenueFromVaxServeSalesOfNonSanofiProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_019ef965-c2b6-72ba-abd2-6692258f559b_terseLabel_en-US" xlink:label="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to non-controlling interests</link:label>
    <link:label id="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Attributable to Non Controlling Interest, Related Party Transactions</link:label>
    <link:label id="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Attributable to Non Controlling Interest, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:to="lab_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_019ef965-c169-7820-8afe-4be3eadf290c_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterests" xlink:to="lab_ifrs-full_NoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_019ef965-c228-7dcf-8022-6c9d85b3e735_terseLabel_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DebtSecuritiesMember" xlink:to="lab_ifrs-full_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage_019f8032-1ecd-70ff-8f1b-6a884569e2e3_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other revenue, on a reported basis (IFRS), percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Other Revenue, On A Reported Basis (IFRS), Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Other Revenue, On A Reported Basis (IFRS), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c2b6-74e9-8f66-5f963a21c32d_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment consolidation items [Axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:to="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c228-7ae8-a7ec-f38a559f418d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c228-74a0-b5dd-88258273b777_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_019ef965-c2b7-7e9c-ae9e-f52b0e705fa5_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise&#160;price per share, exercisable (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c228-7e34-9228-29d050e95788_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c228-77ac-9742-dbf1439b15e1_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c228-752b-9ddc-982c0b1dd8d1_netLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c2b7-722c-8b6a-6341f07a3ce6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_019ef965-c2b6-7a5d-8f32-f6ca791fbbda_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Pound sterling</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Pound Sterling [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInPoundSterlingMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Pound Sterling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:to="lab_sny_ForwardCurrencySalesInPoundSterlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetIncomeRelatedPartyDisclosures_019ef965-c2b6-7289-922f-23c03418217d_terseLabel_en-US" xlink:label="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_sny_NetIncomeRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income, Related Party Disclosures</link:label>
    <link:label id="lab_sny_NetIncomeRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetIncomeRelatedPartyDisclosures" xlink:href="sny-20260630.xsd#sny_NetIncomeRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetIncomeRelatedPartyDisclosures" xlink:to="lab_sny_NetIncomeRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_019f895d-274e-776c-8ac2-49ae6a337e6d_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c2b6-741e-9385-0f9892b31495_terseLabel_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_019ef965-c228-758a-bc8a-e719818a0b5d_totalLabel_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:href="sny-20260630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SubscriptionPricePerShare_019ef965-c169-73f0-901b-a2910c4db678_terseLabel_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription price (in euros per share)</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_label_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Price Per Share</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_documentation_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare" xlink:href="sny-20260630.xsd#sny_SubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SubscriptionPricePerShare" xlink:to="lab_sny_SubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS_019f802b-d17d-736c-8498-0544f0bf8c89_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in cost of sales, at constant exchange rates non-IFRS, percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cost Of sales At Constant Exchange Rates, Percentage Non-IFRS)</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cost Of sales At Constant Exchange Rates Non-IFRS), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" xlink:to="lab_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_019ef965-c228-7e1b-a8a7-17ba8373c5c2_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Instruments [Axis]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis" xlink:to="lab_ifrs-full_HedgingInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-74bc-96bc-84bda2761797_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c228-7453-b841-970593f25516_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [domain]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_019ef965-c169-764f-a446-86e0dfb43ff9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and other increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c228-7a20-8a7e-600229c2d48d_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate and currency derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PreFundedPensionObligations_019ef965-c169-77cd-8fcf-1c2ee85f5633_terseLabel_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded pension obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_label_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Pension Obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_documentation_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-funded pension obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations" xlink:href="sny-20260630.xsd#sny_PreFundedPensionObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PreFundedPensionObligations" xlink:to="lab_sny_PreFundedPensionObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AltuviiioMember_019ef965-c228-7643-80a7-946bf2042219_terseLabel_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALTUVIIIO</link:label>
    <link:label id="lab_sny_AltuviiioMember_label_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Altuviiio [Member]</link:label>
    <link:label id="lab_sny_AltuviiioMember_documentation_en-US" xlink:label="lab_sny_AltuviiioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Altuviiio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember" xlink:href="sny-20260630.xsd#sny_AltuviiioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AltuviiioMember" xlink:to="lab_sny_AltuviiioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementDomain_019ef965-c2b7-7498-a98b-16baf3b01a7a_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_label_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain" xlink:href="sny-20260630.xsd#sny_TypesOfAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementDomain" xlink:to="lab_sny_TypesOfAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_019ef965-c2b6-748e-b31b-80a3a1b6804f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Accounts Receivable [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:to="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerOneMember_019ef965-c228-7e4b-931d-08a603e87f80_terseLabel_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer one</link:label>
    <link:label id="lab_sny_CustomerOneMember_label_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [member]</link:label>
    <link:label id="lab_sny_CustomerOneMember_documentation_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember" xlink:href="sny-20260630.xsd#sny_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerOneMember" xlink:to="lab_sny_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSyndicatedCreditFacilities_019f1dce-9adf-77ff-aa06-1652cab9640a_terseLabel_en-US" xlink:label="lab_sny_NumberOfSyndicatedCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of syndicated credit facilities</link:label>
    <link:label id="lab_sny_NumberOfSyndicatedCreditFacilities_label_en-US" xlink:label="lab_sny_NumberOfSyndicatedCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Syndicated Credit Facilities</link:label>
    <link:label id="lab_sny_NumberOfSyndicatedCreditFacilities_documentation_en-US" xlink:label="lab_sny_NumberOfSyndicatedCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Syndicated Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSyndicatedCreditFacilities" xlink:href="sny-20260630.xsd#sny_NumberOfSyndicatedCreditFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSyndicatedCreditFacilities" xlink:to="lab_sny_NumberOfSyndicatedCreditFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities in business combination [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_019ef965-c228-73f1-a90b-d8c548c6b3ef_terseLabel_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products, trademarks and other rights</link:label>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_label_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products, Trademarks And Other Rights [Member]</link:label>
    <link:label id="lab_sny_ProductsTrademarksAndOtherRightsMember_documentation_en-US" xlink:label="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products, trademarks and other rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember" xlink:href="sny-20260630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProductsTrademarksAndOtherRightsMember" xlink:to="lab_sny_ProductsTrademarksAndOtherRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_019ef965-c228-7b84-ae4b-aaf9e578f033_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restructuring Costs and Similar Items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Restructuring Costs Details [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of restructuring costs details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_019ef965-c169-7430-9ebb-24fafe47579f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosures about major customers and credit risk</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfOwnershipInterestDisposed_019f8f38-1342-7810-86de-fe2f487fdcde_terseLabel_en-US" xlink:label="lab_sny_PercentageOfOwnershipInterestDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership interest disposed</link:label>
    <link:label id="lab_sny_PercentageOfOwnershipInterestDisposed_label_en-US" xlink:label="lab_sny_PercentageOfOwnershipInterestDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Ownership Interest Disposed</link:label>
    <link:label id="lab_sny_PercentageOfOwnershipInterestDisposed_documentation_en-US" xlink:label="lab_sny_PercentageOfOwnershipInterestDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Ownership Interest Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfOwnershipInterestDisposed" xlink:href="sny-20260630.xsd#sny_PercentageOfOwnershipInterestDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfOwnershipInterestDisposed" xlink:to="lab_sny_PercentageOfOwnershipInterestDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_019ef965-c169-714f-b2bd-0fa449db4e27_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, cash and cash equivalents</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Debt Instruments Issued Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of debt instruments issued explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-c2b6-7479-bedd-06e55cd63a29_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_019ef965-c228-7add-864a-f9bb5f1e7003_negatedTerseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Currency Translation On Tax Effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in currency translation on tax effects.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:to="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossOfAcquiree_019f8f2f-63f4-7096-bfc3-b3279a87e6af_negatedLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossOfAcquiree" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss of acquiree since acquisition date</link:label>
    <link:label id="lab_ifrs-full_ProfitLossOfAcquiree_label_en-US" xlink:label="lab_ifrs-full_ProfitLossOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) of acquiree since acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossOfAcquiree" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossOfAcquiree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossOfAcquiree" xlink:to="lab_ifrs-full_ProfitLossOfAcquiree" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_019ef965-c169-7d37-8e29-a1e6556948f3_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c169-72ff-8d28-757a6a6e13ec_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c2b7-7d65-b74c-148b2354ef2c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UpfrontLicensePayment_019f937c-469d-7d69-be91-b532c594bf96_terseLabel_en-US" xlink:label="lab_sny_UpfrontLicensePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license payment</link:label>
    <link:label id="lab_sny_UpfrontLicensePayment_label_en-US" xlink:label="lab_sny_UpfrontLicensePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront License Payment</link:label>
    <link:label id="lab_sny_UpfrontLicensePayment_documentation_en-US" xlink:label="lab_sny_UpfrontLicensePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront License Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontLicensePayment" xlink:href="sny-20260630.xsd#sny_UpfrontLicensePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UpfrontLicensePayment" xlink:to="lab_sny_UpfrontLicensePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstruments_019ef965-c228-7b60-8b81-be4d99ba2389_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative financial instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments" xlink:href="sny-20260630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstruments" xlink:to="lab_sny_DerivativeFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_019ef965-c2b6-78d2-8f06-67ea1fb02c16_terseLabel_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Antibodies Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember" xlink:href="sny-20260630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesCollaborationAgreementMember" xlink:to="lab_sny_AntibodiesCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_019ef965-c228-7a6f-aca4-2610582fca13_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of restricted shares alloted in regards of capital increase (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Alloted In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Alloted In Regards Of Capital Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c228-75b0-a0e1-54c4eba9da8d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfSanofisShareCapitalAcquired_019f2301-0ec8-7ad9-90e6-c0aaacd8cfc8_terseLabel_en-US" xlink:label="lab_sny_PercentageOfSanofisShareCapitalAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Sanofi's share capital acquired</link:label>
    <link:label id="lab_sny_PercentageOfSanofisShareCapitalAcquired_label_en-US" xlink:label="lab_sny_PercentageOfSanofisShareCapitalAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Sanofi's Share Capital Acquired</link:label>
    <link:label id="lab_sny_PercentageOfSanofisShareCapitalAcquired_documentation_en-US" xlink:label="lab_sny_PercentageOfSanofisShareCapitalAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Sanofi's Share Capital Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSanofisShareCapitalAcquired" xlink:href="sny-20260630.xsd#sny_PercentageOfSanofisShareCapitalAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfSanofisShareCapitalAcquired" xlink:to="lab_sny_PercentageOfSanofisShareCapitalAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions_019ef965-c228-7be2-b339-72c2ed31ecc3_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Current Liabilities, Related Party Transactions</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Current Liabilities, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:to="lab_sny_NonCurrentLiabilitiesRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_019ef965-c2b7-7b97-8def-61b41e3de5a0_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_019ef965-c228-7c3d-a876-dae84b04e093_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_019ef965-c2b7-7172-ae9d-ecace79e9e0b_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments To Manage Financial Exposure</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative financial instruments to manage financial exposure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:href="sny-20260630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:to="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NexviazymeNexviadymeMember_019f21f3-dfeb-7e4c-819e-c39c43f2736a_terseLabel_en-US" xlink:label="lab_sny_NexviazymeNexviadymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nexviazyme/Nexviadyme</link:label>
    <link:label id="lab_sny_NexviazymeNexviadymeMember_label_en-US" xlink:label="lab_sny_NexviazymeNexviadymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nexviazyme/Nexviadyme [Member]</link:label>
    <link:label id="lab_sny_NexviazymeNexviadymeMember_documentation_en-US" xlink:label="lab_sny_NexviazymeNexviadymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nexviazyme/Nexviadyme</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeNexviadymeMember" xlink:href="sny-20260630.xsd#sny_NexviazymeNexviadymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NexviazymeNexviadymeMember" xlink:to="lab_sny_NexviazymeNexviadymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_019ef965-c2b6-751b-a5d9-d9759b8c99f3_terseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in other non-current assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_label_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Change In Other Non-Current Assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net change in other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:href="sny-20260630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:to="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_019ef965-c169-7783-a05c-f996f715f3a0_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019ef965-c2b6-7a09-a12f-5d22b291bd14_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense recognized</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019ef965-c2b6-7383-90f2-3d2fc94156ff_netLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total expense for restricted share plans</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsDomain_019ef965-c2b6-73f2-8ecc-312d2f8dba5a_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging instruments [Member]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsDomain_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain" xlink:to="lab_ifrs-full_HedgingInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_019ef965-c2b7-73cc-bdfe-f9a07fdeae8a_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_019ef965-c2b6-7c68-a25f-34f21cce6492_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_019ef965-c2b7-7ee3-acc7-88ca6146dc6c_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_019ef965-c2b7-7d34-b08d-3f3b88bdc631_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee-related expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Employee Related Expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments_019f9380-96f6-79b2-be2b-28d85811e7b9_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement development, regulatory and sales milestone payments</link:label>
    <link:label id="lab_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments_label_en-US" xlink:label="lab_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Development Regulatory And Sales Milestone Payments</link:label>
    <link:label id="lab_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Development Regulatory And Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" xlink:href="sny-20260630.xsd#sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" xlink:to="lab_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_019ef965-c2b7-785b-a5f5-bfb9f91c3750_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassified items [Axis]</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassified items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis" xlink:to="lab_ifrs-full_ReclassifiedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_019ef965-c2b6-7a97-ae25-aceb271f20c0_negatedLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:to="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_019ef965-c2b6-71b6-8495-5bdd0dd06ce4_negatedLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_019ef965-c2b6-7e40-99d0-c23484ba722b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions_019ef965-c228-74aa-ac84-6975f533ac5c_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other changes in non-controlling interests</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Changes In Non-controlling Interests Arising From Divestment And Acquisitions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Changes In Non-controlling Interests Arising From Divestment And Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" xlink:to="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_019ef965-c228-7129-896e-f09991cda130_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_019ef965-c228-7a07-882a-8e54efc4608a_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_019ef965-c169-75b7-acfa-80a047bd3bf9_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_019ef965-c228-7e14-af85-367100be99a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share from discontinued operations (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_019ef965-c2b7-7da7-899b-5935f349c8ad_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated individually immaterial associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:to="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c2b7-7022-90aa-35a913df35ae_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-c169-7547-a881-e874471924a1_negatedLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-c169-755a-b75e-2d09a1f1a604_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating expense</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-c169-74ef-9025-0c66c723ab26_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_019ef965-c169-7938-b3e1-01ca4fa2ac16_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesAxis_019ef965-c2b7-7053-8692-cc2f68a89a16_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint ventures [Axis]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesAxis_label_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis" xlink:to="lab_ifrs-full_JointVenturesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c228-7585-97d0-9dd4af69ea0c_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_019ef965-c228-7900-b442-0c527d53f050_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [Member]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameDomain" xlink:to="lab_ifrs-full_BorrowingsByNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_019ef965-c169-7e58-9dd4-7c7a9b241b33_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other related parties</link:label>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRelatedPartiesMember" xlink:to="lab_ifrs-full_OtherRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_HudsonHeadwatersHealthNetworkMember_019f8011-0d6e-7744-b434-900150cb9947_terseLabel_en-US" xlink:label="lab_sny_HudsonHeadwatersHealthNetworkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hudson Headwaters Health Network</link:label>
    <link:label id="lab_sny_HudsonHeadwatersHealthNetworkMember_label_en-US" xlink:label="lab_sny_HudsonHeadwatersHealthNetworkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hudson Headwaters Health Network [Member]</link:label>
    <link:label id="lab_sny_HudsonHeadwatersHealthNetworkMember_documentation_en-US" xlink:label="lab_sny_HudsonHeadwatersHealthNetworkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hudson Headwaters Health Network</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HudsonHeadwatersHealthNetworkMember" xlink:href="sny-20260630.xsd#sny_HudsonHeadwatersHealthNetworkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_HudsonHeadwatersHealthNetworkMember" xlink:to="lab_sny_HudsonHeadwatersHealthNetworkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2029Member_019ef965-c169-785e-9554-fad7bc261d17_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cross currency swap, expiring 2029</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2029Member_label_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2029 [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySwapExpiring2029Member_documentation_en-US" xlink:label="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Swap, Expiring 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2029Member" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapExpiring2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySwapExpiring2029Member" xlink:to="lab_sny_CrossCurrencySwapExpiring2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_019ef965-c2b6-7388-a173-1af65b9bf1a0_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_019f1db9-1d30-73c0-8fb6-793a63e1d2d4_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019ef965-c228-7dfd-a543-117b23146dec_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_019ef965-c169-7ae8-aa09-65fc86e2a332_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income for the period</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-7cec-9b0c-37070e68e57b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizedCostNettingMember_019ef965-c228-71ad-9d5c-c9416dd7a882_terseLabel_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_sny_AmortizedCostNettingMember_label_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost, Netting [Member]</link:label>
    <link:label id="lab_sny_AmortizedCostNettingMember_documentation_en-US" xlink:label="lab_sny_AmortizedCostNettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember" xlink:href="sny-20260630.xsd#sny_AmortizedCostNettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizedCostNettingMember" xlink:to="lab_sny_AmortizedCostNettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingIncome_019f1e33-d165-7af4-b099-d9d815047866_totalLabel_en-US" xlink:label="lab_sny_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other operating income</link:label>
    <link:label id="lab_sny_OtherOperatingIncome_label_en-US" xlink:label="lab_sny_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income</link:label>
    <link:label id="lab_sny_OtherOperatingIncome_documentation_en-US" xlink:label="lab_sny_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncome" xlink:href="sny-20260630.xsd#sny_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingIncome" xlink:to="lab_sny_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_019ef965-c228-7bbf-9366-1e8e4d04ec96_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [Member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesDomain" xlink:to="lab_ifrs-full_CounterpartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_019ef965-c2b6-711f-a90e-f37345596e25_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_019ef965-c169-79fe-983f-bbad394d8240_terseLabel_en-US" xlink:label="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents reclassified to Assets held for sale as of December 31, 2024</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_label_en-US" xlink:label="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Reclassified to Assets Held for Sale</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_documentation_en-US" xlink:label="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Reclassified to Assets Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:href="sny-20260630.xsd#sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:to="lab_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019ef965-c228-7e51-b9e8-91398a130ecf_totalLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets of Dynavax</link:label>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_label_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdditionalProfitShareForDevelopmentCostMember_019f801e-4b60-78ab-bdc6-467a5fe5ac9a_terseLabel_en-US" xlink:label="lab_sny_AdditionalProfitShareForDevelopmentCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional profit share for development cost</link:label>
    <link:label id="lab_sny_AdditionalProfitShareForDevelopmentCostMember_label_en-US" xlink:label="lab_sny_AdditionalProfitShareForDevelopmentCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Profit Share For Development Cost [Member]</link:label>
    <link:label id="lab_sny_AdditionalProfitShareForDevelopmentCostMember_documentation_en-US" xlink:label="lab_sny_AdditionalProfitShareForDevelopmentCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Profit Share For Development Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalProfitShareForDevelopmentCostMember" xlink:href="sny-20260630.xsd#sny_AdditionalProfitShareForDevelopmentCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdditionalProfitShareForDevelopmentCostMember" xlink:to="lab_sny_AdditionalProfitShareForDevelopmentCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c228-7c48-9c3d-6e54b8a03a6f_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [Axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_019ef965-c169-74a4-97ed-6680910dd103_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of debt</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c2b6-7bff-8337-9edcc51beb30_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c228-7f63-94b7-1a2a7706cbbc_terseLabel_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shire contingent consideration arising from acquisition of Translate Bio</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_label_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shire Contingent Consideration Arising From Acquisition Of Translate Bio [Member]</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_documentation_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shire Contingent Consideration Arising From Acquisition Of Translate Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:href="sny-20260630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:to="lab_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_019ef965-c2b7-778d-b4aa-e4338cb144d0_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital increase by issuance of restricted shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Restricted Shares Issued In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of restricted shares issued in regards of capital increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_019f6b50-1a9a-71a5-a49f-3b7d429da9b4_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_019f8bcd-1e85-7486-bc7a-e5fbe6e965f5_negatedTerseLabel_en-US" xlink:label="lab_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes, net</link:label>
    <link:label id="lab_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Liabilities Recognised As Of AcquisitionDate</link:label>
    <link:label id="lab_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Liabilities Recognised As Of AcquisitionDate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:href="sny-20260630.xsd#sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxEffectRelatedToAmlitelimab_019f9340-f76f-79f2-a46b-2d41b2e387ca_terseLabel_en-US" xlink:label="lab_sny_TaxEffectRelatedToAmlitelimab" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax effect related to amlitelimab</link:label>
    <link:label id="lab_sny_TaxEffectRelatedToAmlitelimab_label_en-US" xlink:label="lab_sny_TaxEffectRelatedToAmlitelimab" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Related To Amlitelimab</link:label>
    <link:label id="lab_sny_TaxEffectRelatedToAmlitelimab_documentation_en-US" xlink:label="lab_sny_TaxEffectRelatedToAmlitelimab" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Related To Amlitelimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxEffectRelatedToAmlitelimab" xlink:href="sny-20260630.xsd#sny_TaxEffectRelatedToAmlitelimab"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxEffectRelatedToAmlitelimab" xlink:to="lab_sny_TaxEffectRelatedToAmlitelimab" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsDomain_019ef965-c169-7bc5-a19a-111ecc3cdce6_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged items [Member]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsDomain_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged items [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsDomain" xlink:to="lab_ifrs-full_HedgedItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_019ef965-c169-793f-904c-c5bf8bed137d_terseLabel_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_label_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_documentation_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract" xlink:href="sny-20260630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract" xlink:to="lab_sny_InterestsInOtherEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_019ef965-c2b7-73ec-b3e0-41aa5d874924_terseLabel_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derivatives used to manage debt</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_GainLossOnDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (loss) on derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt" xlink:href="sny-20260630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnDerivativesUsedToManageDebt" xlink:to="lab_sny_GainLossOnDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EuroapiMember_019ef965-c169-7097-84a0-30dbe79ed281_verboseLabel_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EUROAPI</link:label>
    <link:label id="lab_sny_EuroapiMember_019ef965-c169-7cae-8d26-e8818bff5f3a_terseLabel_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EUROAPI</link:label>
    <link:label id="lab_sny_EuroapiMember_label_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euroapi [Member]</link:label>
    <link:label id="lab_sny_EuroapiMember_documentation_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Euroapi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember" xlink:href="sny-20260630.xsd#sny_EuroapiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EuroapiMember" xlink:to="lab_sny_EuroapiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019ef965-c169-7cc1-95d1-3097e2ad2e15_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingMay2033Member_019f1dcb-25f0-785f-9598-e8adc8c5d461_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingMay2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed rate bond maturing may 2033</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMay2033Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingMay2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing May 2033 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMay2033Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingMay2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing May 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMay2033Member" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMay2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingMay2033Member" xlink:to="lab_sny_FixedRateBondMaturingMay2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CrossCurrencySellerSwapsInUSDollarMember_019ef965-c228-7b74-bb27-b8374a920618_terseLabel_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which US dollar</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsInUSDollarMember_label_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps In US Dollar [Member]</link:label>
    <link:label id="lab_sny_CrossCurrencySellerSwapsInUSDollarMember_documentation_en-US" xlink:label="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cross Currency Seller Swaps In US Dollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:href="sny-20260630.xsd#sny_CrossCurrencySellerSwapsInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:to="lab_sny_CrossCurrencySellerSwapsInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c2b6-7e64-b7b4-f2931b6ec864_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [domain]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_019ef965-c228-765d-8313-987b22bae833_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:to="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_019ef965-c2b7-77a3-bf42-45ced925d271_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [Axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromDiscontinuedOperations_019ef965-c2b7-7edc-a8de-34194dd8457f_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromDiscontinuedOperations_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:to="lab_ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialAssets_019ef965-c228-7826-a9ac-164da5dec0d1_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_019ef965-c228-7133-a3c7-ad320e7333c7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of treasury shares held</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtMarketValueMember_019ef965-c228-7e71-92fb-d936fed27018_terseLabel_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_sny_AtMarketValueMember_label_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At Market Value [member]</link:label>
    <link:label id="lab_sny_AtMarketValueMember_documentation_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember" xlink:href="sny-20260630.xsd#sny_AtMarketValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtMarketValueMember" xlink:to="lab_sny_AtMarketValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_019f1dc9-dfc0-786b-a8a5-a073c94e1c22_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-c2b7-73f8-851c-a32c81376170_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_019ef965-c169-7c60-8913-080d0f37ecbc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_019ef965-c169-77b3-8e15-5d2cbb3d31c0_terseLabel_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative consumer price inflation rate</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_label_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Consumer Price Inflation Rate Over The Last Three Years</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_documentation_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative Consumer Price Inflation Rate Over The Last Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:href="sny-20260630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:to="lab_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c169-7539-8b05-3b259b69589f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_019ef965-c228-75a5-829f-e130b5146fb7_terseLabel_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pensions and other post-employment benefits</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_label_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensions And Other Post-Employment Benefits [Member]</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:href="sny-20260630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:to="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_019ef965-c169-72bb-afca-ccb556ccaf93_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Non-Current Provisions and Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions And Other Non Current Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_019ef965-c228-7caa-a167-b055bb27ee5d_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in associates</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in associates accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c2b6-7963-a284-aca27ba9b851_negatedLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c2b6-799d-a8d2-0ef78cb8e9d5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_019ef965-c2b6-7e5b-a0e5-6f917e557fea_terseLabel_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of liability</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_label_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Increase In Fair Value Liabilities</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_documentation_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage increase in fair value liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:href="sny-20260630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:to="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_019ef965-c2b6-7ad6-81ce-1bdcbdb9579e_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which Chinese yuan renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Sales In Chinese Yuan Renminbi [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency sales in Chinese Yuan Renminbi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_019ef965-c228-7c2b-8696-9462999ebac2_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_019f22d0-71e9-7435-a55f-db1ab55b3b82_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c2b6-7723-95aa-158ac22193cd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_019ef965-c228-7896-90fc-47ec42d2b707_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-c2b7-7b59-a5cd-1a9b8e94f6dd_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow before changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock_019f1d25-451d-7c41-bc7c-c384a8f76bcb_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of unaudited financial statements of subsidiaries explanatory</link:label>
    <link:label id="lab_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Unaudited Financial Statements Of Subsidiaries Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Unaudited Financial Statements Of Subsidiaries Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LOrealMember_019f89ce-2703-7ea1-8d44-950f3c49c5e2_terseLabel_en-US" xlink:label="lab_sny_LOrealMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">L'Or&#233;al</link:label>
    <link:label id="lab_sny_LOrealMember_label_en-US" xlink:label="lab_sny_LOrealMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">L'Or&#233;al [Member]</link:label>
    <link:label id="lab_sny_LOrealMember_documentation_en-US" xlink:label="lab_sny_LOrealMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">L'Or&#233;al</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LOrealMember" xlink:href="sny-20260630.xsd#sny_LOrealMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LOrealMember" xlink:to="lab_sny_LOrealMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_019ef965-c2b7-7fde-98df-9c982cffa3da_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_019ef965-c228-713b-8f08-320096531b73_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Of which capitalized interest</link:label>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_label_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest costs capitalised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestCostsCapitalised" xlink:to="lab_ifrs-full_InterestCostsCapitalised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsAxis_019ef965-c2b7-73e3-90c3-dc062826667f_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsAxis" xlink:to="lab_ifrs-full_SegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_019ef965-c228-7c23-badf-1c168c490f52_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MSPVaccineCompanyMember_019ef965-c228-7fc8-be6b-ed60e03fb046_terseLabel_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_label_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company [Member]</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_documentation_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MSP Vaccine Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember" xlink:href="sny-20260630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MSPVaccineCompanyMember" xlink:to="lab_sny_MSPVaccineCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c2b6-7979-aca9-e89285aa7b96_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_019ef965-c228-7f7a-be30-050fe02e783d_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges, gains or losses on assets</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Related To Property Plant And Equipment And To Inventories</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense of restructuring activities related to property plant and equipment to inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_019ef965-c169-7ee5-8361-38fea2273077_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of Hedges [Axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of hedges [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesAxis" xlink:to="lab_ifrs-full_TypesOfHedgesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_019ef965-c228-7e1c-b93b-7f93a0ad3954_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation and foreign currency ranslation of the financial statements of subsidiaries in hyperinflationary economies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about hyperinflationary reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:to="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_019ef965-c2b7-74b4-886d-6363b93d6425_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAbstract" xlink:to="lab_ifrs-full_ProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_019ef965-c2b7-7ccb-96b3-3878f4584572_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_019ef965-c169-71b0-9e1a-484785a33da0_terseLabel_en-US" xlink:label="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to Opella</link:label>
    <link:label id="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_label_en-US" xlink:label="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from intragroup sales from continuing to discontinued operations</link:label>
    <link:label id="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from intragroup sales from continuing to discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:to="lab_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019ef965-c2b7-77e5-b80c-8502fa7f1096_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_019ef965-c228-7c6a-a896-41c7fd77486a_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_019ef965-c2b6-71ad-8e36-223a4d2bf0ce_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_019ef965-c169-7371-82f1-cca5820c56cd_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_019f6b41-0d76-7e46-a6d9-b9d8088cb959_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_019ef965-c228-75b0-8e5b-b089b4353351_terseLabel_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Of which Manufacturing &amp; Supply</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_label_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing And Supply [Member]</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_documentation_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing and supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember" xlink:href="sny-20260630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ManufacturingAndSupplyMember" xlink:to="lab_sny_ManufacturingAndSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_019ef965-c228-7728-ba4b-3c9a0d05748f_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value On Debt Instrument Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019ef965-c2b7-7f9b-ade7-3ab3209acc2c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_019ef965-c228-7935-8871-45ef42e68d6d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c169-7ed6-b43a-52f1a654194a_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs and similar items</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c169-7d21-920c-71ee488fc118_totalLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_label_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense of restructuring activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:to="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c169-70b5-a499-5fb863dd6f07_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_019ef965-c2b6-7932-96cd-03edccfd030d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Receivables [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:to="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_019ef965-c228-7364-babe-737501b2384e_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of transformation programs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RSVVaccinesBeyfortusMember_019f21f6-d1f0-7ba4-8c87-e4195d6c0ca1_terseLabel_en-US" xlink:label="lab_sny_RSVVaccinesBeyfortusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSV vaccines (Beyfortus)</link:label>
    <link:label id="lab_sny_RSVVaccinesBeyfortusMember_label_en-US" xlink:label="lab_sny_RSVVaccinesBeyfortusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSV Vaccines (Beyfortus) [Member]</link:label>
    <link:label id="lab_sny_RSVVaccinesBeyfortusMember_documentation_en-US" xlink:label="lab_sny_RSVVaccinesBeyfortusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RSV Vaccines (Beyfortus)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesBeyfortusMember" xlink:href="sny-20260630.xsd#sny_RSVVaccinesBeyfortusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RSVVaccinesBeyfortusMember" xlink:to="lab_sny_RSVVaccinesBeyfortusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_019f1e13-943c-750e-8703-6326e24b5fe7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisions utilized</link:label>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_019ef965-c228-78ac-8827-17c1a76870ac_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of services obtained from employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of services obtained from employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeDomain_019ef965-c228-705b-bb63-d804863494e0_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [Member]</link:label>
    <link:label id="lab_ifrs-full_RangeDomain_label_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain" xlink:to="lab_ifrs-full_RangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_019ef965-c228-790c-acf3-477f31a3f858_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of Contingent Liabilities [Axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentDomain_019ef965-c169-797a-befa-7f4fe2adac3f_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_label_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_documentation_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain" xlink:href="sny-20260630.xsd#sny_DebtInstrumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentDomain" xlink:to="lab_sny_DebtInstrumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_019ef965-c228-7c8d-9825-ee9ceefed50b_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue by 1-3 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:to="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmlitelimabAssetMember_019f8f3e-c0b4-7ce2-8ca6-c3b04601935c_terseLabel_en-US" xlink:label="lab_sny_AmlitelimabAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amlitelimab asset</link:label>
    <link:label id="lab_sny_AmlitelimabAssetMember_label_en-US" xlink:label="lab_sny_AmlitelimabAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amlitelimab Asset [Member]</link:label>
    <link:label id="lab_sny_AmlitelimabAssetMember_documentation_en-US" xlink:label="lab_sny_AmlitelimabAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amlitelimab Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmlitelimabAssetMember" xlink:href="sny-20260630.xsd#sny_AmlitelimabAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmlitelimabAssetMember" xlink:to="lab_sny_AmlitelimabAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019ef965-c2b7-7059-b105-57b9b0be9741_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_019ef965-c228-7676-b8bf-11323c63e677_terseLabel_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of class action lawsuits</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_label_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_documentation_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits" xlink:href="sny-20260630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfClassActionLawsuits" xlink:to="lab_sny_NumberOfClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_019ef965-c228-7274-b6c9-2132f7b6a41c_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From &#8364;70.00 to &#8364;80.00 per share</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeThreeMember" xlink:to="lab_sny_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7928-bcc5-dcedd984213c_terseLabel_en-US" xlink:label="lab_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortisation of Inventories</link:label>
    <link:label id="lab_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate_label_en-US" xlink:label="lab_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and Expenses from Inventories of Acquiree Since Acquisition Date</link:label>
    <link:label id="lab_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate_documentation_en-US" xlink:label="lab_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and Expenses from Inventories of Acquiree Since Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" xlink:href="sny-20260630.xsd#sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" xlink:to="lab_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c228-712f-8de3-0f13a98ddfb3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c228-7ab9-8829-400f4b0d4159_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FixedRateBondMaturingMay2037Member_019f1dcb-64b0-78da-a63c-2e4782e64969_terseLabel_en-US" xlink:label="lab_sny_FixedRateBondMaturingMay2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed rate bond maturing May 2037</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMay2037Member_label_en-US" xlink:label="lab_sny_FixedRateBondMaturingMay2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing May 2037 [Member]</link:label>
    <link:label id="lab_sny_FixedRateBondMaturingMay2037Member_documentation_en-US" xlink:label="lab_sny_FixedRateBondMaturingMay2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Rate Bond Maturing May 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMay2037Member" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMay2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FixedRateBondMaturingMay2037Member" xlink:to="lab_sny_FixedRateBondMaturingMay2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_019ef965-c228-713f-ae14-9df7e79c4a99_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_019ef965-c228-7c53-902a-5ca23e2140fd_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_019ef965-c228-7e6f-bb84-6cdb787ae565_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_019ef965-c228-7d29-a1f8-031ac91a782c_terseLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c2b7-7c22-9e77-79c8eef6d249_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">of which US dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward Currency Purchases In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forward currency purchases in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasesInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_019ef965-c2b7-7ace-b77a-2977d7f4ba11_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures</link:label>
    <link:label id="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:to="lab_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_019ef965-c169-772c-91c7-1b0633fb9105_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage_019f8035-bbc2-7544-a09a-4799460c2365_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in selling and general expenses, at constant exchange rates non-IFRS, percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Selling And General Expenses, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Selling And General Expenses, At Constant Exchange Rates Non-IFRS, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_019ef965-c169-74f6-8711-0910213a3bcd_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of goods and services (including research expenses)</link:label>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_019ef965-c2b6-77eb-80ff-2247fbcf6a17_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_019f3754-3103-74c7-aa7f-4c88130e42fc_negatedTerseLabel_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liability recognised for estimated future royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_label_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_documentation_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:href="sny-20260630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:to="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage_019f8032-b185-7ee8-9f83-8b745d31f644_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in revenue, on a reported basis (IFRS), percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue, On A Reported Basis (IFRS), Percentage</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue, On A Reported Basis (IFRS), Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" xlink:to="lab_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_019f805d-7c4a-78dd-a402-99a46b99c254_totalLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-c2b6-726e-a905-f9c33d02ce6e_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in contingent consideration asset (liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:to="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityDomain_019ef965-c169-709a-930b-205e8d9e1a13_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands [Member]</link:label>
    <link:label id="lab_ifrs-full_MaturityDomain_label_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityDomain" xlink:to="lab_ifrs-full_MaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_019ef965-c2b7-7dcb-b402-6c32345fba4a_terseLabel_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of profit or loss from commercialization of monoclonal antibodies</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_label_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_documentation_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of profit or loss from commercialization of monoclonal antibodies member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:href="sny-20260630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:to="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c169-7537-b093-c51d1b9e5515_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_019ef965-c228-7175-b8f8-6a7b85e0dcf9_terseLabel_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_label_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income, Related Party Disclosures</link:label>
    <link:label id="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_documentation_en-US" xlink:label="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income, Related Party Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:to="lab_sny_OtherComprehensiveIncomeRelatedPartyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_019ef965-c228-7101-a440-0093c4071084_totalLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_label_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AtFairValueMember_019ef965-c2b7-7098-bb95-3439d9b40c0c_terseLabel_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_ifrs-full_AtFairValueMember_label_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At fair value [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_019ef965-c2b6-715c-965f-aa6cabb9a99a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Reconciliation of Carrying Amount to Value on Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionAxis_019ef965-c2b7-7fb8-9111-3d0656ff3c6c_terseLabel_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_label_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_documentation_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis" xlink:href="sny-20260630.xsd#sny_MarketConditionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionAxis" xlink:to="lab_sny_MarketConditionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_019ef965-c228-7402-b01c-060bcd3fb527_verboseLabel_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overdue receivables gross value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_label_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overdue Receivables Gross Value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_documentation_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue" xlink:href="sny-20260630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OverdueReceivablesGrossValue" xlink:to="lab_sny_OverdueReceivablesGrossValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_019ef965-c2b6-7711-8228-c78a1cb2abaa_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other gains and losses, and litigation</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Gains And Losses, And Litigation [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of other gains and losses, and litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:to="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_019f7fbe-3f26-7de8-9eec-7415d9140448_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of number of shares used to compute diluted earnings per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCrossCurrencySwaps_019f1ded-0ff0-7dee-9fa2-4db7ad0f72b4_terseLabel_en-US" xlink:label="lab_sny_NumberOfCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of cross currency swaps</link:label>
    <link:label id="lab_sny_NumberOfCrossCurrencySwaps_label_en-US" xlink:label="lab_sny_NumberOfCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Cross Currency Swaps</link:label>
    <link:label id="lab_sny_NumberOfCrossCurrencySwaps_documentation_en-US" xlink:label="lab_sny_NumberOfCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Cross Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCrossCurrencySwaps" xlink:href="sny-20260630.xsd#sny_NumberOfCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCrossCurrencySwaps" xlink:to="lab_sny_NumberOfCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2026ProgramMember_019f8a40-fa73-753f-a87c-86185b40f9ef_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2026ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase 2026 Program</link:label>
    <link:label id="lab_sny_ShareRepurchase2026ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2026ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase 2026 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2026ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2026ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase 2026 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2026ProgramMember" xlink:href="sny-20260630.xsd#sny_ShareRepurchase2026ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2026ProgramMember" xlink:to="lab_sny_ShareRepurchase2026ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c228-7979-90cb-0561700876e0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019ef965-c228-7c88-87e7-7ec38aa985be_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of other intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_019ef965-c2b7-7814-8777-a87f443d90d7_terseLabel_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in currency translation differences:</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_label_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation [Member]</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_documentation_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember" xlink:href="sny-20260630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForeignCurrencyTranslationMember" xlink:to="lab_sny_ForeignCurrencyTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_019ef965-c169-755a-85e9-0cf4f49aeb9a_terseLabel_en-US" xlink:label="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Revenue, Disposal Group Including Discontinued Operations</link:label>
    <link:label id="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Revenue, Disposal Group Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:href="sny-20260630.xsd#sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>sny-20260630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ef965-bc7d-7da2-bb2f-04e26164615a,g:d543d692-5b77-4127-b010-746b44ca828b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20260630.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019ef965-bfdf-7c24-bb18-40ade5635795" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_019ef965-bfdf-7090-b8b1-b59cf2c46842" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019ef965-bfdf-7c24-bb18-40ade5635795" xlink:to="loc_dei_EntitiesTable_019ef965-bfdf-7090-b8b1-b59cf2c46842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_019ef965-bfdf-7090-b8b1-b59cf2c46842" xlink:to="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019ef965-bfdf-7666-859c-c0eb9c2b69d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentType_019ef965-bfdf-7666-859c-c0eb9c2b69d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019ef965-bfdf-762a-b1b8-5cb2b8ae0cb1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_EntityRegistrantName_019ef965-bfdf-762a-b1b8-5cb2b8ae0cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019ef965-bfdf-7f3a-9ac6-a64f7064fcae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_AmendmentFlag_019ef965-bfdf-7f3a-9ac6-a64f7064fcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019ef965-bfdf-734a-a0bb-1b59de139baf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_EntityCentralIndexKey_019ef965-bfdf-734a-a0bb-1b59de139baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019ef965-bfdf-7f61-bf6d-e175b66ff305" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_CurrentFiscalYearEndDate_019ef965-bfdf-7f61-bf6d-e175b66ff305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019ef965-bfdf-7c02-9a65-24409aee78ed" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentPeriodEndDate_019ef965-bfdf-7c02-9a65-24409aee78ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019ef965-bfdf-7c61-b12c-6092d45921ef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentFiscalYearFocus_019ef965-bfdf-7c61-b12c-6092d45921ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019ef965-bfdf-7ccc-8b84-76056889ade2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_019ef965-bfdf-7dbd-8d32-6c2722cced23" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019ef965-bfdf-7ccc-8b84-76056889ade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedbalancesheets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_019ef965-bfdf-7650-b893-c06f40df3ed3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019ef965-bfdf-7650-b893-c06f40df3ed3" xlink:to="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-bfdf-7f90-a9c1-f485931c8a56" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-bfdf-7f90-a9c1-f485931c8a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_019ef965-bfdf-7dd7-b8c8-d502fefaafd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_RightofuseAssets_019ef965-bfdf-7dd7-b8c8-d502fefaafd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_019ef965-bfdf-7832-aa96-4cd2eb23b38c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_Goodwill_019ef965-bfdf-7832-aa96-4cd2eb23b38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7b06-a658-d62f1f91cf32" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7b06-a658-d62f1f91cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-bfdf-7130-9517-8408f399d5e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-bfdf-7130-9517-8408f399d5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_019ef965-bfdf-7cc0-9693-f0fb7dbe99ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_019ef965-bfdf-7cc0-9693-f0fb7dbe99ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_019ef965-bfdf-7a5d-8276-b84d4dde845e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_019ef965-bfdf-7a5d-8276-b84d4dde845e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_019ef965-bfdf-74d7-a65b-c27421fc2fba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_DeferredTaxAssets_019ef965-bfdf-74d7-a65b-c27421fc2fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-7c18-a107-bfe9a2570a70" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_NoncurrentAssets_019ef965-bfdf-7c18-a107-bfe9a2570a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_019ef965-bfdf-72e2-9506-b1fecb65e5cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_Inventories_019ef965-bfdf-72e2-9506-b1fecb65e5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_019ef965-bfdf-7687-8465-744dccac6464" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_CurrentTradeReceivables_019ef965-bfdf-7687-8465-744dccac6464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_019ef965-bfdf-7ee9-918a-7451d0d21663" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_OtherCurrentAssets_019ef965-bfdf-7ee9-918a-7451d0d21663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_019ef965-bfdf-7d3c-9a56-849d79d2dc2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_019ef965-bfdf-7d3c-9a56-849d79d2dc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfdf-7de6-82be-4b4348ff9ecb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfdf-7de6-82be-4b4348ff9ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7c46-b08e-f4d48e65dd8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7c46-b08e-f4d48e65dd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_019ef965-bfdf-7de0-847a-edf68d2df9cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_CurrentAssets_019ef965-bfdf-7de0-847a-edf68d2df9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_019ef965-bfdf-755a-832d-39b9347f730b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_019ef965-bfdf-7f2e-85f3-9e4ce3e1ec5f" xlink:to="loc_ifrs-full_Assets_019ef965-bfdf-755a-832d-39b9347f730b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_019ef965-bfdf-7650-b893-c06f40df3ed3" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_019ef965-bfdf-7b4f-a016-2761e6258248" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_019ef965-bfdf-7b4f-a016-2761e6258248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_019ef965-bfdf-7b7a-9658-bdbcd0cf3233" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_NoncontrollingInterests_019ef965-bfdf-7b7a-9658-bdbcd0cf3233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019ef965-bfdf-7abd-8b8f-180befd89efa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_Equity_019ef965-bfdf-7abd-8b8f-180befd89efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_019ef965-bfdf-730a-a088-109d3418604d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_LongtermBorrowings_019ef965-bfdf-730a-a088-109d3418604d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_019ef965-bfdf-7711-8a77-1b00d133c17b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_019ef965-bfdf-7711-8a77-1b00d133c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-7ca5-bfd7-e7f1aab309e6" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-7ca5-bfd7-e7f1aab309e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfdf-7008-ba4f-22beebf059aa" xlink:href="sny-20260630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfdf-7008-ba4f-22beebf059aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_019ef965-bfdf-7692-8081-aacfdfe07a16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_019ef965-bfdf-7692-8081-aacfdfe07a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_019ef965-bfdf-76d4-9ebf-46b871ccd14e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_019ef965-bfdf-76d4-9ebf-46b871ccd14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-754c-8341-1001d817a835" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_NoncurrentLiabilities_019ef965-bfdf-754c-8341-1001d817a835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_019ef965-bfdf-70a1-999d-971dfdbad7ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_019ef965-bfdf-70a1-999d-971dfdbad7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-711e-884d-4f574c59b605" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-bfdf-711e-884d-4f574c59b605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_019ef965-bfdf-7e34-99f9-94d173e5719f" xlink:href="sny-20260630.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_019ef965-bfdf-7e34-99f9-94d173e5719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_019ef965-bfdf-7d7e-8351-b1e40e34999a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_019ef965-bfdf-7d7e-8351-b1e40e34999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_019ef965-bfdf-765c-a206-03fde4d4352a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_019ef965-bfdf-765c-a206-03fde4d4352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-bfdf-702a-8ba2-ca38947d039e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-bfdf-702a-8ba2-ca38947d039e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7155-b975-670bf5d30d8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_019ef965-bfdf-7155-b975-670bf5d30d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-771d-9d8e-db4c4ea4b9b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_CurrentLiabilities_019ef965-bfdf-771d-9d8e-db4c4ea4b9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_019ef965-bfdf-7af6-9fa6-79a02969d6d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_019ef965-bfdf-740f-8106-1eda5fb8e842" xlink:to="loc_ifrs-full_EquityAndLiabilities_019ef965-bfdf-7af6-9fa6-79a02969d6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedincomestatements"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-bfdf-705d-904d-6e0782f34f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-bfdf-705d-904d-6e0782f34f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019ef965-bfdf-7a8c-b307-22c5960c49aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_OtherRevenue_019ef965-bfdf-7a8c-b307-22c5960c49aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_019ef965-bfdf-7512-8c1c-60430418c144" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_CostOfSales_019ef965-bfdf-7512-8c1c-60430418c144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_019ef965-bfdf-7738-91af-e238e73a6d2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_GrossProfit_019ef965-bfdf-7738-91af-e238e73a6d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-bfdf-7fd1-a225-668da04a75c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-bfdf-7fd1-a225-668da04a75c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-bfdf-790a-9fe0-deea2fe0777c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-bfdf-790a-9fe0-deea2fe0777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019ef965-bfdf-7f6e-8ce9-aadb9b6c2372" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019ef965-bfdf-7f6e-8ce9-aadb9b6c2372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-bfdf-7184-8869-e6a1e7aad46a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-bfdf-7184-8869-e6a1e7aad46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-727b-a149-23baeac11101" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-727b-a149-23baeac11101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7bc3-b525-e6a026e3657c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019ef965-bfdf-7bc3-b525-e6a026e3657c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-bfdf-74c7-a38a-9920a1fe0d0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-bfdf-74c7-a38a-9920a1fe0d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-bfdf-75c5-aae5-24ccb37ede10" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-bfdf-75c5-aae5-24ccb37ede10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_019ef965-bfdf-7113-9811-51874f9feccc" xlink:href="sny-20260630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_sny_OtherGainsLossesAndLitigation_019ef965-bfdf-7113-9811-51874f9feccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-7834-bb23-47fa807904b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-bfdf-7834-bb23-47fa807904b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019ef965-bfdf-74eb-bdb8-ebf6a6c4024d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_FinanceCosts_019ef965-bfdf-74eb-bdb8-ebf6a6c4024d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019ef965-bfdf-7b17-8c64-43f6d55c2bd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_FinanceIncome_019ef965-bfdf-7b17-8c64-43f6d55c2bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-71aa-9e40-40cede6890a9" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-bfdf-71aa-9e40-40cede6890a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-bfdf-763f-935d-982deff814f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-bfdf-763f-935d-982deff814f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019ef965-bfdf-7e89-a102-dc41ba60427c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019ef965-bfdf-7e89-a102-dc41ba60427c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_019ef965-bfdf-7688-a2c1-5a2d0c4bf740" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperations_019ef965-bfdf-7688-a2c1-5a2d0c4bf740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019ef965-bfdf-713a-a37a-7ef3bb7036a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019ef965-bfdf-713a-a37a-7ef3bb7036a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7c42-ae23-e43338aeffb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7c42-ae23-e43338aeffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfdf-70c0-9da1-529c0398983c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7c42-ae23-e43338aeffb0" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfdf-70c0-9da1-529c0398983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-bfdf-7a3e-a975-cd420028943d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7c42-ae23-e43338aeffb0" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-bfdf-7a3e-a975-cd420028943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_019ef965-bfdf-7327-b921-dc6294dde5c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_019ef965-bfdf-7327-b921-dc6294dde5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_019ef965-bfdf-7a54-b031-36d01e692db1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_019ef965-bfdf-7a54-b031-36d01e692db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_019ef965-bfdf-70c6-8c17-61152e2b54db" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_019ef965-bfdf-70c6-8c17-61152e2b54db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_019ef965-bfdf-7a71-aede-100653fe82a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_019ef965-bfdf-7a71-aede-100653fe82a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_019ef965-bfdf-7a6c-b42d-d88b7348c249" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_019ef965-bfdf-7a6c-b42d-d88b7348c249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_019ef965-bfdf-7643-90c9-a2a441b93c68" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_019ef965-bfdf-780d-a5ed-d997f5f33c46" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_019ef965-bfdf-7643-90c9-a2a441b93c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofcomprehensiveincome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7726-a2bb-ebc9ce075325" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:to="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7726-a2bb-ebc9ce075325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-bfdf-7327-8b57-d6e4d873b240" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019ef965-bfdf-7327-8b57-d6e4d873b240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfdf-7967-b0f8-13893e82cc50" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfdf-7967-b0f8-13893e82cc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_019ef965-bfdf-7012-834b-71f541ef87bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_019ef965-bfdf-7012-834b-71f541ef87bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_019ef965-bfdf-7663-8294-1a24bbcf7254" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_019ef965-bfdf-7663-8294-1a24bbcf7254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_019ef965-bfdf-7014-b5fc-ce5cbd2a49e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_019ef965-bfdf-7014-b5fc-ce5cbd2a49e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7820-892d-c111cb303f89" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7820-892d-c111cb303f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_019ef965-bfdf-705d-acb8-71da276fc684" xlink:href="sny-20260630.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_019ef965-bfdf-705d-acb8-71da276fc684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-bfdf-7c61-9236-d6777add2521" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-bfdf-7c61-9236-d6777add2521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_019ef965-bfdf-79b0-8984-b216ece707ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_019ef965-bfdf-79b0-8984-b216ece707ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_019ef965-bfdf-7d23-803b-d035718eb98f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_019ef965-bfdf-7d23-803b-d035718eb98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7801-bad0-345c1ad9289e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-bfdf-7801-bad0-345c1ad9289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-bfdf-78f3-b1d1-a079386e6f1d" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeFromContinuedOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_sny_OtherComprehensiveIncomeFromContinuedOperations_019ef965-bfdf-78f3-b1d1-a079386e6f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_019ef965-bfdf-7309-83f7-3d6b8eb95e23" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeFromDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_019ef965-bfdf-74ce-81ab-9ad25985694d" xlink:to="loc_sny_OtherComprehensiveIncomeFromDiscontinuedOperations_019ef965-bfdf-7309-83f7-3d6b8eb95e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-7576-bf46-a2e0d1ba7753" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:to="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-7576-bf46-a2e0d1ba7753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-7729-99f5-7c9b1e020684" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-7729-99f5-7c9b1e020684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_019f8900-3330-7f9d-ab94-77d2104ad224" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-7729-99f5-7c9b1e020684" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_019f8900-3330-7f9d-ab94-77d2104ad224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_019f7f50-1b0f-7b98-9e62-14a78816f533" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_019ef965-bfdf-7729-99f5-7c9b1e020684" xlink:to="loc_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_019f7f50-1b0f-7b98-9e62-14a78816f533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_019ef965-bfdf-7362-ba88-4309e74e0dc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_019ef965-bfdf-71b4-930e-498c222f4e20" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_019ef965-bfdf-7362-ba88-4309e74e0dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofchangesinequity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_019ef965-bfdf-7508-8599-bb099f574d57" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_019ef965-bfdf-78be-9d87-04119ea6bd7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_019ef965-bfdf-7508-8599-bb099f574d57" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_019ef965-bfdf-78be-9d87-04119ea6bd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-bfdf-742f-9516-94e4fd46adf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_019ef965-bfdf-78be-9d87-04119ea6bd7f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-bfdf-742f-9516-94e4fd46adf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-bfdf-742f-9516-94e4fd46adf4" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019ef965-bfdf-7889-92ff-06c6e3f1dfe4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_IssuedCapitalMember_019ef965-bfdf-7889-92ff-06c6e3f1dfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_019ef965-bfdf-76fb-a6ff-e7dba7e7024b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_019ef965-bfdf-76fb-a6ff-e7dba7e7024b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_019ef965-bfdf-7d3c-961d-fc5d361d0dbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_TreasurySharesMember_019ef965-bfdf-7d3c-961d-fc5d361d0dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_019ef965-bfdf-7edb-a179-6add43756ddb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_RetainedEarningsMember_019ef965-bfdf-7edb-a179-6add43756ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019ef965-bfdf-724d-a3b6-2c1582822570" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_019ef965-bfdf-724d-a3b6-2c1582822570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-bfdf-7e55-b617-57d99c68b1af" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_019ef965-bfdf-7af4-ba06-24b3e318863d" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-bfdf-7e55-b617-57d99c68b1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_019ef965-bfdf-7743-a5b9-e8ecf322978a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-bfdf-7b96-bfd6-d4d31549635f" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_019ef965-bfdf-7743-a5b9-e8ecf322978a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_019ef965-bfdf-78be-9d87-04119ea6bd7f" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019ef965-bfdf-7f14-9c34-6dd8ec13a533" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_Equity_019ef965-bfdf-7f14-9c34-6dd8ec13a533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_019ef965-bfdf-7f6d-a114-4dc21a64d99e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_019ef965-bfdf-7f6d-a114-4dc21a64d99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7f4d-ba24-aeb52048a6fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_ProfitLoss_019ef965-bfdf-7f4d-ba24-aeb52048a6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-7773-9c62-8eefe2f7bd8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_ComprehensiveIncome_019ef965-bfdf-7773-9c62-8eefe2f7bd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_019ef965-bfdf-7745-8969-0dfa1e2b4137" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_019ef965-bfdf-7745-8969-0dfa1e2b4137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_019ef965-bfe0-77cf-801f-1624ff8c52f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_019ef965-bfe0-77cf-801f-1624ff8c52f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_019ef965-bfe0-7b38-aec1-8cb308cbc60f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_019ef965-bfe0-7b38-aec1-8cb308cbc60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_019ef965-bfe0-7df0-ae0c-b374bcba5cac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_019ef965-bfe0-7df0-ae0c-b374bcba5cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxesOnShareCancellations_019f182d-bdba-73a0-b7a2-81c924ef954d" xlink:href="sny-20260630.xsd#sny_TaxesOnShareCancellations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_TaxesOnShareCancellations_019f182d-bdba-73a0-b7a2-81c924ef954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:href="sny-20260630.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019ef965-bfe0-7ba6-855e-a109422929e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_019ef965-bfe0-7ba6-855e-a109422929e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_019ef965-bfe0-76f0-811a-032b4808af0c" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_019ef965-bfe0-76f0-811a-032b4808af0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_019ef965-bfe0-7f66-a2ab-baa71c777960" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_019ef965-bfe0-7f66-a2ab-baa71c777960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_019ef965-bfe0-7e16-87ae-8055e12cfee9" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_019ef965-bfe0-7e16-87ae-8055e12cfee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_019f1821-0a4d-746f-9bb2-64ed89c1c453" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_019ef965-bfe0-7978-8b3b-41e8e32a376a" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_019f1821-0a4d-746f-9bb2-64ed89c1c453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_019ef965-bfe0-7be5-80c3-a3b7db244c81" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_019ef965-bfe0-7be5-80c3-a3b7db244c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions_019f1829-85a4-712b-9265-74174e2231e9" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions_019f1829-85a4-712b-9265-74174e2231e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_019ef965-bfe0-7cd5-bdf6-2ae83aab90b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_Equity_019ef965-bfe0-7cd5-bdf6-2ae83aab90b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_019ef965-bfe0-77fd-9ca0-17de12eef5d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_019ef965-bfdf-7ee7-ae42-f595c3bebcaf" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_019ef965-bfe0-77fd-9ca0-17de12eef5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedstatementsofcashflows"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_019ef965-bfe0-70e1-bd7e-d38d78fc994d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_019ef965-bfe0-70e1-bd7e-d38d78fc994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_019ef965-bfe0-7b7f-989a-806c36f25c04" xlink:href="sny-20260630.xsd#sny_AdjustmentsForLossesGainsOnTransferOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_sny_AdjustmentsForLossesGainsOnTransferOfBusiness_019ef965-bfe0-7b7f-989a-806c36f25c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfe0-7ef7-b602-09ac18ff6dfa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-bfe0-7ef7-b602-09ac18ff6dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_019ef965-bfe0-732e-82e3-553521c25060" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_019ef965-bfe0-732e-82e3-553521c25060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_019ef965-bfe0-7033-8659-500bf2c6b158" xlink:href="sny-20260630.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_019ef965-bfe0-7033-8659-500bf2c6b158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_019ef965-bfe0-75de-ba9d-98802c29ad17" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_019ef965-bfe0-75de-ba9d-98802c29ad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_019ef965-bfe0-7cb6-81e3-61d761694679" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_019ef965-bfe0-7cb6-81e3-61d761694679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfe0-7f65-963d-fd56d5d3bf63" xlink:href="sny-20260630.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-bfe0-7f65-963d-fd56d5d3bf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_019ef965-bfe0-79a8-b591-187a7294efe4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_019ef965-bfe0-79a8-b591-187a7294efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_019ef965-bfe0-7f53-9d0f-2eb3b8c17fd4" xlink:href="sny-20260630.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_019ef965-bfe0-7f53-9d0f-2eb3b8c17fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019ef965-bfe0-7781-b6ff-4cb7fcc6ea82" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_019ef965-bfe0-7781-b6ff-4cb7fcc6ea82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7662-a166-ca6d1dfe28fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_019ef965-bfe0-7662-a166-ca6d1dfe28fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019ef965-bfe0-7801-994b-444471c4d7d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_019ef965-bfe0-7801-994b-444471c4d7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019ef965-bfe0-71d0-b84a-d59f8e880fd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_019ef965-bfe0-71d0-b84a-d59f8e880fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_019ef965-bfe0-7d47-9a91-9d7cb3d3d0f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_019ef965-bfe0-7d47-9a91-9d7cb3d3d0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_019ef965-bfe0-7378-bde1-7509152ff4f0" xlink:href="sny-20260630.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_019ef965-bfe0-7378-bde1-7509152ff4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-7bdf-b730-cd733d1df9be" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_019ef965-bfe0-7bdf-b730-cd733d1df9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_019ef965-bfe0-7a55-92a1-089affdb223a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_019ef965-bfe0-7a55-92a1-089affdb223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-bfe0-70d2-818b-f07ab002f2ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_019ef965-bfe0-7088-98eb-0f0dc8f130e8" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_019ef965-bfe0-70d2-818b-f07ab002f2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019ef965-bfe0-74da-9306-6cbf7564b57a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019ef965-bfe0-74da-9306-6cbf7564b57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019ef965-bfe0-7ee1-a0c3-70222324de6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019ef965-bfe0-7ee1-a0c3-70222324de6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_019ef965-bfe0-73f5-8620-699a2931bff1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_019ef965-bfe0-73f5-8620-699a2931bff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019ef965-bfe0-706c-b3b2-f8a85243b6fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_019ef965-bfe0-706c-b3b2-f8a85243b6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019ef965-bfe0-76ee-9ffc-3d47eeadb462" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019ef965-bfe0-76ee-9ffc-3d47eeadb462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_019ef965-bfe0-7aab-bb1d-81cf874e4357" xlink:href="sny-20260630.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_019ef965-bfe0-7aab-bb1d-81cf874e4357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019ef965-bfe0-7246-88b3-0db75c5c33ac" xlink:href="sny-20260630.xsd#sny_NetCashProvidedByusedInContinuingInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_sny_NetCashProvidedByusedInContinuingInvestingActivities_019ef965-bfe0-7246-88b3-0db75c5c33ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_019ef965-bfe0-7199-aaef-ee85f01a1775" xlink:href="sny-20260630.xsd#sny_NetCashProvidedByusedInDiscontinuingInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities_019ef965-bfe0-7199-aaef-ee85f01a1775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetCashInflowFromDiscontinuedOperations_019ef965-bfe0-78b8-86d0-81665a21853b" xlink:href="sny-20260630.xsd#sny_NetCashInflowFromDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_sny_NetCashInflowFromDiscontinuedOperations_019ef965-bfe0-78b8-86d0-81665a21853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-7708-9199-dc757eafd0e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_019ef965-bfe0-7708-abfc-6902dbedfbd5" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_019ef965-bfe0-7708-9199-dc757eafd0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_019ef965-bfe0-798d-89aa-207c23bb8fd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_019ef965-bfe0-798d-89aa-207c23bb8fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract_019ef965-bfe0-75db-bff0-f886cd3f8598" xlink:href="sny-20260630.xsd#sny_DividendsPaidAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_sny_DividendsPaidAbstract_019ef965-bfe0-75db-bff0-f886cd3f8598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_019ef965-bfe0-7671-842b-e470fab96375" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_019ef965-bfe0-75db-bff0-f886cd3f8598" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_019ef965-bfe0-7671-842b-e470fab96375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_019ef965-bfe0-771a-88ea-0ef5e8a36c78" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_019ef965-bfe0-75db-bff0-f886cd3f8598" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_019ef965-bfe0-771a-88ea-0ef5e8a36c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_019ef965-bfe0-7f40-984a-fb3da83c2373" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_019ef965-bfe0-7f40-984a-fb3da83c2373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_019ef965-bfe0-7b81-b1ba-24073e964776" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_019ef965-bfe0-7b81-b1ba-24073e964776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019ef965-bfe0-7530-8a4c-220101f75710" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_019ef965-bfe0-7530-8a4c-220101f75710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019ef965-bfe0-706b-a21f-9aa0ddb54d52" xlink:href="sny-20260630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019ef965-bfe0-706b-a21f-9aa0ddb54d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019ef965-bfe0-7ee9-813a-17f01b6d9bd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019ef965-bfe0-7ee9-813a-17f01b6d9bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-76ad-adca-6b1c2f148b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_019ef965-bfe0-76ad-adca-6b1c2f148b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_019ef965-bfe0-7d43-bfed-2d04fd89e8f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_019ef965-bfe0-7d43-bfed-2d04fd89e8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-bfe0-7c12-9fb1-93d84b37f71c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_019ef965-bfe0-7844-ab39-0425faf40d86" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_019ef965-bfe0-7c12-9fb1-93d84b37f71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019ef965-bfe0-7d7d-a879-e8bb8f2f0dfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_019ef965-bfe0-7d7d-a879-e8bb8f2f0dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_019ef965-bfe0-78ae-8c52-32867fee5ef3" xlink:href="sny-20260630.xsd#sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale_019ef965-bfe0-78ae-8c52-32867fee5ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-7073-8269-e99560da4cd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_019ef965-bfe0-7073-8269-e99560da4cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_019f934b-f23a-72d0-b0d7-96b99fed7b3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_019f934b-f23a-72d0-b0d7-96b99fed7b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_019f934c-2350-79ee-ba17-811fe06b39a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7a87-9472-771796e01cb7" xlink:to="loc_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_019f934c-2350-79ee-ba17-811fe06b39a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedstatementsofcashflowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7840-9ebb-f725892a66d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_019ef965-bfe0-7840-9ebb-f725892a66d9" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-bfe0-79f2-9f7c-e9b8380884fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-bfe0-79f2-9f7c-e9b8380884fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-7746-bee6-6b08c7e78d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-bfe0-79f2-9f7c-e9b8380884fb" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-7746-bee6-6b08c7e78d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f6a38-f95c-7fbb-b32a-5a9a911e7c08" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-bfe0-7746-bee6-6b08c7e78d5a" xlink:to="loc_sny_OpellaBusinessMember_019f6a38-f95c-7fbb-b32a-5a9a911e7c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019f1851-cb57-7f55-b029-087b0eeb191b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019f1851-cb57-7f55-b029-087b0eeb191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7ca8-ab6b-7eed6e7d56ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019f1851-cb57-7f55-b029-087b0eeb191b" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7ca8-ab6b-7eed6e7d56ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_019f1851-eea4-7596-b269-b4bf6fdbb7fb" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019f1851-cb57-7ca8-ab6b-7eed6e7d56ab" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_019f1851-eea4-7596-b269-b4bf6fdbb7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f8a39-0919-7536-bdc2-752e2183ba71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f8a39-0919-7536-bdc2-752e2183ba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7538-bc0b-d4f80d6959ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f8a39-0919-7536-bdc2-752e2183ba71" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7538-bc0b-d4f80d6959ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f8a39-710f-7a4e-95f5-b9c18e30392d" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f8a39-0919-7538-bc0b-d4f80d6959ea" xlink:to="loc_sny_DynavaxMember_019f8a39-710f-7a4e-95f5-b9c18e30392d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-bfe0-72b3-ac55-6398d685d8aa" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense_019f184e-4e54-719d-b7dc-f25daf9616ea" xlink:href="sny-20260630.xsd#sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense_019f184e-4e54-719d-b7dc-f25daf9616ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019ef965-bfe0-729c-b987-c28638ce88ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_019ef965-bfe0-729c-b987-c28638ce88ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_019ef965-bfe0-7851-9904-2c325da3ffb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_019ef965-bfe0-7851-9904-2c325da3ffb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_019ef965-bfe0-776a-b5ff-4196f14fff71" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_019ef965-bfe0-776a-b5ff-4196f14fff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_019ef965-bfe0-7546-87e4-f5519bec3226" xlink:href="sny-20260630.xsd#sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities_019ef965-bfe0-7546-87e4-f5519bec3226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfe0-7851-b690-bfa79134be37" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-bfe0-7851-b690-bfa79134be37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019f1851-814a-7e83-9d4a-8714928756d4" xlink:href="sny-20260630.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-bfe0-7271-9301-1600c3cd5f15" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_019f1851-814a-7e83-9d4a-8714928756d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Introduction" xlink:type="simple" xlink:href="sny-20260630.xsd#Introduction"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Introduction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_019ef965-bfe0-7894-929e-e3a7c2a420bf" xlink:href="sny-20260630.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_019ef965-bfe0-7a79-9ae4-13995727dbaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_019ef965-bfe0-7894-929e-e3a7c2a420bf" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_019ef965-bfe0-7a79-9ae4-13995727dbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies" xlink:type="simple" xlink:href="sny-20260630.xsd#Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-71be-892c-a32e132d3919" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_019ef965-bfe0-73ce-bcd1-0990d4ba3259" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-71be-892c-a32e132d3919" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_019ef965-bfe0-73ce-bcd1-0990d4ba3259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026" xlink:type="simple" xlink:href="sny-20260630.xsd#Significantinformationforthefirsthalfof2026"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22ee-aa3c-74d5-a7ac-47da2f2c2dbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_019f22ee-aa3c-7c60-b05d-415376d52f75" xlink:href="sny-20260630.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22ee-aa3c-74d5-a7ac-47da2f2c2dbe" xlink:to="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_019f22ee-aa3c-7c60-b05d-415376d52f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="sny-20260630.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-7df1-8fd8-08250eed2827" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_019ef965-c0a1-7eab-afec-09556f0a17d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-7df1-8fd8-08250eed2827" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_019ef965-c0a1-7eab-afec-09556f0a17d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Goodwillandotherintangibleassets" xlink:type="simple" xlink:href="sny-20260630.xsd#Goodwillandotherintangibleassets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Goodwillandotherintangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7c0e-9f87-b991e1d37bd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_019ef965-c0a1-7df8-b63b-dc59366f4e69" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7c0e-9f87-b991e1d37bd4" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_019ef965-c0a1-7df8-b63b-dc59366f4e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Impairmentofintangibleassets" xlink:type="simple" xlink:href="sny-20260630.xsd#Impairmentofintangibleassets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Impairmentofintangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_019ef965-c0a1-7633-a8fd-7aa9a65e7734" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_019ef965-c0a1-7c7d-9586-051f2d10f4ff" xlink:href="sny-20260630.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_019ef965-c0a1-7633-a8fd-7aa9a65e7734" xlink:to="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_019ef965-c0a1-7c7d-9586-051f2d10f4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod" xlink:type="simple" xlink:href="sny-20260630.xsd#Investmentsaccountedforusingtheequitymethod"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7e43-a8cf-2a8582649ce7" xlink:href="sny-20260630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_019ef965-c0a1-7bf0-8176-407a06939e65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7e43-a8cf-2a8582649ce7" xlink:to="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_019ef965-c0a1-7bf0-8176-407a06939e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Othernoncurrentassets" xlink:type="simple" xlink:href="sny-20260630.xsd#Othernoncurrentassets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Othernoncurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-71f1-b29e-edc55526d75d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_019ef965-c0a1-71f7-a99a-c1cf5e36d38d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-71f1-b29e-edc55526d75d" xlink:to="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_019ef965-c0a1-71f7-a99a-c1cf5e36d38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Accountsreceivable" xlink:type="simple" xlink:href="sny-20260630.xsd#Accountsreceivable"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Accountsreceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-747f-8ef4-829c5e45fdc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock_019ef965-c0a1-7280-8e1a-6ef7e6a54ae3" xlink:href="sny-20260630.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-747f-8ef4-829c5e45fdc5" xlink:to="loc_sny_DisclosureOfTradeReceivablesTextBlock_019ef965-c0a1-7280-8e1a-6ef7e6a54ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedshareholdersequity" xlink:type="simple" xlink:href="sny-20260630.xsd#Consolidatedshareholdersequity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedshareholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-79f2-b62b-795b2d35427b" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_019ef965-c0a1-7061-89ca-88b471b266b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-79f2-b62b-795b2d35427b" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_019ef965-c0a1-7061-89ca-88b471b266b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Debtcashandcashequivalents" xlink:type="simple" xlink:href="sny-20260630.xsd#Debtcashandcashequivalents"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Debtcashandcashequivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7525-80da-c078828de026" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_019ef965-c0a1-7515-9b38-072e093a0716" xlink:href="sny-20260630.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7525-80da-c078828de026" xlink:to="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_019ef965-c0a1-7515-9b38-072e093a0716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Derivativefinancialinstruments" xlink:type="simple" xlink:href="sny-20260630.xsd#Derivativefinancialinstruments"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Derivativefinancialinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-7771-b803-755b8ea9d575" xlink:href="sny-20260630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_019ef965-c0a1-7762-989b-0b8a6b77308e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-7771-b803-755b8ea9d575" xlink:to="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_019ef965-c0a1-7762-989b-0b8a6b77308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests" xlink:type="simple" xlink:href="sny-20260630.xsd#Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-76f2-9ef9-bc50037a2498" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_019f1e07-d076-7332-85a0-2a8c862845b0" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-76f2-9ef9-bc50037a2498" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock_019f1e07-d076-7332-85a0-2a8c862845b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Noncurrentprovisionsandothernoncurrentliabilities" xlink:type="simple" xlink:href="sny-20260630.xsd#Noncurrentprovisionsandothernoncurrentliabilities"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Noncurrentprovisionsandothernoncurrentliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7f8e-bcec-ade7ef4ba971" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_019ef965-c0a1-7679-af1c-2031d4353e43" xlink:href="sny-20260630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7f8e-bcec-ade7ef4ba971" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock_019ef965-c0a1-7679-af1c-2031d4353e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Offbalancesheetcommitments" xlink:type="simple" xlink:href="sny-20260630.xsd#Offbalancesheetcommitments"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Offbalancesheetcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract_019ef965-c0a1-7720-aef1-6562a1d6abc5" xlink:href="sny-20260630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_019ef965-c0a1-7b6d-8bc9-1da9bb1f8cad" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract_019ef965-c0a1-7720-aef1-6562a1d6abc5" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_019ef965-c0a1-7b6d-8bc9-1da9bb1f8cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Litigationandarbitrationproceedings" xlink:type="simple" xlink:href="sny-20260630.xsd#Litigationandarbitrationproceedings"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Litigationandarbitrationproceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_019ef965-c0a1-7c65-b5b7-8bfed180599e" xlink:href="sny-20260630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_019ef965-c0a1-7e04-b47c-45277c8a14f1" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_019ef965-c0a1-7c65-b5b7-8bfed180599e" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_019ef965-c0a1-7e04-b47c-45277c8a14f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Otheroperatingincomeandexpenses" xlink:type="simple" xlink:href="sny-20260630.xsd#Otheroperatingincomeandexpenses"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Otheroperatingincomeandexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7d60-a56a-0fddb62bab7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_019ef965-c0a1-7b74-a6b3-c66d65f2404d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7d60-a56a-0fddb62bab7b" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_019ef965-c0a1-7b74-a6b3-c66d65f2404d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Restructuringcostsandsimilaritems" xlink:type="simple" xlink:href="sny-20260630.xsd#Restructuringcostsandsimilaritems"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Restructuringcostsandsimilaritems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-73e6-bf3c-59216e7d7dd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_019f1e36-2fa1-77bd-894f-e59dd5464491" xlink:href="sny-20260630.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-73e6-bf3c-59216e7d7dd4" xlink:to="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_019f1e36-2fa1-77bd-894f-e59dd5464491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Othergainsandlossesandlitigation" xlink:type="simple" xlink:href="sny-20260630.xsd#Othergainsandlossesandlitigation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Othergainsandlossesandlitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7173-bc45-99d4963620dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_019ef965-c168-76de-9ecf-651910b21140" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7173-bc45-99d4963620dc" xlink:to="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_019ef965-c168-76de-9ecf-651910b21140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Financialexpensesandincome" xlink:type="simple" xlink:href="sny-20260630.xsd#Financialexpensesandincome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Financialexpensesandincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7c42-b242-b30a224b9d4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_019ef965-c168-7698-acce-2c9c76b11447" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7c42-b242-b30a224b9d4d" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_019ef965-c168-7698-acce-2c9c76b11447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Incometaxexpense" xlink:type="simple" xlink:href="sny-20260630.xsd#Incometaxexpense"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Incometaxexpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-79a0-a9d0-4e72f7e32863" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_019ef965-c168-7745-a2da-00115bb2cb0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-79a0-a9d0-4e72f7e32863" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_019ef965-c168-7745-a2da-00115bb2cb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Revenuefromcontractswithcustomers" xlink:type="simple" xlink:href="sny-20260630.xsd#Revenuefromcontractswithcustomers"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Revenuefromcontractswithcustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_019ef965-c168-7e82-90bf-79b502513ef5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_019ef965-c168-7510-903e-e4a84f15423b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019ef965-c168-7e82-90bf-79b502513ef5" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_019ef965-c168-7510-903e-e4a84f15423b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Segmentinformation" xlink:type="simple" xlink:href="sny-20260630.xsd#Segmentinformation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Segmentinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7bad-9a43-f15156299b35" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_019ef965-c168-79b5-8c52-d2bd34ae6a6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7bad-9a43-f15156299b35" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_019ef965-c168-79b5-8c52-d2bd34ae6a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperations" xlink:type="simple" xlink:href="sny-20260630.xsd#InformationrelatedtoOpellapresentedwithindiscontinuedoperations"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DiscontinuedOperationsAbstract_019ef965-c168-74a1-96f1-22810d599a4d" xlink:href="sny-20260630.xsd#sny_DiscontinuedOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_019ef965-c168-74c3-b5fc-ccacb74b39e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DiscontinuedOperationsAbstract_019ef965-c168-74a1-96f1-22810d599a4d" xlink:to="loc_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_019ef965-c168-74c3-b5fc-ccacb74b39e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies" xlink:type="simple" xlink:href="sny-20260630.xsd#BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7240-b9e5-c072b7dbdfd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_019ef965-bfe0-7247-bb66-a56b3ea6cb62" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7240-b9e5-c072b7dbdfd8" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_019ef965-bfe0-7247-bb66-a56b3ea6cb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_019ef965-bfe0-7c8c-8877-066779b5bd0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7240-b9e5-c072b7dbdfd8" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_019ef965-bfe0-7c8c-8877-066779b5bd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_019ef965-bfe0-7f38-bfe5-02f97ab61bf2" xlink:href="sny-20260630.xsd#sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7240-b9e5-c072b7dbdfd8" xlink:to="loc_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock_019ef965-bfe0-7f38-bfe5-02f97ab61bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_019ef965-bfe0-7372-aa8a-f34d8ea0ea95" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7240-b9e5-c072b7dbdfd8" xlink:to="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_019ef965-bfe0-7372-aa8a-f34d8ea0ea95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_019ef965-bfe0-74fb-a65e-bfe8a2003675" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7240-b9e5-c072b7dbdfd8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_019ef965-bfe0-74fb-a65e-bfe8a2003675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_019ef965-bfe0-71c2-a821-992f33bca0fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7240-b9e5-c072b7dbdfd8" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_019ef965-bfe0-71c2-a821-992f33bca0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables" xlink:type="simple" xlink:href="sny-20260630.xsd#BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7cfd-92ce-90044600cd25" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_019ef965-bfe0-7fea-8dfb-7d3f6fa9132a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7cfd-92ce-90044600cd25" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_019ef965-bfe0-7fea-8dfb-7d3f6fa9132a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026Tables" xlink:type="simple" xlink:href="sny-20260630.xsd#Significantinformationforthefirsthalfof2026Tables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22ee-aa3c-78ab-94b9-921c45565121" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_019f22ee-aa3c-779b-9eb9-0dfb8b45339e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22ee-aa3c-78ab-94b9-921c45565121" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_019f22ee-aa3c-779b-9eb9-0dfb8b45339e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="sny-20260630.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-72ef-8a90-0bbd8dbbe833" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_019ef965-c0a1-73d6-9b0d-bc23507712d3" xlink:href="sny-20260630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-72ef-8a90-0bbd8dbbe833" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_019ef965-c0a1-73d6-9b0d-bc23507712d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="sny-20260630.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7113-a4a6-abbb1fdb7a48" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_019ef965-c0a1-719c-8896-47e1569bb7c6" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7113-a4a6-abbb1fdb7a48" xlink:to="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_019ef965-c0a1-719c-8896-47e1569bb7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7dd8-b37c-46341f04df2f" xlink:href="sny-20260630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_019ef965-c0a1-7e07-b2db-0fde42915b0d" xlink:href="sny-20260630.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7dd8-b37c-46341f04df2f" xlink:to="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_019ef965-c0a1-7e07-b2db-0fde42915b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_019ef965-c0a1-7ff6-9ac1-a768cd627b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7dd8-b37c-46341f04df2f" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_019ef965-c0a1-7ff6-9ac1-a768cd627b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock_019f1d25-451d-7c31-be4a-8a9f22417e1f" xlink:href="sny-20260630.xsd#sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7dd8-b37c-46341f04df2f" xlink:to="loc_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock_019f1d25-451d-7c31-be4a-8a9f22417e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsTables" xlink:type="simple" xlink:href="sny-20260630.xsd#OthernoncurrentassetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7b13-a919-80c38691d8c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_019ef965-c0a1-72fe-89f0-7ce0c58ec694" xlink:href="sny-20260630.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7b13-a919-80c38691d8c1" xlink:to="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_019ef965-c0a1-72fe-89f0-7ce0c58ec694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableTables" xlink:type="simple" xlink:href="sny-20260630.xsd#AccountsreceivableTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-789a-829d-db7a95fbd7f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_019ef965-c0a1-7449-9eff-21281795ea2c" xlink:href="sny-20260630.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-789a-829d-db7a95fbd7f3" xlink:to="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_019ef965-c0a1-7449-9eff-21281795ea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_019ef965-c0a1-7287-8e93-c29acc684c70" xlink:href="sny-20260630.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-789a-829d-db7a95fbd7f3" xlink:to="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_019ef965-c0a1-7287-8e93-c29acc684c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityTables" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_019ef965-c0a1-7709-a282-5f8e14f9a8d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_019ef965-c0a1-7709-a282-5f8e14f9a8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_019ef965-c0a1-73d5-b9c5-dd9ebd55f0a8" xlink:href="sny-20260630.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:to="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_019ef965-c0a1-73d5-b9c5-dd9ebd55f0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_019ef965-c0a1-7da7-80a8-62a0b34a64e6" xlink:href="sny-20260630.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:to="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_019ef965-c0a1-7da7-80a8-62a0b34a64e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_019ef965-c0a1-76d7-9aae-dfbde1cea6cb" xlink:href="sny-20260630.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:to="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_019ef965-c0a1-76d7-9aae-dfbde1cea6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_019f1d52-2d6e-7640-a6df-d648d780cead" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_019f1d52-2d6e-7640-a6df-d648d780cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_019f7fbe-3f26-79a2-a65c-76790edba549" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_019f7fbe-3f26-79a2-a65c-76790edba549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_019ef965-c0a1-755d-9b57-2bc77a9cc428" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7ead-a7a2-89bb2998e02e" xlink:to="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_019ef965-c0a1-755d-9b57-2bc77a9cc428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsTables" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-74f6-bfe7-3ee33ae98794" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_019ef965-c0a1-712e-b057-e90828e4486e" xlink:href="sny-20260630.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-74f6-bfe7-3ee33ae98794" xlink:to="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_019ef965-c0a1-712e-b057-e90828e4486e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_019ef965-c0a1-7df3-8449-85132ef0ca3d" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-74f6-bfe7-3ee33ae98794" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_019ef965-c0a1-7df3-8449-85132ef0ca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_019ef965-c0a1-7678-83dc-8312f708996c" xlink:href="sny-20260630.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-74f6-bfe7-3ee33ae98794" xlink:to="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_019ef965-c0a1-7678-83dc-8312f708996c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_019ef965-c0a1-7739-9e38-96f3792ecdb4" xlink:href="sny-20260630.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-74f6-bfe7-3ee33ae98794" xlink:to="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_019ef965-c0a1-7739-9e38-96f3792ecdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsTables" xlink:type="simple" xlink:href="sny-20260630.xsd#DerivativefinancialinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-70b2-8c41-8867447816d6" xlink:href="sny-20260630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_019ef965-c0a1-73c3-b016-cad10aa38f6f" xlink:href="sny-20260630.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-70b2-8c41-8867447816d6" xlink:to="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_019ef965-c0a1-73c3-b016-cad10aa38f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_019ef965-c0a1-701b-bcee-163b217bc2dd" xlink:href="sny-20260630.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-70b2-8c41-8867447816d6" xlink:to="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_019ef965-c0a1-701b-bcee-163b217bc2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_019ef965-c0a1-7b1f-92f9-d492be346d20" xlink:href="sny-20260630.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-70b2-8c41-8867447816d6" xlink:to="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_019ef965-c0a1-7b1f-92f9-d492be346d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables" xlink:type="simple" xlink:href="sny-20260630.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-7595-9032-4583a09d83f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_019ef965-c0a1-7224-a7ce-774d35560d7b" xlink:href="sny-20260630.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-7595-9032-4583a09d83f9" xlink:to="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock_019ef965-c0a1-7224-a7ce-774d35560d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7061-99ae-0ef16f8fd4a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_019ef965-c0a1-7047-b230-277791a9f540" xlink:href="sny-20260630.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7061-99ae-0ef16f8fd4a5" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_019ef965-c0a1-7047-b230-277791a9f540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_019ef965-c0a1-71da-a45a-d24b146abf37" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7061-99ae-0ef16f8fd4a5" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_019ef965-c0a1-71da-a45a-d24b146abf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_019ef965-c0a1-7b99-a814-c590837acb8c" xlink:href="sny-20260630.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7061-99ae-0ef16f8fd4a5" xlink:to="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock_019ef965-c0a1-7b99-a814-c590837acb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesTables" xlink:type="simple" xlink:href="sny-20260630.xsd#OtheroperatingincomeandexpensesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtheroperatingincomeandexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7705-a1ac-1ad0926e016b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock_019ef965-c0a1-7c5b-8787-ae3b812405ee" xlink:href="sny-20260630.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7705-a1ac-1ad0926e016b" xlink:to="loc_sny_OtherOperatingExpensesTableTextBlock_019ef965-c0a1-7c5b-8787-ae3b812405ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables" xlink:type="simple" xlink:href="sny-20260630.xsd#RestructuringcostsandsimilaritemsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7215-9481-1b4c8ea6f79d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_019ef965-c0a1-79cc-9a90-8fe6e8f21a54" xlink:href="sny-20260630.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7215-9481-1b4c8ea6f79d" xlink:to="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_019ef965-c0a1-79cc-9a90-8fe6e8f21a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeTables" xlink:type="simple" xlink:href="sny-20260630.xsd#FinancialexpensesandincomeTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7325-9da1-ac8d8b753866" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_019ef965-c168-7c7d-80a4-ba8d49bc75e9" xlink:href="sny-20260630.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7325-9da1-ac8d8b753866" xlink:to="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_019ef965-c168-7c7d-80a4-ba8d49bc75e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseTables" xlink:type="simple" xlink:href="sny-20260630.xsd#IncometaxexpenseTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7a4a-8d48-79630400f757" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_019ef965-c168-7317-bb6e-14778ec6850e" xlink:href="sny-20260630.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7a4a-8d48-79630400f757" xlink:to="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_019ef965-c168-7317-bb6e-14778ec6850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_019ef965-c168-7fac-9992-df4f4d5c04d1" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7a4a-8d48-79630400f757" xlink:to="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_019ef965-c168-7fac-9992-df4f4d5c04d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables" xlink:type="simple" xlink:href="sny-20260630.xsd#RevenuefromcontractswithcustomersTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_019ef965-c168-7933-91de-bdff12805259" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_019ef965-c168-7e3d-81ed-915c1445501f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019ef965-c168-7933-91de-bdff12805259" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_019ef965-c168-7e3d-81ed-915c1445501f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherRevenueTextBlock_019ef965-c168-7128-ac32-ca997bca8258" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherRevenueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019ef965-c168-7933-91de-bdff12805259" xlink:to="loc_sny_DisclosureOfOtherRevenueTextBlock_019ef965-c168-7128-ac32-ca997bca8258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationTables" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7099-b9d6-3ac613c672fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_019ef965-c168-75a3-a498-51231ce2dbb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7099-b9d6-3ac613c672fb" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_019ef965-c168-75a3-a498-51231ce2dbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_019ef965-c168-78ec-bf58-75aabcb5954e" xlink:href="sny-20260630.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7099-b9d6-3ac613c672fb" xlink:to="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_019ef965-c168-78ec-bf58-75aabcb5954e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_019ef965-c168-785f-9e71-bea9f0e544e0" xlink:href="sny-20260630.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7099-b9d6-3ac613c672fb" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_019ef965-c168-785f-9e71-bea9f0e544e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_019ef965-c168-7db5-ad35-a9842e986e4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7099-b9d6-3ac613c672fb" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_019ef965-c168-7db5-ad35-a9842e986e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables" xlink:type="simple" xlink:href="sny-20260630.xsd#InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DiscontinuedOperationsAbstract_019ef965-c168-7d75-aa39-61dc94da3a52" xlink:href="sny-20260630.xsd#sny_DiscontinuedOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_019f22c7-4f75-7d63-95a5-9cad78992920" xlink:href="sny-20260630.xsd#sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DiscontinuedOperationsAbstract_019ef965-c168-7d75-aa39-61dc94da3a52" xlink:to="loc_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock_019f22c7-4f75-7d63-95a5-9cad78992920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7e85-a3ab-a945721cfc6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-bfe0-70e8-a64a-5e4416991b65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_019ef965-bfe0-7e85-a3ab-a945721cfc6e" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-bfe0-70e8-a64a-5e4416991b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019ef965-bfe0-71c4-bb80-7c5ca79846f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-bfe0-70e8-a64a-5e4416991b65" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019ef965-bfe0-71c4-bb80-7c5ca79846f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-bfe0-71c4-bb80-7c5ca79846f4" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_019ef965-bfe0-7dc1-86d1-1a4dba7c5daf" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:to="loc_country_AR_019ef965-bfe0-7dc1-86d1-1a4dba7c5daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_019ef965-bfe0-70f8-bb86-fffd83e1ec33" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-bfe0-7e60-8d8a-e3c62b46a6ce" xlink:to="loc_country_TR_019ef965-bfe0-70f8-bb86-fffd83e1ec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_019ef965-bfe0-70e8-a64a-5e4416991b65" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_019ef965-bfe0-7a12-854f-9242c2dacc3a" xlink:href="sny-20260630.xsd#sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:to="loc_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears_019ef965-bfe0-7a12-854f-9242c2dacc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementClassificationIFRS18NumberOfCategories_019fa2e1-50de-7daa-89f1-b0ff18a088a0" xlink:href="sny-20260630.xsd#sny_IncomeStatementClassificationIFRS18NumberOfCategories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_019ef965-bfe0-732c-9983-bbeb51fce655" xlink:to="loc_sny_IncomeStatementClassificationIFRS18NumberOfCategories_019fa2e1-50de-7daa-89f1-b0ff18a088a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#Significantinformationforthefirsthalfof2026AdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22f3-0545-72b2-8ec5-449bd56faa27" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22f3-0545-72b2-8ec5-449bd56faa27" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f22f5-8d30-7a5a-a211-f654ef2dc1a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f22f5-8d30-7a5a-a211-f654ef2dc1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-76c4-90d4-13c30a4df40f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f22f5-8d30-7a5a-a211-f654ef2dc1a3" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-76c4-90d4-13c30a4df40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f22f5-8d30-7f9f-ad07-fb02b14a9978" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f22f5-8d30-76c4-90d4-13c30a4df40f" xlink:to="loc_sny_DynavaxMember_019f22f5-8d30-7f9f-ad07-fb02b14a9978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f8f32-368c-7bf5-a6f2-8f0932b7d260" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:to="loc_sny_DisposalGroupAxis_019f8f32-368c-7bf5-a6f2-8f0932b7d260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f8f32-368c-7125-8e1d-e44f5620a59b" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupAxis_019f8f32-368c-7bf5-a6f2-8f0932b7d260" xlink:to="loc_sny_DisposalGroupDomain_019f8f32-368c-7125-8e1d-e44f5620a59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedleyMember_019f22f6-0990-7291-af2b-b7ca10c90362" xlink:href="sny-20260630.xsd#sny_MedleyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupDomain_019f8f32-368c-7125-8e1d-e44f5620a59b" xlink:to="loc_sny_MedleyMember_019f22f6-0990-7291-af2b-b7ca10c90362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019f8f33-6621-7fb5-a511-e3dc3dd9f212" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:to="loc_ifrs-full_SegmentsAxis_019f8f33-6621-7fb5-a511-e3dc3dd9f212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7bb7-99e7-e41ed89303a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_019f8f33-6621-7fb5-a511-e3dc3dd9f212" xlink:to="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7bb7-99e7-e41ed89303a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019f8f33-8ce7-72be-b888-05c6622680f0" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019f8f33-6621-7bb7-99e7-e41ed89303a4" xlink:to="loc_sny_BiopharmaSegmentMember_019f8f33-8ce7-72be-b888-05c6622680f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f5-8d30-740a-abab-e5ef84c0e91f" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare_019f22f5-8d30-7906-9a2c-a6e5f0f9bc58" xlink:href="sny-20260630.xsd#sny_BusinessCombinationEquityInterestsOfAcquirerPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare_019f22f5-8d30-7906-9a2c-a6e5f0f9bc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEquityValueOfAcquirer_019f8bd1-f39c-7c09-bb1a-7f89b7705fa9" xlink:href="sny-20260630.xsd#sny_BusinessCombinationEquityValueOfAcquirer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_BusinessCombinationEquityValueOfAcquirer_019f8bd1-f39c-7c09-bb1a-7f89b7705fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f8f2c-b043-7280-9a5f-51190e54b49a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f8f2c-b043-7280-9a5f-51190e54b49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f5-8d30-73fd-b44c-54d9a9e8f82d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f5-8d30-73fd-b44c-54d9a9e8f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueOfAcquiree_019f8f33-05d2-7734-a315-365af77efce2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueOfAcquiree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_RevenueOfAcquiree_019f8f33-05d2-7734-a315-365af77efce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate_019f8f2e-40c7-792e-9114-be6d1859ff22" xlink:href="sny-20260630.xsd#sny_OperatingIncomeOfAcquireeSinceAcquisitionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate_019f8f2e-40c7-792e-9114-be6d1859ff22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossOfAcquiree_019f8f2f-1a38-72e3-96b3-3a1829f02c8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossOfAcquiree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_ProfitLossOfAcquiree_019f8f2f-1a38-72e3-96b3-3a1829f02c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate_019f8f2f-fd66-7e17-8de9-1453e4c99e43" xlink:href="sny-20260630.xsd#sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate_019f8f2f-fd66-7e17-8de9-1453e4c99e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7121-8b48-e21d6d2b07e8" xlink:href="sny-20260630.xsd#sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7121-8b48-e21d6d2b07e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7be8-b7d4-9fad9c9c2a56" xlink:href="sny-20260630.xsd#sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate_019f22f6-74b7-7be8-b7d4-9fad9c9c2a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f22f6-74b7-7455-9519-70b6f3c62761" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_019f22f6-74b7-7455-9519-70b6f3c62761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfOwnershipInterestDisposed_019f8f38-1342-7915-82fd-0f91fdaa64bf" xlink:href="sny-20260630.xsd#sny_PercentageOfOwnershipInterestDisposed"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f5-8d30-7065-926e-a9bcadbb6805" xlink:to="loc_sny_PercentageOfOwnershipInterestDisposed_019f8f38-1342-7915-82fd-0f91fdaa64bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22ee-aa3c-73e5-a853-e9d0dc021210" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f1-967c-7f53-88d6-0eed6a4f40e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_019f22ee-aa3c-73e5-a853-e9d0dc021210" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f1-967c-7f53-88d6-0eed6a4f40e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f22f1-967c-7160-96c0-b3273b051d1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f1-967c-7f53-88d6-0eed6a4f40e6" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f22f1-967c-7160-96c0-b3273b051d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7c14-8408-4f480e4aaf0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f22f1-967c-7160-96c0-b3273b051d1c" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7c14-8408-4f480e4aaf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f22f1-967c-7518-99e8-1721c80686ae" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f22f1-967c-7c14-8408-4f480e4aaf0b" xlink:to="loc_sny_DynavaxMember_019f22f1-967c-7518-99e8-1721c80686ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_019f22f1-967c-7f53-88d6-0eed6a4f40e6" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e3b-865b-bd2156476dba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e3b-865b-bd2156476dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_019f22f1-967c-7042-a524-144553c4d7fa" xlink:href="sny-20260630.xsd#sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate_019f22f1-967c-7042-a524-144553c4d7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e16-8471-bf9c5e0e32d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_019f22f1-967c-7e16-8471-bf9c5e0e32d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f804e-b583-7d51-9e54-7163433619c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_019f804e-b583-7d51-9e54-7163433619c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_019f22f1-967c-7c17-9173-852473636967" xlink:href="sny-20260630.xsd#sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_019f22f1-967c-7c17-9173-852473636967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f1-967c-721d-a194-ad87eb51cafc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_019f22f1-967c-721d-a194-ad87eb51cafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f1-967c-7ac9-a2db-033a5370d0fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_019f22f1-967c-7ac9-a2db-033a5370d0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_019f22f1-967c-7993-b330-f5c504c56135" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_019f22f1-967c-7db7-b88e-0f7c23e4cf9c" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_019f22f1-967c-7993-b330-f5c504c56135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-7683-bb89-a86110256a86" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-7683-bb89-a86110256a86" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c0a1-70fe-8471-b37766416b2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c0a1-70fe-8471-b37766416b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c0a1-70fe-8471-b37766416b2c" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c0a1-77b6-b70e-89ee5366f982" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c0a1-77b6-b70e-89ee5366f982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OPALJVCoMember_019f932d-0f61-745c-a1f2-68ea2a0aa183" xlink:href="sny-20260630.xsd#sny_OPALJVCoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c0a1-73bf-8818-1cb370e36cc7" xlink:to="loc_sny_OPALJVCoMember_019f932d-0f61-745c-a1f2-68ea2a0aa183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c0a1-766f-b805-4d3bc3ab77f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c0a1-766f-b805-4d3bc3ab77f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-7822-a4fa-588172608eb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_019ef965-c0a1-766f-b805-4d3bc3ab77f2" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-7822-a4fa-588172608eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_019ef965-c0a1-7e28-a7e8-20253b822a7c" xlink:href="sny-20260630.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_019ef965-c0a1-7822-a4fa-588172608eb6" xlink:to="loc_sny_ManufacturingAndSupplyMember_019ef965-c0a1-7e28-a7e8-20253b822a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_019ef965-c0a1-7d25-a954-770b74ecc81b" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_019ef965-c0a1-7819-929a-ba064f5ff53a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_019ef965-c0a1-7819-929a-ba064f5ff53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_019ef965-c0a1-75f8-8e5b-8963d144fa3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_019ef965-c0a1-7741-a043-f1f48a5b8c93" xlink:to="loc_ifrs-full_InterestCostsCapitalised_019ef965-c0a1-75f8-8e5b-8963d144fa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#PropertyplantandequipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-7b2e-8a8a-1b42a5476d4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_019ef965-c0a1-7e31-a5e9-215333db0e39" xlink:href="sny-20260630.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_019ef965-c0a1-7b2e-8a8a-1b42a5476d4f" xlink:to="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_019ef965-c0a1-7e31-a5e9-215333db0e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#GoodwillandotherintangibleassetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7e59-a714-676494ab994f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c0a1-74f6-883d-848cd26a886d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7e59-a714-676494ab994f" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c0a1-74f6-883d-848cd26a886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7da9-88af-233f52796252" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c0a1-74f6-883d-848cd26a886d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7da9-88af-233f52796252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7da9-88af-233f52796252" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_019ef965-c0a1-7c0f-9b70-3104b3891d2f" xlink:href="sny-20260630.xsd#sny_MarketedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:to="loc_sny_MarketedProductsMember_019ef965-c0a1-7c0f-9b70-3104b3891d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_019ef965-c0a1-717f-bfc7-96321ae7790f" xlink:href="sny-20260630.xsd#sny_TechnologicalPlatformsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f187b-e3b1-7e83-b215-f1576d28225a" xlink:to="loc_sny_TechnologicalPlatformsMember_019ef965-c0a1-717f-bfc7-96321ae7790f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_019ef965-c0a1-74f6-883d-848cd26a886d" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_019ef965-c0a1-7f49-a8af-8c6d64f9f489" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:to="loc_ifrs-full_Goodwill_019ef965-c0a1-7f49-a8af-8c6d64f9f489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c0a1-78c7-9730-a81ff2ed3232" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c0a1-78c7-9730-a81ff2ed3232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cde-b6c5-95d94d7aed52" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_019ef965-c0a1-71b1-b426-600107f5f71a" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cde-b6c5-95d94d7aed52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7c7f-8e44-2b62c07896ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_019ef965-c0a1-7c7f-8e44-2b62c07896ba" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7c89-9083-a1dda844eb65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7c89-9083-a1dda844eb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019ef965-c0a1-7c89-9083-a1dda844eb65" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredResearchAndDevelopmentMember_019ef965-c0a1-7135-b06f-c77e609d4edf" xlink:href="sny-20260630.xsd#sny_AcquiredResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:to="loc_sny_AcquiredResearchAndDevelopmentMember_019ef965-c0a1-7135-b06f-c77e609d4edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductsTrademarksAndOtherRightsMember_019ef965-c0a1-7c63-bbbd-96def76ab4cb" xlink:href="sny-20260630.xsd#sny_ProductsTrademarksAndOtherRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:to="loc_sny_ProductsTrademarksAndOtherRightsMember_019ef965-c0a1-7c63-bbbd-96def76ab4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_019ef965-c0a1-7296-9146-106b81ec7d74" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019ef965-c0a1-751b-9015-e35a238a2f79" xlink:to="loc_ifrs-full_ComputerSoftwareMember_019ef965-c0a1-7296-9146-106b81ec7d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-751c-8dea-59681123d7f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-751c-8dea-59681123d7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-751c-8dea-59681123d7f5" xlink:to="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7d4c-a60b-61c2c24c4b59" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7d4c-a60b-61c2c24c4b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_019ef965-c0a1-76cc-b2fa-91a3112d8f9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-71af-9693-be132bc38148" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_019ef965-c0a1-76cc-b2fa-91a3112d8f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_019ef965-c0a1-7f6e-aa69-ad1091e43c31" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019f18b6-3626-7368-bc1f-66e9a6743a09" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019f18b6-3626-7368-bc1f-66e9a6743a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cf2-a779-3ec818b3c944" xlink:href="sny-20260630.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7cf2-a779-3ec818b3c944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-77cf-9538-9d00173aa893" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-77cf-9538-9d00173aa893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-76d4-b734-5b24b40d0871" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-76d4-b734-5b24b40d0871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7bca-b489-7c7393fd1ad0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7bca-b489-7c7393fd1ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-741a-9b75-6a9f217fb397" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-741a-9b75-6a9f217fb397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7c55-a9b7-b0138f70c5f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7c55-a9b7-b0138f70c5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7af9-bbad-2a8a0260c008" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7af9-bbad-2a8a0260c008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7e99-9d7d-4615d783e196" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_019ef965-c0a1-7ed0-9973-48be9f1d854a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c0a1-7e99-9d7d-4615d783e196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ImpairmentofintangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_019ef965-c0a1-776f-9260-8ec429b6e7b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f7fa7-4ab7-7212-a2a2-e32b837c7934" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_019ef965-c0a1-776f-9260-8ec429b6e7b5" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f7fa7-4ab7-7212-a2a2-e32b837c7934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7d62-b7a8-6404fdf811c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract_019ef965-c0a1-776f-9260-8ec429b6e7b5" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7d62-b7a8-6404fdf811c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f8f3e-0081-7abe-8680-68406015dbd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7d62-b7a8-6404fdf811c7" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f8f3e-0081-7abe-8680-68406015dbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7d87-83f6-7e5596750d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f8f3e-0081-7abe-8680-68406015dbd2" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7d87-83f6-7e5596750d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmlitelimabAssetMember_019f8f3e-c0b4-71fc-a726-c7243f937fbd" xlink:href="sny-20260630.xsd#sny_AmlitelimabAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f8f3e-0081-7d87-83f6-7e5596750d91" xlink:to="loc_sny_AmlitelimabAssetMember_019f8f3e-c0b4-71fc-a726-c7243f937fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_019f8f3e-0081-7dd0-a3e5-f014731bd400" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_019f8f3e-0081-7d62-b7a8-6404fdf811c7" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_019f8f3e-0081-7dd0-a3e5-f014731bd400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8f3e-0081-79d6-9e0f-435a097dfe24" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_019f8f3e-0081-7dd0-a3e5-f014731bd400" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8f3e-0081-79d6-9e0f-435a097dfe24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7d1d-af82-dec9fb41162b" xlink:href="sny-20260630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7d1d-af82-dec9fb41162b" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c0a1-7d75-ae84-882c2662d861" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c0a1-7d75-ae84-882c2662d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019ef965-c0a1-7d75-ae84-882c2662d861" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OPALJVCoMember_019ef965-c0a1-7a88-938f-c1084bbb5d43" xlink:href="sny-20260630.xsd#sny_OPALJVCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:to="loc_sny_OPALJVCoMember_019ef965-c0a1-7a88-938f-c1084bbb5d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_019ef965-c0a1-7323-82ad-07038bc1abb5" xlink:href="sny-20260630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:to="loc_sny_EuroapiMember_019ef965-c0a1-7323-82ad-07038bc1abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_019ef965-c0a1-76b8-b205-00fa23595b66" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019ef965-c0a1-7a85-9b5e-f7955ceb136e" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_019ef965-c0a1-76b8-b205-00fa23595b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_019ef965-c0a1-7c0b-81c8-123282c0987f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_ifrs-full_JointVenturesAxis_019ef965-c0a1-7c0b-81c8-123282c0987f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_JointVenturesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_019ef965-c0a1-7c0b-81c8-123282c0987f" xlink:to="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_019ef965-c0a1-72ea-95f8-1707c3d96187" xlink:href="sny-20260630.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_019ef965-c0a1-72ea-95f8-1707c3d96187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-7726-a00f-9da2d36f0cca" xlink:href="sny-20260630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesDomain_019ef965-c0a1-76e5-a907-5ce12b339294" xlink:to="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-7726-a00f-9da2d36f0cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019ef965-c0a1-78d9-95b2-4491ee0f5bdb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_dei_LegalEntityAxis_019ef965-c0a1-78d9-95b2-4491ee0f5bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019ef965-c0a1-78d9-95b2-4491ee0f5bdb" xlink:to="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CDRMember_019f7fa8-6a80-7d66-b7b0-c2e2128e4d7f" xlink:href="sny-20260630.xsd#sny_CDRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_CDRMember_019f7fa8-6a80-7d66-b7b0-c2e2128e4d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BPIFranceMember_019f7fa8-b8b9-78cc-bbdf-5f5aa1eac61f" xlink:href="sny-20260630.xsd#sny_BPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_BPIFranceMember_019f7fa8-b8b9-78cc-bbdf-5f5aa1eac61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_019ef965-c0a1-7a9b-af15-d5c986b4fe58" xlink:href="sny-20260630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_EuroapiMember_019ef965-c0a1-7a9b-af15-d5c986b4fe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-77f1-af50-7f7a94e04ffd" xlink:href="sny-20260630.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019ef965-c0a1-79dd-a19e-d669df380501" xlink:to="loc_sny_MSPVaccineCompanyMember_019ef965-c0a1-77f1-af50-7f7a94e04ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-7df9-8b8a-872fc00b52be" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-7df9-8b8a-872fc00b52be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7ec3-98f3-012a793b0846" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-7df9-8b8a-872fc00b52be" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7ec3-98f3-012a793b0846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_019ef965-c0a1-7280-9db6-c3033f9770e8" xlink:href="sny-20260630.xsd#sny_MCMVaccineBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7ec3-98f3-012a793b0846" xlink:to="loc_sny_MCMVaccineBVMember_019ef965-c0a1-7280-9db6-c3033f9770e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-700b-b234-28383892243f" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_019ef965-c0a1-75a0-8eeb-dec79b08ec36" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_019ef965-c0a1-75a0-8eeb-dec79b08ec36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_019ef965-c0a1-7a29-a173-f177eb84c890" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod_019ef965-c0a1-7a29-a173-f177eb84c890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_019ef965-c0a1-72ed-abd7-5583b39660a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_019ef965-c0a1-72ed-abd7-5583b39660a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_019ef965-c0a1-7d4a-99cc-3fc0162da4c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_019ef965-c0a1-7d4a-99cc-3fc0162da4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c0a1-7ef1-98d6-84247c3b2d9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c0a1-7ef1-98d6-84247c3b2d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LoansToAssociates_019ef965-c0a1-7cb2-851a-86f4322ee80e" xlink:href="sny-20260630.xsd#sny_LoansToAssociates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_sny_LoansToAssociates_019ef965-c0a1-7cb2-851a-86f4322ee80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_019ef965-c0a1-764f-b12c-481062e6fddd" xlink:href="sny-20260630.xsd#sny_StockPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_sny_StockPrice_019ef965-c0a1-764f-b12c-481062e6fddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_019ef965-c0a1-7cce-8da5-b78e59c48b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7933-b49e-74d7baa46258" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_019ef965-c0a1-7cce-8da5-b78e59c48b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_019f1d35-518e-767c-9d1d-0f3511f7bcb9" xlink:href="sny-20260630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019f1d36-33cf-77ef-a8bd-e48ec0f69441" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019f1d35-518e-767c-9d1d-0f3511f7bcb9" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019f1d36-33cf-77ef-a8bd-e48ec0f69441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d36-33cf-7f6d-b0eb-c1c0010eed79" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019f1d36-33cf-77ef-a8bd-e48ec0f69441" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d36-33cf-7f6d-b0eb-c1c0010eed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7bdd-8bba-0ac782202cb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d36-33cf-7f6d-b0eb-c1c0010eed79" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7bdd-8bba-0ac782202cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OPALJVCoMember_019f1d36-33cf-7c40-a519-4a44d18e29b3" xlink:href="sny-20260630.xsd#sny_OPALJVCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d36-33cf-7bdd-8bba-0ac782202cb3" xlink:to="loc_sny_OPALJVCoMember_019f1d36-33cf-7c40-a519-4a44d18e29b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019f1d36-33cf-7c39-a565-551defd6c510" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019f1d36-33cf-77ef-a8bd-e48ec0f69441" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019f1d36-33cf-7c39-a565-551defd6c510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019f1d36-33cf-714e-a0be-e0db94d8c251" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019f1d36-33cf-7c39-a565-551defd6c510" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_019f1d36-33cf-714e-a0be-e0db94d8c251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7e8d-be45-ebd5bf68a8ae" xlink:href="sny-20260630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7e8d-be45-ebd5bf68a8ae" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7367-ae47-95bb9aaf6952" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7367-ae47-95bb9aaf6952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-742f-b4d9-14aac92354c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7367-ae47-95bb9aaf6952" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-742f-b4d9-14aac92354c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7088-b634-1638738f7c6f" xlink:href="sny-20260630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-742f-b4d9-14aac92354c5" xlink:to="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7088-b634-1638738f7c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d40-4514-77cb-98cf-fdb1cff791f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d40-4514-77cb-98cf-fdb1cff791f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-7f84-8203-1358fa70e636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInAssociatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_019f1d40-4514-77cb-98cf-fdb1cff791f3" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-7f84-8203-1358fa70e636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_019f1d40-4514-76aa-9e93-2807fdcc6fd1" xlink:href="sny-20260630.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesDomain_019f1d40-4514-7f84-8203-1358fa70e636" xlink:to="loc_sny_EuroapiMember_019f1d40-4514-76aa-9e93-2807fdcc6fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7583-955c-22ee98c9a179" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_019ef965-c0a1-7e43-a290-f97b8a8d83fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_019ef965-c0a1-7e43-a290-f97b8a8d83fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_019ef965-c0a1-700c-bf64-4f3109b70340" xlink:href="sny-20260630.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_019ef965-c0a1-700c-bf64-4f3109b70340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_019ef965-c0a1-7f7c-9ec1-57b593b9fd5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_019ef965-c0a1-7f7c-9ec1-57b593b9fd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_019ef965-c0a1-7d5e-bb43-d49bbb990255" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_019ef965-c0a1-7d5e-bb43-d49bbb990255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherAssetsRelatedPartyTransactions_019ef965-c0a1-720f-b711-010c6c71aa7b" xlink:href="sny-20260630.xsd#sny_OtherAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_OtherAssetsRelatedPartyTransactions_019ef965-c0a1-720f-b711-010c6c71aa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilitiesRelatedPartyTransactions_019ef965-c0a1-7618-9c1d-ca2d02d4e1e1" xlink:href="sny-20260630.xsd#sny_OtherLiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_OtherLiabilitiesRelatedPartyTransactions_019ef965-c0a1-7618-9c1d-ca2d02d4e1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubordinateHybridBondRelatedPartyTransactions_019ef965-c0a1-76a0-b080-cf860217cdaa" xlink:href="sny-20260630.xsd#sny_SubordinateHybridBondRelatedPartyTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7436-a186-0c29258052e2" xlink:to="loc_sny_SubordinateHybridBondRelatedPartyTransactions_019ef965-c0a1-76a0-b080-cf860217cdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7de1-a139-a3062dbbde0b" xlink:href="sny-20260630.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7878-84f7-bc0447f6a6c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_019ef965-c0a1-7de1-a139-a3062dbbde0b" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7878-84f7-bc0447f6a6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7553-9c50-982be07216ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7878-84f7-bc0447f6a6c2" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7553-9c50-982be07216ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7245-9c0f-75603a5d7a5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7553-9c50-982be07216ad" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7245-9c0f-75603a5d7a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7e8c-917d-06f5d41c00a1" xlink:href="sny-20260630.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019ef965-c0a1-7245-9c0f-75603a5d7a5d" xlink:to="loc_sny_AssociatesAndJointVenturesMember_019ef965-c0a1-7e8c-917d-06f5d41c00a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_019ef965-c0a1-7878-84f7-bc0447f6a6c2" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_019f1d44-34cf-7264-844c-5b35652d589e" xlink:href="sny-20260630.xsd#sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures_019f1d44-34cf-7264-844c-5b35652d589e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetIncomeRelatedPartyDisclosures_019f1d44-34cf-79a1-bd4c-b52e240e428c" xlink:href="sny-20260630.xsd#sny_NetIncomeRelatedPartyDisclosures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NetIncomeRelatedPartyDisclosures_019f1d44-34cf-79a1-bd4c-b52e240e428c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-7abf-9f32-3e644eb27b9a" xlink:href="sny-20260630.xsd#sny_OtherComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_OtherComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-7abf-9f32-3e644eb27b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-773f-9ce3-4508e5bcdf83" xlink:href="sny-20260630.xsd#sny_ComprehensiveIncomeRelatedPartyDisclosures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_ComprehensiveIncomeRelatedPartyDisclosures_019f1d44-34cf-773f-9ce3-4508e5bcdf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsRelatedPartyTransactions_019f1d44-5afb-7290-8985-630313959174" xlink:href="sny-20260630.xsd#sny_NonCurrentAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NonCurrentAssetsRelatedPartyTransactions_019f1d44-5afb-7290-8985-630313959174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsRelatedPartyTransactions_019f1d44-5afb-76c3-8b31-3cbbe0cc932c" xlink:href="sny-20260630.xsd#sny_CurrentAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_CurrentAssetsRelatedPartyTransactions_019f1d44-5afb-76c3-8b31-3cbbe0cc932c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssetsRelatedPartyTransactions_019f1d44-5afb-7c35-834a-47acd486d51c" xlink:href="sny-20260630.xsd#sny_AssetsRelatedPartyTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_AssetsRelatedPartyTransactions_019f1d44-5afb-7c35-834a-47acd486d51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_019f1d44-5afb-7c32-b82a-ba9a98cba339" xlink:href="sny-20260630.xsd#sny_EquityAttributableToEquityHoldersRelatedPartyTransactions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions_019f1d44-5afb-7c32-b82a-ba9a98cba339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_019f1d44-5afb-790e-90be-4c60a8dcd422" xlink:href="sny-20260630.xsd#sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions_019f1d44-5afb-790e-90be-4c60a8dcd422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRelatedPartyTransactions_019f1d44-5afb-7385-b228-f203c2b003fe" xlink:href="sny-20260630.xsd#sny_EquityRelatedPartyTransactions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityRelatedPartyTransactions_019f1d44-5afb-7385-b228-f203c2b003fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7681-8085-9357e54a4d0f" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7681-8085-9357e54a4d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-79a1-b804-7ce58a452d7f" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_CurrentLiabilitiesRelatedPartyTransactions_019f1d44-5afb-79a1-b804-7ce58a452d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d44-5afb-742f-8ad7-40489c708b52" xlink:href="sny-20260630.xsd#sny_LiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_LiabilitiesRelatedPartyTransactions_019f1d44-5afb-742f-8ad7-40489c708b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7672-ad97-30f9e42569cb" xlink:href="sny-20260630.xsd#sny_EquityAndLiabilitiesRelatedPartyTransactions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_019ef965-c0a1-7792-8cfa-841876edbc27" xlink:to="loc_sny_EquityAndLiabilitiesRelatedPartyTransactions_019f1d44-5afb-7672-ad97-30f9e42569cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OthernoncurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-710c-99c0-41bfdb8e23ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c0a1-79e0-ab18-9f4769108a60" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-710c-99c0-41bfdb8e23ae" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c0a1-79e0-ab18-9f4769108a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-73c3-a2db-0913cbc20c1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c0a1-79e0-ab18-9f4769108a60" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-73c3-a2db-0913cbc20c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-73c3-a2db-0913cbc20c1d" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_019ef965-c0a1-7421-af43-e73aa097e1ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_019ef965-c0a1-7421-af43-e73aa097e1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_019ef965-c0a1-7f88-9f55-63174bf3c36a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-7174-975b-c4aabfedddaf" xlink:to="loc_ifrs-full_DebtSecuritiesMember_019ef965-c0a1-7f88-9f55-63174bf3c36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_019ef965-c0a1-79e0-ab18-9f4769108a60" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_019ef965-c0a1-7712-9a24-de9dc53d040d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_019ef965-c0a1-7712-9a24-de9dc53d040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_019ef965-c0a1-7f02-ae6a-cf548c4d56e9" xlink:href="sny-20260630.xsd#sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss_019ef965-c0a1-7f02-ae6a-cf548c4d56e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_019ef965-c0a1-744e-b9b0-3556fe2c4dec" xlink:href="sny-20260630.xsd#sny_PreFundedPensionObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_PreFundedPensionObligations_019ef965-c0a1-744e-b9b0-3556fe2c4dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_019ef965-c0a1-73c1-96ed-cb25c10438d1" xlink:href="sny-20260630.xsd#sny_LongTermPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_LongTermPrepaidExpenses_019ef965-c0a1-73c1-96ed-cb25c10438d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLoansAndReceivables_019ef965-c0a1-73c7-aa11-f270d102d81a" xlink:href="sny-20260630.xsd#sny_NonCurrentLoansAndReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_sny_NonCurrentLoansAndReceivables_019ef965-c0a1-73c7-aa11-f270d102d81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_019ef965-c0a1-7c43-8618-473a69eb8359" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_019ef965-c0a1-7c43-8618-473a69eb8359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-79de-bde4-42f3dc4fcbe7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_019ef965-c0a1-7b62-b971-a0d3bf204ba4" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_019ef965-c0a1-79de-bde4-42f3dc4fcbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#AccountsreceivableSummaryofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-745f-8e4b-25d301a72eb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_019ef965-c0a1-7c11-acec-efd11d24205f" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-745f-8e4b-25d301a72eb3" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_019ef965-c0a1-7c11-acec-efd11d24205f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-750d-8b30-a46675310d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_019ef965-c0a1-7c11-acec-efd11d24205f" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-750d-8b30-a46675310d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_019ef965-c0a1-750d-8b30-a46675310d60" xlink:to="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7f5a-88a7-2a3d46fa97a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_019ef965-c0a1-7f5a-88a7-2a3d46fa97a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_019ef965-c0a1-75e8-8d1b-dc9966977f5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_019ef965-c0a1-751d-9ecb-a0b915f485cf" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_019ef965-c0a1-75e8-8d1b-dc9966977f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_019ef965-c0a1-7bcc-bc88-c352a78132a7" xlink:href="sny-20260630.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_019ef965-c0a1-7c11-acec-efd11d24205f" xlink:to="loc_sny_DisclosureOfAccountsReceivableLineItems_019ef965-c0a1-7bcc-bc88-c352a78132a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_019ef965-c0a1-76ef-bd8f-f634a91d7845" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_019ef965-c0a1-7bcc-bc88-c352a78132a7" xlink:to="loc_ifrs-full_CurrentTradeReceivables_019ef965-c0a1-76ef-bd8f-f634a91d7845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#AccountsreceivableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-7d21-a9e4-dcd02e57d743" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_019ef965-c0a1-728d-9ce8-a7e579ff4400" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-7d21-a9e4-dcd02e57d743" xlink:to="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_019ef965-c0a1-728d-9ce8-a7e579ff4400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables_019ef965-c0a1-7d1b-9040-2d377b7685d6" xlink:href="sny-20260630.xsd#sny_DerecognizedReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-7d21-a9e4-dcd02e57d743" xlink:to="loc_sny_DerecognizedReceivables_019ef965-c0a1-7d1b-9040-2d377b7685d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-70e1-813e-23b26388b768" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c0a1-7f13-97c9-1541431dedb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TradeAndOtherReceivablesAbstract_019ef965-c0a1-70e1-813e-23b26388b768" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c0a1-7f13-97c9-1541431dedb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-77bf-b12e-4ea949c51f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c0a1-7f13-97c9-1541431dedb2" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-77bf-b12e-4ea949c51f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-77bf-b12e-4ea949c51f18" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_019ef965-c0a1-7f0a-9d7f-5d7471c030ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_019ef965-c0a1-7f0a-9d7f-5d7471c030ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_019ef965-c0a1-70ab-ab42-973ab46e4979" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_019ef965-c0a1-70ab-ab42-973ab46e4979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_019ef965-c0a1-72d9-9882-27df3ec7e2ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_019ef965-c0a1-72d9-9882-27df3ec7e2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_019ef965-c0a1-7c95-986c-3b4851c28835" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_019ef965-c0a1-7c95-986c-3b4851c28835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_019ef965-c0a1-7d1f-9943-f192adb23be4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-746e-985a-ce39dacdd35f" xlink:to="loc_ifrs-full_LaterThanOneYearMember_019ef965-c0a1-7d1f-9943-f192adb23be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_019ef965-c0a1-7561-afad-c33bcee8a1bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_019ef965-c0a1-7f13-97c9-1541431dedb2" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_019ef965-c0a1-7561-afad-c33bcee8a1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_019ef965-c0a1-759e-bbbe-23e09a960bba" xlink:href="sny-20260630.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_019ef965-c0a1-7561-afad-c33bcee8a1bf" xlink:to="loc_sny_OverdueReceivablesGrossValue_019ef965-c0a1-759e-bbbe-23e09a960bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-709b-9117-6dd68e616605" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-709b-9117-6dd68e616605" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019f1dab-334a-79cd-8060-df019c837186" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_dei_LegalEntityAxis_019f1dab-334a-79cd-8060-df019c837186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019f1dab-334a-7849-a34c-754f57f4bf5d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019f1dab-334a-79cd-8060-df019c837186" xlink:to="loc_dei_EntityDomain_019f1dab-334a-7849-a34c-754f57f4bf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_019f1dab-334a-7afb-8d9c-a4becff19bd9" xlink:href="sny-20260630.xsd#sny_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019f1dab-334a-7849-a34c-754f57f4bf5d" xlink:to="loc_sny_SanofiMember_019f1dab-334a-7afb-8d9c-a4becff19bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019f1dab-334a-70ce-9bbb-210363fcd672" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019f1dab-334a-70ce-9bbb-210363fcd672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-79c7-8c4d-57f11b553f4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019f1dab-334a-70ce-9bbb-210363fcd672" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-79c7-8c4d-57f11b553f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_019f1dab-334a-783a-8ee5-73e0e03ce77d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019f1dab-334a-79c7-8c4d-57f11b553f4f" xlink:to="loc_ifrs-full_IssuedCapitalMember_019f1dab-334a-783a-8ee5-73e0e03ce77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019f1dab-9cbe-7eec-8497-776cdb944a20" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019f1dab-9cbe-7eec-8497-776cdb944a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-74b1-aa46-bb1ed9074fa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019f1dab-9cbe-7eec-8497-776cdb944a20" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-74b1-aa46-bb1ed9074fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeShareOwnershipPlanMember_019f1dab-9cbe-780f-a45d-4609972861ed" xlink:href="sny-20260630.xsd#sny_EmployeeShareOwnershipPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019f1dab-9cbe-74b1-aa46-bb1ed9074fa3" xlink:to="loc_sny_EmployeeShareOwnershipPlanMember_019f1dab-9cbe-780f-a45d-4609972861ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-777d-8572-023f7e060013" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-777d-8572-023f7e060013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_019f7fb8-008e-777d-8572-023f7e060013" xlink:to="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2025ProgramMember_019f7fb9-cbbb-76e0-9b76-3fb9a4a27ace" xlink:href="sny-20260630.xsd#sny_ShareRepurchase2025ProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:to="loc_sny_ShareRepurchase2025ProgramMember_019f7fb9-cbbb-76e0-9b76-3fb9a4a27ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2026ProgramMember_019f9374-2742-7b59-af04-a5aec656a859" xlink:href="sny-20260630.xsd#sny_ShareRepurchase2026ProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_019f7fb8-008e-7b9f-ba4b-9e3478b1571c" xlink:to="loc_sny_ShareRepurchase2026ProgramMember_019f9374-2742-7b59-af04-a5aec656a859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019f89cd-e857-7030-af3a-e294a539b042" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_ifrs-full_CounterpartiesAxis_019f89cd-e857-7030-af3a-e294a539b042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7246-a65c-2e2d3cf3bfdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_019f89cd-e857-7030-af3a-e294a539b042" xlink:to="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7246-a65c-2e2d3cf3bfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LOrealMember_019f89ce-2703-7c25-b77b-fb34e42aabc5" xlink:href="sny-20260630.xsd#sny_LOrealMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019f89cd-e857-7246-a65c-2e2d3cf3bfdb" xlink:to="loc_sny_LOrealMember_019f89ce-2703-7c25-b77b-fb34e42aabc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7cd7-8eea-dd737f41eaa6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_019f1dab-085a-7f86-8b66-9c77384a65af" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_IssuedCapital_019f1dab-085a-7f86-8b66-9c77384a65af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_019f1dab-085a-7877-9f9f-56c52e816945" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_NumberOfSharesIssued_019f1dab-085a-7877-9f9f-56c52e816945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_019f1dab-085a-78b7-91e0-66e0c332c85f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_ParValuePerShare_019f1dab-085a-78b7-91e0-66e0c332c85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_019f1dab-334a-71f5-9ef2-97e8f1f48fc8" xlink:href="sny-20260630.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_019f1dab-334a-71f5-9ef2-97e8f1f48fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_019f1dab-334a-7258-b1ed-14765f50a92f" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease_019f1dab-334a-7258-b1ed-14765f50a92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_019f1dab-334a-72d0-9afd-c16c4dfd11b6" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_019f1dab-334a-72d0-9afd-c16c4dfd11b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_019f1dab-334a-75cf-8728-3ec2710c3b8d" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease_019f1dab-334a-75cf-8728-3ec2710c3b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchaseProgramPeriod_019f1dab-5d4b-7db8-8dbb-7171a7e562f0" xlink:href="sny-20260630.xsd#sny_ShareRepurchaseProgramPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_ShareRepurchaseProgramPeriod_019f1dab-5d4b-7db8-8dbb-7171a7e562f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_019f1dab-5d4b-7bd8-87de-e3b09f75a5b0" xlink:href="sny-20260630.xsd#sny_NumberOfSharesRepurchased"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfSharesRepurchased_019f1dab-5d4b-7bd8-87de-e3b09f75a5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019f8a41-fcd2-7b12-8af8-d36d47586192" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_019f8a41-fcd2-7b12-8af8-d36d47586192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019f7fb7-d4fd-78ae-bc23-f10bedeb3811" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019f7fb7-d4fd-78ae-bc23-f10bedeb3811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSanofisShareCapitalAcquired_019f2301-0ec8-7064-be83-dd80e28758f1" xlink:href="sny-20260630.xsd#sny_PercentageOfSanofisShareCapitalAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_PercentageOfSanofisShareCapitalAcquired_019f2301-0ec8-7064-be83-dd80e28758f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchaseProgramAmountPaid_019f8aec-4220-72d8-acfb-0c9a7ff532ad" xlink:href="sny-20260630.xsd#sny_ShareRepurchaseProgramAmountPaid"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_ShareRepurchaseProgramAmountPaid_019f8aec-4220-72d8-acfb-0c9a7ff532ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerShareValueOfSharesRepurchased_019f1dab-5d4b-712e-9f80-66275a2b3c6f" xlink:href="sny-20260630.xsd#sny_PerShareValueOfSharesRepurchased"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_PerShareValueOfSharesRepurchased_019f1dab-5d4b-712e-9f80-66275a2b3c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CancellationOfTreasuryShares_019f1dab-5d4b-7e32-941a-9dfcd1a6cbac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CancellationOfTreasuryShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_CancellationOfTreasuryShares_019f1dab-5d4b-7e32-941a-9dfcd1a6cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_019f1dab-9cbe-70e2-8942-d020115041c6" xlink:href="sny-20260630.xsd#sny_SubscriptionPricePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_SubscriptionPricePerShare_019f1dab-9cbe-70e2-8942-d020115041c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesSubscribed_019f1dab-9cbe-71cf-9813-2ce76d173f2c" xlink:href="sny-20260630.xsd#sny_NumberOfSharesSubscribed"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_NumberOfSharesSubscribed_019f1dab-9cbe-71cf-9813-2ce76d173f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_019f1dab-9cbe-7d0e-b12c-17826e0fa47e" xlink:href="sny-20260630.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_019f1dab-9cbe-7d0e-b12c-17826e0fa47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019f1dab-9cbe-7e3a-b800-147d2b2bea16" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019f1dab-085a-753f-a02c-2ca8f9ea6ff7" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019f1dab-9cbe-7e3a-b800-147d2b2bea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7d5d-8ca2-ba5d814070ca" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld_019ef965-c0a1-7d58-a764-d687ebfb0bc0" xlink:href="sny-20260630.xsd#sny_NumberOfSharesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7d5d-8ca2-ba5d814070ca" xlink:to="loc_sny_NumberOfSharesHeld_019ef965-c0a1-7d58-a764-d687ebfb0bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod_019ef965-c0a1-7e25-98f9-4023602cdeb4" xlink:href="sny-20260630.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7d5d-8ca2-ba5d814070ca" xlink:to="loc_sny_PercentageOfShareCapitalForThePeriod_019ef965-c0a1-7e25-98f9-4023602cdeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-742e-a8cd-8cf3c6ea969b" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-742e-a8cd-8cf3c6ea969b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-70c9-9dd4-7e374e7b7b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-70c9-9dd4-7e374e7b7b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7160-86cb-746b636ba0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-70c9-9dd4-7e374e7b7b26" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7160-86cb-746b636ba0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7994-b66a-9f514b4658cd" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7160-86cb-746b636ba0ae" xlink:to="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7994-b66a-9f514b4658cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_019ef965-c0a1-7c89-b0f0-6abb2d249e6d" xlink:href="sny-20260630.xsd#sny_MarketConditionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_sny_MarketConditionAxis_019ef965-c0a1-7c89-b0f0-6abb2d249e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:href="sny-20260630.xsd#sny_MarketConditionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionAxis_019ef965-c0a1-7c89-b0f0-6abb2d249e6d" xlink:to="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_019ef965-c0a1-7b11-868c-e493a74103aa" xlink:href="sny-20260630.xsd#sny_WithoutMarketConditionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:to="loc_sny_WithoutMarketConditionMember_019ef965-c0a1-7b11-868c-e493a74103aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_019ef965-c0a1-73a8-ac18-31854040bcb6" xlink:href="sny-20260630.xsd#sny_WithMarketConditionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_019ef965-c0a1-71b0-b1e5-c48a310dfb8d" xlink:to="loc_sny_WithMarketConditionMember_019ef965-c0a1-73a8-ac18-31854040bcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_019ef965-c0a1-736d-b2b3-1aea163465b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_srt_TitleOfIndividualAxis_019ef965-c0a1-736d-b2b3-1aea163465b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_019ef965-c0a1-736d-b2b3-1aea163465b5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExcludingChiefExecutiveOfficerMember_019ef965-c0a1-7b59-9a51-9c57de4008e7" xlink:href="sny-20260630.xsd#sny_ExcludingChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:to="loc_sny_ExcludingChiefExecutiveOfficerMember_019ef965-c0a1-7b59-9a51-9c57de4008e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_019ef965-c0a1-7c2a-b850-b665fb07d945" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_019ef965-c0a1-7dc4-b722-80deee581451" xlink:to="loc_srt_ChiefExecutiveOfficerMember_019ef965-c0a1-7c2a-b850-b665fb07d945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f" xlink:href="sny-20260630.xsd#sny_TypesOfVestingConditionsAxisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:href="sny-20260630.xsd#sny_TypesOfVestingConditionsAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfVestingConditionsAxisAxis_019f8f54-9d2f-7ca2-86ab-6d3ef300f56f" xlink:to="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ThreeYearServicePeriodMember_019f8f55-6a6b-7b90-81de-50264d84bd60" xlink:href="sny-20260630.xsd#sny_ThreeYearServicePeriodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:to="loc_sny_ThreeYearServicePeriodMember_019f8f55-6a6b-7b90-81de-50264d84bd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FiveYearServicePeriodMember_019f8f55-d423-7fe1-9445-f9774973d4be" xlink:href="sny-20260630.xsd#sny_FiveYearServicePeriodMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfVestingConditionsAxisDomain_019f8f54-9d2f-7cb8-a5bd-75be70b31ea5" xlink:to="loc_sny_FiveYearServicePeriodMember_019f8f55-d423-7fe1-9445-f9774973d4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7d30-abe1-a9a6c0a41358" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019ef965-c0a1-7507-9933-868263c9dbad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_019ef965-c0a1-7507-9933-868263c9dbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_019ef965-c0a1-71af-b98d-c0f348f3bcdd" xlink:href="sny-20260630.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_019ef965-c0a1-71af-b98d-c0f348f3bcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForFiveYearServicePeriod_019f8f4d-da66-746a-8860-4e73b1874e05" xlink:href="sny-20260630.xsd#sny_FairValuePerShareAwardedForFiveYearServicePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_FairValuePerShareAwardedForFiveYearServicePeriod_019f8f4d-da66-746a-8860-4e73b1874e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_019ef965-c0a1-7735-b9d0-96fcae64de0a" xlink:href="sny-20260630.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_019ef965-c0a1-7735-b9d0-96fcae64de0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_019ef965-c0a1-7bdf-862d-3e59e3b38e98" xlink:href="sny-20260630.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7dc3-9894-f849e313189a" xlink:to="loc_sny_NumberOfYearsServicePeriod_019ef965-c0a1-7bdf-862d-3e59e3b38e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7fbb-907e-23151ae0c35d" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7bc3-a1ce-5061b7c5dbd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7fbb-907e-23151ae0c35d" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7bc3-a1ce-5061b7c5dbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-73fa-bbc5-2f345560c176" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7bc3-a1ce-5061b7c5dbd6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-73fa-bbc5-2f345560c176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7927-95fb-82944fff30e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_019ef965-c0a1-73fa-bbc5-2f345560c176" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7927-95fb-82944fff30e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:href="sny-20260630.xsd#sny_RestrictedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_019ef965-c0a1-7927-95fb-82944fff30e9" xlink:to="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2026Member_019f372f-fa4c-762c-bfa9-ac2e40792281" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2026Member_019f372f-fa4c-762c-bfa9-ac2e40792281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7f41-9dd3-8d825f95dd17" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2025Member_019ef965-c0a1-7f41-9dd3-8d825f95dd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2024Member_019ef965-c0a1-7150-948d-2d9ef9e868b2" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2024Member_019ef965-c0a1-7150-948d-2d9ef9e868b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_019ef965-c0a1-7cce-8c82-acea80acfa24" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2023Member_019ef965-c0a1-7cce-8c82-acea80acfa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_019ef965-c0a1-739e-96cc-2771896b13d3" xlink:href="sny-20260630.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_019ef965-c0a1-7361-8137-23c82bd0d73e" xlink:to="loc_sny_RestrictedSharePlan2022Member_019ef965-c0a1-739e-96cc-2771896b13d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_019ef965-c0a1-7bc3-a1ce-5061b7c5dbd6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019ef965-c0a1-7792-b8ca-91745b399da7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_019ef965-c0a1-7792-b8ca-91745b399da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_019ef965-c0a1-7443-8f10-6c4b9e814bde" xlink:href="sny-20260630.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_019ef965-c0a1-7e6a-97a2-c78b29aa1d3f" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_019ef965-c0a1-7443-8f10-6c4b9e814bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-79b9-a90f-2e9250561494" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-79b9-a90f-2e9250561494" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_019ef965-c0a1-7908-9601-af03111057a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:to="loc_ifrs-full_RangeAxis_019ef965-c0a1-7908-9601-af03111057a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_019ef965-c0a1-7908-9601-af03111057a8" xlink:to="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_019ef965-c0a1-73bc-9040-04232ef7d19e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:to="loc_ifrs-full_BottomOfRangeMember_019ef965-c0a1-73bc-9040-04232ef7d19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_019ef965-c0a1-7ef4-a0b2-08a1e8f6262a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_019ef965-c0a1-7049-9821-af7077444cef" xlink:to="loc_ifrs-full_TopOfRangeMember_019ef965-c0a1-7ef4-a0b2-08a1e8f6262a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_019ef965-c0a1-7c44-9dcd-6dffa6f77c5c" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_019ef965-c0a1-7fbb-a814-c1728d8d4f5e" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:to="loc_sny_ExercisePriceRangeTwoMember_019ef965-c0a1-7fbb-a814-c1728d8d4f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_019ef965-c0a1-774d-969e-e1bf5cce92e5" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:to="loc_sny_ExercisePriceRangeThreeMember_019ef965-c0a1-774d-969e-e1bf5cce92e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_019ef965-c0a1-78b8-9bca-be11c2427b4e" xlink:href="sny-20260630.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_019ef965-c0a1-7c0e-96ee-3fb2153c2dbb" xlink:to="loc_sny_ExercisePriceRangeFourMember_019ef965-c0a1-78b8-9bca-be11c2427b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-7bda-9e23-265f46864f5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-7bda-9e23-265f46864f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-78dd-9b55-237b70ebeb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-7bda-9e23-265f46864f5e" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-78dd-9b55-237b70ebeb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_019ef965-c0a1-77e3-a324-a05913d9c3bf" xlink:href="sny-20260630.xsd#sny_StockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-78dd-9b55-237b70ebeb96" xlink:to="loc_sny_StockOptionPlanMember_019ef965-c0a1-77e3-a324-a05913d9c3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_019ef965-c0a1-7804-be0e-d277216d27a1" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_019ef965-c0a1-7d6a-9ee1-3572779c7dca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_019ef965-c0a1-7d6a-9ee1-3572779c7dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_019ef965-c0a1-76ad-8eba-4304f5185e23" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_019ef965-c0a1-76ad-8eba-4304f5185e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_019ef965-c0a1-77e5-b507-9fc092482e76" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_019ef965-c0a1-77e5-b507-9fc092482e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_019ef965-c0a1-7e2f-9991-f4efc1ce61a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_019ef965-c0a1-7e2f-9991-f4efc1ce61a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_019ef965-c0a1-7d26-ae91-5aacf9c960ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_019ef965-c0a1-7d26-ae91-5aacf9c960ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_019ef965-c0a1-7b84-86cb-408103270c29" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_019ef965-c0a1-7418-84ee-3d9008929894" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_019ef965-c0a1-7b84-86cb-408103270c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofearningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019f1d64-144c-7611-99e0-b199be525c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_019f1d64-144c-7611-99e0-b199be525c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_019f1d66-609c-7e57-9e0b-dc4908c2c6d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_019f1d66-609c-7e57-9e0b-dc4908c2c6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_019f1d66-609c-786f-90a3-83d3ad403838" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_019f1d66-609c-786f-90a3-83d3ad403838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_019ef965-c0a1-72a4-a122-19ec8de5e96a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:to="loc_ifrs-full_WeightedAverageShares_019ef965-c0a1-72a4-a122-19ec8de5e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_019ef965-c0a1-7655-90e8-619d8a97691a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_019ef965-c0a1-7655-90e8-619d8a97691a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_019ef965-c0a1-709a-a6e9-7f9540597b62" xlink:href="sny-20260630.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_019ef965-c0a1-709a-a6e9-7f9540597b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_019ef965-c0a1-7aa1-8b3d-71fd1fe6bc6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-731d-b8b6-5ea0c33b92ff" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_019ef965-c0a1-7aa1-8b3d-71fd1fe6bc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019f1d6b-bc2b-7f22-b571-7160d17565a9" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_019f1d78-ec46-70ed-8f48-b36e3a044533" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019f1d6b-bc2b-7f22-b571-7160d17565a9" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_019f1d78-ec46-70ed-8f48-b36e3a044533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_019f1d78-ec46-7f4f-8bbd-66abd58df504" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019f1d6b-bc2b-7f22-b571-7160d17565a9" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations_019f1d78-ec46-7f4f-8bbd-66abd58df504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_019f1d78-ec46-7bf3-afff-f915f1441dda" xlink:href="sny-20260630.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019f1d6b-bc2b-7f22-b571-7160d17565a9" xlink:to="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_019f1d78-ec46-7bf3-afff-f915f1441dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_019f1d78-ec46-7ac2-8316-2adf55436bfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019f1d6b-bc2b-7f22-b571-7160d17565a9" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_019f1d78-ec46-7ac2-8316-2adf55436bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_019f1d78-ec46-7f67-85ed-33044b113a72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019f1d6b-bc2b-7f22-b571-7160d17565a9" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations_019f1d78-ec46-7f67-85ed-33044b113a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_019f1d78-ec46-7d5e-be47-bd86eb7dd4a5" xlink:href="sny-20260630.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019f1d6b-bc2b-7f22-b571-7160d17565a9" xlink:to="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_019f1d78-ec46-7d5e-be47-bd86eb7dd4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7e42-8d02-0b2938dadafe" xlink:href="sny-20260630.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_019ef965-c0a1-7e42-8d02-0b2938dadafe" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-767b-aa68-2eab67a97a7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-767b-aa68-2eab67a97a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-75cc-b1f3-d698a956e8ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_019ef965-c0a1-767b-aa68-2eab67a97a7b" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-75cc-b1f3-d698a956e8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-c0a1-7a21-90ed-56a0a7b8e0e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_019ef965-c0a1-75cc-b1f3-d698a956e8ff" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_019ef965-c0a1-7a21-90ed-56a0a7b8e0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_019ef965-c0a1-7320-9b3d-a9e1c4156690" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_019ef965-c0a1-7320-9b3d-a9e1c4156690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReclassifiedItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_019ef965-c0a1-7320-9b3d-a9e1c4156690" xlink:to="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-76a4-9c16-ac4afb2883af" xlink:href="sny-20260630.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-76a4-9c16-ac4afb2883af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-729e-be97-94e44ee22e3a" xlink:href="sny-20260630.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsDomain_019ef965-c0a1-7f8b-89f0-3fd4a51a390c" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_019ef965-c0a1-729e-be97-94e44ee22e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c0a1-72d9-9b7b-371d44a17cad" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c0a1-72d9-9b7b-371d44a17cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_019ef965-c0a1-72d9-9b7b-371d44a17cad" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_019ef965-c0a1-766c-8b74-fb9d8d6c5b25" xlink:href="sny-20260630.xsd#sny_EquityInstrumentsIncludedInFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetsMember_019ef965-c0a1-766c-8b74-fb9d8d6c5b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_019ef965-c0a1-769e-bb73-7f7e06e718d7" xlink:href="sny-20260630.xsd#sny_DebtInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_DebtInstrumentsMember_019ef965-c0a1-769e-bb73-7f7e06e718d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_019ef965-c0a1-7568-b309-dfb21e7d672a" xlink:href="sny-20260630.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_019ef965-c0a1-7568-b309-dfb21e7d672a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_019ef965-c0a1-73a2-9425-8b10884bf64e" xlink:href="sny-20260630.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_019ef965-c0a1-7d02-ac87-a3e0e799419b" xlink:to="loc_sny_ForeignCurrencyTranslationMember_019ef965-c0a1-73a2-9425-8b10884bf64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_019ef965-c0a1-72d6-b0a6-462d047e6e72" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_019ef965-c0a1-7974-a30d-696451241bbe" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_019ef965-c0a1-7974-a30d-696451241bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7d29-af04-eb17fdad6e13" xlink:href="sny-20260630.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7d29-af04-eb17fdad6e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_019ef965-c0a1-7726-9868-dc76ca8053fb" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments_019ef965-c0a1-7726-9868-dc76ca8053fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_019ef965-c0a1-73e6-a5f0-ea91c0511359" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_019ef965-c0a1-73e6-a5f0-ea91c0511359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_019ef965-c0a1-7a56-a304-05df2d3c2e1d" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_019ef965-c0a1-7a56-a304-05df2d3c2e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_019ef965-c0a1-7530-bfa5-f874054e78c6" xlink:href="sny-20260630.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_019ef965-c0a1-7530-bfa5-f874054e78c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_019ef965-c0a1-710d-8e45-fcebb9f23ee8" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_019ef965-c0a1-710d-8e45-fcebb9f23ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7c2d-ba5a-430f046be715" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-7c2d-ba5a-430f046be715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_019ef965-c0a1-7a60-ad89-61095558bdf2" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_019ef965-c0a1-7a60-ad89-61095558bdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_019ef965-c0a1-7cc8-a620-2676d3d723da" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures_019ef965-c0a1-7cc8-a620-2676d3d723da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_019ef965-c0a1-76f4-91d2-febc24015c9f" xlink:href="sny-20260630.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments_019ef965-c0a1-76f4-91d2-febc24015c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_019ef965-c0a1-7fb4-9d6f-6b48be347230" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_019ef965-c0a1-7fb4-9d6f-6b48be347230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7717-a26e-11d36741bada" xlink:href="sny-20260630.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7717-a26e-11d36741bada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_019ef965-c0a1-7ea6-ad3f-21b0f1bc6371" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_019ef965-c0a1-7ea6-ad3f-21b0f1bc6371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_019ef965-c0a1-7af6-bd67-9003db01c6b6" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_019ef965-c0a1-7af6-bd67-9003db01c6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7043-a676-3879cbf11057" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_019ef965-c0a1-7043-a676-3879cbf11057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_019ef965-c0a1-7a07-a7e3-ae5bdd7f3714" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_019ef965-c0a1-7a07-a7e3-ae5bdd7f3714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_019ef965-c0a1-7437-9b51-05dac590f924" xlink:href="sny-20260630.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_019ef965-c0a1-7437-9b51-05dac590f924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-70c8-9aa3-ae223b71ec6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_019ef965-c0a1-77c0-8ec9-7e2baff3b3e4" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_019ef965-c0a1-70c8-9aa3-ae223b71ec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7c43-8ded-5012f44126cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7c43-8ded-5012f44126cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-740d-9af0-ac77e159af92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-740d-9af0-ac77e159af92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-7b89-b30c-d656963f4caf" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-7b89-b30c-d656963f4caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7aed-b4c2-386931eb87e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-7aed-b4c2-386931eb87e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-78b7-b1d5-ebff78e9c9e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-78b7-b1d5-ebff78e9c9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-7948-8c61-bcec58cea298" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-7948-8c61-bcec58cea298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7c75-8634-41bbc960c7a9" xlink:href="sny-20260630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7c75-8634-41bbc960c7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019ef965-c0a1-71ec-96d3-7c1931a1b5ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7192-891f-e224c6d44efd" xlink:to="loc_ifrs-full_LeaseLiabilities_019ef965-c0a1-71ec-96d3-7c1931a1b5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-70cc-9ff1-1ed8119cea1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7683-ac32-86162a9c46f0" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-70cc-9ff1-1ed8119cea1d" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7683-ac32-86162a9c46f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7632-88f0-a76df101ad97" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7683-ac32-86162a9c46f0" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7632-88f0-a76df101ad97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7632-88f0-a76df101ad97" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostNettingMember_019ef965-c0a1-70f8-9e9d-6e90c4f900a4" xlink:href="sny-20260630.xsd#sny_AmortizedCostNettingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:to="loc_sny_AmortizedCostNettingMember_019ef965-c0a1-70f8-9e9d-6e90c4f900a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_019ef965-c0a1-7b25-beb1-51dbf785e1f7" xlink:href="sny-20260630.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_019ef965-c0a1-7b25-beb1-51dbf785e1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7f79-826b-0eb1384b51de" xlink:href="sny-20260630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c53-99b7-138eab440673" xlink:to="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7f79-826b-0eb1384b51de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7683-ac32-86162a9c46f0" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7fbd-8fa0-8b153c7f093f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_LongtermBorrowings_019ef965-c0a1-7fbd-8fa0-8b153c7f093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-71bd-ba2e-1ccace50a4e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_019ef965-c0a1-71bd-ba2e-1ccace50a4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-75ca-be1a-707f2c4bc3b6" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-75ca-be1a-707f2c4bc3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7f84-befd-d3042b7fe7f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-7f84-befd-d3042b7fe7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-7125-a425-361785faa020" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-7125-a425-361785faa020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-77ec-89c4-c1fa2fd01c2e" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-77ec-89c4-c1fa2fd01c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-716d-abaf-fca822b6d112" xlink:href="sny-20260630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-716d-abaf-fca822b6d112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_019ef965-c0a1-7f1a-b583-5c8bdc2864cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-73bf-b770-254dc7de2cd9" xlink:to="loc_ifrs-full_LeaseLiabilities_019ef965-c0a1-7f1a-b583-5c8bdc2864cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7032-8289-3d8408140b90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7032-8289-3d8408140b90" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7fce-9163-a28153d7350f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7fce-9163-a28153d7350f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7777-acc5-36dd70e474ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7fce-9163-a28153d7350f" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7777-acc5-36dd70e474ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-73e8-94bb-464d57614906" xlink:href="sny-20260630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7777-acc5-36dd70e474ee" xlink:to="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-73e8-94bb-464d57614906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-78e0-b96d-7569d9c035f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-78e0-b96d-7569d9c035f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_019ef965-c0a1-78e0-b96d-7569d9c035f9" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_019ef965-c0a1-7a94-b65e-41a5d174852b" xlink:href="sny-20260630.xsd#sny_NonCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:to="loc_sny_NonCurrentAssetsMember_019ef965-c0a1-7a94-b65e-41a5d174852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_019ef965-c0a1-7e00-9987-030716b229f1" xlink:href="sny-20260630.xsd#sny_CurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_019ef965-c0a1-797f-b2b0-54ec79012692" xlink:to="loc_sny_CurrentAssetsMember_019ef965-c0a1-7e00-9987-030716b229f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7a7c-b641-5c02a9c4ac42" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7a7c-b641-5c02a9c4ac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7fc3-94c4-2b53dd8c628d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7a7c-b641-5c02a9c4ac42" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7fc3-94c4-2b53dd8c628d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_019ef965-c0a1-7f05-95ca-e85a00d72676" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7fc3-94c4-2b53dd8c628d" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_019ef965-c0a1-7f05-95ca-e85a00d72676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_019f1db9-1d30-7f97-95be-969ae794aeb5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_srt_StatementGeographicalAxis_019f1db9-1d30-7f97-95be-969ae794aeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7c08-9dc5-2ed11b805a57" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_019f1db9-1d30-7f97-95be-969ae794aeb5" xlink:to="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7c08-9dc5-2ed11b805a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019f1db9-5899-7b7b-a066-d2ba41ddc60f" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019f1db9-1d30-7c08-9dc5-2ed11b805a57" xlink:to="loc_country_US_019f1db9-5899-7b7b-a066-d2ba41ddc60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_019f6afe-116b-7679-ba75-9b0ce95aad01" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_HedgedItemsAxis_019f6afe-116b-7679-ba75-9b0ce95aad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-76a3-b220-ea35f391fe6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_019f6afe-116b-7679-ba75-9b0ce95aad01" xlink:to="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-76a3-b220-ea35f391fe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInvestmentHedgeMember_019f6afe-116b-7140-9818-31b94caf0f85" xlink:href="sny-20260630.xsd#sny_NetInvestmentHedgeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsDomain_019f6afe-116b-76a3-b220-ea35f391fe6a" xlink:to="loc_sny_NetInvestmentHedgeMember_019f6afe-116b-7140-9818-31b94caf0f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-711b-8c92-099cf56612f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-711b-8c92-099cf56612f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_019f7fc9-2224-711b-8c92-099cf56612f2" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_019f7fc9-83a0-7073-b54e-a4169052f0bf" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:to="loc_sny_NonCurrentLiabilitiesMember_019f7fc9-83a0-7073-b54e-a4169052f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_019f7fc9-8b11-7e31-962c-9c88e2c19040" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_019f7fc9-2224-7ed6-99ba-9830632ae0ae" xlink:to="loc_sny_CurrentLiabilitiesMember_019f7fc9-8b11-7e31-962c-9c88e2c19040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:href="sny-20260630.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_019ef965-c0a1-7144-86a3-1661129b47f5" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_019ef965-c0a1-7ee8-abb8-5b1d1f1d31ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_BondsIssued_019ef965-c0a1-7ee8-abb8-5b1d1f1d31ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_019ef965-c0a1-7c1d-9e25-25d8d147fd92" xlink:href="sny-20260630.xsd#sny_OtherBankBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_OtherBankBorrowings_019ef965-c0a1-7c1d-9e25-25d8d147fd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_019ef965-c0a1-7b99-92cc-7be803b78eda" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_OtherBorrowings_019ef965-c0a1-7b99-92cc-7be803b78eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_019ef965-c0a1-7e56-afe4-23f100991b33" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_019ef965-c0a1-7e56-afe4-23f100991b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-755f-bb9a-eb62eaa6e446" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_019ef965-c0a1-755f-bb9a-eb62eaa6e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7295-8aaa-d0c6405c5b4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-7295-8aaa-d0c6405c5b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-727b-b0b8-09e6d26ba01a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_CashAndCashEquivalents_019ef965-c0a1-727b-b0b8-09e6d26ba01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-724e-a5eb-da7d9f26d6dc" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_019ef965-c0a1-724e-a5eb-da7d9f26d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7702-803b-e374271077ec" xlink:href="sny-20260630.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_019ef965-c0a1-7702-803b-e374271077ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019f6afd-f1b3-7867-b01f-a6223c1b5250" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_019ef965-c0a1-7709-b678-c8676a56ba01" xlink:to="loc_ifrs-full_NotionalAmount_019f6afd-f1b3-7867-b01f-a6223c1b5250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7c75-8c98-f60aca69a080" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-7c75-8c98-f60aca69a080" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7e61-a280-6449472ba64d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7e61-a280-6449472ba64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_019ef965-c0a1-7e61-a280-6449472ba64d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TwoBillionThreeHundredMillionBondsMember_019f1dd9-c4e2-7be5-9eda-60adb2acd99d" xlink:href="sny-20260630.xsd#sny_TwoBillionThreeHundredMillionBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_TwoBillionThreeHundredMillionBondsMember_019f1dd9-c4e2-7be5-9eda-60adb2acd99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMarch2029Member_019f1dd9-c4e2-73cf-b862-50f901b4f1dd" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMarch2029Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondMaturingMarch2029Member_019f1dd9-c4e2-73cf-b862-50f901b4f1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMay2033Member_019f1dd9-c4e2-7d92-84e0-b08c0b862fe0" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMay2033Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondMaturingMay2033Member_019f1dd9-c4e2-7d92-84e0-b08c0b862fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondMaturingMay2037Member_019f1dd9-c4e2-77ce-aa00-7ecb5d5d37d3" xlink:href="sny-20260630.xsd#sny_FixedRateBondMaturingMay2037Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondMaturingMay2037Member_019f1dd9-c4e2-77ce-aa00-7ecb5d5d37d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FixedRateBondIssueFromMarch2018Member_019f1dd9-c4e2-77d8-9c5a-56eadd68bb70" xlink:href="sny-20260630.xsd#sny_FixedRateBondIssueFromMarch2018Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FixedRateBondIssueFromMarch2018Member_019f1dd9-c4e2-77d8-9c5a-56eadd68bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingOnMarch2030Member_019f1dd9-c4e2-79a8-bd40-ea49f7284785" xlink:href="sny-20260630.xsd#sny_FourBillionFacilityMaturingOnMarch2030Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FourBillionFacilityMaturingOnMarch2030Member_019f1dd9-c4e2-79a8-bd40-ea49f7284785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member_019f1dd9-c4e2-7598-808a-0d9a2cc7b700" xlink:href="sny-20260630.xsd#sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member_019f1dd9-c4e2-7598-808a-0d9a2cc7b700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingApril2026Member_019f1dd9-c4e2-743c-972e-9cf85dd95f49" xlink:href="sny-20260630.xsd#sny_FourBillionFacilityMaturingApril2026Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_FourBillionFacilityMaturingApril2026Member_019f1dd9-c4e2-743c-972e-9cf85dd95f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_019f1dd9-c4e2-7d7a-ac69-48d69fdcd100" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_019f1dd9-c4e2-7d7a-ac69-48d69fdcd100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_019f1dd9-c4e2-739a-98f6-0c4149315048" xlink:href="sny-20260630.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_019ef965-c0a1-7cf4-8f90-7e8e8a5c997d" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_019f1dd9-c4e2-739a-98f6-0c4149315048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentAxis_019f1dd9-c4e2-713c-96fa-7ec5544573b7" xlink:href="sny-20260630.xsd#sny_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:to="loc_sny_DebtInstrumentAxis_019f1dd9-c4e2-713c-96fa-7ec5544573b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-7fb2-975d-db598b22a455" xlink:href="sny-20260630.xsd#sny_DebtInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentAxis_019f1dd9-c4e2-713c-96fa-7ec5544573b7" xlink:to="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-7fb2-975d-db598b22a455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_019f1dd9-c4e2-7afd-a27f-32f1df96d7d3" xlink:href="sny-20260630.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_019f1dd9-c4e2-7fb2-975d-db598b22a455" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_019f1dd9-c4e2-7afd-a27f-32f1df96d7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_019f6afd-50d5-7a31-9a04-b176d777483b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:to="loc_ifrs-full_HedgedItemsAxis_019f6afd-50d5-7a31-9a04-b176d777483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7222-9d08-17873c2dd01c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_019f6afd-50d5-7a31-9a04-b176d777483b" xlink:to="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7222-9d08-17873c2dd01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInvestmentHedgeMember_019f6afd-8abd-7248-96ad-746778cb4929" xlink:href="sny-20260630.xsd#sny_NetInvestmentHedgeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsDomain_019f6afd-50d5-7222-9d08-17873c2dd01c" xlink:to="loc_sny_NetInvestmentHedgeMember_019f6afd-8abd-7248-96ad-746778cb4929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-72c9-bfd7-a2cf822ed30d" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019f1dd9-c4e2-7f8b-b07b-36fcd10cf99e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_ifrs-full_NotionalAmount_019f1dd9-c4e2-7f8b-b07b-36fcd10cf99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTranches_019f1dd9-c4e2-74d9-a218-6755ef1b9777" xlink:href="sny-20260630.xsd#sny_NumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfTranches_019f1dd9-c4e2-74d9-a218-6755ef1b9777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_019f1dd9-c4e2-7c7a-80da-800db3e8cfc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_ifrs-full_BorrowingsInterestRate_019f1dd9-c4e2-7c7a-80da-800db3e8cfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondRedeemed_019f1dd9-c4e2-7560-b149-1297e9d80d25" xlink:href="sny-20260630.xsd#sny_NumberOfBondRedeemed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfBondRedeemed_019f1dd9-c4e2-7560-b149-1297e9d80d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSyndicatedCreditFacilities_019f1dd9-c4e2-7545-8c25-5590a0a7d0b5" xlink:href="sny-20260630.xsd#sny_NumberOfSyndicatedCreditFacilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfSyndicatedCreditFacilities_019f1dd9-c4e2-7545-8c25-5590a0a7d0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOneYearExtensionOptions_019f8f7c-3515-70a1-8706-47cfa0b2a7b5" xlink:href="sny-20260630.xsd#sny_NumberOfOneYearExtensionOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfOneYearExtensionOptions_019f8f7c-3515-70a1-8706-47cfa0b2a7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExtensionTerm_019f8f7d-54b0-798b-8464-c3e3d3cf524b" xlink:href="sny-20260630.xsd#sny_ExtensionTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_ExtensionTerm_019f8f7d-54b0-798b-8464-c3e3d3cf524b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShortTermDebtProgram_019f1dd9-c4e2-757d-bb1a-513468b8e776" xlink:href="sny-20260630.xsd#sny_NumberOfShortTermDebtProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_NumberOfShortTermDebtProgram_019f1dd9-c4e2-757d-bb1a-513468b8e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_019f1dd9-c4e2-7e0f-a281-ed4a64777211" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_ifrs-full_CommercialPapersIssued_019f1dd9-c4e2-7e0f-a281-ed4a64777211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_019f1dd9-c4e2-7b8a-adb6-5464646429bb" xlink:href="sny-20260630.xsd#sny_BorrowingAverageDrawdown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019f1dd9-c4e2-7f35-b9c0-91ad271ed6a8" xlink:to="loc_sny_BorrowingAverageDrawdown_019f1dd9-c4e2-7b8a-adb6-5464646429bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-796b-bdb7-3a265e8c43ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-7d76-89bf-b804872ab4b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_019ef965-c0a1-796b-bdb7-3a265e8c43ac" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-7d76-89bf-b804872ab4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a12-aef8-8d34d68d7dfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-7d76-89bf-b804872ab4b0" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a12-aef8-8d34d68d7dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a12-aef8-8d34d68d7dfd" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_019ef965-c0a1-7db8-b3cc-5bb7b69887f4" xlink:href="sny-20260630.xsd#sny_AtMarketValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:to="loc_sny_AtMarketValueMember_019ef965-c0a1-7db8-b3cc-5bb7b69887f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7a06-9a96-25735f898513" xlink:href="sny-20260630.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-75ef-92ef-528fe5b4c991" xlink:to="loc_sny_ValueOnRedemptionMember_019ef965-c0a1-7a06-9a96-25735f898513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_019ef965-c0a1-7d76-89bf-b804872ab4b0" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_019ef965-c0a1-7c1e-b1aa-9bae37b180f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:to="loc_ifrs-full_Borrowings_019ef965-c0a1-7c1e-b1aa-9bae37b180f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_019ef965-c0a1-75cc-b21d-eee6fdbdbabf" xlink:href="sny-20260630.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_019ef965-c0a1-7d54-b338-01c18c72c5fa" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_019ef965-c0a1-75cc-b21d-eee6fdbdbabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-7e68-8022-04c47a6bfd48" xlink:href="sny-20260630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-7e68-8022-04c47a6bfd48" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-71b2-b44e-9e8277183068" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-71b2-b44e-9e8277183068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-71b2-b44e-9e8277183068" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c13-aa14-298c5b5decb7" xlink:href="sny-20260630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:to="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c13-aa14-298c5b5decb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7fd9-9bb4-20cb2b4e48cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7c33-af7c-19b5449c7eae" xlink:to="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7fd9-9bb4-20cb2b4e48cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-75fc-8c14-d93946c4f61c" xlink:href="sny-20260630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7fd9-9bb4-20cb2b4e48cb" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-75fc-8c14-d93946c4f61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-7250-aeec-db09ba1faaa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-7250-aeec-db09ba1faaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-7250-aeec-db09ba1faaa2" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-75de-abd0-f057ae87666e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:to="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-75de-abd0-f057ae87666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_019ef965-c0a1-73e9-b036-9c5e2f8ed8f4" xlink:href="sny-20260630.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-73c7-8678-c810e4ee2e88" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_019ef965-c0a1-73e9-b036-9c5e2f8ed8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7caf-b6f3-6ba76f51394f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7caf-b6f3-6ba76f51394f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7caf-b6f3-6ba76f51394f" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:to="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-7288-b60e-fec0bb5833ef" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-7288-b60e-fec0bb5833ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_019ef965-c0a1-73a3-8dce-766e4b3039a1" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_019ef965-c0a1-73a3-8dce-766e4b3039a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_019ef965-c0a1-7b68-93d0-c9a6929bae71" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_019ef965-c0a1-7b68-93d0-c9a6929bae71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65a1-0037-79df-a9a8-6f3aa76dbf00" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65a1-0037-79df-a9a8-6f3aa76dbf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSaudiArabianRiyalMember_019f65a2-e824-794a-999b-932e9106e336" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInSaudiArabianRiyalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7512-bcdc-a7674807ca30" xlink:to="loc_sny_ForwardCurrencySalesInSaudiArabianRiyalMember_019f65a2-e824-794a-999b-932e9106e336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7e9b-ae4d-c2d0512a0849" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-79e4-a361-da4314ddb354" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-79e4-a361-da4314ddb354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-74fa-bb39-76dfeee2928a" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-74fa-bb39-76dfeee2928a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_019ef965-c0a1-72e4-b656-c115e6de23f7" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember_019ef965-c0a1-72e4-b656-c115e6de23f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_019ef965-c0a1-74f2-b20f-855072abe252" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInTurkishLiraMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInTurkishLiraMember_019ef965-c0a1-74f2-b20f-855072abe252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember_019f1de6-252b-7f55-9eb2-0eece2e63485" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7722-8824-9147bce59e1a" xlink:to="loc_sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember_019f1de6-252b-7f55-9eb2-0eece2e63485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f65a9-e9e0-781d-ad8a-2c802b00d217" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_sny_DisposalGroupAxis_019f65a9-e9e0-781d-ad8a-2c802b00d217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f65a9-e9e0-7284-87c1-0548d4b197a3" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupAxis_019f65a9-e9e0-781d-ad8a-2c802b00d217" xlink:to="loc_sny_DisposalGroupDomain_019f65a9-e9e0-7284-87c1-0548d4b197a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedleyMember_019f65aa-28ff-761f-b94b-8c4e409ae789" xlink:href="sny-20260630.xsd#sny_MedleyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupDomain_019f65a9-e9e0-7284-87c1-0548d4b197a3" xlink:to="loc_sny_MedleyMember_019f65aa-28ff-761f-b94b-8c4e409ae789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_019ef965-c0a1-7461-8e4a-c2ad3069d697" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_019ef965-c0a1-7e1a-9311-f6c130a4e4e1" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_019ef965-c0a1-7461-8e4a-c2ad3069d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_019ef965-c0a1-7f6a-b037-0c9b73b3edbd" xlink:href="sny-20260630.xsd#sny_DerivativeFinancialInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_019ef965-c0a1-7461-8e4a-c2ad3069d697" xlink:to="loc_sny_DerivativeFinancialInstruments_019ef965-c0a1-7f6a-b037-0c9b73b3edbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-7838-8e30-1bc94b10ff3c" xlink:href="sny-20260630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-7838-8e30-1bc94b10ff3c" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a27-b8d8-199cb0e08880" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a27-b8d8-199cb0e08880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7a27-b8d8-199cb0e08880" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_019ef965-c0a1-73cb-8f31-42e9072b8188" xlink:href="sny-20260630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:to="loc_sny_AtNotionalAmountMember_019ef965-c0a1-73cb-8f31-42e9072b8188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7712-9f9d-be14f9402636" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7b2f-9473-049973feb68b" xlink:to="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7712-9f9d-be14f9402636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7805-a1b2-17ee315f762c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7805-a1b2-17ee315f762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7805-a1b2-17ee315f762c" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsMember_019ef965-c0a1-7c23-afd5-e07262f7760d" xlink:href="sny-20260630.xsd#sny_CrossCurrencySellerSwapsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySellerSwapsMember_019ef965-c0a1-7c23-afd5-e07262f7760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_019ef965-c0a1-7b01-b8b5-69ee2ddf3e51" xlink:href="sny-20260630.xsd#sny_CrossCurrencySellerSwapsInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CrossCurrencySellerSwapsMember_019ef965-c0a1-7c23-afd5-e07262f7760d" xlink:to="loc_sny_CrossCurrencySellerSwapsInUSDollarMember_019ef965-c0a1-7b01-b8b5-69ee2ddf3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-77e9-897a-0f12e9a7a755" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_019ef965-c0a1-77e9-897a-0f12e9a7a755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInPoundSterlingMember_019ef965-c0a1-7153-b095-fc6e6fec4a79" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInPoundSterlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:to="loc_sny_ForwardCurrencySalesInPoundSterlingMember_019ef965-c0a1-7153-b095-fc6e6fec4a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65ab-68cf-71f1-a8e1-883171e4b901" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_019ef965-c0a1-7dc2-81fc-e5cfbc41e6e6" xlink:to="loc_sny_ForwardCurrencySalesInBrazilianRealMember_019f65ab-68cf-71f1-a8e1-883171e4b901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-7743-90c6-57587c0dbfbd" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarMember_019ef965-c0a1-7743-90c6-57587c0dbfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-7106-b0fb-25915663f3cc" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:to="loc_sny_ForwardCurrencyPurchasesInSingaporeDollarMember_019ef965-c0a1-7106-b0fb-25915663f3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_019ef965-c0a1-786d-bb1a-543a9eab22cf" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInHungarianFlorintMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_019ef965-c0a1-7f41-90d8-d338c43aac46" xlink:to="loc_sny_ForwardCurrencyPurchasesInHungarianFlorintMember_019ef965-c0a1-786d-bb1a-543a9eab22cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2029Member_019ef965-c0a1-7d6b-8b6f-083cabf7db04" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapExpiring2029Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySwapExpiring2029Member_019ef965-c0a1-7d6b-8b6f-083cabf7db04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapExpiring2032Member_019ef965-c0a1-7c5f-b687-00e3c42c5fc0" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapExpiring2032Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySwapExpiring2032Member_019ef965-c0a1-7c5f-b687-00e3c42c5fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CrossCurrencySwapMember_019ef965-c0a1-742a-a100-35fe8fa79b39" xlink:href="sny-20260630.xsd#sny_CrossCurrencySwapMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_CrossCurrencySwapMember_019ef965-c0a1-742a-a100-35fe8fa79b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member_019f65b0-a5e8-737f-bd08-2e3915f15884" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member_019f65b0-a5e8-737f-bd08-2e3915f15884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member_019f65b9-2ff4-720c-9843-593325f96895" xlink:href="sny-20260630.xsd#sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member_019f65b9-2ff4-720c-9843-593325f96895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_019f1df8-c3f1-7c22-8ad9-e906d6ad8a22" xlink:href="sny-20260630.xsd#sny_ForwardCurrencyPurchasesInUSDollarUSBondMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7866-9e1b-00e517634467" xlink:to="loc_sny_ForwardCurrencyPurchasesInUSDollarUSBondMember_019f1df8-c3f1-7c22-8ad9-e906d6ad8a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7dff-b996-f98498d4322b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7dff-b996-f98498d4322b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7dff-b996-f98498d4322b" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7a9d-b81e-07a1aed74048" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7a9d-b81e-07a1aed74048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-7e07-9856-e77c2755f66b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7404-9700-219bfe2e46a0" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-7e07-9856-e77c2755f66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_019ef965-c0a1-7a7f-a973-3899a000443e" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_019ef965-c0a1-7e76-8aca-5f866d2a7c2a" xlink:href="sny-20260630.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_019ef965-c0a1-7e76-8aca-5f866d2a7c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCrossCurrencySwaps_019f1ded-0ff0-714d-bdae-a2c698c657f7" xlink:href="sny-20260630.xsd#sny_NumberOfCrossCurrencySwaps"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_sny_NumberOfCrossCurrencySwaps_019f1ded-0ff0-714d-bdae-a2c698c657f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_019ef965-c0a1-7820-8500-72bb1e387795" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_NotionalAmount_019ef965-c0a1-7820-8500-72bb1e387795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_019f65c1-c98e-776f-bddb-1126e4ee43a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_019f65c1-c98e-776f-bddb-1126e4ee43a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-c0a1-7595-9e6e-d6e62e832671" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_019ef965-c0a1-7595-9e6e-d6e62e832671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_019f65b5-bcd4-7c15-8c1c-7a2e109e9c04" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_019ef965-c0a1-73cc-adc8-85fcaeceaad2" xlink:to="loc_ifrs-full_FinanceIncomeCost_019f65b5-bcd4-7c15-8c1c-7a2e109e9c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-74d1-a8f9-649ca002da8f" xlink:href="sny-20260630.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_019ef965-c0a1-74d1-a8f9-649ca002da8f" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7ad2-9f01-9c5f1c760921" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7ad2-9f01-9c5f1c760921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgingInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_019ef965-c0a1-7ad2-9f01-9c5f1c760921" xlink:to="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember_019f1e04-f0ae-7a2e-9669-d008309202aa" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember_019f1e04-f0ae-7a2e-9669-d008309202aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember_019f1e04-f0ae-7b80-ad91-459641b88dec" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember_019f1e04-f0ae-7b80-ad91-459641b88dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member_019f1e04-f0ae-7423-b660-e7a2004a680e" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member_019f1e04-f0ae-7423-b660-e7a2004a680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member_019f1e04-f0ae-70dd-940b-1bbce6c2c188" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member_019f1e04-f0ae-70dd-940b-1bbce6c2c188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember_019f1e04-f0ae-7df9-a285-a5128c603c49" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember_019f1e04-f0ae-7df9-a285-a5128c603c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_019f1e04-f0ae-7347-afb8-3c259f39bf1c" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_019f1e04-f0ae-7347-afb8-3c259f39bf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member_019f65c3-12c8-7047-9ea5-b1f887ec3e58" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member_019f65c3-12c8-7047-9ea5-b1f887ec3e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member_019f65c3-65bb-724f-bf83-fbfb05e88fb6" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member_019f65c3-65bb-724f-bf83-fbfb05e88fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member_019f1e04-f0ae-76db-9c1f-37f2e1e37717" xlink:href="sny-20260630.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsDomain_019ef965-c0a1-7114-ba66-ce8e3011b15c" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member_019f1e04-f0ae-76db-9c1f-37f2e1e37717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7caf-b773-abcafe8d2a70" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7caf-b773-abcafe8d2a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MeasurementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_019ef965-c0a1-7caf-b773-abcafe8d2a70" xlink:to="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c48-a693-ce36a532e656" xlink:href="sny-20260630.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:to="loc_sny_AtNotionalAmountMember_019ef965-c0a1-7c48-a693-ce36a532e656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7f2d-aa2c-5871e24deec7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:to="loc_ifrs-full_AtFairValueMember_019ef965-c0a1-7f2d-aa2c-5871e24deec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-7ed5-84e5-8b8fe5485cad" xlink:href="sny-20260630.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementDomain_019ef965-c0a1-7552-8bb0-56a2a96afcab" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_019ef965-c0a1-7ed5-84e5-8b8fe5485cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7eb9-9697-195ac8d7f5e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7eb9-9697-195ac8d7f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7eb9-9697-195ac8d7f5e9" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7949-bd38-1fbd3fcecb45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_019ef965-c0a1-7949-bd38-1fbd3fcecb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-766b-809c-2f426798d319" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_019ef965-c0a1-766b-809c-2f426798d319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_019ef965-c0a1-73d2-9bab-e1423b6a5182" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_019ef965-c0a1-73d2-9bab-e1423b6a5182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_019ef965-c0a1-7bee-aec7-ee540e6b50a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_019ef965-c0a1-7bee-aec7-ee540e6b50a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_019ef965-c0a1-777a-b131-48a709f743f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7461-b7fa-053f155d8f4e" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_019ef965-c0a1-777a-b131-48a709f743f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-77a7-9041-52edb6b38428" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-77a7-9041-52edb6b38428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TypesOfHedgesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_019ef965-c0a1-77a7-9041-52edb6b38428" xlink:to="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_019ef965-c0a1-7ad6-ad6f-0d7e953c5736" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:to="loc_ifrs-full_FairValueHedgesMember_019ef965-c0a1-7ad6-ad6f-0d7e953c5736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-7cff-b6f7-a521deee263c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesDomain_019ef965-c0a1-7689-9866-7cdc5253054d" xlink:to="loc_ifrs-full_CashFlowHedgesMember_019ef965-c0a1-7cff-b6f7-a521deee263c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_019ef965-c0a1-72e7-a468-5573c29f8bbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_019ef965-c0a1-7a3d-9891-e21587299542" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_019ef965-c0a1-72e7-a468-5573c29f8bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_019ef965-c0a1-7da1-ad6e-13436f89d09a" xlink:href="sny-20260630.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_019ef965-c0a1-72e7-a468-5573c29f8bbb" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_019ef965-c0a1-7da1-ad6e-13436f89d09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-7570-a4f6-89f7bd004e5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-78ce-a1b3-6d6c1355e1d5" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-7570-a4f6-89f7bd004e5d" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-78ce-a1b3-6d6c1355e1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-7025-ba49-c7928e2bc215" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-78ce-a1b3-6d6c1355e1d5" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-7025-ba49-c7928e2bc215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-7025-ba49-c7928e2bc215" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-76cf-8ff9-3b84fa46ab8c" xlink:href="sny-20260630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-76cf-8ff9-3b84fa46ab8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember_019f1e09-22f8-7460-8533-04966b2023a5" xlink:href="sny-20260630.xsd#sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember_019f1e09-22f8-7460-8533-04966b2023a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember_019f1e09-5e40-7e7a-bbfd-575b90b472ce" xlink:href="sny-20260630.xsd#sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember_019f1e09-5e40-7e7a-bbfd-575b90b472ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_019ef965-c0a1-70f3-a1a1-a6eae3e1ba18" xlink:href="sny-20260630.xsd#sny_OtherLiabilities1Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7cce-b7e0-ef69939e0b7d" xlink:to="loc_sny_OtherLiabilities1Member_019ef965-c0a1-70f3-a1a1-a6eae3e1ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-78ce-a1b3-6d6c1355e1d5" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:href="sny-20260630.xsd#sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:to="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-7536-be1f-0fe43c825bd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-7536-be1f-0fe43c825bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-71bf-99b1-50ea09c130e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-71bf-99b1-50ea09c130e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_019ef965-c0a1-7832-b71d-e6a1034f1b77" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_019ef965-c0a1-7832-b71d-e6a1034f1b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_019ef965-c0a1-7fe8-8c99-994537018c34" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests_019ef965-c0a1-7fe8-8c99-994537018c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-7e07-bfd9-67a7743a0739" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward_019ef965-c0a1-7617-bef0-9b7ff61112d7" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-7e07-bfd9-67a7743a0739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-77c4-95fb-1838e5f6219c" xlink:href="sny-20260630.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-77c4-95fb-1838e5f6219c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-7081-a220-6dedbe0dc2c2" xlink:href="sny-20260630.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7b4a-a4d5-7854887dc4e3" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_019ef965-c0a1-7081-a220-6dedbe0dc2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-7e1f-9ec6-1e4190db6715" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-76e3-9550-23088e17476a" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract_019ef965-c0a1-7e1f-9ec6-1e4190db6715" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-76e3-9550-23088e17476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-70fe-939c-7236c2f91dc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-76e3-9550-23088e17476a" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-70fe-939c-7236c2f91dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7e19-a69f-1adf49d9eac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019ef965-c0a1-70fe-939c-7236c2f91dc6" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7e19-a69f-1adf49d9eac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-7b7a-8a65-c28efd504a1a" xlink:href="sny-20260630.xsd#sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019ef965-c0a1-7e19-a69f-1adf49d9eac9" xlink:to="loc_sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember_019ef965-c0a1-7b7a-8a65-c28efd504a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:href="sny-20260630.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable_019ef965-c0a1-76e3-9550-23088e17476a" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-729b-ab77-cf66fe41fab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_019ef965-c0a1-729b-ab77-cf66fe41fab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_019ef965-c0a1-74d6-abee-81af57b153c9" xlink:href="sny-20260630.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems_019ef965-c0a1-7260-a1ef-07ff6104848c" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_019ef965-c0a1-74d6-abee-81af57b153c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7325-af92-c577d3f6414d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-7325-af92-c577d3f6414d" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8" xlink:href="sny-20260630.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:to="loc_sny_PrincipalAlliancesAxis_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-7da5-b78e-1655fe03736a" xlink:href="sny-20260630.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_019ef965-c0a1-73e5-bff6-a2bc9a69a0d8" xlink:to="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-7da5-b78e-1655fe03736a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_019ef965-c0a1-7a2d-b19c-0691bf296d44" xlink:href="sny-20260630.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_019ef965-c0a1-7da5-b78e-1655fe03736a" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_019ef965-c0a1-7a2d-b19c-0691bf296d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:to="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7f09-8445-269526cba260" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7ecb-8cfc-8c30d1b0ef4c" xlink:to="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7f09-8445-269526cba260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_019ef965-c0a1-76a6-8bd6-9ab2cf306378" xlink:href="sny-20260630.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-7f09-8445-269526cba260" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_019ef965-c0a1-76a6-8bd6-9ab2cf306378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7a53-a11d-e40791c89569" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:to="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7a53-a11d-e40791c89569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_019ef965-c0a1-7a53-a11d-e40791c89569" xlink:to="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_019ef965-c0a1-72f6-996b-cee19566891a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_019ef965-c0a1-72f6-996b-cee19566891a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_019ef965-c0a1-700f-a386-f6c0a915081b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_019ef965-c0a1-7cdb-b888-3f96d53dc1f9" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_019ef965-c0a1-700f-a386-f6c0a915081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7b59-98aa-152a17e383c9" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-70af-8d9c-ec151f6fad45" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:to="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-70af-8d9c-ec151f6fad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_019ef965-c0a1-7498-be37-17ea6a2bf7df" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_019ef965-c0a1-7498-be37-17ea6a2bf7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c0a1-721d-a2ae-4c6afc63ec52" xlink:href="sny-20260630.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-72e4-ae0a-1897a0c7eb37" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_019ef965-c0a1-721d-a2ae-4c6afc63ec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-75be-88dd-d6fa168eb74a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7595-8551-11e092c5160d" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-75be-88dd-d6fa168eb74a" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7595-8551-11e092c5160d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_019ef965-c0a1-79db-987d-49eedf38a140" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7595-8551-11e092c5160d" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_019ef965-c0a1-79db-987d-49eedf38a140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_019ef965-c0a1-79db-987d-49eedf38a140" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_019ef965-c0a1-7989-93c2-a7765c721906" xlink:href="sny-20260630.xsd#sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember_019ef965-c0a1-7989-93c2-a7765c721906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_019ef965-c0a1-7917-a423-38110c77ec24" xlink:href="sny-20260630.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_019ef965-c0a1-7917-a423-38110c77ec24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_019ef965-c0a1-752c-9b01-735b29e21aa4" xlink:href="sny-20260630.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_019ef965-c0a1-752c-9b01-735b29e21aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_019ef965-c0a1-767d-a78f-737429cdf31e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_019ef965-c0a1-77c6-b865-763effa27276" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_019ef965-c0a1-767d-a78f-737429cdf31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-77ac-b287-07802b41398e" xlink:href="sny-20260630.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_019ef965-c0a1-7595-8551-11e092c5160d" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-77ac-b287-07802b41398e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_019ef965-c0a1-77ac-b287-07802b41398e" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7c84-90d2-7a5b67b95eb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7c84-90d2-7a5b67b95eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_019f7fda-b67f-7b2f-821f-2154100e4103" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_019f7fda-b67f-7b2f-821f-2154100e4103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities_019f1e13-943c-76d7-8040-4db59185c0ea" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInProvisionsAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities_019f1e13-943c-76d7-8040-4db59185c0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_019f1e13-943c-7360-a720-cc5f8d0be80f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_019f1e13-943c-7360-a720-cc5f8d0be80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_019f1e13-943c-7c06-9e93-419f59902f9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_019f1e13-943c-7c06-9e93-419f59902f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_019f1e13-943c-7ee9-87ae-c19d5d5470ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_019f1e13-943c-7ee9-87ae-c19d5d5470ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_019f1e13-943c-75dc-b0ed-b987602b0517" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions_019f1e13-943c-75dc-b0ed-b987602b0517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_019f1e13-943c-77d3-b0f9-25ef6f6d48d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_019f1e13-943c-77d3-b0f9-25ef6f6d48d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_019f1e13-943c-73bb-8a6e-1df8fde3b1e6" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions_019f1e13-943c-73bb-8a6e-1df8fde3b1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7488-82bc-82b5fb323ec9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_019ef965-c0a1-7c4a-926b-6a0f9319e3ca" xlink:to="loc_ifrs-full_NoncurrentProvisions_019ef965-c0a1-7488-82bc-82b5fb323ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-715c-85ec-3b3312a784cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_019ef965-c0a1-715c-85ec-3b3312a784cc" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c0a1-73c4-b1a7-d5b853318dac" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c0a1-73c4-b1a7-d5b853318dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_019ef965-c0a1-73c4-b1a7-d5b853318dac" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_019ef965-c0a1-74c9-b460-eeaa5bef98aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PlanAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:to="loc_ifrs-full_PlanAssetsMember_019ef965-c0a1-74c9-b460-eeaa5bef98aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_019f7fdd-5021-78db-b28b-d2d2ce0f3605" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetDomain_019ef965-c0a1-7231-be57-8c2f114ac150" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_019f7fdd-5021-78db-b28b-d2d2ce0f3605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_019ef965-c0a1-7fd5-98ed-4e846edc4080" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_019ef965-c0a1-7fd5-98ed-4e846edc4080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-723f-a53a-e3f633796d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_019ef965-c0a1-7fd5-98ed-4e846edc4080" xlink:to="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-723f-a53a-e3f633796d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_019ef965-c0a1-7ac3-865f-3818569f7e36" xlink:href="sny-20260630.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansDomain_019ef965-c0a1-723f-a53a-e3f633796d60" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_019ef965-c0a1-7ac3-865f-3818569f7e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019ef965-c0a1-79d8-84f8-9aea209f3026" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019ef965-c0a1-79d8-84f8-9aea209f3026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-7e3c-abe5-435cbab765e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-c0a1-79d8-84f8-9aea209f3026" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-7e3c-abe5-435cbab765e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_019ef965-c0a1-704c-87ac-4f74e4ac6df7" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c0a1-7e3c-abe5-435cbab765e4" xlink:to="loc_country_GB_019ef965-c0a1-704c-87ac-4f74e4ac6df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_019ef965-c0a1-7a4f-9905-e36cef59fa65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_019ef965-c0a1-7a4f-9905-e36cef59fa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_019ef965-c0a1-7a4f-9905-e36cef59fa65" xlink:to="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_019ef965-c0a1-7e8f-bab6-45007dbc3e19" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_019ef965-c0a1-7e8f-bab6-45007dbc3e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_019ef965-c0a1-7fae-aab8-de9334a1928d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsDomain_019ef965-c0a1-7d55-87ed-2c00f87c1af7" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_019ef965-c0a1-7fae-aab8-de9334a1928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019ef965-c0a1-77a1-b02e-2e3954f530dc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_srt_RangeAxis_019ef965-c0a1-77a1-b02e-2e3954f530dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019ef965-c0a1-77a1-b02e-2e3954f530dc" xlink:to="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019ef965-c0a1-7e42-8819-5b21197ea7fa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:to="loc_srt_MinimumMember_019ef965-c0a1-7e42-8819-5b21197ea7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019ef965-c0a1-7056-84b3-a8ba7d707899" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019ef965-c0a1-7680-98e7-d5c2c2072d34" xlink:to="loc_srt_MaximumMember_019ef965-c0a1-7056-84b3-a8ba7d707899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-71da-b7ac-23ddff242a31" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-71da-b7ac-23ddff242a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7fca-bd3f-b943e848737a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019ef965-c0a1-71da-b7ac-23ddff242a31" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7fca-bd3f-b943e848737a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019ef965-c0a1-7921-91ed-1e26ffec5425" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019ef965-c0a1-7fca-bd3f-b943e848737a" xlink:to="loc_sny_OpellaBusinessMember_019ef965-c0a1-7921-91ed-1e26ffec5425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_019ef965-c0a1-76ab-b227-12bafa3720e6" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_019ef965-c0a1-751d-a01e-327e5e8caeb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_019ef965-c0a1-751d-a01e-327e5e8caeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_019ef965-c0a1-77d4-b78e-b58f99db141c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_019ef965-c0a1-77d4-b78e-b58f99db141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_019ef965-c0a1-7fc3-a876-1966c9a27e85" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_019ef965-c0a1-7fc3-a876-1966c9a27e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_019ef965-c0a1-790e-a0e9-e01622936c97" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_019ef965-c0a1-7a26-99b7-a5cf3e5326ec" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_019ef965-c0a1-790e-a0e9-e01622936c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OffbalancesheetcommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsAbstract_019ef965-c0a1-7c37-942f-04dbb4c8b90b" xlink:href="sny-20260630.xsd#sny_OffBalanceSheetCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OffBalanceSheetCommitmentsAbstract_019ef965-c0a1-7c37-942f-04dbb4c8b90b" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7d9b-be0e-a38d5239e202" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:to="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7d9b-be0e-a38d5239e202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_019ef965-c0a1-7d9b-be0e-a38d5239e202" xlink:to="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CTTQMember_019f937e-2bf5-778f-ad68-bd7c424bc148" xlink:href="sny-20260630.xsd#sny_CTTQMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:to="loc_sny_CTTQMember_019f937e-2bf5-778f-ad68-bd7c424bc148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KaliTherapeuticsMember_019fa2c7-bd6b-7851-a752-d1d7bb35e7b0" xlink:href="sny-20260630.xsd#sny_KaliTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_019ef965-c0a1-74e2-935c-3380fb63a5f1" xlink:to="loc_sny_KaliTherapeuticsMember_019fa2c7-bd6b-7851-a752-d1d7bb35e7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_019f937c-a757-7aaa-a302-ff4c02e7aa39" xlink:href="sny-20260630.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:to="loc_sny_TypesOfAgreementAxis_019f937c-a757-7aaa-a302-ff4c02e7aa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:href="sny-20260630.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_019f937c-a757-7aaa-a302-ff4c02e7aa39" xlink:to="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CTTQRovidicitinibLicenseAgreementMember_019f937c-da30-7828-b6e6-70636c3d0dff" xlink:href="sny-20260630.xsd#sny_CTTQRovidicitinibLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:to="loc_sny_CTTQRovidicitinibLicenseAgreementMember_019f937c-da30-7828-b6e6-70636c3d0dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KaliTherapeuticsLicenseAgreementMember_019fa2c8-4e0b-78de-9931-4c1096372b0f" xlink:href="sny-20260630.xsd#sny_KaliTherapeuticsLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_019f937c-a757-7cf2-a631-d0c84ddf7673" xlink:to="loc_sny_KaliTherapeuticsLicenseAgreementMember_019fa2c8-4e0b-78de-9931-4c1096372b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c0a1-771c-af1d-6066eb942b01" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontLicensePayment_019f937c-469d-7ade-9d33-6a106b171d27" xlink:href="sny-20260630.xsd#sny_UpfrontLicensePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:to="loc_sny_UpfrontLicensePayment_019f937c-469d-7ade-9d33-6a106b171d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments_019f9380-96f6-712e-96f2-953f90759ddb" xlink:href="sny-20260630.xsd#sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019ef965-c0a1-7b72-b27e-154365b3f35f" xlink:to="loc_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments_019f9380-96f6-712e-96f2-953f90759ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#LitigationandarbitrationproceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_019ef965-c0a1-7a9f-9231-bee1819a6c76" xlink:href="sny-20260630.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_019ef965-c0a1-7a9f-9231-bee1819a6c76" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_019f9382-51b8-77d8-9584-5006197004e1" xlink:href="sny-20260630.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_019f9382-51b8-77d8-9584-5006197004e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:href="sny-20260630.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_019f9382-51b8-77d8-9584-5006197004e1" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember_019f9382-51b8-7e06-9910-5376416a09a2" xlink:href="sny-20260630.xsd#sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:to="loc_sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember_019f9382-51b8-7e06-9910-5376416a09a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HudsonHeadwatersHealthNetworkMember_019f9382-51b8-7be0-9276-8272188d6a1d" xlink:href="sny-20260630.xsd#sny_HudsonHeadwatersHealthNetworkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:to="loc_sny_HudsonHeadwatersHealthNetworkMember_019f9382-51b8-7be0-9276-8272188d6a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MosaicHealthInTheUSMember_019f9382-51b8-71a1-b915-2ab47581d439" xlink:href="sny-20260630.xsd#sny_MosaicHealthInTheUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_019f9382-51b8-7e32-b9ca-ebde75ea7d8b" xlink:to="loc_sny_MosaicHealthInTheUSMember_019f9382-51b8-71a1-b915-2ab47581d439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_019f9382-51b8-721e-9615-21a6fa6d577e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_019f9382-51b8-721e-9615-21a6fa6d577e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_019f9382-51b8-721e-9615-21a6fa6d577e" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TalcProductLitigationInTheUSMember_019f9383-a750-7110-9f0e-dfebcffc687f" xlink:href="sny-20260630.xsd#sny_TalcProductLitigationInTheUSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:to="loc_sny_TalcProductLitigationInTheUSMember_019f9383-a750-7110-9f0e-dfebcffc687f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A340BDrugPricingProgramInTheUSMember_019f9382-51b8-7356-9ecb-15d7f8359aa7" xlink:href="sny-20260630.xsd#sny_A340BDrugPricingProgramInTheUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:to="loc_sny_A340BDrugPricingProgramInTheUSMember_019f9382-51b8-7356-9ecb-15d7f8359aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentProductLitigationInTheUSMember_019fa41e-81e3-7102-8901-f629c11c05b0" xlink:href="sny-20260630.xsd#sny_DupixentProductLitigationInTheUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_019f9382-51b8-7f07-bca1-3e199386b761" xlink:to="loc_sny_DupixentProductLitigationInTheUSMember_019fa41e-81e3-7102-8901-f629c11c05b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:href="sny-20260630.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_019ef965-c0a1-74cb-87be-473150f83308" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_019f9382-51b8-7b46-bed3-3d0e96410b78" xlink:href="sny-20260630.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfClassActionLawsuits_019f9382-51b8-7b46-bed3-3d0e96410b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfProductLiabilityCases_019f9383-a750-751e-bda4-12e07d18c178" xlink:href="sny-20260630.xsd#sny_NumberOfProductLiabilityCases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfProductLiabilityCases_019f9383-a750-751e-bda4-12e07d18c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCasesFiledInNewJerseyCourt_019fa2e4-3489-71c8-a4e1-cf0ce950dd19" xlink:href="sny-20260630.xsd#sny_NumberOfCasesFiledInNewJerseyCourt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfCasesFiledInNewJerseyCourt_019fa2e4-3489-71c8-a4e1-cf0ce950dd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOtherDefendantsInLegalProceeding_019f9382-51b8-7e36-92b3-96199b2f9de5" xlink:href="sny-20260630.xsd#sny_NumberOfOtherDefendantsInLegalProceeding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfOtherDefendantsInLegalProceeding_019f9382-51b8-7e36-92b3-96199b2f9de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLegalDecisionAspectsChallenged_019f9382-51b8-701c-a40b-05180bf4463b" xlink:href="sny-20260630.xsd#sny_NumberOfLegalDecisionAspectsChallenged"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_019f9382-51b8-7384-8e20-0acb593dd515" xlink:to="loc_sny_NumberOfLegalDecisionAspectsChallenged_019f9382-51b8-701c-a40b-05180bf4463b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OtheroperatingincomeandexpensesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtheroperatingincomeandexpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-772e-8685-8d3444650c10" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019ef965-c0a1-79dc-b64f-a7c720b4aa70" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-772e-8685-8d3444650c10" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019ef965-c0a1-79dc-b64f-a7c720b4aa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-c0a1-7ebc-be72-14eabf3745c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-772e-8685-8d3444650c10" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019ef965-c0a1-7ebc-be72-14eabf3745c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7a39-8644-0976d5845426" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7a39-8644-0976d5845426" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7f6a-977a-9dcb07d510d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7f6a-977a-9dcb07d510d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_019ef965-c0a1-7f6a-977a-9dcb07d510d2" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmvuttraMember_019f1e32-2d1c-73da-ae0a-71069f481be1" xlink:href="sny-20260630.xsd#sny_AmvuttraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:to="loc_sny_AmvuttraMember_019f1e32-2d1c-73da-ae0a-71069f481be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_019f1e32-2d1c-7e2d-b0d5-16c08262ce12" xlink:href="sny-20260630.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:to="loc_sny_RegeneronMember_019f1e32-2d1c-7e2d-b0d5-16c08262ce12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_019f1e32-2d1c-7c8b-9256-0e404933d3a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_019f1e32-2d1c-7138-a8f2-520fccedf61d" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_019f1e32-2d1c-7c8b-9256-0e404933d3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019f1e32-2d1c-76f3-8507-1f2f48f9024a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019f1e32-2d1c-76f3-8507-1f2f48f9024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_019f1e32-2d1c-76f3-8507-1f2f48f9024a" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_019f1e32-2d1c-7a2a-bf34-73dc1d5fb213" xlink:href="sny-20260630.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_019f1e32-2d1c-7a2a-bf34-73dc1d5fb213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionalProfitShareForDevelopmentCostMember_019f801e-4b60-725a-a4fc-d22fa146c90b" xlink:href="sny-20260630.xsd#sny_AdditionalProfitShareForDevelopmentCostMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:to="loc_sny_AdditionalProfitShareForDevelopmentCostMember_019f801e-4b60-725a-a4fc-d22fa146c90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_019f1e32-2d1c-78fd-93b2-61ff8beae636" xlink:href="sny-20260630.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_019f1e32-2d1c-7797-8b21-444e135a0914" xlink:to="loc_sny_CommercializationRelatedExpensesMember_019f1e32-2d1c-78fd-93b2-61ff8beae636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:href="sny-20260630.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_019ef965-c0a1-7130-9460-6d0fc861d4c6" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossOnDivestmentOfProducts_019f1e32-2d1c-70b5-859c-3d74faa527df" xlink:href="sny-20260630.xsd#sny_GainsLossOnDivestmentOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_GainsLossOnDivestmentOfProducts_019f1e32-2d1c-70b5-859c-3d74faa527df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_019f1e32-2d1c-7d9e-b696-bb4bf1cc9e11" xlink:href="sny-20260630.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_IncomeResultingFromOutLicensing_019f1e32-2d1c-7d9e-b696-bb4bf1cc9e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f1e32-2d1c-7614-b628-4d5268b5e704" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_019f1e32-2d1c-7614-b628-4d5268b5e704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncome_019f1e32-2d1c-700f-aa6f-0584e441bc6e" xlink:href="sny-20260630.xsd#sny_OtherOperatingIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_OtherOperatingIncome_019f1e32-2d1c-700f-aa6f-0584e441bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019f1e32-2d1c-71af-be59-0480405d15bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_019f1e32-2d1c-71af-be59-0480405d15bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpense_019f1e32-2d1c-7680-b6b9-f401792408d8" xlink:href="sny-20260630.xsd#sny_OtherOperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_019f1e32-2d1c-7ff5-a620-59723deba758" xlink:to="loc_sny_OtherOperatingExpense_019f1e32-2d1c-7680-b6b9-f401792408d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7a01-b36d-df92f43a97fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7f83-aa41-803fe274cdc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c0a1-7a01-b36d-df92f43a97fc" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7f83-aa41-803fe274cdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_019f1e3b-2237-7359-b418-4292ea8c6471" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7f83-aa41-803fe274cdc1" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_019f1e3b-2237-7359-b418-4292ea8c6471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7620-bc44-f6236d21167a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_019f1e3b-2237-7359-b418-4292ea8c6471" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7620-bc44-f6236d21167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DynavaxMember_019f801f-c452-7fc7-9374-563a59f80682" xlink:href="sny-20260630.xsd#sny_DynavaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_019f1e3b-2237-7620-bc44-f6236d21167a" xlink:to="loc_sny_DynavaxMember_019f801f-c452-7fc7-9374-563a59f80682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_019f1e3b-2237-7f83-aa41-803fe274cdc1" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_019ef965-c0a1-74b1-ae12-c228f2d16c48" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_019ef965-c0a1-74b1-ae12-c228f2d16c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_019ef965-c0a1-709c-bc7a-143db88a82e9" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_019ef965-c0a1-709c-bc7a-143db88a82e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_019ef965-c0a1-7743-8d4b-a31c06b211a7" xlink:href="sny-20260630.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_019ef965-c0a1-7743-8d4b-a31c06b211a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCosts_019ef965-c0a1-7a73-99ff-74db50fad79b" xlink:href="sny-20260630.xsd#sny_OtherRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_sny_OtherRestructuringCosts_019ef965-c0a1-7a73-99ff-74db50fad79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-7ce4-a635-1a4ff31a57d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_019f1e3b-2237-7151-b7d6-c3632a1d4362" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c0a1-7ce4-a635-1a4ff31a57d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#OthergainsandlossesandlitigationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7e67-8e94-97ffeb6ac8c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_019ef965-c168-7e78-8700-7147f8581e91" xlink:href="sny-20260630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7e67-8e94-97ffeb6ac8c6" xlink:to="loc_sny_OtherGainsLossesAndLitigation_019ef965-c168-7e78-8700-7147f8581e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#FinancialexpensesandincomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7228-83f8-a8c65c7f9f63" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c168-79db-bd7e-583d5eaa266c" xlink:href="sny-20260630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_019ef965-c168-7228-83f8-a8c65c7f9f63" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c168-79db-bd7e-583d5eaa266c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_019ef965-c168-7a59-b297-9a9022990572" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c168-79db-bd7e-583d5eaa266c" xlink:to="loc_ifrs-full_HedgedItemsAxis_019ef965-c168-7a59-b297-9a9022990572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-79bd-a9c1-735097591676" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_HedgedItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_019ef965-c168-7a59-b297-9a9022990572" xlink:to="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-79bd-a9c1-735097591676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_019ef965-c168-7145-b3ec-09b40a029249" xlink:href="sny-20260630.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsDomain_019ef965-c168-79bd-a9c1-735097591676" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_019ef965-c168-7145-b3ec-09b40a029249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:href="sny-20260630.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_019ef965-c168-79db-bd7e-583d5eaa266c" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_019ef965-c168-7335-afbf-a42d655fc8d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_019ef965-c168-7335-afbf-a42d655fc8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_019ef965-c168-74fe-9fe0-1b199f89ee13" xlink:href="sny-20260630.xsd#sny_InterestIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_InterestIncome_019ef965-c168-74fe-9fe0-1b199f89ee13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_019ef965-c168-7ac3-80d9-76659f49ecfc" xlink:href="sny-20260630.xsd#sny_CostOfDebtNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_CostOfDebtNet_019ef965-c168-7ac3-80d9-76659f49ecfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_019ef965-c168-7e44-8e51-63237834a178" xlink:href="sny-20260630.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_019ef965-c168-7e44-8e51-63237834a178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_019ef965-c168-7534-a190-4f257049fade" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_019ef965-c168-7534-a190-4f257049fade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_019ef965-c168-7a44-a35d-c69da54480cf" xlink:href="sny-20260630.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_019ef965-c168-7a44-a35d-c69da54480cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_019f65d0-e083-7923-b621-2bd5b4481d9c" xlink:href="sny-20260630.xsd#sny_ImpairmentLossesOnFinancialAssetsNetOfReversals"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals_019f65d0-e083-7923-b621-2bd5b4481d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_019ef965-c168-7660-be2c-347545474dd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_019ef965-c168-7660-be2c-347545474dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_019ef965-c168-74b1-b581-c894055625c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_019ef965-c168-74b1-b581-c894055625c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-7eb7-90cf-e99d1a29a329" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_FinanceIncomeCost_019ef965-c168-7eb7-90cf-e99d1a29a329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019ef965-c168-7ed2-ac59-014667f7daae" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_FinanceCosts_019ef965-c168-7ed2-ac59-014667f7daae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019ef965-c168-7dd7-8755-e5aad0ca9d65" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_ifrs-full_FinanceIncome_019ef965-c168-7dd7-8755-e5aad0ca9d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageDebt_019ef965-c168-7202-8d4a-3979db539f00" xlink:href="sny-20260630.xsd#sny_GainLossOnDerivativesUsedToManageDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageDebt_019ef965-c168-7202-8d4a-3979db539f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_019ef965-c168-7494-8606-9a34f0051392" xlink:href="sny-20260630.xsd#sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents_019ef965-c168-7494-8606-9a34f0051392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_019ef965-c168-7c1f-9cdb-a2d0f1bdde3a" xlink:href="sny-20260630.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_019ef965-c168-7c15-a314-5870753f865b" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_019ef965-c168-7c1f-9cdb-a2d0f1bdde3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7803-81f1-8afb17ee4197" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_019ef965-c168-7625-a214-3b918403d149" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7803-81f1-8afb17ee4197" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_019ef965-c168-7625-a214-3b918403d149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_019ef965-c168-7f4a-b145-f10abfd13b07" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7803-81f1-8afb17ee4197" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_019ef965-c168-7f4a-b145-f10abfd13b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-c168-7305-b930-27ae5c413849" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7803-81f1-8afb17ee4197" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_019ef965-c168-7305-b930-27ae5c413849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c168-7b06-adef-b73a1eaaf982" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7803-81f1-8afb17ee4197" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c168-7b06-adef-b73a1eaaf982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_019ef965-c168-713a-a5aa-8c385f9790e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:to="loc_ifrs-full_ApplicableTaxRate_019ef965-c168-713a-a5aa-8c385f9790e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_019ef965-c168-71c4-82d0-eeb907efdd98" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_019ef965-c168-71c4-82d0-eeb907efdd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxEffectRelatedToAmlitelimab_019f9340-f76f-778c-b89b-128b2e16fc0b" xlink:href="sny-20260630.xsd#sny_TaxEffectRelatedToAmlitelimab"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:to="loc_sny_TaxEffectRelatedToAmlitelimab_019f9340-f76f-778c-b89b-128b2e16fc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_019ef965-c168-762d-a28f-753f49871437" xlink:href="sny-20260630.xsd#sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:to="loc_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes_019ef965-c168-762d-a28f-753f49871437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_019ef965-c168-7f27-94f9-9fc14eb51e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_019ef965-c168-7f27-94f9-9fc14eb51e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-78ab-9ee6-746a121ebdfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_019ef965-c168-78ab-9ee6-746a121ebdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes_019f8023-de72-78e2-97e2-1820fac1bda0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_019ef965-c168-7ded-bed6-30a647485286" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes_019f8023-de72-78e2-97e2-1820fac1bda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_019f21f7-5d8b-7404-bcfd-586af1df6772" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019f21f7-5d8b-7404-bcfd-586af1df6772" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019f21f7-88ba-75b4-88b6-42c8053c5515" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019f21f7-88ba-75b4-88b6-42c8053c5515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019f21f7-88ba-75b4-88b6-42c8053c5515" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_019f21f7-88ba-7fb2-87c8-5ad2f0bfd524" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:to="loc_srt_EuropeMember_019f21f7-88ba-7fb2-87c8-5ad2f0bfd524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019f21f7-88ba-77b9-8a18-2203c73cf584" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:to="loc_country_US_019f21f7-88ba-77b9-8a18-2203c73cf584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesInSegmentResultsMember_019f21f7-88ba-7fb4-b41d-ee47f0b77ad4" xlink:href="sny-20260630.xsd#sny_OtherCountriesInSegmentResultsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019f21f7-88ba-74c2-bda5-88d1a82916e5" xlink:to="loc_sny_OtherCountriesInSegmentResultsMember_019f21f7-88ba-7fb4-b41d-ee47f0b77ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_019f21f7-88ba-741e-a454-5b55be4b3dc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_019f21f7-88ba-741e-a454-5b55be4b3dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_019f21f7-88ba-741e-a454-5b55be4b3dc1" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_019f21f7-88ba-7137-944a-8382d708961c" xlink:href="sny-20260630.xsd#sny_DupixentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_DupixentMember_019f21f7-88ba-7137-944a-8382d708961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AltuviiioMember_019f21f7-88ba-723d-ace3-b7288267b236" xlink:href="sny-20260630.xsd#sny_AltuviiioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_AltuviiioMember_019f21f7-88ba-723d-ace3-b7288267b236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_019f65d5-ddf8-775e-bff0-277ea919742e" xlink:href="sny-20260630.xsd#sny_FabrazymeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_FabrazymeMember_019f65d5-ddf8-775e-bff0-277ea919742e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NexviazymeNexviadymeMember_019f21f7-88ba-7f3b-9b4d-c9a859a8fa8d" xlink:href="sny-20260630.xsd#sny_NexviazymeNexviadymeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_NexviazymeNexviadymeMember_019f21f7-88ba-7f3b-9b4d-c9a859a8fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_019f65d6-9abc-7d68-83b0-37097b105a9e" xlink:href="sny-20260630.xsd#sny_CerezymeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_CerezymeMember_019f65d6-9abc-7d68-83b0-37097b105a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AyvakitMember_019f21f7-88ba-78f2-9099-4f94fb1ae82a" xlink:href="sny-20260630.xsd#sny_AyvakitMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_AyvakitMember_019f21f7-88ba-78f2-9099-4f94fb1ae82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SarclisaMember_019f21f7-88ba-70b7-8643-984faa2cea14" xlink:href="sny-20260630.xsd#sny_SarclisaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_SarclisaMember_019f21f7-88ba-70b7-8643-984faa2cea14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_019f65d4-5eb1-7d2a-bd2c-cab84abeb04f" xlink:href="sny-20260630.xsd#sny_LantusMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_LantusMember_019f65d4-5eb1-7d2a-bd2c-cab84abeb04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_019f65d4-7ed2-7149-9e52-dcaec2a8f5f4" xlink:href="sny-20260630.xsd#sny_ToujeoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_ToujeoMember_019f65d4-7ed2-7149-9e52-dcaec2a8f5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_019f65d4-9b35-754a-9c86-eaf7013fd6c2" xlink:href="sny-20260630.xsd#sny_PlavixMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_PlavixMember_019f65d4-9b35-754a-9c86-eaf7013fd6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_019f65d4-b975-793f-ba2e-f3f29de238e5" xlink:href="sny-20260630.xsd#sny_LovenoxMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_LovenoxMember_019f65d4-b975-793f-ba2e-f3f29de238e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RezurockMember_019f21f7-88ba-76de-88c8-d5376fe83fc4" xlink:href="sny-20260630.xsd#sny_RezurockMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_RezurockMember_019f21f7-88ba-76de-88c8-d5376fe83fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_019f21f7-88ba-7abc-a4fd-bf742300ed8c" xlink:href="sny-20260630.xsd#sny_IndustrialSalesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_IndustrialSalesMember_019f21f7-88ba-7abc-a4fd-bf742300ed8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember_019f21f7-88ba-7bec-8862-af2451834048" xlink:href="sny-20260630.xsd#sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember_019f21f7-88ba-7bec-8862-af2451834048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RSVVaccinesBeyfortusMember_019f21f7-88ba-789f-966a-02c0b9bede12" xlink:href="sny-20260630.xsd#sny_RSVVaccinesBeyfortusMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_RSVVaccinesBeyfortusMember_019f21f7-88ba-789f-966a-02c0b9bede12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MeningitisTravelAndEndemicsVaccinesMember_019f21f7-88ba-7298-a4d8-45fc08a6bfc7" xlink:href="sny-20260630.xsd#sny_MeningitisTravelAndEndemicsVaccinesMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_MeningitisTravelAndEndemicsVaccinesMember_019f21f7-88ba-7298-a4d8-45fc08a6bfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_COVID19AndInfluenzaVaccinesMember_019f21f7-88ba-7da5-8aa2-6a3288af5672" xlink:href="sny-20260630.xsd#sny_COVID19AndInfluenzaVaccinesMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_COVID19AndInfluenzaVaccinesMember_019f21f7-88ba-7da5-8aa2-6a3288af5672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LaunchesMember_019f21f7-88ba-7f9f-b060-18a2aba763d9" xlink:href="sny-20260630.xsd#sny_LaunchesMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_019f21f7-88ba-7c2d-8763-e0816b43e866" xlink:to="loc_sny_LaunchesMember_019f21f7-88ba-7f9f-b060-18a2aba763d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019f21f7-88ba-70f4-a34a-90a8c8185c67" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019f21f7-88ba-753e-a36b-f39a059f33ec" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019f21f7-88ba-70f4-a34a-90a8c8185c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019f21f7-88ba-76b6-b2b9-186c8f1e0ae5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019f21f7-88ba-70f4-a34a-90a8c8185c67" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019f21f7-88ba-76b6-b2b9-186c8f1e0ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_019ef965-c168-79ab-b1d3-1568e77b0c44" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c168-7e09-be0d-24bca4f2c60f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_019ef965-c168-79ab-b1d3-1568e77b0c44" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c168-7e09-be0d-24bca4f2c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c168-7e28-8586-71db3e83943e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c168-7e09-be0d-24bca4f2c60f" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c168-7e28-8586-71db3e83943e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7e28-8586-71db3e83943e" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c168-7799-b507-fe8b46fd910b" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c168-7799-b507-fe8b46fd910b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019ef965-c168-72ae-8d8e-8fc74d82a5be" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7d61-9a0c-726fb4d3df6d" xlink:to="loc_sny_OpellaBusinessMember_019ef965-c168-72ae-8d8e-8fc74d82a5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_019ef965-c168-7e09-be0d-24bca4f2c60f" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_019ef965-c168-7a76-a3e4-aae46f9885ef" xlink:href="sny-20260630.xsd#sny_RevenueFromVaxServeSalesOfNonSanofiProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_sny_RevenueFromVaxServeSalesOfNonSanofiProducts_019ef965-c168-7a76-a3e4-aae46f9885ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_019ef965-c168-758b-989e-5d2587000aec" xlink:href="sny-20260630.xsd#sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations_019ef965-c168-758b-989e-5d2587000aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties_019ef965-c168-769c-ac44-bfda77358e3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_ifrs-full_RevenueFromRoyalties_019ef965-c168-769c-ac44-bfda77358e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherRevenue_019ef965-c168-7963-b23a-60e5443f510e" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_sny_MiscellaneousOtherRevenue_019ef965-c168-7963-b23a-60e5443f510e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019ef965-c168-7794-ac20-d80c3261bf5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_019ef965-c168-7ea2-9c81-8a1e0af946a8" xlink:to="loc_ifrs-full_OtherRevenue_019ef965-c168-7794-ac20-d80c3261bf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7107-b76c-76c9ff38e4bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019f804a-5079-724e-8361-e8c5ab746722" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7107-b76c-76c9ff38e4bd" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019f804a-5079-724e-8361-e8c5ab746722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f804a-5079-70de-9a36-bc321c1432e0" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019f804a-5079-724e-8361-e8c5ab746722" xlink:to="loc_sny_DisposalGroupAxis_019f804a-5079-70de-9a36-bc321c1432e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f804a-5079-7915-bf9a-445f3344d3c8" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupAxis_019f804a-5079-70de-9a36-bc321c1432e0" xlink:to="loc_sny_DisposalGroupDomain_019f804a-5079-7915-bf9a-445f3344d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f804a-5079-7486-a7f8-ab360ac5d7ca" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupDomain_019f804a-5079-7915-bf9a-445f3344d3c8" xlink:to="loc_sny_OpellaBusinessMember_019f804a-5079-7486-a7f8-ab360ac5d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019f804a-5079-724e-8361-e8c5ab746722" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments_019ef965-c168-71ff-bb94-557c9082c50f" xlink:href="sny-20260630.xsd#sny_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:to="loc_sny_NumberOfOperatingSegments_019ef965-c168-71ff-bb94-557c9082c50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProportionOfOwnershipInterestDisposedInSubsidiary_019f804a-5079-7faf-9df3-4a90e1c78e8a" xlink:href="sny-20260630.xsd#sny_ProportionOfOwnershipInterestDisposedInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019f804a-5079-7d66-a730-a35c205efa3e" xlink:to="loc_sny_ProportionOfOwnershipInterestDisposedInSubsidiary_019f804a-5079-7faf-9df3-4a90e1c78e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofSegmentResultsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7ce6-a6b7-f575301945d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-78e2-8fd2-82c239520869" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7ce6-a6b7-f575301945d9" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-78e2-8fd2-82c239520869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c168-7121-b429-1c5a4f89158e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-78e2-8fd2-82c239520869" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c168-7121-b429-1c5a4f89158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7121-b429-1c5a4f89158e" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c168-7348-af06-4e3e5209a403" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c168-7348-af06-4e3e5209a403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_019ef965-c168-7af0-ad9d-17a0ba0510b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_019ef965-c168-7af0-ad9d-17a0ba0510b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_019f22b0-92f1-7d18-90d8-c6a63c305ba1" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7283-8a2e-2315da85049c" xlink:to="loc_ifrs-full_ReportableSegmentsMember_019f22b0-92f1-7d18-90d8-c6a63c305ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-78e2-8fd2-82c239520869" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-70eb-9823-93ae33f70344" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-70eb-9823-93ae33f70344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage_019f8032-b185-7196-8c84-ef3e53544ad1" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage_019f8032-b185-7196-8c84-ef3e53544ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage_019f802f-4568-7f27-a94a-2acf97f6c2bd" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage_019f802f-4568-7f27-a94a-2acf97f6c2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_019ef965-c168-7f0f-b279-3b4ee79a8e70" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_OtherRevenue_019ef965-c168-7f0f-b279-3b4ee79a8e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage_019f802c-c6af-763e-8d19-5cb35abec61e" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage_019f802c-c6af-763e-8d19-5cb35abec61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage_019f8032-5eb3-7441-9228-3d8705dd2f4b" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage_019f8032-5eb3-7441-9228-3d8705dd2f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_019ef965-c168-72a5-b6bd-ea9075964800" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_CostOfSales_019ef965-c168-72a5-b6bd-ea9075964800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage_019f8031-7c25-7f10-813a-7dd331d42152" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage_019f8031-7c25-7f10-813a-7dd331d42152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS_019f802b-d17d-778c-8b0a-b32616eb4538" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS_019f802b-d17d-778c-8b0a-b32616eb4538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-c168-7686-a87d-1be0f25982a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_019ef965-c168-7686-a87d-1be0f25982a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage_019f8034-6d8b-797e-b409-c4b4ddec373f" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage_019f8034-6d8b-797e-b409-c4b4ddec373f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage_019f802e-b20e-7fde-9f1c-47fccf919049" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage_019f802e-b20e-7fde-9f1c-47fccf919049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-c168-74c1-bbf7-58aa2029668e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_019ef965-c168-74c1-bbf7-58aa2029668e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage_019f8035-2d7d-78a9-898a-b8779b14a518" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage_019f8035-2d7d-78a9-898a-b8779b14a518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage_019f8035-bbc2-7975-bbf0-bb23338b6e71" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage_019f8035-bbc2-7975-bbf0-bb23338b6e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_019ef965-c168-7471-b947-030a52a5e756" xlink:href="sny-20260630.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_019ef965-c168-7471-b947-030a52a5e756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7365-8ff9-b819691dfb92" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7365-8ff9-b819691dfb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7c5b-b16d-5ca2e76ab8a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7c5b-b16d-5ca2e76ab8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_019ef965-c168-7b8a-8814-257d64bc63be" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_BusinessOperatingIncome_019ef965-c168-7b8a-8814-257d64bc63be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage_019f8039-3b5e-7c19-8b66-503c747c9dfe" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage_019f8039-3b5e-7c19-8b66-503c747c9dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage_019f8039-c3d3-7b0e-aebe-007222da1c17" xlink:href="sny-20260630.xsd#sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage_019f8039-c3d3-7b0e-aebe-007222da1c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncomeAsPercentOfNetSales_019f22b6-52d0-7be2-9af0-c4972072bef5" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncomeAsPercentOfNetSales"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-7c88-983d-9d1d7c70e802" xlink:to="loc_sny_BusinessOperatingIncomeAsPercentOfNetSales_019f22b6-52d0-7be2-9af0-c4972072bef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7788-b36a-f12db91986f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7788-b36a-f12db91986f6" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c168-7f8e-8269-e9b7b98efb1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c168-7f8e-8269-e9b7b98efb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_019ef965-c168-7f8e-8269-e9b7b98efb1b" xlink:to="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_019ef965-c168-74de-956f-c44e4856c33c" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:to="loc_ifrs-full_OperatingSegmentsMember_019ef965-c168-74de-956f-c44e4856c33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_019ef965-c168-7e91-825e-c4c8aa996fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsDomain_019ef965-c168-7998-b025-eeae9313188e" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_019ef965-c168-7e91-825e-c4c8aa996fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f9393-085d-7f89-8778-db4697b1ab43" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f9393-085d-7f89-8778-db4697b1ab43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7109-9355-8bc3fce4b32a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_019f9393-085d-7f89-8778-db4697b1ab43" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7109-9355-8bc3fce4b32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmlitelimabAssetMember_019f9393-085d-7feb-be6c-7c5ef08f5345" xlink:href="sny-20260630.xsd#sny_AmlitelimabAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_019f9393-085d-7109-9355-8bc3fce4b32a" xlink:to="loc_sny_AmlitelimabAssetMember_019f9393-085d-7feb-be6c-7c5ef08f5345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-78f1-abc6-dd35aa6f4279" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_019ef965-c168-76d9-b843-b7f333584796" xlink:href="sny-20260630.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_BusinessOperatingIncome_019ef965-c168-76d9-b843-b7f333584796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7882-90b1-bdddbc945935" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_019ef965-c168-7882-90b1-bdddbc945935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7523-acf3-e7d00cf56af9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_019ef965-c168-7523-acf3-e7d00cf56af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019f9343-7435-7c39-8bd3-7547c58f4446" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_019f9343-7435-7c39-8bd3-7547c58f4446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8042-7989-75ae-ac37-4d57b265571f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_019f8042-7989-75ae-ac37-4d57b265571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-c168-7a75-8e43-5bcadfd99fbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_019ef965-c168-7a75-8e43-5bcadfd99fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_019ef965-c168-7b2e-8fa4-51a34d63d044" xlink:href="sny-20260630.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_019ef965-c168-7b2e-8fa4-51a34d63d044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c168-715d-8de7-ce3aca3fda7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_019ef965-c168-715d-8de7-ce3aca3fda7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_019ef965-c168-7d2e-acb5-a46a775631f8" xlink:href="sny-20260630.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_OtherGainsLossesAndLitigation_019ef965-c168-7d2e-acb5-a46a775631f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-741c-a0f0-45f86b61ba7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_019ef965-c168-741c-a0f0-45f86b61ba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_019ef965-c168-735b-baea-956c0561b0bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_FinanceCosts_019ef965-c168-735b-baea-956c0561b0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_019ef965-c168-7d74-8d96-3d33e65e0306" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_ifrs-full_FinanceIncome_019ef965-c168-7d74-8d96-3d33e65e0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c168-7eb1-8bdc-dc0f26c99812" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-71f5-b055-05ed05fdfb5d" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_019ef965-c168-7eb1-8bdc-dc0f26c99812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7f91-b1d5-b59a76a2edd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-7181-b222-5fbae397234f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7f91-b1d5-b59a76a2edd4" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-7181-b222-5fbae397234f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_019ef965-c168-7053-9d3f-749ad6026ff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-7181-b222-5fbae397234f" xlink:to="loc_ifrs-full_SegmentsAxis_019ef965-c168-7053-9d3f-749ad6026ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsDomain_019ef965-c168-7906-b474-17f3db4430a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_019ef965-c168-7053-9d3f-749ad6026ff2" xlink:to="loc_ifrs-full_SegmentsDomain_019ef965-c168-7906-b474-17f3db4430a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_019ef965-c168-7dcb-ab67-3f935fec2469" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsDomain_019ef965-c168-7906-b474-17f3db4430a5" xlink:to="loc_ifrs-full_ReportableSegmentsMember_019ef965-c168-7dcb-ab67-3f935fec2469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_019ef965-c168-70db-a426-e5bd1b5587ba" xlink:href="sny-20260630.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_019ef965-c168-7dcb-ab67-3f935fec2469" xlink:to="loc_sny_BiopharmaSegmentMember_019ef965-c168-70db-a426-e5bd1b5587ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_019ef965-c168-7181-b222-5fbae397234f" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c168-73c8-a062-8b0e0421783f" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_019ef965-c168-73c8-a062-8b0e0421783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019ef965-c168-709f-88b8-78bb19f45f12" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_019ef965-c168-709f-88b8-78bb19f45f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019ef965-c168-79d3-8ee1-1ea70c9a3b3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_019ef965-c168-706a-ad98-34fdf3ff007d" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_019ef965-c168-79d3-8ee1-1ea70c9a3b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-78c8-9e85-ff019c078b19" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-70cd-9dad-00fcba2bd6b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-78c8-9e85-ff019c078b19" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-70cd-9dad-00fcba2bd6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_019ef965-c168-7c2c-ae3e-9425b68c8183" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-70cd-9dad-00fcba2bd6b6" xlink:to="loc_ifrs-full_GeographicalAreasAxis_019ef965-c168-7c2c-ae3e-9425b68c8183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_019ef965-c168-7c2c-ae3e-9425b68c8183" xlink:to="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_019ef965-c168-7920-bbfd-af4350698f84" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:to="loc_srt_EuropeMember_019ef965-c168-7920-bbfd-af4350698f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_019ef965-c168-79e1-aec7-387bdea770f1" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EuropeMember_019ef965-c168-7920-bbfd-af4350698f84" xlink:to="loc_country_FR_019ef965-c168-79e1-aec7-387bdea770f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019ef965-c168-7168-ac84-7ee49f172718" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:to="loc_country_US_019ef965-c168-7168-ac84-7ee49f172718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_019ef965-c168-736f-a89b-fb95b65eba80" xlink:href="sny-20260630.xsd#sny_OtherCountriesExcludingEuropeAndNorthAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_019ef965-c168-7d5d-ba2e-0c5f1e0cca90" xlink:to="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_019ef965-c168-736f-a89b-fb95b65eba80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_019ef965-c168-735b-b29d-6454825a5fad" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherCountriesExcludingEuropeAndNorthAmericaMember_019ef965-c168-736f-a89b-fb95b65eba80" xlink:to="loc_country_CN_019ef965-c168-735b-b29d-6454825a5fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_019ef965-c168-70cd-9dad-00fcba2bd6b6" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-793f-9de7-617635068bea" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_019ef965-c168-793f-9de7-617635068bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_019ef965-c168-76ab-a739-ac9d145d1473" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-c168-76aa-a456-c534cfdc17fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_019ef965-c168-76aa-a456-c534cfdc17fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c168-7aa9-b967-1c5ee6508174" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_019ef965-c168-7ebe-b737-e615b8033023" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_019ef965-c168-7aa9-b967-1c5ee6508174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#SegmentinformationPrincipalCustomersandCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7d1d-b934-14737f84cd1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c168-70f9-8a3f-689a7dacd405" xlink:href="sny-20260630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_019ef965-c168-7d1d-b934-14737f84cd1a" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c168-70f9-8a3f-689a7dacd405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_019ef965-c168-75c2-9acf-b9544afb468e" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c168-70f9-8a3f-689a7dacd405" xlink:to="loc_ifrs-full_MajorCustomersAxis_019ef965-c168-75c2-9acf-b9544afb468e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_MajorCustomersDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_019ef965-c168-75c2-9acf-b9544afb468e" xlink:to="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CertainWholesalersInTheUnitedStatesMember_019ef965-c168-7d3d-8083-1632e4941616" xlink:href="sny-20260630.xsd#sny_CertainWholesalersInTheUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CertainWholesalersInTheUnitedStatesMember_019ef965-c168-7d3d-8083-1632e4941616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_019ef965-c168-76f1-83c0-b628d01b4f11" xlink:href="sny-20260630.xsd#sny_CustomerOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CustomerOneMember_019ef965-c168-76f1-83c0-b628d01b4f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_019ef965-c168-7373-8af9-360ea2911054" xlink:href="sny-20260630.xsd#sny_CustomerTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CustomerTwoMember_019ef965-c168-7373-8af9-360ea2911054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_019ef965-c168-76dd-91fd-21ef962f9e50" xlink:href="sny-20260630.xsd#sny_CustomerThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersDomain_019ef965-c168-7f43-9102-52b7585322ee" xlink:to="loc_sny_CustomerThreeMember_019ef965-c168-76dd-91fd-21ef962f9e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:href="sny-20260630.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_019ef965-c168-70f9-8a3f-689a7dacd405" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLargestCustomers_019f22c2-55de-7264-87f2-088ff6501b22" xlink:href="sny-20260630.xsd#sny_NumberOfLargestCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:to="loc_sny_NumberOfLargestCustomers_019f22c2-55de-7264-87f2-088ff6501b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_019ef965-c168-75c4-95fa-42af6f3feed0" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_019ef965-c168-7c69-8494-d7bb6f8aec41" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_019ef965-c168-75c4-95fa-42af6f3feed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails" xlink:type="simple" xlink:href="sny-20260630.xsd#InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DiscontinuedOperationsAbstract_019ef965-c168-7afe-826d-5d71c122b6ea" xlink:href="sny-20260630.xsd#sny_DiscontinuedOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DiscontinuedOperationsAbstract_019ef965-c168-7afe-826d-5d71c122b6ea" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019f22c9-74f4-7f95-9f18-6cd963e65d87" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019f22c9-74f4-7f95-9f18-6cd963e65d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-73eb-a8d9-9d0e621faae9" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_019f22c9-74f4-7f95-9f18-6cd963e65d87" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-73eb-a8d9-9d0e621faae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f22c9-74f4-7ba8-b846-af9e2f4de0a1" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesDomain_019f22c9-74f4-73eb-a8d9-9d0e621faae9" xlink:to="loc_sny_OpellaBusinessMember_019f22c9-74f4-7ba8-b846-af9e2f4de0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupAxis_019f8044-f10f-7074-bbad-3bdbe5e9d59d" xlink:href="sny-20260630.xsd#sny_DisposalGroupAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:to="loc_sny_DisposalGroupAxis_019f8044-f10f-7074-bbad-3bdbe5e9d59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalGroupDomain_019f8044-f10f-7434-b797-6fd3395045b8" xlink:href="sny-20260630.xsd#sny_DisposalGroupDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupAxis_019f8044-f10f-7074-bbad-3bdbe5e9d59d" xlink:to="loc_sny_DisposalGroupDomain_019f8044-f10f-7434-b797-6fd3395045b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaBusinessMember_019f8045-1eb1-7af5-b2ee-302835bef8fc" xlink:href="sny-20260630.xsd#sny_OpellaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisposalGroupDomain_019f8044-f10f-7434-b797-6fd3395045b8" xlink:to="loc_sny_OpellaBusinessMember_019f8045-1eb1-7af5-b2ee-302835bef8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:href="sny-20260630.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_019ef965-c168-7fbf-85c1-f6820b17b8e3" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-79ef-8314-684c45d1e509" xlink:href="sny-20260630.xsd#sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-79ef-8314-684c45d1e509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7dfa-875d-7c7c9db7fb0f" xlink:href="sny-20260630.xsd#sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7dfa-875d-7c7c9db7fb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-719c-99f8-352800ddf890" xlink:href="sny-20260630.xsd#sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-719c-99f8-352800ddf890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7f36-80b1-9ee89ece5e44" xlink:href="sny-20260630.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-7f36-80b1-9ee89ece5e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-768c-b116-14c82642aa94" xlink:href="sny-20260630.xsd#sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations_019f22c9-4090-768c-b116-14c82642aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019f22c9-4090-76a3-80ec-6a8d32be1c63" xlink:href="https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_019f22c9-4090-75e1-914a-19642520b2a3" xlink:to="loc_ifrs-full_ProfitLossFromDiscontinuedOperations_019f22c9-4090-76a3-80ec-6a8d32be1c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a2026coverhalf-yearfinanci.jpg
<TEXT>
begin 644 a2026coverhalf-yearfinanci.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
MYVEI*#4%BFBBB@8G2BEHSF@ S0*.M% A":*** "BEI*  4444 '2EI**  FC
MWHHH ***,T !HHH- !UI:0T T %&:6DH !24M'6@ -%!H% "4HI*44 &,T44
M&@ I*6B@ H)Q11B@ %!H%!H ,T4&B@!.M+G%%&* "BBDQ0 M%&:* #I1110
M4E+0: #%%&<4G2@!:*.M)0 M%'2DH *4&DHS0 M%)2T )2YI,44 %&:,4&@
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MM+UH 2BEI,T +11FDZT %**04&@ H-+G-)0 4444 +THI#0* %ZTG2@4M "
MTHI** #%&:,T4 %&:*,T %%!HH *.M HH #10:,T %%% H ,T4E+F@ H-%%
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MTE A*444"@!12XI*6@8M.%- IU(!<8I112YQ3 6E%(.:6@ I:**0"TM&*!0
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M%%  :2BCK0 M&:*,T  HI*6@ S244"@!:*!2'B@ HI0:2@ HS10: "BB@\T
M!HS10: "BBDH 6DI10: "BBC% !1FDZT8H 6BBDH **#0>: "BB@T  HS12'
MB@!>M'2BDQ0 M)2T4 %)FBB@!<T4E% !129I: "BBB@ HHZTAYH 6C% HQ0
ME+F@T$4 )1110 "ES244 +0*2B@!:2BC%  .* <444 !-(*6B@ HH-)0(6BD
MHH *3-%!IH3$ZTAH/%%4A,;BBE/% IDA112@U#!B$4TC-.ZTAXJ&1(8::13B
M*:>:#,0T44"F "EHHH*0HI:3K2TRD%(!2TE4BD% XHHJD,<#3A3:<*!CP*>#
M3 ,T\4AC@*>.:8#3Q0 X"G"FBG"D,6@T=:!2&%)2XHI@(128I:3K0(2EHI:
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MQ0 &C&:7%)0 #FBBB@!.M %+10 E%+BB@!"*4448H 2@4H%% "8H HQ03F@
MZ44M)TH 2C%+10 @%&**6@!*,4M% ""CI2TE !10!WI30 E&*#Q2B@!M*10:
M * $Q2T4IH 3%'2C%% "8HQ2T8H !1BBB@  H H%&: $HI:* $%%*!2'F@!,
M44M'6F)C*0T[-!JD2QF*,4HHIDB8S2XHHS4L!*2E-!.*ADL8:;FG&FTC-B44
M$T4Q!2T4G6@I"@4M(*=3*0E%!H-4BD%)2T50Q13A2 4X<T#0X4]1313Q2&/%
M/%,%/%(:%%.IO2G4#"BCI10 M(:*#0(2B@4&@ I:0"G"@8"EI,4M( I]-%**
M!CJ,4"EH$+112T %+2=:7% "T44"@!:,444AA2T44 %+24M PHHI*0"TE%%
M"&F&G&F&D4AAJ-ZD-1OQ2&B)Z@>IVJ)Z0R!ZA:IF&:A:M(F4B(CTHI2:*T,S
M4'%*!2=:45F:"TE+29H&+BDI:3% !BEHHH *2EHH$(/6E-%)0 4449H 6DHQ
M10 &BC% % !0:*#0 &BBB@!:2C- H ,T&BB@ H)HS1B@ %&*,4 4 &*!110
M44 4&@!:2C%(10,6BBB@ I<T@H- @H!HHZ4 %&:** "C-%% !1110,***,4
M&:*,44"#K0.**,4 %(:44G2@8M HZ4G6@0M)BBEH 2BEQ10 F**6DH ,YH)H
M I<9H 2BEI*  <T4O6DQ0 44N*0T +24M)B@ S0.:**!AG-% HH$%%!% H *
M*** "@<4$9HH *6DHZT '6@T44 (*,XHI: $HHQ1B@ HHHH **4\T4 )1110
M $4444 &,48HHS0 =**** "BD%** $HI<4$4 )12TF* "D-*!10 AHHH- "T
MF:6DZT +2=:6DS0 I-%&*0T %%+2&@ -&**6@!*,9I:* $-'2EH- ""EI**
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MH6I#(7&:A:IW%0L*N)G(A:BG$45J9&EBC%%+69H%***,T %%% YH&%!HHQ0
M4$T4=*!"448HH *,TN*2@ ZT444 &,48HS10 448HH **,T4  HH-'6@ H-%
M%  *6DZ4IYH 2B@44  HQ110 8HHS10,**4TE "DTE+24 &***#0(**!10 4
ME+24 +0:*#0 4444#"BBB@ HHS1F@ HHH% !10:*!"4O2C%% !UHHHH *.E%
M% !B@T8HH **#1TH *2@4M !1FB@\4#"D%**",T""BDI: $H)H-+0 E% H-
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M4H]:3K0* %HHQ2B@ IIIU)UH *!12B@84ZDI:0"4M)2B@8X"BBEH *44 T4
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M4E4ACA3U%,'%/6AC0\4\4P4\<5(Q].%- IPH&.%&,4@I: %SBBBEH 2BC%%
M!BG 4E.Q0,*,4HI,4A@!2T THXH ,XI:04HH 6EI** '"EQ24N:!!BE%)2TP
M#I112T@"BC-+2&%)2BCI0 8HH'-'2@8448H)I %)3LTV@8AIIYI],I ,(IAJ
M0\5&U)E(C:H6J=A4+TBB%A43"IF%1M51(D0T4IHK4Q+U+2=*6H+$Z4M)2T +
M24M H ,T"BC% !28HHH 4'% -(:* "BBB@ H!HS0: $HHI: #- %%% !0***
M "@BEQ24#"C-'6B@ HS12YH$)1UH-&: "@44&@ -%+24 %&:** "@&CK0* #
M- I:;UH 4F@448H #0*** "BBB@ S2&EZ44#"BBCI0 O2DZT4E "T,:#10(.
ME&*** "DZ4[K2"@ )HH-&* "BBB@ HZ448H *!1F@B@ %%%!H **.M&*0PH%
M% I@%%%% A**6DH 44E+24 +24M)0 &@T$TM "448I: $HHHH **** "BB@4
M )BE-%)B@!:**2@!2**#1B@ -%%&*!A0>:.E&*!"8Q11UHS0 4444 )2YHHH
M *2EHS0 E%%% !11G% - !12TE !2"E'-)TI##-+28I:8A*!2F@"@!*!0!2X
MH ****  4444 %%%(* %-&*,T4 )BBCK2T %)2YQ0: $HH'% H !24M)0  8
MHHI*8F!IIIQI#5(EB9I*7I2"F(4444M3(0AII&:<:0UFR6,;FD-.---(S8T^
ME%%%,2%HHI:90"EI *6F4@HHHIHI"'FBBBJ0Q13EIHI],:'BGBF"GK2&/%.%
M-6G 4ABTHI*44 .HHHQF@ Q111UH !3NM I128T&* <T48H&'6C%**6@ HI
M*44 +2@4E+0 N: :**!"FEI*6F 4M)12 6BBBD,*6DI: #I0*#12&%+24N:
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M1B@044$9HI@%% % H ,T9S110 4444 %&*,44 % H%% !1110 8I*4TAH *
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MBBBDI **,44&@!*6DI<4P"DI310 @I>M)2YH$&*3K2FC% "44M)F@ HI124
M+UI*6DH 4T444AATI*6B@!*#2DT'F@ '-%%)3$+TI*6DH 6DZTM!H&)2T44@
M$-+29HH ,9I<4E+0 E+0:2F 444N*!"44M)0 $T=**6@!.M%%% "TF:,YI:
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M,0[-)FDI,T .S13:,T .S2YIF:,TP'DT;L4S-+FD \FC--S1F@!U*33,THH
M<#2$TW-+F@8N:0FDHS0 $TTFBD/%(8AIN:<::>: &TTFG9IIYI --,(IYIM-
M"9&RT4XT51)9I:2EJ"PHZ4"B@ HHI:!B"E-%&*0!1110 4F:6BF(2BB@B@8M
M)12T"$I:2B@!:**.E PQ24O2DH 7-)BEHZT )FEHQ2=: %-)2T4"$H-+1F@
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MD)HH **,T4A@11FDHZ4 .I#Q12"@!W6BDS13$+124 T +FBD-% "]**0G-%
M"X[T4E&: %I*,T4 **3% %&:  T9I,TM !FBDS1G- !2TAH- "YH/%)29H$.
MZTAHI#S3 ,4F:6DJD2Q,T444Q"YI:3K14L I*6DJ&2QK4PT\TW%29,:: :,4
M4Q"XHZ4@%+FF,44HI,4O6F4A:#2&EIHM#:7%)BE/%4A@!2@4@IP-,8X4]::*
M<M)C' TX4S%.%(!PYIXI@IXH&*#2TE.Q0,44X"FBG4@% I:**0PQ24M% #32
M-S3J3% #::33CQ24Q#:2E(I"*8A#1244 %!HI,T +1FDHI@+FCK110(6C-%'
M6@!12@YI!Q2TAAF@&DI: $HI:;0,#333J:32 :12$4XTE #"*0TXTV@!N*0B
MEI"* $HHHIB)Z3-)1FI*'$TM-S2YH .E+3:6D N*!Q244#' TF:3-% "T4G6
MB@!:,TE!H 6EW4W-&:8A0:*2EZT# T9HHZ4 % -%% A11FD%% P)Q1F@\T4"
M%I,TAI10 44G2EH ,T9H)HH&**2B@4 &:6DHS0 4N:2B@ S2TW-&: '"DH-)
M0 ZC--SFEZT &:*,T4"#-%&:,4 %&:*,T +FDS11F@!:0FBDH 7-%%)0 M&:
M2B@!<TN::#2B@ HHS1UH *,T"DH 7-%'6DH 6BD-+2&**2@4F: %%%!I*8"@
MT9I*#0 M'6@4E @S1FC-% !FEIHI: #%%+2=* #-%'6B@849HH- @I*7.*.M
M !1244 +2444 *:,TE&*  T4 T4 &:*2EQ0 &@\T4F: %S244I- !12"@T %
M'6BDSB@ S0*6D'- "T#GFD-+0 9HHI!0 44'BBD 4"BBF =*,T4=* #-*:,9
MI.M "TF:** %I :6C- "44&B@ HHS10 9HHHH ,XI,YI:2@!:,4F:6@!*444
M&@!*6DH)H$%%%&:8"4AI>M)31+$-&:*,50A:6DZ4H%)@!H-%(:S9+&XIIIQ-
M--29,2DI328IB "G4VEZ4QBTX4T"EIE(7I2&EI*:+09HHI/:J0QU**;3@*8Q
MP-/!I@IP-(8X4\4T4X'- "BGBF@4ZD,=2BD!IPH&%/%-%.%)C%-+2 TM( HQ
M110,3---.-(>:!##2&G$4TTP&TA%.Q333$(:2EI*!!2444 %%%+0 E+24M "
MB@4F:44P%HHHS2 6@TE% !24N*2@89IN:<:::0"&FTN::30 4TTXFFT (33:
M6DZ4 )1113$24M)FEJ2@ZTM)1F@!<T4F:* %-&:2ES2 *6DHH&%%%'6@ (I:
M3I0#0 4M%%, HHHI %%%%,0444=:  F@<T"B@ %!YH!HH *,T48H .M*:04"
M@ Q2TF:,T##K10*,T@"C%!H%,04II*,T '6BBB@ HHHH *6DHH *44@HH *,
MT9HH * :** "C% HS0 N**2B@ -% %'6@ HHHH !10.:*  T444 +2444 %
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M Z44$48H 6DHZ44#"BBEQ0(3%!I:2@ (HHHQ2&&*!2TE  :**#3$&:,T48H
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MBE-&*0" 4H%+C%** $Q3L4 8I0*=@ "EQ2BEQ2 ;B@BG8HVT#&XI,4_%)BD
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M@!:3%%% "T@XHHH *.E%!% !1BEHH 0T44N* $Q1BEI,4 %&*6DH #0:*!0
M4444P#-%&*,4@"@BB@4 %%%% !1110 AHI:#0 G6CI2B@T )FBC%%, S11FB
M@ )H-)2F@ Q1BBBD 4E*310 E%+BCI0 E%+13$)1FBD- PHH-)2 *,4=:2@
M%%'2DQ0 N*,4 4N* "EI,4M !BBBEQ0 E&***!!0!113 *,4M)0 E+10: "@
M4$44 &:*#2 4 **2E-% "&CI2]**0"8H S2XHQ0,2BCI10 &@T44"#%)BEHI
M@%%%(:  T4'BEIH3&YHI32&K1+ 4M XHH8@I,4M!%9R$QC4QJ>PIC5!G(8:2
MG&FT$ !112D4QBTJFDI:92%HI1S15%H3K2T4M-#0@IP--IRFJ&/ZTHIH-.%(
M8X&GCFF TX4 2 4H%-%.!H&+3P:;2@T@'4H--I:!CJ6DS0* '"ES3<TM #J*
M2C- AV:*2C-,!:2BDI !III<TAI@-)I*4TE "4=*6DH 44M)FE!H$.%.%,%.
M% QU**:**0#J2C-% PI#2YI*0P--I3Q32:0"&D-.IIJ66AII#S2GFD-26)BD
MS2T=: $Q1113$5Z6DS0*HS%HHHH 6@FBC% !UHQ1BCI0 "B@&B@ HHQ10 E+
M110 8HHHH ,444 4 %%%% !1B@BB@ HHQ2T )12FB@!!2T8HH 2EHHZ4P#I1
M1UH(I %!I:* "BB@4 %)1G%+0 4F,T&B@ Q2TE** $Z4&EI*  44N** $Q12
MT4 &:,4=:* $I:6DS0 =:**,9H  *#110 E*!12XH 2BBDQ3 6C-%%(!*6C%
M% !BBEI* "DI<T4 %'6BB@ HHHS0 4444 %&*** $-+1BC% "8I:*2@!:0BB
MC% !1BE HH 2B@4H% "448H% "44O2BF 444E(!:,4 4=* $Q2]:!0: $%%!
MI: $-&* ** $HQ2TE "9HH]Z* $S0:#10 449I* %% HI10 4"@THH ,4E+B
M@4 '6BBC% !28I:*8@S2&EZT4 %&***0Q#12XHIB$I:2E- "&@T44 !HHH-(
M %'2B@4#$I:*!0 E+1FB@04AI:2F =:,4N*,T -- I2**:$Q,T445:( "BE%
M!H8!BD-+BDK.0F--1M4AIC5!G(C-%%)31 "G4T4M Q12BDI13*0ZC%%%4BT%
M)FEI*:&+FG"FBE%4,?FE!IHIPH >.:<*:*<*0QX-+313@*0Q:<*:*=0 [I2Y
MI :6@8M+2"C- "THYI,T T .Z44@-&:!"YI<TVB@!V[%(329I,T +FDHIN:
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M!,4"EZ4E "TAI:2@ I<4A-+0 E%+10 E%!HQ0 E%%% "4G6E-% #:.E!H!H
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MHVK,RD,)I,TII,8H( 444"F,6EI*=3*0HI<4BTM-%H2BEI*M%!B@4 4HI@.
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M** %HS0#0.: "C%%% !C%&:6DH  *6DS1G% "T4E!- !2@9I*7- "=*6BB@
M-&*,TN: $H-*#29H *6DS1F@!<44 T9H&%!I :6@!**6B@04&DZT9H 6BD-*
M#0 E+BBC- !TH-% H 2EH-% "4HHQ24 +244N:  4444 !H-)10 M!I#10 N
M**3.*4F@!**** "EI*,T +124N: "C%)0* "BB@F@!:/>DHH *6DS1F@!:3-
M&*7- "48HZT8H *!1F@T %%&:* "@TO2DH 2BC-% !2&E-)0 F***6@!*6@T
M"@!,4ZFTM "BEIN:* %%'6BB@ Z4&BC- !0:#2&@!:*** "BBDS0 II!110
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M "4F*7%+B@!M%+BE(H ;1TIU)B@!*2EHQ0 F:*7%)C%  *#Q110 E!I<THH
M2BEHQ0 4@%*:,4 &*0TZB@!,48I<44 )B@44N* $-%&*6@!M&*6EH :!0:7%
M&*8"44N,48I )28IPHI@-HIV*,4@&XHIV*2F(2BEQ10 F**6B@!,4AI<44 )
M0!2TO6@!F,4M+BB@!*6C%&*:$PQ12XHJD2&*7%+013$(::13J2HD#&-4;5*P
MJ,BLV9R(R:;BE-)0C,,9I1S113&A:4"D%.%,I"BEI.M+3*0M(***M%@*44E*
M*8#A3A30*<*0QPI12"G"D,<*>M,%/% T/%.IHIPI#'4M(*<*0!2T"EH&%% I
M: $I*6DH *.E%% @I*7%%  !BEH%%,04M&**8!12T4 %%+24@%HI!2BD,*6B
MB@8444M(!**6B@!*2EI*!C&II%/---2RD1FF-4A%,:D41FBE(I* %HI113$4
MJ448HJC,,4H%)2T %&*6B@!*6@4N* $'%+1BEH 2C%+TI* $Q2XHH H 2@TZ
MDH 2EHHH #244M "8I:,48H&&*,4M)0 8H%%% @HHQ2XH 3%**** #%&*,44
M %)2FC% "8I:**  4F,TN** #%&**!0 8HQBBC- !1BB@4 +24M)0 M%)2T
M)2T4&@ HHQ10 44H%)0 44M % PHH HH *2E%% A#2D444 %)2T4 &:**.E
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M48H$-Q28IV*,4 -H-.Q1B@!N*,8IP%&* &T4N*7% #<48I:-M #<4N*=BD%
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MM% Q,44M% "8HQ2XHH 0T4O6DQ3 ,44H% H$)BC&:6B@!*,4M'6D E!%+13
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M1BBEH 2C%*32 4 %+110 E&*7%% "8HI:,4 )2T48IB#% % %&*  "BC%+0
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M@44M(8E&*6DQ0 4&EHH 2EHHH ***,4 &,T44"@ Q11BB@ HI:3K0 48HI:
M$HI<48H 2E%%&* "BBEH 0T8HI: $HI:*!"8I:,8HH&%%&**  T444 !HI:2
M@048H%% !THHS2F@!,44M!H&)1BEHH 2C%+BC% "4IHHH *3%+10 8I*6@T
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M2EIE#A2BD'-.%,M!2TE+FJ10H%**04HJ@%IU-S3J0Q12YI*44#'BG"FBG"D
M\4\4Q:>*3&AU.%-%.%(8M+FDI:!BT444@"BBB@!****8!1110(*!12TP 4M)
MBEH$+1110 4444#"EI*6D 44M% !112TAA24M% "&DI32&D,::8:>13#0-##
M3&IYIC4AD9YIN*>:90, **7I10(AI1Q12XJB!*6BE!H !2TE.H 2E%&*6@!,
M4M%&*0!1BBB@8M)2XI* "BEHH 2CK11B@!:2EQ10 "DI:* #K10!1UH 6DHI
M: $-&*,THH 3I1B@BEH ***!0 8HI:,4 )12XHQ0(2BEHQ0,**!24 +1110
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M*6B@!**4TE !1BEHH 0T4M)B@ HQ2XHQ0 4448H **6B@!,444M "4N***
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M444 '2BBB@ I*7%% "8HHHS0 44M(* $-+1010 E&*444 (**6DH 2EHQ10
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M $HI:2@!*6BB@ I,8IU)0 4@I324 %%!%+B@!**** "DI:2@ HI:2@ HHHH
M#110* "E% I130F*!2BD IP%42**,4M&:8AAIAIYIK4,")ZB>IFJ%JSD3(A>
MH2*F<5%4F,MQ,48H-+3 ,TX4T4X4RD.%**04X4T6@H%%+5(H*<*;2CFJ ?2B
MD%+4E"XIPIHI10 X4\4P4\4 /%/6F"GK28T. IU(*<*0Q12TE+0 444M Q*,
M4M)0(#24M)0 E+0*.E !2CFD%+3 *4444" 4M%% !FBBB@!:!112&+124HH
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M%!HHH ,4444# T44M "44M% !1110 449HH **** "BEI* #%%+10 E%+10
M48I*6@04E+13 2BEQ10 4444@"B@T=: "BBB@ HHH-, HHHI %%%% !UHHI:
M8"4444 %%%%( HQ110 4444 %)BEHH *2EQ24P%HHI* %I*** "C%%+0 E(:
M6DH *2BB@!**,TE( I:2EH .M&*!3AQ0,2G4E+0 4&C%% @HI:*8"8HHZ44
M%%!YHI %&*** #%)2T4 (:*** "BC-%, Z4AI:* $%%+24 %%!YHH *0TM%
M!244M "4=**6@!*,T=:* "DI:2@ Z4M)UHQ0 &@44"@!*6DI: %HI!3A30F*
M*=313A5"%I<TE+3)&&FFGM3#0P(V%0O4[5"]9R)9 ]0FIFJ$U)E(0C%***#3
M$A:=312BF4APXIPIHIPYIHI"CF@4"BJ184X4E*HJ@'4N:*7-(84N*04[- Q1
M3Q3:<*0#P*>M,%/% QP-/I@IXI#%%.IM.%( HHQ2T )0:**!A24M)0 E+110
M(****8"T444"%I:2EH 2BBEH ***44AA2BDI: "BC%%(84444 %)2TAI#0TT
MTTXTUN:!C&%,-/-1M28T1FFFG-3*0Q<T4E%,!F*6DI:HS"EI!2B@ %.I*44
M%+UI*7I0 "E%(** %HHHH #12TE( HH-+3 ****0!B@444#"BBB@ I:2C% "
MTE%+TH *,444""@444 %%)2FF 44HI*0PI:*.E !B@49HH !1110 44HHH 2
MBBEH 2BEQ10 4F*6B@ HHHH ****!!1110 448HH ****8!1112 ***.M !B
MB@T9I@%+249H **** #%%%% !BBBB@!:2C- H **!2XH 2BBBD 4444 %%%!
MH 6D-%% !1113 2EHHH 3%+BBB@!#Q24O2D- "4E*:2@ %%%&* "BBE%( %+
M24HH&%**04M "TE+13$%)2TE "BDI<4G6@ HS110 4&@4&@ HHHI %%%)3 *
M*#10 8HHH- !1110 4E+10 E%%% !10310 E%%+0 E'2C-% !1THQ10 E+0*
M,4 %%)10 &BBB@!:44F:44Q,<*6D%.%4(448HHIDC33#4AIA%# C:H7J9JA<
M5G(ED+5 U3/43"I,9"4"@FBF N*444H-,:'+2YI!2TRT+1115(M"BG"D%**H
M!U+2=*<*0P'-+24HI#'"G"F 8IX- #Q3Q3 *>*!CQ3A313A2&.%**04M( I:
M** $H-%+0 E)2TE !1110 4444P%%+2"@4"%I:2B@ I:*!2 *6DI:!A2TE+0
M 444M(8E%+10 E(:7K0:0QIIAIYIC"@8QJC-2&HS28T,-1FGM3#0,444@HH
M92T4E49BTO6DI<T **7-)2T +12"E%  *6DI: "BBB@!:2BBD,!2T4@H$+11
M10 4HI**!A2XI,4M !1FBB@ HHHH *,T48H$ HHHQ3 ****0!2@49HH&%%)T
MI<T &<T444 %%%!H **44E !BBBB@!:**!0(****  4444  H!HHH *!113
M**#10 444"@ HQ12T )12T4@$H%+24P"BEI.M "T44E !12TE !2TF<TN: "
MDI124 %+124 %%%%( HHHH **6DH **** "BBBF 4=*** "BBB@!#24II#0
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M04Q:>#2&.%/%,%/ I#' THI!2B@!:*2EH&%!HHH 2BEI*!"44M)0 4M(*6F
M4M HH$%%%+0 4444AA2XHHH *6DI: "EQ24M(88I*6B@!****!C33#3S36I
M1FHVJ1J8:3*1$:93VIIH&)1110(;124H-40%+244 .%+3:6@!12T@I: %'%%
M)2T %%)2T@"BBC- "YI**6@ HHI* %HHHH&+249HH *6DHH 6BDHH 6BBB@0
M4444P"BBC%(!:,TE**!A124M !UHHHH ,T444 %%%% !111F@0M%)BB@!112
M9HI@+1112 **2EI@%%%% !111TH *,444 %%%% !THHH- !1110 4"BB@ HH
MHH ***,T %%%% "TE%% !110* %I#10: "B@44@"@4&B@ HS124P%%!HHH *
M***  TE+2&@ -)0>*2@ -)1FBD 44E+0 9I:04HH&+2T@H% "TM&**8@I*6@
MT )12FDH ,9I:2C% !FBBB@ HHZT8H #1110 449S10 4E!HS0 9HHS10 44
ME*: #-%%% "&BBB@ HHHH ***2@ I:2@4 %%%% !11FDH 7-(:** "EI#10
MHI124"F(>*=313J8A12TE+5$C33#3S330P(FJ-ZD:HGK.0F0O4!XJ>2H&J#"
M0F*44F:4'%4)"THIHIPIE(<!2XI!2BF6AV:*44E4BT**5:2G"J <*44@I:10
M"G4E%(!V*<*:*<* '@TX4P5(*0QPIXI@IXI#'"E%(*6@!0***44#$HI:* $I
M*6DH$)2T4E "T44E "BEHHIB%HHI* %HH%%(8M%%% "T444#%Q1112 ****
M"D-+BDH&(:8U/-,-(!AJ-JD:HR*3*1$U,J0BF&@!!10:*8#**,T4R!:*2E%
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M0"TE&:* %%)2TE "T444P"@444 +THI*,T@%HI** %-%%%, %%%% !1UHHH
M6DS112 6@4E+0,,T49I,T +FBDI: "BBB@ HI :6F(6BDH)H 6DHHS0 O6CK
M244 **2BB@!<4F:6DH 6@4E+F@ HI!2T@"BBBF 49HHH **3-+0 449I,YH
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MDH!H =FDHS29H =29H%)F@!:4&DH- "YHI** %HI,T9H =249HI +1TI*,T
M+FBDS13 7-%)10 N:,TF:,T +1FDS10 M&:3-% "YHI*6@!<TG2DI: %I*3-
M+F@ H%)0#0 N:*3-&: '4$TF:2@!U%-I<T &:6D-!XH 7-&:2@T  -+2"C-
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ME "YHI,TH- !2TE&: %HI!12 7K1124P'44E - "BDHSBB@ I:2B@!:*2EH
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M "T4E+2&%%%% !2&EI*0Q#32:<::: &&HS4AIC4F4B)J814AJ,T#$S1110!
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M &** :": %I,T44 %+UI#2T &*.E%&,T %&***  4M)FB@ -)2T4 %+29HH
M6BDHH 6BDI: "BBB@!:2CK10 4444 %%%% !2TE% !2TF:7% !FDHHI@%+FC
M-)2$+BBBC%, HHI* %Q249HH&%+24H-( HHHH *6DHH **** "BDI: #-%%%
M !1110 E+28HI@+24M)0(*6BBD,2EI!2T )11FEQ3$)12T8H& I*7%)2 "<4
MVG4TT )FB@BC% !1C%%*: #I1BBB@!:6DQ2T %+24HH *,TM(* "BC%&* #K
M111BF 44N*2@ HH%&*!"4M%+0,2BC%% @I,4M&* $HI<4E !10*6@!***,4
M%%&*,4 %%%+0 E%+28H .M%%)0 44O6B@!.E HHH ***,4 )2T48H *2E-%
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M%% !2TE!H 6@T@I: #%+24"@!<TE %'2@!31244 +0:044 +G-%%)0 N:.M
MI* %%!HHZT %%&<T4 !H-%!H *#10:8 #BC-%%(!:*2B@!<T4&B@ S0*.E%
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M2YI %!I*6F 9H)H%% @HI!2T '6BBCI0,,T444@ &BBC- !1FC-%, I<TE%
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M112 T *:3%!HS0 N:2@FCK0 M)110 M I,T9H *":!10 4M)10 4N:0&ES0
M44E% !244A% Q332<T$4E(!:3-%%,04O2D)I>M !2@8I!2B@!U%(#2B@!:!1
MFC% "T9I*#0 M%)FB@!:3-'2@4 %%%% !1BBDH 6C-!-)F@!11110 =:*2B@
M!:,4@I: $-%%% "T4AHH ,T9HI* "B@4E !THH)I* #K12=** "BDH%,09HH
MHI )FC-%)F@!2:*0T9I@+2FDH% "BE'--S2]: %H- HI .%.7BF4\4P)%J05
M&M2+3$2"E%(M.%, IIIQI#0(C-1-4K5&]3(&5WJ!CFK#U7?BLS&9&:*#0*9
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MDHH 6DHI30 4&DI:0!F@4E&:8"FC-)2T &<T$444@$I:*,TP"BBDH$+2TE%
MPH)HZT4""ES29HS0,*7-)2T@ '% HS24P%Q11F@4@ 4449H 6DHS0* "E%)B
MC%,0M!I** "C- I: $Q2TE&: %S124M P6BDI: "@T4AH$%+10#0 9HI*4T
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M2TE "@T=:** #-&:"** #-%)TI: "C-%% "FDHSF@<T +FDH-!- !TH)H-%
M"YI**2@!<T&C-)0 M%%% !11FBD,*6DHH 7I24E%, IN:#24" TO6DS24 *3
M1FC%*: #I2TE+0 M**0&EH 6BBB@ )I>E)2=* '&@TAHH ":,T&DH 4&BBDH
M 7-%%&: "BBDS0 M%(:* %HSFDHH 6BBDH 6DQ0#030 N:2B@4 +1TI#29H
M4F@4AI10 AXH)I<TAH$%(:4BDH **":*  4E!H% !F@T44#"BBB@ I#2T8H
M**#10 F:4\44=*!!TI32'FEH *<E,IZTP)5%2K4:U(M,1(M2"HUIXI@+2&EI
M#0(C-1.*E:HVJ9 0257>K#U7<5FS&9$:!0:!S00**<*04N*8T IXI!2TRT.'
M%%%%,M *44"BK10X<4Y::*<*& HIU-%+2&+1UH%% "THI!2B@!P-/%-%. H
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MH 7K1244 +0*2@"@!31FBB@ H-)2T &:*2EH .M&:** #- I:04 +24=:3-
M"TGO2TA% "]:!1G-% !1FC-)0 O6@4F:* '4@HZ49I##-*#24&@ I#0:#0 E
M)124Q"T@I*,T *32YS2"E H 6E%-Q3A0 HH!I*6@!V:*2DS0 M%(:": %%&:
M3-&: %%*:;FC- "T9Q244 +124N: #K129HH 6BD%+NH **;FEH #2YI,T4
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MI7%$R);&;,>:*27DT5F<<MQ,T4O2D)JST0HHHZT"%%%)10 [-%)10 ZDHI:
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M.:*2@4 %+24N:  F@4$YI* %I":,T4 %+2"@4 &:**.M !FC-!H- !2BDHH
M4TE%+0 =:*2EH  :4TVC- "TI--I:  <T444 +124N: $-%%% !1FBB@!:*;
MUHH 6EI#10 N:*2B@!:2CI10 M%)10 4M)10 4M)10 9S2GFDS0*  4M(:3-
M "T49H(H 6DS1[4"@ H-%(30 HHSBBB@!:2DH- !2$T$XIN: %)HIHH!H$+1
MFDSB@<4 .H%(*44 .%+312T#%HH!HH ,TM)1F@!:3-%)0 HHS110(**2EH ,
MT49H- "XI,XI.E+0 9HH-&: "ES3:6@8II*.M% "TE%% !FBBDS0 M&:#10
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M!3*0ZE%)2GBFBT%% I15HL44]135%3*E#! HJ0+2JE/"TAB**D5:4+3U6D,
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M*#24 +B@T"C- @)HI!1F@!:,4E+F@ -(:4TE "BC-%&:  T8HS24 +BBD%%
M"BC-)1B@!:"*,4F: %HI,T4 +2444 +12"B@ I:3-&: %HI :* "@4F:7K0
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M]Q6E.*SY!4Q.2H]009HI4XHILA&O12TV@](*<YSS313ASQ0 VE%%% !1110
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MBBBD% "YHI!2@T &,TM)FB@!:2@T T %'6BDI@+0:*3%(!<T&BDH *6DI:
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M8K1&Y(HJ513%%2BAC0H%+12U)0AI*#10(0TE+24 &*7%%+0 4M(*44 %%%%
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M 3;Z-U1;J-U $OF4;ZBW4FZ@"??2%\5$'HW4 2[J3=46ZE+T 2[Z-U0EJ-]
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M:,TE "T49HH 6DZT9HI !HS1FB@ S2TG6C- !0:**  49I!1F@!0<44E&<4
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M% "[J,TE% "YH+4E% "YH)I"** %S1FDHH 7-+3310 N:,TF*7% !FC-%&*
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MA%%.VT%: &44[%)B@!**=BDQ0 E.Q1BEH 2BG!:,4 )BC%+MI<4 -HIV* M
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M04$TE!XH&*#1FDHS0 4II,YI,T *31FDHS0(4FD)I#2T !HI*#0 9HH'-%
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MP(P*7%/VXIK4 1L:A:I&J-J3 :33":4FF,:!"YII-(332:0"L:8S4A?-,+4
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M4IHQ1B@!I%+BEI*8"8HI:,4  IV*3%.%(88I0*7;2@4  YI5%*!2BD,,4H%
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M&:*,4=* #- HHH ***#Q3 ,4AXHZTIH 2BC-% !11BCI0 4F*6@T )0*4TE
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MC-( "TM I:8"&K^F\&J-7M-/--"9TUM5Y*HVM78Z&")UIXIBT\4(!U(:6BF
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M&:>>:9B@!*0TXTV@ HHI10 "EI ,4[%,0M**,9I<4Q"T48I10(,48HQ2XQ0
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M6C% "4"EI* #-!HH)H ***6@!*,444  %)2D9XI,4 (:.M%'2@0E(:4G-)0
ME!&: *,4P&FHVJ4BHVJD2R,TPBI#32*HDC-%.Q3:0PI*6@4 &*<IIHYIRTQ$
M@IXI@IXI,8\4\4U:<!4LI"BEQ1BEJ1C<4F*?28I@,(I.M.Q32* $H-+BD(Q0
M TBD-.IM(:$Q1110,6BDHI#%HI12'F@!*0TIHH ;BDIQIIH ;BDQ2D44P"D
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MFF,*>:8W%6B61D4PU(:9BJ)&&DQ3\4TT@&T=*4T4# "G+313A3$2**>*C%2
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M'.T@CH0",CO]0#0!U<.M:1$0ZP3!E(((8@@CH0?.J[8:Y%K6JPW$*E1L8-N
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MFMM_$UA;8N;>V(N,Y^9CY:L0>0 Q!P>@VKZC:0* L<_XFU"/4KB2XB4JCD$
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MH >S5"[4UGJ,O2 &>H7:AFIC'- A":832FFFF 4TFE)III &:***8"@444M
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M* #%)BE-% "48I<4E "T9HQ0*! ::U+B@TT)D+#-,(J5JB:K1 TTTT[K32*
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M\8ZK_:5U)*#E0VU?FW#"\9!]"<MQZ]^M9UIJ<MEGRG9-V,[&*YQTS@CIFJU
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MM/%)C0\4\4VG"I*0N:*2C-(8N:0T4TF@!U)2$TF: %I":3-(: %I":"::30
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M&TAIU(10 VDI:,4Q#:*7%(: &FFXIYI#2&,-)BGD4TT -I*=BDQ3 0BBC%%
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M &BDHH **.M I %%%+0 G2E!I#2T#$HHHS0 M)11F@09HH)I* %)I.M+BC%
M""@\T4=: "C-%&*8!1110 AH%'6B@ HHHH ,XI,4M%(!*#110 F*6@T$4P#%
M!HHH$)2T4&@ Q36IU---"9&U-ZT]A3*LD2FTXTAI -HI2*,4 (*=29I10 Y:
MD6F+3Q0QH>M.ZT@I14LI"BC%**6D,:*4BC%+BD,9B@BG$48H ::;BGE:,8H
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MBB@  J15IJK4B+2 EB6KT*XJO M7XDIC'QI5N)<5&B58C6D,D0586HT6IE%
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MFDI:8A<4M)2BF(.E&:*6F(2C%+2&@!*,4M(: $HZTAH% !2T4HH *<*2E I
M. I<4@YI:!BBGBFBG4 %+110 "BBEH&-Q28IV:::!#Q4JFHEJ5.: )EJ534*
M\5*II#)@:,TW-%,0,:B>I#43"K1+(B*:14A%1DU)(TTF*#0M-#%Q0*#S1FJ
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M%)BEHH 2E-)2T )UH- HH 3%+11F@ IM.(IK4T#&M3*>U,(IDB=*::<:0TF
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M)!2XI5%#"A RO)4#U9D%0,*M$LKN*@<59<5 U B!JC<5,U0M0(B:FDT]JC-
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MY&:C(JD2RLPQ4#U<9,U$T=%PL47&*B85=D2H3'3%8IE:395EHZ:8\4"*^RE
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ME)BEI#28T%(:6DJ2A.M)TIU-- #3S3:<::: &FFTZD:F(::3-+24Q"4"EHH
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M*,T4&D4@I#1C-)2*$-)2FD-(!IIII32&@!M(:6DQ3 0TG6E-%,0A&***7I0
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M[%**2EI#"CI12]: #.*,T=:,TAA11F@B@!*,TM)2*0E&*#2'BD4)333LTAI
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M+10(2BC&*7%,3 4M HIDBTM)2BF(7.:6DHS3 7%)2YS24 '2FTZDI % H%%
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M$YJ5:BC%3+4%D@IPI!3J8!2B@4\"D F*,4[%+BD,9BC%/Q1B@!F,48I^*,4
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M6@ %**2E H <*44E.% "BG4T#-/%(8"G4@I<4#"ES0:2@!310*2@!31FD-%
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M:HWJ1JB:MHDL92XI0*6A@)BG"DI:R8T*#3J8*7-2,?FC--S1F@0N:3-)FC-
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M)12TE @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ H-%% PHHHH **** "BBB@ HHHH **** "BBB@ HHI* %HHHH
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MBB@ HHHH 2EHHH 2EHHH 2EHHH ***2@ HHHH&%%%% !2TE% @HHHH ****
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M IC0Y:F2HA4JFF4BU%5N.J<9Q5J,T(W@64-6%JLAJ=3392)A3P:C4TX&I*)
M:,TW-+F@!<TA-)2&@ )IA-*::: &FFDTIIIH ***7%,!<4HI!3A2 7%+BBE%
M A<4HI *6@844M% A**6DH&&:0F@TTF@8$TF:0FFYIQ0#B:8:"U--;11,F+1
M115$A2&@TAJ&6A,TE!I*R92%S1244@%S2$T9I#S0 A---*::33 0FHG-25&_
M-"%(C-%)UHILS.1%.*CK4LD%0D[.*1H.ADQ6E!<D\9K*VYYJ1)-M#0&_'<;>
MM2[L_=K(@G-6XKPCK4@7XI-O-61?8K/+;^:43'H:=PL7VN >O-592#TXJ'?G
MI3<^IHL"8\S=C3.#43'TH"8HL%R4**D53ZU$AQ4T8[T@N31@CD5.CDU$@J9/
MI2*)-YJ6*3=TIL;9X-3(HH 41D]:<(A0.*>IS0( N*7%%%,!,4;0:6CI0(;Y
M8IP.**7% !112T %%&*6F(2BBB@ I*6DH&%%+1B@!**6DH *!110 4444 %%
M%% !1110(***!0 4444 %%%% !1FBC% !1110 M)110 4444 %+110 E%%%
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ME%%+0 E+110(**2B@ HI124#"BEI*!!2TE% !1110 &BEHH 2BEHH 2EHI*
M"EHHH 2EHHH #24N** $I:*2@ HHI: $HHHH **6B@!,44I%)0 8HHHH .E%
M%+0 E%%% P-%%% !1FBB@!**6B@!*4T4E !2TE% @I:** $HI:* "DHHH **
M**!A1110(****!A1110 4444""BBB@84444"$I:**!A24M)2 **6DH ****
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M1110 44&B@!*6BB@ HHHH *,444 !HI*6@!*6DI: "BBB@!**6DH *,8HH-
M!12TE !1110 4444 %&*** "DI:2@!11110 4E+24 +24M)0 M)110 4444
M%%%% PHHHH ***,4 %)2TE "T4E+0(**** $HHHH ****0PHHI* "DI<TE,
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M %%%+0 E%+10 @HHHH **** "BBB@ HHHH *2EHS0 44&C- !124M !1110
M4444 %%%&: "BBB@ I*6B@ HHHH *,444 )12T4 %)2T4 %(:6B@!*6DHQ0
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M%  :*** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* $Z4M)2T )12T4
M)112T )1110 4444 %%&** "DI:#0 4E+24 %%%!H ***,4 % H-% PHHHI
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M<TF: !C43FGL:B<TTB6R*0U4F.*L2&JLQJD#*<QJF[59F:J<AQ3(;'!J4/4
M:EWT["N6!)2AZ@#T!J=B7(L!Z<'JN&IP:J2(<RQNQ3@]0 TX&BPN8MQ&K2&J
M<!JXE%@4B5:D%1K4@I#N/%% I0*!W$I*=BDQ0%QIIM.84VDRHL*6DQ2FI9HA
M*3-+12&---)IYIAIB8TFF&G$4PU2(D)FES331FF1<?FC.:;2T"N.S2YIH-%
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M2XHHJ6:(2DI:*0QIIK4\TQJ:$QAIAXI^:8U4C.0TTE*:2J(%I124M @I:**
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M,6GBD 4444P"BBB@!**6DH ***2@ HHHH$%%%% "4444 )12TE "&FTXTTT
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MD:-"$U:C;-5(15N(5)?0LQU.M01BIUI%(E6GBF+3@: %HHHH **** $HHHH
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M&14;K4Q%,9:!%9EJ%EJVRU"RYI@5)%JM(M7G6J\BT 4I%JK(M7I%JLZT$LA
MJ1>*;BG 4Q,E%.%,%/!ID,>O%/%,6GBF!- >U:,-9T/%:,-(:+*U*M1)4JTB
MT/%+2"EI %%%!H 8U1&I6J.DRHA2TVEJ6:(#3:4TF*10AIC4\TQJ!,C-,)J1
MJC-6C.1&:!2FDJC,4444M !2BDHH 444F** %HHHH **** "@444 %%%% "&
MB@FB@!*#030: "DS2$T&@ -%% % "4$4N**0"=:3%+BBF TT4II#0 W%--/I
M*!#",4AI32&@!#32*<>*;3 3%%'2BD 4G2EHH 2BBC% !1BBC- "8H%*:3%
M !2444 &*3%+UHI@-IN*>:2D TBD(I2<4A% #32&G4TT ,(IC"I#36H&1$4;
M:=BE"TAH:$J14I0E3)'4LM")'5F)*:B591:1HB2-:L*M1HM3J*@T'**D I *
M<HI .%+2"EH ****8!1110 4E&:* "BBB@!**** "DI<4E !1110(2BE-)0
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M+10 44"B@!:*,TE "YHHHH ":*#S24 %%% H 6D-+24 -I#2FDH$-:DI324
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M9I,T .I*3-!- "YH%,S2@T"'YI,TW-!- "YIIHS29H #2&C--H *::4FFEJ
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MIB(E6XUJ*-*M1K0421BIE%,05(*3&+2$4M(30,3%&**,T &**6DH *0BEI:
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M"U-W4 2[J,U"7H#T[")J,4P-3@U( *TFVG T9H 9MI"E24&@"(I2%*EQ28H
MA,=,,=6"M)MIW!HK&*F&*K96DV47%8I&&F-#5XQTTQT[A8H&"BKIBHHN*PE%
M%%68A1110 N*!24M "TM)2T %+24M(:%IPIHIU)EH6FFG4AI%$;"HVJ5JB>D
M,@DJJ]6I*K2BF)E.6JKU:EJK(*TB85"+&:<M--.!K1'.V/6G4T4\4R;B@5-"
M:AJ6,T!<O1FIU:JB&K"FI9HF3@T_-1*:>#2*3),TN:8#2YJ2T.S2&DS2&DRX
M@*6DI:@T0M(:6FTBAIJ-J>U1L:8B-JB8U(]0.:I$2&L:CS0S5&6JT9,EW4;J
MBW4!J!$V:-U1[J;OH F+4TM3-](6H DW4$XJ/=2;Z )=U(6J/=FFEJ )-U-W
MU&6Q3"U $I>F%ZC+TPO0(D,E(7Q41DS3"],"5I*:SU$S4PO2 F,E-\RH"])O
MH"Q9WT@DJ#?1NIA8L%Z<&JL&J0/BD%BP'J9#55&J=#3$6%-/!J):>#0 ^BDH
M%  U1O4C"HVIB9$]025*]02&@1$YJ-FI7J-C29: M3=U-)II-26D/W4H:H=U
M+NH'8G#4X-4 :G!J L3!J7?4.Z@M0%B3=2EJBS1NH"P_?2;J9NS29H"Q,K5*
MAJLIJ9#0)HLI4Z&JT=6(S3)+"FI5YJ%*G04P'BEQ0*7% #2* *4T4AH44]:8
M!3Q4LTB2K4JU"M2K4,T1*M2+48J1:EE(=2T@I:!A1124 +24M)2 **** "DH
MHI@%%%% A*#110 4E+1B@8E%%% "4444 (::U.IK4 ,-1/4K5$U# KR55DJU
M)5644 RG/522K<W%5'-4B"N_%0MQ4S5"QI@"U9BJLM6HJ8F7H.*O0U0@J_%4
M,I%N.K"57CJ=*DHF2GTP4X4T# TQJ>:8:HAC34;4\FHS31FQK5$:D-1FJ(8F
M::32DTPF@0A-(6I":B9J0R3=1YE0%J;YG:@+ER-LUHVW-95N=U:]L*EEPU9=
MB%3BH8Q4XI,U0ZDHIN: %HI*=0 4M I0* %%**04Z@ HHHH *0TM(: $HHI:
M  4M I: #%(12T4 ,(I,4^D- 7&$4TT\TTT6'<8:2G$4TT@"DS2TAH :33&:
ME8U"[4T@8XO0'JN6I5:JL%BTK5(K565JD4U+ GW4;JBW4;Z0$VZC=4&ZC?0!
M/NHW5#OI=] $N:7-1!J4-0,DHQ30U.#4"#%(5I0:6@!A6BGT4"*=%/=<4RM4
M8M6"EHHH$%%%% "T444 +BEI*44#0HIPIHI14LM#J0T9H-)E(8U1-4K5$U(9
M!)563FK4E59:8F5)15:2K,E59*TB85"(BG#BFBG+6J.23)!Q2XI%XIPYIDW'
M=:>O%(M.% 7+"&IT-5D-3(:3-$RPII^:A5J>#4LM,F!I0:C!IP-2RXC\TF:2
MEJ6:Q%I12"E%0:(*0TM(:10QJB:I34+&FA,B<U YJ:0U6D-4B)$3&HMU.D:H
M"U6C)DN^C-0[J-V:"2;?0&J+=0&Q0!-NI-U1[Z3=B@9*6I-]1[Z;NH EWTA:
MHR]-WT /+4UGIA?%1EJ )&-,+4PM36:@5AS-32U,9J9NH'8>7IA:FEJ;F@=A
MQ:D#4S-% [$@-*#48-.!H"Q(#BI%:H*D4T"984U.AJLE6$-,AEA#4BU%&*F
MIB%Z4HHQ3@* &FHV%3E:CD6@&5G%5I:M.*@D6@14?BHFJ9Q4+"DS2)&QJ,FI
M&J,BI9K$;FG TV@4BB0&E!I@-+F@5A^Z@FFTN:!"YI<TVEH ,T9H%% #EJ53
M42U*E,EEB,U:C-54XJRE,AEA#4Z5 E6%-,"113J:#2T (:2@FDS2&APXJ0&H
MQQ3@<U+-(DJFI5-0K4PJ&:(D6I5J)14@J64AXI:2EH&%%%%(!**6DH ****
M"DI:0TP"DI<T4" TE%% !24M)0,*#110 E!I<TAH 0TTTXTTT ,:HFJ4U$U
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M6BB@8M**044A#LT]:C%/6F)EA#5B*JJ&K,9IF;+*5,M0(:E%,1*#3Q48.*D
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M4J):E0UFS9$RU(M1+4JU+*'BEH%%(8M)2TE !2TE%, HHHH$%%%&:0Q****
M"BBD- !1113 *2BEH$)1110,0TTTZD- ##3#4AIAI 0L*@?BK#BH'%- RO)5
M:05:DJNXIDE9QBJ[BK,E0.M"!D0%2+3#3U-426HJMQ54CJW%4LI%J.K"57CJ
MP@J2B9:<*:M/%- Q#3&J0U&U4B61M43FI6J)C31FR)C4;&GM4;4R&----.-,
M)H9+(WXJ"3BIY*@?FH9G(A;FF,*D:HZ!(:11BE(HIEH;2@4M H*#%)BG$4=*
M!H3%&*44&A&B#&*44F*450Q:,4NVEV4AB 448HQ2 2BEQ2A":+#N-H S4RPY
MJ>.VS18+E()FGB$FM%;.I4M*- U,U;:IDM,UI+:U,MM2YAJ)FK:T[[+6F(*=
MY-*Y2B9)M::UI6OY%-,%%PY3%:SS3#9YK:-O3?L]/F%R&(UG3#:FMPVU,-K3
MYA.!A&V-(8B*VS:TPV>:=R;&)MQ2\UKM8U$UEBBX6,[<:<)35MK/%,-I0!"L
MU2":E^RXI# :+(-1ZS5(LU0".E$=39#399$U/62JH%/#4FBE)EM9*>'JJK4]
M3FD-,M"2E$E5P<TX&D,L"7%.\VJQ-+NH L^=157?11<#H8.E2T459 4M%% !
M2&BB@"K<"H1115QV,I;BBGBBBF)#A3Q114LM"B@T44BAIJ,T45)1!)566BBJ
M1+*DE5)***N)C4(:<M%%;(XY#AU-.:BBJ,QN*::** (V/-*W%%%)FD1M/%%%
M26B9:LQT45+-8%B.ITHHK-FT2=:D6BBI9HAU--%%(I$;5$U%%-$LK256DHHJ
MD0RK)5.6BBK1C(C-&:**H@2BBB@ IIHHI%(0TE%% Q*;11290AI#110,2D-%
M%(8E%%% "4HHHH&%+110(4"BBB@!PHHHH$+3EHHIB9(#5A***9#'+2BBBF2.
M6ES110(:>:C:BB@"%Z@:BBDS2(TTC445)HAIIM%%(I!2444#$-(:** %%.%%
M% F+3A113)8\5*M%%-$2)DJ>.BBJ,V64%3I110")*4444#"FBBB@8X"GK114
M,T@2+4RT45#-D2K4@HHJ&4/%+112&%+110 E%%% !0***!!1110,*2BB@ -!
MHHH 2BBBF 4E%% @H-%% PIK444 --,-%%("-J@:BBA R!Q5=^E%%42RNU5Y
M***$#(A4J"BBJ$6(JN1"BBI8T68ZL)114E$PJ0444P8&HVHHJD2R)C4;444(
MS9":B-%%40QI---%%#)9&U0/114,R9"U-(HHH! :::**9:%Q2"BB@H=2444#
M049HHH1HA:<HHHIC)5%2 444#&N*C HHH$2JH-3(@HHH&6D45,BT44F-$Z+4
MJK114,T0\+3E%%% (<!2XHHJ2A,4F***8#2*;113 "*3%%% A,4A6BBF)C2H
MIA4444Q,8RBHRHHHIDD;**C9!110(85%)M%%%)C&E: ***0Q0*>!BBB@!U+1
.12&%!HHI#"BBB@9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>a2026coverhalf-yearfinancia.jpg
<TEXT>
begin 644 a2026coverhalf-yearfinancia.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZB
MWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
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M@!**7K28H *2EI* $I*6DS0 4W-+2&@ HHI* #-&:*2@09HI,T9H 7-%)10
MN:3-)10 M%)10,6C-)10(,T4E% "YI*":3- Q:*2B@ HHI*!"T4F:* "C-%%
M !129HH 7--HS10 A-%&:0T %+2"EH&%+244"%HHS10 44F:* -RP^XO^Z/Y
M5H1BJ%@/D7_='\JT(Z&$2P@J45&E2BD,7%--.I#0 PTTBGFFFF(C-,-2&F&F
M(8:::<:::!#33:<:0TP$I:** "BB@TAC332*>1333$,-,-/---,0RD-.--H
M****3$Q#3:<:2I(8E.%-IRTF(D%+2"EJD:(6G"FBG"FQH=10*.M24%%%% Q*
M*** "BBB@ HHHH *6DHH 6DHHH **** "BBB@ HHHH **** "BBB@!*6DHH
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M "BBB@0M&:*2@8"BBB@ HH-% !1112 2@TII* "BBB@ I*** "BBB@ HHHH
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M(*6G$U0"GBFTX53&A:44E+4E!1110,3-%%% "4444 %%%% "T4E+0 49HHH
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M>*0T )1110 E%%% !0*** "BBB@!*,4&B@ H-&:*  4E+10 E%%% @I*6BF
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MI":!B4M)0* %'-.I*7% "T444 %!HHH 2BBD%  :#2XIIH *,444 )24ZFT
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M-( 5(Z88\D]!AB>.YQS@5QU)C0&@444@"BBBF 4444 %%%% !1110 44E+0
ME%%% !111F@ HHHH *2EI* %I*6B@!****!A10310 44E%(!:*!0:8 ***2D
M M)110 4444 %)2TE !2YI** "BBB@ HI*6@!*#110 4E%% !1110 444E "
MTAI:2@ HHHH **2B@ I:2B@ %+2 TM !2444 %)2YI* $)I*6DI#%%**;2TP
M%S2TE% A:*2CI0 M)1FB@ H-%% "4444 %%%)0 AI*4TTT##-*#3:<* %%.%
M)C%+0 M HHH "**!0: $H-%% "9HH-% !24M(: $HH-% "4E+BDH #24M)0
M&DI:2@ HHHH **** "DI:3% !24M% "444M "444M "44M% "4E*:0T""DI:
M2@!*0\TII#0 E)2TE "&D-*:2@!#11TI* "BBD- !1110 444E !1113 **2
MEH 2DI310 E%%% !2444 %%%)0 4E%% "444N* "EI*6@ HHI*!"TE%% !11
M10 444E !1110,Z2R^ZO^Z/Y5<CJG9_=7_='\JN)4C1.M/%1K4@IB%I#113
M*::6D- AII#2FD-,0VD-.IIH ::::<:;0 TT4II* -7PQ_Q\)_P+_P!!-=Y7
M!^&/^/A/^!?^@FN\IB/+Z0TM(:0QAIC5(:C:F(C->MUY(U>MT ><^+?^/J3_
M (#_ .@+6/6QXL_X^I/^ _\ H K(I,EB&FTM)2(8"G"FBG"D)#Q11151-$%=
M=X#_ .6O_ /_ &:N1%==X"_Y:_\  /\ V:F-&OXJ_P"/9_\ @/\ Z$*\^KT'
MQ5_Q[/\ \!_]"%>?4F4@KK?!-@I#7!Y8-M''3C)/XY_SFN2KT'PK_P >R?\
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M&E--- ""GBF4X4#'B@&DI<4 .Q24 YI: %I*,T4 )10:#0 4E*:2@ I*6DH
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M  G_ ,?,?_ O_0#7H;H'!4C((P0>1S30F<EH'A)9D$\_.X9"@X&"."2.>>H
M/'?T'5P6RVXVHH49SA0 /TK)\0>(QI6$ W2,,\\ #D GUY[#\QQGEG\77+$D
M/C)Z!5P/;D$T72"S9-XTG$MQM'\"*#]>6_D:P*FN[MKMC+(<L<9/ Z#':H:1
M09HI*4T@"BDHH 6DHHH ****  T44E !2TE% !1FBD- "TE%% "TF:**  T4
M4E "TF:*.M !24N:2@!:*,T@H 6BDHH 7-%)0: %I***  FFDTM(30 E%%)0
M N:44VES0 ZC-)FC- "T4E% "T9I** %I*** #-%)FB@ HI*,T (:::6DH !
M3A30:,T#'TZF"E!H =BES3<T9H$.S129H)H&+0:3-)F@!:*2D)Q0 O2E[XIN
M<<TT-GFD \C'%&:8SXJO)?*G)/Z4#+74TAJ@FIHW0_XU8%Z@H G6GE0>G2J]
MP3(,K@UEO))&<CM^/ZTKA8VB@!P:0%4!<]JI6VH&1?FZBGB575DZ!AUZX/O[
M4,:+>]7^H&:54W8/8UA?9Y(N3R!T*G(K0MI,8)R%Z\4,$6V3;Q3HHS^%49[T
MQD,#GL:FAO0X# _Y[T 6YE,C=,=*@!*U;6429QU &*JVH$RF0D8!Y^OI0F#%
M)W?-W%-[9-22W*KA!WI$^8\\ =Z=Q6&%>].V@#W-3^8.F1C&*A,H[=>U*X[#
M"*0TC28ZG%*3CI3N*PTG%)NII;-&:=Q#^M(:C+T>;ZT7 DS28HSFDS0(*0TN
M<TTT !I#1FDH&%(:*2@0AHH-% !29HHH **** "DHHH **** $HHHH 0T444
MP"D-+24 %!H-)0 4E%!I %%%% "T4E+3 ***2@ HHHH$%%%% PI*6DH$+244
M4 )1110,Z:T^ZO\ NC^56UJK9_=7_='\JM)4E$JT\4Q:?3)8M%)13 #24M)0
M(2D-+13$-I#3C330 AIIIQIIH ;24XTAH T_#/\ Q\)_P+_T$UWE<'X9_P"/
MA/\ @7_H)KO*8CC?^$RF_NI^3?\ Q5!\93?W4_)O_BJPJ0TAFX?&DP_A3\F_
M^*II\;3#^%/R;_XJL(TQJ8C>/CB?^ZGY-_\ %5W%>2M7K5 'G/BS_CZD_P"
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M?[G_ (\G_P 51_PB=S_<_P#'D_\ BJZW_A*[;^__ ..O_P#$T?\ "66W]_\
M\=?_ .)I60[LY[1M N;*9)2G ;G+*>#P3PWH:[BLC_A++;^__P".O_\ $T?\
M)9;?W_\ QU__ (F@&>?W,!MV:,]58@XZ<'%1XJQJ4PFED=>0SL0?8DD4:?I[
MW[B*,9)_(#U/M_GK2&5^E)7?Z9X0AM/F?]XW^T/E[_P_XY]1BMA46V7  5%!
M/& !W/L*=@N>:?V//_SS?_OAO\*Z#P7;2VTCJZLJLG\2D#((QR1Z$UTG]L0?
M\]$_[[7_ !J6"_CN#M1U8XSA6!/Z&BPKE?781+!(&Y&QC^*C(_45YE7J&L?Z
MB7_KF_\ Z":\PI2'$UO"?_'S'_P+_P! :O1:\Z\)_P#'S'_P+_T UZ+30I'E
M>HWIOI&F;JQ_(= .W0<57HI*DH#2T4E !110: $I:** $I:** $I<44E !11
MFC- !29I:2@!:2BB@ HHHS0,#2444" FB@TAH 6DI:* $HHHH **** "C-%%
M "49HHH ,T44E !332YI,T %)110 M%)2T +1110 4444 &:,T44 &:**2@
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MG)QS1G-,1^U.)VT" TF:4FD/%,09I-U&:* $SFB@BDQ0 44F:,T +12 TA-
M#J*;FES0 4$T9I* %-)FBC- !1244P"BDHS0 4444@$HHHH *,T44P"BDI:
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M &*,444AC328I3S24P$HQ2T8H$%&*!2T &**** #%%%+0 F*,4M)0 &DI:*
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M+FF(;UHHQ24 % IU)UH *2C%% !28I:2@ I*6B@ H)I*,4 !HHI*8 :**2@
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M%L"KL#U!4?,>.H(' ].<5YTX /'([9&#^63245+*05W7AK48H;=%9U!&[@L
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M_,8__KI,$U:+QC^]^8_PI/M" ]#^?_UJ=P*VXCO3EG<=&/YFK1ND;KN_$_\
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M^:3--W4FZ@!Q---(6I,T #4TT$YI*0!2T"EI#$HHI: "BBB@ I*6BF E%%%
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MC-)10 M&:2DH =FDS29I,T .S29JUI""2:)6&09$!!Y!!8<5Z=_8D'_/*/\
M[X7_  II7$W8\FS3=U6]801SRJHP!(X '  #'BJ9-(8N: :;2T .S2YIN:*
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M<G[P'7GG(X!SGKU]^U'*')8\^I*FN+=K9C&XPRGD&H:I%""EJ]I&COJ;[%X
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MF;L">;A,Y"]V'U[#]2/3@UV%I8QV@VQJ%Z=!R<=,GJ?QII";/-O['G_YY/\
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MI/)Z]ZI(39YE_8T__/*3_OAO\*JS0-"=C@AAU##!_(U[!45Q:I<#:ZAAG.&
M(SZ\T<H<QY#178:]X*V S6W8?ZODGW().3]/K@]!7'TFK#3N)FCI1BN^\ ?Z
MAO\ KJ?_ $%:%J#=C@,45W_BW2VU.2"%>,^9DX)  VY/^'O@9K8TS18M-&(U
MP<<L>6/3O^'08&>U'*+F/-/[%G_YY2?]\-_A5(UZ_>W/V6-Y<9V*S8Z9P,XK
MD_AU_P MO^V?_LU.P7.8T7_7Q?\ 75/_ $(5ZU1132L)NYY'KG^OE_ZZO_Z$
M:HFO:J*7*/F/%*6KNN?\?$O_ %U?_P!"-4QQ2&&:*,4M !12XHQ0 E)2T8I#
M"BEI.M !37&_Y?6GXQ3 22<=<4 ALS9P!T!K.E?&:MW5QY8)]>!^-91R!N/2
MA(;(&R3FCS2O J-GS3&.[I5DB[P.O6F$YHZ4JINH =$F\_SJ65"XX&$'K_GD
MTP-MZ=/YTUY">O04"#<L?'4TUI2_7@"F#YN:0G?]*8 3GZ4\$+UII(Z]J0_/
MR>E !C/-2=?K2=.:51GC\S0 8]*7=MI"W84W?GI0 X#/6IE;L*CC7MU-7(;?
M/6DP&1P>M7(K8&K$%F#5V"VSTJ'(M1*T-GGG%7(K;UJRMN:GC@Q6;D:*)$EN
M!5B**GK'BI56IN7815Q3\4*E.'- " 4H%&VGT"$'%/%(12BF(<*4'%%%,0-3
M2*4T4 )BF]*<::: &$4A%/III 0E: *EQ28H'<B"TC+4NW%(PIA<K,F:A>/-
M6RN:C*8I6'<SY(=OTJNT>RM22+-5FAS1<#-ECSR.M573/7KWK2EB*\U#)%N'
MO5)B:,F2'TJ$KBM22#/(JK)!QFK4B'$HLN:@=:O-'BH9(\U29#14W;>*D5L<
MBD9<?2H\[:H1<23S?8TX+G@U64[ZFBEW_*W7UJ6AIBD[*4'-.*[OE/7M4&2I
MP:0R];3;>#TJPR[3D=*S5?%78+CC!Z=J30TR;K]:6HRVWFI1SS0A,,44N<TE
M A**4TE, HHHH$%%%% !2444P"BBB@ HI*6@!**** "BBDH 6BDS10 4444"
M"BBDH&%%!HH ZR!<*/H*E I(1\H^@J0"I1;$Q1BGXI=M4C-C-M&VGXHQ3$1D
M4F*D(II% #,48IU&*8A,4!:<!3@* &[:7;3L48I#&XHIV*0T -->@Z7_ *J/
M_KFO\A7G^*] TS_51_[B_P A0@9S'C'_ %R_]<Q_Z$U<^:Z#QB,RK_US'\VK
M!(I@1FNH\"_\M?\ @'_LU<PU=1X&_P"6O_ /_9J!&GXK_P"/:3_@/_H0KSRO
M1/%?_'M)_P !_P#0A7G= F:WA3_CYC_X%_Z :]$KSSPI_P ?,?\ P+_T%J]#
MH!')>*O$S0M]G@;&!\S#KGD;?;'<CG/I@UR,LS3'>Y)8]23D_F:6>4S,7;EF
M))/N3DU'4-F<G<O:;K$NG',;<9Y4\J>G;\.HY]Z]$TK4EU&,3+QGJ,YP1U'^
M>V#7ERUV?@.4E9$[ J1]3D'^0HB]1P8GCFSX2X'^Z>N?4>WK^=<C7H7BQ UL
MY(Z;2/;Y@/Y&O/C5HLW_  YXD&GCR9!\A;[PZC/J,<_S ]>!6EX@\5^3^ZMR
M"W=A@@>PZ@GU]/KTXVEI,:'RS-,=[$DGJ2<G\S3K6[>T;?&Q4^WYX]Q['BGQ
M:=+,-ZHQ!Z$*2/SQ5[_A%;G^Y_X\O^-(HZWP_K7]J(2>'7[P ('.<$<GM^OX
M53\9V EB\\ ;D(R>^T\8_,C]?Q@\*Z/-82,TB[5*?W@1G(QP">V:V]90/!("
M,_NV//L"1^1I]!=3S2M;PK_Q\Q_\"_\ 03636MX5_P"/E/\ @7_H)I#/0JY3
MQ/XD:)OL\)Q@?,PZYZ;1Z8]1SGT(-=77E4TIF8NQY8DD^YY--B02RF8[W))/
M4DY/YFK.G:O+IYS&V!W4\J>G;\.HY]ZIT5)1Z;I>HKJ,8F7C/49S@CJ/\]L&
MN?\ '-GPDX_W3USZCVXY_.G>!925D3L"I'U.0?Y"M'Q8@:V<D="I'M\P'\C5
M;HGJ>?5J>'-)&HR[6'R+RW4?09]_PXSBLLUVW@BWV1-)C!9^O/(4#'ZDTD-G
M032B%2[<!02?H.37 :UXGDOR50E8^F!P2.1R1ZYZ=/KUK?\ &]YY42PC_EHW
M/3&%YQ^9'Y5P]#8)!70Z!XI:U;9,Q9&/4DDK[^I'J/Q'H>=I:5QGK'RS+V96
M'U!!_F#7G.O:;_9\S1C[IY7Z'\3TZ<^F:4>(IEC6W5L*HQD?>(SD<]1CH,8X
MXK/=RY+$Y)Y)/7)IMW$E8M:1_KHO^NB?^A"O3J\QTC_7Q_\ 71/_ $(5Z=3B
M*1YAJ_\ KY?^NC_^A&HK2Y-JZRKC*G(R,C_/Z^G-3:O_ *^7_KH__H1JIBI*
M.]M/%L,T9E?Y67JN<D^F.F?Z=^.:Y/5=?EU$D,<)GA1T[=?7IW[],5G4Z*%I
MCM4$D]@,G\A3N*PRM[0/$S63".0YB)[Y)7C QSTZ<<\=!FJ4'AZXGSB-N/[W
MR_\ H6,U-_PBES_<_P#'E_QHU'H>@N@<%2,@C!!Z5YIK%E]BF>(= W&,G@\@
M<^QKT:P5DC17^\$7=DY.<#//?FN,\;H%G! ZQ@GWY8?R%-DHY_%>G:1_J(O^
MN:?^@BO,:]/TC_4Q?]<T_P#012B.1R/CG_7K_P!<Q_Z$U<[BNC\<?Z]?^N8_
M]":N=H8(3%&*6BD,3%=SX&_U#?\ 70_^@K7#UW'@;_4-_P!=#_Z"M..XI;'0
M.X0%B< #))X'%<'JWBZ6[)6,[$SQCACTZGM^&.N#FNA\8W30087C>P4_3!)_
M/&#[9K@:&P2++ZK,X*F1R",$%VQ_.JR(7(4#))P .2<]J2M7PM;>?<(",A26
M/7C )!X]\?RI#.WT32%TR,(!\Q W'U/UXX';_'-87BGQ,T+?9X&Q@?,PZYY&
MT>F.Y'.?3!KK:X9_!%PY+%D))R268GG_ (#5,E'..Q<EB<DG))Y/UJ2UNWM&
M\R-BK>WYX/J/8\5O?\(+/_>3\V_^)H_X06?^\GYM_P#$U-F5='3Z!K(U6/?C
M#J<,/ZCO@^_N.<9K#\<:5TNE'^RV/_'3T_ DGT%7?#6@2Z4S%V4HR]%R3D'@
M\@=LUH>(K?S[>1<XPN?^^?FQ^.*KH3LSS.NO^'X_UO\ P#_V:N1KKO '_+7_
M (!_[-4QW*EL=?7'>)O%;*QMX#C:2&;OGH0/3'KUSTXZ])K5[]BA>4=0O&,'
MD\ \^YKRXTY,44$CF0EB<D\DGJ<U<TW69=..8VP,\J>5/3M^'4<^]4\45)1Z
MAI&JKJ<8E7CG!!['TSWZ]?Z\5S_CG21@7:]<A6P..^&)_3GV'UI>!KORIC$3
M@2+TQU*\C],_YQ77ZQ:?;(7BQDLIP,XY'*_J!_6KW1&S/+,5J^&M'_M.7:P_
M=J,MU'T&?<_3C.#677<^!+;9"TF,%WZ\\A0,?J3_ )%2EJ4SHOE@7LJJ/H !
M_("O/M8\62WK'RV*1@\!3AOJ2.>?3./KUKH/'-WY4(B!YD;D8ZA>3^N/\YK@
MZ<F**$-:NE^)9M/(^8L@P"K'(P., G.W\/;.>E9=%24>M6=VMVBRI]UAD?X<
M=QT/O7#>--&^R2>>@^64DGJ<-U/;OU'/KV%7O %Y_K("?1@,?@QS_P!\_P!.
M]:_B^V\^V8XR4(88SQ@X)X]B?YU6Z(V9YOBN]\ _ZAO^NI_]!6N#KO/ 7^H;
M_KJ?_05I1W*EL=&[B,%B< #))X  [UY]K'C&6\)6([$SQCAR..I[=.V.N#FN
MD\:W;6]OA?XV"GZ8)/YXP?;->>4Y,4469-6FD!4R.00007;!SVZU4Q2T&I*+
M>BC]_%_UU3_T(5ZQ7E&B_P"OB_ZZI_Z$*]7JHDR/)=;'[^7_ *ZO_P"A&J.*
MOZW_ *^7_KJ__H1JB:DH3% H(I:  "EQ0*6@  HI:* &D4N*6B@!*3%+10 A
MJ)1M!;N:E/IW-12Q[N3]T?SI#,VZD+=>@Z5GSOO//X"I[J4S-@=O\YJN1CW-
M4D)D;#UIN,T]EQ43$FJ$*!NX'4U*R;1CMGD^I],U(L0@'S=6_/'_ ->HYY=W
M!Z"@".5]_MZ5&1O^@IX4MR>/\*C8YZ=!0 $Y_P *3[] XYJ0CRA[G^5,0S;S
M3@.<T*N*<!W/2@! N.?6D=^PIK-^=(* %Z\"I5B]*(XJNV\6*+@+!!NZUH6T
M&*6W@]:T(HL5E*1I&.HL2 #I5J*/%)%%NJTD>*S;-4AHCJ:-*<J4]5Q2&($I
MV*<%I:!7$Q3<8I](*8@ I:*7K0 M HI* '4M-S2TQ 329H-% "&DH-% "9IM
M.I* $/%,I^** &XI"*=BD- #"*:%S4A%-H"XTK43Q9J<TTBBP[E%XJKR6_<5
MHNN:88LTAW,HQ9^M0O#^=:LEOFH7M\T7 R)+7?5.XA\NMJ6+U%5I8>W:K4B9
M1,65*KM'W%:<T&S@=*J.F.:T3,FBEG;4K'?SWI7BW=*B'RTQ%N&7?\IZ]J<T
M?F<=ZJ_>Z5-'+OX/45+0TQH..#UJ2)\&G3+Y@W=QUJ!7VT ::@..O6G0-CY3
M56WESQ5DMG#=QUI6'<G(HI5.ZD(H$)24II*8!1FBB@0E+124 %%%%, HHHI
M)1110 4444 )12T4P$HHHI &:2EHI@)12TE A**,44#.RA' ^@J4"HX>@^@J
M05*+8X4N*04ZJ1FPH(I:*8AI%-(IQIIIB&XI!3C24 *!3@*04X&@ Q1BEH-
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M*X[QQ_KE_P"N8_\ 0FIO82W.>KT[2/\ 4Q?]<T_]!%>8UZ=I'^IB_P"N:?\
MH(I1'(Y+QQ_KE_ZYC_T)JYVNB\<?ZY?^N8_]":N>I/<:V$Q12TE !7<>!_\
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MA27//W1QD>Y['U&:+(+LUKNZ6T1I6Z*,_P#UN>YZ#WKS?5-1;49#,W&>@SG
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MX'K7*T,%L%)2FC% ST/P]KBZD@4G]XH&X'O_ +0]C^AX],OUO0$U4#/RN.C
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M^V8/^>J?]]K_ (UGWWC&"W!VG>P)&%!Q_P!]$8Q[C/L#19#NS9^6!>RJH^@
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M/]*K%L\GM4EX^]@HZ  #\._XU!*-QP* !?F^8]!43R;SGM3IVQ\@[=:B/%-
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MG6:<A1"BC-)FI*%I*,T9H *.M)FC- !24N:3- !11F@F@ I*,T9H **,TF:
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M:(L;12TE)E(****0PHHHI#"BB@T %%&** "BBB@ HI<4E !24M+0 F*2EHH
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MNWZT>S%[5DK6LGH/S%5)(9&X']*N_:,#FJJ7Z/ZTN2P_:7*4VDR2=1^M5)-
M;/0?G6\)%;H?UJ&6X\KG^M-*P<S9CG1I ,8&/8U/;:%G[R@X]S6A::LCG:QP
M3ZXQ5S..1T/<4Q7,>71(F^]M!'HQ'\S5:?P\F-H;ITR16]<6"3C![U5O]/0X
MP<?4U4$F[,4I-*YSL_AZ1.1S5%86@.&!'U%=I!.L>(]P)'O46K6ZW2%<#>!U
MI.#0XS3,"!]PJ1SD54M),<&K9Y%0,=33QS0IH/- A:*13FEH **2B@ HHHH
M**** $HHHH *2EI*8!1110 4444"$HI:2@ HHHH&=I#T'T%3"HH>@^@J45"+
M8\4HI!2U1 4444 (:2G4E,0E%%%,0E(:6DH&)12T4@"BBB@8E--/IIH$,:HV
MJ1JC--"9&:8:>:8:8AII*4TE,0E--.-(:ADL::;2D4E20QZU*M1)4ZT(J N*
M*6C%:&@PBD-/--I,:$HI:*DH2C%+BB@!**6C% "44M% "48I<48H 3%%.I*
M$HI<48H 3%%+BC% #<4F*?BD(H ;BDQ3B*3%(8=:*,4N* "BE%&* $I*=10(
M;12XHQ3 2C%+BC%(!**6B@!*2G8I,4 )12XHQ0,0TF*7%% "4&EQ1B@!**6D
MQ0 4F*7%&* $I,4[%% #<44N*"* &XHI<4M #:*7%)B@!**=BDQ0 E)3J3%
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M8>@^@J85##T'T%3"DBF.%.I!2TR0I*6B@!*2EHIB$HHHI@)2&EI#0 E%+12
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ML#_/ [_AD:-CIZ62[$&/4]S]3W_SBIW<("QX ZD]*Y#6O$;71,<9Q'TSW;_
M>WY^@3T&M3I+G6H;8X9QGG@98C'KC./QK/\ ^$PA_NO^2_\ Q5<A12YA\IV<
M/BR&0X.Y?=AQ^A-:L,ZSC<A##U4@C]*\WJ>RO6LV$B'D?D1Z'VHY@Y3T6N;U
MSPT"/-@&".JCO[CW]OR]]K3;\7R"5>,]1G.".W^>U6J>XMCS*BM;Q%I?V&3*
M_=?)'3@]QQV';\NU9-06@HHHH *2EHH 2C%+10 E%+24@"BBBF 4AI:2D 44
MM)0,**** $HI:* $I*4T4 )24M% "4444 )12TE !1110 E%%% "44M)0 E%
M+10 VD-*:2@0A%,-/--- QM%*:2@ %+24HI@*****0!4<K8!Q4AJ*3FA@B.X
M;:OX&L&Z&![_ .-;5R_;L ?UK"F;/Z41'(8HPIQ[4L/5CZ(?\*3.,_2FIP&/
ML!^O_P!:J)$B/(^HJM-QD58BZCZU4F;G-4A$;<44,<_A_2FU0@H7UI":OZ1:
M"=\'D#G'K[4TKNPF[(CLM,>[(VC@UUNEZ='I7S2'#$?4_P"'_P!;UK8T.SC@
M&207].@ ^E,U.Q2X<;F V]23BM(V4K$2UB^XT7"EEVJ<-GGW&/\ &II(/-8#
M/ Y/T]:$OH[- JL&.>, ''M38+M2"YSAAT[U,H/730<)I]=2U9S>621P@!R3
MQC\_6LO5M:4*57Y8P<^Y/J:6\N2P$8Y'4^O/0?@*Y2Y=M0?RU^ZI_#ZU@[-^
MALVTO46$MJT@+<(*W891@(OW5X'X4S3K182%'<'I]*@239P."":4M1Q5B[))
MG@53E@\T[!2R9QDU=M6&/>H*L,M=-V 9JV@513-P/>J\LAZ TFRTB=IRHS5:
M60GD&H/./3-5;F?90E<;:1;:;;SZ53GU58<CN:S9;EYN%S]:6'26DZ]?>ME3
M2W,G4;V$N-7:7IQ429D&2:T5T+'6M*VTE(^,4U.*(<)2,2.+::N/J#Q#Y<#\
M :V/L"J0 O7O4XTY!R0*?M"?8]SDVA:;C!IL>COZ5UWV=4Z"I$0=,5/.R_9I
M'*QPR6OS 5T&G7XG&#U%7)+7CI51=.&=R\&E>X)6+>,TR2+O3T0]ZE?"CFI*
M,^=L<56E_> H>XJQ*NWFH@*CJ:6T,S1)C [0GL?Y5TL;\US#IY5QQ_%_A72V
MT?<]JJ2NR4[(M@BIXP7X455C_OM^ JS!*<YJXHRD.FMG7KBJYRO6M:YPRYK*
M:?;P>13$5;JW\X%?6JFFQ&W!0]C5YG\LY_A-$L0;YA2L6F,;FF9Q4@IKKQ4E
M$)7-(T>:D*T;:!#8DJ792JN*=5$,A=>132VVI"<FD<9-2V6D-#9IP7/-1XIR
M"IN58EI*7I3@<TQ#:*?MI"M%@N(!10>*3-(:$-,<4\FF-0,S-:D\J/;W8XI;
M"W\J,#U'\ZKW+?;)UC_A7^G-:TBXJGHA+<R+Q,UD3/Y61ZUO7*<UB7J<YJX$
M5$5]-;#CZUH:V<./I6?:+AP:MZZ<E?I6\':QSR5[D<)SBMOK&P]JPK5_6M[^
M!OI55GH9T%:7S.6B."1ZJ:C/-*IY_2H]W:L#H'+UK0LY]E9V>]31/MI20TS2
MD39R.AJ:"7(YJ&)Q(I4]N1_A3(VVG%9ELT*2D1\BE!S5$L2BEQ0:!"4444 )
M12TE, I*6B@!**** "BBB@!**6BD!V</0?2IEJ&'H/I4ZTD4QPI:!13)"BBB
M@!*2EI*8@I#2TE "4E*:* $I:*!0 M)2T4#&FFM3C3#0(8U1FI&J,TQ##2&E
M-;FA^&VNR)91B/J/5O\  >_ITZY !GZ7HLFI'Y1A0<%CT'^)]A[9Q7=V-BEB
M@B08 _,GU/O_ )Z5);VZVZB-!A1T JCJ^N)I@&[ECT4=?J?09_\ K X-,1;O
M+U+-?,D.%SC_ "!S7!:]KK:HV.D:GY5_J??^70=R8-2U234&W2'.,X X SZ#
M_)]35$U+9$F--"F@T"I9FR>.NL\%H,R-W&WGZY_PKE(ZZSP7_P M/^ ?^S4X
MFL=CIZBN9O(1I.NU2<?09J6LSQ'/Y4#<X+8 _/)'Y U91Q!IIIQIIJ64A***
M*0Q:*** "NX\-0>5 O&"V2<_7 /Y 5Q"J7( Y)["O1X(1 HC'10 ,]>!BG$4
MB2L_7;D6\+D]QM'./O<?IU_"M"N8\8W7*0?\"/\ (?UIL2.;I***DH**6BD
M4459L-.>^.U!G&,D\ 9_S]: (8(&G8(HRQZ 5U^A:$+(>8_,A_\ '?;Z^I_
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MY*^\)RVW*?.OMP>!Z'],9I-#3,;-.S4_]E3?\\W_ .^&_P *EAT2>8X$;?\
M AM'YMBE8=RGFNA\*:3YK?:7'RK]W(X)]?P_GWXJQIW@\(=TY##GY5SCZD\'
M\/U[5TB($ 4< = .E-(38ZLS7M7&G)Q]]\A?\?PS^-2ZIJZ:<N6.6[*#R?\
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M10:2@ IPIN:<#2&+10#13$%%&:* $HI:* $I:,TE PHHHI  HHHH 2B@FB@
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M:*2@!<TF:*2@!2:**3- "YI*3-+0 M)FDS10,7-%)0:0@S24M-S3 **,TF:
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MEI#%HI**8"YHS24M !1FDS1FD M%)1F@ S1124 +11FDH 6DHHH 0TVEIIH
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M0 _-+312T#"C-%(:!"FDHS10 N:2DHS0 M%(:6@ I,T44 +249I* "BBDS0
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MJ5'HL%RXC5,IJFCU81JFP[D^:":8#2YH ":::4FFT#"BBB@ I:04M !12T4
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M/GV'%=%!+N&:Y(''-;NEW7F#'I6=2-U<NG*S-I'S4JG-58WJ537.T="+(-2
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M$Q4FVG*N:!$83-."4_9B@+3 8(Z794F*4B@5R+%&W-28H"XH 9LH(Q4E-(H
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M(HI@%2**!$T=3+4:5*M9LM"TM)BEI#"EHHH&%%)2T %%!H- !1110 $T44E
M#J2BB@!<T9I!0: "EI*#2 7-%)FC- Q30*2C- A: :2EH&%%)F@4 .HI*.M
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MFI*)P:45$#3\T@)%-+FF T4Q#B:<#3 :-U,1+F@&HRU*K4#),T]6[5%FG 4
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M8:U+U\#%9YCQ30F4I5Q4(JQ-5<UHC-@*4MGBC%.1<<U0@SM^M1.<T]FSS45
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M43-$GRU-MQ5=_G^E BBZ[SFH94K2:*J<_%5<EHR;D8JK5RZ'4U54=ZTCL9R
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M]-F4N"/2IV915638VZMZ)]X!]17/$9'TK7TV3<N*;V$BT10]+2&H*&FB@T4
M:20X4?05#)'BM?R.!]*ISQ8K0P,TC%)4DJXIE,84X4VE% #J0T9I* #-&:0T
M4") :GBDQ54&GJ:5@-**2K"R5FQR5826A#+P?-(:KK)4JOFF \'%2(U14 T
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M,4#$%+UHHH *!2T4@&FBG4E,!**6C% !1112 *2EHH&%%%% "44M)0 444M
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MG24T<4F-!3:=BD-(8QC4;&GM4;4Q,:::>*4FF$TQ#LTHIH-+F@!U)UI,T9H
M#333B::>*3&AIIII33<U+*0II13:,TBA]%-S2YIBN+13<TZF(<*<*8*>#0(=
M2YIN:7- @I#2YI*8$;"H7%3,*BD%4B65V&:3&:<:2F2*M2(*8*D2@"9:=2+2
MXJ&:(2BEI.M(84"E%%( HHI: #%)3J3- PI*44&@!*2EH(H$)BBEHH&)12XH
MH 0T"BEH 2@T9HQ0 4444 %+1BB@!*7I0!10 "EHHS0 4444 %%%% "44M%
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M,7-%)FB@!:*2B@!<T49HH 7-(:*2D N:,T4E PH!HHH 7.:,YI**!!2YI**
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M(!2&E%-- #T-.(I(O6G$TP(S2BDI10 -TIM/?I3#0 4448I %)12T )112T
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M4T4X4T!**4T@%.Q292$%&*6DI %&:7%&* &TM+10,;BEQ2TF* $Q2D4N*#2
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M*6@ HHHI (::5S3C24 -P5I0^:=363- #LT5'DK3@^: %(II%.S24#&T4M%
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M=QK:84GTKSZ1_,)-)EPV$45<ABQ26UOGDU84;.*ELT2$'45L6;YK*3FM*T;
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MH **** $HHHH&%)2TE(!**7%% "4M%-=L4P&NW:F&@\4TT""B@4HI#"BEI*
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M@!*2EI* "D-+24 %%%)0,*2EHH 2BEI*!"4444 )2&EI#0 E)2TE "44II*
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M81CC-1&W/<X_S]*W[>P,_+&KOD16O4;C^=-7!V..:W9.<<>M 4I747%QD<
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M4AH 2@T4A-(!#3":<:90, *<!2 4X4 %%+24 %)FE)I* "FDTIIM  :2BB@
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MZKRU8:H)*!%.:JQJU**K$9JB6"59CJ!!5B,4,$68Q5A:@2IUJ"R04M(.*6@
MHHHH 6EI**0Q:*** %HHHIB$I:**!A11BB@ H%%% !1112 *,444Q!1110,*
M*** "BBBD 444M, HI*6@ I*6B@ HHHH$%%%%(84444P"BBB@04444 %%%%
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MD HIU-%+0 M%)1F@ -)0:* $I*6DH *2EI* "@T44 %)2TE !0:*2@ HHI*
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MQ2B@!2:GM%[U7-7H%P*0R44M(*6@ I*6D)H 2D-+24 %%%% "&BBB@!****
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MG4 **44E+0,.E+24M !1110 X5(!3%IXH >!3Q35IXH 6G"DI12&&**6D-
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M<BM2C%-.SN.+L[F?I&F"R7W(YJ^:6EHE)R=Q-W=S&N?#:7+^:YS[5I6]LMN
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M#'H*F IBBI!0(,4X"@"B@8$TE&:*  TPTXTTT@&TAI32&@8E%+10 E!I:::
M'1#)JTHJ" 58 H 6EI*6@!*#10: &FBBB@!:*!10 E%+24 (:2EI* "DHHH
M2B@T4 (:**2@ -)2TTT )333C3: %%(:6D-(!IIC#-.-(:!D&TKTIPR>M/HH
M :$I0N*6EIB#%%+2&D 4E+10 E+BB@T )BD(I:*8#=HI-E.HH ;MI,&G&DH
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M4""BBBD E+113 2BBB@ I***0"&BBBF AI#2T4@$H-%)3 *2EHI (:2EI#0
ME%+24 %)2TE, I,4M% #2*3;3J2@!NRD*T^DH ;R* Y%.Q1B@!/-H\R@BDH
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M*!$Z/4RM5)'Q5A'H&6 :ANVPM.#5!>'C'O4E$4 JR*AA7%3"J(8M-)IQJ-J
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M% "44M)0 E)2TE !110: $HH-% "4E+24 !I*4TE  :2BB@!**** $-%!HH
M0TE+24 )1124P"FFG4TT@&DU!,^>*ED;%5HOG.:8F3QC IU(*6D AI!0:510
M,<*44@IPI#"D-.I*8"4E+BB@!*3%.I* $HI:* -/=1FE"4X)4%#12T\)2[:
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M!*:32FF.<4A%:YD[>M/A3;4*C>V:M 8IB%I#2TA-(H3K3J113J!@*<*04HH
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M\:G$4C)N#4476GW!ID'6M#,U[.MFWK&LZVK85$BXE^.IA4,=3"I*8M%)2T
MI:2B@!:6DH+;>: %I:JK=ASQTJ5)_P JW6&G8OE%<54F3-7B _2H7BK)QE'<
MEHR)X,U4-K6S)%FH?(HN0T4!!BD:.M$PXJO)'BE<:1ESK63=BMNZ6L6\JHDR
M,E^M-IS]:;3 **** "EI*6@ HHI:0!1110 4"B@4 :%H*W[*L*T%;UE3>PEN
M;-O5U!5*WJ\@K,U8,*C*5.12;:JY-BOY='E58VT;*.85B#RJ/*JQLHVT7"Q7
M\JE\NK&VC;3N*Q!Y=)Y56-M&RBX6*QBI/)JWLI-M*X[%<14]8ZFVT8HN%AH6
MC;4F*-M%PL0%:88\U9VTFVBX6*;14QH,U>*4TQT[BL9[6]1&WK2,=-,=',/E
M,W[-33;5I&.FF.ES!RF8T%1-#6H\=0O%1S!RF? FQ@:ZR$Y%<XT6*W[4Y ^E
M.Y+5BS3'IPI'%,1 ]1FGR5$33$30BI&;%1QGBD=LTBD**E6HT&:EZ4"8AI5%
M-J1!0!(HI^*112YI@+2$T4TF@!.M.44T<U(*0!12T8H&-Q24XTTT -IP%(*>
M!0(4"EH%% "&HY#4AJ&0T .C%2"F**?0 M&:*0T +FC--S1F@!U+2"E% Q:*
M7%(: $-(:4TTF@!*0T&DH #24M)0 AHI324 %(3132: #-(32$TF:!"DTE-)
MHS0 M&:2C- "TE%% Q12TE% !0*#10 &BBB@!**6B@!***2@!:2BDH ****
M"DI:2@ I*6D- "44M)0 E)3J0T )1110 E)2TE !24II* $-%%% "4E*:2@
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MC?BL35?#"W&9(N&].U:8DJ>-\5G.FI(U4KJQYU/;M =K#!%1XKTBXM$O!M<
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MGH*8W6I%% #J*!10 4UJ=3&H C)I132:5: )0:=FF"EH 4FDS124 !I**2F
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MC@U;W \BHK[3?(RZ=!V/6JMO=;>N?PKTZ<U-71C*+1<5-U7K:'R_K56&\4\
M?G3FN<\"J=V)-(NO)GY135CQ5$2%*LQW&ZE:Q2E<LJ*E!JN)*D5Z31:991L5
M*IW<'FJ@DJ4-@5G*-S12,V_T+;\Z<@]O2LPV==9$W%03Z>'^9?RKCJTG'5"E
M!/5',_8Z3['FMTVE)]DK#F,^0POL5*MG6W]DI1:4<PN0Q399IT=CSFMG[+2B
MVJ>8KE*4%MBM"&+%/2"ITCQ0%A\:XJRM1HM2=*0Q:*:6IIDH >31NJ%I:C,]
M %K=1OJGY]*)Z +FZEJL):E63- $E+30U+FF M&::7IC24 2;J-U5S+3?.H
MM;J7-5EEJ19,T 344P/1OH =29J-I<4PRT@L39I*A\V@2T#)J:U('I": L1.
M<5 \E3255EJ)%Q&M+47F4UZCQ2L#9T%LV0*LBJ&GME15X5OT.=[@U0-UJ<U
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M7S%^!MW)Z5()-W-4C+GY15J$]ZEHI2+B'%2JV*JA\T]6K-Q-$RTT8?ZTSR:
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MQ0 4E%!H *#129IB"DH-&:!B4AI:2@!IIIIQIAH *CD-24>7NI 0#FG@4\1
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M!%H-(*=0"&F@4&@4#)5IX-1K3Z '$TWJ:#2Q#/- $ZT[--!Q2&0"D ^BHA<
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ME&: "EIN:6@ HHS10 AI*6DH 2BBB@!#1110 E%%% "4444 )1112 2BBB@
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M I  6EQ2@4N*!B8HQ2TM "8I0*44M "!:7;2T4 -(I*>:::  &G8S2**D I
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M@J*J1(M+24M !FEI**8"T44E "T444 %+244 +1124 +2444@"DHHH ****
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MFT4 *3129HS0 9I:;2YH ****0!24M)0 AHI:2@!*2EI*8"&F5(:C:@!])2
MTM(84AHH- ##3:<:;0 AI::32TQ :*2B@!#333C3":!C#3E%-IXI +24M)3
M*2EI*0!24M)0 E%+24 %(:6B@!*2EI* "DI:2@ I*6DH :::13S330 PTE.(
MIIIB"C-)10 [-%)2T#"BBB@!K4Q&J0U6=MAH LT4Q6HH UO,I/,J,"G!*0#M
M]*&H6.GB.@!H-+3PE+LH 8*<!3@M. I ,VTNVGXHH 0+2@49I-] #Q2YJ/?2
M>90,ES2AJAWTY3FD!(35>5JF-5Y: *TDE,W9I).#2"J$.%**04HI@**6D%%
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M44 &:,TE&: #-%)2T (:;3C2"@8M)2TE(!*0FE)II- #6-,:EIKTQ **!10
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M"RYIXDJJ#3@U(+EG?1NJ /2[J N3;J,U%NHW4#N2YHS4>ZC=0!)FDINZC=0
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M!6Q07KA;NS11'O)4><TQJ,XI7'RD@%.%1AZ<)*!6),48IH>C=0(6D-&ZFEJ
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MHS3 6ES249I +1FDH!I@+FBBBD M%)2T &:*** #-&:** #-%)0: %S1244
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M2YI@+2TW-+2 6BDS1F@!U%)FC-,!:6FYHS0 ZBFYI<T +1FDHS2 =13<T9H
M=13<TN: "BDS1F@!:7--S2YH **3-&: %HI,T9H 6BDS1FF M)1FC- !1124
M@%HI** "BBB@ HI** %S2AJ;FD)I#'[J-U1YHS0,DS29IFZC=2 <34;4I--)
MH&-:FTI-)3$%+24N:9(4444 %%%%  #BI'B$@J.I(WQQ3$Q(3L^6INM1SIQD
M4L3[A3$.Q2BC%% #LT9Q24H]*!!NQ0&[4 9XI0,\4"&[<<4*-M2*-U."9XI@
M,4;:?C'TI57L:<HQQ0 FSO4FW/-*B&GJNVD%AH7?3U7;1NIKGO0.P_-5+J^6
M$9)I+N[\I<URES=&YR3TK6C1YWY#-&Y\0Y.%JNVJ._-92=:O!>*[%1A'H3>X
MQ]0<]32).3S4,HQ1$<5?)'L&Y=6]*U<BO]PYK+QFK$9Q42I0?0I11+)&&.ZJ
MTGR]*M9S4,8W'%4MBN5$449DY-6HT]:D"!!0&J="DDAJBI0M1$XIP>@=R3%%
M,\RD\R@+CR<U3F7!S5C?FH)6JHB9#<#<*K0''%67.:K;=IJT]#*18W5!+)B@
MO5::3/%(AR&*-YS5@FH8SM%/#428DA2V*0/2')XIPMV/.*ARL4H@6II-'E,W
M&*N6VF%^M)U$A\A6$1;H*LV.EF3DUL0V0C'-6+= M<L\0WL4HD4&G+'5L1 4
MM&:P<FQC@@I#1FD-( -**:*<*!CA3J:*=2 0TTT^FXH ::,T&FFF N:3I12$
MT@$)IC4XFF$T ----.)I *8#&J2+I01FE08%("-A2$T]JC:F ;\4])LU":;0
M(N+)3A)5$-BE\TBF*Q?W4N^J(N:D%Q0*Q:+4FZH1+FE\R@+$I:F$TW=FD+TQ
M"DTTFD+4W=0,<#FEQFD7FID3-(!JC;3U:G%*B(VT 3 TZH%:I U $@IV:C#4
MNZD,?FBFYI<T +32:7--)I@)2@4E*#0 \4$TF:0FD $TPFE)IA- "$U&S4YF
MJ)FI@-<TRE/-% A*#2TE "4E+24 )BBBB@!0:=FF4M "DT44E "TE%% "T4E
M% Q:*2C- !1F@TF: #-)1FDS2 ,T4F:* "BBB@!*6BDH <#2YIM**8#LTAHH
MI#$HH-% B""^(J]#?9K$#5(KXH&C3NF\RF6D(CYJNES3S=>E%AE^2?%5VGS5
M4R[J4-0D%R;=FE'-1@BGAJ!#UIXJ,-3PU QX-.S3 U.W4 .%.!IFZG T /%.
M%,!I0: 'TN:9FES2 =FES30:,T .S2YIN:7-,!<TM-S1FD ZBFYI<T +129H
MS0 N:,TF:,T .S29I,T9H 7-&:2C- #LT9IN:6F N:*2B@!:7--HI +FES3:
M*8"YI:2BD 49I**8"T4E%(!:*2B@!:2BB@ HHI* %HI**0PI*,T9H 3-)2TT
MF@ S1FD)I"U(8[--S32])OH <:3%)NI: 849HHJB1:*2EQ0 4444 %+24M %
MA#O&*K+^[-/1]E3A5>J3):&JV:6FM;[>5I%DSP>M!-R44X<TT'-.'% "XIV.
M](#BG*,\4 *1CFG8QS0J=C3UPM 6$,>>:> !2$TF:!V'YII--S29H&.S2AJC
M)I-U C-UZ,[3BN<5\BNPN<."#7(W=N8B2.E=6&J)*P/5$48YS5Q6JBLF*E6:
MNJ]Q)6))5S4:IBG>;FD\RF,>.*D#8J'=2%Z0RRLM"M@YJJ)*<'I%7+WFYIAD
MQ5<2TADHL%RP9*42U5+]J02T6#F+9DI!+FJWF9IIDQ183D6&DQ43RYJ%Y:9O
MS3V%<G$M12/2QVC25H6NDY^]42K1B3:YCLQ;@5<MM*,O)K9CTU5JQMV<5SSQ
M+Z#Y3)71QFK":8%JZ.M#&L75D^H[$ L5%3+;J.U -/!J')L8P6J]<5(%"TM)
MBE<!&-+!2,*6"@";%(:>*0B@!F:,TAHS0 9IRU'NIZT#N2BEIHI<T" TTTI-
M)2&(:0TII* $S32:<:8: $)IE.-)3 8:*4TTT &ZI!TJ$59V\4 0&F&I66FE
M:!$1%-(J5EIA% $>*0T_%-(I@,-."YI"*5*!#>4J19#4H3=1]GH$-\R@O3_L
M]!MJ8$>Z@'-.,9%.CCH EC7%2H:832QFD!8QFF.F:>IIQ&:!E0KB@&IV2F%*
M!#0:4&EVT;:  &GBF8IXI#%-(*0THI@&***6@ II-*33":  FF,:":C9J $8
MTPTII,4"$Q1BGA<U($Q0(@Q28J<INJ-EQ0!$124YA3#0,**0T9H 6G4T4M "
MT4E% "T4E% !1124 +244E Q<TAHI* $-%%% !12T4""DI:,4 )12XHQ0,**
M** %HI**0 :*2B@#F!>U(+ZL/S32^<:!V-T7U.%_6!YYI?M!H"QT(OZ>+^N<
M^TFE^U&@-3I5U"GC4!7,"[-+]L- :G4"_P#>GC4/>N5%\:=]O- :G5B_IPOZ
MY,7Y%._M T6'=G6"_IPOQ7(_VB:<-3- KLZ\7U/%\*X\:H:<-5H"YU_VT4X7
MHKD!JU*-6HL.YUXO12B\KD1J_O2C5Z+!<ZX7=+]KKD1J]*-8H%<Z[[72_:A7
M)#6/>E&L46#F.M^U"E^TUR0UCWIW]L>]*P71U?VFE^T5R@UCWIW]L>] ^9'4
M_:*/M%<O_;'O2_VQ[T6"YT_VBE\^N7_MBE_MCWHL%T=/]HH\\5S']L4O]L>]
M%@NCIQ/2^?7,C5Z>NK>]%@NCI/.H\ZN=&K4X:M18+HZ'S:/-KG_[6]Z/[6]Z
M+!<Z#S:7S:Y_^UJ4:M18+HW_ #:/-K _M44O]JBBS"Z-[S11YM87]JB@ZJ*+
M,+HW/-%'G5@-JU-.KT6"Z.A\X4GG5S_]KTAU>BP71T/G4>=7.'6*3^V*+,+H
MZ3SJ3SJYT:QGO2_VM19CNCH//I#/7/G5J8=7HL%T=$9Z:;G%<V=6IAU6CE#F
M.D:[J-KRN;;5,U&=2-'*',=(U]49OZYLWQ- N2:?*+F9T1OJ47F:P$E)JU$Q
M-'*+F-M)\U.KYK,@-7HZ5AW+(-+3%-.H 6EI** %%%%% "BBBBF M*#BDS10
M!*D^.M/V++SWJO11<35R<1,O%2+$:K"4BG>=3N+E+84"G;ZIB6G>;0%BSOHW
MU7\RE\R@1/OI-]0[Z3?0!,7I/,J'?2%Z )_,I"U0;Z0R4 /<;JSKV('I5LR5
M PR>::$9CZ5YW*U1GL7AKHQ#W%1NI[\UK&M*(U)G,B3%.$E;$]HK=L52ET[T
MK:-=,::95\RCS*5[5EJ(J16BFF.Q*&I=U0[J7=3YA$OF4OF5#NI54M3Y@)"]
M(STJVS'M4@T]S2YT#1$)<4F\FK4.E,QYK7MM'"<U$ZT8BL8T%@TO-:UKHX7K
M6HD(3M3JYIUY2"Q MLJ=J>12L*:165[C&YIC&GFHF:D,!2$T+1UH 513P*:!
M3P* '8HQ110 UZ2"AZ2*@"PC4\U7Z43W/EC- #VIO6LR:QEN1O!QGM3M&N&R
MT4G53WH'8T *>O%)THW4"),T9I@-.% !F@4N** $-(:4TE Q#3#3C3#0 AIM
M.--- A#333C28H :!5JJZCFK!- "%:85J3.:"* (&%1,*L.*B(I@18I-M2XI
M,4"(BM,(Q4^VF,M "Q25.KU3Z5,CYH$6@]/ZU5W5/$V10#&D4T4LAQ2+0 II
M%?%*:B;B@"[&V:E4U3ADJRK4#'D4TK3@:* &8I,4_%)BD W%%*:833 44ZD%
M+2 *0T&FDT !-,)I2:C9J $9JC)S03FE IB#%.5<TJI4@&* $"XILC8I7;%5
MV;- $D;5(1FJZG%3*U #)(ZA(JWUICQYH"Q4(IM3M%BHRM #0:=FFD4"@!U%
M)10 M+249H ***2@!:2BB@!**** #%%%% "T8HHH ****!AB@T44@$HQ2TE
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MT *E/ J-*E% #@*<*0"G8H 2BE(I* &/S4UO%Q4+"K"-@4 /V 5GW \R0+V
MS5_-9,L_ES[3_$HQ^M S46LFX?RYQ@?>7G\ZT'E\ODU0M#]ID+^G^- %_.:<
MJYI?+J1%H$-"4H&*E*TPK0 W-)FE-)2 3-)2D4E,8A-,-/-,H$(:;3C24Q#2
M**6DH 6,9-3O4,/6IF%(!!2T 4M $;BHS4S"HB*8#*,4[%+B@!F*8RU-BFE:
M!%9EIBMMJPRU#(M $F[-2P-51&QQ4\#4 2S4B4Z6FPT .-1N*G*TQEH A1]M
M6XWS5-UQ4D#]J!ET-2[JC!I<T@)-U(33<T9H &-,'-#&E04 .HS2TTFF $TP
MFE)J-FI #-41.:4G-*J4Q JT\+3@N*=B@+" 4C-BAFQ5:::@8DLF>*:*C7FG
MT"%!J0-45*#0!,&IVZH0U/!H DJ-H\TX&EI#*[1XIA%6R,U&T>:8B#%)3V7%
M-(H 2EHQ28H **** "DI:7% QM+BEQ10(3%%+24 %%%% !1249I#%S29HS24
M +1FDHH 6BDHH&+1244 8(CIXCJU/:F,U'Y=(9$(Z7RZF$=+Y= $ BI1&*G$
M=*(Z (?*H\JIQ'3A'0!7\JE$ JT(J>L-(95$%*+<5<$-.$5 RF+>E^SU<\JE
M\JD!2^S4?9ZN^72^53 HBWI?LXJ[Y5'E4 4OL])]FJ_Y5'E4!8H?9A1]FJ_Y
M5'E4 4/LU+]EJ]Y='E4 4?LU)]F%7_*H\J@"A]FH^RBM#RJ3RJ *'V6D^RUH
M^71Y5 &=]DH^R5H>5BCRJ!6,[[)1]D%:/ET>70!GBTIWV05>$=.$= S/^R4?
M9!6AY='ET 4/LE'V2M#RZ/+H S_L@H^R5H>71Y=(#/\ LE'V05H>71Y= :&<
M;,4W[$*T_+I#'3#0S/L= M!6D8Z3RJ ,_P"QTOV2M#RZ/+H S_L@I1:BK_ET
M>72#0I"UIXMJMB.G;* *HMZ46^*M;*/+H KB"G>55C91LH&0"*G!*FV4;*+
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M1%<5.Q>Y'Y=*(JF5*?LH KB*G"*IMM*!0!"L5/$52A:<%H"Q&(J>(Z>!2XH
M8$I=E28S0!0!'LI=E28I<4"(]E*$J0"E H&1[*/+J3%&* (]E&RI<48H$1[*
M-E28I<4 1;*-E2XHQ0!%Y=&RI<4N* (=E&RI<4NV@"'91LJ7;1MH BV4FRI\
M4F* (?+H\NIMM&V@"+91LJ;;1B@"'92[*EQ1MH BV4;*EQ1B@"+91LJ7%+B@
M"'91LJ7%+B@"'91Y=2XHQ0!#Y='EU-BDVT#(O+H\NIL4FV@"+RZ7RZDQ2XH
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MB:F Y*?UIB4\4@'K3Q313J %I":*0F@!\53"HHNE2B@ I#2TAH 810!0:44
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M0!;;I4#R8J>Y.P5FO)GBI2*N/>:HN6I\<.:G$>* L0I'4RI2@4Z@8 4ZDI:
M%%**04X4 **6DHI .HI*44Q"BEI*6@ I:2EH *6DI: "BC-% "T4E% "T44E
M "T444 %%%% !1110 4444 +1244 +1244 +2444 %+244#"BBBD 4444P"D
MHHS2 **** "EI** %HI** "EHI* %I***0!2TE% PHHI,T +32:4FFDTP$8U
M&U.8TPTT2Q****8!2BDI10(44HI*44 +2TE+0 4M)2TP"BBBD M%)2T %%%%
M "T4E+0,6EI!2T@"EI** %I**,T (1FH7M0WM4])3$4)83%[U$9JTRN[@U2N
M+;;R.E-,5B S4TS9II7-"Q4Q-"[Z:S9I^S%5Y&Q3$!-,9L5$TM,.32N!=L9,
MMBM1:QK$88&MA:!HG2I *AC-3+0!(*4T@I:0#::QIU-/- #2::33C330!&QJ
M%JG:H&I@.6GBF"GK2 D6G4U:=F@89IK4ZFL: )X^*DJ-*?0 4A-+330 AI13
M:<* 'T4@I: "DI310 E--.IM ,*2E-(:"0S1113 0TTTZFF@!IIK4\TQJ (S
M24II!0 Z.3RSFKK?,,U1/-6+63^$T,$ X-/I''-%  :2EI* %HI** $-(:=3
M30 QJ8:>:8: (R*C85,13"* (&%1,*L$5&5H A(I Q%2,M-*TP%6:K<%SBJ6
MVDQBD!M),#3C(*QUG*U*+C-%AW-+S::TN:HB>G"<4 6,TTM59[L"HC>4 6G?
M%5W;=4?V@-2AJ!#@*<*;FES0 \4HIN:4&@!U&:3-&: %S0:0TF: "C-&:3-
M :2C-)0 M&:2EH ,TF:** %S1FFT9H ?FC--S1F@8[-&:;FC-(!V:,TW-&:
M'9HS3<T9H ?NI0U1YHS0!+NI0U1;J7=0,DW4;J9NHW4 /S1FH]U+NH ?28IN
MZC=0 [%)2;J-U #J*3-% RW=+NJFD'>K]Q5;.*D8!<4&D)I,TAA2TE+3 44M
M)FC- #A2BD%** '44@I<T@%I12"EIB%HI*6@8M%)2T"%HI*6@!:*2C- "T44
M4 %%%% !1110 4444 +1244 +1244 +1244 +1124 +1249H 6DHHI#%I**,
MTP"BDHI +2444 +2444 +1244 +111FD 444E Q:*3-)FF M&:3-)F@0N:":
M;FDS0 XFFDT9II- "$TVE)I*8@HHHI@%%%% "TZFTZ@04M)2T +124M,!:**
M*0!1110 M%)10 M**2EH&+124M(!:*2B@!:2BB@ HHHH$ I2,TE**!E*YL\<
MK53I6S5:YLM_(ZT)@T9KM5.5MU7)4*<&J[+BJ)L1"/'6@BE:HV-,5B:W?##Z
MUKK6'%P0?>MM#2 L)4JFH4-3+3 E%+2"E-(!M--.--- "$4PBG&FF@!C5 U3
MFH&I@.%.6FBG"@"5:6D6EI +3>]*::O6@982GTQ:=F@ I#2TTT )3A3:<*!"
MTN:;2YH&+FC-)FDH"XM)110*X4AI:0TQ""EI** "FFE-(30 AJ-J?FHS0 TT
ME!I* 'BDSMYH!I: +(;?S2&H$<I]*>)J ),T4T24H<4 +10&HS0 E(:=330
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M%)10 M%)10 4444 +1FDHH 7-%)FC-(!:3-)FC-,8I-)FDS030(,T9I":3-
M"DTTFC-(: %S32:":3-, -)0310(,T4E+3 6@4E+0 M**04M A<TN:2B@!12
MTE% "T444 +1244 +1110 M%)2T#%I:045("TM-I:8!1110 44E% "THI*!2
M <*<*:*<*!C9;<2\&LZXTHCE>:U13A0F%CF);9EX(/Y569=M=@8PW45#)IL<
MG4?E5<PN4Y/!K:A.0/I4TN@ _=-1F$P?(>U-,5K$\9J=:KQU.M,DE%+2"EI
M)333J:30 W---.III@,8U W6IGJ%J '"G 4T4\4 2+2XI%IU(!II$ZTII(^M
M %A:6F@TZ@ --)I2:0T %+24M "T4"@T %%)10 4444""DI33:8!2TF:* "F
MFG4TT --,8T\U&U #:2@TE #A2BFTX4 +FES3:=3$*#01FDI:0"XHI*,T %!
M-%(:!B%C2;C2TE A"YII>G&FD4 )OI-]!%)0 F^D+YHQ28I@+F@FDQ010 9H
MI,48H 6@BDQ10 A6FE:?FD+4 -VTQEJ3=29H B*4W94I(HXH AV4FRIL"DQ0
M!%MI-M38INV@8PK4;<5.>*KN<T 0OS3>E2E:;MH 02D4Y;HTW;2!: )A=X[4
MHO*@(II6@"V+L5(LP/>LXK2 4@-3=2YK,6=EJ=+O- RWFC-0B;-.\R@"3-&:
M8'S2YH =FDS29IN: 'YI,TW?2;Z 'YHW5'YE(7H EW4;JAWT;J!DN^C?4.:,
MT 3>91OJ&BD!-OHWU#FC- $V^C?46:,T 2[Z*BS10!KR2;J;FD%**@T"BBEH
M$*#244"F M%%+0 M**04HI +2TE** %%&:**!"T444P%HI*6@ S2TE% "T9I
M,T4 +FC-)10 N:,TE% "YHS110 N:,TF:* %S1FDHH&+FC-)10(7-&:2B@8N
M:,TE% "YHS244 &:7-)10 N:,TE%( S1FDHH 7-&:2B@!<TF:*2@!<T9I,T4
M +FC-)FC- "YI,TF:3- "YHS29I* %S244F: %-)FDS1FF 9I*#24"%I***
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M444 )2&EHH ::0TZD(H 8:2G&C% #:;BGXI,4 (:0BGXI"* &8HQ3L48I@-
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M@!:*** "BBB@ HHHH **** "BBBD,***2@!<T4E% "T4E% "T4E% !FBDI*
M'9I*3-% "T9I,TE "YHS29I,T .S29I,TF: %S1FD)I* %I#29HS3 6DHHH$
M%%&:2@!:*** "ES244 +2TF:* %%+24M,!<T4E+0 M%)10(6EI** %HI** %
MHHHH&+124M(!:*2EH&+FBDHH$+FC-)10 4444 +2BFTHH&.%.%-IPI .%/%,
M%.%(8\4X4P4X4 .J"^7<AJ<4C#<,4Q&/$:M(:J(-IQZ590U9FR=33ZC4T\4
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M +FEI!10 N:7--I:8"YHI**0#LT4E% "T4E%,0M+FDHI#%I<TVES0!U_@BU
M5YNY;;TY&!D\^^?TKIZYKP/.&C>/NK9]OF&!_P"@UTM,3,?7O$ TS" ;G89Y
MX '."?7GM^HXK"_X36;^ZGY-_P#%5NZ]X>&IX<':ZC'/((Y(!].>_P"AXKEK
MSPW/:_P[AZI\W;TZ_I2&;MKXU1SB12O3D'</<GH?RS6[!>I.OFJP*CJ<\#C/
M/IQUSTKS)T*$J>"#@@]>*2BX6-;Q)J?VZ4X/R)POI[GJ1R>_IBJ>FVGVR18O
M[Q&<8!QU)Y]JJUT'@N+=,6QD*AYQT)([]CC/X9H [**(0J$7@* !]!P*5W"
ML3@#J3TIU8'C"^,$8B4D&0G./0#D?CD?K3$17OC)8R5B7<,<,20,_3&<?E_6
MJT'C-QG>@/IM)7^>ZN:%.%3<JQZ+IFHKJ">8O'8@]CZ>]6ZPO!W^I;_KH?\
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MCQ2,,TT/BD9J0 &Q2%@:3.:;F@!3333Y%SR*A,G&: !N*C+$56:4DYJS&=]
M"%Z3=3I(2E,H **2B@!:,TE)0 M)110 44E% PHI**!!1244P%I**2@!:2BB
M@ HI** "EI**!"T4E% Q:!110(7-&:2B@!U%)10 ZBDI: %HS244 **6DHH
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M_P#0EJOXLNA/.0/X %R#GW/Y$X_"I_!7^N;_ *YG_P!"6F+J=K6#XR_U*_\
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M"QO36ZSC:ZAAZ, 1^M1Q:?'$=RHH([A0#^8%1IK$+@$2)SZL ?R/-+_:L/\
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MB@!**#24""DI:2@ HHI* "DI:2@ -)2TE !24M)0 4AI:2@ I*6DH&%!HH-
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M #24&B@ I*6DH 0T4&B@ -)2FDH *0TM(:  TE%!H 2BBDH 6DHI* "BBB@
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MMHVT +24F*3% #LTAI,44P%HS3:* %HIIHH =13:* %S1FDS1F@!<T9IN:*
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M#10 E%%% "4E+10 E!HI#0 N:2BB@ HI** %HHI*0"T444#"DI:2@!:2EI*
M"BBB@#2"FIUXIVVC%(8H-(:4"D(I &:3=2XH*TP 4/@TBK4<O% %*6 9IGD"
MIR,T;: (/(%'D"I]M&V@+$'D"CR14^VC;0%B#R!1Y(J?%&V@"#R11Y J?;1M
MH K^0*7R!4VVC%%Q$'V<4OV<5-BEQ1<"#[,*7[.*FQ1BBX$0@%.$=/ I<4#&
M!2*=S3L4X"@!@)IP)IP%+B@! QHW&EQ2@4 5Y!(W1L?A59[61^KG\A6EBDQ0
M!G1:?CDDFKBIMJ0B@+2&-5<T\#%%)FD,,TF:#3: '$TW-(32$TP%S24E%(!<
MTE)13 7-)244 +2$T4E "TE)10(***2@ HHHH **2B@ HHHH **2C- "T4E&
M:8"TF:*2D N:,TE)F@!V:,TW-%,!V:-U-S29H =NHS3<TF:!#\T9IF:,T /S
M29I*3- #LT4VC- #J,TW-% "T4VEH&+BC%)12 =BBDHH 7%%)2BF M%% I .
M!-*,T@IPH <":>I-,'%/4TF-$@)J0$U&*>M(8\$T\-3!3Q0 [-&ZDIU !N-&
M\T44 077S+TIL39JP1FJD?RDCTJHD2+%,%/!IAJB08U&U.<XJ)C0 QC13<TZ
MF 4JTE*M #Q2,:6F.:!$D1XJ2HHNE29H 6BD-)FD M%(:!3 6E%)0* '4E%%
M !124&@!:*2B@!&I,T-330 &FFE--- "9I:;1F@!3332FFF@!*44VE% #A3J
M8*=0 M*:044 **44W-+0 X4M-%.H 6BDI10,6BBDI +1124 %%)13 6BDHI
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M48IU&* $HQ2TN*!B8HQ2T8H ,48I:* $Q2XI:* $%*!2T4@ "E%%** %%/I
M*<!2&**>*:*=0,>M**;3P: %I:04M "YHI**  UG:K=>4N!U-7G;%<WJMQYK
M8]*$KL3=D:NFW/G*&JXW-<_HMUL/EGOTK?!R*LS*\AJ$M3Y^#4)-,!P-+FHP
M:7=0!(#4J&JX:ID- $E1R5)4<AH GCZ4A%$9XIQ% #<T&@TV@09I0:;F@&@!
MX-.%,!IPH =24F:,T +129HS0 M&:2DS0 $TTFE)IA- !332YI* "DI:2@!*
M0TII#0 E**3- H =3A30:6@!:*2C- #LT4E** %I:044 .%+312T#%S2YIM&
M: '4E&:*0!1129H ,T444 +1244 %+29HH ***2@ HHHH *2BB@8444E !11
M24 %%%% !2&BB@!***2@ I*6DH *2EI*  TE!HH *2EI* "BBDH ***2@ HH
MHH 2BBB@!****!!1110,*!110 4M)10 444E !11FB@ HI**!EX5*HJ-14E2
M,0TE-8T@:@!]+3,T;J '@4^FK2F@!,T449H *6DHH 44II!10 UJB9:E-,84
M 1&@"G&DIB'1BK J&,5+0,?29I**0"T4E% "T9I** %HIM&: '9I,TF:3- #
MLT9IN:,T +F@FDHS0 A--)H)II- "YI":0FFDT *32$TA-)F@ S1FDS29I@+
MFC-)29H =FDS24F: '9I,TF:3- "YH)I,TF: %S1FFYI,T"'9I*3-)F@!V:,
MTW-)FF [-&:;FC- #LT4W-&: '9HS3<T9H 7-&::31F@!V:3-)FB@!<T9IM&
M:0#J*3-%,!PI:;FES2 >*44T4X4 .%+2"EH *6DI: "BBEH **,4"@84M%+B
M@!*6BB@ Q12T4 %&*6B@!,4M%+2 !3A3:<* %%.%(*<*0QPIXI@IXH 44X4@
MI10 HI:04M !24M!H JWDFP9KF9^2370:@V>*RVA!IQ%(S03&0PZBNET^[^T
M*#^=9!M ::)3IQ#C[I/(_K5D&Q>\<U5W\5:G83)N'<9%9J29% B8-3MU5PU2
M;J ) U3Q-53-30O0!;!J.0TH:F.:!EB,U)FHDI] @---.-,- "44AHH >*<*
M8*<* %HS124 +FC--S2YH 6BDHH 1J8:<QIE !244E  :**2@ -)2DTTT !I
M12&@4 .I0:04HH 6DHHH 6E%-I: '4M-!I:!CJ6FBEH 6BBBD 4M)10 4&BB
M@ HS244 +12"B@!:*2B@ HHI*!A1124 +1244 %%%)0 M)124 %%%% !2444
M %)110 4E%% "444E !1124 +2444 %)2TE !24M)0 4E+24 %%%)0 4444
M%%%% !1110 444E !1110 4E%% !1110!HJ,4IHII:H*$/-+BDS1F@!<4**
M:<M #A2$TIIA-, S3L4S-&: 'T"D!IPH *2E--)H *:30QIA- "&DI:%%,1*
MM.%-%.%(8M%)10 M%)10 M)249H 6BDHS0 9HS244 +1249H *":*0F@!K&F
MTIIII@!--S0332: %-)FBDH **2B@ HS124 &:,TE% @S1FDH- !FC-(:2@
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M -%%% "4M)10 &BBB@8444E !1124 +1244 !HHI* "BBDH 6DHHH 2BBB@
MI*** "DI:2@!**** $HHHH *2EI* "BBDH ***2@ H-%% "44M)0 4444 )1
M110 4444 %%%% "4444#"BBB@ HHHH T2:C8T\TF*D8RBI-M&V@!%%2"D I:
M  TQJ>:0C- $1H!IS+3,4 2+3Q3$I]  332:&-,)H #2&BDIB"E2D-.2@!]+
M3:6D,7-&:3-&: %HIN:,T +1FDHH 7-)FBDH 6BDHH ***3- "YI":,TTF@
M)IN:":0TP$-)2TV@ HHI*!!24M)0 444E !24M)0 4AI:2@!#1113 2DI:*
M&T4M% "4444 %)2T4@$HHHZ4 %%%+3 2BEZTE( HHHH 2EHHH *6DI: %%.%
M- IPI@.%.%-%.%(!12T44 +124M !2TE% Q:6DHH 6EI** %HHI* '44E&:
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M+0 4444#"DHHH **2B@ HHHH *2BB@ HI** "BBDH 6DHI#0 M)110 44E%
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MB986GBHU-.!I .)III:0T %*:3-!- !112&@ -(:,T9H #332FD- !2&BC-
M#2:0TIIIH 6BFYIPH <*44E*#0 M%)FB@!:*2B@!:,T44 .%%)2T#' TM-S2
MYI +1244 +112&@8M%)10 M%%(: %I*** "BDHH ***2@ H-%% "4444 %%%
M)0 M)124 +2444 %%%)0 4E+24 %%)10 4444 )1110 444E !1110 E%%%
M!1124 %%%% !1124 %%%% !1244#"BBB@04E+24#"BBB@#1IP%)2U(Q<44F:
M* %HI*6@ I":7--- ##3EI,4X4 +36I3330 E%%% "4&B@TP!:?35IU( IM.
M--H *6DHH 6BDI: "EI** "BBDH *2BBF 4F:*2@04E+24#$HHHH 2BBB@ I
M*6DH$%)2XHH&)24M% A**6DH 2BEI*!B&BEI*8A,44M&* $Q24M%(!,48I:,
M4 -Q1BG44 )BDQ2T8H 3%&*6B@!,48IU&* &XHQ3L48H 3%%+10 E+BC%+0
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MH&.S2TT4HH 6BBBD N:7--HH 6ES3:*!CLT4VEH 6DHI* %HI*2@!U)FDHH
M6DS124 +FC-)10 M&:;10 M&:2DH 6BDHH 6BDI* %HI** #-%)10 4444 %
M)2TE !1124 +2444 %%)10 44E% "TE%% PHI** %I**2@!:*2B@!:*2B@ I
M**2@!:*2B@ HHHH T0:<***0"T444 %%%% Q:*** "BBB@!**** %HHHH 0T
M444"&T444AA2&BB@ I*** "BBB@!:*** $HHHH 2D-%%  :0T44P$HHHH 2B
MBB@ I*** %I*** "DHHH *4BBB@!****! :***!B4444 %%%% "4"BB@0444
M4 )1110,6DHHH **** %HHHH$%%%% "T444 %+110 4444 +2T44 %%%% !1
M110,****!!1110,****!!1110,**** "BBB@04444 %%%% "4E%% PHHHH$%
M%%% !1110 M%%% #A2T44Q :2BB@ K+U =?I110@9FV]61115$"KUJ:.BB@
MDJU8]*** +@I:**0P-(U%% #335XHHI@3*:5J**0%:2FK113 E6GBBBD M(:
M** $%.-%% "4C444 -I#110 PTVBB@!PI1110 X4M%% "4M%% "&DHHH&.%.
MHHH *<*** %I#112 *6BB@ HHHH *6BB@8E%%%  :2BB@ I*** "BBB@ I**
M* "BBB@ I*** "BBB@!**** "DHHH&%%%% @HHHI )1113&%)110(**** $-
K)110 4444#$HHHH **** $HHHH *2BB@ HHHH 2BBB@ HHHH 2BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANOFI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001121404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">&#8364; 10,364<span></span>
</td>
<td class="nump">&#8364; 10,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">41,954<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">26,359<span></span>
</td>
<td class="nump">26,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">3,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsNoncurrent', window );">Non-current income tax assets</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">8,763<span></span>
</td>
<td class="nump">8,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">97,538<span></span>
</td>
<td class="nump">95,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">11,127<span></span>
</td>
<td class="nump">10,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">8,714<span></span>
</td>
<td class="nump">8,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">4,282<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Current income tax assets</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="nump">7,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">31,522<span></span>
</td>
<td class="nump">30,952<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">129,060<span></span>
</td>
<td class="nump">126,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilitiesAbstract', window );"><strong>Equity and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to equity holders of Sanofi</a></td>
<td class="nump">69,207<span></span>
</td>
<td class="nump">71,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Equity attributable to non-controlling interests</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">69,567<span></span>
</td>
<td class="nump">71,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">14,646<span></span>
</td>
<td class="nump">14,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="nump">1,677<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Non-current provisions and other non-current liabilities</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">6,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Non-current income tax liabilities</a></td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">1,553<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">27,563<span></span>
</td>
<td class="nump">26,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">7,150<span></span>
</td>
<td class="nump">7,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentProvisionsAndOtherCurrentLiabilities', window );">Current provisions and other current liabilities</a></td>
<td class="nump">16,446<span></span>
</td>
<td class="nump">15,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">7,026<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities related to assets held for sale</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">31,930<span></span>
</td>
<td class="nump">28,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 129,060<span></span>
</td>
<td class="nump">&#8364; 126,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 164<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_164_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 89<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_89&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 89<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_89&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2025-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentProvisionsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentProvisionsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated income statements - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Profit (loss) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 22,106<span></span>
</td>
<td class="nump">&#8364; 19,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(6,155)<span></span>
</td>
<td class="num">(5,881)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">17,389<span></span>
</td>
<td class="nump">15,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,980)<span></span>
</td>
<td class="num">(3,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(4,792)<span></span>
</td>
<td class="num">(4,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(3,436)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization of intangible assets</a></td>
<td class="num">(1,087)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">(1,031)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="num">(563)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">3,168<span></span>
</td>
<td class="nump">3,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(465)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(871)<span></span>
</td>
<td class="num">(711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the&#160;equity method</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">2,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income from discontinued operations</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">5,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="nump">&#8364; 1,957<span></span>
</td>
<td class="nump">&#8364; 5,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share from continuing operations (in euros per share)</a></td>
<td class="nump">&#8364; 1.61<span></span>
</td>
<td class="nump">&#8364; 2.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings per share from discontinued operations (in euros per share)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">2.34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings per share (in euros per share)</a></td>
<td class="nump">1.63<span></span>
</td>
<td class="nump">4.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share from continuing operations (in euros per share)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="nump">2.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings per share from discontinued operations (in euros per share)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">2.33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings per share (in euros per share)</a></td>
<td class="nump">&#8364; 1.62<span></span>
</td>
<td class="nump">&#8364; 4.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of comprehensive income - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">&#8364; 1,997<span></span>
</td>
<td class="nump">&#8364; 5,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">5,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses)</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments', window );">Change in fair value of equity instruments included in financial assets and financial liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax', window );">Change in fair value of debt instruments included in financial assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Change in currency translation differences</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="num">(5,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="num">(5,318)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherComprehensiveIncomeFromContinuedOperations', window );">Other comprehensive income/(loss) from continuing operations for the period, net of taxes (A+B)</a></td>
<td class="nump">1,617<span></span>
</td>
<td class="num">(5,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherComprehensiveIncomeFromDiscontinuedOperations', window );">Other comprehensive income/(loss) for the period from discontinued operations, net of taxes (C)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="nump">3,614<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">3,562<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent', window );">Continuing operations</a></td>
<td class="nump">3,536<span></span>
</td>
<td class="num">(2,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent', window );">Discontinued operations</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="num">&#8364; (13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The comprehensive income from continuing operations attributable to owners of the parent. [Refer: Comprehensive income from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The comprehensive income from discontinued operations attributable to owners of the parent. [Refer: Comprehensive income from discontinued operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) On Remeasuring Debt Instruments, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherComprehensiveIncomeFromContinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income from continued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherComprehensiveIncomeFromContinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherComprehensiveIncomeFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income from discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherComprehensiveIncomeFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of changes in equity - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Attributable to equity holders of Sanofi</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Reserves and retained earnings</div></th>
<th class="th"><div>Stock options and other share-based payments</div></th>
<th class="th"><div>Other comprehensive income</div></th>
<th class="th"><div>Attributable to&#160;non-controlling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 77,857<span></span>
</td>
<td class="nump">&#8364; 77,507<span></span>
</td>
<td class="nump">&#8364; 2,526<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="num">&#8364; (840)<span></span>
</td>
<td class="nump">&#8364; 68,185<span></span>
</td>
<td class="nump">&#8364; 5,260<span></span>
</td>
<td class="nump">&#8364; 2,376<span></span>
</td>
<td class="nump">&#8364; 350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,774)<span></span>
</td>
<td class="num">(4,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,979)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,837<span></span>
</td>
<td class="nump">5,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,979)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,772)<span></span>
</td>
<td class="num">(4,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,988)<span></span>
</td>
<td class="num">(3,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,868<span></span>
</td>
<td class="num">(3,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxesOnShareCancellations', window );">Tax on share cancellations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions', window );">Other changes in non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 70,279<span></span>
</td>
<td class="nump">70,008<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="nump">65,689<span></span>
</td>
<td class="nump">5,430<span></span>
</td>
<td class="num">(2,603)<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend paid per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 84<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,027)<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="num">(742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxesOnShareCancellations', window );">Tax on share cancellations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans', window );">Employee share ownership plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">165<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions', window );">Other changes in non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,710<span></span>
</td>
<td class="nump">71,376<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1,072)<span></span>
</td>
<td class="nump">66,877<span></span>
</td>
<td class="nump">5,572<span></span>
</td>
<td class="num">(2,441)<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,617<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,614<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,923)<span></span>
</td>
<td class="num">(4,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,003)<span></span>
</td>
<td class="num">(1,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="num">(581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxesOnShareCancellations', window );">Tax on share cancellations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">184<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Tax effects of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 69,567<span></span>
</td>
<td class="nump">&#8364; 69,207<span></span>
</td>
<td class="nump">&#8364; 2,428<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="num">&#8364; (1,380)<span></span>
</td>
<td class="nump">&#8364; 63,528<span></span>
</td>
<td class="nump">&#8364; 5,757<span></span>
</td>
<td class="num">&#8364; (1,126)<span></span>
</td>
<td class="nump">&#8364; 360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividend paid per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 4.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2 and B.8.3. (for amounts relating to 2025, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2025).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2025-01-01<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 246<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_246_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 246<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_246_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2025-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Changes In Non-controlling Interests Arising From Divestment And Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through issuance of restricted shares, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee share ownership plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of services obtained from employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareBasedPaymentPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareBasedPaymentPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxesOnShareCancellations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxes on Share Cancellations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxesOnShareCancellations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of cash flows - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from (used in) operating activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,957<span></span>
</td>
<td class="nump">&#8364; 5,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForLossesGainsOnTransferOfBusiness', window );">Net (income)/loss from the discontinued Opella business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod', window );">Share of undistributed earnings from investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset', window );">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,880<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Gains and losses on disposals of non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Net change in deferred taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(218)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Net change in non-current provisions and other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">195<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of employee benefits (stock options and other share-based payments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">184<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue', window );">Impact of the workdown of acquired inventories remeasured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">210<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other profit or loss items with no cash effect on cash flows generated by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating cash flow before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,233<span></span>
</td>
<td class="nump">3,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">(Increase)/decrease in inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(958)<span></span>
</td>
<td class="num">(635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase)/decrease in accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(340)<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities', window );">Net change in other current assets and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">735<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by/(used in) continuing operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,643<span></span>
</td>
<td class="nump">3,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) operating activities of the discontinued Opella business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">4,643<span></span>
</td>
<td class="nump">3,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from (used in) investing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Acquisitions of property, plant and equipment and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,296)<span></span>
</td>
<td class="num">(1,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisitions of consolidated undertakings and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(1,408)<span></span>
</td>
<td class="num">(538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisitions of other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">424<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposals of consolidated undertakings and investments accounted for using the equity method, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherNonCurrentAssets', window );">Net change in other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashProvidedByusedInContinuingInvestingActivities', window );">Net cash provided by/(used in) continuing investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,423)<span></span>
</td>
<td class="num">(1,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities', window );">Net cash provided by/(used in) investing activities of the discontinued Opella business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetCashInflowFromDiscontinuedOperations', window );">Net cash inflow/(outflow) from the Opella transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="num">(220)<span></span>
</td>
<td class="nump">10,742<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,643)<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from (used in) financing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Issuance of Sanofi shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsPaidAbstract', window );"><strong>Dividends paid:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,923)<span></span>
</td>
<td class="num">(4,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities', window );">to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Additional long-term debt contracted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,505)<span></span>
</td>
<td class="num">(1,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">3,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares and related tax effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,009)<span></span>
</td>
<td class="num">(4,003)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by/(used in) continuing financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,332)<span></span>
</td>
<td class="num">(4,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) financing activities of the discontinued Opella business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,332)<span></span>
</td>
<td class="num">(4,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of exchange rates on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale', window );">Cash and cash equivalents reclassified to Assets held for sale as of December 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net change in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,313)<span></span>
</td>
<td class="nump">7,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="nump">7,663<span></span>
</td>
<td class="nump">7,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 6,350<span></span>
</td>
<td class="nump">&#8364; 15,359<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes non-current financial assets and deferred taxes, amounting to zero as of June 30, 2026 and to &#8364;48&#160;million as of June 30, 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item includes contributions paid to pension funds (see Note B.12.).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Of which:</span><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(925)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(206)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2026, this line item includes the net cash outflow arising from the acquisition of Dynavax (see Note B.1.1.). For the six months ended June 30, 2025 it includes the net cash outflow arising from the acquisition of Dren-0201.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">For the six months ended June 30, 2026 and June 30, 2025, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025, this amount includes &#8364;(667)&#160;million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2026, this line item mainly comprises (i) a commercial paper program in the United States for &#8364;2,388 million and (ii) a cash outflow of &#8364;249 million arising from the settlement of the financial liabilities of Dynavax, acquired on February 10, 2026 (see Note B.1.1.). For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#8364;3,353&#160;million.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.58pt">Includes the impact of the IFRS 9 amendment relating to the classification of financial instruments applicable from January 1, 2026.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForLossesGainsOnTransferOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on transfer of business</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForLossesGainsOnTransferOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for noncurrent provisions and other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents Reclassified to Assets Held for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetCashInflowFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Inflow from Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetCashInflowFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetCashProvidedByusedInContinuingInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by/(used in) Continuing Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetCashProvidedByusedInContinuingInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetCashProvidedByusedInDiscontinuingInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by/(used in) Discontinuing Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetCashProvidedByusedInDiscontinuingInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net change in other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of cash flows (Parenthetical) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense', window );">Adjustments for non current financial assets and deferred tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(925)<span></span>
</td>
<td class="num">(1,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities', window );">Dividends received from non-consolidated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">3,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember', window );">Dynavax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,388<span></span>
</td>
<td class="nump">&#8364; 3,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 667<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2026, this line item mainly comprises (i) a commercial paper program in the United States for &#8364;2,388 million and (ii) a cash outflow of &#8364;249 million arising from the settlement of the financial liabilities of Dynavax, acquired on February 10, 2026 (see Note B.1.1.). For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#8364;3,353&#160;million.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Non Current Financial Assets and Deferred Tax Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends received from non-consolidated entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Introduction<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GeneralInformationAboutFinancialStatementsAbstract', window );"><strong>General Information About Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Introduction</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if01b92328be14713b8ccdb292d93bd83"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for the six months ended June 30, 2026 were reviewed by the Sanofi Board of Directors at the Board meeting on July 29, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 128<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_128&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GeneralInformationAboutFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General Information About Financial Statements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GeneralInformationAboutFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation of the half-year financial statements and accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation of the half-year financial statements and accounting policies</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i4f7c6c891c2b4d6d95f7e8f036bb2556"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A/ Basis of preparation of the half-year financial statements and accounting policies</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="iade2723bf556405fa760300135f156fe"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.1. International financial reporting standards (IFRS)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2026 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2026 are available via the following web link: https://www.efrag.org/en/financial-reporting/endorsement-status.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2026 are identical to those presented in the consolidated financial statements for the year ended December 31, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable from January 1, 2026. The amendments did not have a material impact on the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026. Those improvements to various standards, which are essentially in the nature of clarifications, did not have a material impact on the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments could potentially result in an enhancement of the disclosures provided in the 2026 annual financial statements. As a reminder, renewable energy purchase contracts entered into by Sanofi as of December 31, 2025 are described in Note D.21. to the consolidated financial statements included in Sanofi&#8217;s Form 20-F for the year ended December 31, 2025 (the &#8220;2025 20-F&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In its 2026 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. As in the previous year, the effective tax rate also includes a one-off impact from the 2025 component of the exceptional surcharge in respect of French corporate income taxes (see Note B.19.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i7eb8d7ed82b1409781780df5af14fc37"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2. Use of estimates and judgments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. </span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i1ec2cb66eb2744b6b48188cdb25eabbf"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.3. Seasonal trends</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5f4805e586d9457eb40667dbfc3eea9d"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.4. Consolidation and foreign currency translation of the financial statements of subsidiaries in hyperinflationary economies </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2026, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="ia00b620899cb4c70a41e134ebd8334b7"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.996%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2025.</span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span id="i5c5175867eaf486690e7e1ad01ca77b2"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.6. New pronouncements issued by the IASB and applicable from 2027</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027. In terms of adapting Sanofi&#8217;s chart of accounts and financial information systems, the transition is continuing on schedule. In line with the information communicated in the 2025 financial statements as published, Sanofi&#8217;s IFRS 18 rollout project &#8211; which began in the fourth quarter of 2025 &#8211; is progressing, and the impact analysis has evolved in line with the schedule. The future structure of Sanofi&#8217;s consolidated income statement will present operating expenses by function, and will reflect presentational choices based on the &#8220;useful structured summary&#8221; principle established by IFRS 18. Those choices involve the classification of income statement items according to five categories (operating, investing, financing, income tax and discontinued operations), with the sub-totals limited solely to those specified in IFRS 18. The income statement structure will also reflect the fact that Sanofi as a whole operates a single principal activity. As regards the requirement to disclose alternative management performance measures (MPMs) that meet the IFRS 18 definition in the notes to the financial statements, Sanofi has identified the relevant MPMs. In accordance with the information communicated in Sanofi&#8217;s 2025 consolidated financial statements, the main MPMs are &#8220;Business gross profit&#8221;, &#8220;Business operating income&#8221; and &#8220;Business net income&#8221;, all of which are non-IFRS measures that Sanofi currently uses in its financial communication. No significant impact on these performance measures has been identified at this stage.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transition note intended for publication in Sanofi&#8217;s 2026 Annual Report on Form 20-F will include a reconciliation, for the comparative years 2026 and 2025, between (i) the amounts for each income statement line item presented in accordance with IFRS&#160;18 as applicable from 2027 and (ii) those presented in accordance with the currently applicable standard (IAS 1).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, the presentation of the consolidated statement of cash flows will be modified such that it starts from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> instead of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, as mentioned in Sanofi&#8217;s 2025 year-end financial communications, Sanofi is not early adopting IFRS 18.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November 13, 2025, the IASB issued &#8220;Translation to a Hyperinflationary Presentation Currency&#8221;, an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), applicable from January 1, 2027 (subject to endorsement by the European Union). Sanofi does not expect any material impact and will not early adopt this amendment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant information for the first half of 2026<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure of detailed information about business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock', window );">Significant information for the first half of 2026</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ib491210deb284e268395afcc5ff6478b"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.1. Significant transactions for the first half of 2026</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i9834acbe5e0941f6b802ffcc6c644dcc"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.1. Acquisition of Dynavax Technologies Corporation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February 10, 2026, Sanofi finalized the acquisition of Dynavax Technologies Corporation (Dynavax), a vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi&#8217;s presence in adult immunization by bringing together Dynavax&#8217;s vaccines with Sanofi&#8217;s global scale, development capabilities and commercial reach.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Dynavax&#8217;s adult hepatitis B vaccine HEPLISAV-B is currently marketed in the United States and is differentiated by its two-dose regimen over one month, enabling high levels of seroprotection faster than other hepatitis B vaccines (which are given in three doses over six months).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition also includes Dynavax&#8217;s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 clinical development, and additional vaccine pipeline projects.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction involved a cash tender offer by Sanofi to acquire all outstanding shares of Dynavax for $15.50 per share in cash, reflecting a total equity value on a fully diluted basis of approximately $2.2&#160;billion, including the subsequent reimbursement of the short-term debt for $0.3&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of &#8364;204&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(249)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(132)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Dynavax</span></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,367</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,571</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Other intangible assets&#8221; mainly comprise Dynavax&#8217;s marketed vaccine HEPLISAV-B.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of Dynavax into the Sanofi group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Dynavax's contributions to Biopharma segment net sales and business operating income (for a definition refer to Note B.21. &#8220;Segment Information&#8221;) since the acquisition date amount to &#8364;144&#160;million and &#8364;89&#160;million, respectively. Over the same period, Dynavax made a negative contribution of &#8364;63&#160;million to consolidated net income, including amortization of intangible assets of &#8364;38&#160;million; amortization and expenses arising from the impact of acquired inventories of &#8364;44&#160;million; and restructuring costs and similar items of &#8364;63&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition, as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, is a net cash outflow of &#8364;1,403&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i33c30c05833240ffaf9267814059a54e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.1.2. Proposed divestment of Medley, Sanofi&#8217;s Brazilian generics business</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March 6, 2026, Sanofi and EMS Group, a major pharmaceutical conglomerate in Brazil, announced the signing of a definitive agreement for the purchase and sale of 100% of Medley, one of Brazil&#8217;s leading generic drug brands.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With effect from that date, given that completion of the transaction is considered highly probable, all of the assets of Medley, and the liabilities directly associated with those assets (subsequently transferred to Medley Farmaceutica Ltda, a new legal entity formed on May 1, 2026, the equity interests in which will be divested), are presented in the consolidated balance sheet within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations); they are the main component of those line items as of June 30, 2026. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s Brazilian generics business does not meet the definition of a discontinued operation under IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2025), as a result of which the net income from this business is not presented separately in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A net gain is expected upon closing of the transaction. Consequently, no impairment was recognized on the carrying amount of the net assets of Medley Farmaceutica Ltda as of the date of reclassification as held for sale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction is expected to close no earlier than the fourth quarter of 2026 subject to the fulfilment of customary closing conditions, primarily clearance from the Brazilian Antitrust Authority (Administrative Council for Economic Defense &#8211; CADE).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i93a93c63f0ea45e195349fc8fc299e76"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2. Property, plant and equipment</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:76.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">763</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">702</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">453&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella (discontinued operation)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">23</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Firm orders for property, plant and equipment stood at &#8364;1,336&#160;million as of June 30, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and other intangible assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ic132ebcff5c64c81a9061580740797ab"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3. Goodwill and other intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill amounted to &#8364;41,954&#160;million as of June 30, 2026, versus &#8364;41,300 million as of December&#160;31, 2025. The movement during the period reflects the impact of changes in exchange rates and the recognition of the goodwill arising on the Dynavax acquisition (see note B.1.1.), partially offset by the reclassification of the goodwill relating to the Brazilian generics business to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as a result of the proposed divestment (see note B.1.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2026 were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:45.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,951</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66,746</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,888</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">83,585</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(534)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(579)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(162)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(411)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at June 30, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,817</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69,070</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,957</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85,844</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,220)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(49,624)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,480)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57,324)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,106)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(970)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,048)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(785)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(930)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,791)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(51,159)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,535)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(59,485)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,731</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,122</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">408</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,261</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2026</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,026</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,911</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">422</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,359</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the intangible assets recognized as part of the Dynavax  acquisition (see Note B.1.)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">See Note B.4.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other products&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">marketed products, with a carrying amount of &#8364;17.1 bil</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">lion as of June 30, 2026 (versus &#8364;16.2 billion as of December 31, 2025) and a weighted average amortization period of approximately</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 11 years</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">technological platforms brought into service, with a carrying amou</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nt of &#8364;0.8 billion as</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">June 30, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (versus </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;0.9 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as of December 31, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and a weighted average amortization period of approximately </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of intangible assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock', window );">Impairment of intangible assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i4ab9c4fdfc0e4b64a6daaec19209502e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4. Impairment of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The monitoring of impairment indicators for other intangible assets (excluding software) led to the recognition of impairment losses of &#8364;1,031&#160;million in the first half of 2026, mainly comprising a &#8364;952&#160;million impairment loss taken against the amlitelimab asset, corresponding to the entire carrying amount of this intangible asset.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impairment of intangible assets and property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments accounted for using the equity method</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i2ed1b062d6704c48ae354d7c6de4df94"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5. Investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2025), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OPAL JV Co </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,965</span></td><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,934</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,207</span></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,259</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella in 2025, Sanofi holds 48.2% of OPAL JV Co (CD&amp;R holds 50% and Bpifrance holds 1.8%). As of December&#160;31, 2025 the investment included a &#8364;241&#160;million loan to OPAL JV Co being in substance part of the investment. In 2026, following finalization of the Opella completion accounts as of April 30, 2025, this loan was converted into ordinary shares.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#8364;1.33 as of June 30, 2026, and &#8364;2.27 as of December&#160;31, 2025). </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> showed net income of &#8364;2 million&#160;for the first half of 2026 (including a net loss of &#8364;39 million for Sanofi&#8217;s share of losses from the associate OPAL JV Co), versus net income of &#8364;85 million for the first half of 2025 (including net income of &#8364;11&#160;million for Sanofi&#8217;s share of profits from the associate OPAL JV Co for the period from May&#160;1, 2025 through June 30, 2025). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:74.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services (including research expenses)  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#8364;200&#160;million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2026 was &#8364;84&#160;million, versus &#8364;143&#160;million as of December 31, 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key items from the unaudited half-year consolidated financial statements of OPAL JV Co as of June 30, 2026, as provided in accordance with Sanofi&#8217;s consolidation timelines, are presented below: </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:74.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated income statement</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net sales and other revenues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">887</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated statement of comprehensive income</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated balance sheet</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,673&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,013&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,925&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,598</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,872</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of OPAL JV Co</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,958&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,380&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,394</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,870</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,575&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,204</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,002</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,598</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,872</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory', window );">Other non-current assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i87905fc66c7b49b89f2037c9405e25d1"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6. Other non-current assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,732</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,364</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current assets. [Refer: Other non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTradeReceivablesTextBlock', window );">Accounts receivable</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i8a86659307ea4443ba42dfcb5d3b4e96"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.7. Accounts receivable</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,818&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,510&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,410</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in the first half of 2026 was a net expense of &#8364;6 million (versus a net expense of &#8364;4 million for the first half of 2025).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:18.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&lt;1 month</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>1-3 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>3-6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>6-12 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">522</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">183</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">127</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">142</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amounts overdue by more than one month relate mainly to public-sector customers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2025 and hence were derecognized was &#8364;11 million as of June&#160;30, 2026 (versus zero as of December 31, 2025). The residual guarantees relating to those transfers were immaterial as of June 30, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfTradeReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfTradeReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Consolidated shareholders' equity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i0d5e6157a9da4039a10239b9799b7eaa"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8. Consolidated shareholders&#8217; equity</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ia7d079fa575843689ca15d686ccf06c5"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, the share capital was &#8364;2,428,198,054 and consisted of 1,214,099,027 shares (the total number of shares outstanding) with a par value of &#8364;2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16.03</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.320</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December&#160;31, 2025</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.96&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.981</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.868</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2025</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.53&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.755</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of 30,070 shares were issued in the first half of 2026 as a result of the exercise of Sanofi stock subscription options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, 3,072,520 shares vested under Sanofi restricted share plans during the first half of 2026, of which 1,886,523&#160;were fulfilled by issuance of new shares and 1,185,997 by allotment of existing shares free of charge.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i91f7c2d3c7534cfd8ccaccf0cd785e5d"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.2. Repurchase of Sanofi shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2025, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program, Sanofi repurchased 12,571,455 of its own shares during the first half of 2026 for a total amount of &#8364;1,003&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding &#8364;5&#160;billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Or&#233;al on February&#160;2, 2025 for the acquisition of 2.34% of Sanofi&#8217;s share capital, equivalent to 29,556,650 shares, for a total amount of approximately &#8364;3&#160;billion, representing a price of &#8364;101.50 per share. The conclusion of that agreement was approved by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth in Articles L. 225-38 et seq. of the French Commercial Code.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 29, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did n</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ot use that authorization during the first half of 2026.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="idd55326c6f4f42359cf73c8a329501bb"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.3. Reduction in share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2026, treasury shares amounting to &#8364;596&#160;million were cancelled further to decisions taken by the Sanofi Board of Directors on March 4, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those reductions have no impact on shareholders&#8217; equity, except for the impact of the tax on share cancellations.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ie4aae90ce3ea41c0bceff57eca296b4d"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.4. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2025. The principal features of the plans awarded in 2026 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:82.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.541%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April, 29, 2026</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plans awarded to the Chief Executive Officer</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 1, 2026</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 3-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,087,518&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,367,862&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;65.86&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,719,656&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (1,674,656 shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;57.99&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (45,000 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;53.46&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 5-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (180,000 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;40.46&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plans at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">329</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 3 years.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 5 years.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:69.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12,995,668&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,550,347&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2026 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,267,518&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2025 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,897,342&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,020,451&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,772,461&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,110,089&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">58,347&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,313,588&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">106,219&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i77cbafef4d014f33b235e0d519481bbb"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.5. Employee stock purchase plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 28, 2026, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the opportunity to subscribe for new Sanofi shares at a price of &#8364;59.87 per share. The subscription period was open from June&#160;9 through June&#160;29, 2026. Sanofi employees subscribed for a total of 2,431,494 shares, and the resulting capital increase was supplemented by the immediate issuance of a further 104,327 shares for the employer&#8217;s contribution. The total expense recognized for this plan in the first half of 2026 was &#8364;46 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 29, 2025, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the opportunity to subscribe for new Sanofi shares at a price of &#8364;72.97 per share. The subscription period was open from June&#160;10 through June&#160;30, 2025. Sanofi employees subscribed for a total of 2,260,776 shares, and the resulting capital increase was supplemented by the immediate issuance of a further 116,794 shares for the employer&#8217;s contribution. The total expense recognized for this plan in the first half of 2025 was &#8364;31 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i1684c1a55e2d4d5280f95522eb2195d4"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.6. Stock subscription option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock subscription option plans were awarded in the first half of 2026 or in 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No further stock option plan expenses were recognized through equity in either the first half of 2026 or 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.234%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average residual life</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213,400&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.84</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.71&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213,400&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.71&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.86</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">639,194</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">639,194</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="iae4940e55e3f422eb90dc30c896cfb60"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.7. Earnings per share</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net income:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.923%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,957.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,812.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which net income from continuing operations</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,931.0&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,941.0&#160;</span></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which net income from discontinued operations</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,871.0&#160;</span></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number of shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(number of shares in million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,200.4&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,205.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,230.7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026 and June 30, 2025, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Earnings per share:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in euros)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.63</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.74</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diluted earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.62</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.72</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ia974d4d9952a48af8a624f4df1a8865a"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.8.8. Other comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">290</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">243</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,266)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,327</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(5,017)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#8364;1&#160;million in the first half of 2026; &#8364;2&#160;million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></div> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#8364;146&#160;million loss in the first half of 2026 and a &#8364;459 million loss in the first half of 2025 relating to the deconsolidation of Opella<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock', window );">Debt, cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if3c50351e3a9496d81a572fcb437eb25"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9. Debt, cash and cash equivalents</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,646&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,248&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,026&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,893</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,702</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,513</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,008</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,904 million as of June 30, 2026 and &#8364;1,739 million as of December&#160;31, 2025.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i152be4776fb742e294ebcac319167d5e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.1. Net debt at value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2026 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:28.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,646&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,751&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,360&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,026&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,344&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(131)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,893</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(70)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,868</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,716</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,513</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,488</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,022</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,904 million as of June 30, 2026 and &#8364;1,739 million as of December&#160;31, 2025.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,702&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,599&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,301&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,306&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,165&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,471&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,291&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,340&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,751</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,117</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,868</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,360</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,356</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,716</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,751</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">737</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,488</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,360</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,338)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,022</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts include $3&#160;billion designated  as a hedge of Sanofi&#8217;s net investment in the United States.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) As of Ju</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ne 30, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, current other bank borrowings include &#8364;3,217&#160;million related to the US commercial paper program.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span id="ib114c4f84689446085e75d598afd9d11"></span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Principal financing and debt reduction transactions during the period</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the period, Sanofi carried out a bond issue of &#8364;2.3&#160;billion in three tranches:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">&#8364;1,000&#160;million of fixed-rate bonds maturing May 2029, with annual coupons and bearing interest at an annual rate of 3.000%;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">&#8364;650&#160;million of fixed-rate bonds maturing May 2033, with annual coupons and bearing interest at an annual rate of 3.375%; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">&#8364;650&#160;million of fixed-rate bonds maturing May 2037, with annual coupons and bearing interest at an annual rate of 3.750%.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">One bond issue was redeemed during the period: a &#8364;1.5&#160;billion issue from March 2018, redeemed at maturity on March 21, 2026.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a syndicated credit facility of &#8364;4&#160;billion, drawable in euros and US dollars and expiring on March 6, 2030, for which no further extension options are available; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a syndicated credit facility of &#8364;3.85&#160;billion, drawable in euros and US dollars and expiring on  April 23, 2031, for which two  one-year extension options are available. This facility became effective on April&#160;23, 2026, and replaced an existing &#8364;4&#160;billion facility that was cancelled on the same date and had originally been scheduled to mature on December 6, 2027.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, neither facility was drawn down.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has two short-term debt programs:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a &#8364;6 billion Negotiable European Commercial Paper program in France; and </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">a $10&#160;billion Commercial Paper program in the United States. </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the first half of 2026:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average drawdown under the US Commercial Paper program was $3.0&#160;billion; and </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the average drawdown under the Negotiable European Commercial Paper program in France was &#8364;0.1&#160;billion.</span></div><div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of June 30, 2026 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i37c1361e63e94fd097254f65bc03ccbd"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.9.2. Market value of net debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,989&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,424&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,488&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,022&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of debt instruments issued explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative financial instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative financial instruments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i0dd095bcf8014bcb94796df400f45795"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.10. Derivative financial instruments</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i6cb113c951b7447ab149c5d57111e97e"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.1 Currency derivatives used to manage operating risk exposures</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as&#160;cash&#160;flow hedges</span></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,536</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(66)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,315</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">555&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">555&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">530&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">530&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Brazilian real </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">422&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which  Saudi Arabian riyal</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,039</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,039</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">596&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">596&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which United Arab Emirates dirham</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,575</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,354</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes forward sales with a notional amount of BRL 1,300&#160;million expiring in 2027, designated as a cash flow hedge on the divestment of Medley in Brazil.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2026 and recognized in the balance sheet at that date. Gains and losses on hedging in</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ib51fa0ee829f4b729dfe5c70efa6459c"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.10.2. Currency and interest rate derivatives used to manage financial exposure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#8217;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#8217;s debt once those instruments are taken into account.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:53.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum expiry&#160;date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cross currency seller swaps</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,523</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,423</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(272)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">13,361&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Pound sterling</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Brazilian real</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,466</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">170</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29,412</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(139)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a hedge of Sanofi&#8217;s net investment in the United States. As of June 30, 2026, the fair value of the swaps was a liability of &#8364;37&#160;million, with &#8364;33&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment and &#8364;4&#160;million debited to financial result.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $12,275&#160;million expiring in 2026 and 2027, designated as a hedge of Sanofi&#8217;s net investment in the United States.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#8364;223&#160;million, with &#8364;222&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and &#8364;1&#160;million debited to</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) &#160;Includes forward sales with a notional amount of BRL 1,200&#160;million  expiring in 2027, designated as a hedge of Sanofi&#8217;s net investment in Brazil.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#8364;9&#160;million, with &#8364;10&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, and &#8364;1&#160;million credited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Financial income.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000&#160;million expiring in 2026, designated as a fair value hedge of the exposure of $1,000&#160;million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2026, the fair value of these contracts represented a liability of &#8364;6&#160;million, with &#8364;6&#160;million&#160;debited to</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">; the impact on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> is immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as&#160;cash&#160;flow hedges</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2030 and beyond</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 2.08% / receive Euribor 3M</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 3.77% / receive <br/>capitalized SOFR + 46bps </span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized SOFR USD/ <br/>receive 1.03%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/ <br/>receive 1.32%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 3.82% / receive <br/>capitalized SOFR USD + 54 bps </span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester/receive 0.92%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 2.53%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 2.71%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 2.91%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,288</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,313</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,400</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">950</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,951</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,226</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,726</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract', window );"><strong>Disclosure of contingent liabilities in business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock', window );">Liabilities related to business combinations and to non-controlling interests</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i441d86681a7946cc9b530ec9161251d5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.11. Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2026 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:45.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CVRs issued in connection with the acquisition of Blueprint</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CVRs issued in connection with the acquisition of Vigil</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2026</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">531</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">585</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">585</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">58</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">652</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Non-current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2026, this comprised a non-current portion of &#8364;585 million. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprised the contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#8364;585 million as of June&#160;30, 2026, compared with &#8364;531 million as of December 31, 2025. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 13%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to business combination and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current provisions and other non-current liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock', window );">Non-current provisions and other non-current liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ib5e43f9013e14d0887318696ae285733"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.12. Non-current provisions and other non-current liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,592&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,848</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,703</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes &#8364;1,647 million as of June 30, 2026 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States (see Note C.2. to the consolidated financial statements for the year ended December 31, 2025). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;916&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,150 million.</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:29.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,440</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">827</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">654</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,620</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,541</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(137)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(129)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(104)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,343</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">897</span></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">676</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,676</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,592</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions and other liabilities&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i1a226aca6ee943b898373876de7825d0"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December&#160;31, 2025, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal assumptions used (in particular, discount and inflation rates) and the market value of plan assets for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2026 to take into account changes during the first half of the year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:65.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.114%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between +0.05% and +0.50%) and (ii) the +0.15% change in the inflation rate in the United Kingdom in the first half of 2026.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes actuarial gains/ (losses) related to Opella of &#8364;(4)&#160;million for the first half of 2025..</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Provisions And Other Non-Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off balance sheet commitments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OffBalanceSheetCommitmentsAbstract', window );"><strong>Off-Balance Sheet Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock', window );">Off balance sheet commitments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="if2ef66ecc61249b8827c28488e19b089"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13. Off balance sheet commitments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments to third parties as of December&#160;31, 2025 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal commitments entered into the period are described below:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">In March 2026, Sanofi entered into an exclusive license agreement to develop, manufacture, and commercialize rovadicitinib worldwide from CTTQ, a Sino Biopharmaceutical Limited subsidiary. Rovadicitinib is a global first-in-class oral small molecule dual-target JAK/ ROCK inhibitor which received its first approval in China in February 2026 as a first-line treatment for MF (myelofibrosis) indication. Under the terms of the agreement, CTTQ received an upfront payment of $135&#160;million and is entitled to receive up to $1.4&#160;billion in development, regulatory and sales milestones, and up to double-digit tiered royalties on product sales. </span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">In March 2026, Sanofi entered into a worldwide exclusive license agreement with Kali Therapeutics for a next-generation tri-specific T-cell engager for autoimmune diseases, under which Sanofi will obtain exclusive worldwide rights to KT501, a novel tri-specific antibody utilizing Kali Therapeutics&#8217; proprietary discovery and research platform. Under the terms of the agreement, Kali Therapeutics is entitled to receive up to $1.2&#160;billion including upfront payments (of which $0.1&#160;billion has already been paid) plus development and sales milestones, and tiered royalties ranging from high-single to double digits on product sales.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, Sanofi has not entered into any material new long-term renewable energy contract agreements as part of its sustainability strategy. The main existing agreements are presented in Note D.21.1. to the consolidated financial statements in the 2025 Form 20-F.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of off-balance sheet commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OffBalanceSheetCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off-Balance Sheet Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OffBalanceSheetCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation and arbitration proceedings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock', window );">Litigation and arbitration proceedings</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="idcc102ea9b2046cc83a259304e2abadf"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.14. Litigation and arbitration proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2025.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i4c3e61ca8b9141d0b7fa8d2daa67610a"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.1. Products</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i8b1c17e995d64e019397b3fb59609de6"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zantac product litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the Multi-District Litigation (MDL) where Federal court cases were coordinated, the Eleventh Circuit held oral argument for the appeal in the fourth quarter of 2025 and a decision is expected in the second half of 2026.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In those cases pending in Delaware (State court) where the issue is to rule on defendants&#8217; Daubert motions to exclude plaintiffs&#8217; experts, in the second quarter of 2026, the Delaware Superior Court granted summary judgment and dismissed all the cases pending against Sanofi. The plaintiffs are appealing this ruling to the Delaware Supreme Court and Sanofi does not expect a decision on the appeal until the fourth quarter of 2027.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="iec0d81a85e37464bb85c5c2447256a99"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talc product litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2026, Sanofi was named as a defendant in approximately 1,430 ongoing product liability actions. To date, no cases have proceeded to trial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i97325ef9fa90480584d9004faf31c3d0"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent product litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Approximately 30 product liability cases have been filed in Federal courts around the country alleging that Dupixent (dupilumab) causes or exacerbates T-Cell lymphoma. In June 2026, those cases were consolidated into a Multi-District Litigation (MDL) in New Jersey Federal court. In addition, eight cases have been filed in New Jersey State court. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess reliably the outcome of these ongoing cases.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i10d555f1b9f3459bbe1a9e0eee1c96c5"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.2. Patents</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="idee49d17dbab49a198e6d3e9dd3eeeb1"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Praluent (alirocumab)-related Amgen patent litigation in Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March 6, 2026, Sanofi, Regeneron and Amgen entered into a settlement agreement resolving these disputes. The terms of the settlement are confidential. These cases are now closed.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i0088217aa4f2473782ecce2ebc49b741"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.14.3. Other litigation</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="icef0d62496c244a381edef675d01510c"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plavix (clopidogrel) - Attorney General Action in Texas </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the action filed by Sanofi and Bristol Myers Squibb (BMS) against the Texas Attorney General (Texas AG) in Travis County, on April 28, 2026 the Travis County court granted the Texas AG&#8217;s motion to abate the companies&#8217; suit against it; and on June 4, 2026 the companies filed a mandamus petition with the Texas Court of Appeals seeking to vacate that ruling.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"><span id="i1cbe1487d6d04115b3675a499302b6f1"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B drug pricing program in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The US Health Resources and Services Administration (HRSA) withdrew its 340B Rebate Model Pilot Program in February 2026 but is expected to announce a new 340B Rebate Model Pilot Program later in 2026. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">ADR Proceedings in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the 340B Administrative Dispute Resolution (ADR) proceedings against Sanofi, one filed by University of Washington/Harborview Medical Center in 2023 and one filed by Hudson Headwaters Health Network in 2024 (both alleging that Sanofi&#8217;s 340B Integrity Initiative caused &#8220;overcharges&#8221; under Section 340B), on March 9, 2026 the ADR Panel determined that there was no overcharge violation by Sanofi in the proceeding involving University of Washington Medical Center/Harborview Medical Center; and on May 27, 2026 the ADR Panel determined that there was no overcharge violation by Sanofi in the proceeding involving Hudson Headwaters Network, which has requested reconsideration of the ADR Panel&#8217;s decision.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mosaic Health in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since the case was remanded by the Court of Appeal to the District Court in August 2025 following the second amended complaint filed by plaintiffs, defendants (Sanofi and three other manufacturers) filed a motion to dismiss certain state law claims.  Defendants also filed a petition for a writ of certiorari with the Supreme Court of the United States challenging two aspects of the Second Circuit&#8217;s decision.  In July 2026, certain state law claims and plaintiffs&#8217; unjust enrichment claims were dismissed.  The District Court set a case schedule with fact discovery closing in November 2027.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Adventist Health System/West in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the appeal filed by Adventist Health System/West following the dismissal granted by the court in March 2024 in favor of the drug manufacturers including Sanofi, the Ninth Circuit Court of Appeals reversed and ordered the case to be remanded to the District Court on March 17, 2026.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Legal And Arbitral Proceedings [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income and expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">Other operating income and expenses</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="icc0e2fd5b6c74cd6b05c37034b5c2038"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.15. Other operating income and expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;800 million in the first half of 2026 (versus &#8364;533 million in the first half of 2025), and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;3,436 million (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">versus</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#8364; 2,476 million in the first half of 2025), as shown in the table below.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net gains / (losses) on disposals of operating assets or businesses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amvuttra licensing income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">800</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">533</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regeneron alliance:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(i) (Profit)/loss sharing</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,486)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,475)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(ii) Additional profit share for development cost from Regeneron</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(iii) Selling expense reimbursements to Regeneron</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(346)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(149)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,436)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,476)</span></td><td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs and similar items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock', window );">Restructuring costs and similar items</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i139e0fb357da4970a6636ccc777d86be"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16. Restructuring costs and similar items</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">563</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">430</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line includes transaction, integration and separation costs in connection with material acquisitions or divestitures amounting to &#8364;73 million for the first half of 2026, mainly related to the Dynavax acquisition (see note B.1.).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of restructuring costs and similar items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other gains and losses, and litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock', window );">Other gains and losses, and litigation</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i20b78eca92d7471d8d4493af61426d49"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17. Other gains and losses, and litigation</span></div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the first half of 2026, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represents a charge of &#8364;95 million mainly related to major litigation, compared with a charge of &#8364;57 m</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">illion in the first half of </span>2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other gains and losses, and litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses and income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial expenses and income</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i74ae65716b9a487992160b7c640c03ed"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.18. Financial expenses and income</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses on financial assets, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(328)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(177)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(465)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(361)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;12 million in the first half of 2026 and &#8364;(25) million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;6 million in the first half of 2026 and &#8364;(4)&#160;million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes a financial expense of &#8364;146 million for the six months ended June 30, 2026 and &#8364;50 million for the six months ended June 30, 2025 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United States.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of the ineffective portion of hedging relationships was not material in either 2026 or 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax expense</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i629ae0ca518d4a3799c6c6b12cd80b9e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.19. Income tax expense</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(871)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(711)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,840</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(as a percentage)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effect related to amlitelimab </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30.6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France, and the impact of patent-favorable tax regimes.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2025 component of the temporary exceptional corporate income tax surcharge, introduced under the 2026 French Finance Act, is included in the<br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)  This relates to the non-deductibility of the impairment loss on the amlitelimab intangible asset (see Note B.4.), and associated effects on deferred tax assets.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2026, this line includes a tax expense of &#8364;57 million representing the estimated impact of Pillar Two based on Sanofi&#8217;s current understanding of Pillar Two rules, compared with &#8364;17 million for the six months ended June 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue from contracts with customers</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i9da410b1c04b43f39d6815feab11f47e"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.20. Revenue from contracts with customers</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="if7fb0c15c7e14188b423f83b19015d10"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.1. Analysis of net sales</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.690%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="6" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="42" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Group</span></div></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,304</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,633</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,169</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,535</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,922&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,324&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,283&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabrazyme</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme/Nexviadyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerezyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ayvakit</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lantus</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Toujeo</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plavix</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lovenox</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">181</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">241</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">251</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">COVID-19 and Influenza vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which total launches </span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">546</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,891</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">610</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">423</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,204</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">473</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-right:0.25pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i9915491664724057bf9655002fbed8b1"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.20.2. Other revenues</span></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:72.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe sales of non-Sanofi products</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales to Opella </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biopharma Other revenues</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,168</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,246</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales / Revenues from Opella products</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Other revenues</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,452</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</span></div>(c)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment information</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="i467d65866f844e78b863815e9b5709f5"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21. Segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The segment information presented by Sanofi consists of a single operating segment: Biopharma.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines, and Vaccines franchises, plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella Healthcare SAS (Opella), which constitutes a related party with effect from April 30, 2025, the deconsolidation date, corresponding to the closing of Sanofi's sale of a controlling stake of approximately 50% in Opella to Clayton, Dubilier &amp; Rice (CD&amp;R). Those revenues, which before the deconsolidation date represented intragroup transactions classified within continuing operations, are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i884faad2f1f94bc3832619db02e9fdaa"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.1. Segment results</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.025em;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of the operating segment and to allocate resources.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts reported within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other gains and losses (including gains and losses on major divestments), presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">other costs and provisions related to litigation, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates (i)&#160;to joint ventures or (ii) to associates with which Sanofi has entered into R&amp;D agreements and/or whose operations are managed as an integral part of Sanofi&#8217;s business activities, and;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">net income attributable to non-controlling interests related to continuing operations, and excluding the effects of the above reconciling items, is deducted. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:27.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026 (6 months)</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+11.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+15.7</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+11.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+15.7</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-6.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-2.0</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+31.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+31.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.0</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+2.7</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,812)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+1.0</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.8</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+1.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.8</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,979)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+7.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,980)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+7.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.5</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+9.4</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+72.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+76.3</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,792)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+6.3</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+10.3</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,630)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,636)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,230</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+16.5</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+22.2</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+75.0</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+68.8</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,258</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+16.7</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+22.3</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">28.2</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">28.3</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:50.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6 months)</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,753)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(128)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,881)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,716)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,717)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,447)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,506)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,941)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,943)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,347</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,258</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(777)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(430)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,168</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,759</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,840</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Mainly joint ventures.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;1,031&#160;million in the first half of 2026 mainly comprising a &#8364;952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly comprises impairment losses of &#8364;210  million linked to research and development projects.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026 relate to the Blueprint Medicines and Dynavax acquisitions.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">See Note B.16.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.17.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i17f4673892234e26865e7dfa66a30da2"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.2. Other segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method related (a) to joint ventures or (b) to associates with which Sanofi has entered into R&amp;D agreements and/or whose operations are managed as an integral part of Sanofi&#8217;s business activities; (ii) acquisitions of property, plant and equipment; and (iii) acquisitions of intangible assets. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method mainly comprise MSP Vaccine Company and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note B.5.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:61.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="ic5ce3e905560415e91636d287653d938"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.3. Information by geographical region</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:60.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">835&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,633&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,535&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,210&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:53.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.610%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.149%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,998&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,951&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,760&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,094&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,161&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,972&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,694&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,063&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,364</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,359</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,052</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,261</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2025, goodwill is not allocated by geographical region.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span id="i6ee48613616140ac9120c037d6917ecb"></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.21.4. Disclosures about major customers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented 42% of net sales in the first half of 2026. Sanofi&#8217;s three largest customers respectively accounted for approximately 22%, 14% and 6% of consolidated net sales in the first half of 2026 (versus approximately 18%, 12% and 5% in the first half of 2025).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Information related to Opella, presented within discontinued operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DiscontinuedOperationsAbstract', window );"><strong>Discontinued Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Information related to Opella, presented within discontinued operations</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><span id="ia9eff4859f124b0d914e6bab5e9a4ad8"></span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.22. Information related to Opella, presented within discontinued operations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 30, 2025, the Opella transaction was closed triggering loss of control, and resulting in the derecognition of all assets and liabilities of Opella subsidiaries. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the main items presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:74.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales and other revenues </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,736</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(158)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,881</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In 2025, this line includes an expense of &#8364;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for non-current assets held for sale and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Section Presentation and disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IFRS05_g30-42_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation of the half-year financial statements and accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">International financial reporting standards (IFRS)</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2026 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2026 are available via the following web link: https://www.efrag.org/en/financial-reporting/endorsement-status.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies applied effective January 1, 2026 are identical to those presented in the consolidated financial statements for the year ended December 31, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable from January 1, 2026. The amendments did not have a material impact on the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 18, 2024, the IASB issued Volume 11 of &#8220;Annual Improvements to IFRS&#8221;, applicable from January 1, 2026. Those improvements to various standards, which are essentially in the nature of clarifications, did not have a material impact on the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments could potentially result in an enhancement of the disclosures provided in the 2026 annual financial statements. As a reminder, renewable energy purchase contracts entered into by Sanofi as of December 31, 2025 are described in Note D.21. to the consolidated financial statements included in Sanofi&#8217;s Form 20-F for the year ended December 31, 2025 (the &#8220;2025 20-F&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In its 2026 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. As in the previous year, the effective tax rate also includes a one-off impact from the 2025 component of the exceptional surcharge in respect of French corporate income taxes (see Note B.19.).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Use of estimates and judgments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">impairment of property, plant and equipment and intangible assets;</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the valuation of goodwill and the valuation and useful life of acquired intangible assets; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity </span></div>method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock', window );">Seasonal trends</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are not subject to significant seasonal fluctuations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory', window );">Consolidation and foreign currency ranslation of the financial statements of subsidiaries in hyperinflationary economies</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2026, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">Level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.996%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2025.</span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New pronouncements issued by the IASB and applicable from 2027</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027. In terms of adapting Sanofi&#8217;s chart of accounts and financial information systems, the transition is continuing on schedule. In line with the information communicated in the 2025 financial statements as published, Sanofi&#8217;s IFRS 18 rollout project &#8211; which began in the fourth quarter of 2025 &#8211; is progressing, and the impact analysis has evolved in line with the schedule. The future structure of Sanofi&#8217;s consolidated income statement will present operating expenses by function, and will reflect presentational choices based on the &#8220;useful structured summary&#8221; principle established by IFRS 18. Those choices involve the classification of income statement items according to five categories (operating, investing, financing, income tax and discontinued operations), with the sub-totals limited solely to those specified in IFRS 18. The income statement structure will also reflect the fact that Sanofi as a whole operates a single principal activity. As regards the requirement to disclose alternative management performance measures (MPMs) that meet the IFRS 18 definition in the notes to the financial statements, Sanofi has identified the relevant MPMs. In accordance with the information communicated in Sanofi&#8217;s 2025 consolidated financial statements, the main MPMs are &#8220;Business gross profit&#8221;, &#8220;Business operating income&#8221; and &#8220;Business net income&#8221;, all of which are non-IFRS measures that Sanofi currently uses in its financial communication. No significant impact on these performance measures has been identified at this stage.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transition note intended for publication in Sanofi&#8217;s 2026 Annual Report on Form 20-F will include a reconciliation, for the comparative years 2026 and 2025, between (i) the amounts for each income statement line item presented in accordance with IFRS&#160;18 as applicable from 2027 and (ii) those presented in accordance with the currently applicable standard (IAS 1).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, the presentation of the consolidated statement of cash flows will be modified such that it starts from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> instead of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, as mentioned in Sanofi&#8217;s 2025 year-end financial communications, Sanofi is not early adopting IFRS 18.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November 13, 2025, the IASB issued &#8220;Translation to a Hyperinflationary Presentation Currency&#8221;, an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), applicable from January 1, 2027 (subject to endorsement by the European Union). Sanofi does not expect any material impact and will not early adopt this amendment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 180<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_180_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 180<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_180_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about financial reporting in hyperinflationary economies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 29<br> -IssueDate 2025-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=29&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS29_g39-40_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Seasonality Or Cyclicality Of Interim Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation of the half-year financial statements and accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of Measurement Principles Applied to Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:3.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.996%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial<br/>instrument</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in fair value hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation technique</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="padding-right:5.35pt;text-align:justify"><span><br/></span></div></td><td colspan="12" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation model</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Volatilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1<br/></span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost/ Peer comparison (primarily)</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2025.</span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under post-employment benefit plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.6.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.<br/>B.12.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial liabilities</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. <br/>For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).<br/>For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.9.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="15" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future lease payments are discounted using the incremental borrowing rate.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market<br/>&gt;&#160;1 year:&#160;Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.10.</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue-based approach</span></div></td><td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mid Market Spot</span></td><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures <br/>&gt;&#160;1 year: Mid Zero Coupon</span></td><td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B.11.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 43<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_43&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant information for the first half of 2026 (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure of detailed information about business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Disclosure of detailed information about business combination</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of &#8364;204&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(249)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(132)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Dynavax</span></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,367</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,571</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock', window );">Summary of acquisitions and capitalized interest by operating segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:76.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">763</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">702</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma </span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">453&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella (discontinued operation)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">23</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">22</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock', window );">Schedule of movements in other intangible assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets during the first half of 2026 were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:45.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products, trademarks and other rights</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,951</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66,746</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,888</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">83,585</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(534)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(579)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(162)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(411)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at June 30, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,817</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69,070</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,957</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85,844</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,220)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(49,624)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,480)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57,324)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,106)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(970)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,048)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(785)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(930)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization and impairment at June 30, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,791)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(51,159)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,535)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(59,485)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at January&#160;1, 2026</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,731</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,122</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">408</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,261</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at June 30, 2026</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,026</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,911</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">422</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,359</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the intangible assets recognized as part of the Dynavax  acquisition (see Note B.1.)</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">See Note B.4.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of changes in other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock', window );">Summary of Investments in Associates and Joint Ventures</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2025), and comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:55.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OPAL JV Co </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,965</span></td><td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,934</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH &amp; Co. H&#246;chst KG </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,207</span></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,259</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Following the loss of control of Opella in 2025, Sanofi holds 48.2% of OPAL JV Co (CD&amp;R holds 50% and Bpifrance holds 1.8%). As of December&#160;31, 2025 the investment included a &#8364;241&#160;million loan to OPAL JV Co being in substance part of the investment. In 2026, following finalization of the Opella completion accounts as of April 30, 2025, this loan was converted into ordinary shares.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#8364;1.33 as of June 30, 2026, and &#8364;2.27 as of December&#160;31, 2025). </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Joint venture. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Summary of Principal Transactions and Balances with Related Parties</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:74.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases of goods and services (including research expenses)  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#8364;200&#160;million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2026 was &#8364;84&#160;million, versus &#8364;143&#160;million as of December 31, 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock', window );">Disclosure of unaudited financial statements of subsidiaries explanatory</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key items from the unaudited half-year consolidated financial statements of OPAL JV Co as of June 30, 2026, as provided in accordance with Sanofi&#8217;s consolidation timelines, are presented below: </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:74.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated income statement</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net sales and other revenues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">887</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated statement of comprehensive income</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated balance sheet</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,673&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,013&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,925&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,598</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,872</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of OPAL JV Co</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,958&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,380&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,394</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,870</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,575&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,204</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,002</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,598</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,872</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of investments in associates and joint ventures explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Unaudited Financial Statements Of Subsidiaries Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock', window );">Summary of other non-current assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-current assets comprise:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,732</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,364</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of components of other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock', window );">Summary of accounts receivable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,818&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,510&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,410</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock', window );">Summary of gross value of overdue receivables</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ageing profile of overdue accounts receivable, based on gross value:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:18.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue accounts gross value</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&lt;1 month</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>1-3 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>3-6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>6-12 months</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue by <br/>&gt; 12 months</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">522</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">183</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">127</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">142</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of current trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfCurrentTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of treasury shares held</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital<br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16.03</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.320</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December&#160;31, 2025</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.96&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.981</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.868</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2025</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.53&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.755</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock', window );">Summary of principal characteristics of restricted share plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2025. The principal features of the plans awarded in 2026 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:82.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.541%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plan</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April, 29, 2026</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plans awarded to the Chief Executive Officer</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 1, 2026</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 3-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,087,518&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,367,862&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;65.86&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market conditions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,719,656&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer (1,674,656 shares in total) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;57.99&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (45,000 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;53.46&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares subject to a 5-year service period</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer (180,000 shares) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;40.46&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plans at the date of grant (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">329</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 3 years.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 5 years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock', window );">Summary of number of restricted shares not yet fully vested</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:69.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans (&#8364; million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12,995,668&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,550,347&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2026 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,267,518&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2025 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,897,342&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,020,451&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2024 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,772,461&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,110,089&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">58,347&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,313,588&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">106,219&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock', window );">Summary of options outstanding and exercisable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.234%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average residual life</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price per&#160;share</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213,400&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.84</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.71&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213,400&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.71&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.86</span></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">639,194</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">639,194</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Summary of earnings per share</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net income:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.923%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,957.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,812.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which net income from continuing operations</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,931.0&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,941.0&#160;</span></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which net income from discontinued operations</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,871.0&#160;</span></td><td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number of shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(number of shares in million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,200.4&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,225.5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,205.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,230.7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of number of shares used to compute diluted earnings per share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(in euros)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Basic earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.63</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.74</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from continuing operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share from discontinued operations (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diluted earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.62</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.72</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock', window );">Summary of movements within other comprehensive income</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) excluding investments accounted for using the equity method</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">290</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">243</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow hedges and fair value hedges:</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (excluding investments accounted for using the equity method)&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,266)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Currency translation differences (investments accounted for using the equity method) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Hedges of net investments in foreign operations </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:7.09pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,327</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(5,017)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes reclassifications to profit or loss: immaterial over all periods.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes reclassifications to profit or loss: &#8364;1&#160;million in the first half of 2026; &#8364;2&#160;million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.</span></div> &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#8364;146&#160;million loss in the first half of 2026 and a &#8364;459 million loss in the first half of 2025 relating to the deconsolidation of Opella<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information of accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number of restricted share plans Not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock', window );">Summary of Changes in Financial Position</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,646&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,248&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,026&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,893</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,702</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,513</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,008</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,904 million as of June 30, 2026 and &#8364;1,739 million as of December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock', window );">Summary of Reconciliation of Carrying Amount to Value on Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2026 is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:28.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at</span></div><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment to debt measured at fair value</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,646&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,751&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,360&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,026&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,027&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,344&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(131)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,893</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(70)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,868</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,716</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,513</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(70)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,488</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,022</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Net debt does not include lease liabilities, which amounted to &#8364;1,904 million as of June 30, 2026 and &#8364;1,739 million as of December&#160;31, 2025.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock', window );">Summary of Net Debt by Type Valuation of Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows an analysis of net debt by type, at value on redemption:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">non-current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,702&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,599&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,301&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,306&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,165&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,471&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,291&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,340&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,751</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,117</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,868</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,360</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,356</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,716</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,657)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,751</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">737</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,488</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,360</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,338)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,022</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts include $3&#160;billion designated  as a hedge of Sanofi&#8217;s net investment in the United States.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) As of Ju</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ne 30, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2026</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, current other bank borrowings include &#8364;3,217&#160;million related to the US commercial paper program.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock', window );">Summary of Market Value of Net Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,989&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,424&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,488&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,022&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in financial position [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt net of cash and cash equivalents by type at value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of market value of net debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMarketValueOfNetDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock', window );">Summary of Operating Currency Hedging Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:26.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as&#160;cash&#160;flow hedges</span></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,536</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(66)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,315</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">555&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">555&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">530&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">530&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Brazilian real </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">422&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which  Saudi Arabian riyal</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,039</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,039</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">596&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">596&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">306&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Turkish lira</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which United Arab Emirates dirham</span></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,575</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,354</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes forward sales with a notional amount of BRL 1,300&#160;million expiring in 2027, designated as a cash flow hedge on the divestment of Medley in Brazil.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock', window );">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:53.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum expiry&#160;date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cross currency seller swaps</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,523</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2032</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,423</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(272)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">13,361&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Pound sterling</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Brazilian real</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,466</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">170</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29,412</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(139)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a hedge of Sanofi&#8217;s net investment in the United States. As of June 30, 2026, the fair value of the swaps was a liability of &#8364;37&#160;million, with &#8364;33&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> under the cost of hedging accounting treatment and &#8364;4&#160;million debited to financial result.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes forward sales with a notional amount of $12,275&#160;million expiring in 2026 and 2027, designated as a hedge of Sanofi&#8217;s net investment in the United States.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#8364;223&#160;million, with &#8364;222&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and &#8364;1&#160;million debited to</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) &#160;Includes forward sales with a notional amount of BRL 1,200&#160;million  expiring in 2027, designated as a hedge of Sanofi&#8217;s net investment in Brazil.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#8364;9&#160;million, with &#8364;10&#160;million debited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, and &#8364;1&#160;million credited to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Financial income.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000&#160;million expiring in 2026, designated as a fair value hedge of the exposure of $1,000&#160;million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2026, the fair value of these contracts represented a liability of &#8364;6&#160;million, with &#8364;6&#160;million&#160;debited to</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">; the impact on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> is immaterial.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock', window );">Disclosure of Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows instruments of this type in place as of June 30, 2026:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as fair value hedges</span></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as&#160;cash&#160;flow hedges</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2030 and beyond</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which recognized in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 2.08% / receive Euribor 3M</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 3.77% / receive <br/>capitalized SOFR + 46bps </span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized SOFR USD/ <br/>receive 1.03%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/ <br/>receive 1.32%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay 3.82% / receive <br/>capitalized SOFR USD + 54 bps </span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester/receive 0.92%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 2.53%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 2.71%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">pay capitalized Ester / receive 2.91%</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,288</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,313</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,400</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">950</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,951</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,226</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,726</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest rates hedging instruments with notional amount by expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract', window );"><strong>Disclosure of contingent liabilities in business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock', window );">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2026 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"><tr><td style="width:1.0%"></td><td style="width:45.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire contingent consideration arising from acquisition of Translate Bio</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CVRs issued in connection with the acquisition of Blueprint</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CVRs issued in connection with the acquisition of Vigil</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2026</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">531</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">585</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">585</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">58</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">652</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">Non-current portion</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">As of January 1, 2026, this comprised a non-current portion of &#8364;585 million. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#8220;Fair value remeasurement of contingent consideration&#8221;.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current provisions and other non-current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock', window );">Summary of Non-Current Provisions and Other Non-Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.098%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,592&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,848</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,703</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes &#8364;1,647 million as of June 30, 2026 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States (see Note C.2. to the consolidated financial statements for the year ended December 31, 2025). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;916&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,150 million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock', window );">Summary of Movements in Non-Current Provisions</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in provisions:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:29.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for pensions &amp; other post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions for other long-term benefits</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2026</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,440</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">827</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">654</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,620</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,541</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions and other liabilities</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(137)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(129)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(104)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at June 30, 2026</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,343</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">897</span></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">676</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,676</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,592</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions and other liabilities&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly transfers to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock', window );">Disclosure of Remeasurement of Net Defined Benefit Liability Asset</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:65.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.114%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%">(c)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) on benefit obligations</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes the effects of (i) the change in discount rates (in a range between +0.05% and +0.50%) and (ii) the +0.15% change in the inflation rate in the United Kingdom in the first half of 2026.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Includes actuarial gains/ (losses) related to Opella of &#8364;(4)&#160;million for the first half of 2025..</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of noncurrent provisions explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Provisions And Other Non Current Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income and expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherOperatingExpensesTableTextBlock', window );">Schedule of Other Operating Expenses</a></td>
<td class="text">, as shown in the table below.<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net gains / (losses) on disposals of operating assets or businesses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amvuttra licensing income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">800</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">533</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regeneron alliance:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(i) (Profit)/loss sharing</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,486)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,475)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(ii) Additional profit share for development cost from Regeneron</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(iii) Selling expense reimbursements to Regeneron</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(346)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(149)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,436)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,476)</span></td><td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherOperatingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherOperatingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs and similar items (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock', window );">Summary of Restructuring Costs and Similar Items</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs of transformation programs</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">563</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">430</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This line includes transaction, integration and separation costs in connection with material acquisitions or divestitures amounting to &#8364;73 million for the first half of 2026, mainly related to the Dynavax acquisition (see note B.1.).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of restructuring costs details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses and income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock', window );">Summary of Analysis of Financial Income and Expenses</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of financial expenses and income is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses on financial assets, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(328)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(177)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(465)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(361)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">184</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#8364;12 million in the first half of 2026 and &#8364;(25) million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;6 million in the first half of 2026 and &#8364;(4)&#160;million in the first half of 2025.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Includes a financial expense of &#8364;146 million for the six months ended June 30, 2026 and &#8364;50 million for the six months ended June 30, 2025 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United States.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock', window );">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(871)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(711)</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,840</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock', window );">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(as a percentage)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months) </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effect related to amlitelimab </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30.6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France, and the impact of patent-favorable tax regimes.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">                 The 2025 component of the temporary exceptional corporate income tax surcharge, introduced under the 2026 French Finance Act, is included in the<br/>                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)  This relates to the non-deductibility of the impairment loss on the amlitelimab intangible asset (see Note B.4.), and associated effects on deferred tax assets.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) For the six months ended June 30, 2026, this line includes a tax expense of &#8364;57 million representing the estimated impact of Pillar Two based on Sanofi&#8217;s current understanding of Pillar Two rules, compared with &#8364;17 million for the six months ended June 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of allocation of income tax between current and deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of average effective tax rate and applicable tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Disclosures about major customers and credit risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.690%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="6" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="42" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Group</span></div></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,304</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,633</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,169</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,535</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immunology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,922&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,324&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,283&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare diseases</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabrazyme</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nexviazyme/Nexviadyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cerezyme</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ayvakit</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sarclisa </span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other medicines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lantus</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Toujeo</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plavix</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lovenox</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rezurock</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">181</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">241</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">251</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RSV vaccines (Beyfortus) </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">COVID-19 and Influenza vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which total launches </span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">546</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,891</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">610</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">423</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,204</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">473</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-right:0.25pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherRevenueTextBlock', window );">Disclosure of other revenue</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:72.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe sales of non-Sanofi products</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales to Opella </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biopharma Other revenues</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,168</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,246</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales / Revenues from Opella products</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Other revenues</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,452</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.</span></div>(c)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2025-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Segment Results</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Segment results are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"><tr><td style="width:1.0%"></td><td style="width:27.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026 (6 months)</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 on a reported basis (IFRS)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">Change vs. June 30, 2025 at constant exchange rates (non-IFRS)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+11.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+15.7</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+11.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">+15.7</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-6.3</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-2.0</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+31.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+31.1</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-1.0</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+2.7</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,812)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+1.0</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.8</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,945)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+1.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+3.8</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,979)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+7.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,980)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+7.1</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+9.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,690)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+5.5</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+9.4</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+72.9</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+76.3</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,792)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+6.3</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+10.3</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,630)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,636)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,230</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+16.5</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+22.2</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+75.0</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+68.8</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,258</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+16.7</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+22.3</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">28.2</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">28.3</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:50.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025 (6 months)</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,753)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(128)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,881)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,716)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,717)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,447)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,506)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,941)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,943)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,347</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock', window );">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between &#8220;Business operating income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:70.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026            (6 months)</span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025           (6 months)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,258</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,363</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(777)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(430)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,168</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,759</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,840</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,582</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Mainly joint ventures.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#8364;1,031&#160;million in the first half of 2026 mainly comprising a &#8364;952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly comprises impairment losses of &#8364;210  million linked to research and development projects.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026 relate to the Blueprint Medicines and Dynavax acquisitions.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">See Note B.16.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">See Note B.17.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock', window );">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:61.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><span><br/></span></div></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of Geographical Information on Net Sales and Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:60.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">835&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,633&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,535&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,169&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,210&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,106</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,889</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:53.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.610%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.149%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December&#160;31, 2025</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other intangible assets</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,998&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,951&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,760&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,094&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,161&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,972&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,694&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,063&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,364</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,359</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,052</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,261</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments reconciling items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Information related to Opella, presented within discontinued operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DiscontinuedOperationsAbstract', window );"><strong>Discontinued Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock', window );">Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the main items presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income from discontinued operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:74.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.074%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales and other revenues </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,736</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,039&#160;</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(158)</span></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income from discontinued  operations (Opella)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,881</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In 2025, this line includes an expense of &#8364;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation of the half-year financial statements and accounting policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>categorie</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeStatementClassificationIFRS18NumberOfCategories', window );">Number of categories</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AR', window );">Argentina</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears', window );">Cumulative consumer price inflation rate</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_TR', window );">Turkey</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears', window );">Cumulative consumer price inflation rate</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Consumer Price Inflation Rate Over The Last Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeStatementClassificationIFRS18NumberOfCategories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Categories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeStatementClassificationIFRS18NumberOfCategories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Significant information for the first half of 2026 - Additional information (Details)<br> $ / shares in Units, &#8364; in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2026</div></th>
<th class="th">
<div>Feb. 10, 2026 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 10, 2026 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,408<span></span>
</td>
<td class="nump">&#8364; 538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisposalGroupAxis=sny_MedleyMember', window );">Medley</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfOwnershipInterestDisposed', window );">Percentage of ownership interest disposed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember', window );">Dynavax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare', window );">Equity interests of acquirer (in USD per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationEquityValueOfAcquirer', window );">Equity value of acquirer | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember', window );">Dynavax | Biopharma</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueOfAcquiree', window );">Revenue of acquiree since acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate', window );">Operating income of acquiree since acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossOfAcquiree', window );">Loss of acquiree since acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate', window );">Amortization of intangible assets of acquiree since acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate', window );">Amortisation of Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate', window );">Restructuring and similar costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2026, this line item includes the net cash outflow arising from the acquisition of Dynavax (see Note B.1.1.). For the six months ended June 30, 2025 it includes the net cash outflow arising from the acquisition of Dren-0201.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer: Borrowings; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Expenses from Inventories of Acquiree Since Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Intangible Assets of Acquiree Since Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationEquityInterestsOfAcquirerPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interests Of Acquirer, Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationEquityInterestsOfAcquirerPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationEquityValueOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Value Of Acquirer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationEquityValueOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OperatingIncomeOfAcquireeSinceAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Income Of Acquiree Since Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OperatingIncomeOfAcquireeSinceAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfOwnershipInterestDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Ownership Interest Disposed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfOwnershipInterestDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Costs and Other Items of Acquiree Since Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisposalGroupAxis=sny_MedleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisposalGroupAxis=sny_MedleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant information for the first half of 2026 - Summary of detailed information about business combination Dynavax (Details) - Feb. 10, 2026 - Dynavax<br> &#8364; in Millions, $ in Billions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate', window );">Other current and non-current assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate', window );">Short-term debt</a></td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets of Dynavax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer: Borrowings; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Liabilities Recognised As Of AcquisitionDate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets and non-current assets and liabilities as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">&#8364; 763<span></span>
</td>
<td class="nump">&#8364; 702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestCostsCapitalised', window );">Of which capitalized interest</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Of which Manufacturing &amp; Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OPALJVCoMember', window );">OPAL JV Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OPALJVCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OPALJVCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FirmOrdersOfPropertyPlantAndEquipment', window );">Firm orders of property, plant and equipment</a></td>
<td class="nump">&#8364; 1,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FirmOrdersOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Firm orders of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FirmOrdersOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 41,954<span></span>
</td>
<td class="nump">&#8364; 41,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="nump">26,359<span></span>
</td>
<td class="nump">26,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="nump">&#8364; 17,100<span></span>
</td>
<td class="nump">16,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Weighted average amortization period</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember', window );">Technological platforms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Carrying amount of intangible assets</a></td>
<td class="nump">&#8364; 800<span></span>
</td>
<td class="nump">&#8364; 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Weighted average amortization period</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2025-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 254<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_254_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 255<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_255_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">&#8364; 26,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="num">(1,087)<span></span>
</td>
<td class="num">&#8364; (777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">26,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">83,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill', window );">Changes in scope of consolidation</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">1,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="num">(411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">85,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="num">(57,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="nump">1,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="num">(59,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">8,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">8,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">14,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="num">(245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">14,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember', window );">Acquired R&amp;D | Accumulated amortization and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="num">(6,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="num">(6,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">17,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">17,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">66,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill', window );">Changes in scope of consolidation</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">69,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Accumulated amortization and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="num">(49,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="num">(51,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill', window );">Changes in scope of consolidation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Accumulated amortization and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="num">(1,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="num">&#8364; (1,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Scope Of Consolidation Through Business Combination, Intangible Assets Other Than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ProductsTrademarksAndOtherRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of intangible assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="nump">&#8364; 1,031<span></span>
</td>
<td class="nump">&#8364; 210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">&#8364; 210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AmlitelimabAssetMember', window );">Amlitelimab asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="nump">952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment loss on other intangible assets</a></td>
<td class="nump">&#8364; 952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AmlitelimabAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AmlitelimabAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 3,207<span></span>
</td>
<td class="nump">&#8364; 3,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockPrice', window );">Stock price (in euro per share)</a></td>
<td class="nump">&#8364; 1.33<span></span>
</td>
<td class="nump">&#8364; 2.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company | MCM Vaccine BV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember', window );">Infraserv GmbH &amp; Co. H&#246;chst KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="nump">31.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="nump">&#8364; 93<span></span>
</td>
<td class="nump">&#8364; 112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Investments in joint ventures</a></td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="nump">&#8364; 59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember', window );">OPAL JV Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="nump">48.20%<span></span>
</td>
<td class="nump">48.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod', window );">Investments in associates</a></td>
<td class="nump">&#8364; 2,965<span></span>
</td>
<td class="nump">&#8364; 2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LoansToAssociates', window );">Loans to Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember', window );">OPAL JV Co | CD&amp;R</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember', window );">OPAL JV Co | BPIFrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="nump">29.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod', window );">Investments in associates</a></td>
<td class="nump">&#8364; 38<span></span>
</td>
<td class="nump">&#8364; 64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod', window );">Investments in associates</a></td>
<td class="nump">&#8364; 59<span></span>
</td>
<td class="nump">&#8364; 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 89<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_89&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 89<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_89&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Total for all joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LoansToAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loans to Associates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LoansToAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_StockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_StockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MCMVaccineBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MCMVaccineBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_CDRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_CDRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_BPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_BPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the&#160;equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="nump">&#8364; 85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember', window );">OPAL JV Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the&#160;equity method</a></td>
<td class="nump">&#8364; 11<span></span>
</td>
<td class="num">&#8364; (39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_OPALJVCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SubordinateHybridBondRelatedPartyTransactions', window );">Subordinate hybrid bond, related party transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember', window );">Associates and joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions', window );">Sales</a></td>
<td class="nump">&#8364; 31<span></span>
</td>
<td class="nump">&#8364; 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions', window );">Royalties and other income</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions', window );">Purchases of goods and services (including research expenses)</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">&#8364; 371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Accounts receivable and other receivables</a></td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherAssetsRelatedPartyTransactions', window );">Other assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherLiabilitiesRelatedPartyTransactions', window );">Other liabilities</a></td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember', window );">Associates and joint ventures | EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherAssetsRelatedPartyTransactions', window );">Other assets</a></td>
<td class="nump">&#8364; 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 230<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_230_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goods purchased by the entity in related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 234<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_234_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 234<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_234_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2025-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 234<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_234_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 234<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_234_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherLiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherLiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties and other income, related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SubordinateHybridBondRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subordinate Hybrid Bond, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SubordinateHybridBondRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Summary of Key Items Which Have Not Been Audited (Details) - Associates and joint ventures - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures', window );">Net sales and other revenues</a></td>
<td class="nump">&#8364; 2,657<span></span>
</td>
<td class="nump">&#8364; 887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetIncomeRelatedPartyDisclosures', window );">Net Income</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherComprehensiveIncomeRelatedPartyDisclosures', window );">Other comprehensive income</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ComprehensiveIncomeRelatedPartyDisclosures', window );">Comprehensive income</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">&#8364; 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentAssetsRelatedPartyTransactions', window );">Non-current assets</a></td>
<td class="nump">16,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentAssetsRelatedPartyTransactions', window );">Current assets</a></td>
<td class="nump">2,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AssetsRelatedPartyTransactions', window );">Total assets</a></td>
<td class="nump">19,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions', window );">Equity attributable to equity holders of OPAL JV Co</a></td>
<td class="nump">5,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions', window );">Equity attributable to non-controlling interests</a></td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityRelatedPartyTransactions', window );">Total equity</a></td>
<td class="nump">6,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedPartyTransactions', window );">Non-current liabilities</a></td>
<td class="nump">11,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedPartyTransactions', window );">Current liabilities</a></td>
<td class="nump">1,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilitiesRelatedPartyTransactions', window );">Total liabilities</a></td>
<td class="nump">13,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityAndLiabilitiesRelatedPartyTransactions', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 19,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ComprehensiveIncomeRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ComprehensiveIncomeRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityAndLiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity and Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityAndLiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityAttributableToEquityHoldersRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Attributable to Equity Holders, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityAttributableToEquityHoldersRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Attributable to Non Controlling Interest, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetIncomeRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetIncomeRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Sales and Other Revenues, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Current assets, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Current Liabilities, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherComprehensiveIncomeRelatedPartyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income, Related Party Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherComprehensiveIncomeRelatedPartyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other non-current assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Other financial assets at fair value through profit or loss</a></td>
<td class="nump">&#8364; 1,099<span></span>
</td>
<td class="nump">&#8364; 1,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PreFundedPensionObligations', window );">Pre-funded pension obligations</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LongTermPrepaidExpenses', window );">Long-term prepaid expenses</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLoansAndReceivables', window );">Long-term loans and advances and other non-current receivables</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Derivative financial instruments</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember', window );">Trading equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Instruments at fair value through other comprehensive income</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Instruments at fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 363<span></span>
</td>
<td class="nump">&#8364; 389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 44<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 44<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_44_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherNonCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LongTermPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LongTermPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLoansAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non current loans and receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLoansAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Assets At Fair Value Through Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PreFundedPensionObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded pension obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PreFundedPensionObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable - Summary of Accounts Receivable (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 8,714<span></span>
</td>
<td class="nump">&#8364; 8,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">8,818<span></span>
</td>
<td class="nump">8,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember', window );">Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 104<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccountsReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounts Receivable [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccountsReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and other receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</a></td>
<td class="nump">&#8364; 6<span></span>
</td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerecognizedReceivables', window );">Derecognized receivables</a></td>
<td class="nump">&#8364; 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerecognizedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognized receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerecognizedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 522<span></span>
</td>
<td class="nump">&#8364; 468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Overdue by less than 1 month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Overdue by 1-3 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember', window );">Overdue by 3-6 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember', window );">Overdue by 6-12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Overdue by &gt; 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 43<span></span>
</td>
<td class="nump">&#8364; 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OverdueReceivablesGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OverdueReceivablesGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Additional Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Feb. 02, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 29, 2026</div></th>
<th class="th"><div>Jan. 28, 2026</div></th>
<th class="th"><div>Jan. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,428,198,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,214,099,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Payments to acquire or redeem entity's shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,009,000,000<span></span>
</td>
<td class="nump">&#8364; 4,003,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CancellationOfTreasuryShares', window );">Cancellation of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 596,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=sny_ShareRepurchase2025ProgramMember', window );">Share Repurchase 2025 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareRepurchaseProgramPeriod', window );">Period of share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,571,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Payments to acquire or redeem entity's shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,003,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=sny_ShareRepurchase2025ProgramMember', window );">Share Repurchase 2025 Program | L'Or&#233;al</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,556,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfSanofisShareCapitalAcquired', window );">Percentage of Sanofi's share capital acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareRepurchaseProgramAmountPaid', window );">Share repurchase program, amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PerShareValueOfSharesRepurchased', window );">Per share value of shares repurchased (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 101.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=sny_ShareRepurchase2026ProgramMember', window );">Share Repurchase 2026 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareRepurchaseProgramPeriod', window );">Period of share repurchase program</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember', window );">Employees share ownership plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SubscriptionPricePerShare', window );">Subscription price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 59.87<span></span>
</td>
<td class="nump">&#8364; 72.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesSubscribed', window );">Number of shares subscribed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,776<span></span>
</td>
<td class="nump">2,431,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution', window );">Number of shares issued immediately for employer's contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,794<span></span>
</td>
<td class="nump">104,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46,000,000<span></span>
</td>
<td class="nump">&#8364; 31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease', window );">Number of restricted shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,072,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease', window );">Number of restricted shares alloted in regards of capital increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_SanofiMember', window );">Sanofi | Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions', window );">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease', window );">Capital increase by issuance of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,886,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CancellationOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of treasury stock cancelled during the period. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CancellationOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B9<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B9_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph B10<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B10_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 160<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_160_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Further shares as an employers contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IssuanceOfFurtherSharesAsAnEmployersContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Restricted Shares Alloted In Regards Of Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares issued in regards of capital increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Restricted Shares Vested In Regards Of Capital Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in regards of capital increase by exercise of stock subscription options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subscribed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PerShareValueOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per Share Value of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PerShareValueOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfSanofisShareCapitalAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Sanofi's Share Capital Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfSanofisShareCapitalAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareRepurchaseProgramAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Amount Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareRepurchaseProgramAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareRepurchaseProgramPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of share repurchase program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareRepurchaseProgramPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=sny_ShareRepurchase2025ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=sny_ShareRepurchase2025ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_LOrealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_LOrealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=sny_ShareRepurchase2026ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=sny_ShareRepurchase2026ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeeShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Summary of Treasury Shares Held (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesHeld', window );">Number of shares (in shares)</a></td>
<td class="nump">16,030<span></span>
</td>
<td class="nump">11,960<span></span>
</td>
<td class="nump">10,660<span></span>
</td>
<td class="nump">9,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfShareCapitalForThePeriod', window );">% of share capital for the period</a></td>
<td class="nump">1.32%<span></span>
</td>
<td class="nump">0.981%<span></span>
</td>
<td class="nump">0.868%<span></span>
</td>
<td class="nump">0.755%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfShareCapitalForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfShareCapitalForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Summary of Principal Characteristics of Restricted Share Plans (Details) - Under 2025 plans<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="nump">&#8364; 329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">3 year service period</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">5,087,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">5 year service period</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Chief executive officer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForFiveYearServicePeriod', window );">Fair value per share awarded for five year service period (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 40.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">3,367,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded for three year service period (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 65.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">1,719,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">With market condition | Excluding general director</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">1,674,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded for three year service period (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 57.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">With market condition | Chief executive officer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Total number of shares awarded (in shares)</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded for three year service period (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 53.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValueOfPlanAtDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of plan at the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValueOfPlanAtDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValuePerShareAwardedForFiveYearServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Per Share Awarded For Five Year Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValuePerShareAwardedForFiveYearServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per share awarded to a three year service period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValuePerShareAwardedForThreeYearServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfYearsServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Years, Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfYearsServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfVestingConditionsAxisAxis=sny_ThreeYearServicePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfVestingConditionsAxisAxis=sny_ThreeYearServicePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfVestingConditionsAxisAxis=sny_FiveYearServicePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfVestingConditionsAxisAxis=sny_FiveYearServicePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithoutMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithoutMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sny_ExcludingChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sny_ExcludingChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Total expense for restricted share plans</a></td>
<td class="nump">&#8364; 138<span></span>
</td>
<td class="nump">&#8364; 146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">12,995,668<span></span>
</td>
<td class="nump">11,550,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2026Member', window );">Under 2026 plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">5,267,518<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member', window );">Under 2025 plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">3,897,342<span></span>
</td>
<td class="nump">4,020,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member', window );">Under 2024 plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">3,772,461<span></span>
</td>
<td class="nump">4,110,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Under 2023 plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">58,347<span></span>
</td>
<td class="nump">3,313,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Under 2022 plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesNotYetFullyVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesNotYetFullyVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Summary of stock subscription option plans (Details) - Stock option plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options, outstanding (in shares) | shares</a></td>
<td class="nump">639,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options, exercisable (in shares) | shares</a></td>
<td class="nump">639,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember', window );">From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options, outstanding (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">1 year 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price per&#160;share, outstanding (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options, exercisable (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember', window );">From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options, outstanding (in shares) | shares</a></td>
<td class="nump">213,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">2 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price per&#160;share, outstanding (in euros per share)</a></td>
<td class="nump">&#8364; 76.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options, exercisable (in shares) | shares</a></td>
<td class="nump">213,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 76.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember', window );">From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number&#160;of options, outstanding (in shares) | shares</a></td>
<td class="nump">257,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual life (years)</a></td>
<td class="text">10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price per&#160;share, outstanding (in euros per share)</a></td>
<td class="nump">&#8364; 88.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options, exercisable (in shares) | shares</a></td>
<td class="nump">257,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 88.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">60.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;60.00 to &#8364;70.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;70.00 to &#8364;80.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | From &#8364;80.00 to &#8364;90.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">&#8364; 90.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_31_b_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Summary of earnings per share (Details) - EUR (&#8364;)<br> &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">&#8364; 1,957.0<span></span>
</td>
<td class="nump">&#8364; 5,812.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Net income from continuing operations</a></td>
<td class="nump">1,931.0<span></span>
</td>
<td class="nump">2,941.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">&#8364; 26.0<span></span>
</td>
<td class="nump">&#8364; 2,871.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="nump">1,200.4<span></span>
</td>
<td class="nump">1,225.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Adjustment for stock options with dilutive effect (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares', window );">Adjustment for restricted shares (in shares)</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Average number of shares used to compute diluted earnings per share (in shares)</a></td>
<td class="nump">1,205.5<span></span>
</td>
<td class="nump">1,230.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive effect of share options on number of restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Summary of number of shares used to compute diluted earnings per share (Details) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic earnings per share from continuing operations (in euros per share)</a></td>
<td class="nump">&#8364; 1.61<span></span>
</td>
<td class="nump">&#8364; 2.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations', window );">Basic earnings per share from discontinued operations (in euros per share)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">2.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted earnings per share from continuing operations (in euros per share)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="nump">2.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations', window );">Diluted earnings per share from discontinued operations (in euros per share)</a></td>
<td class="nump">&#8364; 0.02<span></span>
</td>
<td class="nump">&#8364; 2.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2025-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders' equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="nump">&#8364; 290<span></span>
</td>
<td class="nump">&#8364; 241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="num">(5,318)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures', window );">Actuarial gains/(losses) excluding investments accounted for using the equity method</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures', window );">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments', window );">Tax effects</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss | Equity instruments included in financial assets and financial liabilities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges', window );">Equity risk hedging instruments designated as fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod', window );">Tax effects</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="num">(5,017)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Debt instruments included in financial assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments', window );">Tax effects</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Cash flow hedges and fair value hedges:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax effects</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Change in currency translation differences:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures', window );">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="num">(5,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures', window );">Currency translation differences (investments accounted for using the equity method)</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations', window );">Hedges of net investments in foreign operations</a></td>
<td class="num">(489)<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnTaxEffects', window );">Tax effects</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">&#8364; 146<span></span>
</td>
<td class="nump">&#8364; 459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation before tax excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnTaxEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnTaxEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Debt Instrument Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Risk Hedging Instruments Designated At Fair Value Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_CashFlowAndFairValueHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_CashFlowAndFairValueHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents - Summary of Changes in Financial Position (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">&#8364; 14,646<span></span>
</td>
<td class="nump">&#8364; 14,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">7,026<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">21,893<span></span>
</td>
<td class="nump">18,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="num">(7,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">15,513<span></span>
</td>
<td class="nump">11,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 1,904<span></span>
</td>
<td class="nump">&#8364; 1,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">&#8364; 14,646<span></span>
</td>
<td class="nump">&#8364; 14,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">7,026<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">21,893<span></span>
</td>
<td class="nump">18,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="num">(7,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">15,513<span></span>
</td>
<td class="nump">11,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember', window );">Adjustment to debt measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">14,751<span></span>
</td>
<td class="nump">14,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">7,027<span></span>
</td>
<td class="nump">4,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">21,868<span></span>
</td>
<td class="nump">18,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="num">(7,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 15,488<span></span>
</td>
<td class="nump">&#8364; 11,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AmortizedCostNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)<br> &#8364; in Millions, $ in Billions</strong></div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">&#8364; 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">21,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">15,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">18,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">3,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">21,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">15,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">14,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">14,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">3,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">3,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">7,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | United States | Net Investment Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | Commercial paper program in USA | current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">3,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">14,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (3,338)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 169<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_169&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherBankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other bank borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherBankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_NonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_NonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=sny_NetInvestmentHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=sny_NetInvestmentHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents - Additional Information (Details) - 6 months ended Jun. 30, 2026<br> &#8364; in Millions, $ in Billions</strong></div></th>
<th class="th">
<div>USD ($) </div>
<div>bond </div>
<div>extension </div>
<div>program </div>
<div>credit_facility </div>
<div>tranche</div>
</th>
<th class="th">
<div>EUR (&#8364;) </div>
<div>extension </div>
<div>program </div>
<div>credit_facility </div>
<div>bond</div>
</th>
<th class="th">
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfBondRedeemed', window );">Number of bonds redeemed | bond</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSyndicatedCreditFacilities', window );">Number of syndicated credit facilities | credit_facility</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfShortTermDebtProgram', window );">Number of short-term debt programs | program</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_TwoBillionThreeHundredMillionBondsMember', window );">Two billion three hundred million bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2029Member', window );">Fixed rate bond maturing march 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMay2033Member', window );">Fixed rate bond maturing may 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMay2037Member', window );">Fixed rate bond maturing May 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromMarch2018Member', window );">Fixed rate bond issue from March 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingOnMarch2030Member', window );">Four billion facility maturing on March, 2030 | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member', window );">Three billion eight hundred fifty million facility maturing April 2031 | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOneYearExtensionOptions', window );">Number of one-year extension options | extension</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExtensionTerm', window );">Term of option to extend lease</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingApril2026Member', window );">Four billion facility maturing April 2026 | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember', window );">Commercial paper program in France | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs | $</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown | $</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BorrowingAverageDrawdown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Average Drawdown</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BorrowingAverageDrawdown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extension, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfBondRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Bond Redeemed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfBondRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOneYearExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of One-Year Extension Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOneYearExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfShortTermDebtProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Short-Term Debt Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfShortTermDebtProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSyndicatedCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Syndicated Credit Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSyndicatedCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_TwoBillionThreeHundredMillionBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_TwoBillionThreeHundredMillionBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMarch2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMay2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMay2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMay2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondMaturingMay2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromMarch2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FixedRateBondIssueFromMarch2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingOnMarch2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingOnMarch2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtInstrumentAxis=sny_SanofiEuroMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtInstrumentAxis=sny_SanofiEuroMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents - Summary of Market Value of Net Debt (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">&#8364; 21,893<span></span>
</td>
<td class="nump">&#8364; 18,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">14,989<span></span>
</td>
<td class="nump">10,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Market value</a></td>
<td class="nump">21,868<span></span>
</td>
<td class="nump">18,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RedemptionOfDebtInstrumentIssued', window );">Value on redemption</a></td>
<td class="nump">&#8364; 15,488<span></span>
</td>
<td class="nump">&#8364; 11,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RedemptionOfDebtInstrumentIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of debt instrument issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RedemptionOfDebtInstrumentIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtMarketValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative financial instruments - Summary of Operating Currency Hedging Instruments (Details) - Jun. 30, 2026<br> &#8364; in Millions, R$ in Millions</strong></div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>BRL (R$)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 11,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Brazilian real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Saudi Arabian riyal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">5,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which United Arab Emirates dirham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Brazilian real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Brazilian real | Medley</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place | R$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Saudi Arabian riyal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | of which United Arab Emirates dirham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">11,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which Brazilian real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which Saudi Arabian riyal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">5,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | of which United Arab Emirates dirham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Brazilian real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Saudi Arabian riyal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which United Arab Emirates dirham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which Brazilian real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which Saudi Arabian riyal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | of which United Arab Emirates dirham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which Brazilian real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which Saudi Arabian riyal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | of which United Arab Emirates dirham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which Brazilian real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which Saudi Arabian riyal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which Singapore dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which Chinese yuan renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which Turkish lira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges | of which United Arab Emirates dirham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInBrazilianRealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInBrazilianRealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSaudiArabianRiyalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSaudiArabianRiyalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInTurkishLiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInTurkishLiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisposalGroupAxis=sny_MedleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisposalGroupAxis=sny_MedleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative financial instruments- Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)<br> &#8364; in Millions, R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;) </div>
<div>swaps</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>BRL (R$)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCrossCurrencySwaps', window );">Number of cross currency swaps | swaps</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="nump">&#8364; 14<span></span>
</td>
<td class="num">&#8364; (23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income (cost)</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">&#8364; (177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2029Member', window );">Cross currency swap, expiring 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2032Member', window );">Cross currency swap, expiring 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapMember', window );">Cross currency swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income (cost)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member', window );">Forward currency sales In US dollar, expiring in 2026 and 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="num">(222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income (cost)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member', window );">Forward currency sales in BRL, expiring in 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | R$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income (cost)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember', window );">Forward currency purchases in US dollar, US bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income (cost)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">29,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cross currency seller swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which US dollar | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">16,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which US dollar | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">13,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Pound sterling | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Brazilian real | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">11,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which US dollar | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">8,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Singapore dollar | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">1,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | of which Hungarian forint | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cross currency seller swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which US dollar | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which US dollar | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Pound sterling | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Brazilian real | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which US dollar | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Singapore dollar | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | of which Hungarian forint | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">&#8364; 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in US dollar, US bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments to manage financial exposure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstrumentsToManageFinancialExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Cross Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapExpiring2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarUSBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CrossCurrencySellerSwapsInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInPoundSterlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInPoundSterlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInBrazilianRealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInBrazilianRealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInHungarianFlorintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesInHungarianFlorintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative financial instruments - Disclosure of Instruments (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 4,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">3,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember', window );">pay 2.08% / receive Euribor 3M | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember', window );">pay 3.77% / receive capitalized SOFR + 46bps | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member', window );">pay capitalized SOFR USD/ receive 1.03% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member', window );">pay capitalized SOFR USD/ receive 1.32% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember', window );">pay 3.82% / receive capitalized SOFR USD + 54 bps | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">pay capitalized Ester/receive 0.92% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member', window );">pay capitalized Ester / receive 2.53% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member', window );">pay capitalized Ester / receive 2.71% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount | 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Notional amount | 2030 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Fair value | Fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member', window );">pay capitalized Ester / receive 2.91% | Value of hedge recognized in equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">&#8364; 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current portion</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">&#8364; 585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising from acquisition of Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember', window );">CVRs issued in connection with the acquisition of Blueprint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember', window );">CVRs issued in connection with the acquisition of Vigil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward', window );"><strong>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests', window );">Currency translation differences</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2025-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 95<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_95_d_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through net exchange differences business combinations and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="nump">&#8364; 652<span></span>
</td>
<td class="nump">&#8364; 585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising from acquisition of Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="nump">&#8364; 585<span></span>
</td>
<td class="nump">&#8364; 531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageIncreaseInFairValueLiabilities', window );">Increase in fair value of liability</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageIncreaseInFairValueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in fair value liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageIncreaseInFairValueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-current provisions and other non-current liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 4,592<span></span>
</td>
<td class="nump">&#8364; 4,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">2,256<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Non-current provisions</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">&#8364; 6,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Later than one year and not later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">&#8364; 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-current Provisions [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current provisions and other non-current liabilities - Summary of Movements in Non-Current Provisions (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">&#8364; 4,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities', window );">Increases in provisions and other liabilities</a></td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">4,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember', window );">Provisions for pensions &amp; other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities', window );">Increases in provisions and other liabilities</a></td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember', window );">Provisions for other long-term benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities', window );">Increases in provisions and other liabilities</a></td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember', window );">Restructuring provisions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities', window );">Increases in provisions and other liabilities</a></td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember', window );">Other provisions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">1,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities', window );">Increases in provisions and other liabilities</a></td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">&#8364; 1,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2025-01-01<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 257<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_257_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInProvisionsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Provisions And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInProvisionsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains and losses on defined-benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest related to employees benefits and unwinding of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current provisions and other non-current liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">United Kingdom | Actuarial assumption of expected rates of inflation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase in actuarial assumption</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Decrease in actuarial assumption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | Opella Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on benefit obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember', window );">Plan assets | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on plan assets</a></td>
<td class="nump">&#8364; 71<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember', window );">Present value of defined benefit obligation | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) on benefit obligations</a></td>
<td class="nump">&#8364; 86<span></span>
</td>
<td class="nump">&#8364; 152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [domain]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 207<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_207_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off balance sheet commitments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_CTTQMember', window );">CTTQ | CTTQ Rovidicitinib license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontLicensePayment', window );">Upfront license payment</a></td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments', window );">Collaboration agreement development, regulatory and sales milestone payments</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_KaliTherapeuticsMember', window );">Kali Therapeutics | Kali Therapeutics License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontLicensePayment', window );">Upfront license payment</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments', window );">Collaboration agreement development, regulatory and sales milestone payments</a></td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Development Regulatory And Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UpfrontLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront License Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UpfrontLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_CTTQMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_CTTQMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_CTTQRovidicitinibLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_CTTQRovidicitinibLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_KaliTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_KaliTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_KaliTherapeuticsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_KaliTherapeuticsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation and arbitration proceedings (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>case</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>aspects </div>
<div>defendant</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>proceeding</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>proceeding</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>proceeding</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_TalcProductLitigationInTheUSMember', window );">Talc product litigation in the US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClassActionLawsuits', window );">Number of class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_DupixentProductLitigationInTheUSMember', window );">Dupixent product litigation in the US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfProductLiabilityCases', window );">Number of product liability cases | case</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCasesFiledInNewJerseyCourt', window );">Number of cases filed in New Jersey court | case</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember', window );">University of Washington and Harborview medical center | 340B Drug Pricing Program in the US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClassActionLawsuits', window );">Number of class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_HudsonHeadwatersHealthNetworkMember', window );">Hudson Headwaters Health Network | 340B Drug Pricing Program in the US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClassActionLawsuits', window );">Number of class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_MosaicHealthInTheUSMember', window );">Mosaic Health in the US | 340B Drug Pricing Program in the US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOtherDefendantsInLegalProceeding', window );">Number of other manufacturers in legal proceeding | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfLegalDecisionAspectsChallenged', window );">Number of legal decision aspects challenged | aspects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal and arbitral proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCasesFiledInNewJerseyCourt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Cases Filed In New Jersey Court</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCasesFiledInNewJerseyCourt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfLegalDecisionAspectsChallenged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Legal Decision Aspects Challenged</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfLegalDecisionAspectsChallenged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOtherDefendantsInLegalProceeding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Defendants In Legal Proceeding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOtherDefendantsInLegalProceeding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfProductLiabilityCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Liability Cases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfProductLiabilityCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_TalcProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_TalcProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_DupixentProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_DupixentProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_A340BDrugPricingProgramInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_A340BDrugPricingProgramInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_HudsonHeadwatersHealthNetworkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_HudsonHeadwatersHealthNetworkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_MosaicHealthInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_MosaicHealthInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income and expenses - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">&#8364; 800<span></span>
</td>
<td class="nump">&#8364; 533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expense</a></td>
<td class="nump">&#8364; 3,436<span></span>
</td>
<td class="nump">&#8364; 2,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income and expenses - Schedule of Other Operating Expenses (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossOnDivestmentOfProducts', window );">Net gains / (losses) on disposals of operating assets or businesses</a></td>
<td class="nump">&#8364; 241<span></span>
</td>
<td class="nump">&#8364; 344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherOperatingIncome', window );">Total other operating income</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Miscellaneous other operating expense</a></td>
<td class="num">(3,436)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherOperatingExpense', window );">Total other operating expenses</a></td>
<td class="num">(3,436)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AmvuttraMember', window );">Amvuttra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeResultingFromOutLicensing', window );">Amvuttra licensing income</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_RegeneronMember', window );">Regeneron | Share of profit or loss from commercialization of monoclonal antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Miscellaneous other operating expense</a></td>
<td class="num">(3,486)<span></span>
</td>
<td class="num">(2,475)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_RegeneronMember', window );">Regeneron | Additional profit share for development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_RegeneronMember', window );">Regeneron | Commercialization related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Miscellaneous other operating expense</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Miscellaneous other operating expense</a></td>
<td class="num">&#8364; (208)<span></span>
</td>
<td class="num">&#8364; (149)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income (expenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherOperatingIncomeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossOnDivestmentOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains on divestment of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossOnDivestmentOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeResultingFromOutLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Resulting From Out-Licensing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeResultingFromOutLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AmvuttraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AmvuttraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_AdditionalProfitShareForDevelopmentCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_AdditionalProfitShareForDevelopmentCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_CommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sny_CommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses', window );">Employee-related expenses</a></td>
<td class="nump">&#8364; 284<span></span>
</td>
<td class="nump">&#8364; 201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories', window );">Charges, gains or losses on assets</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts', window );">Costs of transformation programs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherRestructuringCosts', window );">Others</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Total</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">&#8364; 430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember', window );">Dynavax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherRestructuringCosts', window );">Others</a></td>
<td class="nump">&#8364; 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense of restructuring activities related to property plant and equipment to inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Of Restructuring Activities, Transformation Programs Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_DynavaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other gains and losses, and litigation (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other losses and litigation</a></td>
<td class="nump">&#8364; 95<span></span>
</td>
<td class="nump">&#8364; 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses and income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Cost of debt</a></td>
<td class="num">&#8364; (253)<span></span>
</td>
<td class="num">&#8364; (219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestIncome', window );">Interest income</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CostOfDebtNet', window );">Cost of net debt</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonOperatingForeignExchangeGainsLosses', window );">Non-operating foreign exchange gains/(losses)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Unwinding of discounting of provisions</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestCostRelatedToEmployeeBenefits', window );">Net interest cost related to employee benefits</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals', window );">Impairment losses on financial assets, net of reversals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Net interest expense on lease liabilities</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income/(expenses)</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(465)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties', window );">Liability recognised for estimated future royalties</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember', window );">Interest rate and currency derivatives used to hedge debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnDerivativesUsedToManageDebt', window );">Gain on derivatives used to manage debt</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents', window );">Gain on derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">&#8364; 6<span></span>
</td>
<td class="num">&#8364; (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 115<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_115_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CostOfDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of debt net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CostOfDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent detailed information about finance income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on derivatives used to manage cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentLossesOnFinancialAssetsNetOfReversals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Losses On Financial Assets, Net Of Reversals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentLossesOnFinancialAssetsNetOfReversals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Recognised For Estimated Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilityRecognisedForEstimatedFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetInterestCostRelatedToEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest cost related to employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetInterestCostRelatedToEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonOperatingForeignExchangeGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-operating foreign exchange gains/(losses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonOperatingForeignExchangeGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current taxes</a></td>
<td class="num">&#8364; (1,089)<span></span>
</td>
<td class="num">&#8364; (1,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred taxes</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total</a></td>
<td class="num">(871)<span></span>
</td>
<td class="num">(711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 2,840<span></span>
</td>
<td class="nump">&#8364; 3,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 193<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_193_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 193<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_193_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph f<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_f_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2025-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 192<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_192&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Standard tax rate applicable in France</a></td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Difference between the standard French tax rate and the rates applicable to Sanofi</a></td>
<td class="num">(17.90%)<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxEffectRelatedToAmlitelimab', window );">Tax effect related to amlitelimab</a></td>
<td class="nump">19.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes', window );">Revisions to tax exposures and settlements of tax disputes</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">30.60%<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes', window );">Current tax expense (income), related to Pillar Two income taxes</a></td>
<td class="nump">&#8364; 57<span></span>
</td>
<td class="nump">&#8364; 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) related to Pillar Two income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 88B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_88B&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 197<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_197&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 197<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_197&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 194<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_194_c_ii&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revisions to tax exposures and settlements of tax disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxEffectRelatedToAmlitelimab">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Related To Amlitelimab</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxEffectRelatedToAmlitelimab</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers - Disclosures about major customers and credit risk (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 22,106<span></span>
</td>
<td class="nump">&#8364; 19,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_DupixentMember', window );">Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">9,324<span></span>
</td>
<td class="nump">7,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember', window );">ALTUVIIIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember', window );">Fabrazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_NexviazymeNexviadymeMember', window );">Nexviazyme/Nexviadyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember', window );">Cerezyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_AyvakitMember', window );">Ayvakit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember', window );">Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_LantusMember', window );">Lantus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember', window );">Toujeo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_PlavixMember', window );">Plavix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember', window );">Lovenox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_RezurockMember', window );">Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember', window );">Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember', window );">Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesBeyfortusMember', window );">RSV vaccines (Beyfortus)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicsVaccinesMember', window );">Meningitis, travel and endemics vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_COVID19AndInfluenzaVaccinesMember', window );">COVID-19 and Influenza vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_LaunchesMember', window );">Of which total launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,047<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,304<span></span>
</td>
<td class="nump">4,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | ALTUVIIIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Fabrazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Nexviazyme/Nexviadyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Cerezyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Ayvakit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Lantus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Toujeo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Plavix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Lovenox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | RSV vaccines (Beyfortus)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Meningitis, travel and endemics vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | COVID-19 and Influenza vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Of which total launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">11,633<span></span>
</td>
<td class="nump">9,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,922<span></span>
</td>
<td class="nump">5,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | ALTUVIIIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Fabrazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Nexviazyme/Nexviadyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Cerezyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Ayvakit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Lantus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Toujeo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Plavix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Lovenox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | RSV vaccines (Beyfortus)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Meningitis, travel and endemics vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | COVID-19 and Influenza vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Of which total launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,169<span></span>
</td>
<td class="nump">6,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Dupixent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | ALTUVIIIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Fabrazyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Nexviazyme/Nexviadyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Cerezyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Ayvakit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Sarclisa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Lantus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Toujeo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Plavix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Lovenox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Rezurock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | RSV vaccines (Beyfortus)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Meningitis, travel and endemics vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | COVID-19 and Influenza vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Of which total launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 610<span></span>
</td>
<td class="nump">&#8364; 473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_DupixentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_DupixentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_NexviazymeNexviadymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_NexviazymeNexviadymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AyvakitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AyvakitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_LantusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_LantusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_PlavixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_PlavixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_RezurockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_RezurockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesBeyfortusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesBeyfortusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicsVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicsVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_COVID19AndInfluenzaVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_COVID19AndInfluenzaVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_LaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_LaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers - Disclosure of other revenue (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 1,438<span></span>
</td>
<td class="nump">&#8364; 1,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevenueFromVaxServeSalesOfNonSanofiProducts', window );">VaxServe sales of non-Sanofi products</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations', window );">Sales to Opella</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalties</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherRevenue', window );">Other</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 270<span></span>
</td>
<td class="nump">&#8364; 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous other revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from intragroup sales from continuing to discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevenueFromVaxServeSalesOfNonSanofiProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from VaxServe sales of non-Sanofi products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevenueFromVaxServeSalesOfNonSanofiProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Additional Information (Details) - segment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisposalGroupAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProportionOfOwnershipInterestDisposedInSubsidiary', window );">Proportion of ownership interest disposed in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ProportionOfOwnershipInterestDisposedInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proportion Of Ownership Interest Disposed In Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ProportionOfOwnershipInterestDisposedInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisposalGroupAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisposalGroupAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Segment Results (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 22,106<span></span>
</td>
<td class="nump">&#8364; 19,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(6,155)<span></span>
</td>
<td class="num">(5,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,980)<span></span>
</td>
<td class="num">(3,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(4,792)<span></span>
</td>
<td class="num">(4,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 22,106<span></span>
</td>
<td class="nump">19,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage', window );">Change in revenue, on a reported basis (IFRS), percentage</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage', window );">Change in revenue, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 1,168<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage', window );">Change in other revenue, on a reported basis (IFRS), percentage</a></td>
<td class="num">(6.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage', window );">Change in other revenue, at constant exchange rates non-IFRS, percentage</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">&#8364; (5,812)<span></span>
</td>
<td class="num">(5,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage', window );">Change in cost of sales, on a reported basis (IFRS), percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS', window );">Change in cost of sales, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">&#8364; (3,979)<span></span>
</td>
<td class="num">(3,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage', window );">Change in research and development expenses, on a reported basis (IFRS), percentage</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage', window );">Change in research and development expenses, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">&#8364; (4,690)<span></span>
</td>
<td class="num">(4,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage', window );">Change in selling and general expenses, on a reported basis (IFRS), percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage', window );">Change in selling and general expenses, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">&#8364; (2,630)<span></span>
</td>
<td class="num">(1,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">&#8364; 6,230<span></span>
</td>
<td class="nump">5,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage', window );">Change in business operating income, on a reported basis (IFRS), percentage</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage', window );">Change in business operating income, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">22.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncomeAsPercentOfNetSales', window );">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</a></td>
<td class="nump">28.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 270<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage', window );">Change in other revenue, on a reported basis (IFRS), percentage</a></td>
<td class="nump">31.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage', window );">Change in other revenue, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">31.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">&#8364; (133)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage', window );">Change in cost of sales, on a reported basis (IFRS), percentage</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS', window );">Change in cost of sales, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage', window );">Change in research and development expenses, on a reported basis (IFRS), percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage', window );">Change in research and development expenses, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">&#8364; (102)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage', window );">Change in selling and general expenses, on a reported basis (IFRS), percentage</a></td>
<td class="nump">72.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage', window );">Change in selling and general expenses, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">76.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">&#8364; (6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">&#8364; 28<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage', window );">Change in business operating income, on a reported basis (IFRS), percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage', window );">Change in business operating income, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">68.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 22,106<span></span>
</td>
<td class="nump">19,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage', window );">Change in revenue, on a reported basis (IFRS), percentage</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage', window );">Change in revenue, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">&#8364; 1,438<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage', window );">Change in other revenue, on a reported basis (IFRS), percentage</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage', window );">Change in other revenue, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">&#8364; (5,945)<span></span>
</td>
<td class="num">(5,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage', window );">Change in cost of sales, on a reported basis (IFRS), percentage</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS', window );">Change in cost of sales, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">&#8364; (3,980)<span></span>
</td>
<td class="num">(3,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage', window );">Change in research and development expenses, on a reported basis (IFRS), percentage</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage', window );">Change in research and development expenses, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">&#8364; (4,792)<span></span>
</td>
<td class="num">(4,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage', window );">Change in selling and general expenses, on a reported basis (IFRS), percentage</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage', window );">Change in selling and general expenses, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">&#8364; (2,636)<span></span>
</td>
<td class="num">(1,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">&#8364; 6,258<span></span>
</td>
<td class="nump">&#8364; 5,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage', window );">Change in business operating income, on a reported basis (IFRS), percentage</a></td>
<td class="nump">16.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage', window );">Change in business operating income, at constant exchange rates non-IFRS, percentage</a></td>
<td class="nump">22.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncomeAsPercentOfNetSales', window );">&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales</a></td>
<td class="nump">28.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 266<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_266&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncomeAsPercentOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Operating Income As Percent Of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncomeAsPercentOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Business Operating Income, At Constant Exchange Rates Non-IFRS, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Business Operating Income, On A Reported Basis (IFRS), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cost Of sales At Constant Exchange Rates Non-IFRS), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cost Of Sales, On A Reported Basis (IFRS), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Other Revenue, At Constant Exchange Rates Non-IFRS, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Other Revenue, On A Reported Basis (IFRS), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Research And Development Expenses, At Constant Exchange Rates Non-IFRS, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Research And Development Expenses, On A Reported Basis (IFRS), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Revenue, At Constant Exchange Rates Non-IFRS, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Revenue, On A Reported Basis (IFRS), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Selling And General Expenses, At Constant Exchange Rates Non-IFRS, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Selling And General Expenses, On A Reported Basis (IFRS), Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 40<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization of intangible assets</a></td>
<td class="num">(1,087)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">(1,031)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="num">(563)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">3,168<span></span>
</td>
<td class="nump">3,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(465)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AmlitelimabAssetMember', window );">Amlitelimab asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">(952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">6,258<span></span>
</td>
<td class="nump">5,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember', window );">Material reconciling items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization of intangible assets</a></td>
<td class="num">(1,087)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">(1,031)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories', window );">Expense arising from the impact of acquisitions on inventories</a></td>
<td class="num">(210)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="num">(563)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="num">&#8364; (95)<span></span>
</td>
<td class="num">&#8364; (57)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_vi&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e_iv&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2025-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2025-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses arising from the impact of acquisitions on inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AmlitelimabAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AmlitelimabAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 3,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">&#8364; 483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="nump">&#8364; 414<span></span>
</td>
<td class="nump">&#8364; 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 89<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_89&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 89<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_89&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2025-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 22,106<span></span>
</td>
<td class="nump">&#8364; 19,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">10,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">26,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">4,304<span></span>
</td>
<td class="nump">4,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">5,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">3,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">of which France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">3,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">11,633<span></span>
</td>
<td class="nump">9,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">21,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember', window );">Rest of the World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,169<span></span>
</td>
<td class="nump">6,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CN', window );">of which China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">&#8364; 1,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2025-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 263<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_263_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2025-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2027-01-01<br> -Name IFRS<br> -Number 19<br> -IssueDate 2025-01-01<br> -Paragraph 200<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=19&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_200_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesExcludingEuropeAndNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information- Principal Customers and Credit Risk (Details) - customer<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfLargestCustomers', window );">Number of largest customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember', window );">Certain wholesalers in the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember', window );">Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember', window );">Customer two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember', window );">Customer three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2025-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about major customers and credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfLargestCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Largest Customers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfLargestCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CertainWholesalersInTheUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Information related to Opella, presented within discontinued operations (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income from discontinued operations</a></td>
<td class="nump">&#8364; 26<span></span>
</td>
<td class="nump">&#8364; 2,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisposalGroupAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations', window );">Net sales and other revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations', window );">Operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations', window );">Gain on disposal of Opella before tax</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations', window );">Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">3,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations', window );">Income tax expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net income from discontinued operations</a></td>
<td class="nump">&#8364; 26<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember', window );">Opella Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (88)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2025-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2025-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2025-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2025-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2025-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2027-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2025-01-01<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2025-en-b&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2025-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on Disposal of Opella, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Revenue, Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Disposal Group Including Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisposalGroupAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisposalGroupAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>736</ContextCount>
  <ElementCount>456</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>206</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>20</UnitCount>
  <MyReports>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedbalancesheets</Role>
      <ShortName>Consolidated balance sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated income statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedincomestatements</Role>
      <ShortName>Consolidated income statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated statements of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome</Role>
      <ShortName>Consolidated statements of comprehensive income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated statements of changes in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity</Role>
      <ShortName>Consolidated statements of changes in equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedstatementsofcashflows</Role>
      <ShortName>Consolidated statements of cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated statements of cash flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical</Role>
      <ShortName>Consolidated statements of cash flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Introduction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Introduction</Role>
      <ShortName>Introduction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies</Role>
      <ShortName>Basis of preparation of the half-year financial statements and accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Significant information for the first half of 2026</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026</Role>
      <ShortName>Significant information for the first half of 2026</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Goodwill and other intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Goodwillandotherintangibleassets</Role>
      <ShortName>Goodwill and other intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Impairment of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Impairmentofintangibleassets</Role>
      <ShortName>Impairment of intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Investments accounted for using the equity method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod</Role>
      <ShortName>Investments accounted for using the equity method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Other non-current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Othernoncurrentassets</Role>
      <ShortName>Other non-current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Accounts receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Accountsreceivable</Role>
      <ShortName>Accounts receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Consolidated shareholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedshareholdersequity</Role>
      <ShortName>Consolidated shareholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Debt, cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Debtcashandcashequivalents</Role>
      <ShortName>Debt, cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Derivative financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Derivativefinancialinstruments</Role>
      <ShortName>Derivative financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Liabilities related to business combinations and to non-controlling interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Non-current provisions and other non-current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Noncurrentprovisionsandothernoncurrentliabilities</Role>
      <ShortName>Non-current provisions and other non-current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Off balance sheet commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Offbalancesheetcommitments</Role>
      <ShortName>Off balance sheet commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Litigation and arbitration proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Litigationandarbitrationproceedings</Role>
      <ShortName>Litigation and arbitration proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Other operating income and expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Otheroperatingincomeandexpenses</Role>
      <ShortName>Other operating income and expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Restructuring costs and similar items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Restructuringcostsandsimilaritems</Role>
      <ShortName>Restructuring costs and similar items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Other gains and losses, and litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Othergainsandlossesandlitigation</Role>
      <ShortName>Other gains and losses, and litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Financial expenses and income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Financialexpensesandincome</Role>
      <ShortName>Financial expenses and income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Incometaxexpense</Role>
      <ShortName>Income tax expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Revenuefromcontractswithcustomers</Role>
      <ShortName>Revenue from contracts with customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Segmentinformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9952180 - Disclosure - Information related to Opella, presented within discontinued operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperations</Role>
      <ShortName>Information related to Opella, presented within discontinued operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies</Role>
      <ShortName>Basis of preparation of the half-year financial statements and accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables</Role>
      <ShortName>Basis of preparation of the half-year financial statements and accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Significant information for the first half of 2026 (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026Tables</Role>
      <ShortName>Significant information for the first half of 2026 (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Propertyplantandequipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Goodwill and other intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables</Role>
      <ShortName>Goodwill and other intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Goodwillandotherintangibleassets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Investments accounted for using the equity method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables</Role>
      <ShortName>Investments accounted for using the equity method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Other non-current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthernoncurrentassetsTables</Role>
      <ShortName>Other non-current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Othernoncurrentassets</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Accounts receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableTables</Role>
      <ShortName>Accounts receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Accountsreceivable</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Consolidated shareholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequityTables</Role>
      <ShortName>Consolidated shareholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Consolidatedshareholdersequity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Debt, cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsTables</Role>
      <ShortName>Debt, cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Debtcashandcashequivalents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Derivative financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsTables</Role>
      <ShortName>Derivative financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Derivativefinancialinstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Liabilities related to business combinations and to non-controlling interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Non-current provisions and other non-current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables</Role>
      <ShortName>Non-current provisions and other non-current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Noncurrentprovisionsandothernoncurrentliabilities</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Other operating income and expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtheroperatingincomeandexpensesTables</Role>
      <ShortName>Other operating income and expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Otheroperatingincomeandexpenses</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Restructuring costs and similar items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables</Role>
      <ShortName>Restructuring costs and similar items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Restructuringcostsandsimilaritems</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Financial expenses and income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialexpensesandincomeTables</Role>
      <ShortName>Financial expenses and income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Financialexpensesandincome</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Income tax expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncometaxexpenseTables</Role>
      <ShortName>Income tax expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Incometaxexpense</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Revenue from contracts with customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables</Role>
      <ShortName>Revenue from contracts with customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Revenuefromcontractswithcustomers</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Segment information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationTables</Role>
      <ShortName>Segment information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Segmentinformation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Information related to Opella, presented within discontinued operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables</Role>
      <ShortName>Information related to Opella, presented within discontinued operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperations</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails</Role>
      <ShortName>Basis of preparation of the half-year financial statements and accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Significant information for the first half of 2026 - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails</Role>
      <ShortName>Significant information for the first half of 2026 - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Significant information for the first half of 2026 - Summary of detailed information about business combination Dynavax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails</Role>
      <ShortName>Significant information for the first half of 2026 - Summary of detailed information about business combination Dynavax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails</Role>
      <ShortName>Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Property, plant and equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails</Role>
      <ShortName>Property, plant and equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Goodwill and other intangible assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and other intangible assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Impairment of intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails</Role>
      <ShortName>Impairment of intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Impairmentofintangibleassets</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails</Role>
      <ShortName>Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Investments accounted for using the equity method - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails</Role>
      <ShortName>Investments accounted for using the equity method - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Investments accounted for using the equity method - Summary of Key Items Which Have Not Been Audited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails</Role>
      <ShortName>Investments accounted for using the equity method - Summary of Key Items Which Have Not Been Audited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Other non-current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthernoncurrentassetsDetails</Role>
      <ShortName>Other non-current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OthernoncurrentassetsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Accounts receivable - Summary of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails</Role>
      <ShortName>Accounts receivable - Summary of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Accounts receivable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails</Role>
      <ShortName>Accounts receivable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails</Role>
      <ShortName>Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Consolidated shareholders' equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails</Role>
      <ShortName>Consolidated shareholders' equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Consolidated shareholders' equity - Summary of Treasury Shares Held (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails</Role>
      <ShortName>Consolidated shareholders' equity - Summary of Treasury Shares Held (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Consolidated shareholders' equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails</Role>
      <ShortName>Consolidated shareholders' equity - Summary of Principal Characteristics of Restricted Share Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Consolidated shareholders' equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails</Role>
      <ShortName>Consolidated shareholders' equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Consolidated shareholders' equity - Summary of stock subscription option plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails</Role>
      <ShortName>Consolidated shareholders' equity - Summary of stock subscription option plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Consolidated shareholders' equity - Summary of earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails</Role>
      <ShortName>Consolidated shareholders' equity - Summary of earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Consolidated shareholders' equity - Summary of number of shares used to compute diluted earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails</Role>
      <ShortName>Consolidated shareholders' equity - Summary of number of shares used to compute diluted earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Consolidated shareholders' equity - Summary of Movements within Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails</Role>
      <ShortName>Consolidated shareholders' equity - Summary of Movements within Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Debt, cash and cash equivalents - Summary of Changes in Financial Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails</Role>
      <ShortName>Debt, cash and cash equivalents - Summary of Changes in Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Debt, cash and cash equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails</Role>
      <ShortName>Debt, cash and cash equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Debt, cash and cash equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails</Role>
      <ShortName>Debt, cash and cash equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Debt, cash and cash equivalents - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails</Role>
      <ShortName>Debt, cash and cash equivalents - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Debt, cash and cash equivalents - Summary of Market Value of Net Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails</Role>
      <ShortName>Debt, cash and cash equivalents - Summary of Market Value of Net Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Derivative financial instruments - Summary of Operating Currency Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails</Role>
      <ShortName>Derivative financial instruments - Summary of Operating Currency Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Derivative financial instruments- Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails</Role>
      <ShortName>Derivative financial instruments- Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Derivative financial instruments - Disclosure of Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails</Role>
      <ShortName>Derivative financial instruments - Disclosure of Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Non-current provisions and other non-current liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Non-current provisions and other non-current liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Non-current provisions and other non-current liabilities - Summary of Movements in Non-Current Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails</Role>
      <ShortName>Non-current provisions and other non-current liabilities - Summary of Movements in Non-Current Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Non-current provisions and other non-current liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails</Role>
      <ShortName>Non-current provisions and other non-current liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Off balance sheet commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails</Role>
      <ShortName>Off balance sheet commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Offbalancesheetcommitments</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Litigation and arbitration proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails</Role>
      <ShortName>Litigation and arbitration proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Litigationandarbitrationproceedings</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Other operating income and expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtheroperatingincomeandexpensesAdditionalInformationDetails</Role>
      <ShortName>Other operating income and expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Other operating income and expenses - Schedule of Other Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails</Role>
      <ShortName>Other operating income and expenses - Schedule of Other Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails</Role>
      <ShortName>Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Other gains and losses, and litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails</Role>
      <ShortName>Other gains and losses, and litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Othergainsandlossesandlitigation</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Financial expenses and income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialexpensesandincomeDetails</Role>
      <ShortName>Financial expenses and income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/FinancialexpensesandincomeTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails</Role>
      <ShortName>Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails</Role>
      <ShortName>Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Revenue from contracts with customers - Disclosures about major customers and credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails</Role>
      <ShortName>Revenue from contracts with customers - Disclosures about major customers and credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Revenue from contracts with customers - Disclosure of other revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails</Role>
      <ShortName>Revenue from contracts with customers - Disclosure of other revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Segment information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails</Role>
      <ShortName>Segment information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Segment information - Schedule of Segment Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails</Role>
      <ShortName>Segment information - Schedule of Segment Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails</Role>
      <ShortName>Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails</Role>
      <ShortName>Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails</Role>
      <ShortName>Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Segment information- Principal Customers and Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails</Role>
      <ShortName>Segment information- Principal Customers and Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="sny-20260630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Information related to Opella, presented within discontinued operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails</Role>
      <ShortName>Information related to Opella, presented within discontinued operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="sny-20260630.htm">sny-20260630.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="sny-20260630_d2.htm">sny-20260630_d2.htm</File>
    <File>sny-20260630.xsd</File>
    <File>sny-20260630_cal.xml</File>
    <File>sny-20260630_def.xml</File>
    <File>sny-20260630_lab.xml</File>
    <File>sny-20260630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1091">https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sny-20260630.htm sny-20260630_d2.htm": {
   "nsprefix": "sny",
   "nsuri": "http://www.sanofi.com/20260630",
   "dts": {
    "inline": {
     "local": [
      "sny-20260630.htm",
      "sny-20260630_d2.htm"
     ]
    },
    "schema": {
     "local": [
      "sny-20260630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sny-20260630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sny-20260630_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml",
      "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sny-20260630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sny-20260630_pre.xml"
     ]
    }
   },
   "keyStandard": 237,
   "keyCustom": 219,
   "axisStandard": 39,
   "axisCustom": 7,
   "memberStandard": 52,
   "memberCustom": 148,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2025": 6,
    "http://www.sanofi.com/20260630": 1
   },
   "contextCount": 736,
   "entityCount": 1,
   "segmentCount": 206,
   "elementCount": 851,
   "unitCount": 20,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1091,
    "http://xbrl.sec.gov/dei/2025": 8,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://www.sanofi.com/role/Coverpage",
     "longName": "0000001 - Document - Cover page",
     "shortName": "Cover page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.sanofi.com/role/Consolidatedbalancesheets",
     "longName": "9952151 - Statement - Consolidated balance sheets",
     "shortName": "Consolidated balance sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.sanofi.com/role/Consolidatedincomestatements",
     "longName": "9952152 - Statement - Consolidated income statements",
     "shortName": "Consolidated income statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GrossProfit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome",
     "longName": "9952153 - Statement - Consolidated statements of comprehensive income",
     "shortName": "Consolidated statements of comprehensive income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
     "longName": "9952154 - Statement - Consolidated statements of changes in equity",
     "shortName": "Consolidated statements of changes in equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
     "longName": "9952155 - Statement - Consolidated statements of cash flows",
     "shortName": "Consolidated statements of cash flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
     "longName": "9952156 - Statement - Consolidated statements of cash flows (Parenthetical)",
     "shortName": "Consolidated statements of cash flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.sanofi.com/role/Introduction",
     "longName": "9952157 - Disclosure - Introduction",
     "shortName": "Introduction",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.sanofi.com/role/Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies",
     "longName": "9952158 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies",
     "shortName": "Basis of preparation of the half-year financial statements and accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026",
     "longName": "9952159 - Disclosure - Significant information for the first half of 2026",
     "shortName": "Significant information for the first half of 2026",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.sanofi.com/role/Propertyplantandequipment",
     "longName": "9952160 - Disclosure - Property, plant and equipment",
     "shortName": "Property, plant and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.sanofi.com/role/Goodwillandotherintangibleassets",
     "longName": "9952161 - Disclosure - Goodwill and other intangible assets",
     "shortName": "Goodwill and other intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.sanofi.com/role/Impairmentofintangibleassets",
     "longName": "9952162 - Disclosure - Impairment of intangible assets",
     "shortName": "Impairment of intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod",
     "longName": "9952163 - Disclosure - Investments accounted for using the equity method",
     "shortName": "Investments accounted for using the equity method",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.sanofi.com/role/Othernoncurrentassets",
     "longName": "9952164 - Disclosure - Other non-current assets",
     "shortName": "Other non-current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.sanofi.com/role/Accountsreceivable",
     "longName": "9952165 - Disclosure - Accounts receivable",
     "shortName": "Accounts receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.sanofi.com/role/Consolidatedshareholdersequity",
     "longName": "9952166 - Disclosure - Consolidated shareholders' equity",
     "shortName": "Consolidated shareholders' equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.sanofi.com/role/Debtcashandcashequivalents",
     "longName": "9952167 - Disclosure - Debt, cash and cash equivalents",
     "shortName": "Debt, cash and cash equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.sanofi.com/role/Derivativefinancialinstruments",
     "longName": "9952168 - Disclosure - Derivative financial instruments",
     "shortName": "Derivative financial instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests",
     "longName": "9952169 - Disclosure - Liabilities related to business combinations and to non-controlling interests",
     "shortName": "Liabilities related to business combinations and to non-controlling interests",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.sanofi.com/role/Noncurrentprovisionsandothernoncurrentliabilities",
     "longName": "9952170 - Disclosure - Non-current provisions and other non-current liabilities",
     "shortName": "Non-current provisions and other non-current liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.sanofi.com/role/Offbalancesheetcommitments",
     "longName": "9952171 - Disclosure - Off balance sheet commitments",
     "shortName": "Off balance sheet commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.sanofi.com/role/Litigationandarbitrationproceedings",
     "longName": "9952172 - Disclosure - Litigation and arbitration proceedings",
     "shortName": "Litigation and arbitration proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.sanofi.com/role/Otheroperatingincomeandexpenses",
     "longName": "9952173 - Disclosure - Other operating income and expenses",
     "shortName": "Other operating income and expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.sanofi.com/role/Restructuringcostsandsimilaritems",
     "longName": "9952174 - Disclosure - Restructuring costs and similar items",
     "shortName": "Restructuring costs and similar items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.sanofi.com/role/Othergainsandlossesandlitigation",
     "longName": "9952175 - Disclosure - Other gains and losses, and litigation",
     "shortName": "Other gains and losses, and litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.sanofi.com/role/Financialexpensesandincome",
     "longName": "9952176 - Disclosure - Financial expenses and income",
     "shortName": "Financial expenses and income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.sanofi.com/role/Incometaxexpense",
     "longName": "9952177 - Disclosure - Income tax expense",
     "shortName": "Income tax expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.sanofi.com/role/Revenuefromcontractswithcustomers",
     "longName": "9952178 - Disclosure - Revenue from contracts with customers",
     "shortName": "Revenue from contracts with customers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.sanofi.com/role/Segmentinformation",
     "longName": "9952179 - Disclosure - Segment information",
     "shortName": "Segment information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperations",
     "longName": "9952180 - Disclosure - Information related to Opella, presented within discontinued operations",
     "shortName": "Information related to Opella, presented within discontinued operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies",
     "longName": "9955511 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Policies)",
     "shortName": "Basis of preparation of the half-year financial statements and accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables",
     "longName": "9955512 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Tables)",
     "shortName": "Basis of preparation of the half-year financial statements and accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026Tables",
     "longName": "9955513 - Disclosure - Significant information for the first half of 2026 (Tables)",
     "shortName": "Significant information for the first half of 2026 (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentTables",
     "longName": "9955514 - Disclosure - Property, plant and equipment (Tables)",
     "shortName": "Property, plant and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables",
     "longName": "9955515 - Disclosure - Goodwill and other intangible assets (Tables)",
     "shortName": "Goodwill and other intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables",
     "longName": "9955516 - Disclosure - Investments accounted for using the equity method (Tables)",
     "shortName": "Investments accounted for using the equity method (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.sanofi.com/role/OthernoncurrentassetsTables",
     "longName": "9955517 - Disclosure - Other non-current assets (Tables)",
     "shortName": "Other non-current assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.sanofi.com/role/AccountsreceivableTables",
     "longName": "9955518 - Disclosure - Accounts receivable (Tables)",
     "shortName": "Accounts receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables",
     "longName": "9955519 - Disclosure - Consolidated shareholders' equity (Tables)",
     "shortName": "Consolidated shareholders' equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsTables",
     "longName": "9955520 - Disclosure - Debt, cash and cash equivalents (Tables)",
     "shortName": "Debt, cash and cash equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsTables",
     "longName": "9955521 - Disclosure - Derivative financial instruments (Tables)",
     "shortName": "Derivative financial instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables",
     "longName": "9955522 - Disclosure - Liabilities related to business combinations and to non-controlling interests (Tables)",
     "shortName": "Liabilities related to business combinations and to non-controlling interests (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables",
     "longName": "9955523 - Disclosure - Non-current provisions and other non-current liabilities (Tables)",
     "shortName": "Non-current provisions and other non-current liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.sanofi.com/role/OtheroperatingincomeandexpensesTables",
     "longName": "9955524 - Disclosure - Other operating income and expenses (Tables)",
     "shortName": "Other operating income and expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables",
     "longName": "9955525 - Disclosure - Restructuring costs and similar items (Tables)",
     "shortName": "Restructuring costs and similar items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.sanofi.com/role/FinancialexpensesandincomeTables",
     "longName": "9955526 - Disclosure - Financial expenses and income (Tables)",
     "shortName": "Financial expenses and income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.sanofi.com/role/IncometaxexpenseTables",
     "longName": "9955527 - Disclosure - Income tax expense (Tables)",
     "shortName": "Income tax expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables",
     "longName": "9955528 - Disclosure - Revenue from contracts with customers (Tables)",
     "shortName": "Revenue from contracts with customers (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.sanofi.com/role/SegmentinformationTables",
     "longName": "9955529 - Disclosure - Segment information (Tables)",
     "shortName": "Segment information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables",
     "longName": "9955530 - Disclosure - Information related to Opella, presented within discontinued operations (Tables)",
     "shortName": "Information related to Opella, presented within discontinued operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails",
     "longName": "9955531 - Disclosure - Basis of preparation of the half-year financial statements and accounting policies (Details)",
     "shortName": "Basis of preparation of the half-year financial statements and accounting policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:IncomeStatementClassificationIFRS18NumberOfCategories",
      "unitRef": "categorie",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:IncomeStatementClassificationIFRS18NumberOfCategories",
      "unitRef": "categorie",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
     "longName": "9955532 - Disclosure - Significant information for the first half of 2026 - Additional information (Details)",
     "shortName": "Significant information for the first half of 2026 - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-72",
      "name": "sny:PercentageOfOwnershipInterestDisposed",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails",
     "longName": "9955533 - Disclosure - Significant information for the first half of 2026 - Summary of detailed information about business combination Dynavax (Details)",
     "shortName": "Significant information for the first half of 2026 - Summary of detailed information about business combination Dynavax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
       "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
       "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
     "longName": "9955534 - Disclosure - Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "shortName": "Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails",
     "longName": "9955535 - Disclosure - Property, plant and equipment - Additional Information (Details)",
     "shortName": "Property, plant and equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
     "longName": "9955536 - Disclosure - Goodwill and other intangible assets - Additional Information (Details)",
     "shortName": "Goodwill and other intangible assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
     "longName": "9955537 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)",
     "shortName": "Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails",
     "longName": "9955538 - Disclosure - Impairment of intangible assets (Details)",
     "shortName": "Impairment of intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
     "longName": "9955539 - Disclosure - Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)",
     "shortName": "Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "sny:StockPrice",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
     "longName": "9955540 - Disclosure - Investments accounted for using the equity method - Additional Information (Details)",
     "shortName": "Investments accounted for using the equity method - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "9955541 - Disclosure - Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "shortName": "Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-143",
      "name": "sny:SubordinateHybridBondRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "sny:SubordinateHybridBondRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
     "longName": "9955542 - Disclosure - Investments accounted for using the equity method - Summary of Key Items Which Have Not Been Audited (Details)",
     "shortName": "Investments accounted for using the equity method - Summary of Key Items Which Have Not Been Audited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-139",
      "name": "sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.sanofi.com/role/OthernoncurrentassetsDetails",
     "longName": "9955543 - Disclosure - Other non-current assets (Details)",
     "shortName": "Other non-current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
     "longName": "9955544 - Disclosure - Accounts receivable - Summary of Accounts Receivable (Details)",
     "shortName": "Accounts receivable - Summary of Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails",
     "longName": "9955545 - Disclosure - Accounts receivable - Additional Information (Details)",
     "shortName": "Accounts receivable - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails",
     "longName": "9955546 - Disclosure - Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "shortName": "Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
       "sny:DisclosureOfTradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
     "longName": "9955547 - Disclosure - Consolidated shareholders' equity - Additional Information (Details)",
     "shortName": "Consolidated shareholders' equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails",
     "longName": "9955548 - Disclosure - Consolidated shareholders' equity - Summary of Treasury Shares Held (Details)",
     "shortName": "Consolidated shareholders' equity - Summary of Treasury Shares Held (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails",
     "longName": "9955549 - Disclosure - Consolidated shareholders' equity - Summary of Principal Characteristics of Restricted Share Plans (Details)",
     "shortName": "Consolidated shareholders' equity - Summary of Principal Characteristics of Restricted Share Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-178",
      "name": "sny:FairValueOfPlanAtDateOfGrant",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-178",
      "name": "sny:FairValueOfPlanAtDateOfGrant",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
     "longName": "9955550 - Disclosure - Consolidated shareholders' equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "shortName": "Consolidated shareholders' equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-179",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-179",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails",
     "longName": "9955551 - Disclosure - Consolidated shareholders' equity - Summary of stock subscription option plans (Details)",
     "shortName": "Consolidated shareholders' equity - Summary of stock subscription option plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-211",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-211",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails",
     "longName": "9955552 - Disclosure - Consolidated shareholders' equity - Summary of earnings per share (Details)",
     "shortName": "Consolidated shareholders' equity - Summary of earnings per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails",
     "longName": "9955553 - Disclosure - Consolidated shareholders' equity - Summary of number of shares used to compute diluted earnings per share (Details)",
     "shortName": "Consolidated shareholders' equity - Summary of number of shares used to compute diluted earnings per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:BasicEarningsLossPerShareFromContinuingOperations",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
     "longName": "9955554 - Disclosure - Consolidated shareholders' equity - Summary of Movements within Other Comprehensive Income (Details)",
     "shortName": "Consolidated shareholders' equity - Summary of Movements within Other Comprehensive Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
     "longName": "9955555 - Disclosure - Debt, cash and cash equivalents - Summary of Changes in Financial Position (Details)",
     "shortName": "Debt, cash and cash equivalents - Summary of Changes in Financial Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R77": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
     "longName": "9955556 - Disclosure - Debt, cash and cash equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "shortName": "Debt, cash and cash equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-224",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
     "longName": "9955557 - Disclosure - Debt, cash and cash equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "shortName": "Debt, cash and cash equivalents - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "sny:InterestRateAndCurrencyDerivativesUsedToManageDebt",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-226",
      "name": "ifrs-full:BondsIssued",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
     "longName": "9955558 - Disclosure - Debt, cash and cash equivalents - Additional Information (Details)",
     "shortName": "Debt, cash and cash equivalents - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfBondRedeemed",
      "unitRef": "bond",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-238",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails",
     "longName": "9955559 - Disclosure - Debt, cash and cash equivalents - Summary of Market Value of Net Debt (Details)",
     "shortName": "Debt, cash and cash equivalents - Summary of Market Value of Net Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-251",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMarketValueOfNetDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails",
     "longName": "9955560 - Disclosure - Derivative financial instruments - Summary of Operating Currency Hedging Instruments (Details)",
     "shortName": "Derivative financial instruments - Summary of Operating Currency Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-339",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-339",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
     "longName": "9955561 - Disclosure - Derivative financial instruments- Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "shortName": "Derivative financial instruments- Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfCrossCurrencySwaps",
      "unitRef": "swaps",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfCrossCurrencySwaps",
      "unitRef": "swaps",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
     "longName": "9955562 - Disclosure - Derivative financial instruments - Disclosure of Instruments (Details)",
     "shortName": "Derivative financial instruments - Disclosure of Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-339",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-339",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
     "longName": "9955563 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "shortName": "Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
     "longName": "9955564 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)",
     "shortName": "Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-497",
      "name": "sny:PercentageIncreaseInFairValueLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
     "longName": "9955565 - Disclosure - Non-current provisions and other non-current liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)",
     "shortName": "Non-current provisions and other non-current liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
     "longName": "9955566 - Disclosure - Non-current provisions and other non-current liabilities - Summary of Movements in Non-Current Provisions (Details)",
     "shortName": "Non-current provisions and other non-current liabilities - Summary of Movements in Non-Current Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
     "longName": "9955567 - Disclosure - Non-current provisions and other non-current liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)",
     "shortName": "Non-current provisions and other non-current liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-520",
      "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-520",
      "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails",
     "longName": "9955568 - Disclosure - Off balance sheet commitments (Details)",
     "shortName": "Off balance sheet commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-527",
      "name": "sny:UpfrontLicensePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-527",
      "name": "sny:UpfrontLicensePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails",
     "longName": "9955569 - Disclosure - Litigation and arbitration proceedings (Details)",
     "shortName": "Litigation and arbitration proceedings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-529",
      "name": "sny:NumberOfClassActionLawsuits",
      "unitRef": "proceeding",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-529",
      "name": "sny:NumberOfClassActionLawsuits",
      "unitRef": "proceeding",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.sanofi.com/role/OtheroperatingincomeandexpensesAdditionalInformationDetails",
     "longName": "9955570 - Disclosure - Other operating income and expenses - Additional Information (Details)",
     "shortName": "Other operating income and expenses - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R92": {
     "role": "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails",
     "longName": "9955571 - Disclosure - Other operating income and expenses - Schedule of Other Operating Expenses (Details)",
     "shortName": "Other operating income and expenses - Schedule of Other Operating Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:GainsLossOnDivestmentOfProducts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:GainsLossOnDivestmentOfProducts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails",
     "longName": "9955572 - Disclosure - Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)",
     "shortName": "Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails",
     "longName": "9955573 - Disclosure - Other gains and losses, and litigation (Details)",
     "shortName": "Other gains and losses, and litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherGainsLossesAndLitigation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://www.sanofi.com/role/FinancialexpensesandincomeDetails",
     "longName": "9955574 - Disclosure - Financial expenses and income (Details)",
     "shortName": "Financial expenses and income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
     "longName": "9955575 - Disclosure - Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "shortName": "Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails",
     "longName": "9955576 - Disclosure - Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "shortName": "Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails",
     "longName": "9955577 - Disclosure - Revenue from contracts with customers - Disclosures about major customers and credit risk (Details)",
     "shortName": "Revenue from contracts with customers - Disclosures about major customers and credit risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-556",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
     "longName": "9955578 - Disclosure - Revenue from contracts with customers - Disclosure of other revenue (Details)",
     "shortName": "Revenue from contracts with customers - Disclosure of other revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherRevenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOtherRevenueTextBlock",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "sny:RevenueFromVaxServeSalesOfNonSanofiProducts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOtherRevenueTextBlock",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails",
     "longName": "9955579 - Disclosure - Segment information - Additional Information (Details)",
     "shortName": "Segment information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-700",
      "name": "sny:ProportionOfOwnershipInterestDisposedInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-700",
      "name": "sny:ProportionOfOwnershipInterestDisposedInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
     "longName": "9955580 - Disclosure - Segment information - Schedule of Segment Results (Details)",
     "shortName": "Segment information - Schedule of Segment Results (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
     "longName": "9955581 - Disclosure - Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "shortName": "Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-705",
      "name": "sny:BusinessOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
     "longName": "9955582 - Disclosure - Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "shortName": "Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-709",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
     "longName": "9955583 - Disclosure - Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "shortName": "Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-717",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails",
     "longName": "9955584 - Disclosure - Segment information- Principal Customers and Credit Risk (Details)",
     "shortName": "Segment information- Principal Customers and Credit Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfLargestCustomers",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfLargestCustomers",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
     "longName": "9955585 - Disclosure - Information related to Opella, presented within discontinued operations (Details)",
     "shortName": "Information related to Opella, presented within discontinued operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossFromDiscontinuedOperations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-734",
      "name": "sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20260630_d2.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sny_A340BDrugPricingProgramInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "A340BDrugPricingProgramInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "340B Drug Pricing Program in the US",
        "label": "340B Drug Pricing Program in the US [Member]",
        "documentation": "340B Drug Pricing Program in the US"
       }
      }
     },
     "auth_ref": []
    },
    "country_AR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "AR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Argentina",
        "label": "ARGENTINA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization and impairment",
        "label": "Accumulated depreciation, amortisation and impairment [member]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r12",
      "r52",
      "r65",
      "r68",
      "r234",
      "r258",
      "r267",
      "r270"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "verboseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "sny_AcquiredResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AcquiredResearchAndDevelopmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired R&amp;D",
        "label": "Acquired Research And Development [Member]",
        "documentation": "Acquired Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Consideration transferred, acquisition-date fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r135",
      "r277"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumption of discount rates",
        "label": "Actuarial assumption of discount rates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfInflationMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumption of expected rates of inflation",
        "label": "Actuarial assumption of expected rates of inflation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of inflation used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialAssumptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [axis]",
        "label": "Actuarial assumptions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_ActuarialAssumptionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialAssumptionsDomain",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [domain]",
        "label": "Actuarial assumptions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial gains/(losses)",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) excluding investments accounted for using the equity method",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionalPaidinCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional paid-in capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "sny_AdditionalProfitShareForDevelopmentCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AdditionalProfitShareForDevelopmentCostMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional profit share for development cost",
        "label": "Additional Profit Share For Development Cost [Member]",
        "documentation": "Additional Profit Share For Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and other increases",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r53",
      "r259"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquisitions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r235"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Average number of shares used to compute diluted earnings per share (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "sny_AdjustmentToDebtMeasuredAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AdjustmentToDebtMeasuredAtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to debt measured at fair value",
        "label": "Adjustment To Debt Measured At Fair Value [Member]",
        "documentation": "Adjustment to debt measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in accounts receivable",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in deferred taxes",
        "label": "Adjustments for deferred tax expense"
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets",
        "label": "Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-Of Use Assets And Intangible Asset",
        "documentation": "Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in accounts payable",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains and losses on disposals of non-current assets, net of tax",
        "label": "Adjustments for losses (gains) on disposal of non-current assets"
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "sny_AdjustmentsForLossesGainsOnTransferOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AdjustmentsForLossesGainsOnTransferOfBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (income)/loss from the discontinued Opella business",
        "label": "Adjustments for losses (gains) on transfer of business",
        "documentation": "Adjustments for losses (gains) on transfer of business"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for non current financial assets and deferred tax expense",
        "label": "Adjustments For Non Current Financial Assets and Deferred Tax Expense",
        "documentation": "Adjustments For Non Current Financial Assets and Deferred Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in non-current provisions and other non-current liabilities",
        "label": "Adjustments For Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "Adjustments for noncurrent provisions and other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of employee benefits (stock options and other share-based payments)",
        "label": "Adjustments for share-based payments"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of undistributed earnings from investments accounted for using the equity method",
        "label": "Adjustments for undistributed profits of investments accounted for using equity method"
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AggregatedIndividuallyImmaterialAssociatesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Aggregated individually immaterial associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the aggregation of associates that are individually immaterial. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ifrs-full_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "All other segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for business activities and operating segments that are not reportable."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r164",
      "r205"
     ]
    },
    "ifrs-full_AllowanceForCreditLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AllowanceForCreditLossesMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances",
        "label": "Allowance for credit losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an allowance account used to record impairments to financial assets due to credit losses."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "sny_AltuviiioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AltuviiioMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALTUVIIIO",
        "label": "Altuviiio [Member]",
        "documentation": "Altuviiio"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmlitelimabAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AmlitelimabAssetMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amlitelimab asset",
        "label": "Amlitelimab Asset [Member]",
        "documentation": "Amlitelimab Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization expense",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r262"
     ]
    },
    "sny_AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortisation of Inventories",
        "label": "Amortization and Expenses from Inventories of Acquiree Since Acquisition Date",
        "documentation": "Amortization and Expenses from Inventories of Acquiree Since Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets of acquiree since acquisition date",
        "label": "Amortization of Intangible Assets of Acquiree Since Acquisition Date",
        "documentation": "Amortization of Intangible Assets of Acquiree Since Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmortizedCostNettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AmortizedCostNettingMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Amortized Cost, Netting [Member]",
        "documentation": "Amortized cost."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable and other receivables",
        "label": "Amounts receivable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r28",
      "r243"
     ]
    },
    "sny_AmvuttraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AmvuttraMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amvuttra",
        "label": "Amvuttra [Member]",
        "documentation": "Amvuttra"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of income and expense [abstract]",
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AntibodiesCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antibodies Collaboration Agreement",
        "label": "Antibodies Collaboration Agreement [Member]",
        "documentation": "Antibodies Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard tax rate applicable in France",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r230"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r110",
      "r167",
      "r170",
      "r295",
      "r296",
      "r327"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AssetsRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Related Party Transactions",
        "documentation": "Assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssociatesAndJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AssociatesAndJointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates and joint ventures",
        "label": "Associates And Joint Ventures [Member]",
        "documentation": "Associates and Joint Ventures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r67",
      "r90",
      "r106",
      "r269",
      "r293",
      "r295"
     ]
    },
    "sny_AtMarketValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AtMarketValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market value",
        "label": "At Market Value [member]",
        "documentation": "At market value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AtNotionalAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AtNotionalAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "At Notional Amount [member]",
        "documentation": "At notional amount."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r436"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [domain]",
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r436"
     ]
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r230"
     ]
    },
    "sny_AyvakitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "AyvakitMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ayvakit",
        "label": "Ayvakit [Member]",
        "documentation": "Ayvakit"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BPIFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BPIFrance",
        "label": "BPIFrance [Member]",
        "documentation": "BPIFrance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BankOverdraftsClassifiedAsCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank credit balances",
        "label": "Bank overdrafts"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Basic earnings per share (in euros per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "sny_BasicEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BasicEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share (in euros per share)",
        "label": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShareFromContinuingOperations",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share from continuing operations (in euros per share)",
        "label": "Basic earnings (loss) per share from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share from discontinued operations (in euros per share)",
        "label": "Basic earnings (loss) per share from discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "sny_BiopharmaSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BiopharmaSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biopharma",
        "label": "Biopharma Segment [Member]",
        "documentation": "Pharmaceuticals segment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BondsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BondsIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond issues",
        "label": "Bonds issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of bonds issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "sny_BorrowingAverageDrawdown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BorrowingAverageDrawdown",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, average drawdown",
        "label": "Borrowing, Average Drawdown",
        "documentation": "Borrowing, Average Drawdown"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt",
        "verboseLabel": "Market value",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [Axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ifrs-full_BorrowingsByNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsByNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [Member]",
        "label": "Borrowings by name [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BorrowingsRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "negatedTerseLabel": "Short-term debt",
        "label": "Borrowings recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer: Borrowings; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r112",
      "r125",
      "r131",
      "r224",
      "r371",
      "r373",
      "r426"
     ]
    },
    "sny_BusinessCombinationEquityInterestsOfAcquirerPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BusinessCombinationEquityInterestsOfAcquirerPerShare",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interests of acquirer (in USD per share)",
        "label": "Business Combination, Equity Interests Of Acquirer, Per Share",
        "documentation": "Business Combination, Equity Interests Of Acquirer, Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationEquityValueOfAcquirer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BusinessCombinationEquityValueOfAcquirer",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity value of acquirer",
        "label": "Business Combination, Equity Value Of Acquirer",
        "documentation": "Business Combination, Equity Value Of Acquirer"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Axis]",
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r278"
     ]
    },
    "ifrs-full_BusinessCombinationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "BusinessCombinationsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for business combinations [Member]",
        "label": "Business combinations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r141",
      "r278"
     ]
    },
    "sny_BusinessOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BusinessOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business operating income",
        "terseLabel": "Business operating income",
        "label": "Business Operating Income",
        "documentation": "Business operating income."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessOperatingIncomeAsPercentOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "BusinessOperatingIncomeAsPercentOfNetSales",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "As % of net sales",
        "label": "Business Operating Income As Percent Of Net Sales",
        "documentation": "Business Operating Income As Percent Of Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CDRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CDRMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CD&amp;R",
        "label": "CD&amp;R [Member]",
        "documentation": "CD&amp;R"
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CN",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "sny_COVID19AndInfluenzaVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "COVID19AndInfluenzaVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID-19 and Influenza vaccines",
        "label": "COVID-19 And Influenza Vaccines [Member]",
        "documentation": "COVID-19 And Influenza Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CTTQMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CTTQMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CTTQ",
        "label": "CTTQ [Member]",
        "documentation": "CTTQ"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CTTQRovidicitinibLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CTTQRovidicitinibLicenseAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CTTQ Rovidicitinib license agreement",
        "label": "CTTQ Rovidicitinib License Agreement [Member]",
        "documentation": "CTTQ Rovidicitinib License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVRs issued in connection with the acquisition of Blueprint",
        "label": "CVRs issued in connection with the acquisition of Blueprint [Member]",
        "documentation": "CVRs issued in connection with the acquisition of Blueprint"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CVRs issued in connection with the acquisition of Vigil",
        "label": "CVRs issued in connection with the acquisition of Vigil [Member]",
        "documentation": "CVRs issued in connection with the acquisition of Vigil"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CancellationOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CancellationOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of treasury shares",
        "label": "Cancellation of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of treasury stock cancelled during the period. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r10",
      "r52",
      "r58",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r140",
      "r154",
      "r155",
      "r234",
      "r236",
      "r258",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r280",
      "r287",
      "r288"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [Member]",
        "label": "Carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r58",
      "r64",
      "r66",
      "r67",
      "r140",
      "r154",
      "r155",
      "r236",
      "r263",
      "r266",
      "r268",
      "r269",
      "r280",
      "r287",
      "r288"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "negatedLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r100",
      "r225",
      "r320"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash and cash equivalents if different from statement of financial position"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "sny_CashAndCashEquivalentsReclassifiedToAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CashAndCashEquivalentsReclassifiedToAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents reclassified to Assets held for sale as of December 31, 2024",
        "label": "Cash and Cash Equivalents Reclassified to Assets Held for Sale",
        "documentation": "Cash and Cash Equivalents Reclassified to Assets Held for Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "sny_CashFlowAndFairValueHedgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CashFlowAndFairValueHedgeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges and fair value hedges:",
        "label": "Cash Flow And Fair Value Hedge [Member]",
        "documentation": "Cash Flow And Fair Value Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges",
        "label": "Cash flow hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Types of hedges [domain]]"
       }
      }
     },
     "auth_ref": [
      "r62",
      "r149",
      "r150",
      "r151",
      "r283",
      "r284",
      "r285"
     ]
    },
    "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "sny_NetCashProvidedByusedInContinuingInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals of consolidated undertakings and investments accounted for using the equity method, net of tax",
        "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r78"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) financing activities [abstract]",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) continuing financing activities",
        "label": "Cash flows from (used in) financing activities, continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) financing activities]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by/(used in) financing activities of the discontinued Opella business",
        "label": "Cash flows from (used in) financing activities, discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in short-term debt and other financial instruments",
        "label": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments",
        "documentation": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r78"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) investing activities [abstract]",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      }
     },
     "auth_ref": [
      "r69",
      "r78"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) operating activities [abstract]",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) continuing operating activities",
        "label": "Cash flows from (used in) operating activities, continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Cash flows from (used in) operating activities]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by/(used in) operating activities of the discontinued Opella business",
        "label": "Cash flows from (used in) operating activities, discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating cash flow before changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r421"
     ]
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "sny_NetCashProvidedByusedInContinuingInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of consolidated undertakings and investments accounted for using the equity method",
        "terseLabel": "Net cash flow on acquisition",
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [axis]",
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r246"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [domain]",
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r246"
     ]
    },
    "sny_CerezymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CerezymeMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cerezyme",
        "label": "Cerezyme [Member]",
        "documentation": "Cerezyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CertainWholesalersInTheUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CertainWholesalersInTheUnitedStatesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain wholesalers in the United States",
        "label": "Certain Wholesalers, In The United States [Member]",
        "documentation": "Certain Wholesalers, In The United States"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)",
        "label": "Change In Currency Translation Before Tax Excluding Associates And Joint Ventures",
        "documentation": "Change in currency translation before tax excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences (investments accounted for using the equity method)",
        "label": "Change In Currency Translation Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in currency translation net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges of net investments in foreign operations",
        "label": "Change In Currency Translation On Hedges Of Net Investments In Foreign Operations",
        "documentation": "Change in currency translation on hedges of net investments in foreign operations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnTaxEffects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInCurrencyTranslationOnTaxEffects",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Change In Currency Translation On Tax Effects",
        "documentation": "Change in currency translation on tax effects."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Debt Instrument Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Debt Instrument Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax",
        "documentation": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets Other Than Goodwill",
        "documentation": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ChangesInLiabilitiesRelatedToBusinessCombinationsAndNonControllingInterestsRollForward",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]",
        "label": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]",
        "documentation": "Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief executive officer",
        "label": "Chief Executive Officer [Member]",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [Axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r111",
      "r120",
      "r209",
      "r250",
      "r299"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [Member]",
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r111",
      "r120",
      "r209",
      "r250",
      "r299"
     ]
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of Contingent Liabilities [Axis]",
        "label": "Classes of contingent liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r139",
      "r256"
     ]
    },
    "ifrs-full_ClassesOfContingentLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of contingent liabilities [domain]",
        "label": "Classes of contingent liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r139"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [Axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r159",
      "r160",
      "r177",
      "r178",
      "r306"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, class [Member]",
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r159",
      "r160",
      "r177",
      "r178",
      "r306"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r264"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [domain]",
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r264"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r299"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [domain]",
        "label": "Classes of liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r111",
      "r299"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions [Member]",
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r255"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [Axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r237"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r237"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [Axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r255"
     ]
    },
    "sny_CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement development, regulatory and sales milestone payments",
        "label": "Collaboration Agreement Development Regulatory And Sales Milestone Payments",
        "documentation": "Collaboration Agreement Development Regulatory And Sales Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CommercialPaperProgramInFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in France",
        "label": "Commercial Paper Program In France [Member]",
        "documentation": "Commercial paper program In France."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInUSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CommercialPaperProgramInUSAMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in USA",
        "label": "Commercial Paper Program In USA [Member]",
        "documentation": "Commercial paper program in USA."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommercialPapersIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CommercialPapersIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper programs",
        "label": "Commercial papers issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of commercial paper issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "sny_CommercializationRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CommercializationRelatedExpensesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization related expenses",
        "label": "Commercialization Related Expenses [Member]",
        "documentation": "Commercialization related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [domain]",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r96",
      "r248",
      "r272",
      "r308",
      "r340",
      "r369"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to non-controlling interests",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r308",
      "r343"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to equity holders of Sanofi",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r308",
      "r344"
     ]
    },
    "ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations",
        "label": "Comprehensive income from continuing operations, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The comprehensive income from continuing operations attributable to owners of the parent. [Refer: Comprehensive income from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations",
        "label": "Comprehensive income from discontinued operations, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The comprehensive income from discontinued operations attributable to owners of the parent. [Refer: Comprehensive income from discontinued operations]"
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "sny_ComprehensiveIncomeRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ComprehensiveIncomeRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income",
        "label": "Comprehensive Income, Related Party Disclosures",
        "documentation": "Comprehensive Income, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Fair value of contingent consideration payable",
        "label": "Contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Classes of contingent liabilities [domain]; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CostOfDebtNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CostOfDebtNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Cost of net debt",
        "label": "Cost Of Debt Net",
        "documentation": "Cost of debt net."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "negatedTerseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      }
     },
     "auth_ref": [
      "r307",
      "r355"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [Axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [Member]",
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySellerSwapsInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CrossCurrencySellerSwapsInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which US dollar",
        "label": "Cross Currency Seller Swaps In US Dollar [Member]",
        "documentation": "Cross Currency Seller Swaps In US Dollar [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySellerSwapsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CrossCurrencySellerSwapsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross currency seller swaps",
        "label": "Cross Currency Seller Swaps [Member]",
        "documentation": "Cross Currency Seller Swaps [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySwapExpiring2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CrossCurrencySwapExpiring2029Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross currency swap, expiring 2029",
        "label": "Cross Currency Swap, Expiring 2029 [Member]",
        "documentation": "Cross Currency Swap, Expiring 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySwapExpiring2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CrossCurrencySwapExpiring2032Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross currency swap, expiring 2032",
        "label": "Cross Currency Swap, Expiring 2032 [Member]",
        "documentation": "Cross Currency Swap, Expiring 2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CrossCurrencySwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CrossCurrencySwapMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cross currency swap",
        "label": "Cross Currency Swap [Member]",
        "documentation": "Cross Currency Swap [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CumulativeConsumerPriceInflationRateOverTheLastThreeYears": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CumulativeConsumerPriceInflationRateOverTheLastThreeYears",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative consumer price inflation rate",
        "label": "Cumulative Consumer Price Inflation Rate Over The Last Three Years",
        "documentation": "Cumulative Consumer Price Inflation Rate Over The Last Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency and interest rate derivatives",
        "label": "Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents",
        "documentation": "Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r332",
      "r369"
     ]
    },
    "sny_CurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "current",
        "label": "Current Assets [Member]",
        "documentation": "Current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentAssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CurrentAssetsRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_AssetsRelatedPartyTransactions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets, Related Party Transactions",
        "documentation": "Current assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term debt and current portion of long-term debt",
        "label": "Current borrowings and current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current lease liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r333",
      "r369"
     ]
    },
    "sny_CurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "current",
        "label": "Current Liabilities [Member]",
        "documentation": "Current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CurrentLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_LiabilitiesRelatedPartyTransactions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current Liabilities, Related Party Transactions",
        "documentation": "Current Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails": {
       "parentTag": "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities related to business combinations and to non-controlling interests",
        "verboseLabel": "Current portion",
        "label": "Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentProvisionsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CurrentProvisionsAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provisions and other current liabilities",
        "label": "Current Provisions And Other Current Liabilities",
        "documentation": "The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax assets",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_CurrentTaxAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax assets",
        "label": "Current tax assets, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current taxes",
        "label": "Current tax expense (income)"
       }
      }
     },
     "auth_ref": [
      "r356",
      "r396"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense (income), related to Pillar Two income taxes",
        "label": "Current tax expense (income), related to Pillar Two income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) related to Pillar Two income taxes."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r233"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax liabilities",
        "label": "Current tax liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax liabilities",
        "label": "Current tax liabilities, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r404",
      "r406"
     ]
    },
    "sny_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer one",
        "label": "Customer One [member]",
        "documentation": "Customer one."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer three",
        "label": "Customer Three [member]",
        "documentation": "Customer three."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer two",
        "label": "Customer Two [member]",
        "documentation": "Customer two."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Debt Instrument"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DebtInstrumentDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Domain]",
        "label": "Debt Instrument [Domain]",
        "documentation": "Debt Instrument [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DebtInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instruments included in financial assets:",
        "label": "Debt Instruments [Member]",
        "documentation": "Debt Instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DebtNetOfCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net debt",
        "label": "Debt Net Of Cash And Cash Equivalents",
        "documentation": "Debt net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for instruments held by the entity that represent indebtedness."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r372"
     ]
    },
    "ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects of share-based payments",
        "label": "Decrease (increase) through tax on share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r231",
      "r323",
      "r328"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred taxes",
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r232"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r231",
      "r323",
      "r328"
     ]
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [Axis]",
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r238"
     ]
    },
    "ifrs-full_DefinedBenefitPlansDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansDomain",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [Member]",
        "label": "Defined benefit plans [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r238"
     ]
    },
    "sny_DerecognizedReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DerecognizedReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognized receivables",
        "label": "Derecognized Receivables",
        "documentation": "Derecognized receivables."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DerivativeFinancialInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating currency hedging instruments in place",
        "label": "Derivative Financial Instruments",
        "documentation": "Derivative financial instrument"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialInstrumentsToManageFinancialExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DerivativeFinancialInstrumentsToManageFinancialExposure",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial currency hedging instruments in place",
        "label": "Derivative Financial Instruments To Manage Financial Exposure",
        "documentation": "Derivative financial instruments to manage financial exposure."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New pronouncements issued by the IASB and applicable from 2027",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r227"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Diluted earnings per share (in euros per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DilutedEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share (in euros per share)",
        "label": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShareFromContinuingOperations",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share from continuing operations (in euros per share)",
        "label": "Diluted earnings (loss) per share from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofnumberofsharesusedtocomputedilutedearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share from discontinued operations (in euros per share)",
        "label": "Diluted earnings (loss) per share from discontinued operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for stock options with dilutive effect (in shares)",
        "label": "Dilutive effect of share options on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for restricted shares (in shares)",
        "label": "Dilutive Effect Of Share Options On Number Of Restricted Shares",
        "documentation": "Dilutive effect of share options on number of restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates and judgments",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "sny_DisclosureOfAccountsReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfAccountsReceivableLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Accounts Receivable [Line Items]",
        "label": "Disclosure Of Accounts Receivable [line items]",
        "documentation": "Disclosure Of Accounts Receivable [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccountsReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfAccountsReceivableTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Accounts Receivable [Table]",
        "label": "Disclosure Of Accounts Receivable [Table]",
        "documentation": "Disclosure of Accounts receivable Table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of movements within other comprehensive income",
        "label": "Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information of accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]",
        "documentation": "The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of acquisitions and capitalized interest by operating segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]",
        "documentation": "Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes",
        "label": "Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]",
        "documentation": "The disclosure of allocation of income tax between current and deferred taxes."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [Line Items]",
        "label": "Disclosure of analysis of other comprehensive income by item [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [Table]",
        "label": "Disclosure of analysis of other comprehensive income by item [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the analysis of other comprehensive income by item."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]",
        "label": "Disclosure of attribution of expenses by nature to their function [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]",
        "label": "Disclosure of attribution of expenses by nature to their function [table]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r436"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Basisofpreparationofthehalfyearfinancialstatementsandaccountingpolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation of the half-year financial statements and accounting policies",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [abstract]",
        "label": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [line items]",
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [table]",
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r278"
     ]
    },
    "sny_DisclosureOfChangesInFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfChangesInFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Financial Position",
        "label": "Disclosure Of Changes In Financial Position [Table Text Block]",
        "documentation": "Disclosure of changes in financial position [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests",
        "label": "Disclosure Of Changes In Liabilities Related To Business Combinations And To Noncontrolling Interests [Table Text Block]",
        "documentation": "The disclosure of changes in liabilities related to business combinations and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of treasury shares held",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r301",
      "r336"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [Line Items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r301",
      "r336"
     ]
    },
    "sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of other non-current assets",
        "label": "Disclosure Of Components Of Other Non-Current Assets [Table Text Block]",
        "documentation": "The disclosure of components of other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities in business combination [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfCurrentTradeReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfCurrentTradeReceivablesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of accounts receivable",
        "label": "Disclosure Of Current Trade Receivables [Table Text Block]",
        "documentation": "The disclosure of current trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Debtcashandcashequivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, cash and cash equivalents",
        "label": "Disclosure Of Debt Instruments Issued Explanatory [Text Block]",
        "documentation": "Disclosure of debt instruments issued explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Debt by Type Valuation of Redemption",
        "label": "Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]",
        "documentation": "The disclosure of debt net of cash and cash equivalents by type at value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Derivativefinancialinstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial instruments",
        "label": "Disclosure of derivative financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [Line Items]",
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [Table]",
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination",
        "label": "Disclosure of detailed information about business combination [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about finance income expense [Line Items]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [Line Items]",
        "documentation": "Line items represent detailed information about finance income expense."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "documentation": "Schedule disclosing information related to details of finance income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Measurement Principles Applied to Financial Instruments",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r156",
      "r161",
      "r281"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosures about major customers and credit risk",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r204"
     ]
    },
    "sny_DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures",
        "label": "Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Text Block]",
        "documentation": "Disclosure Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of earnings per share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of principal characteristics of restricted share plans",
        "label": "Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]",
        "documentation": "Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Segmentinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Financialexpensesandincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial expenses and income",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]",
        "label": "Disclosure of financial assets that are either past due or impaired [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets that are Either Past Due or Impaired [Table]",
        "label": "Disclosure of financial assets that are either past due or impaired [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets that are either past due or impaired."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated",
        "label": "Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]",
        "documentation": "The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Analysis of Financial Income and Expenses",
        "label": "Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]",
        "documentation": "The entire disclosure for financial income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r156",
      "r161",
      "r281"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Introduction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Introduction",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r315"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Geographical Information on Net Sales and Non-Current Assets",
        "label": "Disclosure of geographical areas [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [line items]",
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [table]",
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfHyperinflationaryReportingExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation and foreign currency ranslation of the financial statements of subsidiaries in hyperinflationary economies",
        "label": "Disclosure of information about hyperinflationary reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about financial reporting in hyperinflationary economies."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant information for the first half of 2026",
        "label": "Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]",
        "documentation": "The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of impairment loss and reversal of impairment loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of impairment loss and reversal of impairment loss [line items]",
        "label": "Disclosure of impairment loss and reversal of impairment loss [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of impairment loss and reversal of impairment loss [table]",
        "label": "Disclosure of impairment loss and reversal of impairment loss [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to impairment loss and the reversal of impairment loss."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r250"
     ]
    },
    "sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Impairmentofintangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]",
        "documentation": "The entire disclosure for impairment of intangible assets and property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Incometaxexpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to credit exposures designated as measured at fair value through profit or loss."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of information about major customers and credit risk [line items]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Line Items]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information About Major Customers and Credit Risk [Table]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Table]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the terms and conditions of hedging instruments and how they affect future cash flows."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [line items]",
        "label": "Disclosure of initial application of standards or interpretations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [table]",
        "label": "Disclosure of initial application of standards or interpretations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the initial application of standards or interpretations."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r226"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Goodwillandotherintangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and other intangible assets",
        "label": "Disclosure of intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r264"
     ]
    },
    "sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Instruments",
        "label": "Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]",
        "documentation": "The disclosure of interest rates hedging instruments with notional amount by expiry date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Disclosure of investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investments in Associates and Joint Ventures",
        "label": "Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]",
        "documentation": "The entire disclosure of investments in associates and joint ventures explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Line Items]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Line Items]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTable",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Table]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Table]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Litigationandarbitrationproceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation and arbitration proceedings",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Text Block]",
        "documentation": "Disclosure Of Legal And Arbitral Proceedings [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities related to business combinations and to non-controlling interests",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Explanatory [Text Block]",
        "documentation": "The entire disclosure for liabilities related to business combination and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTable",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMarketValueOfNetDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfMarketValueOfNetDebtTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Market Value of Net Debt",
        "label": "Disclosure Of Market Value Of Net Debt [Table Text Block]",
        "documentation": "Disclosure of market value of net debt [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [Line Items]",
        "label": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [Table]",
        "label": "Disclosure of net defined benefit liability (asset) [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r241"
     ]
    },
    "sny_DisclosureOfNonCurrentProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfNonCurrentProvisionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non-current Provisions [Line Items]",
        "label": "Disclosure Of Non-Current Provisions [Line Items]",
        "documentation": "Disclosure Of Non-current Provisions [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfNonCurrentProvisionsTable",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Noncurrent Provisions [Table]",
        "label": "Disclosure Of Non-Current Provisions [Table]",
        "documentation": "Disclosure Of Noncurrent Provisions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfNonCurrentProvisionsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Non-Current Provisions",
        "label": "Disclosure Of Non-Current Provisions [Table Text Block]",
        "documentation": "Disclosure of noncurrent provisions explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Information related to Opella, presented within discontinued operations",
        "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of number of restricted shares not yet fully vested",
        "label": "Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]",
        "documentation": "Disclosure of number of restricted share plans Not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Offbalancesheetcommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off balance sheet commitments",
        "label": "Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]",
        "documentation": "Disclosure of off-balance sheet commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Line Items]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Line Items]",
        "documentation": "[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Table]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Table]",
        "documentation": "Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Operating Currency Hedging Instruments",
        "label": "Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]",
        "documentation": "The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Results",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [Line Items]",
        "label": "Disclosure of operating segments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method",
        "label": "Disclosure Of Operating Segments Reconciling Items [Table Text Block]",
        "documentation": "The disclosure of operating segments reconciling items."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [Table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Othergainsandlossesandlitigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other gains and losses, and litigation",
        "label": "Disclosure Of Other Gains And Losses, And Litigation [Text Block]",
        "documentation": "The entire disclosure of other gains and losses, and litigation."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOtherNonCurrentAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non Current Assets [Line Items]",
        "label": "Disclosure Of Other Non-Current Assets [Line Items]",
        "documentation": "Disclosure of other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOtherNonCurrentAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non-current Assets [Table]",
        "label": "Disclosure Of Other Non-Current Assets [Table]",
        "documentation": "Schedule disclosing information related to other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Othernoncurrentassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Disclosure of other non-current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Otheroperatingincomeandexpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income and expenses",
        "label": "Disclosure of other operating income (expense) [text block]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "label": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "documentation": "Disclosure of other operating income (expenses)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesTable",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Other Operating Income Expenses [Table]",
        "label": "Disclosure Of Other Operating Income Expenses [Table]",
        "documentation": "Disclosure of other operating income expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOtherRevenueTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other revenue",
        "label": "Disclosure of other revenue [Text Block]",
        "documentation": "Disclosure of other revenue [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of gross value of overdue receivables",
        "label": "Disclosure Of Overdue Receivables Gross Value [Table Text Block]",
        "documentation": "The disclosure of overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Propertyplantandequipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r237"
     ]
    },
    "sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Non-Current Provisions and Other Non-Current Liabilities",
        "label": "Disclosure Of Provisions And Other Non Current Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Provisions And Other Non Current Liabilities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Noncurrentprovisionsandothernoncurrentliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current provisions and other non-current liabilities",
        "label": "Disclosure Of Provisions And Other Non-Current Liabilities [Text Block]",
        "documentation": "Disclosure Of Provisions And Other Non-Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate",
        "label": "Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]",
        "documentation": "Disclosure of reconciliation of average effective tax rate and applicable tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [line items]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [Table]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption [table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Carrying Amount to Value on Redemption",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [line items]",
        "label": "Disclosure of reconciliation of changes in goodwill [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [table]",
        "label": "Disclosure of reconciliation of changes in goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in goodwill."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r280"
     ]
    },
    "sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of movements in other intangible assets",
        "label": "Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]",
        "documentation": "Disclosure of reconciliation of changes in other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Remeasurement of Net Defined Benefit Liability Asset",
        "label": "Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset [Table Text Block]",
        "documentation": "Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Restructuringcostsandsimilaritems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs and similar items",
        "label": "Disclosure Of Restructuring Costs And Similar Items [Text Block]",
        "documentation": "The entire disclosure of restructuring costs and similar items."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsDetailsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfRestructuringCostsDetailsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restructuring Costs and Similar Items",
        "label": "Disclosure Of Restructuring Costs Details [Table Text Block]",
        "documentation": "The disclosure of restructuring costs details."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Revenuefromcontractswithcustomers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contracts with customers",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of options outstanding and exercisable",
        "label": "Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]",
        "documentation": "The disclosure of share based compensation shares authorized under stock option plans by exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedshareholdersequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated shareholders' equity",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r302",
      "r337"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r276"
     ]
    },
    "sny_DisclosureOfTradeReceivablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfTradeReceivablesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Accountsreceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Disclosure Of Trade Receivables [Text Block]",
        "documentation": "The disclosure of trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Transactions and Balances with Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r244"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r246"
     ]
    },
    "sny_DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of unaudited financial statements of subsidiaries explanatory",
        "label": "Disclosure Of Unaudited Financial Statements Of Subsidiaries Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Unaudited Financial Statements Of Subsidiaries Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DiscontinuedOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations [Abstract]",
        "documentation": "Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisposalGroupAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisposalGroupAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails",
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group [Axis]",
        "label": "Disposal Group [Axis]",
        "documentation": "Disposal Group"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisposalGroupDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DisposalGroupDomain",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails",
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group [Domain]",
        "label": "Disposal Group [Domain]",
        "documentation": "Disposal Group [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposals and other decreases",
        "label": "Disposals and retirements, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "sny_DividendsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DividendsPaidAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends paid:",
        "label": "Dividends Paid [Abstract]",
        "documentation": "Dividends Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsPaidOrdinarySharesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DividendsPaidOrdinarySharesPerShare",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend paid per share (in euros per share)",
        "label": "Dividends paid, ordinary shares per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends paid per ordinary share."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r249"
     ]
    },
    "ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "to equity holders of Sanofi",
        "label": "Dividends paid to equity holders of parent, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to equity holders of the parent, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "to non-controlling interests",
        "label": "Dividends paid to non-controlling interests, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "sny_DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends received from non-consolidated entities",
        "label": "Dividends Received From Nonconsolidated Entities Classified As Operating Activities",
        "documentation": "Dividends received from non-consolidated entities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of dividends to non-controlling interests",
        "label": "Dividends recognised as distributions to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToOwnersOfParent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend paid out of earnings",
        "label": "Dividends recognised as distributions to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DupixentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DupixentMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dupixent",
        "label": "Dupixent [Member]",
        "documentation": "Dupixent [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DupixentProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DupixentProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dupixent product litigation in the US",
        "label": "Dupixent Product Litigation In The US [Member]",
        "documentation": "Dupixent Product Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DynavaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "DynavaxMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dynavax",
        "label": "Dynavax [Member]",
        "documentation": "Dynavax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of number of shares used to compute diluted earnings per share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of exchange rates on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "sny_EmployeeShareOwnershipPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EmployeeShareOwnershipPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees share ownership plan",
        "label": "Employee Share Ownership Plan [Member]",
        "documentation": "Employees share ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83",
      "r106",
      "r107",
      "r110",
      "r247",
      "r271",
      "r295",
      "r296",
      "r304",
      "r327",
      "r334"
     ]
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityAndLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EquityAndLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and Liabilities, Related Party Transactions",
        "documentation": "Equity and Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityAttributableToEquityHoldersRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EquityAttributableToEquityHoldersRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_EquityRelatedPartyTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity attributable to equity holders of OPAL JV Co",
        "label": "Equity Attributable to Equity Holders, Related Party Transactions",
        "documentation": "Equity Attributable to Equity Holders, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityAttributableToNonControllingInterestRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EquityAttributableToNonControllingInterestRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_EquityRelatedPartyTransactions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity attributable to non-controlling interests",
        "label": "Equity Attributable to Non Controlling Interest, Related Party Transactions",
        "documentation": "Equity Attributable to Non Controlling Interest, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to equity holders of Sanofi",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "sny_EquityInstrumentsIncludedInFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EquityInstrumentsIncludedInFinancialAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments included in financial assets and financial liabilities:",
        "label": "Equity Instruments Included In Financial Assets [Member]",
        "documentation": "Equity Instruments Included In Financial Assets[member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EquityRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_EquityAndLiabilitiesRelatedPartyTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "label": "Equity, Related Party Transactions",
        "documentation": "Equity, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity risk hedging instruments designated as fair value hedges",
        "label": "Equity Risk Hedging Instruments Designated At Fair Value Hedges",
        "documentation": "Equity Risk Hedging Instruments Designated At Fair Value Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EuroapiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "EuroapiMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "EUROAPI",
        "terseLabel": "EUROAPI",
        "label": "Euroapi [Member]",
        "documentation": "Euroapi"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431"
     ]
    },
    "sny_ExcludingChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExcludingChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excluding general director",
        "label": "Excluding Chief Executive Officer [Member]",
        "documentation": "Excluding Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of outstanding options (in euros per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "sny_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac80.00 to \u20ac90.00 per share",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac70.00 to \u20ac80.00 per share",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From \u20ac60.00 to \u20ac70.00 per share",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExpenseArisingFromTheImpactOfAcquisitionsOnInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expense arising from the impact of acquisitions on inventories",
        "label": "Expense Arising From The Impact Of Acquisitions On Inventories",
        "documentation": "Expenses arising from the impact of acquisitions on inventories."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseDueToUnwindingOfDiscountOnProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unwinding of discounting of provisions",
        "label": "Expense arising from passage of time on other provisions"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense recognized",
        "netLabel": "Total expense for restricted share plans",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_ExpenseOfRestructuringActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ExpenseOfRestructuringActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      },
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restructuring costs and similar items",
        "totalLabel": "Total",
        "label": "Expense of restructuring activities"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related expenses",
        "label": "Expense Of Restructuring Activities, Employee Related Expenses",
        "documentation": "Employee related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges, gains or losses on assets",
        "label": "Expense Of Restructuring Activities, Related To Property Plant And Equipment And To Inventories",
        "documentation": "Expense of restructuring activities related to property plant and equipment to inventories."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExpenseOfRestructuringActivitiesTransformationProgramsCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of transformation programs",
        "label": "Expense Of Restructuring Activities, Transformation Programs Costs",
        "documentation": "Expense Of Restructuring Activities, Transformation Programs Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ExtensionTerm",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of option to extend lease",
        "label": "Extension, Term",
        "documentation": "Extension, Term"
       }
      }
     },
     "auth_ref": []
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "FR",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which France",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FabrazymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FabrazymeMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fabrazyme",
        "label": "Fabrazyme [Member]",
        "documentation": "Fabrazyme [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FairValueHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FairValueHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hedges",
        "label": "Fair value hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to changes in fair value of a recognised asset or liability or an unrecognised firm commitment, or an identified portion of such an asset, liability or firm commitment, that is attributable to a particular risk and could affect profit or loss. [Refer: Types of hedges [domain]]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r149",
      "r150",
      "r151",
      "r283",
      "r284",
      "r285"
     ]
    },
    "sny_FairValueOfPlanAtDateOfGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FairValueOfPlanAtDateOfGrant",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of plan at the date of grant",
        "label": "Fair Value Of Plan At Date Of Grant",
        "documentation": "Fair value of plan at the date of grant."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValuePerShareAwardedForFiveYearServicePeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FairValuePerShareAwardedForFiveYearServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share awarded for five year service period (in euros per share)",
        "label": "Fair Value Per Share Awarded For Five Year Service Period",
        "documentation": "Fair Value Per Share Awarded For Five Year Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValuePerShareAwardedForThreeYearServicePeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FairValuePerShareAwardedForThreeYearServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share awarded for three year service period (in euros per share)",
        "label": "Fair Value Per Share Awarded For Three Year Service Period",
        "documentation": "Fair value per share awarded to a three year service period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Financial expenses",
        "label": "Finance costs"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial income",
        "terseLabel": "Financial income",
        "label": "Finance income"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income (cost)",
        "totalLabel": "Net financial income/(expenses)",
        "label": "Finance income (cost)"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "sny_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "documentation": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FirmOrdersOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FirmOrdersOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Firm orders of property, plant and equipment",
        "label": "Firm Orders Of Property Plant And Equipment",
        "documentation": "Firm orders of property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FiveYearServicePeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FiveYearServicePeriodMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5 year service period",
        "label": "Five Year Service Period [Member]",
        "documentation": "Five Year Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondIssueFromMarch2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FixedRateBondIssueFromMarch2018Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed rate bond issue from March 2018",
        "label": "Fixed Rate Bond Issue from March 2018 [Member]",
        "documentation": "Fixed Rate Bond Issue from March 2018"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingMarch2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FixedRateBondMaturingMarch2029Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed rate bond maturing march 2029",
        "label": "Fixed Rate Bond Maturing March 2029 [Member]",
        "documentation": "Fixed Rate Bond Maturing March 2029"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingMay2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FixedRateBondMaturingMay2033Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed rate bond maturing may 2033",
        "label": "Fixed Rate Bond Maturing May 2033 [Member]",
        "documentation": "Fixed Rate Bond Maturing May 2033"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FixedRateBondMaturingMay2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FixedRateBondMaturingMay2037Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed rate bond maturing May 2037",
        "label": "Fixed Rate Bond Maturing May 2037 [Member]",
        "documentation": "Fixed Rate Bond Maturing May 2037"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForeignCurrencyTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForeignCurrencyTranslationMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in currency translation differences:",
        "label": "Foreign Currency Translation [Member]",
        "documentation": "Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Chinese yuan renminbi",
        "label": "Forward Currency Purchases In Chinese Yuan Renminbi [Member]",
        "documentation": "Forward Currency Purchases In Chinese Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInHungarianFlorintMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesInHungarianFlorintMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Hungarian forint",
        "label": "Forward Currency Purchases In Hungarian florint [Member]",
        "documentation": "Forward Currency Purchases In Hungarian florint"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Singapore dollar",
        "label": "Forward Currency Purchases In Singapore Dollar [Member]",
        "documentation": "Forward currency purchases in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInTurkishLiraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesInTurkishLiraMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Turkish lira",
        "label": "Forward Currency Purchases In Turkish lira [Member]",
        "documentation": "Forward Currency Purchases In Turkish lira"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which US dollar",
        "label": "Forward Currency Purchases In US Dollar [Member]",
        "documentation": "Forward currency purchases in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUSDollarUSBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesInUSDollarUSBondMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar, US bond",
        "label": "Forward Currency Purchases In US Dollar, US Bond [Member]",
        "documentation": "Forward Currency Purchases In US Dollar, US Bond"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which United Arab Emirates dirham",
        "label": "Forward Currency Purchases In United Emirates Dirham [Member]",
        "documentation": "Forward Currency Purchases In United Emirates Dirham"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencyPurchasesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases",
        "label": "Forward Currency Purchases [Member]",
        "documentation": "Forward currency purchases."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInBrazilianRealExpiringIn2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInBrazilianRealExpiringIn2027Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in BRL, expiring in 2027",
        "label": "Forward Currency Sales In Brazilian Real Expiring In 2027 [Member]",
        "documentation": "Forward Currency Sales In Brazilian Real Expiring In 2027"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInBrazilianRealMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInBrazilianRealMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Brazilian real",
        "label": "Forward Currency Sales In Brazilian Real [Member]",
        "documentation": "Forward Currency Sales In Brazilian Real"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Chinese yuan renminbi",
        "label": "Forward Currency Sales In Chinese Yuan Renminbi [member]",
        "documentation": "Forward currency sales in Chinese Yuan Renminbi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInPoundSterlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInPoundSterlingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Pound sterling",
        "label": "Forward Currency Sales In Pound Sterling [Member]",
        "documentation": "Forward Currency Sales In Pound Sterling"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInSaudiArabianRiyalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInSaudiArabianRiyalMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Saudi Arabian riyal",
        "label": "Forward Currency Sales In Saudi Arabian Riyal [Member]",
        "documentation": "Forward Currency Sales In Saudi Arabian Riyal"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which Singapore dollar",
        "label": "Forward Currency Sales In Singapore Dollar [member]",
        "documentation": "Forward currency sales in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales In US dollar, expiring in 2026 and 2027",
        "label": "Forward Currency Sales In US Dollar Expiring In 2026 And 2027 [Member]",
        "documentation": "Forward Currency Sales In US Dollar Expiring In 2026 And 2027"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "of which US dollar",
        "label": "Forward Currency Sales In US Dollar [Member]",
        "documentation": "Forward currency sales in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ForwardCurrencySalesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales",
        "label": "Forward Currency Sales [Member]",
        "documentation": "Forward currency sales."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FourBillionFacilityMaturingApril2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FourBillionFacilityMaturingApril2026Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four billion facility maturing April 2026",
        "label": "Four Billion Facility Maturing April 2026 [Member]",
        "documentation": "Four Billion Facility Maturing April 2026"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FourBillionFacilityMaturingOnMarch2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "FourBillionFacilityMaturingOnMarch2030Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four billion facility maturing on March, 2030",
        "label": "Four Billion Facility Maturing On March, 2030 [Member]",
        "documentation": "Four Billion Facility Maturing December 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnDerivativesUsedToManageCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "GainLossOnDerivativesUsedToManageCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage cash and cash equivalents",
        "label": "Gain (Loss) On Derivatives Used To Manage Cash And Cash Equivalents",
        "documentation": "Gain (loss) on derivatives used to manage cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "GainLossOnDerivativesUsedToManageDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage debt",
        "label": "Gain (Loss) On Derivatives Used To Manage Debt",
        "documentation": "Gain (loss) on derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) on benefit obligations",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r242"
     ]
    },
    "sny_GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on disposal of Opella before tax",
        "label": "Gain on Disposal of Opella, Disposal Group Including Discontinued Operations",
        "documentation": "Gain on Disposal of Opella, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainsLossOnDivestmentOfProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "GainsLossOnDivestmentOfProducts",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails": {
       "parentTag": "sny_OtherOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net gains / (losses) on disposals of operating assets or businesses",
        "label": "Gains (Loss) On Divestment Of Products",
        "documentation": "Gains on divestment of products."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnCashFlowHedgesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of cash flow hedges",
        "label": "Gains (losses) on cash flow hedges, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in currency translation differences",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "GainsLossesOnRemeasuringDebtInstrumentsBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of debt instruments included in financial assets",
        "label": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax",
        "documentation": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of equity instruments included in financial assets and financial liabilities",
        "label": "Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r109",
      "r298"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)",
        "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r297"
     ]
    },
    "sny_GeneralInformationAboutFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "GeneralInformationAboutFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information About Financial Statements [Abstract]",
        "label": "General Information About Financial Statements [Abstract]",
        "documentation": "General Information About Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [Axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r357",
      "r375",
      "r377",
      "r395"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [Member]",
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r357",
      "r375",
      "r377",
      "r395"
     ]
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r140",
      "r251",
      "r252",
      "r280",
      "r317"
     ]
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r399"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross value",
        "label": "Gross carrying amount [member]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r65",
      "r68",
      "r140",
      "r155",
      "r157",
      "r234",
      "r258",
      "r267",
      "r270",
      "r288",
      "r289",
      "r382"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit"
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "ifrs-full_HedgedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HedgedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [Axis]",
        "label": "Hedged items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r284"
     ]
    },
    "ifrs-full_HedgedItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HedgedItemsDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [Member]",
        "label": "Hedged items [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedged items. A hedged item can be a recognised asset or liability, an unrecognised firm commitment, a forecast transaction or a net investment in a foreign operation. The hedged item can be: (a) a single item; or (b) a group of items (subject to paragraphs 6.6.1\u20136.6.6 and B6.6.1\u2013B6.6.16 of IFRS 9). A hedged item can also be a component of such an item or group of items (see paragraphs 6.3.7 and B6.3.7\u2013B6.3.25 of IFRS 9). This member also represents the standard value for the 'Hedged items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r284"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Instruments [Axis]",
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r283"
     ]
    },
    "ifrs-full_HedgingInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "HedgingInstrumentsDomain",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging instruments [Member]",
        "label": "Hedging instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r283"
     ]
    },
    "sny_HudsonHeadwatersHealthNetworkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "HudsonHeadwatersHealthNetworkMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hudson Headwaters Health Network",
        "label": "Hudson Headwaters Health Network [Member]",
        "documentation": "Hudson Headwaters Health Network"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets of Dynavax",
        "label": "Identifiable assets acquired (liabilities assumed)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r398"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Identifiable intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r379",
      "r381",
      "r398"
     ]
    },
    "sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of the workdown of acquired inventories remeasured at fair value",
        "label": "Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value",
        "documentation": "Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment losses, net of reversals",
        "label": "Impairment loss recognised in other comprehensive income, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r54",
      "r260"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of intangible assets",
        "terseLabel": "Impairment loss on other intangible assets",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r261"
     ]
    },
    "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables",
        "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "sny_ImpairmentLossesOnFinancialAssetsNetOfReversals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ImpairmentLossesOnFinancialAssetsNetOfReversals",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment losses on financial assets, net of reversals",
        "label": "Impairment Losses On Financial Assets, Net Of Reversals",
        "documentation": "Impairment Losses On Financial Assets, Net Of Reversals"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before tax and investments accounted for using the equity method",
        "terseLabel": "Income before tax and investments accounted for using the equity method",
        "label": "Income Before Tax And Investments Accounted For Equity Method Investments",
        "documentation": "Income before tax and investments accounted for equity method investments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax",
        "label": "Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations",
        "documentation": "Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeResultingFromOutLicensing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeResultingFromOutLicensing",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails": {
       "parentTag": "sny_OtherOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amvuttra licensing income",
        "label": "Income Resulting From Out-Licensing",
        "documentation": "Income Resulting From Out-Licensing"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeStatementClassificationIFRS18NumberOfCategories": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeStatementClassificationIFRS18NumberOfCategories",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of categories",
        "label": "Income Statement Classification, IFRS 18, Number Of Categories",
        "documentation": "Number Of Categories"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations",
        "documentation": "Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "negatedTotalLabel": "Total",
        "label": "Tax expense (income)"
       }
      }
     },
     "auth_ref": [
      "r0",
      "r2",
      "r3",
      "r29",
      "r101",
      "r166",
      "r228",
      "r229",
      "r230",
      "r347"
     ]
    },
    "sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments",
        "documentation": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income tax relating to cash flow hedges included in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r349"
     ]
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments",
        "documentation": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method",
        "documentation": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r363"
     ]
    },
    "sny_IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in business operating income, at constant exchange rates non-IFRS, percentage",
        "label": "Increase (Decrease) In Business Operating Income, At Constant Exchange Rates Non-IFRS, Percentage",
        "documentation": "Increase (Decrease) In Business Operating Income, At Constant Exchange Rates Non-IFRS, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in business operating income, on a reported basis (IFRS), percentage",
        "label": "Increase (Decrease) In Business Operating Income, On A Reported Basis (IFRS), Percentage",
        "documentation": "Increase (Decrease) In Business Operating Income, On A Reported Basis (IFRS), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r225"
     ]
    },
    "ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInContingentConsiderationAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value remeasurement of contingent consideration",
        "label": "Increase (decrease) in contingent consideration asset (liability)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a contingent consideration asset (liability) relating to a business combination."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r279"
     ]
    },
    "sny_IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in cost of sales, at constant exchange rates non-IFRS, percentage",
        "label": "Increase (Decrease) In Cost Of sales At Constant Exchange Rates, Percentage Non-IFRS)",
        "documentation": "Increase (Decrease) In Cost Of sales At Constant Exchange Rates Non-IFRS), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in cost of sales, on a reported basis (IFRS), percentage",
        "label": "Increase (Decrease) In Cost Of Sales, On A Reported Basis (IFRS), Percentage",
        "documentation": "Increase (Decrease) In Cost Of Sales, On A Reported Basis (IFRS), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in other revenue, at constant exchange rates non-IFRS, percentage",
        "label": "Increase (Decrease) In Other Revenue, At Constant Exchange Rates Non-IFRS, Percentage",
        "documentation": "Increase (Decrease) In Other Revenue, At Constant Exchange Rates Non-IFRS, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in other revenue, on a reported basis (IFRS), percentage",
        "label": "Increase (Decrease) In Other Revenue, On A Reported Basis (IFRS), Percentage",
        "documentation": "Increase (Decrease) In Other Revenue, On A Reported Basis (IFRS), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInProvisionsAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInProvisionsAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases in provisions and other liabilities",
        "label": "Increase (Decrease) In Provisions And Other Liabilities",
        "documentation": "Increase (Decrease) In Provisions And Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in research and development expenses, at constant exchange rates non-IFRS, percentage",
        "label": "Increase (Decrease) In Research And Development Expenses, At Constant Exchange Rates Non-IFRS, Percentage",
        "documentation": "Increase (Decrease) In Research And Development Expenses, At Constant Exchange Rates Non-IFRS, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in research and development expenses, on a reported basis (IFRS), percentage",
        "label": "Increase (Decrease) In Research And Development Expenses, On A Reported Basis (IFRS), Percentage",
        "documentation": "Increase (Decrease) In Research And Development Expenses, On A Reported Basis (IFRS), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in revenue, at constant exchange rates non-IFRS, percentage",
        "label": "Increase (Decrease) In Revenue, At Constant Exchange Rates Non-IFRS, Percentage",
        "documentation": "Increase (Decrease) In Revenue, At Constant Exchange Rates Non-IFRS, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in revenue, on a reported basis (IFRS), percentage",
        "label": "Increase (Decrease) In Revenue, On A Reported Basis (IFRS), Percentage",
        "documentation": "Increase (Decrease) In Revenue, On A Reported Basis (IFRS), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in selling and general expenses, at constant exchange rates non-IFRS, percentage",
        "label": "Increase (Decrease) In Selling And General Expenses, At Constant Exchange Rates Non-IFRS, Percentage",
        "documentation": "Increase (Decrease) In Selling And General Expenses, At Constant Exchange Rates Non-IFRS, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in selling and general expenses, on a reported basis (IFRS), percentage",
        "label": "Increase (Decrease) In Selling And General Expenses, On A Reported Basis (IFRS), Percentage",
        "documentation": "Increase (Decrease) In Selling And General Expenses, On A Reported Basis (IFRS), Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains and losses on defined-benefit plans",
        "label": "Increase (Decrease) Through Actuarial Gains And Losses On Defined Benefit Plans, Other Provisions",
        "documentation": "Actuarial gains and losses on defined-benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other changes in non-controlling interests",
        "label": "Increase (Decrease) Through Changes In Non-controlling Interests Arising From Divestment And Acquisitions",
        "documentation": "Increase (Decrease) Through Changes In Non-controlling Interests Arising From Divestment And Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions",
        "documentation": "Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other changes arising from issuance of restricted shares",
        "label": "Increase (Decrease) Through Issuance Of Restricted Shares, Equity",
        "documentation": "Increase (decrease) through issuance of restricted shares, equity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (Decrease) Through Net Exchange Differences Business Combinations And Noncontrolling Interests",
        "documentation": "Increase decrease through net exchange differences business combinations and noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "sny_IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net interest related to employee benefits, and unwinding of discount",
        "label": "Increase (Decrease) Through Net Interest Related To Employees Benefits And Unwinding Of Discount, Other Provisions",
        "documentation": "Net interest related to employees benefits and unwinding of discount."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee share ownership plan",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans",
        "documentation": "Employee share ownership plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted shares and vesting of existing restricted shares",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares",
        "documentation": "Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of services obtained from employees",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees",
        "documentation": "Value of services obtained from employees."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers and other changes, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "sny_IndustrialSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IndustrialSalesMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industrial sales",
        "label": "Industrial Sales [Member]",
        "documentation": "Industrial Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfraservGmbhAndCoHochstKGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InfraservGmbhAndCoHochstKGMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infraserv GmbH &amp; Co. H\u00f6chst KG",
        "label": "Infraserv Gmbh And Co Hochst KG [member]",
        "documentation": "Infraserv GmbH and Co. Hochst KG."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "terseLabel": "Carrying amount of intangible assets",
        "periodStartLabel": "Intangible assets other than goodwill at beginning of period",
        "periodEndLabel": "Intangible assets other than goodwill at end of period",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r263",
      "r317"
     ]
    },
    "ifrs-full_InterestCostsCapitalised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestCostsCapitalised",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which capitalized interest",
        "label": "Interest costs capitalised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of debt",
        "label": "Interest expense on borrowings"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r207"
     ]
    },
    "sny_InterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income",
        "documentation": "Interest Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "sny_InterestRateAndCurrencyDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateAndCurrencyDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate and currency derivatives used to hedge debt",
        "label": "Interest Rate And Currency Derivatives [Member]",
        "documentation": "Interest rate and currency derivatives used to hedge debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage cash and cash equivalents",
        "label": "Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent",
        "documentation": "Interest rate and currency derivatives used to manage cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage debt",
        "label": "Interest Rate And Currency Derivatives Used To Manage Debt",
        "documentation": "Interest rate and currency derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPay2.08ReceiveEuribor3MMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPay2.08ReceiveEuribor3MMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay 2.08% / receive Euribor 3M",
        "label": "Interest Rate Swaps Pay 2.08%/Receive Euribor 3M [Member]",
        "documentation": "Interest Rate Swaps Pay 2.08%/Receive Euribor 3M"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay 3.77% / receive capitalized SOFR + 46bps",
        "label": "Interest Rate Swaps Pay 3.77% / Receive Capitalized SOFR + 46bps [Member]",
        "documentation": "Interest Rate Swaps Pay 3.77% / Receive Capitalized SOFR + 46bps"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay 3.82% / receive capitalized SOFR USD + 54 bps",
        "label": "Interest Rate Swaps Pay 3.82% / Receive Capitalized SOFR USD + 54 bps [Member]",
        "documentation": "Interest Rate Swaps Pay 3.82% / Receive Capitalized SOFR USD + 54 bps"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive092Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive092Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester/receive 0.92%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive2.53Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive2.53Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 2.53%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 2.53% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 2.53%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive2.71Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive2.71Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 2.71%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 2.71% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 2.71%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive2.91Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive2.91Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized Ester / receive 2.91%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 2.91% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 2.91%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized SOFR USD/ receive 1.03%",
        "label": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "pay capitalized SOFR USD/ receive 1.32%",
        "label": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "sny_InterestsInOtherEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "InterestsInOtherEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interests In Other Entities [Abstract]",
        "label": "Interests In Other Entities [Abstract]",
        "documentation": "Interests In Other Entities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r223",
      "r319",
      "r404"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r168",
      "r294",
      "r318"
     ]
    },
    "ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentsInAssociatesAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in associates",
        "label": "Investments in associates accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "InvestmentsInJointVenturesAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in joint ventures",
        "label": "Investments in joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in joint ventures accounted for using the equity method. [Refer: Total for all joint ventures [member]; Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "sny_IssuanceOfFurtherSharesAsAnEmployersContribution": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "IssuanceOfFurtherSharesAsAnEmployersContribution",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued immediately for employer's contribution (in shares)",
        "label": "Issuance Of Further Shares As An Employers Contribution",
        "documentation": "Further shares as an employers contribution."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r407"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ItemsNotSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Items Not Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items not subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ItemsSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items subsequently reclassifiable to profit or loss",
        "label": "Items Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_JointVenturesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "JointVenturesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint ventures [Axis]",
        "label": "Joint ventures [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r104",
      "r291"
     ]
    },
    "ifrs-full_JointVenturesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "JointVenturesDomain",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint ventures [domain]",
        "label": "Joint ventures [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r104",
      "r291"
     ]
    },
    "sny_KaliTherapeuticsLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "KaliTherapeuticsLicenseAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kali Therapeutics License Agreement",
        "label": "Kali Therapeutics License Agreement [Member]",
        "documentation": "Kali Therapeutics License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_KaliTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "KaliTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kali Therapeutics",
        "label": "Kali Therapeutics [Member]",
        "documentation": "Kali Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LOrealMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LOrealMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "L'Or\u00e9al",
        "label": "L'Or\u00e9al [Member]",
        "documentation": "L'Or\u00e9al"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LantusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LantusMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lantus",
        "label": "Lantus [Member]",
        "documentation": "Lantus."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r126",
      "r212",
      "r216",
      "r386",
      "r391",
      "r393"
     ]
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 and beyond",
        "label": "Later than four years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r126",
      "r386",
      "r393",
      "r436"
     ]
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneMonthAndNotLaterThanThreeMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 1-3 months",
        "label": "Later than one month and not later than three months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than three months."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r388",
      "r393"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Later than one year and not later than five years",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r215",
      "r385",
      "r393"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r126",
      "r386",
      "r393",
      "r436"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Overdue by > 12 months",
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 6-12 months",
        "label": "Later than six months and not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r390",
      "r393"
     ]
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by 3-6 months",
        "label": "Later than three months and not later than six months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r389",
      "r393"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Later than three years and not later than four years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r126",
      "r386",
      "r393",
      "r436"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Later than two years and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r126",
      "r386",
      "r393",
      "r436"
     ]
    },
    "sny_LaunchesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LaunchesMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which total launches",
        "label": "Launches [Member]",
        "documentation": "Launches"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "sny_LegalAndArbitralProceedingsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LegalAndArbitralProceedingsAxis",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Axis]",
        "label": "Legal And Arbitral Proceedings [Axis]",
        "documentation": "Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LegalAndArbitralProceedingsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LegalAndArbitralProceedingsDomain",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Domain]",
        "label": "Legal And Arbitral Proceedings [Domain]",
        "documentation": "[Domain] for Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities related to assets held for sale",
        "label": "Liabilities included in disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r324"
     ]
    },
    "sny_LiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_EquityAndLiabilitiesRelatedPartyTransactions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Related Party Transactions",
        "documentation": "Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LiabilityRecognisedForEstimatedFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LiabilityRecognisedForEstimatedFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liability recognised for estimated future royalties",
        "label": "Liability Recognised For Estimated Future Royalties",
        "documentation": "Liability Recognised For Estimated Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LoansToAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LoansToAssociates",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans to Associates",
        "label": "Loans to Associates",
        "documentation": "Loans to Associates"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LongTermPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LongTermPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term prepaid expenses",
        "label": "Long Term Prepaid Expenses",
        "documentation": "Long term prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "sny_LovenoxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "LovenoxMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lovenox",
        "label": "Lovenox [Member]",
        "documentation": "Lovenox."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MCMVaccineBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MCMVaccineBVMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Vaccine BV",
        "label": "MCM Vaccine BV [Member]",
        "documentation": "MCM Vaccine BV"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MSPVaccineCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MSPVaccineCompanyMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSP Vaccine Company",
        "label": "MSP Vaccine Company [Member]",
        "documentation": "MSP Vaccine Company"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [Axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_MajorCustomersDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MajorCustomersDomain",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customers [Member]",
        "label": "Major customers [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "sny_ManufacturingAndSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ManufacturingAndSupplyMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which Manufacturing &amp; Supply",
        "label": "Manufacturing And Supply [Member]",
        "documentation": "Manufacturing and supply"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MarketConditionAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Axis]",
        "label": "Market Condition [Axis]",
        "documentation": "Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MarketConditionDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Domain]",
        "label": "Market Condition [Domain]",
        "documentation": "Market Condition [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MarketedProductsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed products",
        "label": "Marketed Products [Member]",
        "documentation": "Marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material reconciling items",
        "label": "Material reconciling items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [Axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r148",
      "r158",
      "r203",
      "r206",
      "r213",
      "r217",
      "r286",
      "r331",
      "r359",
      "r386"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands [Member]",
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r148",
      "r203",
      "r206",
      "r213",
      "r217",
      "r286",
      "r331",
      "r359",
      "r386",
      "r392"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r183",
      "r184",
      "r186",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [Axis]",
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r67",
      "r106",
      "r269",
      "r295"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated measurement [Member]",
        "label": "Measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r67",
      "r106",
      "r269",
      "r295"
     ]
    },
    "sny_MedleyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MedleyMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medley",
        "label": "Medley [Member]",
        "documentation": "Medley"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MeningitisTravelAndEndemicsVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MeningitisTravelAndEndemicsVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Meningitis, travel and endemics vaccines",
        "label": "Meningitis, Travel And Endemics Vaccines [Member]",
        "documentation": "Meningitis, Travel And Endemics Vaccines"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r183",
      "r184",
      "r186",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails": {
       "parentTag": "sny_OtherOperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating expenses",
        "terseLabel": "Other operating expense",
        "negatedTerseLabel": "Miscellaneous other operating expense",
        "label": "Miscellaneous other operating expense"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails": {
       "parentTag": "sny_OtherOperatingIncome",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other operating income",
        "terseLabel": "Other",
        "label": "Miscellaneous other operating income"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "sny_MiscellaneousOtherOperatingIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MiscellaneousOtherOperatingIncomeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income and expenses",
        "label": "Miscellaneous Other Operating Income (Expenses)",
        "documentation": "Other operating income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "MiscellaneousOtherProvisionsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Miscellaneous other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for miscellaneous other provisions. [Refer: Classes of other provisions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r255"
     ]
    },
    "sny_MiscellaneousOtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MiscellaneousOtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails": {
       "parentTag": "ifrs-full_OtherRevenue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Miscellaneous other revenue",
        "documentation": "Miscellaneous other revenue"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MosaicHealthInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "MosaicHealthInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mosaic Health in the US",
        "label": "Mosaic Health in the US [Member]",
        "documentation": "Mosaic Health in the US"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetCashInflowFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetCashInflowFromDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash inflow/(outflow) from the Opella transaction",
        "label": "Net Cash Inflow from Discontinued Operations",
        "documentation": "Net Cash Inflow from Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetCashProvidedByusedInContinuingInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetCashProvidedByusedInContinuingInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) continuing investing activities",
        "label": "Net Cash Provided by/(used in) Continuing Investing Activities",
        "documentation": "Net Cash Provided by/(used in) Continuing Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetCashProvidedByusedInDiscontinuingInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetCashProvidedByusedInDiscontinuingInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by/(used in) investing activities of the discontinued Opella business",
        "label": "Net Cash Provided by/(used in) Discontinuing Investing Activities",
        "documentation": "Net Cash Provided by/(used in) Discontinuing Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in other current assets and other current liabilities",
        "label": "Net Change In Other Current Assets And Other Current Liabilities",
        "documentation": "Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetChangeInOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetChangeInOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "sny_NetCashProvidedByusedInContinuingInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in other non-current assets",
        "label": "Net Change In Other Non-Current Assets",
        "documentation": "Net change in other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred taxes, net",
        "label": "Net Deferred Tax Liabilities Recognised As Of AcquisitionDate",
        "documentation": "Net Deferred Tax Liabilities Recognised As Of AcquisitionDate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [Axis]",
        "label": "Net defined benefit liability (asset) [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r241"
     ]
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetDomain",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [Member]",
        "label": "Net defined benefit liability (asset) [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r241"
     ]
    },
    "sny_NetIncomeRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetIncomeRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income",
        "label": "Net Income, Related Party Disclosures",
        "documentation": "Net Income, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetInterestCostRelatedToEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetInterestCostRelatedToEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net interest cost related to employee benefits",
        "label": "Net Interest Cost Related To Employee Benefits",
        "documentation": "Net interest cost related to employee benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetInvestmentHedgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetInvestmentHedgeMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedge",
        "label": "Net Investment Hedge [Member]",
        "documentation": "Net Investment Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetSalesAndOtherRevenuesRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NetSalesAndOtherRevenuesRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales and other revenues",
        "label": "Net Sales and Other Revenues, Related Party Disclosures",
        "documentation": "Net Sales and Other Revenues, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NexviazymeNexviadymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NexviazymeNexviadymeMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nexviazyme/Nexviadyme",
        "label": "Nexviazyme/Nexviadyme [Member]",
        "documentation": "Nexviazyme/Nexviadyme"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "non-current",
        "label": "Non-Current Assets [Member]",
        "documentation": "Non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentAssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentAssetsRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_AssetsRelatedPartyTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non Current assets, Related Party Transactions",
        "documentation": "Non Current assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "non-current",
        "label": "Non-Current Liabilities [Member]",
        "documentation": "Non-current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails": {
       "parentTag": "sny_LiabilitiesRelatedPartyTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non Current Liabilities, Related Party Transactions",
        "documentation": "Non Current Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails": {
       "parentTag": "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities related to business combinations and to non-controlling interests",
        "verboseLabel": "Non-current portion",
        "label": "Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLoansAndReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentLoansAndReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term loans and advances and other non-current receivables",
        "label": "Non current loans and receivables",
        "documentation": "Non current loans and receivables"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current provisions and other non-current liabilities",
        "totalLabel": "Non-current provisions",
        "label": "Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentRestructuringProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonCurrentRestructuringProvisionMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring provisions",
        "label": "Non-Current Restructuring Provision [Member]",
        "documentation": "Restructuring provisions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonOperatingForeignExchangeGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NonOperatingForeignExchangeGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-operating foreign exchange gains/(losses)",
        "label": "Non-Operating Foreign Exchange Gains/(Losses)",
        "documentation": "Non-operating foreign exchange gains/(losses)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r325"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to\u00a0non-controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r332",
      "r369"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets [abstract]",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale",
        "label": "Non-current assets or disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial instruments",
        "label": "Non-current derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instruments at fair value through other comprehensive income",
        "label": "Non-current financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r282"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r95",
      "r333",
      "r369"
     ]
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "sny_NotEligibleForHedgeAccountingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NotEligibleForHedgeAccountingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not eligible for hedge accounting",
        "label": "Not Eligible For Hedge Accounting [Member]",
        "documentation": "Not eligible for hedge accounting."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneMonthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotLaterThanOneMonthMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overdue by less than 1 month",
        "label": "Not later than one month [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one month."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r387",
      "r393"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r126",
      "r210",
      "r214",
      "r329",
      "r386",
      "r393"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "sny_NumberOfBondRedeemed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfBondRedeemed",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of bonds redeemed",
        "label": "Number Of Bond Redeemed",
        "documentation": "Number Of Bond Redeemed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCasesFiledInNewJerseyCourt": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfCasesFiledInNewJerseyCourt",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of cases filed in New Jersey court",
        "label": "Number Of Cases Filed In New Jersey Court",
        "documentation": "Number Of Cases Filed In New Jersey Court"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfClassActionLawsuits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfClassActionLawsuits",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of class action lawsuits",
        "label": "Number Of Class Action Lawsuits",
        "documentation": "Number Of Class Action Lawsuits"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCrossCurrencySwaps": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfCrossCurrencySwaps",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of cross currency swaps",
        "label": "Number Of Cross Currency Swaps",
        "documentation": "Number Of Cross Currency Swaps"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total number of shares awarded (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r423"
     ]
    },
    "sny_NumberOfLargestCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfLargestCustomers",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of largest customers",
        "label": "Number Of Largest Customers",
        "documentation": "Number Of Largest Customers"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfLegalDecisionAspectsChallenged": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfLegalDecisionAspectsChallenged",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of legal decision aspects challenged",
        "label": "Number Of Legal Decision Aspects Challenged",
        "documentation": "Number Of Legal Decision Aspects Challenged"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOneYearExtensionOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfOneYearExtensionOptions",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of one-year extension options",
        "label": "Number Of One-Year Extension Options",
        "documentation": "Number Of One-Year Extension Options"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number Of Operating Segments",
        "documentation": "Number of operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOtherDefendantsInLegalProceeding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfOtherDefendantsInLegalProceeding",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other manufacturers in legal proceeding",
        "label": "Number Of Other Defendants In Legal Proceeding",
        "documentation": "Number Of Other Defendants In Legal Proceeding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number\u00a0of options, outstanding (in shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r273",
      "r274"
     ]
    },
    "sny_NumberOfProductLiabilityCases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfProductLiabilityCases",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product liability cases",
        "label": "Number Of Product Liability Cases",
        "documentation": "Number Of Product Liability Cases"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares alloted in regards of capital increase (in shares)",
        "label": "Number Of Restricted Shares Alloted In Regards Of Capital Increase",
        "documentation": "Number Of Restricted Shares Alloted In Regards Of Capital Increase"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase by issuance of restricted shares (in shares)",
        "label": "Number Of Restricted Shares Issued In Regards Of Capital Increase",
        "documentation": "Number of restricted shares issued in regards of capital increase."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesNotYetFullyVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfRestrictedSharesNotYetFullyVested",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares not yet fully vested (in shares)",
        "label": "Number Of Restricted Shares Not Yet Fully Vested",
        "documentation": "Number of restricted shares not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of restricted shares vested (in shares)",
        "label": "Number Of Restricted Shares Vested In Regards Of Capital Increase",
        "documentation": "Number Of Restricted Shares Vested In Regards Of Capital Increase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, exercisable (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r275"
     ]
    },
    "sny_NumberOfSharesHeld": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfSharesHeld",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number Of Shares Held",
        "documentation": "Number of shares held."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital\u00a0increase\u00a0by\u00a0exercise\u00a0of stock subscription options (in shares)",
        "label": "Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options",
        "documentation": "Number of shares issued in regards of capital increase by exercise of stock subscription options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfSharesRepurchased",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares repurchased (in shares)",
        "label": "Number Of Shares Repurchased",
        "documentation": "Number of shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesSubscribed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfSharesSubscribed",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares subscribed (in shares)",
        "label": "Number Of Shares Subscribed",
        "documentation": "Number of shares subscribed."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfShortTermDebtProgram": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfShortTermDebtProgram",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of short-term debt programs",
        "label": "Number Of Short-Term Debt Program",
        "documentation": "Number Of Short-Term Debt Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSyndicatedCreditFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfSyndicatedCreditFacilities",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of syndicated credit facilities",
        "label": "Number Of Syndicated Credit Facilities",
        "documentation": "Number Of Syndicated Credit Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Number Of Tranches",
        "documentation": "Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfYearsServicePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "NumberOfYearsServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service period",
        "label": "Number Of Years, Service Period",
        "documentation": "Number Of Years, Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OPALJVCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OPALJVCoMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPAL JV Co",
        "label": "OPAL JV Co [Member]",
        "documentation": "OPAL JV Co"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OffBalanceSheetCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OffBalanceSheetCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Off-Balance Sheet Commitments [Abstract]",
        "documentation": "Off-Balance Sheet Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OpellaBusinessMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Business",
        "label": "Opella Business [Member]",
        "documentation": "Opella Business [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OperatingIncomeOfAcquireeSinceAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OperatingIncomeOfAcquireeSinceAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating income of acquiree since acquisition date",
        "label": "Operating Income Of Acquiree Since Acquisition Date",
        "documentation": "Operating Income Of Acquiree Since Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OperatingRevenueDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OperatingRevenueDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating income",
        "label": "Operating Revenue, Disposal Group Including Discontinued Operations",
        "documentation": "Operating Revenue, Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segments",
        "label": "Operating segments [member]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other profit or loss items with no cash effect on cash flows generated by operating activities",
        "label": "Other adjustments to reconcile profit (loss)"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "sny_OtherAssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherAssetsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Related Party Transactions",
        "documentation": "Other Assets, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherBankBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherBankBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other bank borrowings",
        "label": "Other Bank Borrowings",
        "documentation": "Other bank borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Other borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income for the period",
        "label": "Other comprehensive income"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r310",
      "r339",
      "r350"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income:",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherComprehensiveIncomeFromContinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherComprehensiveIncomeFromContinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_2": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income/(loss) from continuing operations for the period, net of taxes (A+B)",
        "label": "Other comprehensive income from continued operations",
        "documentation": "Other comprehensive income from continued operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherComprehensiveIncomeFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherComprehensiveIncomeFromDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_2": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income/(loss) for the period from discontinued operations, net of taxes (C)",
        "label": "Other comprehensive income from discontinued operations",
        "documentation": "Other comprehensive income from discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherComprehensiveIncomeRelatedPartyDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherComprehensiveIncomeRelatedPartyDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofKeyItemsWhichHaveNotBeenAuditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income, Related Party Disclosures",
        "documentation": "Other Comprehensive Income, Related Party Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "sny_OtherComprehensiveIncomeFromContinuedOperations",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items subsequently reclassifiable to profit or loss",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "sny_OtherComprehensiveIncomeFromContinuedOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409"
     ]
    },
    "sny_OtherCountriesExcludingEuropeAndNorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherCountriesExcludingEuropeAndNorthAmericaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of the World",
        "label": "Other Countries, Excluding Europe And North America [Member]",
        "documentation": "Other Countries, Excluding Europe And North America"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherCountriesInSegmentResultsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherCountriesInSegmentResultsMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other countries",
        "label": "Other Countries In Segment Results [Member]",
        "documentation": "Other Countries In Segment Results"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "sny_OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026SummaryofdetailedinformationaboutbusinesscombinationDynavaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current and non-current assets and liabilities",
        "label": "Other Current Assets And Non-Current Assets And Liabilities As Of Acquisition Date",
        "documentation": "Other assets and non-current assets and liabilities as of acquisition date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other finance income (cost)"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "sny_OtherFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets at fair value through profit or loss",
        "label": "Other Financial Assets At Fair Value Through Profit Or Loss",
        "documentation": "Other Financial Assets At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherGainsLossesAndLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherGainsLossesAndLitigation",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other gains and losses, and litigation",
        "negatedNetLabel": "Other losses and litigation",
        "label": "Other Gains, (Losses) And Litigation",
        "documentation": "The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherLiabilities1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherLiabilities1Member",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities1 [member]",
        "documentation": "Other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Related Party Transactions",
        "documentation": "Other Liabilities, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other non-current assets",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "sny_OtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total other operating expenses",
        "label": "Other Operating Expense",
        "documentation": "Other Operating Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherOperatingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherOperatingExpensesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Operating Expenses",
        "label": "Other Operating Expenses [Table Text Block]",
        "documentation": "Other Operating Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other operating income",
        "label": "Other Operating Income",
        "documentation": "Other Operating Income"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "label": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "documentation": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r245"
     ]
    },
    "sny_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Restructuring Costs",
        "documentation": "Other restructuring costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "totalLabel": "Other revenues",
        "label": "Other revenue"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r230"
     ]
    },
    "sny_OverdueReceivablesGrossValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "OverdueReceivablesGrossValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Overdue receivables gross value",
        "label": "Overdue Receivables Gross Value",
        "documentation": "Overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in euros per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r300",
      "r335"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of treasury shares and related tax effect",
        "terseLabel": "Payments to acquire or redeem entity's shares",
        "label": "Payments to acquire or redeem entity's shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "sny_PensionsAndOtherPostEmploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PensionsAndOtherPostEmploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pensions and other post-employment benefits",
        "label": "Pensions And Other Post-Employment Benefits [Member]",
        "documentation": "Pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PerShareValueOfSharesRepurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PerShareValueOfSharesRepurchased",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share value of shares repurchased (in euros per share)",
        "label": "Per Share Value of Shares Repurchased",
        "documentation": "Per Share Value of Shares Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageIncreaseInFairValueLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PercentageIncreaseInFairValueLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of liability",
        "label": "Percentage Increase In Fair Value Liabilities",
        "documentation": "Percentage increase in fair value liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationPrincipalCustomersandCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of entity's revenue",
        "label": "Percentage of entity's revenue"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "sny_PercentageOfOwnershipInterestDisposed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PercentageOfOwnershipInterestDisposed",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest disposed",
        "label": "Percentage Of Ownership Interest Disposed",
        "documentation": "Percentage Of Ownership Interest Disposed"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in actuarial assumption",
        "label": "Percentage of reasonably possible decrease in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in actuarial assumption",
        "label": "Percentage of reasonably possible increase in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "sny_PercentageOfSanofisShareCapitalAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PercentageOfSanofisShareCapitalAcquired",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of Sanofi's share capital acquired",
        "label": "Percentage Of Sanofi's Share Capital Acquired",
        "documentation": "Percentage Of Sanofi's Share Capital Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfShareCapitalForThePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PercentageOfShareCapitalForThePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "% of share capital for the period",
        "label": "Percentage Of Share Capital For The Period",
        "documentation": "Percentage of share capital for the period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PlanAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PlanAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets",
        "label": "Plan assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r239"
     ]
    },
    "sny_PlavixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PlavixMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix",
        "label": "Plavix [Member]",
        "documentation": "Plavix [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B",
        "label": "Polio Pertussis Hib Primary Vaccines And Boosters, incl. Heplisav-B [Member]",
        "documentation": "Polio Pertussis Hib Primary Vaccines And Boosters, incl. Heplisav-B"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PreFundedPensionObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PreFundedPensionObligations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded pension obligations",
        "label": "Pre-Funded Pension Obligations",
        "documentation": "Pre-funded pension obligations."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentValueOfDefinedBenefitObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PresentValueOfDefinedBenefitObligationMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of defined benefit obligation",
        "label": "Present value of defined benefit obligation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r240"
     ]
    },
    "sny_PrincipalAlliancesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PrincipalAlliancesAxis",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Axis]",
        "label": "Principal Alliances [Axis]",
        "documentation": "Principal Alliances"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalAlliancesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "PrincipalAlliancesDomain",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Domain]",
        "label": "Principal Alliances [Domain]",
        "documentation": "Principal Alliances [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "sny_NetCashProvidedByusedInContinuingInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax",
        "label": "Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Sanofi shares",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProceedsFromNoncurrentBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional long-term debt contracted",
        "label": "Proceeds from non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r374",
      "r394"
     ]
    },
    "ifrs-full_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [domain]",
        "label": "Products and services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r374",
      "r394"
     ]
    },
    "sny_ProductsTrademarksAndOtherRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ProductsTrademarksAndOtherRightsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products, trademarks and other rights",
        "label": "Products, Trademarks And Other Rights [Member]",
        "documentation": "Products, trademarks and other rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_2": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r167",
      "r169",
      "r248",
      "r272",
      "r309",
      "r338",
      "r369",
      "r376"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit (loss) [abstract]",
        "label": "Profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to non-controlling interests",
        "terseLabel": "Attributable to non-controlling interests",
        "netLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r341"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to equity holders of Sanofi",
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income from continuing operations",
        "label": "Profit (loss) from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r167",
      "r169",
      "r338"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from continuing operations",
        "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income from discontinued operations",
        "label": "Profit (loss) from discontinued operations"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r143",
      "r348",
      "r354"
     ]
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income from discontinued operations",
        "label": "Profit (loss) from discontinued operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Profit (loss) from operating activities"
       }
      }
     },
     "auth_ref": [
      "r361",
      "r440"
     ]
    },
    "ifrs-full_ProfitLossOfAcquiree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProfitLossOfAcquiree",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss of acquiree since acquisition date",
        "label": "Profit (loss) of acquiree since acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment owned",
        "verboseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r236",
      "r316"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [abstract]",
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProportionOfOwnershipInterestDisposedInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ProportionOfOwnershipInterestDisposedInSubsidiary",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest disposed in subsidiary",
        "label": "Proportion Of Ownership Interest Disposed In Subsidiary",
        "documentation": "Proportion Of Ownership Interest Disposed In Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in associate",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r89"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInJointVenture": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInJointVenture",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in joint venture",
        "label": "Proportion of ownership interest in joint venture"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Total for all joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r89"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in subsidiary",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r88"
     ]
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Provisions utilized",
        "label": "Provision used, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r253"
     ]
    },
    "sny_ProvisionsForOtherLongTermBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ProvisionsForOtherLongTermBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for other long-term benefits",
        "label": "Provisions For Other Long Term Benefits [member]",
        "documentation": "Provisions for other long term benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsForPensionsAndOtherPostemploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ProvisionsForPensionsAndOtherPostemploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for pensions &amp; other post-employment benefits",
        "label": "Provisions For Pensions And Other Postemployment Benefits [member]",
        "documentation": "Provisions for pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "sny_NetCashProvidedByusedInContinuingInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of other equity investments",
        "label": "Purchase of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of other intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "sny_NetCashProvidedByusedInContinuingInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of property, plant and equipment and intangible assets",
        "label": "Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share repurchase program",
        "label": "Purchase of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of goods and services (including research expenses)",
        "label": "Purchases of goods, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r397"
     ]
    },
    "sny_RSVVaccinesBeyfortusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RSVVaccinesBeyfortusMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSV vaccines (Beyfortus)",
        "label": "RSV Vaccines (Beyfortus) [Member]",
        "documentation": "RSV Vaccines (Beyfortus)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r183",
      "r184",
      "r186",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r112",
      "r125",
      "r131",
      "r224",
      "r371",
      "r373",
      "r426"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [Member]",
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r112",
      "r125",
      "r131",
      "r224",
      "r371",
      "r373",
      "r426"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r183",
      "r184",
      "r186",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]",
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [domain]",
        "label": "Ranges of exercise prices for outstanding share options [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_ReclassifiedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReclassifiedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items [Axis]",
        "label": "Reclassified items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r303",
      "r314"
     ]
    },
    "ifrs-full_ReclassifiedItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReclassifiedItemsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items [Member]",
        "label": "Reclassified items [domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r303",
      "r314"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInOtherProvisionsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in other provisions [abstract]",
        "label": "Reconciliation of changes in other provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RedemptionOfDebtInstrumentIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RedemptionOfDebtInstrumentIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption",
        "label": "Redemption Of Debt Instrument Issued",
        "documentation": "Redemption of debt instrument issued."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReductionOfIssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReductionOfIssuedCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reduction in share capital",
        "label": "Reduction of issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "sny_RegeneronMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RegeneronMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron",
        "label": "Regeneron [Member]",
        "documentation": "Regeneron"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of long-term debt",
        "label": "Repayments of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ifrs-full_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "verboseLabel": "Reportable segments [member]",
        "label": "Reportable segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for operating segments for which IFRS 8 requires information to be disclosed. The entity shall report separately information about an operating segment that meets any of the following quantitative thresholds: (a) reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; (b) the absolute amount of its reported profit or loss is 10 per cent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; or (c) assets are 10 per cent or more of the combined assets of all operating segments. Additionally operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r167",
      "r205",
      "r358",
      "r378"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "negatedTerseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r265"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payments",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "sny_RestrictedSharePlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RestrictedSharePlan2022Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Under 2022 plans",
        "label": "Restricted Share Plan 2022 [Member]",
        "documentation": "Restricted Share Plan 2022"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RestrictedSharePlan2023Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Under 2023 plans",
        "label": "Restricted Share Plan 2023 [Member]",
        "documentation": "Restricted Share Plan 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RestrictedSharePlan2024Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Under 2024 plans",
        "label": "Restricted Share Plan 2024 [Member]",
        "documentation": "Restricted Share Plan 2024"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RestrictedSharePlan2025Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Under 2025 plans",
        "label": "Restricted Share Plan 2025 [Member]",
        "documentation": "Restricted Share Plan 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RestrictedSharePlan2026Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Under 2026 plans",
        "label": "Restricted Share Plan 2026 [Member]",
        "documentation": "Restricted Share Plan 2026"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RestrictedSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares",
        "label": "Restricted Shares [Member]",
        "documentation": "Restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and similar costs",
        "label": "Restructuring Costs and Other Items of Acquiree Since Acquisition Date",
        "documentation": "Restructuring Costs and Other Items of Acquiree Since Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves and retained earnings",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r403"
     ]
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial gains/(losses) on plan assets",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [domain]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r242"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue [abstract]",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RevenueFromDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RevenueFromDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales and other revenues",
        "label": "Revenue From Disposal Group Including Discontinued Operations",
        "documentation": "Revenue From Disposal Group Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails": {
       "parentTag": "ifrs-full_OtherRevenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales to Opella",
        "label": "Revenue from intragroup sales from continuing to discontinued operations",
        "documentation": "Revenue from intragroup sales from continuing to discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromRoyalties",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails": {
       "parentTag": "ifrs-full_OtherRevenue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalty income"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "label": "Revenue from sale of goods"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoodsRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "label": "Revenue from sale of goods, related party transactions"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r397"
     ]
    },
    "sny_RevenueFromVaxServeSalesOfNonSanofiProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RevenueFromVaxServeSalesOfNonSanofiProducts",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails": {
       "parentTag": "ifrs-full_OtherRevenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VaxServe sales of non-Sanofi products",
        "label": "Revenue from VaxServe sales of non-Sanofi products",
        "documentation": "Revenue from VaxServe sales of non-Sanofi products"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueOfAcquiree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RevenueOfAcquiree",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue of acquiree since acquisition date",
        "label": "Revenue of acquiree since acquisition date"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "sny_RevisionsToTaxExposuresAndSettlementsOfTaxDisputes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RevisionsToTaxExposuresAndSettlementsOfTaxDisputes",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revisions to tax exposures and settlements of tax disputes",
        "label": "Revisions To Tax Exposures And Settlements Of Tax Disputes",
        "documentation": "Revisions to tax exposures and settlements of tax disputes."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RezurockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RezurockMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rezurock",
        "label": "Rezurock [Member]",
        "documentation": "Rezurock"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r119",
      "r208"
     ]
    },
    "sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "RoyaltiesAndOtherIncomeRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties and other income",
        "label": "Royalties And Other Income, Related Party Transactions",
        "documentation": "Royalties and other income, related party transactions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiEuroMediumTermNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "SanofiEuroMediumTermNotesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi",
        "label": "Sanofi Euro Medium Term Notes [Member]",
        "documentation": "Sanofi Euro Medium Term Notes"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "SanofiMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi",
        "label": "Sanofi [member]",
        "documentation": "Sanofi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SarclisaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "SarclisaMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarclisa",
        "label": "Sarclisa [Member]",
        "documentation": "Sarclisa"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seasonal trends",
        "label": "Seasonality Or Cyclicality Of Interim Operations [Policy Text Block]",
        "documentation": "Seasonality Or Cyclicality Of Interim Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SegmentConsolidationItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment consolidation items [Axis]",
        "label": "Segment consolidation items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_SegmentConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SegmentConsolidationItemsDomain",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for segment consolidation items [Member]",
        "label": "Segment consolidation items [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r182",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r114",
      "r167",
      "r205",
      "r358",
      "r378"
     ]
    },
    "ifrs-full_SegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SegmentsDomain",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosureofotherrevenueDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/Significantinformationforthefirsthalfof2026AdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Member]",
        "label": "Segments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r114",
      "r172",
      "r205",
      "r358",
      "r378"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling and general expenses",
        "negatedTerseLabel": "Selling and general expenses",
        "label": "Selling, general and administrative expense"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments made",
        "label": "Settled liabilities, contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "sny_ShareBasedPaymentPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShareBasedPaymentPlansAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment plans:",
        "label": "Share Based Payment Plans [abstract]",
        "documentation": "Share based payment plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "documentation": "Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the\u00a0equity method",
        "label": "Share of profit (loss) of associates accounted for using equity method"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the equity method",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r171",
      "r346"
     ]
    },
    "sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeandexpensesScheduleofOtherOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit or loss from commercialization of monoclonal antibodies",
        "label": "Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]",
        "documentation": "Share of profit or loss from commercialization of monoclonal antibodies member."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2025ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShareRepurchase2025ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2025 Program",
        "label": "Share Repurchase 2025 Program [Member]",
        "documentation": "Share Repurchase 2025 Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2026ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShareRepurchase2026ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase 2026 Program",
        "label": "Share Repurchase 2026 Program [Member]",
        "documentation": "Share Repurchase 2026 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchaseProgramAmountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShareRepurchaseProgramAmountPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, amount paid",
        "label": "Share Repurchase Program, Amount Paid",
        "documentation": "Share Repurchase Program, Amount Paid"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchaseProgramPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShareRepurchaseProgramPeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of share repurchase program",
        "label": "Share Repurchase Program, Period",
        "documentation": "Period of share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shire contingent consideration arising from acquisition of Translate Bio",
        "label": "Shire Contingent Consideration Arising From Acquisition Of Translate Bio [Member]",
        "documentation": "Shire Contingent Consideration Arising From Acquisition Of Translate Bio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates [Axis]",
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r105",
      "r292"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesDomain",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates [domain]",
        "label": "Associates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r105",
      "r292"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [axis]",
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r103",
      "r290"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/InformationrelatedtoOpellapresentedwithindiscontinuedoperationsDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesDisclosureofRemeasurementofNetDefinedBenefitLiabilityAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [domain]",
        "label": "Subsidiaries [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r103",
      "r290"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r182",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of comprehensive income [abstract]",
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International financial reporting standards (IFRS)",
        "label": "Statement of IFRS compliance [text block]"
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "sny_StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "StockOptionPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option plan",
        "label": "Stock Option Plan [member]",
        "documentation": "Stock Option Plan [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "StockPrice",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price (in euro per share)",
        "label": "Stock Price",
        "documentation": "Stock Price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, authorized, amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]",
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SubordinateHybridBondRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "SubordinateHybridBondRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subordinate hybrid bond, related party transactions",
        "label": "Subordinate Hybrid Bond, Related Party Transactions",
        "documentation": "Subordinate Hybrid Bond, Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "SubscriptionPricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription price (in euros per share)",
        "label": "Subscription Price Per Share",
        "documentation": "Subscription price per share."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SwedishOrphanBiovitrumABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "SwedishOrphanBiovitrumABMember",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofNonCurrentProvisionsandOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swedish Orphan Biovitrum AB",
        "label": "Swedish Orphan Biovitrum AB [Member]",
        "documentation": "Swedish Orphan Biovitrum AB"
       }
      }
     },
     "auth_ref": []
    },
    "country_TR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "TR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationofthehalfyearfinancialstatementsandaccountingpoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Turkey",
        "label": "T\u00dcRKIYE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TalcProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TalcProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Talc product litigation in the US",
        "label": "Talc Product Litigation In The US [Member]",
        "documentation": "Talc Product Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxEffectRelatedToAmlitelimab": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TaxEffectRelatedToAmlitelimab",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect related to amlitelimab",
        "label": "Tax Effect Related To Amlitelimab",
        "documentation": "Tax Effect Related To Amlitelimab"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TaxRateEffectOfForeignTaxRates",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference between the standard French tax rate and the rates applicable to Sanofi",
        "label": "Tax rate effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r230"
     ]
    },
    "sny_TaxesOnShareCancellations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TaxesOnShareCancellations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax on share cancellations",
        "label": "Taxes on Share Cancellations",
        "documentation": "Taxes on Share Cancellations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TechnologicalPlatformsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TechnologicalPlatformsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technological platforms",
        "label": "Technological Platforms [Member]",
        "documentation": "Technological Platforms"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Three billion eight hundred fifty million facility maturing April 2031",
        "label": "Three Billion Eight Hundred Fifty Million Facility Maturing April 2031 [Member]",
        "documentation": "Three Billion Eight Hundred Fifty Million Facility Maturing April 2031"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ThreeYearServicePeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ThreeYearServicePeriodMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3 year service period",
        "label": "Three Year Service Period [Member]",
        "documentation": "Three Year Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r112",
      "r125",
      "r131",
      "r224",
      "r371",
      "r373",
      "r426"
     ]
    },
    "sny_ToujeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ToujeoMember",
     "presentation": [
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toujeo",
        "label": "Toujeo [Member]",
        "documentation": "Toujeo."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r405",
      "r439"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradingEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TradingEquitySecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading equity securities",
        "label": "Trading equity securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that (a) are acquired or incurred principally for the purpose of selling or repurchasing it in the near term; or (b) on initial recognition are part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r372"
     ]
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "sny_TwoBillionThreeHundredMillionBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TwoBillionThreeHundredMillionBondsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two billion three hundred million bonds",
        "label": "Two Billion Three Hundred Million Bonds [Member]",
        "documentation": "Two Billion Three Hundred Million Bonds"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TypesOfAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TypesOfAgreementAxis",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Axis]",
        "label": "Types Of Agreement [Axis]",
        "documentation": "Types Of Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TypesOfAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TypesOfAgreementDomain",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Domain]",
        "label": "Types Of Agreement [Domain]",
        "documentation": "Types Of Agreement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfHedgesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfHedgesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of Hedges [Axis]",
        "label": "Types of hedges [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r283",
      "r284",
      "r285"
     ]
    },
    "ifrs-full_TypesOfHedgesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfHedgesDomain",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges [Member]",
        "label": "Types of hedges [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of hedges. It also represents the standard value for the 'Types of hedges' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r283",
      "r284",
      "r285"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [Axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r276"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payment [Member]",
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r276"
     ]
    },
    "sny_TypesOfVestingConditionsAxisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TypesOfVestingConditionsAxisAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Vesting Conditions Axis [Axis]",
        "label": "Types Of Vesting Conditions Axis [Axis]",
        "documentation": "Types Of Vesting Conditions Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TypesOfVestingConditionsAxisDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "TypesOfVestingConditionsAxisDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Vesting Conditions Axis [Domain]",
        "label": "Types Of Vesting Conditions Axis [Domain]",
        "documentation": "Types Of Vesting Conditions Axis [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/RevenuefromcontractswithcustomersDisclosuresaboutmajorcustomersandcreditriskDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "verboseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UniversityOfWashingtonAndHarborviewMedicalCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "UniversityOfWashingtonAndHarborviewMedicalCenterMember",
     "presentation": [
      "http://www.sanofi.com/role/LitigationandarbitrationproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University of Washington and Harborview medical center",
        "label": "University Of Washington And Harborview Medical Center [Member]",
        "documentation": "University Of Washington And Harborview Medical Center"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedProvisionReversedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UnusedProvisionReversedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NoncurrentprovisionsandothernoncurrentliabilitiesSummaryofMovementsinNonCurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reversals of unutilized provisions",
        "label": "Unused provision reversed, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r254"
     ]
    },
    "sny_UpfrontLicensePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "UpfrontLicensePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront license payment",
        "label": "Upfront License Payment",
        "documentation": "Upfront License Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average amortization period",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r51",
      "r257"
     ]
    },
    "sny_ValueOfHedgeRecognizedInEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ValueOfHedgeRecognizedInEquityMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of hedge recognized in equity",
        "label": "Value Of Hedge Recognized In Equity [Member]",
        "documentation": "Value Of Hedge Recognized In Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOnRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "ValueOnRedemptionMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption",
        "label": "Value On Redemption [Member]",
        "documentation": "Value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise\u00a0price per share, exercisable (in euros per share)",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r130",
      "r275"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price per\u00a0share, outstanding (in euros per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r273",
      "r274"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofstocksubscriptionoptionplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average residual life (years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofearningspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average number of shares outstanding (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "sny_WithMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "WithMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "With market condition",
        "label": "With Market Condition [Member]",
        "documentation": "With Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_WithoutMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20260630",
     "localname": "WithoutMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Without market condition",
        "label": "Without Market Condition [Member]",
        "documentation": "Without Market Condition"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "88B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_88B&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2025-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2025-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "145",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "29",
   "IssueDate": "2025-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=29&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS29_g39-40_TI",
   "URIDate": "2025-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2025-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "34",
   "IssueDate": "2025-01-01",
   "Paragraph": "16A",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2025-en-r&anchor=para_16A_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2025-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2025-01-01",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2025-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2025-01-01",
   "Paragraph": "86",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2025-en-r&anchor=para_86_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2025-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B4",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2025-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2025-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
   "URIDate": "2025-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI",
   "URIDate": "2025-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "24B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24B&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "24C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24C&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "24G",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_24G&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2025-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2026-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "30A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "128",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "129",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_129&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "160",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "164",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "168",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "169",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "178",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "180",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "192",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "194",
   "Subparagraph": "f",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "197",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_197&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "200",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "204",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "206",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "206",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "206",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "207",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "230",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "230",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "231",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "246",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_246_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "250",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "254",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "255",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "257",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "259",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "263",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "266",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "269",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "271",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "273",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "274",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "43",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "44",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_60&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "62",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_62&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "64A",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "71",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "75",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "88",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "89",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "95",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2025-03-27"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2026-01-01",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2025-01-01",
   "Paragraph": "7.2.49",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_41&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_p&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82",
   "Subparagraph": "ea",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_ea&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_90&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "91",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "98",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "98",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2025-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2025-03-27"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2025-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2025-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2025-03-27"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "193",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "234",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_234_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2027-01-01",
   "Name": "IFRS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "B9",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2025-03-27"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2025-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2025-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2025-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2025-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2025-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2025-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2025-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2025-03-27"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2025-01-01",
   "Paragraph": "33",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2025-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2025-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard",
   "URIDate": "2025-03-27"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expiry date 2027-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2025-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard",
   "URIDate": "2025-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0001628280-26-050803-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-050803-xbrl.zip
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M*L=E?\!E\3D7@C^HY.9\>D/&],G6<EJ,J;"9RO;EV=[-WH;1]KYWFT:6PU7
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M*QE088,#*$Y_6#*D%#?Z_296"5SA[E!V^DW.!?<R&L_*ZYHO.O'=?Y$Q8,D
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MT7Q1/VDJ9JW.';E8,;_%D# 7LU[GKE0TO]T1,Q7-@M_\SL.!X<?=[:R8WP2
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MAY/WZ*?%+][[=V^]#Y].C][//GX\>G=R^O%H=GQR?/3QW8?9NW<N^OGTYYE
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M9!9*HK(]08QM(#-D!84&[JB\71=,L(=7ZXX"VKD/"^4&9W>W&-(A:K,'SS:
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M!U)@MQ+D11?8%"7W'WL4[XZXGWS3]>L;+K;07>(5^OUO_PM02P,$%     @
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M:#B52C81+184V(ED[ -C0J74I\K"[-(<?DM,BFSG$=Y5#X!&8 J0J#PFBLI
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M:&KY?^W('2X,7I,_8T67?CYE[*7 B?@;%^M?T3(?DW@-7QD^RXF\FOQI%0>
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MTY>TKES6!6.:_%B:O'8$: 0!DB8R%5\?R^_\GRB*TZZ#I., :BJ"D)M%T'H
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M-:C"H' -Q0GV<B0%LHE'6Y__VLK^9F.O_N;SKO,OZ'27]8MTXEBK6M:QIK+
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MD#WQ%'-3![)#_QH#Z1;CZ#<"HZW:$*JG2NXS9<GB@R6+-]8_564W[,,H?BS
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M<D>*I B28:H*,B7\#Y)$Y$CBOV4%2['PY<+J@S_1P@<0!:@AD<D38$>9P\
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M*XM)$<FXCR654*:.YF 5N-O@&K)\G!^B/2Q@0[G;M [9(%-*Q-P&-L/<"F/
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MYX-88KP+@@_$3$"LC^Y\^@I+!+*"]@8M#$_G$^&E=_HCYX7$(8MXZ7UNN>2
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MUO4L&G_+RBTK[\'*92KO:F9EH=/7I:ZB*RTO[]L1>SA/8:]A8#4$16Z2LH_
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MY4X01DG(B%+41OT/THI[B8BUEN2.[WF2:L?W.*[ITD1H$,(';!GX<OQ-M,=
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MYFI?)YYXVC^GP[O0]HVG<+$9;SZC.,V- ,E['*YJYL,2G-GZ>_%%0W."N92
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MA(C0Z8M9-*@V==H@[MB@90[-'6*GGX,[VJ8_3]D!=<B^M/N03 /.]6 O\V%
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M>6-*0TD]*GG0# @W,QT/G#9[03TUY+HY!\3AJ29>!@OQX+4_?G"V[[IFL 6
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M-7B%-<,]Q0/"WD!S?T1[5XS:X'%.@W(:V&,0JPUBQ]K^6X;!H6#3!B.M1$-
MEL'2-V&S-XI^A";48TVHEFH!Q33A.8NIFN/X1X#3B!O#"]F3_%Z"L_N<G+/-
MV&>-X4^[,;PA\*PQ?&\!4W<VSP&(V7GB(%0]<6#0Z'L>T-'0$$\/&DS_')DD
M5(\&DI@&.A?([$\>J@<R,AM.TOND(3:<I&[;O[$1%8:@L.$D_;#4:DLF*F#]
MX0:=RK*+^F6M=X !EKK?.]509)8WJ!QTIAQZPOL"^[I!WAML=A6;7<5F5YW
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M(.;XHB B7OP&A-4L3EI*GI-%\SJ)DE1R/+5]CN?=*C?P.Z8&AO=XT&!G'5"
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M,R4/^]3ACV74\%AG/U9R:3@=,E&RJ=4VV4,^O\JCG0.,4Z37TG).G(3$?*Y
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M+LCL^@8LQA:9*&.$<6]DYVPCC \D6@WK3D_[CCM-$++JH!!/>5YXKXZ'2\6
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MQ</*$ZVX_5"8]Y4\$]XZX9SMDR0B2T&51IKOI4&Z@'NZQ3C53E7?WD>(&:3
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MXX(9^GU-I\U2G/$BVHCAT_Q7#S81CL6DV:_[+HF&")Z.QH'^0R5:O_S@^%'
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MT$H6>C9Q"KU/,5T$'([0/#7! 7L:\.W5_?98ZW0?YV:+9?9$*7N"QG:Q]WP
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MPYBN7,W?I3KYL.=I70$:==-U:<@;3'R?P,T' '&N[\])]JUI'GG*#^ZZ(GE
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M",]!3]A>U(QUN9L"GJ@I@%9Y';^NF1/^%,+;<3V<[=*&M.AC?I3?PT1,LWC
M5</U(92K!JX:N&K@".6JH3F$/U4U-&!]3,4^VCT)H_;KO4J@L8M5FK(+JM .
M7=S1\S#YQ?/&0?%Q[;@'4.Y*&<LV&KD5JH$K7RX*P06UY?\N.MUG"]=*<KC/
MG3ORB1V0+R3Z_SLWAOB#.WB,S[M/>-RAHOV=^'ADV$\D>\0/;N*3>NFUI;7
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MW:T@K*D+S_YG)(,X\][V1U.JM<?DF<R\!7WZA>_]FXRN3PF/FZR$5P?QSS6
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M4IK6H/LKNGK1P%UK##+>X]L^.<CM\66H-W74FZ*5;NEHR*')[;-:$':$ILT
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M>)O^AZ$W?H/_FX;S6?__ U!+ P04    "  ]7/Y<TA[H$HN>  #21 @ %
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M!87C%_.K^.G5;)YB>&5($GFZI'OE-P^/8>9Z<N?@92\FZ"5J69>_^$S( >/
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MPUQ+R8=K6;L__G%.27O29?-I:0^$'L^IZ:/_O=$'[\$K>1AEW2;,:14'J0/
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M7H<J\IDZ=V%]DFFZGJCR5VEE_>KW@JI- "H0#(CGE'J#A5GO8[H]F-[^L:]
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MZWUI6]+,3Y_F#J;L*<A^FRY)OUE>=ODX;<ET:.SC; 4$3!V- M' 8T4U(\I
M.N0QWCJ^D_3^LA'22W/AYYA6WHE=J$8XNMM$.MZQ73<F=TBC PT#S"3UZ'#<
M%6O.+, >.V(#,<&9$Q1'BV.Z$;31:/W,ON+'\\H_.Q**.'RD)/(B;.3'"&%
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MDHQ""HUM57JT]0$OG<WN5LO<8^^BF$^B8_ A OI:N%L]J9M]"'? 8$, TNG
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M?IF6>7@?ZC[1=.Y&/9BI.O:D7A0:KKPHST&=KX&Z*.\C/$^@MKXQQ 1@A(
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MHNMEF"2 66F<Q9)3.]Q-$NOH7HUV,A&TM9Y^V(2>1=<T,S=W%Q%/LM1]MLI
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M[7VEI]9O<7&%!MIR!:AT7 5G'6HU:[1YU@D0G]VD&7,'6K?%>[9_5:DJ*G
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M:DB;0W[-X\]3LT>(KM_:/%M.IB?F?9HF/5U,7?Q/;)P\#02:>0D$$9&"#DJ
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M9\8 @6D )D@"@@D&,B]E,&VJ$1TU^-OCR5%BSYQW>!!@A:H70.X,4!8%0$3
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M<J!1UN,6$%%4 >.(!"C$_X+UUM!!TV5?30&11AT>7T"D40&G5T"$I^*\4%F
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M9PVWHV&KM]?*IX_M^,JDO3*K%#.?*W<159^&*C%5.ZY::G@,AU,N'32JM(,
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M QQVV'H8"(?#Q:$=@OQL^=27]GI9@RJ\:U4+<' ,*.D=H%Y2[IVE4 ZWF]6
M?#/F> XE]1+67P&LIG9G%;3!S>Y:N&.9VED4VX8N';0RU+)3M_@&H!G1P)/
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M4M_F@GC/,&-[C?*JM>Q'O)GMUP9H&[9[,[@#G$E[!QS>KY15/>W4WD&V8Q/
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M;2"GOES.JV2Q8[,C&B%B":ACF$O#O(##'8WVPCU'(O6EK<Q;2!L\$ :@-0\
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MFCY?C%S$KQ?S.(ET%Y4:>.O)P^469PX"#R6)ASA,4LXJ M@X9B)2Y%0;J^7
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M,3!.L_BE0UIBA;@?<?$9-<A^1)XTJB%G1.5L\:\/RU3T8:VJS1J.8#"0PDK
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MP]W;$V.'F4<KJ)=0Y2<TU7U1*O$,'MB^B7&L:/;C]59+@0Y"'X$,CB.@-+1
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MMGX@5Q9H2RDPP6DA"),[M1R'<4Z/4/?Q)*B645V9,WO^B$))N_#4E\OYJK+
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MH-X.#.)K)?01R( E 3*5!L$$,:<E@U0-U^;KY ,YLW*@4=:C!'(2&@_M 7)
M/?%QC5.:0G)&@9S-$C\XD+-17!F/P2_3NYA,5G>O3].LQA4Q >V4 TAH:#1D
M")JF9B1Y7^)JC*^4#%E%WU/$53JA)YME%UG V$"@<$@5\%"TC:&3P'+-B260
M&3U<:XLZE*^>%EG$WTN+BOJTX_7I0I]"!#$!BFA/2!"0T.'6BM/,%._MP)E!
M)9F]JY^F-DW0O_</_W^:/F*\FEX\4-N[=WI>S#]]_'+].9ZQ(L/US=.]*\'
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MRKR(&OY_=$A!T4 %"<4*LCR#?;34_ZCA_MO[G<+K/9S-:Z5\H\AVBQ(PF.
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M4#Y\MA<XN*+/Z:B-#&_(1^@ZQ8H(-(S8-!,_<9R(2)XX&Y:D.YC<!,6:'I*
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M@!4W03](*=AR7//SG?Z,O8ZG)AD"KA_81088:L!A@\L,U"A #SF@&$$/.^C
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MISD:MUN+:2[I6JDH+=4R9U(II?8YIT==K97.I&+]MCK3%ZNNY>HJ1D>M75
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MX5?<LYE/POXFS +CJ7KO==5O=@*+=3JYI%\KQ'9OSN(J?4P/6P>Q;(W0#&!
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MBRE,L!.Q #MF>Q*I.Q%UT;9? IT\T>5M0,EK*GG['$K9$T\; *DY]:E4;#+
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M#,I7;XJR0E;(2FAKYHK,5&H_"=3SH^]V5[U=,RT-<8N;P&@JN63)\.NEG!@
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M#X=I3:?$*@P ,J:O>D\\J= ;7A7+ #5]6RPU@JZS^0]2/#QR:M,7)N2!"(J
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M;!O*=9BQ;"*-X=*3JV4HS*@^3#Z8^ZANX'%?(_[N;7F'[DB^J\5EX%D]M A
MPB2 *$QS&*,4.PC3D*2*A9&3\BP[GDYV3]75[*6K1AO3H,E&'<:@4/-'%U$
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M<YA@FD$W2)$?890%8?9721ZX7Y7=B W&E_HFINTW<2A%(<>E$8</#9)>AE)
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M14NF\- EN=?'1340DK%T.KZ9'&'-L$7&E)-H1.H1W2#CD(9WVW;38@'.%;]
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M/1F:A\1C:X/WC>:30OFD=.1RA^^^."0[3 HO$SQ*D#)5 6@4P:E39B-RUCN
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MU*=55ROU,3#I[W-O24KR9^9"U-*MEN<&,O>L<LF#>(9J+]Q0WV1178T_Q+-
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M5"=<'SI &W=$-DW-_K4//IH>>YT=C8AZNXV*T(?E#[_:([7;O/[7KP3?\\Z
MN]#Q2U+G]P7SX"^:CRBO_D";+6$?(R<WEX[-[A823(VDYX1)Z'HV%NI0O@"#
MX27<H@(5A04>6EP'J1=XAXRYX!G%!IX9./YA45]AR13,GWJM0*R<H>@X98A
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M)6K!EC\G<I9,7F\%BS:ME''+=D;\RA9NFH132S?S>1VG>L,(WW>D^49(,0@
MSDG]X?L3?5K8_+X<9]([F0LCXJ0PR#S+QF[J)\A7/\J3@6+:>=EGN-Y4U)7/
MG]#F(/:?KY=W:,-ZY=;@&ZNL.$P44 AP4YX4E9,Z4U0O.9X;Y@. I 5UD#+
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ML6PL%J[^7#;_(,W'[6;STAJZZ7Z\29PPAS.#?AHX."%^9B7BID@/)L.F:Y#
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M]Z2UB)9#Z![5(C!,K PFKD<]8&(G*"(6LF*AAEDF01JVI.^Y:':37W5P>9
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M[EO9_IY^CM1]P(\+,0D=&+I)0/U%;,$L1;$7A9E--\5R]ED%ANF0GJZX!UT
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MPD8]N;[G;V&<>#!Q/!OBD" _B[W )YZL#S,NRKSC0K_%PG*2%_"7^^9OP';
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M@TNG9=ZO7I%L.1/+@8$=,L!X[K"!'AS/%WMWEF<%!WPIX>(^^8K$J[GI&B9
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M6+!#, ?<L#TY=*&O3OJ"M(J G29@KPH[%.B5 :@!3!W ]0&=0J#5B 7?,YW
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M<IR,QS/&J><&&">![-JL*MSV#<EI$8&"X>.)[^LU)?RB:O4F+N*[>,?Z7QN
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ML$;_?U7W.L2)0.G6E5,7S3\7[=;7GR(==\)2Q,]Q+.AW[N/+2#:^C"S=OF^
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MM +]JP6)3ZL;F^/TU,-)(7>I[T/B,EL3HSR F9.FD*0D<4,GB),HDJE%<TF
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M0W]L0,9>B'\:/=3HD&#=]BB!6M@(Z1!V;HVT1M'H-+?Y$]7_I)N_H]66#KM
M:>S"U,LS2%(_RBGQ8D?^1GI@?,N&I94'OG&!"OW-!G@8-Q,&M%.S [<;T.DF
MQ$T[+*645&C5-D]9S89L&[#N3:BA9(T15<9:JPT\M5P#M<N0C]JDC7QLOB=T
ME_'VL*NZY!*<0I)C'JH791 EO.:?$_LX#:C+S(>N+[0O:#%OZ T[U70->6KI
M&D"3-*G[0W65U_6(RNH]RR,ZI-2"/M$C\5?SB@Z1,.87'?R\[FO,.VE_6E7?
MA8^$9V+=E>U]*Y-TB]EI1R2OGB65Y@E,0A>SHX>'$]>/(S=VU)I:RPE6>LWU
MVEECW@U>7/D12D#V]K=?1#Y@4?[*_K\#!- >D:H!D"18UB"8ITW-0'#Y(.<
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M57]'-6F/'_CM"WO+7E!#F[ORK\</%5OEZO-,'!ZCSC8=,*4QCU;'":5Y1+Q
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MO.-8E+-T#J8(L) '"ET@WNT["DRK-<J>Z1_UN+Y_;EXS  G XN>&BO0;KY^
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MW$:GSC<C;^_][*YVIUC?(YZ>Y;;_1&8R) .\3$R]'#?Y'<LDNEW@]32!UP:
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M+_4M+?7Q=:F=<1R&0/N  &<<:^2X-NL7Q=LGUAU<*9<UVKU2F\,MPQV0QBJ
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MTZ'*SE9"*\*D'!W3+5ES,8 W4OH8=0F+TVU!4/WM9WESL4NI*CUQ@^M&AT7
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MZZ%'&S_:4?XE>  J2@](;RE6AGMA^G/;SF*ERX.0KY.HU=G5)'W?[GI*!"T
MU='E$1AAH+'&P!-L)(FAKB+]Y0IG8JJHB\=.47[,04AWN"C"6SA)Z"_9"$$&
MXD'T@%*V%<? ""T!IY &%R1"/8ZZ/)V/HJXP>X9]3]HO NG'%_>M\A>?""27
M$'!)(8?1Z3+N_W9VS8CH$U"5H1JXM8K?&817>@&NBE,*($G@J?,S4UPPZ%1_
M=X]__FK@]FC*T^&UK6J'K@:^'U4S/ZKNM6EX6IGIVG!@H:% H&"!%I@#*S E
M01$1C#L0^>U^^OL!SRGZK+,*MPC;=M*F\>;\Y8WX' 2:> 8"1%009!R%_=U&
MG\?+NW1(<VS?/4*@",CG##I7&%>. ^5A )0P#95PP>/_>QC1QTMP(A8[/8UH
M"XPRN^!=CI_\=-9<TVMK4ZF.=Z&>I#S#V\ANFFPV>[[WL[O:?7N\O]>3YSJL
M_)MJ'$53IT(<'Y_L_KVNQK._QQ]$M9YSWMP]43F.JWL6W9FGW<F760X=G"[R
MCSZ/9]6L\CM/.QQR0 >)@?-6!4,1XKA-GX]#Z^3U9IK+QOC4E W[P<^^>S^^
M]DV9V%<]2<MN+>Z!T "#"058DO@_A9/?-H@'TX[^80QV=M3L]THZ4&41GLBW
M*FXPH;)Z/%LQ 9<K)F#K$!/!@/:2 BFQQ9QC)WE_QPGM:"[)C^@"/1MP[4"5
M[P2BVUO.:,F ,LR#(!1CUAM$N"\(I&6<=76!FA.@>8(*!S[;NOIZ\>7?__ZQ
MWE[,K:4$BL@ +(*2&F.8HZ2%@_+VJ>6#XQ2]U5F$.+#Z/S].:OU0;2><8 (D
MU@Y  8DT%FFSGFFQ5?MO'CKT:5#GRC]=A(5,M;^XO9W,<[<OQZYZJMRC'HV>
M+V-(%3%6Z=&KI'9T?# R;O P;B P:$R88H;WEW]W+/5#%SAVBL>>E%J$0_4F
MHM_:SS8ZGA)9"1 F.&[P4$G17P2Z0=[0AK!W3_X\!96'L>WO)?>I;@ *$-])
MA TA"JO^3JNW$#BTMW6FVO?#Z 0=#.QA78[#1$_]Y.G7>Y/:&7^L_U;;N^GL
MO_^ZHQNHUT"Q$*4CH+#$*8ZD:.%T'5JG*%B<HL:Z(YD./3[VV]>_:VNKL4_5
MJGK\O)V%=/>M89ISZC1VA =HK6X!BQV/'WHSRHF&'!(<$ 3.5__X$EVU47/N
M^[S-8DJG(GX-!I0JY#T,S+A]#?*FWO[UMG[Z.3ZZV5W2AP0-UL!BRX)#.\4]
M^2;GBGI@E,RIWOZV*.> CE\!Q[ER@4C(X+ZS[,,065UMF,WC;'75&60W\/;P
M\=/U2D:4""D914N8<E,X,,) 8+''"$M/W7ITL[V1UO*!P^GT=%W4YPIF8&U^
M^'KY2S1OUJ^3;J11:;RE!<:X %A@6B.O+4=M=+KVV&$V]VR:/4=()1^G:F6
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MU-HS)-'& 2$V !%M1*"E<<!3Z2T,7%$Z7T.&E]8S)!LU8_4,R19E%==Z?LN
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M"@%EB (AK %1JP<0G$$V!*%0J"DZ_C*:19YYB4X@R@N!Z),X\@-E(74EQQ%
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MCB:F@XGWO() *LE Q Y!1+'H-]&<NS%SO9>1!I!_1TXAAM*ZJP]!W!(@#4&
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MPRT[UBCM0,\M[68"UH^H1T=]ZWO3+-?-[<*E%^;U313(S6Z\C]]U8AXW&V?
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MYE_>=O(0=[F/"5-)IO!5&2]WFP1UG:(TVVK?]3[/[L_43K=C A& WDH@(*?
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M&G0*L0KW_IS>?D]&0E@%E',TN4V">F&$P?,YY*.V]JQN;D(W:@:U]LP6X<6
MLWWZ'>(02&Y-FH-G..%&0^VK@F<=/4&FP<[ UI[9@BSL_K283 D2[:,3E:+
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M'"8CL?>B*Z=V/#@J_%G_UFS^Z3?OHB1^[%KA3UXT=?9.YJN7&L:D*DJE@C%
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MK8@+ *LE<W02*5>!X)^)AR>(.B2(:P=DY#>@!$:[!TD6+:'98/O,9DL'76K
MZICR[ W0[WYEFM$@^@^_N+[9>/<J?JR^]I]\,L1V/9FW^5]W*0$WG'<PA6?
M;!N !@L5IA+[&3N3C$'1);OL8X%]=F14H;(/J#ZXG?;IVR/[_;)+(&V,\#@
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MU;+09G&;WHJ35GG[9[(XXP?%KYKX3S?;K)K_IUDL-W^/PK]K*:U5T>#4!#K
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MCWG9'YOU(BW;O[/[*,N.T,A]?/(']FW?JS6.^XG6:?KM[>.V3G701@H#J5
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M61L:3S0^(03HE':'E&&4*BN\GJ]\Z-)"P-T"/S\$W,G]XB'@IX5-[:&L>(J
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MB;;Y1O2=W&8M4.HC_R,PC2.,*G!U2$?4WOO4??FC2=\]$>SU4$0;DG'@130
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M-N/A] NKIT![& T(J82&5GA#<GI%92]8KI)[VD#T-!RO0C<]/H,^DG-T&'0
MTBD+O$4,!1ZTH_/5G[3ML-X7CYY0.%)4@^52!;I^OHG;HS?QH^0,)8'Q1(!X
M#C77V 3APFP8.[W/>F.:8R%M)!D5OA3;./2J*RGCB&O12])8>T MU\%RXBT[
MKXHX<^%ZHP[#$#6]%/I#K-GHV_IRM/:F3[4QKD1&5N:6BN9?]6%;==E6S'@@
MI7/ Q6L;<>F-H/,%&RXFVXHI!B1C"*#4"!U;ACAT([@L+RK;JA-+@[.M.D50
MA97Y)C$QC17>NW1:@J'*F>CN"0>H\MX%(C6B,SYLMF^R7D^F!QB.'SI'D$Q=
M$-N:,GN736M02E@.C(Q?BFC A*"QP&*^ NWNO996>J- XC30ALNG>,K@S[V_
M:U8?_?*)#?VQ64?[_-MM\R,90*_]TH?%YD0(4Z4YZL1BH(7@S$;36D&><77V
MWD UR!H! \W< JD)=;L9),WR^HM??7V&)I1F4&,"B$0H.H;"6YR3I9B[7NG'
MASDP-1:[JXG ?/)I>+E-SS;+ZP=2VREBV )E8,H)9@8KCY'6.0#*6ZWT**F)
MX#,!JZNPLGZ-)JF_O=5+W]RM#UAV(A4J6@A:R!!I$A0K&RT%Y&>SM)[?;^D)
M51, <#)Q7>JSJM 6&"P%@$)";"@B2N8,QQOW6;6>O.HL'W$ZCE>AR5))_-(N
M;A=ZUPKEH;ORP3$Y%=*Q5 .%N0%<PZ!(_"&Q\X4'S]U]O4&,GA Z4G63RK,*
MQ.8\.%M)@8(.I\1"PX51S)O_Q$2 N7#1*RN@4TC%QR1US#EXX-UGVWS;-:!<
M-[<+MV/M4WXFHH,(3H-(8C0G# Y 8A0 1HPB"'W\)6<4Y A;*>VBS@+!$F*K
M;"C+=OK,P9OVP4MV0!X1H"BQT=1U DA((:#.,(4DL]#GE/2>N6QI#[<8^L84
M1Q47\ ,YOZ^]:SLW>]20U"M'8 BL94$Z:+R$\V5+=>VTM,,[\X4\FM"&#F;[
M,B(2?U_>16H>"/GDOZ</?XX\"SE07A% X_>94A '-9_+DK?G,N-UBJ%S D'6
MA-,3!LFV[6C<V<.U<,_E9\CV7@$IM <6*<<<HP+J^4*)PVC)PC5_,;B>4?"5
M&:&/(^%^-M1[:,3W=OL,Z?WZYQ-2Y,+ORS\62[=87E^%%"E))<O/,(,Y"PST
M#A@E!8?80(9R:D0FWV@6Q,6%0[P^D5=A&I\U&/$9:H4CD=J@ &8^\, =E6Z^
M+K1#*,DZ ?+"3T !H=>IXE_9S9U>+?3M=A1N/-B[:;A7RU_B25]Z=W_D/][&
M.^\YQ\.8U&7= ^2"#,X3@WQ.)M#X.\N"L+IP"%<@U"JT=DZPFDH))#8V_<*"
M(9CX&4>&]']1@!>.T1&E-.H(U;*5.8^OB4WXY+\^SA5O0KQVGI[1G['&']N,
M_1EK=89OLD3USLBLK:Z>![%X.IBW@!A"$-9"4CM?+[ZYZWD>5W[R -\MR/9A
M'-H @[$ "!L=-!$8'MHF,\TVS-E]Z>?F6=!Z?$=,*N0Z;)5NJEI[V%H*#-("
M.&8DBVR43L]WXC,V7!JLTZ+FV) 96827@,OV-$Y,$#">"2 M#@A1;1&;K] M
M:\NEL3DZ6,Z%8P_)50'(Y)KN;ISV#%]J%3"40^"]ULS$'TD]WRO@X>XJAUD?
M$!P_00^12!V8VLEE.[_G*CQEV)6Y75QO)?9(7<H@<H!!'*F3J?\7E@8X[+#U
M,! .YTM)/&?GI?/$9L'B5)*L J<M0;JVBR(X!I3T#E O*??.4BCGNWY/;+(T
M^F8V!L<05:V8.W52 ]",:.!)X(0(Q=V,;=M/;K/T#3P*$'+@U4,JI6M^6VJ9
MWV;6,FM+@.0LI$)4R7A4Y)YD%9>?L6:%T.DCY&8&CE>AJO[JF^N5_G:SL/KV
M57KU:N_K((&D00*EO<90!1(A,IN::MUBZ13JF:_&X6*J$VTG!IP3FX9^,D )
MLT8;P9F?+]WCQ"9+:[81(/ \K'K(HR"PMHE2JQ__^]?71UU6J4WI@1;0(*B/
M'A!W070@:.WM7ZZ;[_]S_XE;_/S\(EV(;(N1Q_6J T,?P36#N%B%0GG(S8B:
M]N[KM]T@X[:9"C0 I2"+MSVW/C 5-)\OXG!JEZ7K+F:^Q$815K6P.S$1C[%X
MA**/@BV$00J+=*<BFAYX==QFXV A"V(]!%,KR![3@S_IC3_A='@90-3U'% &
MH7#&$H_F2\_*W76- .R#E!P(#A=;O8!\^^<W;S?>;2F["N^7X?8@7OPD9*,]
MT-I(X+PBA&JDL)QO7GD/ DJ'8.>%Z8C"+!DG6VW^]U/*OVR[4$3\Q4#L ?9$
M,1H8@:XK R3HM=GN,'[JSBWPMYMU^NK1+WBR8.ERQ5F,NOXLK@$7)_I<29C"
MR2E7P&*+H<".=$4=SD)&T0G._85U*.X>G"LL\%\7R\77NZ\G[ER*@91( 68P
M0DIX'97:"")_LFAAH?<163,&_TH+7O]Y>N.0<2"I(4!+HX434$C592-G"WY_
MT4(MX,82?&_^56&L?EY<+[<9M\O-^^5WO]YLIT^\7WZ^,^N%6T33IWTJ-$I]
M;E+,"Q/G0L 4:X)FLU!S=UVZ=GSFR-$DPOS_V_NR[CAR8\WW^2^XQKZ\S#D4
M6[)UIUO42&K[T0<KF78QD[<62O*O'Z"J2-;.K*S,!*@S#Y:II1.Q?  B K&\
M&9@>F5-M(V^.1*=14>(EE8*($8>1M*8[MZ,_#'8Z0;2#(C.G&]P\I%ZQ[Q:S
MN+UGQ_I;8P04BHXG\IB'X"VC>">V?C"MX-"WWP)8NFBQZ5&D19Q;9UP OQ]K
MYZEQ&@)L!-#,!N(9P=R/5XS1A8/<_2S&3L@;6LE%0/F+GR^F]4W]DI/]"J][
MO9/3_#N(/"!8>.:EU=Z,%W _F_S<9^SPJ#K0"7A(%5_:7JNOY)IX*Z76!#?U
M5JWNJT+>BP@Y&@T?Z8%A,BCE#*)HO&.Y*Q>Y _494#V*PHLXHC_[J4WJO(W"
M_1(Y;>IXN_W\''FOXBWWU+?C8WW@46/?3DM!"\$!4IQ;I>-^EB/6GG1GY UE
M//8%\+'4_@8P_M)!MP6S"OIX6WD%/$0<8T4BQ^,EG5S R!M*B!H'X_VIO>\>
MH+TV?;D)P>AHFUD_N_-^'O_\OEJYWMU[M+S^S1Y:JIQ)^(4=4);A@Q#>K5;\
MFE:\?EGQ:&\A(H"B. !(G3'42J.@:1.?>76EOB;W'%_IH!<KD 4Z1(L\TLNC
M'4ZQ@:@%0V<LF6\X2L_Z/3:ZIT^1%W%]7J?T*C^- IX?">@Z98#QZ8PDTC%,
ME(\(&>U6W*>OC $\O0)A?\3K95HI$%F'H[_48Z (LX 0"8/A1+,PWJOA(0IS
M1WDNU?PK4.J@ALQ/*=??OOW?C2)Z180'V 06]Y0,0#LN@7'"4DR-152VN,]>
MOEB6LKOHIKE84)G5^W_TI/IVYZ?ZP2_FE=UXV D:6Q%)Y@8(R1#0@F'@D!/&
M$.:%@2U4??CKN6->O:J]!P%FAL"W^&]2;[?;J5\&XIX.O01AFZ@6T3O4.IYW
M$(,0J(78QS\@J@4 #GV[C!&30Q@0O4BS,#2\;(]-#FS 0'."@(-64N>"X*+-
M#+3#7\]G4EZNK1.J[R"Z B[[+\UCY2I;S:NZ,K]7UM<S_\S2]@5G@8N"B:<;
MCG<;]QR(J&QNB8,NA):60(OERH%'%XTVPXJW,/OA!$?Q.I2 >IBN0^>!4E%B
MU"*H.!'Q-&T#F':KY;M@>L;+ ,(M:/#U\1OX:)#:" P,CH8U8I1P9D@@K UN
MSEPVSYO56!;*D#K(#*\_'Z(XZ_EZGWS6RUXW+]N/<N7B?9[VAR,$<(T@-T@@
MA]N,'3KX\=*C81W5V/0IT]Q&33.)?]),5UIY/IK]HY\T#^G'+_YV,4D?^'E5
MNZ]ZXF=_5/&7>5,_L?MD$Z8B!![B18RP3S]%'Y&1H*!@RKDVCQ-]T%*Z_W0Y
MY$;76&\([?5Y\?=H)*ZZ6.K:Z:FIYBN)/$P;ZWV:NW7!.^,9'^_AP;$K*WV\
M/&Z/,KF.9UE<SM?S[3;V+W^^RK0[]FRE50!JU:K4(XF4YE:TZ49W(1E]&5V_
M^UL]B>M<K70P^?RB@(-6!;4&2&$\H((@!H,D!+8)\IZS9L97RQ&Q<<P$ZU4C
MF:_:$[QL1%8D!@P9F3+X9#R.)04,0HZ4@)#Z-B_BKRQ3ADW6KUZ;881<+EZV
M7.=G9CR))H2R&GCCO&!>1^[:V%VO+I0/,[VJLQU,.L@VMV-75VF>=#7_>1/^
MH6=WD8MH[$7N_A:-B6;Z6/GO?T3>K)Y<^_2VLQ5(>^$P39M6" )&!*>(:Z@T
M;H&>;JL7":DNJF]&U4-FI/UMX69-_3>OW7>=OAA_FLS3)-#OS?3?A]DQ/CH9
M6' @L<!(2A>=8-<"5BV6RN?K#8>AOB6<&3!_-#-=V143'^MO=_[/KX>90*EE
MB4(,8&VH8!(YVNH-]>@"^<*4PX&C'VF6D8"5IJ>EYX##;L6!NQVC%*-(/"'-
M@^:.";'CQP^9CO4JO65$G@8QK =3VQN XN$M&Z  QD8!IH9^\<^Y$7S$W, 6
M%&=/'^L9*6="L8/:<N>6Z(F-N]4M[/PE('CPE"?IJ13&4SX:B2I #USPQH9@
MN11M'OQ>7ZEL\'31;3.8H#/#YHI0^.ZWZ>+V\[2R4521L]NIOC]I'A 670P?
M3W[$G(A'/E-:MWGD:[-6]OS%(:'3N[!S9QPL'JH??CEQ_+7MH&D\GB7R)&X'
MB(%4$(' L;((6<A:);RV6RUW3>R@ !I X+DAU,[XW'KWW-H>D@+I,0106\,4
M<8ZA-IV&SEVWC+25P>+>@ZHA,\0^+=*FB!LR[<PKNWQ>U=]GBVJ^QX:A'!CO
M"" .>L4I@D:T>9$[L43Q#R8===KT+^!"</)\N*YKNZ]U/,]W;3H63U?C- 4(
M>R@<DA:=A92#BQ0? ^@/*Y<+N1"T+ G_4$V\^UA_\M__.WW\YW6SF,[7N:.>
M D*EBM>PE4!3CX -T'K%H'.[0QA.'RY'5RK^<NKQC.E'W(6 9YDC\5M<OW9Z
MV51P*<,7P>V'>J,S@ U)@0ZE# [*^3;63MOU\C3;R *D7D5?")R6+/SF[3+C
MYFJ6!C?,KN_T9.*C'^)V.8(IJ9E" R!#$II *2=MWOO;K99GYD$6*/4H]C*3
M)9=[I7GP*:^POJWJ^!=>U\[_>$AIR[,KYZIE^N'D8QV:Z?URM0NZM%RP6A_]
M6_IB]L+\RHVY+'&QG[-J.7TE41/Q_'Y%S;%D.8&C[\\E ](1&@'&H$7C#9%^
MG=[+7UW^B)L\-<VM?;.8+55V\Z2RU:)[G9"<!8;3$$U+*S T5&LQGDA>)3=W
MR+QGC.V_M_2KL")>_DZPM);=WG ,$WGR @-$O3:!",KL>%-L7Z<W=_0])PJ[
MJ.Q-7M=?[9UWBXEOPD$!7-)?K9^%A[_$.XD@XWVNB8HHIQ1 );ACDC(ZXK3U
MX>[SO<*G _?"DTX.!K@1@4!1#@%W,%C)D:.V3<7(68N^O;OY)%Z.UJOV*OPB
M;NAK/?>W39K0D#II3E+3RL_'NT\%KH$2(O[BK($BNGW0C=@-[B2M93PC] R1
M_:2<_O15./XV'H)12N#$#MDD+@FT#!@P',5EO0M\-]LY"P(+R0GK$1UG0*^#
MJG(G]=P_+N;Q8MA(!]B@G#@-M(<Z)09P%:A$IE5EV/97RP5#%WTUO0@OL]J_
M^%M?1[.W/DRZQPX8Z!A W$*).;8>M:G0V?EL;A]Q,,5?(KXB;IOE[;PMDL.L
M6&F PHP#Z"FDBA!']'AAB*-D9D_=&@)9?:NG"*1=Q0.R,HN7">') 'SW\Y.>
M1S/Q6_/MSE?3#XMZF0KRG*N]P2$/!$@&!4 !QS,T*(CI>(,*SZ6^C+2,H6WO
M077ZYE![>,<+)8 T& %*J4>$::C0> ?G^?3G-M*&Q=1%$.Z@X,SFW=<[G<Z!
MS],F5/.;:1KS]"'*/'4'\E-;Z4GU'[UB_8^(M7ANU.GI>UZ9QAV]:C36P 1"
MDV%KD6,A\MZFUV@?M+PE<'9!2Y-1=;D=T.='\A7+2_X_--.--E/7S6RSQZ),
MD_2HB;>5P"RZ6#18X# .&E%NVPTG.6O1W%[,B. ;3AG9F\_M;)^U<?TDSL/[
M1@8'%#$8<!2"-%Y[3MH\&;1;+;</,R*N!A!_0<4HI\SMW[=2QS:8"X$!S3$$
M3 E,G#=:L',[>K5:N(R,WV%<DN$UD1EF:4CG;#6E\[?J::+X<TK\'BO0L&@$
M*PN($S1HS;!P;>IT7UFF_!>ECLIMAI%T9M"L1//%SQ:3)*ED/MXLUIUCG]*5
M-UAQR@/#%0?&4!.0M<JC-D'^5Y8I/Q1R.6CZE'01<8]6J7=;;C>BD24L 74,
M<VF8%["(-+4S<B6S7GZ7@7 HS64^P=K0#V$ 6O, ()/44XJ,Y:]EG1W[=AG%
M+,.>51?+M#LFFKF>C)I(N_7TH@,PGBD J804,H>8"26<4.<DT@Y>_9+YB.JB
MN[YG$O=Q5!WA@TL8SUJC0* 0"84IE*Z-L]<=,/SM J8?J5Z,CIU#J]>TZV@Q
MSJ?1K5A,(W>VF<WC/W"SZKZ:Z&F5!/=U<7^OIS^;L/4OK]?_\NOJ7RY%W#T%
M>P B>DC''EHT.5.S(0*&< =<4#A0HI4(=K2;:(Q2J\T#XISPXG,$*&UO S F
M J0.1M$8H0A(2(+'@EIGQ^M\=Q$KV=^K^L7F_E4^GJ*+<(O?+:([[V>SZ^;>
M5/52D;/-1^@G3D@T50Q%T:?""GLM+:=B/,@>HS(W&D<$RQY0>]%<L1C<?I9Y
MXB496,92FIIXQ2V-$>)BO)2IXW3FQF$_6&@%L0Z*R?V@];/6C_K']M-N )8R
M'#>=%4 100%+$YC37W'9)A]XZZ,EJK^+GIH^A%;$D=+U8-[S[YX$AUBT(H3C
MP!).L$[-P/EX95$7LY,[TR/G13DN%C(?=FN>;K9]R-2/[G'9>_-]=)^;G][O
MI"GL]4PT"&B/,+ 8RX =XI:V">MT7#[W 3HR1)IQ]54X)->L?6L^+XO5YS\_
M3W0]3X[=_RRJ9696_/E;\[%^C#\N*Q-VN8?*QEM-:( H<49*+;%OTU2N?\K>
MZCD[/) 'UG+A&/\VU?7LN5/2NN7U;!G:VVOF00F0CAJ@";*0FVBCM6HL?@$)
MN?/URD5M7WHKX=5Y/ZJ\%RH3!"@50KQ/G&$P:"=4FZ3C(Y_/\_9< JSZD'<1
M?M1K^V.7(^LIT)PP@#0-@2#-A!LO3/@:M7D>I',#<B!M]I8TT7_;I]N4\:AK
M%V4=A9I^>)X1<&%?IQ9?[JMQT[E,Y'G^0SRUA>4"2*\H4"($;[BV<K<!T9M\
M_GL^RI]3:)?3FE\F3NP)0D@@!4SC;J@(DDGD59N$TY.+Y':.>\;#WCW9BW O
M38KXY.=#'4D?JEK7J4+DJ?%:W,NK9FS=#Z/7O]G#,70FX1D/((PC-$A(G0@L
M9U8$%3CY10Z@3:-A)??4]OW9)[DRS6*^TI3?RE7:K3U9"DHY XP3'C!)'/-:
M8\YMBP/J(B+>W@%V$D_'2G2&54X1[L#?O+N-#"93=*?;U)(!G9X7L1) :04Q
M5@HR,=XCR0YQ993V# R*/1/_$@V5!K&7)\PM@1@'M+(HO69#)9A"7(QG;.Z1
ME_MPNTCAI^#30?K9J\/B=Z)G^R4:=/&,OU[$]6O[\S<_K1ZC1AXWJW$W>4*4
M 4.\!5 9"C7$"M,VSP=MURL((EV4V@PLX=SI(1U/ZZV@S":S%K$4 Z;QQ!90
ML&A&<-8FBGHQ(674)8YSXXVON2)NQZ<-^!3)J]\UTVGS/8URV66&D,A,, %H
MBAUG+-B]RHP![\D3A+X]PZPC8/9NU[ZT=VFPH[>;=F]HQ9)V&CQ0P4. #%(J
M2.5]JWY*VU]]>Z?993"Y4*[9V]#,YDE:9O[)[[G3VA(@H5- <,Y4H,K;W?*0
M(]UF-CY:1L'SN'CH+M6^B\0ZSF1KZN=2MP_-U%>W]?L?]D[7MWXCZKL7Z*5I
M]AA#@!-,A"14MQPKVFJU,BJBQ\71 'HHPAQ:"^BWA?_6_%G'BS0-M8O"C8)N
M%O7\)F5L/"XGTNTQQP@%&BD(:,!,0*J"=GXT\^@,PLNHHLYA+@VEW>SF4SS,
MGV[Z=,(_I\8])7N^\[4/U7P_F!,WI";, <N5TXQ2"6V;)DAMURNC_GKDHW$(
M761'V,?[!UU-4U;EZFB_J9\?\Z[B[^>SR'9* WF,A[&>K/)*.',0>"A)=,$Q
M21U4$,#&,1-Y0TZU,=C.7+85WL2OA;<A-9._;\0)7_=WKY/\5J/.JWUK@W,(
MC,<6$"H89510Y\1H%_*KY+;"JOQUL#J4)DO"Z#+]9$MTZ0K8<[L- H9)!*Q4
M%#+&\9CS*@_3V J-ZE=$8P\Z*\)U>94%;P10T:8 7BF'-%::8#4:[+HA[F7J
MZ*\$N<M4541SL34+NUGH*^H=!MJF5E2(<BZ"<%J/YPEO4M8.8[_DTT!G!95T
MGVX):)>+: , *1@#GFGMH-7*<9;G/&N'LU_H;:$/%170+WK=Q/@EV^#/67+5
M_]"UOO4I2KZ7QP=QJLG2@*CTK,R("G!GWOW1KM&O+M8.1;_8BT3_:B@=5]=Z
M=I=R7>+_I5+51SV)RMD3(%44R @B$.]^&KECB*@V?40Z+M\.>[_8*\88JLJ,
MQB>O^N<7;YO;NHK,?6BF[V?SZCY=UA\6J3KL2_-33PXYWA8%H*PS0&,' S+.
M>:);@/"\5=MA[Q=ZD1A8,7U;<+T6KZS$&$VP=0W(<X_*J\D2R?'CS3JM_IO^
ML1;W.S__[GV]2@^<Z]K]MF8K_A-_05_/ 8GIH5QF+%'U5F?S3(N??=:5BY!8
MU.Y8282,5K5$ 0&I@T'">XK4F.'9$Z3V,*)\)?X7M1RVCWFD3N-X6A"CD*20
M.+2;*#SD9/+#1.;.+NX/10?FD?>@EZQO<1NUWR_[^B0O(9K))N5+!P2U"0X1
M \?;9\>HS-W79DB0]:*90E"V>[U<-_6\JA<I;V*5_W,@5X) !HPB,*)!>V8I
M(G+$4ZT-Q;G[TPR)OMXU5D;FWXJM=S[:YHFYZ)6ESDZKV5.S*[M,X%F9T-%1
MF__\P\_OFLU_LLNRB?Z:=CX (XA&7NN@6O7IO)2.W#UL^H?>Z-KIS:4>Q['Y
MK0J11A]=R+5M_C[^/K5(29)*A4^I%W^RU/7473?3AR9N4O^LIO0/!G!P^B-J
M2$=G(-'E<7CB@L!XQP&!FE-!)<-RO#K3@1V>JX>'2653]=5:\'L5>T0#S;0&
MTA+)@A(*^A%;NNR2]Z:<G)/(.3"P_2)=%)',L"9\M=UOPCK%?/VG>[<%LA1(
MG%+:O%%0^."<&J\R[32M;\K1.1-H/6HI<Y@\F<M++I[3=:_N)]7<3ZI[;98I
MDXI0"(+@ 0@A+3!2&8"P--@C'FRK4>HG%WE3+DDKG/0KU\P ^>+7A0'?FI5K
MM7PT2/VEOOKY?.*75NQ-B'_W6S5[6!R /\<.:"Q#JB4(5$F!*&G3AO7\E=^4
MB]$:2@-KH(AK;YF+N'6JSN*AFEZ(:EM-JJ4.UY;PVJF*;OWG:32FE\V.7XLW
M80$4#0JH8!'UAB&/Q^NFTR]ON3MO#GFM9D1!$;O@ZM%/]:W?]?7V@A/: .4]
M!X)RC3#RQH7QT@R/$)FGXFDDOZ('O121O'KD%>BEHWPUF>CIM^_-AC37(VLP
M <X+'+GT&"@1?T$2PZ M,D[#T=#7A8,\Q5'C0'-PC989<TQ57?7")VG'RV$I
MR-GW:GYG%[-Y9',Z>\EOF>F4RW*O_]5,G_]6U\Y&/JKYM)K]^Y+IJ/U3T<MX
MU(&%TUL8<4WIYEX(& 4!F),F'J.0 F.# TQR'9 +7(S8!7&'N'Y':<6?]>WM
MU*\:]*[*%.-B'Z+.KI]T]H^HL^LGK;S,;UH*2$JCDSGO@2;<@$"4ADP%0OQX
MTV(OYR=W,/(2_)T>CS6"?HLP6?_JTR"/A[O*ZLG5U.N788F;;!B:?N* 8BLA
M(Y8Q-%[!PD$2<R-O;*SL@?5RQ96)OXUIC1N,4(M!M&I8_*U#6F*%N,^(P#(:
MGO8 @==AU4$?.2.>T_D_WR_27*V->9T;= >#@116 J8=#M $Q_"I"N:@9V9)
M9/SP$D)_\9/Y+/TN69)L%>O<6;,X6'118=.#/#/B8!E<FO[\YY]?=RD61@&I
MD0080V(%L8')4PB8>?M?M\WC7]9?7(%@_9L7#+RLE_O9K$_M=Y1B"2.^KI>D
M5W[VL?[J;U.(_8N?+>+>/89CFL9!.^ ]%1''0FBW@XKCXTI>62OW UFOY\$0
M\BW"$/D\;=PB&FK+9YGI8V7]P>N4HFBE448!,XP93PW9F+@[N"%RA,C<9TYV
M8[@/Y96*PL.[U6(7+UY.4C,DQ TE7O+QLI*.DIG;]ND%"&W@U4$KN;N[+QZJ
M'U&(AP]H1-+C&M5 $HF=@%)QU&H<SM97"U1_%T4UO4@ML[ZO)O/%8U55S6'2
M,7% 6T^ $5A*S(7!A+=0^,YG<U\]_6O\$KEE5OD';:;Z/S_O-YTUSAP#S@49
MC7;F@0DA%4L(KQ52@N+7GD@.?#:W/=N_RB^16V:5?_(_'JLE[:N?W#87FR8X
M,4 9ZH!56K+XOZ"E:Z']XROD3M?J'P@]23-W!WH_]?MH3ET>C 7"\331S4!
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M,#(V,#8S,"YH=&U02P$"% ,4    "  ]7/Y<)"L*Y-TR   C@@( $
M        @ $:-   <VYY+3(P,C8P-C,P+GAS9%!+ 0(4 Q0    ( #U<_EPX
MJL?]+C0  &%V @ 4              "  25G  !S;GDM,C R-C V,S!?8V%L
M+GAM;%!+ 0(4 Q0    ( #U<_ERB<OD)FHL! .#5&  3              "
M 86;  !S;GDM,C R-C V,S!?9#(N:'1M4$L! A0#%     @ /5S^7-(>Z!*+
MG@  TD0( !0              ( !4"<" '-N>2TR,#(V,#8S,%]D968N>&UL
M4$L! A0#%     @ /5S^7%>_1G_EE@$ VKD0 !0              ( !#<8"
M '-N>2TR,#(V,#8S,%]L86(N>&UL4$L! A0#%     @ /5S^7(;3*MADW0
M3[4+ !0              ( !)%T$ '-N>2TR,#(V,#8S,%]P<F4N>&UL4$L%
3!@     '  < Q0$  +HZ!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>sny-20260630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sny="http://www.sanofi.com/20260630"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sny-20260630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-10</startDate>
            <endDate>2026-02-10</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-10</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-10</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:MedleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-06</startDate>
            <endDate>2026-03-06</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AmlitelimabAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:CDRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:OPALJVCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LOrealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-02</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2025ProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LOrealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-02</startDate>
            <endDate>2025-02-02</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">sny:ShareRepurchase2026ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-29</startDate>
            <endDate>2026-04-29</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfVestingConditionsAxisAxis">sny:ThreeYearServicePeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sny:ExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfVestingConditionsAxisAxis">sny:FiveYearServicePeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-28</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-29</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:NetInvestmentHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:TwoBillionThreeHundredMillionBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMay2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondMaturingMay2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FixedRateBondIssueFromMarch2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingOnMarch2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ThreeBillionEightHundredFiftyMillionFacilityMaturingApril2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingApril2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrumentAxis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSaudiArabianRiyalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInTurkishLiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUnitedEmiratesDirhamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:MedleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySellerSwapsInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInPoundSterlingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInPoundSterlingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInHungarianFlorintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapExpiring2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CrossCurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarExpiringIn2026And2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealExpiringIn2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInBrazilianRealExpiringIn2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay2.08ReceiveEuribor3MMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.77ReceiveCapitalizedSOFR46bpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.03Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive1.32Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay3.82ReceiveCapitalizedSOFRUSD54BpsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.53Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive2.91Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfBlueprintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:CVRsIssuedInConnectionWithTheAcquisitionOfVigilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CTTQRovidicitinibLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:CTTQMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:KaliTherapeuticsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:KaliTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:TalcProductLitigationInTheUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:DupixentProductLitigationInTheUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:UniversityOfWashingtonAndHarborviewMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:A340BDrugPricingProgramInTheUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:HudsonHeadwatersHealthNetworkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:A340BDrugPricingProgramInTheUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:MosaicHealthInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:A340BDrugPricingProgramInTheUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AmvuttraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AmvuttraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:AdditionalProfitShareForDevelopmentCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:AdditionalProfitShareForDevelopmentCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:DynavaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AltuviiioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NexviazymeNexviadymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AyvakitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SarclisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:RSVVaccinesBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MeningitisTravelAndEndemicsVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:COVID19AndInfluenzaVaccinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesExcludingEuropeAndNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CertainWholesalersInTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DisposalGroupAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="categorie">
        <measure>sny:categorie</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="tranche">
        <measure>sny:tranche</measure>
    </unit>
    <unit id="bond">
        <measure>sny:bond</measure>
    </unit>
    <unit id="credit_facility">
        <measure>sny:credit_facility</measure>
    </unit>
    <unit id="extension">
        <measure>sny:extension</measure>
    </unit>
    <unit id="program">
        <measure>sny:program</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="swaps">
        <measure>sny:swaps</measure>
    </unit>
    <unit id="proceeding">
        <measure>sny:proceeding</measure>
    </unit>
    <unit id="case">
        <measure>sny:case</measure>
    </unit>
    <unit id="defendant">
        <measure>sny:defendant</measure>
    </unit>
    <unit id="aspects">
        <measure>sny:aspects</measure>
    </unit>
    <unit id="customer">
        <measure>sny:customer</measure>
    </unit>
    <unit id="segment">
        <measure>sny:segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-4">0001121404</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-6">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-7">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-8">Q2</dei:DocumentFiscalPeriodFocus>
    <sny:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1826"
      unitRef="segment">1</sny:NumberOfOperatingSegments>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">SANOFI</dei:EntityRegistrantName>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-6" id="f-9" unitRef="eur">10364000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-6" id="f-10" unitRef="eur">10052000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-2" decimals="-6" id="f-11" unitRef="eur">1590000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-6" id="f-12" unitRef="eur">1459000000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill contextRef="c-2" decimals="-6" id="f-13" unitRef="eur">41954000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-3" decimals="-6" id="f-14" unitRef="eur">41300000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-6" id="f-15" unitRef="eur">26359000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-6" id="f-16" unitRef="eur">26261000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-2" decimals="-6" id="f-17" unitRef="eur">3207000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-3" decimals="-6" id="f-18" unitRef="eur">3259000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-2" decimals="-6" id="f-19" unitRef="eur">4732000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-3" decimals="-6" id="f-20" unitRef="eur">4364000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-2" decimals="-6" id="f-21" unitRef="eur">569000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-3" decimals="-6" id="f-22" unitRef="eur">550000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:DeferredTaxAssets contextRef="c-2" decimals="-6" id="f-23" unitRef="eur">8763000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-3" decimals="-6" id="f-24" unitRef="eur">8608000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-2" decimals="-6" id="f-25" unitRef="eur">97538000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-6" id="f-26" unitRef="eur">95853000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-2" decimals="-6" id="f-27" unitRef="eur">11127000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-3" decimals="-6" id="f-28" unitRef="eur">10214000000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-6" id="f-29" unitRef="eur">8714000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-6" id="f-30" unitRef="eur">8410000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-2" decimals="-6" id="f-31" unitRef="eur">4282000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-3" decimals="-6" id="f-32" unitRef="eur">4066000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-2" decimals="-6" id="f-33" unitRef="eur">492000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-3" decimals="-6" id="f-34" unitRef="eur">397000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-35" unitRef="eur">6350000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-36" unitRef="eur">7657000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-2" decimals="-6" id="f-37" unitRef="eur">557000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-3" decimals="-6" id="f-38" unitRef="eur">208000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:CurrentAssets contextRef="c-2" decimals="-6" id="f-39" unitRef="eur">31522000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-6" id="f-40" unitRef="eur">30952000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-2" decimals="-6" id="f-41" unitRef="eur">129060000000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-3" decimals="-6" id="f-42" unitRef="eur">126805000000</ifrs-full:Assets>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-2" decimals="-6" id="f-43" unitRef="eur">69207000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-3" decimals="-6" id="f-44" unitRef="eur">71376000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c-2" decimals="-6" id="f-45" unitRef="eur">360000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c-3" decimals="-6" id="f-46" unitRef="eur">334000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-2" decimals="-6" id="f-47" unitRef="eur">69567000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-48" unitRef="eur">71710000000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-49" unitRef="eur">14646000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-3" decimals="-6" id="f-50" unitRef="eur">14248000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-2" decimals="-6" id="f-51" unitRef="eur">1677000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-3" decimals="-6" id="f-52" unitRef="eur">1467000000</ifrs-full:NoncurrentLeaseLiabilities>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-53" unitRef="eur">652000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-54" unitRef="eur">585000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-2" decimals="-6" id="f-55" unitRef="eur">6848000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-3" decimals="-6" id="f-56" unitRef="eur">6703000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-2" decimals="-6" id="f-57" unitRef="eur">2187000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-3" decimals="-6" id="f-58" unitRef="eur">2081000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-2" decimals="-6" id="f-59" unitRef="eur">1553000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-3" decimals="-6" id="f-60" unitRef="eur">1666000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-2" decimals="-6" id="f-61" unitRef="eur">27563000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-3" decimals="-6" id="f-62" unitRef="eur">26750000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-2" decimals="-6" id="f-63" unitRef="eur">7150000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-3" decimals="-6" id="f-64" unitRef="eur">7361000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-65" unitRef="eur">0</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-66" unitRef="eur">0</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-2" decimals="-6" id="f-67" unitRef="eur">16446000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-3" decimals="-6" id="f-68" unitRef="eur">15565000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-2" decimals="-6" id="f-69" unitRef="eur">884000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-3" decimals="-6" id="f-70" unitRef="eur">751000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-2" decimals="-6" id="f-71" unitRef="eur">227000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-6" id="f-72" unitRef="eur">272000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-73" unitRef="eur">7026000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-6" id="f-74" unitRef="eur">4342000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-2" decimals="-6" id="f-75" unitRef="eur">197000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-3" decimals="-6" id="f-76" unitRef="eur">54000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:CurrentLiabilities contextRef="c-2" decimals="-6" id="f-77" unitRef="eur">31930000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-6" id="f-78" unitRef="eur">28345000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-2" decimals="-6" id="f-79" unitRef="eur">129060000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-6" id="f-80" unitRef="eur">126805000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-81" unitRef="eur">22106000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-4" decimals="-6" id="f-82" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-6" id="f-83" unitRef="eur">1438000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-4" decimals="-6" id="f-84" unitRef="eur">1452000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-6" id="f-85" unitRef="eur">6155000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-4" decimals="-6" id="f-86" unitRef="eur">5881000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c-1" decimals="-6" id="f-87" unitRef="eur">17389000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c-4" decimals="-6" id="f-88" unitRef="eur">15460000000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-89" unitRef="eur">3980000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-6" id="f-90" unitRef="eur">3717000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-91" unitRef="eur">4792000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-4" decimals="-6" id="f-92" unitRef="eur">4506000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-93" unitRef="eur">800000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-4" decimals="-6" id="f-94" unitRef="eur">533000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-95" unitRef="eur">3436000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-4" decimals="-6" id="f-96" unitRef="eur">2476000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-97" unitRef="eur">1087000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-98" unitRef="eur">777000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-99" unitRef="eur">1031000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-100" unitRef="eur">210000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-1" decimals="-6" id="f-101" unitRef="eur">37000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-4" decimals="-6" id="f-102" unitRef="eur">61000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-103" unitRef="eur">563000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-4" decimals="-6" id="f-104" unitRef="eur">430000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-105" unitRef="eur">-95000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-4" decimals="-6" id="f-106" unitRef="eur">-57000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-107" unitRef="eur">3168000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-6" id="f-108" unitRef="eur">3759000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-109" unitRef="eur">465000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-110" unitRef="eur">361000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-111" unitRef="eur">137000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-112" unitRef="eur">184000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-113" unitRef="eur">2840000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-114" unitRef="eur">3582000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-115" unitRef="eur">871000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-6" id="f-116" unitRef="eur">711000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-117" unitRef="eur">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-118" unitRef="eur">85000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c-1" decimals="-6" id="f-119" unitRef="eur">1971000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations contextRef="c-4" decimals="-6" id="f-120" unitRef="eur">2956000000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-121" unitRef="eur">26000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-122" unitRef="eur">2881000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-123" unitRef="eur">1997000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-124" unitRef="eur">5837000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-125" unitRef="eur">40000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-126" unitRef="eur">25000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-127" unitRef="eur">1957000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-128" unitRef="eur">5812000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="2"
      id="f-129"
      unitRef="eurPerShare">1.61</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-4"
      decimals="2"
      id="f-130"
      unitRef="eurPerShare">2.40</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="2"
      id="f-131"
      unitRef="eurPerShare">0.02</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="2"
      id="f-132"
      unitRef="eurPerShare">2.34</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-133"
      unitRef="eurPerShare">1.63</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-134"
      unitRef="eurPerShare">4.74</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="2"
      id="f-135"
      unitRef="eurPerShare">1.60</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-4"
      decimals="2"
      id="f-136"
      unitRef="eurPerShare">2.39</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="2"
      id="f-137"
      unitRef="eurPerShare">0.02</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="2"
      id="f-138"
      unitRef="eurPerShare">2.33</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-139"
      unitRef="eurPerShare">1.62</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-140"
      unitRef="eurPerShare">4.72</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-141" unitRef="eur">1997000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-142" unitRef="eur">5837000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-143" unitRef="eur">1957000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-144" unitRef="eur">5812000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-145" unitRef="eur">40000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-146" unitRef="eur">25000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-6" id="f-147" unitRef="eur">-158000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-4" decimals="-6" id="f-148" unitRef="eur">-111000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-1" decimals="-6" id="f-149" unitRef="eur">175000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-4" decimals="-6" id="f-150" unitRef="eur">222000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-151" unitRef="eur">43000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-4" decimals="-6" id="f-152" unitRef="eur">92000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-153" unitRef="eur">290000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-6" id="f-154" unitRef="eur">241000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-1" decimals="-6" id="f-155" unitRef="eur">5000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-4" decimals="-6" id="f-156" unitRef="eur">3000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-1" decimals="-6" id="f-157" unitRef="eur">14000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-4" decimals="-6" id="f-158" unitRef="eur">-23000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-1" decimals="-6" id="f-159" unitRef="eur">1313000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-4" decimals="-6" id="f-160" unitRef="eur">-5203000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-161" unitRef="eur">5000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-4" decimals="-6" id="f-162" unitRef="eur">95000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-163" unitRef="eur">1327000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-4" decimals="-6" id="f-164" unitRef="eur">-5318000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <sny:OtherComprehensiveIncomeFromContinuedOperations contextRef="c-1" decimals="-6" id="f-165" unitRef="eur">1617000000</sny:OtherComprehensiveIncomeFromContinuedOperations>
    <sny:OtherComprehensiveIncomeFromContinuedOperations contextRef="c-4" decimals="-6" id="f-166" unitRef="eur">-5077000000</sny:OtherComprehensiveIncomeFromContinuedOperations>
    <sny:OtherComprehensiveIncomeFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-167" unitRef="eur">0</sny:OtherComprehensiveIncomeFromDiscontinuedOperations>
    <sny:OtherComprehensiveIncomeFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-168" unitRef="eur">303000000</sny:OtherComprehensiveIncomeFromDiscontinuedOperations>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-169" unitRef="eur">3614000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-6" id="f-170" unitRef="eur">1063000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-171" unitRef="eur">3562000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-172" unitRef="eur">1076000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-173" unitRef="eur">3536000000</ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-174" unitRef="eur">-2097000000</ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-175" unitRef="eur">26000000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-176" unitRef="eur">3173000000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-177" unitRef="eur">52000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-178" unitRef="eur">-13000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-5" decimals="-6" id="f-179" unitRef="eur">2526000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-6" id="f-180" unitRef="eur">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-6" id="f-181" unitRef="eur">-840000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-6" id="f-182" unitRef="eur">68185000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-6" id="f-183" unitRef="eur">5260000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-6" id="f-184" unitRef="eur">2376000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-11" decimals="-6" id="f-185" unitRef="eur">77507000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-6" id="f-186" unitRef="eur">350000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-6" id="f-187" unitRef="eur">77857000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-14" decimals="-6" id="f-188" unitRef="eur">243000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-15" decimals="-6" id="f-189" unitRef="eur">-4979000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-16" decimals="-6" id="f-190" unitRef="eur">-4736000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-17" decimals="-6" id="f-191" unitRef="eur">-38000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-4" decimals="-6" id="f-192" unitRef="eur">-4774000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-14" decimals="-6" id="f-193" unitRef="eur">5812000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-16" decimals="-6" id="f-194" unitRef="eur">5812000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-17" decimals="-6" id="f-195" unitRef="eur">25000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-6" id="f-196" unitRef="eur">5837000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-14" decimals="-6" id="f-197" unitRef="eur">6055000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-15" decimals="-6" id="f-198" unitRef="eur">-4979000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-6" id="f-199" unitRef="eur">1076000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-17" decimals="-6" id="f-200" unitRef="eur">-13000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-6" id="f-201" unitRef="eur">1063000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-4"
      decimals="2"
      id="f-202"
      unitRef="eurPerShare">3.92</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-14" decimals="-6" id="f-203" unitRef="eur">4772000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-16" decimals="-6" id="f-204" unitRef="eur">4772000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-4" decimals="-6" id="f-205" unitRef="eur">4772000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-17" decimals="-6" id="f-206" unitRef="eur">32000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-207" unitRef="eur">32000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-18" decimals="-6" id="f-208" unitRef="eur">3988000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-16" decimals="-6" id="f-209" unitRef="eur">3988000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-4" decimals="-6" id="f-210" unitRef="eur">3988000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-19" decimals="-6" id="f-211" unitRef="eur">74000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-18" decimals="-6" id="f-212" unitRef="eur">-3868000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-14" decimals="-6" id="f-213" unitRef="eur">3794000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-16" decimals="-6" id="f-214" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-4" decimals="-6" id="f-215" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <sny:TaxesOnShareCancellations contextRef="c-18" decimals="-6" id="f-216" unitRef="eur">15000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-16" decimals="-6" id="f-217" unitRef="eur">15000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-4" decimals="-6" id="f-218" unitRef="eur">15000000</sny:TaxesOnShareCancellations>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-19" decimals="-6" id="f-219" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-20" decimals="-6" id="f-220" unitRef="eur">14000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-16" decimals="-6" id="f-221" unitRef="eur">15000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-4" decimals="-6" id="f-222" unitRef="eur">15000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-19" decimals="-6" id="f-223" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-20" decimals="-6" id="f-224" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-16" decimals="-6" id="f-225" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-4" decimals="-6" id="f-226" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-21" decimals="-6" id="f-227" unitRef="eur">177000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-16" decimals="-6" id="f-228" unitRef="eur">177000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-4" decimals="-6" id="f-229" unitRef="eur">177000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-21" decimals="-6" id="f-230" unitRef="eur">7000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-16" decimals="-6" id="f-231" unitRef="eur">7000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-4" decimals="-6" id="f-232" unitRef="eur">7000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-14" decimals="-6" id="f-233" unitRef="eur">15000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-16" decimals="-6" id="f-234" unitRef="eur">15000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-4" decimals="-6" id="f-235" unitRef="eur">15000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions contextRef="c-17" decimals="-6" id="f-236" unitRef="eur">-34000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions contextRef="c-4" decimals="-6" id="f-237" unitRef="eur">-34000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions>
    <ifrs-full:Equity contextRef="c-22" decimals="-6" id="f-238" unitRef="eur">2456000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-6" id="f-239" unitRef="eur">11000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-6" id="f-240" unitRef="eur">-975000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-6" id="f-241" unitRef="eur">65689000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-26" decimals="-6" id="f-242" unitRef="eur">5430000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-6" id="f-243" unitRef="eur">-2603000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-6" id="f-244" unitRef="eur">70008000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-6" id="f-245" unitRef="eur">271000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-6" id="f-246" unitRef="eur">70279000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-31" decimals="-6" id="f-247" unitRef="eur">-71000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-32" decimals="-6" id="f-248" unitRef="eur">160000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-33" decimals="-6" id="f-249" unitRef="eur">89000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-34" decimals="-6" id="f-250" unitRef="eur">-5000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-35" decimals="-6" id="f-251" unitRef="eur">84000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-31" decimals="-6" id="f-252" unitRef="eur">2001000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-33" decimals="-6" id="f-253" unitRef="eur">2001000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-34" decimals="-6" id="f-254" unitRef="eur">13000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-35" decimals="-6" id="f-255" unitRef="eur">2014000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-31" decimals="-6" id="f-256" unitRef="eur">1930000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-32" decimals="-6" id="f-257" unitRef="eur">160000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-33" decimals="-6" id="f-258" unitRef="eur">2090000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-34" decimals="-6" id="f-259" unitRef="eur">8000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-35" decimals="-6" id="f-260" unitRef="eur">2098000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-34" decimals="-6" id="f-261" unitRef="eur">12000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-35" decimals="-6" id="f-262" unitRef="eur">12000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-36" decimals="-6" id="f-263" unitRef="eur">1027000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-33" decimals="-6" id="f-264" unitRef="eur">1027000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-35" decimals="-6" id="f-265" unitRef="eur">1027000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-37" decimals="-6" id="f-266" unitRef="eur">22000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-38" decimals="-6" id="f-267" unitRef="eur">170000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-36" decimals="-6" id="f-268" unitRef="eur">-934000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-31" decimals="-6" id="f-269" unitRef="eur">742000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-33" decimals="-6" id="f-270" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-35" decimals="-6" id="f-271" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <sny:TaxesOnShareCancellations contextRef="c-36" decimals="-6" id="f-272" unitRef="eur">4000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-33" decimals="-6" id="f-273" unitRef="eur">4000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-35" decimals="-6" id="f-274" unitRef="eur">4000000</sny:TaxesOnShareCancellations>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-35" decimals="-6" id="f-275" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-35" decimals="-6" id="f-276" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-37" decimals="-6" id="f-277" unitRef="eur">5000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-38" decimals="-6" id="f-278" unitRef="eur">160000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-33" decimals="-6" id="f-279" unitRef="eur">165000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-35" decimals="-6" id="f-280" unitRef="eur">165000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-39" decimals="-6" id="f-281" unitRef="eur">142000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-33" decimals="-6" id="f-282" unitRef="eur">142000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-35" decimals="-6" id="f-283" unitRef="eur">142000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-35" decimals="-6" id="f-284" unitRef="eur">0</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions contextRef="c-34" decimals="-6" id="f-285" unitRef="eur">68000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions contextRef="c-35" decimals="-6" id="f-286" unitRef="eur">68000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestmentAndAcquisitions>
    <ifrs-full:Equity contextRef="c-40" decimals="-6" id="f-287" unitRef="eur">2439000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-41" decimals="-6" id="f-288" unitRef="eur">1000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-42" decimals="-6" id="f-289" unitRef="eur">-1072000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-43" decimals="-6" id="f-290" unitRef="eur">66877000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-44" decimals="-6" id="f-291" unitRef="eur">5572000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-6" id="f-292" unitRef="eur">-2441000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-293" unitRef="eur">71376000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-294" unitRef="eur">334000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-295" unitRef="eur">71710000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-40" decimals="-6" id="f-296" unitRef="eur">2439000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-41" decimals="-6" id="f-297" unitRef="eur">1000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-42" decimals="-6" id="f-298" unitRef="eur">-1072000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-43" decimals="-6" id="f-299" unitRef="eur">66877000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-44" decimals="-6" id="f-300" unitRef="eur">5572000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-6" id="f-301" unitRef="eur">-2441000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-302" unitRef="eur">71376000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-303" unitRef="eur">334000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-6" id="f-304" unitRef="eur">71710000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-48" decimals="-6" id="f-305" unitRef="eur">290000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-49" decimals="-6" id="f-306" unitRef="eur">1315000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-50" decimals="-6" id="f-307" unitRef="eur">1605000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-51" decimals="-6" id="f-308" unitRef="eur">12000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-309" unitRef="eur">1617000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-48" decimals="-6" id="f-310" unitRef="eur">1957000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-50" decimals="-6" id="f-311" unitRef="eur">1957000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-51" decimals="-6" id="f-312" unitRef="eur">40000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-313" unitRef="eur">1997000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-48" decimals="-6" id="f-314" unitRef="eur">2247000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-49" decimals="-6" id="f-315" unitRef="eur">1315000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-50" decimals="-6" id="f-316" unitRef="eur">3562000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-51" decimals="-6" id="f-317" unitRef="eur">52000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-318" unitRef="eur">3614000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-1"
      decimals="2"
      id="f-319"
      unitRef="eurPerShare">4.12</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-48" decimals="-6" id="f-320" unitRef="eur">4923000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-50" decimals="-6" id="f-321" unitRef="eur">4923000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-1" decimals="-6" id="f-322" unitRef="eur">4923000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-51" decimals="-6" id="f-323" unitRef="eur">26000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-324" unitRef="eur">26000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-52" decimals="-6" id="f-325" unitRef="eur">1003000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-50" decimals="-6" id="f-326" unitRef="eur">1003000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-1" decimals="-6" id="f-327" unitRef="eur">1003000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-53" decimals="-6" id="f-328" unitRef="eur">15000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-52" decimals="-6" id="f-329" unitRef="eur">-596000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-48" decimals="-6" id="f-330" unitRef="eur">581000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-50" decimals="-6" id="f-331" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-1" decimals="-6" id="f-332" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <sny:TaxesOnShareCancellations contextRef="c-52" decimals="-6" id="f-333" unitRef="eur">3000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-50" decimals="-6" id="f-334" unitRef="eur">3000000</sny:TaxesOnShareCancellations>
    <sny:TaxesOnShareCancellations contextRef="c-1" decimals="-6" id="f-335" unitRef="eur">3000000</sny:TaxesOnShareCancellations>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-54" decimals="-6" id="f-336" unitRef="eur">3000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-50" decimals="-6" id="f-337" unitRef="eur">3000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-1" decimals="-6" id="f-338" unitRef="eur">3000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-53" decimals="-6" id="f-339" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-54" decimals="-6" id="f-340" unitRef="eur">-4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-52" decimals="-6" id="f-341" unitRef="eur">102000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-48" decimals="-6" id="f-342" unitRef="eur">-102000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-50" decimals="-6" id="f-343" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-1" decimals="-6" id="f-344" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-55" decimals="-6" id="f-345" unitRef="eur">184000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-50" decimals="-6" id="f-346" unitRef="eur">184000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-1" decimals="-6" id="f-347" unitRef="eur">184000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-55" decimals="-6" id="f-348" unitRef="eur">-1000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-50" decimals="-6" id="f-349" unitRef="eur">-1000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-1" decimals="-6" id="f-350" unitRef="eur">-1000000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-48" decimals="-6" id="f-351" unitRef="eur">10000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-50" decimals="-6" id="f-352" unitRef="eur">10000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-1" decimals="-6" id="f-353" unitRef="eur">10000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <ifrs-full:Equity contextRef="c-56" decimals="-6" id="f-354" unitRef="eur">2428000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-57" decimals="-6" id="f-355" unitRef="eur">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-58" decimals="-6" id="f-356" unitRef="eur">-1380000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-59" decimals="-6" id="f-357" unitRef="eur">63528000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-60" decimals="-6" id="f-358" unitRef="eur">5757000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-61" decimals="-6" id="f-359" unitRef="eur">-1126000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-62" decimals="-6" id="f-360" unitRef="eur">69207000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-63" decimals="-6" id="f-361" unitRef="eur">360000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-2" decimals="-6" id="f-362" unitRef="eur">69567000000</ifrs-full:Equity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-1" decimals="-6" id="f-363" unitRef="eur">1957000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-4" decimals="-6" id="f-364" unitRef="eur">5812000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <sny:AdjustmentsForLossesGainsOnTransferOfBusiness contextRef="c-1" decimals="-6" id="f-365" unitRef="eur">-26000000</sny:AdjustmentsForLossesGainsOnTransferOfBusiness>
    <sny:AdjustmentsForLossesGainsOnTransferOfBusiness contextRef="c-4" decimals="-6" id="f-366" unitRef="eur">-2881000000</sny:AdjustmentsForLossesGainsOnTransferOfBusiness>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-367" unitRef="eur">40000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-4" decimals="-6" id="f-368" unitRef="eur">25000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-369" unitRef="eur">-94000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-370" unitRef="eur">15000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-1" decimals="-6" id="f-371" unitRef="eur">2880000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-4" decimals="-6" id="f-372" unitRef="eur">1779000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-1" decimals="-6" id="f-373" unitRef="eur">-9000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-4" decimals="-6" id="f-374" unitRef="eur">-266000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-1" decimals="-6" id="f-375" unitRef="eur">-218000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-4" decimals="-6" id="f-376" unitRef="eur">-539000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1" decimals="-6" id="f-377" unitRef="eur">195000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-4" decimals="-6" id="f-378" unitRef="eur">-212000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-6" id="f-379" unitRef="eur">184000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-4" decimals="-6" id="f-380" unitRef="eur">171000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-1" decimals="-6" id="f-381" unitRef="eur">210000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-4" decimals="-6" id="f-382" unitRef="eur">0</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-1" decimals="-6" id="f-383" unitRef="eur">-74000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-4" decimals="-6" id="f-384" unitRef="eur">106000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-6" id="f-385" unitRef="eur">5233000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-4" decimals="-6" id="f-386" unitRef="eur">3980000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-6" id="f-387" unitRef="eur">-958000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-4" decimals="-6" id="f-388" unitRef="eur">-635000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-6" id="f-389" unitRef="eur">-27000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-4" decimals="-6" id="f-390" unitRef="eur">-785000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-1" decimals="-6" id="f-391" unitRef="eur">-340000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-4" decimals="-6" id="f-392" unitRef="eur">187000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-1" decimals="-6" id="f-393" unitRef="eur">735000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-4" decimals="-6" id="f-394" unitRef="eur">620000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="c-1" decimals="-6" id="f-395" unitRef="eur">4643000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations contextRef="c-4" decimals="-6" id="f-396" unitRef="eur">3367000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-397" unitRef="eur">0</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-398" unitRef="eur">188000000</ifrs-full:CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-399" unitRef="eur">4643000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-4" decimals="-6" id="f-400" unitRef="eur">3555000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-401" unitRef="eur">1296000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-4" decimals="-6" id="f-402" unitRef="eur">1420000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-403" unitRef="eur">1408000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-404" unitRef="eur">538000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-405" unitRef="eur">189000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-406" unitRef="eur">423000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-407" unitRef="eur">424000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-4" decimals="-6" id="f-408" unitRef="eur">434000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-409" unitRef="eur">78000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-4" decimals="-6" id="f-410" unitRef="eur">0</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-1" decimals="-6" id="f-411" unitRef="eur">-32000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-4" decimals="-6" id="f-412" unitRef="eur">-32000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetCashProvidedByusedInContinuingInvestingActivities contextRef="c-1" decimals="-6" id="f-413" unitRef="eur">-2423000000</sny:NetCashProvidedByusedInContinuingInvestingActivities>
    <sny:NetCashProvidedByusedInContinuingInvestingActivities contextRef="c-4" decimals="-6" id="f-414" unitRef="eur">-1979000000</sny:NetCashProvidedByusedInContinuingInvestingActivities>
    <sny:NetCashProvidedByusedInDiscontinuingInvestingActivities contextRef="c-1" decimals="-6" id="f-415" unitRef="eur">0</sny:NetCashProvidedByusedInDiscontinuingInvestingActivities>
    <sny:NetCashProvidedByusedInDiscontinuingInvestingActivities contextRef="c-4" decimals="-6" id="f-416" unitRef="eur">-36000000</sny:NetCashProvidedByusedInDiscontinuingInvestingActivities>
    <sny:NetCashInflowFromDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-417" unitRef="eur">-220000000</sny:NetCashInflowFromDiscontinuedOperations>
    <sny:NetCashInflowFromDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-418" unitRef="eur">10742000000</sny:NetCashInflowFromDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-419" unitRef="eur">-2643000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-4" decimals="-6" id="f-420" unitRef="eur">8727000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-6" id="f-421" unitRef="eur">18000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-4" decimals="-6" id="f-422" unitRef="eur">29000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-423" unitRef="eur">4923000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-424" unitRef="eur">4772000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-425" unitRef="eur">25000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-426" unitRef="eur">27000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-427" unitRef="eur">2304000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-4" decimals="-6" id="f-428" unitRef="eur">2993000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-429" unitRef="eur">1505000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-4" decimals="-6" id="f-430" unitRef="eur">1859000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-431" unitRef="eur">147000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-4" decimals="-6" id="f-432" unitRef="eur">124000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-1" decimals="-6" id="f-433" unitRef="eur">1955000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-4" decimals="-6" id="f-434" unitRef="eur">3322000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-1" decimals="-6" id="f-435" unitRef="eur">1009000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-4" decimals="-6" id="f-436" unitRef="eur">4003000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="c-1" decimals="-6" id="f-437" unitRef="eur">-3332000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="c-4" decimals="-6" id="f-438" unitRef="eur">-4441000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-439" unitRef="eur">0</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-4" decimals="-6" id="f-440" unitRef="eur">-48000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-441" unitRef="eur">-3332000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-4" decimals="-6" id="f-442" unitRef="eur">-4489000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-443" unitRef="eur">19000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-4" decimals="-6" id="f-444" unitRef="eur">-42000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale contextRef="c-1" decimals="-6" id="f-445" unitRef="eur">0</sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale>
    <sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale contextRef="c-4" decimals="-6" id="f-446" unitRef="eur">167000000</sny:CashAndCashEquivalentsReclassifiedToAssetsHeldForSale>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-447" unitRef="eur">-1313000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-4" decimals="-6" id="f-448" unitRef="eur">7918000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c-3" decimals="-6" id="f-449" unitRef="eur">7663000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c-13" decimals="-6" id="f-450" unitRef="eur">7441000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c-2" decimals="-6" id="f-451" unitRef="eur">6350000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c-30" decimals="-6" id="f-452" unitRef="eur">15359000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense contextRef="c-1" decimals="-6" id="f-453" unitRef="eur">0</sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense>
    <sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense contextRef="c-4" decimals="-6" id="f-454" unitRef="eur">48000000</sny:AdjustmentsForNonCurrentFinancialAssetsAndDeferredTaxExpense>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-455" unitRef="eur">925000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-456" unitRef="eur">1355000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-457" unitRef="eur">260000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-458" unitRef="eur">206000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-459" unitRef="eur">111000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-460" unitRef="eur">170000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-461" unitRef="eur">3000000</sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-4" decimals="-6" id="f-462" unitRef="eur">5000000</sny:DividendsReceivedFromNonconsolidatedEntitiesClassifiedAsOperatingActivities>
    <ifrs-full:CashAndCashEquivalents contextRef="c-64" decimals="-6" id="f-463" unitRef="eur">667000000</ifrs-full:CashAndCashEquivalents>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-65" decimals="-6" id="f-464" unitRef="eur">2388000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-66" decimals="-6" id="f-465" unitRef="eur">-249000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-67" decimals="-6" id="f-466" unitRef="eur">3353000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-467">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="if01b92328be14713b8ccdb292d93bd83"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Introduction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi, together with its subsidiaries (collectively &#x201c;Sanofi&#x201d;, &#x201c;the Group&#x201d; or &#x201c;the Company&#x201d;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements for the six months ended June 30, 2026 were reviewed by the Sanofi Board of Directors at the Board meeting on July 29, 2026.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-468">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i4f7c6c891c2b4d6d95f7e8f036bb2556"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A/ Basis of preparation of the half-year financial statements and accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="iade2723bf556405fa760300135f156fe"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.1. International financial reporting standards (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2026 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2026 are available via the following web link: https://www.efrag.org/en/financial-reporting/endorsement-status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies applied effective January 1, 2026 are identical to those presented in the consolidated financial statements for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable from January 1, 2026. The amendments did not have a material impact on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the IASB issued Volume 11 of &#x201c;Annual Improvements to IFRS&#x201d;, applicable from January 1, 2026. Those improvements to various standards, which are essentially in the nature of clarifications, did not have a material impact on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments could potentially result in an enhancement of the disclosures provided in the 2026 annual financial statements. As a reminder, renewable energy purchase contracts entered into by Sanofi as of December 31, 2025 are described in Note D.21. to the consolidated financial statements included in Sanofi&#x2019;s Form 20-F for the year ended December 31, 2025 (the &#x201c;2025 20-F&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In its 2026 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. As in the previous year, the effective tax rate also includes a one-off impact from the 2025 component of the exceptional surcharge in respect of French corporate income taxes (see Note B.19.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i7eb8d7ed82b1409781780df5af14fc37"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.2. Use of estimates and judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;impairment of property, plant and equipment and intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the valuation of goodwill and the valuation and useful life of acquired intangible assets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i1ec2cb66eb2744b6b48188cdb25eabbf"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.3. Seasonal trends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s activities are not subject to significant seasonal fluctuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5f4805e586d9457eb40667dbfc3eea9d"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.4. Consolidation and foreign currency translation of the financial statements of subsidiaries in hyperinflationary economies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2026, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="ia00b620899cb4c70a41e134ebd8334b7"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.5. Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of financial&lt;br/&gt;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;br/&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;br/&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i5c5175867eaf486690e7e1ad01ca77b2"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.6. New pronouncements issued by the IASB and applicable from 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027. In terms of adapting Sanofi&#x2019;s chart of accounts and financial information systems, the transition is continuing on schedule. In line with the information communicated in the 2025 financial statements as published, Sanofi&#x2019;s IFRS 18 rollout project &#x2013; which began in the fourth quarter of 2025 &#x2013; is progressing, and the impact analysis has evolved in line with the schedule. The future structure of Sanofi&#x2019;s consolidated income statement will present operating expenses by function, and will reflect presentational choices based on the &#x201c;useful structured summary&#x201d; principle established by IFRS 18. Those choices involve the classification of income statement items according to five categories (operating, investing, financing, income tax and discontinued operations), with the sub-totals limited solely to those specified in IFRS 18. The income statement structure will also reflect the fact that Sanofi as a whole operates a single principal activity. As regards the requirement to disclose alternative management performance measures (MPMs) that meet the IFRS 18 definition in the notes to the financial statements, Sanofi has identified the relevant MPMs. In accordance with the information communicated in Sanofi&#x2019;s 2025 consolidated financial statements, the main MPMs are &#x201c;Business gross profit&#x201d;, &#x201c;Business operating income&#x201d; and &#x201c;Business net income&#x201d;, all of which are non-IFRS measures that Sanofi currently uses in its financial communication. No significant impact on these performance measures has been identified at this stage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The transition note intended for publication in Sanofi&#x2019;s 2026 Annual Report on Form 20-F will include a reconciliation, for the comparative years 2026 and 2025, between (i) the amounts for each income statement line item presented in accordance with IFRS&#160;18 as applicable from 2027 and (ii) those presented in accordance with the currently applicable standard (IAS 1).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Furthermore, the presentation of the consolidated statement of cash flows will be modified such that it starts from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; instead of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income attributable to equity holders of Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, as mentioned in Sanofi&#x2019;s 2025 year-end financial communications, Sanofi is not early adopting IFRS 18.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On November 13, 2025, the IASB issued &#x201c;Translation to a Hyperinflationary Presentation Currency&#x201d;, an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), applicable from January 1, 2027 (subject to endorsement by the European Union). Sanofi does not expect any material impact and will not early adopt this amendment.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-469">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS&#160;34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies used in the preparation of the consolidated financial statements as of June&#160;30,&#160;2026 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2026 are available via the following web link: https://www.efrag.org/en/financial-reporting/endorsement-status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The accounting policies applied effective January 1, 2026 are identical to those presented in the consolidated financial statements for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable from January 1, 2026. The amendments did not have a material impact on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the IASB issued Volume 11 of &#x201c;Annual Improvements to IFRS&#x201d;, applicable from January 1, 2026. Those improvements to various standards, which are essentially in the nature of clarifications, did not have a material impact on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS&#160;7, applicable from January 1, 2026. The amendments could potentially result in an enhancement of the disclosures provided in the 2026 annual financial statements. As a reminder, renewable energy purchase contracts entered into by Sanofi as of December 31, 2025 are described in Note D.21. to the consolidated financial statements included in Sanofi&#x2019;s Form 20-F for the year ended December 31, 2025 (the &#x201c;2025 20-F&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In its 2026 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the Pillar Two top-up tax applicable from January 1, 2024. As in the previous year, the effective tax rate also includes a one-off impact from the 2025 component of the exceptional surcharge in respect of French corporate income taxes (see Note B.19.).&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-470">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;impairment of property, plant and equipment and intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the valuation of goodwill and the valuation and useful life of acquired intangible assets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity &lt;/span&gt;&lt;/div&gt;method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates.</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock contextRef="c-1" id="f-471">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s activities are not subject to significant seasonal fluctuations.&lt;/span&gt;&lt;/div&gt;</sny:SeasonalityOrCyclicalityOfInterimOperationsPolicyTextBlock>
    <ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory contextRef="c-1" id="f-472">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2026, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since July&#160;1, 2018) treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has (since January&#160;1, 2022) treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory>
    <sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears contextRef="c-68" decimals="2" id="f-473" unitRef="number">1</sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears>
    <sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears contextRef="c-69" decimals="2" id="f-474" unitRef="number">1</sny:CumulativeConsumerPriceInflationRateOverTheLastThreeYears>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c-1" id="f-475">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;Level 3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of financial&lt;br/&gt;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;br/&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;br/&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c-1" id="f-476">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of financial&lt;br/&gt;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in fair value hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="padding-right:5.35pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Volatilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost/ Peer comparison (primarily)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held to meet obligations under post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.6.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;br/&gt;B.12.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;br/&gt;For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;br/&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.9.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Future lease payments are discounted using the incremental borrowing rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market&lt;br/&gt;&amp;gt;&#160;1 year:&#160;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid&#160;Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.10.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:1pt;margin-top:1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Revenue-based approach&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mid Market Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1 year:&#160;Mid Money Market and Euronext interest rate futures &lt;br/&gt;&amp;gt;&#160;1 year: Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;B.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #23004c;border-top:0.25pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-477">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027. In terms of adapting Sanofi&#x2019;s chart of accounts and financial information systems, the transition is continuing on schedule. In line with the information communicated in the 2025 financial statements as published, Sanofi&#x2019;s IFRS 18 rollout project &#x2013; which began in the fourth quarter of 2025 &#x2013; is progressing, and the impact analysis has evolved in line with the schedule. The future structure of Sanofi&#x2019;s consolidated income statement will present operating expenses by function, and will reflect presentational choices based on the &#x201c;useful structured summary&#x201d; principle established by IFRS 18. Those choices involve the classification of income statement items according to five categories (operating, investing, financing, income tax and discontinued operations), with the sub-totals limited solely to those specified in IFRS 18. The income statement structure will also reflect the fact that Sanofi as a whole operates a single principal activity. As regards the requirement to disclose alternative management performance measures (MPMs) that meet the IFRS 18 definition in the notes to the financial statements, Sanofi has identified the relevant MPMs. In accordance with the information communicated in Sanofi&#x2019;s 2025 consolidated financial statements, the main MPMs are &#x201c;Business gross profit&#x201d;, &#x201c;Business operating income&#x201d; and &#x201c;Business net income&#x201d;, all of which are non-IFRS measures that Sanofi currently uses in its financial communication. No significant impact on these performance measures has been identified at this stage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The transition note intended for publication in Sanofi&#x2019;s 2026 Annual Report on Form 20-F will include a reconciliation, for the comparative years 2026 and 2025, between (i) the amounts for each income statement line item presented in accordance with IFRS&#160;18 as applicable from 2027 and (ii) those presented in accordance with the currently applicable standard (IAS 1).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Furthermore, the presentation of the consolidated statement of cash flows will be modified such that it starts from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; instead of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income attributable to equity holders of Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, as mentioned in Sanofi&#x2019;s 2025 year-end financial communications, Sanofi is not early adopting IFRS 18.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On November 13, 2025, the IASB issued &#x201c;Translation to a Hyperinflationary Presentation Currency&#x201d;, an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), applicable from January 1, 2027 (subject to endorsement by the European Union). Sanofi does not expect any material impact and will not early adopt this amendment.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <sny:IncomeStatementClassificationIFRS18NumberOfCategories
      contextRef="c-1"
      decimals="INF"
      id="f-478"
      unitRef="categorie">5</sny:IncomeStatementClassificationIFRS18NumberOfCategories>
    <sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock contextRef="c-1" id="f-479">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="ib491210deb284e268395afcc5ff6478b"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.1. Significant transactions for the first half of 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i9834acbe5e0941f6b802ffcc6c644dcc"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.1.1. Acquisition of Dynavax Technologies Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On February 10, 2026, Sanofi finalized the acquisition of Dynavax Technologies Corporation (Dynavax), a vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi&#x2019;s presence in adult immunization by bringing together Dynavax&#x2019;s vaccines with Sanofi&#x2019;s global scale, development capabilities and commercial reach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Dynavax&#x2019;s adult hepatitis B vaccine HEPLISAV-B is currently marketed in the United States and is differentiated by its two-dose regimen over one month, enabling high levels of seroprotection faster than other hepatitis B vaccines (which are given in three doses over six months).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition also includes Dynavax&#x2019;s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 clinical development, and additional vaccine pipeline projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The transaction involved a cash tender offer by Sanofi to acquire all outstanding shares of Dynavax for $15.50 per share in cash, reflecting a total equity value on a fully diluted basis of approximately $2.2&#160;billion, including the subsequent reimbursement of the short-term debt for $0.3&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The provisional purchase price allocation led to the recognition of &#x20ac;204&#160;million of goodwill, determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of Dynavax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #21004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,367&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,571&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Other intangible assets&#x201d; mainly comprise Dynavax&#x2019;s marketed vaccine HEPLISAV-B.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of Dynavax into the Sanofi group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Dynavax's contributions to Biopharma segment net sales and business operating income (for a definition refer to Note B.21. &#x201c;Segment Information&#x201d;) since the acquisition date amount to &#x20ac;144&#160;million and &#x20ac;89&#160;million, respectively. Over the same period, Dynavax made a negative contribution of &#x20ac;63&#160;million to consolidated net income, including amortization of intangible assets of &#x20ac;38&#160;million; amortization and expenses arising from the impact of acquired inventories of &#x20ac;44&#160;million; and restructuring costs and similar items of &#x20ac;63&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition, as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows, is a net cash outflow of &#x20ac;1,403&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i33c30c05833240ffaf9267814059a54e"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.1.2. Proposed divestment of Medley, Sanofi&#x2019;s Brazilian generics business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On March 6, 2026, Sanofi and EMS Group, a major pharmaceutical conglomerate in Brazil, announced the signing of a definitive agreement for the purchase and sale of 100% of Medley, one of Brazil&#x2019;s leading generic drug brands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;With effect from that date, given that completion of the transaction is considered highly probable, all of the assets of Medley, and the liabilities directly associated with those assets (subsequently transferred to Medley Farmaceutica Ltda, a new legal entity formed on May 1, 2026, the equity interests in which will be divested), are presented in the consolidated balance sheet within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations); they are the main component of those line items as of June 30, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s Brazilian generics business does not meet the definition of a discontinued operation under IFRS 5 (see Note B.7. to the consolidated financial statements for the year ended December 31, 2025), as a result of which the net income from this business is not presented separately in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A net gain is expected upon closing of the transaction. Consequently, no impairment was recognized on the carrying amount of the net assets of Medley Farmaceutica Ltda as of the date of reclassification as held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The transaction is expected to close no earlier than the fourth quarter of 2026 subject to the fulfilment of customary closing conditions, primarily clearance from the Brazilian Antitrust Authority (Administrative Council for Economic Defense &#x2013; CADE).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock>
    <sny:BusinessCombinationEquityInterestsOfAcquirerPerShare
      contextRef="c-70"
      decimals="2"
      id="f-480"
      unitRef="usdPerShare">15.50</sny:BusinessCombinationEquityInterestsOfAcquirerPerShare>
    <sny:BusinessCombinationEquityValueOfAcquirer contextRef="c-70" decimals="-8" id="f-481" unitRef="usd">2200000000</sny:BusinessCombinationEquityValueOfAcquirer>
    <ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate contextRef="c-70" decimals="-8" id="f-482" unitRef="usd">300000000</ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="c-1" id="f-483">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The provisional purchase price allocation led to the recognition of &#x20ac;204&#160;million of goodwill, determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of Dynavax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #21004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,367&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #21004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,571&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-70" decimals="-6" id="f-484" unitRef="eur">204000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-70" decimals="-6" id="f-485" unitRef="eur">1150000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <sny:OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate contextRef="c-70" decimals="-6" id="f-486" unitRef="eur">429000000</sny:OtherCurrentAssetsAndNonCurrentAssetsAndLiabilitiesAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="c-70" decimals="-6" id="f-487" unitRef="eur">169000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate contextRef="c-70" decimals="-6" id="f-488" unitRef="eur">249000000</ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate>
    <sny:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-70" decimals="-6" id="f-489" unitRef="eur">132000000</sny:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="c-70" decimals="-6" id="f-490" unitRef="eur">1367000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-70" decimals="-6" id="f-491" unitRef="eur">204000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-70" decimals="-6" id="f-492" unitRef="eur">1571000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:RevenueOfAcquiree contextRef="c-71" decimals="-6" id="f-493" unitRef="eur">144000000</ifrs-full:RevenueOfAcquiree>
    <sny:OperatingIncomeOfAcquireeSinceAcquisitionDate contextRef="c-71" decimals="-6" id="f-494" unitRef="eur">89000000</sny:OperatingIncomeOfAcquireeSinceAcquisitionDate>
    <ifrs-full:ProfitLossOfAcquiree contextRef="c-71" decimals="-6" id="f-495" unitRef="eur">-63000000</ifrs-full:ProfitLossOfAcquiree>
    <sny:AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate contextRef="c-71" decimals="-6" id="f-496" unitRef="eur">38000000</sny:AmortizationOfIntangibleAssetsOfAcquireeSinceAcquisitionDate>
    <sny:AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate contextRef="c-71" decimals="-6" id="f-497" unitRef="eur">44000000</sny:AmortizationAndExpensesFromInventoriesOfAcquireeSinceAcquisitionDate>
    <sny:RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate contextRef="c-71" decimals="-6" id="f-498" unitRef="eur">63000000</sny:RestructuringCostsAndOtherItemsOfAcquireeSinceAcquisitionDate>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-66" decimals="-6" id="f-499" unitRef="eur">1403000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:PercentageOfOwnershipInterestDisposed contextRef="c-72" decimals="2" id="f-500" unitRef="number">1</sny:PercentageOfOwnershipInterestDisposed>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-501">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i93a93c63f0ea45e195349fc8fc299e76"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.2. Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;763&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;702&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biopharma &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella (discontinued operation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Firm orders for property, plant and equipment stood at &#x20ac;1,336&#160;million as of June 30, 2026.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;763&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;702&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biopharma &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella (discontinued operation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-503" unitRef="eur">763000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-73" decimals="-6" id="f-504" unitRef="eur">702000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-74" decimals="-6" id="f-505" unitRef="eur">763000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-75" decimals="-6" id="f-506" unitRef="eur">663000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-76" decimals="-6" id="f-507" unitRef="eur">594000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-77" decimals="-6" id="f-508" unitRef="eur">453000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-78" decimals="-6" id="f-509" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-79" decimals="-6" id="f-510" unitRef="eur">39000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:InterestCostsCapitalised contextRef="c-1" decimals="-6" id="f-511" unitRef="eur">23000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:InterestCostsCapitalised contextRef="c-73" decimals="-6" id="f-512" unitRef="eur">22000000</ifrs-full:InterestCostsCapitalised>
    <sny:FirmOrdersOfPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-513" unitRef="eur">1336000000</sny:FirmOrdersOfPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-514">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="ic132ebcff5c64c81a9061580740797ab"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.3. Goodwill and other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill amounted to &#x20ac;41,954&#160;million as of June 30, 2026, versus &#x20ac;41,300 million as of December&#160;31, 2025. The movement during the period reflects the impact of changes in exchange rates and the recognition of the goodwill arising on the Dynavax acquisition (see note B.1.1.), partially offset by the reclassification of the goodwill relating to the Brazilian generics business to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; as a result of the proposed divestment (see note B.1.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets during the first half of 2026 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Products, trademarks and other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,951&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66,746&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,888&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;83,585&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,817&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69,070&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,957&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85,844&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(49,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(970)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(51,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(59,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,731&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,122&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,261&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,026&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,911&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;422&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,359&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;The &#x201c;Changes in scope of consolidation&#x201d; line mainly comprises the intangible assets recognized as part of the Dynavax  acquisition (see Note B.1.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The &#x201c;Transfers&#x201d; line mainly comprises (i)&#160;acquired R&amp;amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;See Note B.4.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Products, trademarks and other products&#x201d; mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;marketed products, with a carrying amount of &#x20ac;17.1 bil&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;lion as of June 30, 2026 (versus &#x20ac;16.2 billion as of December 31, 2025) and a weighted average amortization period of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; 11 years&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;technological platforms brought into service, with a carrying amou&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;nt of &#x20ac;0.8 billion as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;June 30, 2026&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (versus &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x20ac;0.9 billion&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) and a weighted average amortization period of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;18 years.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:Goodwill contextRef="c-2" decimals="-6" id="f-515" unitRef="eur">41954000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-3" decimals="-6" id="f-516" unitRef="eur">41300000000</ifrs-full:Goodwill>
    <sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock contextRef="c-1" id="f-517">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets during the first half of 2026 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Products, trademarks and other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,951&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66,746&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,888&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;83,585&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,817&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69,070&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,957&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85,844&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(49,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(970)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,048)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization and impairment at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(51,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(59,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,731&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,122&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,261&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,026&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,911&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;422&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,359&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;The &#x201c;Changes in scope of consolidation&#x201d; line mainly comprises the intangible assets recognized as part of the Dynavax  acquisition (see Note B.1.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The &#x201c;Transfers&#x201d; line mainly comprises (i)&#160;acquired R&amp;amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;See Note B.4.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-6" id="f-518" unitRef="eur">14951000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-6" id="f-519" unitRef="eur">66746000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-82" decimals="-6" id="f-520" unitRef="eur">1888000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-83" decimals="-6" id="f-521" unitRef="eur">83585000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-6" id="f-522" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-6" id="f-523" unitRef="eur">1149000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-6" id="f-524" unitRef="eur">1000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-6" id="f-525" unitRef="eur">1150000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-6" id="f-526" unitRef="eur">321000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-6" id="f-527" unitRef="eur">122000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-6" id="f-528" unitRef="eur">88000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-6" id="f-529" unitRef="eur">531000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-6" id="f-530" unitRef="eur">534000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-6" id="f-531" unitRef="eur">17000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-6" id="f-532" unitRef="eur">28000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-6" id="f-533" unitRef="eur">579000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-6" id="f-534" unitRef="eur">324000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-6" id="f-535" unitRef="eur">1232000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-6" id="f-536" unitRef="eur">12000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-6" id="f-537" unitRef="eur">1568000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-6" id="f-538" unitRef="eur">-245000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-6" id="f-539" unitRef="eur">-162000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-6" id="f-540" unitRef="eur">-4000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-6" id="f-541" unitRef="eur">-411000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-6" id="f-542" unitRef="eur">14817000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-6" id="f-543" unitRef="eur">69070000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-6" id="f-544" unitRef="eur">1957000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-6" id="f-545" unitRef="eur">85844000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-6" id="f-546" unitRef="eur">-6220000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-93" decimals="-6" id="f-547" unitRef="eur">-49624000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-94" decimals="-6" id="f-548" unitRef="eur">-1480000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-95" decimals="-6" id="f-549" unitRef="eur">-57324000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-6" id="f-550" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-6" id="f-551" unitRef="eur">-1106000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-552" unitRef="eur">-58000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-6" id="f-553" unitRef="eur">-1164000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-6" id="f-554" unitRef="eur">-970000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-6" id="f-555" unitRef="eur">-61000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-556" unitRef="eur">-17000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-6" id="f-557" unitRef="eur">-1048000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-6" id="f-558" unitRef="eur">-534000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-6" id="f-559" unitRef="eur">-17000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-560" unitRef="eur">-26000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-6" id="f-561" unitRef="eur">-577000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-6" id="f-562" unitRef="eur">-135000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-6" id="f-563" unitRef="eur">-785000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-564" unitRef="eur">-10000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-6" id="f-565" unitRef="eur">-930000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-6" id="f-566" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-6" id="f-567" unitRef="eur">400000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-568" unitRef="eur">4000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-6" id="f-569" unitRef="eur">404000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-6" id="f-570" unitRef="eur">-6791000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-6" id="f-571" unitRef="eur">-51159000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-6" id="f-572" unitRef="eur">-1535000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-6" id="f-573" unitRef="eur">-59485000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-6" id="f-574" unitRef="eur">8731000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-105" decimals="-6" id="f-575" unitRef="eur">17122000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-106" decimals="-6" id="f-576" unitRef="eur">408000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-6" id="f-577" unitRef="eur">26261000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-107" decimals="-6" id="f-578" unitRef="eur">8026000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-108" decimals="-6" id="f-579" unitRef="eur">17911000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-109" decimals="-6" id="f-580" unitRef="eur">422000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-6" id="f-581" unitRef="eur">26359000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-110" decimals="-8" id="f-582" unitRef="eur">17100000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-111" decimals="-8" id="f-583" unitRef="eur">16200000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-112" id="f-584">P11Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-113" decimals="-8" id="f-585" unitRef="eur">800000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-114" decimals="-8" id="f-586" unitRef="eur">900000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-115" id="f-587">P18Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock contextRef="c-1" id="f-588">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i4ab9c4fdfc0e4b64a6daaec19209502e"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4. Impairment of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The monitoring of impairment indicators for other intangible assets (excluding software) led to the recognition of impairment losses of &#x20ac;1,031&#160;million in the first half of 2026, mainly comprising a &#x20ac;952&#160;million impairment loss taken against the amlitelimab asset, corresponding to the entire carrying amount of this intangible asset.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-589" unitRef="eur">1031000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-116" decimals="-6" id="f-590" unitRef="eur">952000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c-1" id="f-591">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i2ed1b062d6704c48ae354d7c6de4df94"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.5. Investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2025), and comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;OPAL JV Co &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,934&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH &amp;amp; Co. H&#xf6;chst KG &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,207&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,259&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Following the loss of control of Opella in 2025, Sanofi holds 48.2% of OPAL JV Co (CD&amp;amp;R holds 50% and Bpifrance holds 1.8%). As of December&#160;31, 2025 the investment included a &#x20ac;241&#160;million loan to OPAL JV Co being in substance part of the investment. In 2026, following finalization of the Opella completion accounts as of April 30, 2025, this loan was converted into ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#x20ac;1.33 as of June 30, 2026, and &#x20ac;2.27 as of December&#160;31, 2025). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; showed net income of &#x20ac;2 million&#160;for the first half of 2026 (including a net loss of &#x20ac;39 million for Sanofi&#x2019;s share of losses from the associate OPAL JV Co), versus net income of &#x20ac;85 million for the first half of 2025 (including net income of &#x20ac;11&#160;million for Sanofi&#x2019;s share of profits from the associate OPAL JV Co for the period from May&#160;1, 2025 through June 30, 2025). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases of goods and services (including research expenses)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#x20ac;200&#160;million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2026 was &#x20ac;84&#160;million, versus &#x20ac;143&#160;million as of December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Key items from the unaudited half-year consolidated financial statements of OPAL JV Co as of June 30, 2026, as provided in accordance with Sanofi&#x2019;s consolidation timelines, are presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated income statement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net sales and other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;887&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated statement of comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,598&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,872&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity attributable to equity holders of OPAL JV Co&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,394&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,870&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,204&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,002&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total equity and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,598&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,872&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock contextRef="c-1" id="f-592">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2025), and comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;OPAL JV Co &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #795c8c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #795c8c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,934&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH &amp;amp; Co. H&#xf6;chst KG &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,207&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,259&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Following the loss of control of Opella in 2025, Sanofi holds 48.2% of OPAL JV Co (CD&amp;amp;R holds 50% and Bpifrance holds 1.8%). As of December&#160;31, 2025 the investment included a &#x20ac;241&#160;million loan to OPAL JV Co being in substance part of the investment. In 2026, following finalization of the Opella completion accounts as of April 30, 2025, this loan was converted into ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (&#x20ac;1.33 as of June 30, 2026, and &#x20ac;2.27 as of December&#160;31, 2025). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-117" decimals="3" id="f-593" unitRef="number">0.482</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-118" decimals="-6" id="f-594" unitRef="eur">2965000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-119" decimals="-6" id="f-595" unitRef="eur">2934000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-120" decimals="3" id="f-596" unitRef="number">0.296</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-121" decimals="-6" id="f-597" unitRef="eur">38000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-122" decimals="-6" id="f-598" unitRef="eur">64000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-123" decimals="3" id="f-599" unitRef="number">0.312</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-124" decimals="-6" id="f-600" unitRef="eur">93000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-125" decimals="-6" id="f-601" unitRef="eur">112000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture contextRef="c-126" decimals="3" id="f-602" unitRef="number">0.500</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-127" decimals="-6" id="f-603" unitRef="eur">52000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod contextRef="c-128" decimals="-6" id="f-604" unitRef="eur">59000000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-129" decimals="3" id="f-605" unitRef="number">0</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-130" decimals="-6" id="f-606" unitRef="eur">59000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod contextRef="c-131" decimals="-6" id="f-607" unitRef="eur">90000000</ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-2" decimals="-6" id="f-608" unitRef="eur">3207000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-3" decimals="-6" id="f-609" unitRef="eur">3259000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-132" decimals="3" id="f-610" unitRef="number">0.482</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-133" decimals="2" id="f-611" unitRef="number">0.50</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-134" decimals="3" id="f-612" unitRef="number">0.018</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sny:LoansToAssociates contextRef="c-132" decimals="-6" id="f-613" unitRef="eur">241000000</sny:LoansToAssociates>
    <sny:StockPrice
      contextRef="c-135"
      decimals="2"
      id="f-614"
      unitRef="eurPerShare">1.33</sny:StockPrice>
    <sny:StockPrice
      contextRef="c-136"
      decimals="2"
      id="f-615"
      unitRef="eurPerShare">2.27</sny:StockPrice>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-137" decimals="2" id="f-616" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-617" unitRef="eur">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-117" decimals="-6" id="f-618" unitRef="eur">-39000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-4" decimals="-6" id="f-619" unitRef="eur">85000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-138" decimals="-6" id="f-620" unitRef="eur">11000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-621">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases of goods and services (including research expenses)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;710&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes loans to joint ventures and associates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In October 2024, Sanofi raised its investment in EUROAPI by &#x20ac;200&#160;million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2026 was &#x20ac;84&#160;million, versus &#x20ac;143&#160;million as of December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-622" unitRef="eur">31000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-623" unitRef="eur">29000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-624" unitRef="eur">142000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-625" unitRef="eur">63000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-139" decimals="-6" id="f-626" unitRef="eur">548000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-140" decimals="-6" id="f-627" unitRef="eur">371000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-628" unitRef="eur">430000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-629" unitRef="eur">588000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-630" unitRef="eur">84000000</sny:OtherAssetsRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-631" unitRef="eur">143000000</sny:OtherAssetsRelatedPartyTransactions>
    <sny:OtherLiabilitiesRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-632" unitRef="eur">379000000</sny:OtherLiabilitiesRelatedPartyTransactions>
    <sny:OtherLiabilitiesRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-633" unitRef="eur">710000000</sny:OtherLiabilitiesRelatedPartyTransactions>
    <sny:SubordinateHybridBondRelatedPartyTransactions contextRef="c-143" decimals="-6" id="f-634" unitRef="eur">200000000</sny:SubordinateHybridBondRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-144" decimals="-6" id="f-635" unitRef="eur">84000000</sny:OtherAssetsRelatedPartyTransactions>
    <sny:OtherAssetsRelatedPartyTransactions contextRef="c-145" decimals="-6" id="f-636" unitRef="eur">143000000</sny:OtherAssetsRelatedPartyTransactions>
    <sny:DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock contextRef="c-1" id="f-637">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Key items from the unaudited half-year consolidated financial statements of OPAL JV Co as of June 30, 2026, as provided in accordance with Sanofi&#x2019;s consolidation timelines, are presented below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated income statement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net sales and other revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;887&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated statement of comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,598&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,872&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity attributable to equity holders of OPAL JV Co&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,394&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,870&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,204&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,002&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total equity and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,598&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,872&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfUnauditedFinancialStatementsOfSubsidiariesExplanatoryTableTextBlock>
    <sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures contextRef="c-139" decimals="-6" id="f-638" unitRef="eur">2657000000</sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures>
    <sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures contextRef="c-140" decimals="-6" id="f-639" unitRef="eur">887000000</sny:NetSalesAndOtherRevenuesRelatedPartyDisclosures>
    <sny:NetIncomeRelatedPartyDisclosures contextRef="c-139" decimals="-6" id="f-640" unitRef="eur">-61000000</sny:NetIncomeRelatedPartyDisclosures>
    <sny:NetIncomeRelatedPartyDisclosures contextRef="c-140" decimals="-6" id="f-641" unitRef="eur">24000000</sny:NetIncomeRelatedPartyDisclosures>
    <sny:OtherComprehensiveIncomeRelatedPartyDisclosures contextRef="c-139" decimals="-6" id="f-642" unitRef="eur">83000000</sny:OtherComprehensiveIncomeRelatedPartyDisclosures>
    <sny:OtherComprehensiveIncomeRelatedPartyDisclosures contextRef="c-140" decimals="-6" id="f-643" unitRef="eur">-1000000</sny:OtherComprehensiveIncomeRelatedPartyDisclosures>
    <sny:ComprehensiveIncomeRelatedPartyDisclosures contextRef="c-139" decimals="-6" id="f-644" unitRef="eur">22000000</sny:ComprehensiveIncomeRelatedPartyDisclosures>
    <sny:ComprehensiveIncomeRelatedPartyDisclosures contextRef="c-140" decimals="-6" id="f-645" unitRef="eur">23000000</sny:ComprehensiveIncomeRelatedPartyDisclosures>
    <sny:NonCurrentAssetsRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-646" unitRef="eur">16673000000</sny:NonCurrentAssetsRelatedPartyTransactions>
    <sny:NonCurrentAssetsRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-647" unitRef="eur">15013000000</sny:NonCurrentAssetsRelatedPartyTransactions>
    <sny:CurrentAssetsRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-648" unitRef="eur">2925000000</sny:CurrentAssetsRelatedPartyTransactions>
    <sny:CurrentAssetsRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-649" unitRef="eur">2859000000</sny:CurrentAssetsRelatedPartyTransactions>
    <sny:AssetsRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-650" unitRef="eur">19598000000</sny:AssetsRelatedPartyTransactions>
    <sny:AssetsRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-651" unitRef="eur">17872000000</sny:AssetsRelatedPartyTransactions>
    <sny:EquityAttributableToEquityHoldersRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-652" unitRef="eur">5958000000</sny:EquityAttributableToEquityHoldersRelatedPartyTransactions>
    <sny:EquityAttributableToEquityHoldersRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-653" unitRef="eur">5380000000</sny:EquityAttributableToEquityHoldersRelatedPartyTransactions>
    <sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-654" unitRef="eur">436000000</sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions>
    <sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-655" unitRef="eur">490000000</sny:EquityAttributableToNonControllingInterestRelatedPartyTransactions>
    <sny:EquityRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-656" unitRef="eur">6394000000</sny:EquityRelatedPartyTransactions>
    <sny:EquityRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-657" unitRef="eur">5870000000</sny:EquityRelatedPartyTransactions>
    <sny:NonCurrentLiabilitiesRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-658" unitRef="eur">11575000000</sny:NonCurrentLiabilitiesRelatedPartyTransactions>
    <sny:NonCurrentLiabilitiesRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-659" unitRef="eur">9850000000</sny:NonCurrentLiabilitiesRelatedPartyTransactions>
    <sny:CurrentLiabilitiesRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-660" unitRef="eur">1629000000</sny:CurrentLiabilitiesRelatedPartyTransactions>
    <sny:CurrentLiabilitiesRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-661" unitRef="eur">2152000000</sny:CurrentLiabilitiesRelatedPartyTransactions>
    <sny:LiabilitiesRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-662" unitRef="eur">13204000000</sny:LiabilitiesRelatedPartyTransactions>
    <sny:LiabilitiesRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-663" unitRef="eur">12002000000</sny:LiabilitiesRelatedPartyTransactions>
    <sny:EquityAndLiabilitiesRelatedPartyTransactions contextRef="c-141" decimals="-6" id="f-664" unitRef="eur">19598000000</sny:EquityAndLiabilitiesRelatedPartyTransactions>
    <sny:EquityAndLiabilitiesRelatedPartyTransactions contextRef="c-142" decimals="-6" id="f-665" unitRef="eur">17872000000</sny:EquityAndLiabilitiesRelatedPartyTransactions>
    <ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory contextRef="c-1" id="f-666">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i87905fc66c7b49b89f2037c9405e25d1"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6. Other non-current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,732&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,364&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory>
    <sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock contextRef="c-1" id="f-667">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,732&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,364&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-146" decimals="-6" id="f-668" unitRef="eur">2435000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-147" decimals="-6" id="f-669" unitRef="eur">2200000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-148" decimals="-6" id="f-670" unitRef="eur">363000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-149" decimals="-6" id="f-671" unitRef="eur">389000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-2" decimals="-6" id="f-672" unitRef="eur">1099000000</sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-3" decimals="-6" id="f-673" unitRef="eur">1004000000</sny:OtherFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sny:PreFundedPensionObligations contextRef="c-2" decimals="-6" id="f-674" unitRef="eur">203000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-3" decimals="-6" id="f-675" unitRef="eur">194000000</sny:PreFundedPensionObligations>
    <sny:LongTermPrepaidExpenses contextRef="c-2" decimals="-6" id="f-676" unitRef="eur">185000000</sny:LongTermPrepaidExpenses>
    <sny:LongTermPrepaidExpenses contextRef="c-3" decimals="-6" id="f-677" unitRef="eur">175000000</sny:LongTermPrepaidExpenses>
    <sny:NonCurrentLoansAndReceivables contextRef="c-2" decimals="-6" id="f-678" unitRef="eur">421000000</sny:NonCurrentLoansAndReceivables>
    <sny:NonCurrentLoansAndReceivables contextRef="c-3" decimals="-6" id="f-679" unitRef="eur">393000000</sny:NonCurrentLoansAndReceivables>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-2" decimals="-6" id="f-680" unitRef="eur">26000000</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-3" decimals="-6" id="f-681" unitRef="eur">9000000</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-2" decimals="-6" id="f-682" unitRef="eur">4732000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-3" decimals="-6" id="f-683" unitRef="eur">4364000000</ifrs-full:OtherNoncurrentAssets>
    <sny:DisclosureOfTradeReceivablesTextBlock contextRef="c-1" id="f-684">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i8a86659307ea4443ba42dfcb5d3b4e96"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.7. Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,714&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,410&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of allowances against accounts receivable in the first half of 2026 was a net expense of &#x20ac;6 million (versus a net expense of &#x20ac;4 million for the first half of 2025).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the ageing profile of overdue accounts receivable, based on gross value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue accounts gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;1-3 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;3-6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;6-12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;gt; 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;522&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;183&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amounts overdue by more than one month relate mainly to public-sector customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2025 and hence were derecognized was &#x20ac;11 million as of June&#160;30, 2026 (versus zero as of December 31, 2025). The residual guarantees relating to those transfers were immaterial as of June 30, 2026.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfTradeReceivablesTextBlock>
    <sny:DisclosureOfCurrentTradeReceivablesTableTextBlock contextRef="c-1" id="f-685">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,714&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,410&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfCurrentTradeReceivablesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables contextRef="c-91" decimals="-6" id="f-686" unitRef="eur">8818000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-83" decimals="-6" id="f-687" unitRef="eur">8510000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-150" decimals="-6" id="f-688" unitRef="eur">104000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-151" decimals="-6" id="f-689" unitRef="eur">100000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-6" id="f-690" unitRef="eur">8714000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-6" id="f-691" unitRef="eur">8410000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-1" decimals="-6" id="f-692" unitRef="eur">-6000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-4" decimals="-6" id="f-693" unitRef="eur">-4000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock contextRef="c-1" id="f-694">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the ageing profile of overdue accounts receivable, based on gross value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue accounts gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;1-3 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;3-6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;6-12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue by &lt;br/&gt;&amp;gt; 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;522&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;183&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock>
    <sny:OverdueReceivablesGrossValue contextRef="c-2" decimals="-6" id="f-695" unitRef="eur">522000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-152" decimals="-6" id="f-696" unitRef="eur">183000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-153" decimals="-6" id="f-697" unitRef="eur">127000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-154" decimals="-6" id="f-698" unitRef="eur">142000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-155" decimals="-6" id="f-699" unitRef="eur">27000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-156" decimals="-6" id="f-700" unitRef="eur">43000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-3" decimals="-6" id="f-701" unitRef="eur">468000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-157" decimals="-6" id="f-702" unitRef="eur">184000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-158" decimals="-6" id="f-703" unitRef="eur">134000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-159" decimals="-6" id="f-704" unitRef="eur">71000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-160" decimals="-6" id="f-705" unitRef="eur">27000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-161" decimals="-6" id="f-706" unitRef="eur">52000000</sny:OverdueReceivablesGrossValue>
    <sny:DerecognizedReceivables contextRef="c-2" decimals="-6" id="f-707" unitRef="eur">11000000</sny:DerecognizedReceivables>
    <sny:DerecognizedReceivables contextRef="c-3" decimals="-6" id="f-708" unitRef="eur">0</sny:DerecognizedReceivables>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-709">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i0d5e6157a9da4039a10239b9799b7eaa"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8. Consolidated shareholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ia7d079fa575843689ca15d686ccf06c5"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.1. Share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, the share capital was &#x20ac;2,428,198,054 and consisted of 1,214,099,027 shares (the total number of shares outstanding) with a par value of &#x20ac;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Treasury shares held by Sanofi are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% of share capital&lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16.03&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.320&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.981&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.868&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.755&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A total of 30,070 shares were issued in the first half of 2026 as a result of the exercise of Sanofi stock subscription options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, 3,072,520 shares vested under Sanofi restricted share plans during the first half of 2026, of which 1,886,523&#160;were fulfilled by issuance of new shares and 1,185,997 by allotment of existing shares free of charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i91f7c2d3c7534cfd8ccaccf0cd785e5d"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.2. Repurchase of Sanofi shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 30, 2025, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program, Sanofi repurchased 12,571,455 of its own shares during the first half of 2026 for a total amount of &#x20ac;1,003&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding &#x20ac;5&#160;billion, under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Or&#xe9;al on February&#160;2, 2025 for the acquisition of 2.34% of Sanofi&#x2019;s share capital, equivalent to 29,556,650 shares, for a total amount of approximately &#x20ac;3&#160;billion, representing a price of &#x20ac;101.50 per share. The conclusion of that agreement was approved by the Board of Directors on the same day prior to the signing of the agreement, and in accordance with the procedure set forth in Articles L. 225-38 et seq. of the French Commercial Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 29, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did n&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ot use that authorization during the first half of 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="idd55326c6f4f42359cf73c8a329501bb"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.3. Reduction in share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the first half of 2026, treasury shares amounting to &#x20ac;596&#160;million were cancelled further to decisions taken by the Sanofi Board of Directors on March 4, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Those reductions have no impact on shareholders&#x2019; equity, except for the impact of the tax on share cancellations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ie4aae90ce3ea41c0bceff57eca296b4d"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.4. Restricted share plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2025. The principal features of the plans awarded in 2026 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Performance share plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April, 29, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plans awarded to the Chief Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;May 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 3-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,087,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,367,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;65.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,719,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer (1,674,656 shares in total) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;57.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer (45,000 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;53.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 5-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer (180,000 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;40.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plans at the date of grant (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 5 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12,995,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,550,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2026 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,267,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2025 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,897,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,020,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2024 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,772,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,110,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;58,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,313,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;106,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i77cbafef4d014f33b235e0d519481bbb"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.5. Employee stock purchase plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January 28, 2026, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the opportunity to subscribe for new Sanofi shares at a price of &#x20ac;59.87 per share. The subscription period was open from June&#160;9 through June&#160;29, 2026. Sanofi employees subscribed for a total of 2,431,494 shares, and the resulting capital increase was supplemented by the immediate issuance of a further 104,327 shares for the employer&#x2019;s contribution. The total expense recognized for this plan in the first half of 2026 was &#x20ac;46 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January 29, 2025, the Sanofi Board of Directors approved an employee stock purchase plan, offering employees the opportunity to subscribe for new Sanofi shares at a price of &#x20ac;72.97 per share. The subscription period was open from June&#160;10 through June&#160;30, 2025. Sanofi employees subscribed for a total of 2,260,776 shares, and the resulting capital increase was supplemented by the immediate issuance of a further 116,794 shares for the employer&#x2019;s contribution. The total expense recognized for this plan in the first half of 2025 was &#x20ac;31 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i1684c1a55e2d4d5280f95522eb2195d4"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.6. Stock subscription option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No stock subscription option plans were awarded in the first half of 2026 or in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No further stock option plan expenses were recognized through equity in either the first half of 2026 or 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average residual life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;639,194&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;639,194&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="iae4940e55e3f422eb90dc30c896cfb60"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.7. Earnings per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Net income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income attributable to equity holders of Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,957.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,812.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which net income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,931.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,941.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,871.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Number of shares:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(number of shares in million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,205.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,230.7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026 and June 30, 2025, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Basic earnings per share from continuing operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Basic earnings per share from discontinued operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Basic earnings per share (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.63&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.74&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Diluted earnings per share from continuing operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Diluted earnings per share from discontinued operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.62&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.72&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ia974d4d9952a48af8a624f4df1a8865a"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.8.8. Other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;243&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow hedges and fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences (investments accounted for using the equity method) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Hedges of net investments in foreign operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,327&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(5,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes reclassifications to profit or loss: &#x20ac;1&#160;million in the first half of 2026; &#x20ac;2&#160;million in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.&lt;/span&gt;&lt;/div&gt; &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#x20ac;146&#160;million loss in the first half of 2026 and a &#x20ac;459 million loss in the first half of 2025 relating to the deconsolidation of Opella</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:IssuedCapital contextRef="c-2" decimals="0" id="f-710" unitRef="eur">2428198054</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssued contextRef="c-2" decimals="INF" id="f-711" unitRef="shares">1214099027</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c-2"
      decimals="INF"
      id="f-712"
      unitRef="eurPerShare">2</ifrs-full:ParValuePerShare>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-713">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Treasury shares held by Sanofi are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.073%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% of share capital&lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16.03&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.320&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.981&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.868&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.755&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <sny:NumberOfSharesHeld contextRef="c-2" decimals="-4" id="f-714" unitRef="shares">16030000.00</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-2" decimals="5" id="f-715" unitRef="number">0.01320</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-3" decimals="-4" id="f-716" unitRef="shares">11960000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-3" decimals="5" id="f-717" unitRef="number">0.00981</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-30" decimals="-4" id="f-718" unitRef="shares">10660000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-30" decimals="5" id="f-719" unitRef="number">0.00868</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-13" decimals="-4" id="f-720" unitRef="shares">9530000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-13" decimals="5" id="f-721" unitRef="number">0.00755</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions
      contextRef="c-162"
      decimals="INF"
      id="f-722"
      unitRef="shares">30070</sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions>
    <sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease
      contextRef="c-163"
      decimals="INF"
      id="f-723"
      unitRef="shares">3072520</sny:NumberOfRestrictedSharesVestedInRegardsOfCapitalIncrease>
    <sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease
      contextRef="c-162"
      decimals="INF"
      id="f-724"
      unitRef="shares">1886523</sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease>
    <sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease
      contextRef="c-164"
      decimals="INF"
      id="f-725"
      unitRef="shares">1185997</sny:NumberOfRestrictedSharesAllotedInRegardsOfCapitalIncrease>
    <sny:ShareRepurchaseProgramPeriod contextRef="c-165" id="f-726">P18M</sny:ShareRepurchaseProgramPeriod>
    <sny:NumberOfSharesRepurchased
      contextRef="c-166"
      decimals="INF"
      id="f-727"
      unitRef="shares">12571455</sny:NumberOfSharesRepurchased>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-166" decimals="-6" id="f-728" unitRef="eur">1003000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-167" decimals="-9" id="f-729" unitRef="eur">5000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <sny:PercentageOfSanofisShareCapitalAcquired contextRef="c-168" decimals="4" id="f-730" unitRef="number">0.0234</sny:PercentageOfSanofisShareCapitalAcquired>
    <sny:NumberOfSharesRepurchased
      contextRef="c-169"
      decimals="INF"
      id="f-731"
      unitRef="shares">29556650</sny:NumberOfSharesRepurchased>
    <sny:ShareRepurchaseProgramAmountPaid contextRef="c-169" decimals="-9" id="f-732" unitRef="eur">3000000000</sny:ShareRepurchaseProgramAmountPaid>
    <sny:PerShareValueOfSharesRepurchased
      contextRef="c-169"
      decimals="2"
      id="f-733"
      unitRef="eurPerShare">101.50</sny:PerShareValueOfSharesRepurchased>
    <sny:ShareRepurchaseProgramPeriod contextRef="c-170" id="f-734">P18M</sny:ShareRepurchaseProgramPeriod>
    <ifrs-full:CancellationOfTreasuryShares contextRef="c-1" decimals="-6" id="f-735" unitRef="eur">596000000</ifrs-full:CancellationOfTreasuryShares>
    <sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock contextRef="c-1" id="f-736">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2025. The principal features of the plans awarded in 2026 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Performance share plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April, 29, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plans awarded to the Chief Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;May 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 3-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,087,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,367,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;65.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,719,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer (1,674,656 shares in total) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;57.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer (45,000 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;53.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares subject to a 5-year service period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer (180,000 shares) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;40.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plans at the date of grant (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;329&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period of 5 years.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock>
    <sny:NumberOfYearsServicePeriod contextRef="c-171" id="f-737">P3Y</sny:NumberOfYearsServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-171"
      decimals="INF"
      id="f-738"
      unitRef="shares">5087518</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-172"
      decimals="INF"
      id="f-739"
      unitRef="shares">3367862</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-172"
      decimals="2"
      id="f-740"
      unitRef="eurPerShare">65.86</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-173"
      decimals="INF"
      id="f-741"
      unitRef="shares">1719656</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-174"
      decimals="INF"
      id="f-742"
      unitRef="shares">1674656</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-174"
      decimals="2"
      id="f-743"
      unitRef="eurPerShare">57.99</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-175"
      decimals="INF"
      id="f-744"
      unitRef="shares">45000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-175"
      decimals="2"
      id="f-745"
      unitRef="eurPerShare">53.46</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:NumberOfYearsServicePeriod contextRef="c-176" id="f-746">P5Y</sny:NumberOfYearsServicePeriod>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-176"
      decimals="INF"
      id="f-747"
      unitRef="shares">180000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-177"
      decimals="INF"
      id="f-748"
      unitRef="shares">180000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sny:FairValuePerShareAwardedForFiveYearServicePeriod
      contextRef="c-177"
      decimals="2"
      id="f-749"
      unitRef="eurPerShare">40.46</sny:FairValuePerShareAwardedForFiveYearServicePeriod>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-178" decimals="-6" id="f-750" unitRef="eur">329000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:NumberOfYearsServicePeriod contextRef="c-171" id="f-751">P3Y</sny:NumberOfYearsServicePeriod>
    <sny:NumberOfYearsServicePeriod contextRef="c-176" id="f-752">P5Y</sny:NumberOfYearsServicePeriod>
    <sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock contextRef="c-1" id="f-753">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans (&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12,995,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,550,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2026 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,267,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2025 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,897,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,020,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2024 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,772,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,110,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;58,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,313,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;106,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-179" decimals="-6" id="f-754" unitRef="eur">138000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-180" decimals="-6" id="f-755" unitRef="eur">146000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-181"
      decimals="INF"
      id="f-756"
      unitRef="shares">12995668</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-182"
      decimals="INF"
      id="f-757"
      unitRef="shares">11550347</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-183"
      decimals="INF"
      id="f-758"
      unitRef="shares">5267518</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-184"
      decimals="INF"
      id="f-759"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-185"
      decimals="INF"
      id="f-760"
      unitRef="shares">3897342</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-186"
      decimals="INF"
      id="f-761"
      unitRef="shares">4020451</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-187"
      decimals="INF"
      id="f-762"
      unitRef="shares">3772461</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-188"
      decimals="INF"
      id="f-763"
      unitRef="shares">4110089</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-189"
      decimals="INF"
      id="f-764"
      unitRef="shares">58347</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-190"
      decimals="INF"
      id="f-765"
      unitRef="shares">3313588</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-191"
      decimals="INF"
      id="f-766"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-192"
      decimals="INF"
      id="f-767"
      unitRef="shares">106219</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:SubscriptionPricePerShare
      contextRef="c-193"
      decimals="2"
      id="f-768"
      unitRef="eurPerShare">59.87</sny:SubscriptionPricePerShare>
    <sny:NumberOfSharesSubscribed
      contextRef="c-194"
      decimals="INF"
      id="f-769"
      unitRef="shares">2431494</sny:NumberOfSharesSubscribed>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-194"
      decimals="INF"
      id="f-770"
      unitRef="shares">104327</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-195" decimals="-6" id="f-771" unitRef="eur">46000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:SubscriptionPricePerShare
      contextRef="c-196"
      decimals="2"
      id="f-772"
      unitRef="eurPerShare">72.97</sny:SubscriptionPricePerShare>
    <sny:NumberOfSharesSubscribed
      contextRef="c-197"
      decimals="INF"
      id="f-773"
      unitRef="shares">2260776</sny:NumberOfSharesSubscribed>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-197"
      decimals="INF"
      id="f-774"
      unitRef="shares">116794</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-198" decimals="-6" id="f-775" unitRef="eur">31000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock contextRef="c-1" id="f-776">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of June&#160;30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average residual life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price per&#160;share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;639,194&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;639,194&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-199"
      decimals="2"
      id="f-777"
      unitRef="eurPerShare">60.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-200"
      decimals="2"
      id="f-778"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-201"
      decimals="INF"
      id="f-779"
      unitRef="shares">168784</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-202" id="f-780">P1Y10M2D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-201"
      decimals="2"
      id="f-781"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-201"
      decimals="INF"
      id="f-782"
      unitRef="shares">168784</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-201"
      decimals="2"
      id="f-783"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-203"
      decimals="2"
      id="f-784"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-204"
      decimals="2"
      id="f-785"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-205"
      decimals="INF"
      id="f-786"
      unitRef="shares">213400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-206" id="f-787">P2Y10M2D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-205"
      decimals="2"
      id="f-788"
      unitRef="eurPerShare">76.71</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-205"
      decimals="INF"
      id="f-789"
      unitRef="shares">213400</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-205"
      decimals="2"
      id="f-790"
      unitRef="eurPerShare">76.71</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-207"
      decimals="2"
      id="f-791"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-208"
      decimals="2"
      id="f-792"
      unitRef="eurPerShare">90.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-209"
      decimals="INF"
      id="f-793"
      unitRef="shares">257010</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-210" id="f-794">P0Y10M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-209"
      decimals="2"
      id="f-795"
      unitRef="eurPerShare">88.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-209"
      decimals="INF"
      id="f-796"
      unitRef="shares">257010</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-209"
      decimals="2"
      id="f-797"
      unitRef="eurPerShare">88.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-211"
      decimals="INF"
      id="f-798"
      unitRef="shares">639194</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-211"
      decimals="INF"
      id="f-799"
      unitRef="shares">639194</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-800">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Net income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income attributable to equity holders of Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,957.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,812.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which net income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,931.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,941.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,871.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Number of shares:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(number of shares in million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,205.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,230.7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #200f45;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-801" unitRef="eur">1957000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-4" decimals="-6" id="f-802" unitRef="eur">5812000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-1" decimals="-5" id="f-803" unitRef="eur">1931000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-4" decimals="-5" id="f-804" unitRef="eur">2941000000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-1" decimals="-5" id="f-805" unitRef="eur">26000000.0</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-4" decimals="-5" id="f-806" unitRef="eur">2871000000</ifrs-full:ProfitLossFromDiscontinuedOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-807" unitRef="shares">1200400000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="-5" id="f-808" unitRef="shares">1225500000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-1" decimals="-5" id="f-809" unitRef="shares">0</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-4" decimals="-5" id="f-810" unitRef="shares">100000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-1" decimals="-5" id="f-811" unitRef="shares">5100000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-4" decimals="-5" id="f-812" unitRef="shares">5100000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-813" unitRef="shares">1205500000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-4" decimals="-5" id="f-814" unitRef="shares">1230700000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-815">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Basic earnings per share from continuing operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Basic earnings per share from discontinued operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Basic earnings per share (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.63&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.74&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Diluted earnings per share from continuing operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Diluted earnings per share from discontinued operations (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share (&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.62&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.72&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="2"
      id="f-816"
      unitRef="eurPerShare">1.61</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-4"
      decimals="2"
      id="f-817"
      unitRef="eurPerShare">2.40</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="2"
      id="f-818"
      unitRef="eurPerShare">0.02</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="2"
      id="f-819"
      unitRef="eurPerShare">2.34</ifrs-full:BasicEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-820"
      unitRef="eurPerShare">1.63</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-821"
      unitRef="eurPerShare">4.74</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="2"
      id="f-822"
      unitRef="eurPerShare">1.60</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-4"
      decimals="2"
      id="f-823"
      unitRef="eurPerShare">2.39</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-1"
      decimals="2"
      id="f-824"
      unitRef="eurPerShare">0.02</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations
      contextRef="c-4"
      decimals="2"
      id="f-825"
      unitRef="eurPerShare">2.33</ifrs-full:DilutedEarningsLossPerShareFromDiscontinuedOperations>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-826"
      unitRef="eurPerShare">1.62</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-827"
      unitRef="eurPerShare">4.72</ifrs-full:DilutedEarningsLossPerShare>
    <sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock contextRef="c-1" id="f-828">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025        (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;243&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow hedges and fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Currency translation differences (investments accounted for using the equity method) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Hedges of net investments in foreign operations &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:7.09pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:5.04pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,327&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(5,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes reclassifications to profit or loss: immaterial over all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes reclassifications to profit or loss: &#x20ac;1&#160;million in the first half of 2026; &#x20ac;2&#160;million in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.&lt;/span&gt;&lt;/div&gt; &#160;&#160;&#160;&#160;Includes reclassifications to profit or loss: a &#x20ac;146&#160;million loss in the first half of 2026 and a &#x20ac;459 million loss in the first half of 2025 relating to the deconsolidation of Opella</sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-212" decimals="-6" id="f-829" unitRef="eur">157000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-213" decimals="-6" id="f-830" unitRef="eur">105000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-212" decimals="-6" id="f-831" unitRef="eur">1000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-213" decimals="-6" id="f-832" unitRef="eur">1000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments contextRef="c-212" decimals="-6" id="f-833" unitRef="eur">20000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments contextRef="c-213" decimals="-6" id="f-834" unitRef="eur">25000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingEquityInvestments>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-214" decimals="-6" id="f-835" unitRef="eur">175000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-215" decimals="-6" id="f-836" unitRef="eur">222000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-214" decimals="-6" id="f-837" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-215" decimals="-6" id="f-838" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-214" decimals="-6" id="f-839" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-215" decimals="-6" id="f-840" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-214" decimals="-6" id="f-841" unitRef="eur">23000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-215" decimals="-6" id="f-842" unitRef="eur">60000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-212" decimals="-6" id="f-843" unitRef="eur">290000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-213" decimals="-6" id="f-844" unitRef="eur">243000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-216" decimals="-6" id="f-845" unitRef="eur">5000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-217" decimals="-6" id="f-846" unitRef="eur">3000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures contextRef="c-216" decimals="-6" id="f-847" unitRef="eur">0</sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures contextRef="c-217" decimals="-6" id="f-848" unitRef="eur">0</sny:ChangeInFairValueOnDebtInstrumentAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments contextRef="c-216" decimals="-6" id="f-849" unitRef="eur">0</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments contextRef="c-217" decimals="-6" id="f-850" unitRef="eur">0</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingEquityInvestments>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-218" decimals="-6" id="f-851" unitRef="eur">5000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-219" decimals="-6" id="f-852" unitRef="eur">-23000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-218" decimals="-6" id="f-853" unitRef="eur">9000000</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-219" decimals="-6" id="f-854" unitRef="eur">0</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-218" decimals="-6" id="f-855" unitRef="eur">2000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-219" decimals="-6" id="f-856" unitRef="eur">-6000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-220" decimals="-6" id="f-857" unitRef="eur">1747000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-221" decimals="-6" id="f-858" unitRef="eur">-5266000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-220" decimals="-6" id="f-859" unitRef="eur">55000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-221" decimals="-6" id="f-860" unitRef="eur">-26000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-220" decimals="-6" id="f-861" unitRef="eur">-489000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-221" decimals="-6" id="f-862" unitRef="eur">390000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-220" decimals="-6" id="f-863" unitRef="eur">3000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-221" decimals="-6" id="f-864" unitRef="eur">101000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-222" decimals="-6" id="f-865" unitRef="eur">1327000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-223" decimals="-6" id="f-866" unitRef="eur">-5017000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-218" decimals="-6" id="f-867" unitRef="eur">1000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-219" decimals="-6" id="f-868" unitRef="eur">2000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-220" decimals="-6" id="f-869" unitRef="eur">146000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-221" decimals="-6" id="f-870" unitRef="eur">459000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock contextRef="c-1" id="f-871">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="if3c50351e3a9496d81a572fcb437eb25"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.9. Debt, cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,893&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,702&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,513&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,008&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,904 million as of June 30, 2026 and &#x20ac;1,739 million as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Net debt&#x201d; is a non-IFRS financial measure used by management and investors to measure Sanofi&#x2019;s overall net indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i152be4776fb742e294ebcac319167d5e"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.9.1. Net debt at value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2026 is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Adjustment to debt measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,893&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,868&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,716&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,513&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,488&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,022&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,904 million as of June 30, 2026 and &#x20ac;1,739 million as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows an analysis of net debt by type, at value on redemption:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,751&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,117&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,868&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,360&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,356&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,716&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,751&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;737&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,488&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,360&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,022&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) These amounts include $3&#160;billion designated  as a hedge of Sanofi&#x2019;s net investment in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) As of Ju&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;ne 30, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, current other bank borrowings include &#x20ac;3,217&#160;million related to the US commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span id="ib114c4f84689446085e75d598afd9d11"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal financing and debt reduction transactions during the period&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the period, Sanofi carried out a bond issue of &#x20ac;2.3&#160;billion in three tranches:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;&#x20ac;1,000&#160;million of fixed-rate bonds maturing May 2029, with annual coupons and bearing interest at an annual rate of 3.000%;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;&#x20ac;650&#160;million of fixed-rate bonds maturing May 2033, with annual coupons and bearing interest at an annual rate of 3.375%; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;&#x20ac;650&#160;million of fixed-rate bonds maturing May 2037, with annual coupons and bearing interest at an annual rate of 3.750%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;One bond issue was redeemed during the period: a &#x20ac;1.5&#160;billion issue from March 2018, redeemed at maturity on March 21, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;a syndicated credit facility of &#x20ac;4&#160;billion, drawable in euros and US dollars and expiring on March 6, 2030, for which no further extension options are available; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;a syndicated credit facility of &#x20ac;3.85&#160;billion, drawable in euros and US dollars and expiring on  April 23, 2031, for which two  one-year extension options are available. This facility became effective on April&#160;23, 2026, and replaced an existing &#x20ac;4&#160;billion facility that was cancelled on the same date and had originally been scheduled to mature on December 6, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, neither facility was drawn down.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi also has two short-term debt programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;a &#x20ac;6 billion Negotiable European Commercial Paper program in France; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;a $10&#160;billion Commercial Paper program in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the first half of 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the average drawdown under the US Commercial Paper program was $3.0&#160;billion; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the average drawdown under the Negotiable European Commercial Paper program in France was &#x20ac;0.1&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify;text-indent:3.83pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financing in place as of June 30, 2026 at the level of the holding company (which manages most of Sanofi&#x2019;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i37c1361e63e94fd097254f65bc03ccbd"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.9.2. Market value of net debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock>
    <sny:DisclosureOfChangesInFinancialPositionTableTextBlock contextRef="c-1" id="f-872">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,893&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,702&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,513&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,008&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,904 million as of June 30, 2026 and &#x20ac;1,739 million as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInFinancialPositionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-873" unitRef="eur">14646000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-3" decimals="-6" id="f-874" unitRef="eur">14248000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-875" unitRef="eur">7026000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-3" decimals="-6" id="f-876" unitRef="eur">4342000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-2" decimals="-6" id="f-877" unitRef="eur">-221000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-3" decimals="-6" id="f-878" unitRef="eur">-112000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-2" decimals="-6" id="f-879" unitRef="eur">21893000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-3" decimals="-6" id="f-880" unitRef="eur">18702000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-881" unitRef="eur">6350000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-882" unitRef="eur">7657000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-2" decimals="-6" id="f-883" unitRef="eur">30000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-3" decimals="-6" id="f-884" unitRef="eur">37000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-885" unitRef="eur">15513000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-3" decimals="-6" id="f-886" unitRef="eur">11008000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-2" decimals="-6" id="f-887" unitRef="eur">1904000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-6" id="f-888" unitRef="eur">1739000000</ifrs-full:LeaseLiabilities>
    <sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock contextRef="c-1" id="f-889">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2026 is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Adjustment to debt measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,893&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,868&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,716&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,513&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,488&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,022&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Net debt does not include lease liabilities, which amounted to &#x20ac;1,904 million as of June 30, 2026 and &#x20ac;1,739 million as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-2" decimals="-6" id="f-890" unitRef="eur">14646000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-224" decimals="-6" id="f-891" unitRef="eur">44000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-225" decimals="-6" id="f-892" unitRef="eur">61000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-226" decimals="-6" id="f-893" unitRef="eur">14751000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-227" decimals="-6" id="f-894" unitRef="eur">14360000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-2" decimals="-6" id="f-895" unitRef="eur">7026000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-224" decimals="-6" id="f-896" unitRef="eur">1000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-225" decimals="-6" id="f-897" unitRef="eur">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-226" decimals="-6" id="f-898" unitRef="eur">7027000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-227" decimals="-6" id="f-899" unitRef="eur">4344000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-2" decimals="-6" id="f-900" unitRef="eur">-221000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-224" decimals="-6" id="f-901" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-225" decimals="-6" id="f-902" unitRef="eur">131000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-226" decimals="-6" id="f-903" unitRef="eur">-90000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-227" decimals="-6" id="f-904" unitRef="eur">-12000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-2" decimals="-6" id="f-905" unitRef="eur">21893000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-224" decimals="-6" id="f-906" unitRef="eur">45000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-225" decimals="-6" id="f-907" unitRef="eur">-70000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-226" decimals="-6" id="f-908" unitRef="eur">21868000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-227" decimals="-6" id="f-909" unitRef="eur">18716000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-910" unitRef="eur">6350000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-224" decimals="-6" id="f-911" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-225" decimals="-6" id="f-912" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-913" unitRef="eur">6350000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-227" decimals="-6" id="f-914" unitRef="eur">7657000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-2" decimals="-6" id="f-915" unitRef="eur">30000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-224" decimals="-6" id="f-916" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-225" decimals="-6" id="f-917" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-226" decimals="-6" id="f-918" unitRef="eur">30000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-227" decimals="-6" id="f-919" unitRef="eur">37000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-2" decimals="-6" id="f-920" unitRef="eur">15513000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-224" decimals="-6" id="f-921" unitRef="eur">45000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-225" decimals="-6" id="f-922" unitRef="eur">-70000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-923" unitRef="eur">15488000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-227" decimals="-6" id="f-924" unitRef="eur">11022000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-2" decimals="-6" id="f-925" unitRef="eur">1904000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-6" id="f-926" unitRef="eur">1739000000</ifrs-full:LeaseLiabilities>
    <sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock contextRef="c-1" id="f-927">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows an analysis of net debt by type, at value on redemption:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:1.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,751&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,117&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,868&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,360&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,356&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,716&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,751&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;737&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,488&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,360&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,022&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) These amounts include $3&#160;billion designated  as a hedge of Sanofi&#x2019;s net investment in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) As of Ju&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;ne 30, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, current other bank borrowings include &#x20ac;3,217&#160;million related to the US commercial paper program.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock>
    <ifrs-full:BondsIssued contextRef="c-228" decimals="-6" id="f-928" unitRef="eur">14702000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-229" decimals="-6" id="f-929" unitRef="eur">3599000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-226" decimals="-6" id="f-930" unitRef="eur">18301000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-230" decimals="-6" id="f-931" unitRef="eur">14306000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-231" decimals="-6" id="f-932" unitRef="eur">3165000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-227" decimals="-6" id="f-933" unitRef="eur">17471000000</ifrs-full:BondsIssued>
    <sny:OtherBankBorrowings contextRef="c-228" decimals="-6" id="f-934" unitRef="eur">49000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-229" decimals="-6" id="f-935" unitRef="eur">3291000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-226" decimals="-6" id="f-936" unitRef="eur">3340000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-230" decimals="-6" id="f-937" unitRef="eur">54000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-231" decimals="-6" id="f-938" unitRef="eur">936000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-227" decimals="-6" id="f-939" unitRef="eur">990000000</sny:OtherBankBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-228" decimals="-6" id="f-940" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-229" decimals="-6" id="f-941" unitRef="eur">1000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-226" decimals="-6" id="f-942" unitRef="eur">1000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-230" decimals="-6" id="f-943" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-231" decimals="-6" id="f-944" unitRef="eur">1000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-227" decimals="-6" id="f-945" unitRef="eur">1000000</ifrs-full:OtherBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-228" decimals="-6" id="f-946" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-229" decimals="-6" id="f-947" unitRef="eur">136000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-226" decimals="-6" id="f-948" unitRef="eur">136000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-230" decimals="-6" id="f-949" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-231" decimals="-6" id="f-950" unitRef="eur">242000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-227" decimals="-6" id="f-951" unitRef="eur">242000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-228" decimals="-6" id="f-952" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-229" decimals="-6" id="f-953" unitRef="eur">-90000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-226" decimals="-6" id="f-954" unitRef="eur">-90000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-230" decimals="-6" id="f-955" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-231" decimals="-6" id="f-956" unitRef="eur">-12000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-227" decimals="-6" id="f-957" unitRef="eur">-12000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-228" decimals="-6" id="f-958" unitRef="eur">14751000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-229" decimals="-6" id="f-959" unitRef="eur">7117000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-226" decimals="-6" id="f-960" unitRef="eur">21868000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-230" decimals="-6" id="f-961" unitRef="eur">14360000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-231" decimals="-6" id="f-962" unitRef="eur">4356000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-227" decimals="-6" id="f-963" unitRef="eur">18716000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-232" decimals="-6" id="f-964" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-233" decimals="-6" id="f-965" unitRef="eur">6350000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-966" unitRef="eur">6350000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-234" decimals="-6" id="f-967" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-235" decimals="-6" id="f-968" unitRef="eur">7657000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-227" decimals="-6" id="f-969" unitRef="eur">7657000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-232" decimals="-6" id="f-970" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-233" decimals="-6" id="f-971" unitRef="eur">30000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-226" decimals="-6" id="f-972" unitRef="eur">30000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-234" decimals="-6" id="f-973" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-235" decimals="-6" id="f-974" unitRef="eur">37000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-227" decimals="-6" id="f-975" unitRef="eur">37000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-232" decimals="-6" id="f-976" unitRef="eur">14751000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-233" decimals="-6" id="f-977" unitRef="eur">737000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-226" decimals="-6" id="f-978" unitRef="eur">15488000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-234" decimals="-6" id="f-979" unitRef="eur">14360000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-235" decimals="-6" id="f-980" unitRef="eur">-3338000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-227" decimals="-6" id="f-981" unitRef="eur">11022000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:NotionalAmount contextRef="c-236" decimals="-9" id="f-982" unitRef="usd">3000000000</ifrs-full:NotionalAmount>
    <sny:OtherBankBorrowings contextRef="c-237" decimals="-6" id="f-983" unitRef="eur">3217000000</sny:OtherBankBorrowings>
    <ifrs-full:NotionalAmount contextRef="c-238" decimals="-8" id="f-984" unitRef="eur">2300000000</ifrs-full:NotionalAmount>
    <sny:NumberOfTranches
      contextRef="c-238"
      decimals="INF"
      id="f-985"
      unitRef="tranche">3</sny:NumberOfTranches>
    <ifrs-full:NotionalAmount contextRef="c-239" decimals="-6" id="f-986" unitRef="eur">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate contextRef="c-239" decimals="5" id="f-987" unitRef="number">0.03000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-240" decimals="-6" id="f-988" unitRef="eur">650000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate contextRef="c-240" decimals="5" id="f-989" unitRef="number">0.03375</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-241" decimals="-6" id="f-990" unitRef="eur">650000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate contextRef="c-241" decimals="5" id="f-991" unitRef="number">0.03750</ifrs-full:BorrowingsInterestRate>
    <sny:NumberOfBondRedeemed contextRef="c-1" decimals="INF" id="f-992" unitRef="bond">1</sny:NumberOfBondRedeemed>
    <ifrs-full:NotionalAmount contextRef="c-242" decimals="-8" id="f-993" unitRef="eur">1500000000</ifrs-full:NotionalAmount>
    <sny:NumberOfSyndicatedCreditFacilities
      contextRef="c-1"
      decimals="INF"
      id="f-994"
      unitRef="credit_facility">2</sny:NumberOfSyndicatedCreditFacilities>
    <ifrs-full:NotionalAmount contextRef="c-243" decimals="-9" id="f-995" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-244" decimals="-7" id="f-996" unitRef="eur">3850000000</ifrs-full:NotionalAmount>
    <sny:NumberOfOneYearExtensionOptions
      contextRef="c-245"
      decimals="INF"
      id="f-997"
      unitRef="extension">2</sny:NumberOfOneYearExtensionOptions>
    <sny:ExtensionTerm contextRef="c-245" id="f-998">P1Y</sny:ExtensionTerm>
    <ifrs-full:NotionalAmount contextRef="c-246" decimals="-9" id="f-999" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <sny:NumberOfShortTermDebtProgram
      contextRef="c-1"
      decimals="INF"
      id="f-1000"
      unitRef="program">2</sny:NumberOfShortTermDebtProgram>
    <ifrs-full:CommercialPapersIssued contextRef="c-247" decimals="-9" id="f-1001" unitRef="eur">6000000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued contextRef="c-248" decimals="-9" id="f-1002" unitRef="usd">10000000000</ifrs-full:CommercialPapersIssued>
    <sny:BorrowingAverageDrawdown contextRef="c-249" decimals="-8" id="f-1003" unitRef="usd">3000000000.0</sny:BorrowingAverageDrawdown>
    <sny:BorrowingAverageDrawdown contextRef="c-250" decimals="-8" id="f-1004" unitRef="eur">100000000</sny:BorrowingAverageDrawdown>
    <sny:DisclosureOfMarketValueOfNetDebtTableTextBlock contextRef="c-1" id="f-1005">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfMarketValueOfNetDebtTableTextBlock>
    <ifrs-full:Borrowings contextRef="c-251" decimals="-6" id="f-1006" unitRef="eur">14989000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-252" decimals="-6" id="f-1007" unitRef="eur">10424000000</ifrs-full:Borrowings>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-253" decimals="-6" id="f-1008" unitRef="eur">15488000000</sny:RedemptionOfDebtInstrumentIssued>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-254" decimals="-6" id="f-1009" unitRef="eur">11022000000</sny:RedemptionOfDebtInstrumentIssued>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="c-1" id="f-1010">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i0dd095bcf8014bcb94796df400f45795"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.10. Derivative financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i6cb113c951b7447ab149c5d57111e97e"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.10.1 Currency derivatives used to manage operating risk exposures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,536&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,315&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Brazilian real &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which  Saudi Arabian riyal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,039&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,039&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which United Arab Emirates dirham&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,575&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,354&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Includes forward sales with a notional amount of BRL 1,300&#160;million expiring in 2027, designated as a cash flow hedge on the divestment of Medley in Brazil.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June&#160;30, 2026 and recognized in the balance sheet at that date. Gains and losses on hedging in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ib51fa0ee829f4b729dfe5c70efa6459c"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.10.2. Currency and interest rate derivatives used to manage financial exposure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi&#x2019;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e.&#160;the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi&#x2019;s debt once those instruments are taken into account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maximum expiry&#160;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cross currency seller swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,523&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,423&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;13,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Brazilian real&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,466&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;29,412&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a hedge of Sanofi&#x2019;s net investment in the United States. As of June 30, 2026, the fair value of the swaps was a liability of &#x20ac;37&#160;million, with &#x20ac;33&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; under the cost of hedging accounting treatment and &#x20ac;4&#160;million debited to financial result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes forward sales with a notional amount of $12,275&#160;million expiring in 2026 and 2027, designated as a hedge of Sanofi&#x2019;s net investment in the United States.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#x20ac;223&#160;million, with &#x20ac;222&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; and &#x20ac;1&#160;million debited to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c) &#160;Includes forward sales with a notional amount of BRL 1,200&#160;million  expiring in 2027, designated as a hedge of Sanofi&#x2019;s net investment in Brazil.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#x20ac;9&#160;million, with &#x20ac;10&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, and &#x20ac;1&#160;million credited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000&#160;million expiring in 2026, designated as a fair value hedge of the exposure of $1,000&#160;million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2026, the fair value of these contracts represented a liability of &#x20ac;6&#160;million, with &#x20ac;6&#160;million&#160;debited to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;; the impact on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.141%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2030 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 2.08% / receive Euribor 3M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 3.77% / receive &lt;br/&gt;capitalized SOFR + 46bps &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized SOFR USD/ &lt;br/&gt;receive 1.03%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/ &lt;br/&gt;receive 1.32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 3.82% / receive &lt;br/&gt;capitalized SOFR USD + 54 bps &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester/receive 0.92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester / receive 2.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 2.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester / receive 2.91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,288&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,313&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,400&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;950&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,951&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,226&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,726&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock contextRef="c-1" id="f-1011">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.634%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives not eligible for hedge accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,536&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,315&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Brazilian real &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which  Saudi Arabian riyal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,039&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,039&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Turkish lira&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which United Arab Emirates dirham&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,575&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,354&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Includes forward sales with a notional amount of BRL 1,300&#160;million expiring in 2027, designated as a cash flow hedge on the divestment of Medley in Brazil.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock>
    <sny:DerivativeFinancialInstruments contextRef="c-255" decimals="-6" id="f-1012" unitRef="eur">6536000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-256" decimals="-6" id="f-1013" unitRef="eur">-66000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-257" decimals="-6" id="f-1014" unitRef="eur">221000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-258" decimals="-6" id="f-1015" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-259" decimals="-6" id="f-1016" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-260" decimals="-6" id="f-1017" unitRef="eur">6315000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-261" decimals="-6" id="f-1018" unitRef="eur">-58000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-262" decimals="-6" id="f-1019" unitRef="eur">2968000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-263" decimals="-6" id="f-1020" unitRef="eur">-38000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-264" decimals="-6" id="f-1021" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-265" decimals="-6" id="f-1022" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-266" decimals="-6" id="f-1023" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-267" decimals="-6" id="f-1024" unitRef="eur">2968000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-268" decimals="-6" id="f-1025" unitRef="eur">-38000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-269" decimals="-6" id="f-1026" unitRef="eur">555000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-270" decimals="-6" id="f-1027" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-271" decimals="-6" id="f-1028" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-272" decimals="-6" id="f-1029" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-273" decimals="-6" id="f-1030" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-274" decimals="-6" id="f-1031" unitRef="eur">555000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-275" decimals="-6" id="f-1032" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-276" decimals="-6" id="f-1033" unitRef="eur">530000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-277" decimals="-6" id="f-1034" unitRef="eur">-6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-278" decimals="-6" id="f-1035" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-279" decimals="-6" id="f-1036" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-280" decimals="-6" id="f-1037" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-281" decimals="-6" id="f-1038" unitRef="eur">530000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-282" decimals="-6" id="f-1039" unitRef="eur">-6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-283" decimals="-6" id="f-1040" unitRef="eur">422000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-284" decimals="-6" id="f-1041" unitRef="eur">-9000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-285" decimals="-6" id="f-1042" unitRef="eur">221000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-286" decimals="-6" id="f-1043" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-287" decimals="-6" id="f-1044" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-288" decimals="-6" id="f-1045" unitRef="eur">201000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-289" decimals="-6" id="f-1046" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-290" decimals="-6" id="f-1047" unitRef="eur">224000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-291" decimals="-6" id="f-1048" unitRef="eur">-3000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-292" decimals="-6" id="f-1049" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-293" decimals="-6" id="f-1050" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-294" decimals="-6" id="f-1051" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-295" decimals="-6" id="f-1052" unitRef="eur">224000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-296" decimals="-6" id="f-1053" unitRef="eur">-3000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-297" decimals="-6" id="f-1054" unitRef="eur">5039000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-298" decimals="-6" id="f-1055" unitRef="eur">33000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-299" decimals="-6" id="f-1056" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-300" decimals="-6" id="f-1057" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-301" decimals="-6" id="f-1058" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-302" decimals="-6" id="f-1059" unitRef="eur">5039000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-303" decimals="-6" id="f-1060" unitRef="eur">33000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-304" decimals="-6" id="f-1061" unitRef="eur">3200000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-305" decimals="-6" id="f-1062" unitRef="eur">24000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-306" decimals="-6" id="f-1063" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-307" decimals="-6" id="f-1064" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-308" decimals="-6" id="f-1065" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-309" decimals="-6" id="f-1066" unitRef="eur">3200000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-310" decimals="-6" id="f-1067" unitRef="eur">24000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-311" decimals="-6" id="f-1068" unitRef="eur">596000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-312" decimals="-6" id="f-1069" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-313" decimals="-6" id="f-1070" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-314" decimals="-6" id="f-1071" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-315" decimals="-6" id="f-1072" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-316" decimals="-6" id="f-1073" unitRef="eur">596000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-317" decimals="-6" id="f-1074" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-318" decimals="-6" id="f-1075" unitRef="eur">306000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-319" decimals="-6" id="f-1076" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-320" decimals="-6" id="f-1077" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-321" decimals="-6" id="f-1078" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-322" decimals="-6" id="f-1079" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-323" decimals="-6" id="f-1080" unitRef="eur">306000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-324" decimals="-6" id="f-1081" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-325" decimals="-6" id="f-1082" unitRef="eur">120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-326" decimals="-6" id="f-1083" unitRef="eur">6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-327" decimals="-6" id="f-1084" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-328" decimals="-6" id="f-1085" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-329" decimals="-6" id="f-1086" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-330" decimals="-6" id="f-1087" unitRef="eur">120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-331" decimals="-6" id="f-1088" unitRef="eur">6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-332" decimals="-6" id="f-1089" unitRef="eur">120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-333" decimals="-6" id="f-1090" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-334" decimals="-6" id="f-1091" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-335" decimals="-6" id="f-1092" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-336" decimals="-6" id="f-1093" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-337" decimals="-6" id="f-1094" unitRef="eur">120000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-338" decimals="-6" id="f-1095" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-339" decimals="-6" id="f-1096" unitRef="eur">11575000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-340" decimals="-6" id="f-1097" unitRef="eur">-33000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-341" decimals="-6" id="f-1098" unitRef="eur">221000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-342" decimals="-6" id="f-1099" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-343" decimals="-6" id="f-1100" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-344" decimals="-6" id="f-1101" unitRef="eur">11354000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-345" decimals="-6" id="f-1102" unitRef="eur">-25000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-346" decimals="-6" id="f-1103" unitRef="brl">1300000000</sny:DerivativeFinancialInstruments>
    <sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock contextRef="c-1" id="f-1104">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place as of June&#160;30, 2026. The notional amount is translated into euros at the relevant closing exchange rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.599%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maximum expiry&#160;date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cross currency seller swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,523&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,423&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;13,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Pound sterling&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Brazilian real&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,466&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;29,412&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Comprises two cross currency swaps, (i) with a notional amount of $870&#160;million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870&#160;million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a hedge of Sanofi&#x2019;s net investment in the United States. As of June 30, 2026, the fair value of the swaps was a liability of &#x20ac;37&#160;million, with &#x20ac;33&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; under the cost of hedging accounting treatment and &#x20ac;4&#160;million debited to financial result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes forward sales with a notional amount of $12,275&#160;million expiring in 2026 and 2027, designated as a hedge of Sanofi&#x2019;s net investment in the United States.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#x20ac;223&#160;million, with &#x20ac;222&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; and &#x20ac;1&#160;million debited to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c) &#160;Includes forward sales with a notional amount of BRL 1,200&#160;million  expiring in 2027, designated as a hedge of Sanofi&#x2019;s net investment in Brazil.  As of June 30, 2026, the fair value of these forward contracts represented a liability of &#x20ac;9&#160;million, with &#x20ac;10&#160;million debited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, and &#x20ac;1&#160;million credited to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000&#160;million expiring in 2026, designated as a fair value hedge of the exposure of $1,000&#160;million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2026, the fair value of these contracts represented a liability of &#x20ac;6&#160;million, with &#x20ac;6&#160;million&#160;debited to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;; the impact on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; is immaterial.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-347" decimals="-6" id="f-1105" unitRef="eur">1523000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-348" decimals="-6" id="f-1106" unitRef="eur">-37000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-349" decimals="-6" id="f-1107" unitRef="eur">1523000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-350" decimals="-6" id="f-1108" unitRef="eur">-37000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-255" decimals="-6" id="f-1109" unitRef="eur">16423000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-256" decimals="-6" id="f-1110" unitRef="eur">-272000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-351" decimals="-6" id="f-1111" unitRef="eur">13361000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-352" decimals="-6" id="f-1112" unitRef="eur">-241000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-353" decimals="-6" id="f-1113" unitRef="eur">1401000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-354" decimals="-6" id="f-1114" unitRef="eur">-7000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-355" decimals="-6" id="f-1115" unitRef="eur">204000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-356" decimals="-6" id="f-1116" unitRef="eur">-9000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-297" decimals="-6" id="f-1117" unitRef="eur">11466000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-298" decimals="-6" id="f-1118" unitRef="eur">170000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-357" decimals="-6" id="f-1119" unitRef="eur">8657000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-358" decimals="-6" id="f-1120" unitRef="eur">143000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-359" decimals="-6" id="f-1121" unitRef="eur">1299000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-360" decimals="-6" id="f-1122" unitRef="eur">6000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-361" decimals="-6" id="f-1123" unitRef="eur">543000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-362" decimals="-6" id="f-1124" unitRef="eur">19000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-339" decimals="-6" id="f-1125" unitRef="eur">29412000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-340" decimals="-6" id="f-1126" unitRef="eur">-139000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:NumberOfCrossCurrencySwaps contextRef="c-1" decimals="INF" id="f-1127" unitRef="swaps">2</sny:NumberOfCrossCurrencySwaps>
    <ifrs-full:NotionalAmount contextRef="c-363" decimals="-6" id="f-1128" unitRef="usd">870000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-364" decimals="-6" id="f-1129" unitRef="usd">870000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-365" decimals="-6" id="f-1130" unitRef="eur">37000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-366" decimals="-6" id="f-1131" unitRef="eur">-33000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:FinanceIncomeCost contextRef="c-366" decimals="-6" id="f-1132" unitRef="eur">-4000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:NotionalAmount contextRef="c-367" decimals="-6" id="f-1133" unitRef="usd">12275000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-367" decimals="-6" id="f-1134" unitRef="eur">223000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-368" decimals="-6" id="f-1135" unitRef="eur">-222000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:FinanceIncomeCost contextRef="c-368" decimals="-6" id="f-1136" unitRef="eur">-1000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:NotionalAmount contextRef="c-369" decimals="-6" id="f-1137" unitRef="brl">1200000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-369" decimals="-6" id="f-1138" unitRef="eur">9000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-370" decimals="-6" id="f-1139" unitRef="eur">-10000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:FinanceIncomeCost contextRef="c-370" decimals="-6" id="f-1140" unitRef="eur">1000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:NotionalAmount contextRef="c-371" decimals="-6" id="f-1141" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-372" decimals="-6" id="f-1142" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-371" decimals="-6" id="f-1143" unitRef="eur">6000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinanceIncomeCost contextRef="c-373" decimals="-6" id="f-1144" unitRef="eur">-6000000</ifrs-full:FinanceIncomeCost>
    <sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock contextRef="c-1" id="f-1145">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows instruments of this type in place as of June 30, 2026:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.141%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&#160;cash&#160;flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2030 and beyond&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which recognized in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 2.08% / receive Euribor 3M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 3.77% / receive &lt;br/&gt;capitalized SOFR + 46bps &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized SOFR USD/ &lt;br/&gt;receive 1.03%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/ &lt;br/&gt;receive 1.32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay 3.82% / receive &lt;br/&gt;capitalized SOFR USD + 54 bps &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester/receive 0.92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester / receive 2.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 2.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;pay capitalized Ester / receive 2.91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,288&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,313&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,400&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;950&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,951&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,226&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,726&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-374" decimals="-6" id="f-1146" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-375" decimals="-6" id="f-1147" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-376" decimals="-6" id="f-1148" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-377" decimals="-6" id="f-1149" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-378" decimals="-6" id="f-1150" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-379" decimals="-6" id="f-1151" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-380" decimals="-6" id="f-1152" unitRef="eur">-2000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-381" decimals="-6" id="f-1153" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-382" decimals="-6" id="f-1154" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-383" decimals="-6" id="f-1155" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-384" decimals="-6" id="f-1156" unitRef="eur">-2000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-385" decimals="-6" id="f-1157" unitRef="eur">-2000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-386" decimals="-6" id="f-1158" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-387" decimals="-6" id="f-1159" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-388" decimals="-6" id="f-1160" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-389" decimals="-6" id="f-1161" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-390" decimals="-6" id="f-1162" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-391" decimals="-6" id="f-1163" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-392" decimals="-6" id="f-1164" unitRef="eur">4000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-393" decimals="-6" id="f-1165" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-394" decimals="-6" id="f-1166" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-395" decimals="-6" id="f-1167" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-396" decimals="-6" id="f-1168" unitRef="eur">4000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-397" decimals="-6" id="f-1169" unitRef="eur">4000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-398" decimals="-6" id="f-1170" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-399" decimals="-6" id="f-1171" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-400" decimals="-6" id="f-1172" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-401" decimals="-6" id="f-1173" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-402" decimals="-6" id="f-1174" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-403" decimals="-6" id="f-1175" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-404" decimals="-6" id="f-1176" unitRef="eur">-25000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-405" decimals="-6" id="f-1177" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-406" decimals="-6" id="f-1178" unitRef="eur">-25000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-407" decimals="-6" id="f-1179" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-408" decimals="-6" id="f-1180" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-409" decimals="-6" id="f-1181" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-410" decimals="-6" id="f-1182" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-411" decimals="-6" id="f-1183" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-412" decimals="-6" id="f-1184" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-413" id="f-1185" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-414" decimals="-6" id="f-1186" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-415" decimals="-6" id="f-1187" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-416" decimals="-6" id="f-1188" unitRef="eur">-22000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-417" decimals="-6" id="f-1189" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-418" decimals="-6" id="f-1190" unitRef="eur">-22000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-419" id="f-1191" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-420" id="f-1192" unitRef="eur" xsi:nil="true"/>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-421" decimals="-6" id="f-1193" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-422" decimals="-6" id="f-1194" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-423" decimals="-6" id="f-1195" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-424" decimals="-6" id="f-1196" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-425" decimals="-6" id="f-1197" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-426" decimals="-6" id="f-1198" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-427" decimals="-6" id="f-1199" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-428" decimals="-6" id="f-1200" unitRef="eur">7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-429" decimals="-6" id="f-1201" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-430" decimals="-6" id="f-1202" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-431" decimals="-6" id="f-1203" unitRef="eur">438000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-432" decimals="-6" id="f-1204" unitRef="eur">7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-433" decimals="-6" id="f-1205" unitRef="eur">7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-434" decimals="-6" id="f-1206" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-435" decimals="-6" id="f-1207" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-436" decimals="-6" id="f-1208" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-437" decimals="-6" id="f-1209" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-438" decimals="-6" id="f-1210" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-439" decimals="-6" id="f-1211" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-440" decimals="-6" id="f-1212" unitRef="eur">-28000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-441" decimals="-6" id="f-1213" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-442" decimals="-6" id="f-1214" unitRef="eur">-28000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-443" decimals="-6" id="f-1215" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-444" decimals="-6" id="f-1216" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-445" decimals="-6" id="f-1217" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-446" decimals="-6" id="f-1218" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-447" decimals="-6" id="f-1219" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-448" decimals="-6" id="f-1220" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-449" decimals="-6" id="f-1221" unitRef="eur">750000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-450" decimals="-6" id="f-1222" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-451" decimals="-6" id="f-1223" unitRef="eur">750000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-452" decimals="-6" id="f-1224" unitRef="eur">2000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-453" decimals="-6" id="f-1225" unitRef="eur">750000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-454" decimals="-6" id="f-1226" unitRef="eur">2000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-455" decimals="-6" id="f-1227" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-456" decimals="-6" id="f-1228" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-457" decimals="-6" id="f-1229" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-458" decimals="-6" id="f-1230" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-459" decimals="-6" id="f-1231" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-460" decimals="-6" id="f-1232" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-461" decimals="-6" id="f-1233" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-462" decimals="-6" id="f-1234" unitRef="eur">475000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-463" decimals="-6" id="f-1235" unitRef="eur">475000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-464" decimals="-6" id="f-1236" unitRef="eur">4000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-465" decimals="-6" id="f-1237" unitRef="eur">475000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-466" decimals="-6" id="f-1238" unitRef="eur">4000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-467" decimals="-6" id="f-1239" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-468" decimals="-6" id="f-1240" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-469" decimals="-6" id="f-1241" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-470" decimals="-6" id="f-1242" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-471" decimals="-6" id="f-1243" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-472" decimals="-6" id="f-1244" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-473" decimals="-6" id="f-1245" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-474" decimals="-6" id="f-1246" unitRef="eur">475000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-475" decimals="-6" id="f-1247" unitRef="eur">475000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-476" decimals="-6" id="f-1248" unitRef="eur">7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-477" decimals="-6" id="f-1249" unitRef="eur">475000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-478" decimals="-6" id="f-1250" unitRef="eur">7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-479" decimals="-6" id="f-1251" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-480" decimals="-6" id="f-1252" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-481" decimals="-6" id="f-1253" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-482" decimals="-6" id="f-1254" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-483" decimals="-6" id="f-1255" unitRef="eur">1288000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-484" decimals="-6" id="f-1256" unitRef="eur">1313000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-485" decimals="-6" id="f-1257" unitRef="eur">1400000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-486" decimals="-6" id="f-1258" unitRef="eur">950000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-339" decimals="-6" id="f-1259" unitRef="eur">4951000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-340" decimals="-6" id="f-1260" unitRef="eur">-52000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-487" decimals="-6" id="f-1261" unitRef="eur">3226000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-488" decimals="-6" id="f-1262" unitRef="eur">-62000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-341" decimals="-6" id="f-1263" unitRef="eur">1726000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-342" decimals="-6" id="f-1264" unitRef="eur">10000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-343" decimals="-6" id="f-1265" unitRef="eur">10000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock contextRef="c-1" id="f-1266">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i441d86681a7946cc9b530ec9161251d5"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.11. Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For a description of the nature of the liabilities reported in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2026 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shire contingent consideration arising from acquisition of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;CVRs issued in connection with the acquisition of Blueprint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;CVRs issued in connection with the acquisition of Vigil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;585&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;585&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;58&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;652&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;As of January 1, 2026, this comprised a non-current portion of &#x20ac;585 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#x201c;Fair value remeasurement of contingent consideration&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; mainly comprised the contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at &#x20ac;585 million as of June&#160;30, 2026, compared with &#x20ac;531 million as of December 31, 2025. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 13%.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsExplanatoryTextBlock>
    <sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock contextRef="c-1" id="f-1267">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2026 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.429%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shire contingent consideration arising from acquisition of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;CVRs issued in connection with the acquisition of Blueprint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;CVRs issued in connection with the acquisition of Vigil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;531&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;585&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;585&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;58&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;652&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Non-current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;As of January 1, 2026, this comprised a non-current portion of &#x20ac;585 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts mainly reported within the income statement line item &#x201c;Fair value remeasurement of contingent consideration&#x201d;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-489" decimals="-6" id="f-1268" unitRef="eur">531000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-490" decimals="-6" id="f-1269" unitRef="eur">48000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-491" decimals="-6" id="f-1270" unitRef="eur">5000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-492" decimals="-6" id="f-1271" unitRef="eur">1000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-3" decimals="-6" id="f-1272" unitRef="eur">585000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-493" decimals="-6" id="f-1273" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-494" decimals="-6" id="f-1274" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-495" decimals="-6" id="f-1275" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-496" decimals="-6" id="f-1276" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1" decimals="-6" id="f-1277" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-493" decimals="-6" id="f-1278" unitRef="eur">38000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-494" decimals="-6" id="f-1279" unitRef="eur">8000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-495" decimals="-6" id="f-1280" unitRef="eur">3000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-496" decimals="-6" id="f-1281" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1" decimals="-6" id="f-1282" unitRef="eur">49000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-493" decimals="-6" id="f-1283" unitRef="eur">16000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-494" decimals="-6" id="f-1284" unitRef="eur">2000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-495" decimals="-6" id="f-1285" unitRef="eur">1000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-496" decimals="-6" id="f-1286" unitRef="eur">-1000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-1287" unitRef="eur">18000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-497" decimals="-6" id="f-1288" unitRef="eur">585000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-498" decimals="-6" id="f-1289" unitRef="eur">58000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-499" decimals="-6" id="f-1290" unitRef="eur">9000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-500" decimals="-6" id="f-1291" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-2" decimals="-6" id="f-1292" unitRef="eur">652000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-1293" unitRef="eur">0</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-2" decimals="-6" id="f-1294" unitRef="eur">652000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-3" decimals="-6" id="f-1295" unitRef="eur">585000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-497" decimals="-6" id="f-1296" unitRef="eur">585000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-489" decimals="-6" id="f-1297" unitRef="eur">531000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-497"
      decimals="2"
      id="f-1298"
      unitRef="number">0.13</sny:PercentageIncreaseInFairValueLiabilities>
    <sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock contextRef="c-1" id="f-1299">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="ib5e43f9013e14d0887318696ae285733"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.12. Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,848&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,703&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes &#x20ac;1,647 million as of June 30, 2026 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States (see Note C.2. to the consolidated financial statements for the year ended December 31, 2025). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;916&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,150 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for pensions &amp;amp; other post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Restructuring provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,440&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;654&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,541&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,592&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions and other liabilities&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Mainly transfers to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i1a226aca6ee943b898373876de7825d0"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provisions for pensions and other post-employment benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December&#160;31, 2025, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal assumptions used (in particular, discount and inflation rates) and the market value of plan assets for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2026 to take into account changes during the first half of the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes the effects of (i) the change in discount rates (in a range between +0.05% and +0.50%) and (ii) the +0.15% change in the inflation rate in the United Kingdom in the first half of 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Includes actuarial gains/ (losses) related to Opella of &#x20ac;(4)&#160;million for the first half of 2025..&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesTextBlock>
    <sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-1300">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,848&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,703&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes &#x20ac;1,647 million as of June 30, 2026 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States (see Note C.2. to the consolidated financial statements for the year ended December 31, 2025). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;916&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,150 million.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-6" id="f-1301" unitRef="eur">4592000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-6" id="f-1302" unitRef="eur">4541000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-2" decimals="-6" id="f-1303" unitRef="eur">2256000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-3" decimals="-6" id="f-1304" unitRef="eur">2162000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-2" decimals="-6" id="f-1305" unitRef="eur">6848000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-3" decimals="-6" id="f-1306" unitRef="eur">6703000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-501" decimals="-6" id="f-1307" unitRef="eur">1647000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-502" decimals="-6" id="f-1308" unitRef="eur">916000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-503" decimals="-6" id="f-1309" unitRef="eur">2150000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:DisclosureOfNonCurrentProvisionsTableTextBlock contextRef="c-1" id="f-1310">&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.111%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for pensions &amp;amp; other post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions for other long-term benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Restructuring provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January&#160;1, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,440&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;654&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,541&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at June 30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,343&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,592&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions and other liabilities&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Mainly transfers to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfNonCurrentProvisionsTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-504" decimals="-6" id="f-1311" unitRef="eur">1440000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-505" decimals="-6" id="f-1312" unitRef="eur">827000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-506" decimals="-6" id="f-1313" unitRef="eur">654000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-507" decimals="-6" id="f-1314" unitRef="eur">1620000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-6" id="f-1315" unitRef="eur">4541000000</ifrs-full:NoncurrentProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-508" decimals="-6" id="f-1316" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-509" decimals="-6" id="f-1317" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-510" decimals="-6" id="f-1318" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-511" decimals="-6" id="f-1319" unitRef="eur">13000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1" decimals="-6" id="f-1320" unitRef="eur">13000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseInProvisionsAndOtherLiabilities contextRef="c-508" decimals="-6" id="f-1321" unitRef="eur">57000000</sny:IncreaseDecreaseInProvisionsAndOtherLiabilities>
    <sny:IncreaseDecreaseInProvisionsAndOtherLiabilities contextRef="c-509" decimals="-6" id="f-1322" unitRef="eur">110000000</sny:IncreaseDecreaseInProvisionsAndOtherLiabilities>
    <sny:IncreaseDecreaseInProvisionsAndOtherLiabilities contextRef="c-510" decimals="-6" id="f-1323" unitRef="eur">180000000</sny:IncreaseDecreaseInProvisionsAndOtherLiabilities>
    <sny:IncreaseDecreaseInProvisionsAndOtherLiabilities contextRef="c-511" decimals="-6" id="f-1324" unitRef="eur">126000000</sny:IncreaseDecreaseInProvisionsAndOtherLiabilities>
    <sny:IncreaseDecreaseInProvisionsAndOtherLiabilities contextRef="c-1" decimals="-6" id="f-1325" unitRef="eur">473000000</sny:IncreaseDecreaseInProvisionsAndOtherLiabilities>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-508" decimals="-6" id="f-1326" unitRef="eur">36000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-509" decimals="-6" id="f-1327" unitRef="eur">57000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-510" decimals="-6" id="f-1328" unitRef="eur">4000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-511" decimals="-6" id="f-1329" unitRef="eur">40000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1" decimals="-6" id="f-1330" unitRef="eur">137000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="c-508" decimals="-6" id="f-1331" unitRef="eur">13000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="c-509" decimals="-6" id="f-1332" unitRef="eur">2000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="c-510" decimals="-6" id="f-1333" unitRef="eur">60000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="c-511" decimals="-6" id="f-1334" unitRef="eur">54000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions contextRef="c-1" decimals="-6" id="f-1335" unitRef="eur">129000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-508" decimals="-6" id="f-1336" unitRef="eur">11000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-509" decimals="-6" id="f-1337" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-510" decimals="-6" id="f-1338" unitRef="eur">-104000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-511" decimals="-6" id="f-1339" unitRef="eur">-20000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1" decimals="-6" id="f-1340" unitRef="eur">-113000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-508" decimals="-6" id="f-1341" unitRef="eur">26000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-509" decimals="-6" id="f-1342" unitRef="eur">1000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-510" decimals="-6" id="f-1343" unitRef="eur">8000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-511" decimals="-6" id="f-1344" unitRef="eur">14000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions contextRef="c-1" decimals="-6" id="f-1345" unitRef="eur">49000000</sny:IncreaseDecreaseThroughNetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscountOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-508" decimals="-6" id="f-1346" unitRef="eur">15000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-509" decimals="-6" id="f-1347" unitRef="eur">18000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-510" decimals="-6" id="f-1348" unitRef="eur">2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-511" decimals="-6" id="f-1349" unitRef="eur">17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1" decimals="-6" id="f-1350" unitRef="eur">52000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-508" decimals="-6" id="f-1351" unitRef="eur">-157000000</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-509" decimals="-6" id="f-1352" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-510" decimals="-6" id="f-1353" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-511" decimals="-6" id="f-1354" unitRef="eur">0</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions contextRef="c-1" decimals="-6" id="f-1355" unitRef="eur">-157000000</sny:IncreaseDecreaseThroughActuarialGainsAndLossesOnDefinedBenefitPlansOtherProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-512" decimals="-6" id="f-1356" unitRef="eur">1343000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-513" decimals="-6" id="f-1357" unitRef="eur">897000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-514" decimals="-6" id="f-1358" unitRef="eur">676000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-515" decimals="-6" id="f-1359" unitRef="eur">1676000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-6" id="f-1360" unitRef="eur">4592000000</ifrs-full:NoncurrentProvisions>
    <sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock contextRef="c-1" id="f-1361">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5pt;font-weight:400;line-height:100%"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) on benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes the effects of (i) the change in discount rates (in a range between +0.05% and +0.50%) and (ii) the +0.15% change in the inflation rate in the United Kingdom in the first half of 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Includes actuarial gains/ (losses) related to Opella of &#x20ac;(4)&#160;million for the first half of 2025..&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetTableTextBlock>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-516" decimals="-6" id="f-1362" unitRef="eur">-71000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-517" decimals="-6" id="f-1363" unitRef="eur">45000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-518" decimals="-6" id="f-1364" unitRef="eur">86000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-519" decimals="-6" id="f-1365" unitRef="eur">152000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-520"
      decimals="4"
      id="f-1366"
      unitRef="number">0.0005</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-521"
      decimals="4"
      id="f-1367"
      unitRef="number">0.0050</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-522"
      decimals="4"
      id="f-1368"
      unitRef="number">0.0015</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-523"
      decimals="4"
      id="f-1369"
      unitRef="number">0.0000</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-524"
      decimals="4"
      id="f-1370"
      unitRef="number">0.0030</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="c-525"
      decimals="4"
      id="f-1371"
      unitRef="number">0.0030</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-526" decimals="-6" id="f-1372" unitRef="eur">-4000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock contextRef="c-1" id="f-1373">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="if2ef66ecc61249b8827c28488e19b089"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.13. Off balance sheet commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments to third parties as of December&#160;31, 2025 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal commitments entered into the period are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;In March 2026, Sanofi entered into an exclusive license agreement to develop, manufacture, and commercialize rovadicitinib worldwide from CTTQ, a Sino Biopharmaceutical Limited subsidiary. Rovadicitinib is a global first-in-class oral small molecule dual-target JAK/ ROCK inhibitor which received its first approval in China in February 2026 as a first-line treatment for MF (myelofibrosis) indication. Under the terms of the agreement, CTTQ received an upfront payment of $135&#160;million and is entitled to receive up to $1.4&#160;billion in development, regulatory and sales milestones, and up to double-digit tiered royalties on product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;In March 2026, Sanofi entered into a worldwide exclusive license agreement with Kali Therapeutics for a next-generation tri-specific T-cell engager for autoimmune diseases, under which Sanofi will obtain exclusive worldwide rights to KT501, a novel tri-specific antibody utilizing Kali Therapeutics&#x2019; proprietary discovery and research platform. Under the terms of the agreement, Kali Therapeutics is entitled to receive up to $1.2&#160;billion including upfront payments (of which $0.1&#160;billion has already been paid) plus development and sales milestones, and tiered royalties ranging from high-single to double digits on product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, Sanofi has not entered into any material new long-term renewable energy contract agreements as part of its sustainability strategy. The main existing agreements are presented in Note D.21.1. to the consolidated financial statements in the 2025 Form 20-F.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock>
    <sny:UpfrontLicensePayment contextRef="c-527" decimals="-6" id="f-1374" unitRef="usd">135000000</sny:UpfrontLicensePayment>
    <sny:CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments contextRef="c-527" decimals="-8" id="f-1375" unitRef="usd">1400000000</sny:CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments>
    <sny:CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments contextRef="c-528" decimals="-8" id="f-1376" unitRef="usd">1200000000</sny:CollaborationAgreementDevelopmentRegulatoryAndSalesMilestonePayments>
    <sny:UpfrontLicensePayment contextRef="c-528" decimals="-8" id="f-1377" unitRef="usd">100000000</sny:UpfrontLicensePayment>
    <sny:DisclosureOfLegalAndArbitralProceedingsTextBlock contextRef="c-1" id="f-1378">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="idcc102ea9b2046cc83a259304e2abadf"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.14. Litigation and arbitration proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i4c3e61ca8b9141d0b7fa8d2daa67610a"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.14.1. Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="i8b1c17e995d64e019397b3fb59609de6"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zantac product litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the Multi-District Litigation (MDL) where Federal court cases were coordinated, the Eleventh Circuit held oral argument for the appeal in the fourth quarter of 2025 and a decision is expected in the second half of 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In those cases pending in Delaware (State court) where the issue is to rule on defendants&#x2019; Daubert motions to exclude plaintiffs&#x2019; experts, in the second quarter of 2026, the Delaware Superior Court granted summary judgment and dismissed all the cases pending against Sanofi. The plaintiffs are appealing this ruling to the Delaware Supreme Court and Sanofi does not expect a decision on the appeal until the fourth quarter of 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="iec0d81a85e37464bb85c5c2447256a99"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Talc product litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of June 30, 2026, Sanofi was named as a defendant in approximately 1,430 ongoing product liability actions. To date, no cases have proceeded to trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="i97325ef9fa90480584d9004faf31c3d0"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dupixent product litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Approximately 30 product liability cases have been filed in Federal courts around the country alleging that Dupixent (dupilumab) causes or exacerbates T-Cell lymphoma. In June 2026, those cases were consolidated into a Multi-District Litigation (MDL) in New Jersey Federal court. In addition, eight cases have been filed in New Jersey State court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess reliably the outcome of these ongoing cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i10d555f1b9f3459bbe1a9e0eee1c96c5"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.14.2. Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="idee49d17dbab49a198e6d3e9dd3eeeb1"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Praluent (alirocumab)-related Amgen patent litigation in Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On March 6, 2026, Sanofi, Regeneron and Amgen entered into a settlement agreement resolving these disputes. The terms of the settlement are confidential. These cases are now closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i0088217aa4f2473782ecce2ebc49b741"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.14.3. Other litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="icef0d62496c244a381edef675d01510c"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plavix (clopidogrel) - Attorney General Action in Texas &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the action filed by Sanofi and Bristol Myers Squibb (BMS) against the Texas Attorney General (Texas AG) in Travis County, on April 28, 2026 the Travis County court granted the Texas AG&#x2019;s motion to abate the companies&#x2019; suit against it; and on June 4, 2026 the companies filed a mandamus petition with the Texas Court of Appeals seeking to vacate that ruling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:11.34pt"&gt;&lt;span id="i1cbe1487d6d04115b3675a499302b6f1"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;340B drug pricing program in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The US Health Resources and Services Administration (HRSA) withdrew its 340B Rebate Model Pilot Program in February 2026 but is expected to announce a new 340B Rebate Model Pilot Program later in 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ADR Proceedings in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the 340B Administrative Dispute Resolution (ADR) proceedings against Sanofi, one filed by University of Washington/Harborview Medical Center in 2023 and one filed by Hudson Headwaters Health Network in 2024 (both alleging that Sanofi&#x2019;s 340B Integrity Initiative caused &#x201c;overcharges&#x201d; under Section 340B), on March 9, 2026 the ADR Panel determined that there was no overcharge violation by Sanofi in the proceeding involving University of Washington Medical Center/Harborview Medical Center; and on May 27, 2026 the ADR Panel determined that there was no overcharge violation by Sanofi in the proceeding involving Hudson Headwaters Network, which has requested reconsideration of the ADR Panel&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Mosaic Health in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Since the case was remanded by the Court of Appeal to the District Court in August 2025 following the second amended complaint filed by plaintiffs, defendants (Sanofi and three other manufacturers) filed a motion to dismiss certain state law claims.  Defendants also filed a petition for a writ of certiorari with the Supreme Court of the United States challenging two aspects of the Second Circuit&#x2019;s decision.  In July 2026, certain state law claims and plaintiffs&#x2019; unjust enrichment claims were dismissed.  The District Court set a case schedule with fact discovery closing in November 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adventist Health System/West in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the appeal filed by Adventist Health System/West following the dismissal granted by the court in March 2024 in favor of the drug manufacturers including Sanofi, the Ninth Circuit Court of Appeals reversed and ordered the case to be remanded to the District Court on March 17, 2026.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfLegalAndArbitralProceedingsTextBlock>
    <sny:NumberOfClassActionLawsuits
      contextRef="c-529"
      decimals="INF"
      id="f-1379"
      unitRef="proceeding">1430</sny:NumberOfClassActionLawsuits>
    <sny:NumberOfProductLiabilityCases
      contextRef="c-530"
      decimals="INF"
      id="f-1380"
      unitRef="case">30</sny:NumberOfProductLiabilityCases>
    <sny:NumberOfCasesFiledInNewJerseyCourt
      contextRef="c-530"
      decimals="INF"
      id="f-1381"
      unitRef="case">8</sny:NumberOfCasesFiledInNewJerseyCourt>
    <sny:NumberOfClassActionLawsuits
      contextRef="c-531"
      decimals="INF"
      id="f-1382"
      unitRef="proceeding">1</sny:NumberOfClassActionLawsuits>
    <sny:NumberOfClassActionLawsuits
      contextRef="c-532"
      decimals="INF"
      id="f-1383"
      unitRef="proceeding">1</sny:NumberOfClassActionLawsuits>
    <sny:NumberOfOtherDefendantsInLegalProceeding
      contextRef="c-533"
      decimals="INF"
      id="f-1384"
      unitRef="defendant">3</sny:NumberOfOtherDefendantsInLegalProceeding>
    <sny:NumberOfLegalDecisionAspectsChallenged
      contextRef="c-533"
      decimals="INF"
      id="f-1385"
      unitRef="aspects">2</sny:NumberOfLegalDecisionAspectsChallenged>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="c-1" id="f-1386">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="icc0e2fd5b6c74cd6b05c37034b5c2038"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.15. Other operating income and expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; amounted to &#x20ac;800 million in the first half of 2026 (versus &#x20ac;533 million in the first half of 2025), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; to &#x20ac;3,436 million (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;versus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; &#x20ac; 2,476 million in the first half of 2025), as shown in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net gains / (losses) on disposals of operating assets or businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amvuttra licensing income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;800&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;533&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Regeneron alliance:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(i) (Profit)/loss sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(ii) Additional profit share for development cost from Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(iii) Selling expense reimbursements to Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-1387" unitRef="eur">800000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-4" decimals="-6" id="f-1388" unitRef="eur">533000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-1389" unitRef="eur">3436000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-4" decimals="-6" id="f-1390" unitRef="eur">2476000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <sny:OtherOperatingExpensesTableTextBlock contextRef="c-1" id="f-1391">, as shown in the table below.&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net gains / (losses) on disposals of operating assets or businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amvuttra licensing income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;800&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;533&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #330e74;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Regeneron alliance:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(i) (Profit)/loss sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(ii) Additional profit share for development cost from Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(iii) Selling expense reimbursements to Regeneron&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #330e74;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:OtherOperatingExpensesTableTextBlock>
    <sny:GainsLossOnDivestmentOfProducts contextRef="c-1" decimals="-6" id="f-1392" unitRef="eur">241000000</sny:GainsLossOnDivestmentOfProducts>
    <sny:GainsLossOnDivestmentOfProducts contextRef="c-4" decimals="-6" id="f-1393" unitRef="eur">344000000</sny:GainsLossOnDivestmentOfProducts>
    <sny:IncomeResultingFromOutLicensing contextRef="c-534" decimals="-6" id="f-1394" unitRef="eur">398000000</sny:IncomeResultingFromOutLicensing>
    <sny:IncomeResultingFromOutLicensing contextRef="c-535" decimals="-6" id="f-1395" unitRef="eur">120000000</sny:IncomeResultingFromOutLicensing>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-536" decimals="-6" id="f-1396" unitRef="eur">161000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-537" decimals="-6" id="f-1397" unitRef="eur">69000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:OtherOperatingIncome contextRef="c-1" decimals="-6" id="f-1398" unitRef="eur">800000000</sny:OtherOperatingIncome>
    <sny:OtherOperatingIncome contextRef="c-4" decimals="-6" id="f-1399" unitRef="eur">533000000</sny:OtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-538" decimals="-6" id="f-1400" unitRef="eur">3486000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-539" decimals="-6" id="f-1401" unitRef="eur">2475000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-540" decimals="-6" id="f-1402" unitRef="eur">594000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-541" decimals="-6" id="f-1403" unitRef="eur">494000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-542" decimals="-6" id="f-1404" unitRef="eur">336000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-543" decimals="-6" id="f-1405" unitRef="eur">346000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-536" decimals="-6" id="f-1406" unitRef="eur">208000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-537" decimals="-6" id="f-1407" unitRef="eur">149000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <sny:OtherOperatingExpense contextRef="c-1" decimals="-6" id="f-1408" unitRef="eur">3436000000</sny:OtherOperatingExpense>
    <sny:OtherOperatingExpense contextRef="c-4" decimals="-6" id="f-1409" unitRef="eur">2476000000</sny:OtherOperatingExpense>
    <sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock contextRef="c-1" id="f-1410">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i139e0fb357da4970a6636ccc777d86be"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.16. Restructuring costs and similar items&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) This line includes transaction, integration and separation costs in connection with material acquisitions or divestitures amounting to &#x20ac;73 million for the first half of 2026, mainly related to the Dynavax acquisition (see note B.1.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock>
    <sny:DisclosureOfRestructuringCostsDetailsTableTextBlock contextRef="c-1" id="f-1411">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs of transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) This line includes transaction, integration and separation costs in connection with material acquisitions or divestitures amounting to &#x20ac;73 million for the first half of 2026, mainly related to the Dynavax acquisition (see note B.1.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsDetailsTableTextBlock>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-1" decimals="-6" id="f-1412" unitRef="eur">284000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-4" decimals="-6" id="f-1413" unitRef="eur">201000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-1" decimals="-6" id="f-1414" unitRef="eur">179000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-4" decimals="-6" id="f-1415" unitRef="eur">109000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-1" decimals="-6" id="f-1416" unitRef="eur">10000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-4" decimals="-6" id="f-1417" unitRef="eur">80000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:OtherRestructuringCosts contextRef="c-1" decimals="-6" id="f-1418" unitRef="eur">90000000</sny:OtherRestructuringCosts>
    <sny:OtherRestructuringCosts contextRef="c-4" decimals="-6" id="f-1419" unitRef="eur">40000000</sny:OtherRestructuringCosts>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-1420" unitRef="eur">563000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-4" decimals="-6" id="f-1421" unitRef="eur">430000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherRestructuringCosts contextRef="c-544" decimals="-6" id="f-1422" unitRef="eur">73000000</sny:OtherRestructuringCosts>
    <sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock contextRef="c-1" id="f-1423">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i20b78eca92d7471d8d4493af61426d49"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.17. Other gains and losses, and litigation&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For the first half of 2026, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; represents a charge of &#x20ac;95 million mainly related to major litigation, compared with a charge of &#x20ac;57 m&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;illion in the first half of &lt;/span&gt;2025</sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-1424" unitRef="eur">-95000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-4" decimals="-6" id="f-1425" unitRef="eur">-57000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c-1" id="f-1426">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i74ae65716b9a487992160b7c640c03ed"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.18. Financial expenses and income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of financial expenses and income is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses on financial assets, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#x20ac;12 million in the first half of 2026 and &#x20ac;(25) million in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;6 million in the first half of 2026 and &#x20ac;(4)&#160;million in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes a financial expense of &#x20ac;146 million for the six months ended June 30, 2026 and &#x20ac;50 million for the six months ended June 30, 2025 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of the ineffective portion of hedging relationships was not material in either 2026 or 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock contextRef="c-1" id="f-1427">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of financial expenses and income is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses on financial assets, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: &#x20ac;12 million in the first half of 2026 and &#x20ac;(25) million in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;6 million in the first half of 2026 and &#x20ac;(4)&#160;million in the first half of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Includes a financial expense of &#x20ac;146 million for the six months ended June 30, 2026 and &#x20ac;50 million for the six months ended June 30, 2025 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the United States.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-1" decimals="-6" id="f-1428" unitRef="eur">253000000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-4" decimals="-6" id="f-1429" unitRef="eur">219000000</ifrs-full:InterestExpenseOnBorrowings>
    <sny:InterestIncome contextRef="c-1" decimals="-6" id="f-1430" unitRef="eur">118000000</sny:InterestIncome>
    <sny:InterestIncome contextRef="c-4" decimals="-6" id="f-1431" unitRef="eur">162000000</sny:InterestIncome>
    <sny:CostOfDebtNet contextRef="c-1" decimals="-6" id="f-1432" unitRef="eur">135000000</sny:CostOfDebtNet>
    <sny:CostOfDebtNet contextRef="c-4" decimals="-6" id="f-1433" unitRef="eur">57000000</sny:CostOfDebtNet>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-1" decimals="-6" id="f-1434" unitRef="eur">-3000000</sny:NonOperatingForeignExchangeGainsLosses>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-4" decimals="-6" id="f-1435" unitRef="eur">1000000</sny:NonOperatingForeignExchangeGainsLosses>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-1" decimals="-6" id="f-1436" unitRef="eur">21000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-4" decimals="-6" id="f-1437" unitRef="eur">22000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-1" decimals="-6" id="f-1438" unitRef="eur">27000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-4" decimals="-6" id="f-1439" unitRef="eur">37000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <sny:ImpairmentLossesOnFinancialAssetsNetOfReversals contextRef="c-1" decimals="-6" id="f-1440" unitRef="eur">1000000</sny:ImpairmentLossesOnFinancialAssetsNetOfReversals>
    <sny:ImpairmentLossesOnFinancialAssetsNetOfReversals contextRef="c-4" decimals="-6" id="f-1441" unitRef="eur">0</sny:ImpairmentLossesOnFinancialAssetsNetOfReversals>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-6" id="f-1442" unitRef="eur">26000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-4" decimals="-6" id="f-1443" unitRef="eur">22000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-1" decimals="-6" id="f-1444" unitRef="eur">-115000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-4" decimals="-6" id="f-1445" unitRef="eur">-40000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-6" id="f-1446" unitRef="eur">-328000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-4" decimals="-6" id="f-1447" unitRef="eur">-177000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-1448" unitRef="eur">465000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-1449" unitRef="eur">361000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-1450" unitRef="eur">137000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-1451" unitRef="eur">184000000</ifrs-full:FinanceIncome>
    <sny:GainLossOnDerivativesUsedToManageDebt contextRef="c-545" decimals="-6" id="f-1452" unitRef="eur">12000000</sny:GainLossOnDerivativesUsedToManageDebt>
    <sny:GainLossOnDerivativesUsedToManageDebt contextRef="c-546" decimals="-6" id="f-1453" unitRef="eur">-25000000</sny:GainLossOnDerivativesUsedToManageDebt>
    <sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-545" decimals="-6" id="f-1454" unitRef="eur">6000000</sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-546" decimals="-6" id="f-1455" unitRef="eur">-4000000</sny:GainLossOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-1" decimals="-6" id="f-1456" unitRef="eur">146000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-4" decimals="-6" id="f-1457" unitRef="eur">50000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-1458">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i629ae0ca518d4a3799c6c6b12cd80b9e"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.19. Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,840&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(as a percentage)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax effect related to amlitelimab &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30.6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;This line reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France, and the impact of patent-favorable tax regimes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;                 The 2025 component of the temporary exceptional corporate income tax surcharge, introduced under the 2026 French Finance Act, is included in the&lt;br/&gt;                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)  This relates to the non-deductibility of the impairment loss on the amlitelimab intangible asset (see Note B.4.), and associated effects on deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d) For the six months ended June 30, 2026, this line includes a tax expense of &#x20ac;57 million representing the estimated impact of Pillar Two based on Sanofi&#x2019;s current understanding of Pillar Two rules, compared with &#x20ac;17 million for the six months ended June 30, 2025.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock contextRef="c-1" id="f-1459">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,840&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-1460" unitRef="eur">1089000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-4" decimals="-6" id="f-1461" unitRef="eur">1202000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-1462" unitRef="eur">-218000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-4" decimals="-6" id="f-1463" unitRef="eur">-491000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-1464" unitRef="eur">871000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-6" id="f-1465" unitRef="eur">711000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1466" unitRef="eur">2840000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-1467" unitRef="eur">3582000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock contextRef="c-1" id="f-1468">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(as a percentage)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months) &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax effect related to amlitelimab &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30.6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19.8&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;This line reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France, and the impact of patent-favorable tax regimes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:6.66pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;                 The 2025 component of the temporary exceptional corporate income tax surcharge, introduced under the 2026 French Finance Act, is included in the&lt;br/&gt;                     tax charge but excluded from the calculation of the annual average effective tax rate in accordance with IAS 34.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)  This relates to the non-deductibility of the impairment loss on the amlitelimab intangible asset (see Note B.4.), and associated effects on deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d) For the six months ended June 30, 2026, this line includes a tax expense of &#x20ac;57 million representing the estimated impact of Pillar Two based on Sanofi&#x2019;s current understanding of Pillar Two rules, compared with &#x20ac;17 million for the six months ended June 30, 2025.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="3" id="f-1469" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-4" decimals="3" id="f-1470" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-1" decimals="3" id="f-1471" unitRef="number">-0.179</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-4" decimals="3" id="f-1472" unitRef="number">-0.073</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <sny:TaxEffectRelatedToAmlitelimab contextRef="c-1" decimals="3" id="f-1473" unitRef="number">0.193</sny:TaxEffectRelatedToAmlitelimab>
    <sny:TaxEffectRelatedToAmlitelimab contextRef="c-4" decimals="3" id="f-1474" unitRef="number">0</sny:TaxEffectRelatedToAmlitelimab>
    <sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-1" decimals="3" id="f-1475" unitRef="number">0.018</sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-4" decimals="3" id="f-1476" unitRef="number">0.023</sny:RevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="3" id="f-1477" unitRef="number">0.015</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-4" decimals="3" id="f-1478" unitRef="number">-0.010</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-1" decimals="3" id="f-1479" unitRef="number">0.306</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-4" decimals="3" id="f-1480" unitRef="number">0.198</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes contextRef="c-1" decimals="-6" id="f-1481" unitRef="eur">57000000</ifrs-full:CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes>
    <ifrs-full:CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes contextRef="c-4" decimals="-6" id="f-1482" unitRef="eur">17000000</ifrs-full:CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c-1" id="f-1483">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i9da410b1c04b43f39d6815feab11f47e"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.20. Revenue from contracts with customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="if7fb0c15c7e14188b423f83b19015d10"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.20.1. Analysis of net sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4pt"&gt;&lt;td colspan="6" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="42" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,304&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,633&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,169&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,535&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Dupixent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rare diseases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;ALTUVIIIO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fabrazyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nexviazyme/Nexviadyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cerezyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ayvakit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sarclisa &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lantus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Toujeo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plavix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lovenox&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rezurock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;181&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RSV vaccines (Beyfortus) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Meningitis, travel and endemics vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;COVID-19 and Influenza vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which total launches &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;546&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,891&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;610&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,204&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-right:0.25pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i9915491664724057bf9655002fbed8b1"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.20.2. Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;VaxServe sales of non-Sanofi products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales to Opella &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Biopharma Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,168&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,246&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales / Revenues from Opella products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,452&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.&lt;/span&gt;&lt;/div&gt;(c)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-1484">&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4pt"&gt;&lt;td colspan="6" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="42" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,304&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,633&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,169&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,535&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Dupixent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rare diseases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;ALTUVIIIO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fabrazyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nexviazyme/Nexviadyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cerezyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ayvakit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sarclisa &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lantus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Toujeo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plavix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Lovenox&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rezurock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;181&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RSV vaccines (Beyfortus) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Meningitis, travel and endemics vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;COVID-19 and Influenza vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which total launches &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;546&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,891&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;610&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,204&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-right:0.25pt solid #795c8c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-547" decimals="-6" id="f-1485" unitRef="eur">4304000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-548" decimals="-6" id="f-1486" unitRef="eur">11633000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-549" decimals="-6" id="f-1487" unitRef="eur">6169000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-1488" unitRef="eur">22106000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-550" decimals="-6" id="f-1489" unitRef="eur">4144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-551" decimals="-6" id="f-1490" unitRef="eur">9535000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-552" decimals="-6" id="f-1491" unitRef="eur">6210000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-4" decimals="-6" id="f-1492" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-553" decimals="-6" id="f-1493" unitRef="eur">1146000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-554" decimals="-6" id="f-1494" unitRef="eur">6922000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-555" decimals="-6" id="f-1495" unitRef="eur">1256000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-556" decimals="-6" id="f-1496" unitRef="eur">9324000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-557" decimals="-6" id="f-1497" unitRef="eur">944000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-558" decimals="-6" id="f-1498" unitRef="eur">5283000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-559" decimals="-6" id="f-1499" unitRef="eur">1085000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-560" decimals="-6" id="f-1500" unitRef="eur">7312000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-561" decimals="-6" id="f-1501" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-562" decimals="-6" id="f-1502" unitRef="eur">576000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-563" decimals="-6" id="f-1503" unitRef="eur">98000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-564" decimals="-6" id="f-1504" unitRef="eur">674000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-565" decimals="-6" id="f-1505" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-566" decimals="-6" id="f-1506" unitRef="eur">456000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-567" decimals="-6" id="f-1507" unitRef="eur">86000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-568" decimals="-6" id="f-1508" unitRef="eur">542000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-569" decimals="-6" id="f-1509" unitRef="eur">138000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-570" decimals="-6" id="f-1510" unitRef="eur">256000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-571" decimals="-6" id="f-1511" unitRef="eur">129000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-572" decimals="-6" id="f-1512" unitRef="eur">523000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-573" decimals="-6" id="f-1513" unitRef="eur">134000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-574" decimals="-6" id="f-1514" unitRef="eur">261000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-575" decimals="-6" id="f-1515" unitRef="eur">130000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-576" decimals="-6" id="f-1516" unitRef="eur">525000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-577" decimals="-6" id="f-1517" unitRef="eur">152000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-578" decimals="-6" id="f-1518" unitRef="eur">211000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-579" decimals="-6" id="f-1519" unitRef="eur">63000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-580" decimals="-6" id="f-1520" unitRef="eur">426000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-581" decimals="-6" id="f-1521" unitRef="eur">132000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-582" decimals="-6" id="f-1522" unitRef="eur">195000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-583" decimals="-6" id="f-1523" unitRef="eur">60000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-584" decimals="-6" id="f-1524" unitRef="eur">387000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-585" decimals="-6" id="f-1525" unitRef="eur">126000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-586" decimals="-6" id="f-1526" unitRef="eur">86000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-587" decimals="-6" id="f-1527" unitRef="eur">140000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-588" decimals="-6" id="f-1528" unitRef="eur">352000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-589" decimals="-6" id="f-1529" unitRef="eur">119000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-590" decimals="-6" id="f-1530" unitRef="eur">91000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-591" decimals="-6" id="f-1531" unitRef="eur">153000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-592" decimals="-6" id="f-1532" unitRef="eur">363000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-593" decimals="-6" id="f-1533" unitRef="eur">44000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-594" decimals="-6" id="f-1534" unitRef="eur">322000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-595" decimals="-6" id="f-1535" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-596" decimals="-6" id="f-1536" unitRef="eur">367000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-597" decimals="-6" id="f-1537" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-598" decimals="-6" id="f-1538" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-599" decimals="-6" id="f-1539" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-600" decimals="-6" id="f-1540" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-601" decimals="-6" id="f-1541" unitRef="eur">108000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-602" decimals="-6" id="f-1542" unitRef="eur">132000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-603" decimals="-6" id="f-1543" unitRef="eur">114000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-604" decimals="-6" id="f-1544" unitRef="eur">354000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-605" decimals="-6" id="f-1545" unitRef="eur">83000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-606" decimals="-6" id="f-1546" unitRef="eur">119000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-607" decimals="-6" id="f-1547" unitRef="eur">74000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-608" decimals="-6" id="f-1548" unitRef="eur">276000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-609" decimals="-6" id="f-1549" unitRef="eur">146000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-610" decimals="-6" id="f-1550" unitRef="eur">344000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-611" decimals="-6" id="f-1551" unitRef="eur">323000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-612" decimals="-6" id="f-1552" unitRef="eur">813000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-613" decimals="-6" id="f-1553" unitRef="eur">149000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-614" decimals="-6" id="f-1554" unitRef="eur">395000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-615" decimals="-6" id="f-1555" unitRef="eur">332000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-616" decimals="-6" id="f-1556" unitRef="eur">876000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-617" decimals="-6" id="f-1557" unitRef="eur">259000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-618" decimals="-6" id="f-1558" unitRef="eur">134000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-619" decimals="-6" id="f-1559" unitRef="eur">336000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-620" decimals="-6" id="f-1560" unitRef="eur">729000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-621" decimals="-6" id="f-1561" unitRef="eur">248000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-622" decimals="-6" id="f-1562" unitRef="eur">126000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-623" decimals="-6" id="f-1563" unitRef="eur">318000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-624" decimals="-6" id="f-1564" unitRef="eur">692000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-625" decimals="-6" id="f-1565" unitRef="eur">40000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-626" decimals="-6" id="f-1566" unitRef="eur">2000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-627" decimals="-6" id="f-1567" unitRef="eur">398000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-628" decimals="-6" id="f-1568" unitRef="eur">440000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-629" decimals="-6" id="f-1569" unitRef="eur">44000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-630" decimals="-6" id="f-1570" unitRef="eur">3000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-631" decimals="-6" id="f-1571" unitRef="eur">426000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-632" decimals="-6" id="f-1572" unitRef="eur">473000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-633" decimals="-6" id="f-1573" unitRef="eur">202000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-634" decimals="-6" id="f-1574" unitRef="eur">5000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-635" decimals="-6" id="f-1575" unitRef="eur">157000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-636" decimals="-6" id="f-1576" unitRef="eur">364000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-637" decimals="-6" id="f-1577" unitRef="eur">247000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-638" decimals="-6" id="f-1578" unitRef="eur">9000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-639" decimals="-6" id="f-1579" unitRef="eur">191000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-640" decimals="-6" id="f-1580" unitRef="eur">447000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-641" decimals="-6" id="f-1581" unitRef="eur">36000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-642" decimals="-6" id="f-1582" unitRef="eur">218000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-643" decimals="-6" id="f-1583" unitRef="eur">42000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-644" decimals="-6" id="f-1584" unitRef="eur">296000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-645" decimals="-6" id="f-1585" unitRef="eur">23000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-646" decimals="-6" id="f-1586" unitRef="eur">220000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-647" decimals="-6" id="f-1587" unitRef="eur">20000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-648" decimals="-6" id="f-1588" unitRef="eur">263000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-649" decimals="-6" id="f-1589" unitRef="eur">181000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-650" decimals="-6" id="f-1590" unitRef="eur">7000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-651" decimals="-6" id="f-1591" unitRef="eur">2000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-652" decimals="-6" id="f-1592" unitRef="eur">190000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-653" decimals="-6" id="f-1593" unitRef="eur">241000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-654" decimals="-6" id="f-1594" unitRef="eur">1000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-655" decimals="-6" id="f-1595" unitRef="eur">9000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-656" decimals="-6" id="f-1596" unitRef="eur">251000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-657" decimals="-6" id="f-1597" unitRef="eur">206000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-658" decimals="-6" id="f-1598" unitRef="eur">487000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-659" decimals="-6" id="f-1599" unitRef="eur">671000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-660" decimals="-6" id="f-1600" unitRef="eur">1364000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-661" decimals="-6" id="f-1601" unitRef="eur">223000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-662" decimals="-6" id="f-1602" unitRef="eur">320000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-663" decimals="-6" id="f-1603" unitRef="eur">818000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-664" decimals="-6" id="f-1604" unitRef="eur">1361000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-665" decimals="-6" id="f-1605" unitRef="eur">87000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-666" decimals="-6" id="f-1606" unitRef="eur">65000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-667" decimals="-6" id="f-1607" unitRef="eur">240000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-668" decimals="-6" id="f-1608" unitRef="eur">392000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-669" decimals="-6" id="f-1609" unitRef="eur">85000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-670" decimals="-6" id="f-1610" unitRef="eur">68000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-671" decimals="-6" id="f-1611" unitRef="eur">203000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-672" decimals="-6" id="f-1612" unitRef="eur">356000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-673" decimals="-6" id="f-1613" unitRef="eur">118000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-674" decimals="-6" id="f-1614" unitRef="eur">268000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-675" decimals="-6" id="f-1615" unitRef="eur">179000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-676" decimals="-6" id="f-1616" unitRef="eur">565000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-677" decimals="-6" id="f-1617" unitRef="eur">96000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-678" decimals="-6" id="f-1618" unitRef="eur">319000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-679" decimals="-6" id="f-1619" unitRef="eur">194000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-680" decimals="-6" id="f-1620" unitRef="eur">609000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-681" decimals="-6" id="f-1621" unitRef="eur">33000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-682" decimals="-6" id="f-1622" unitRef="eur">16000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-683" decimals="-6" id="f-1623" unitRef="eur">72000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-684" decimals="-6" id="f-1624" unitRef="eur">121000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-685" decimals="-6" id="f-1625" unitRef="eur">52000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-686" decimals="-6" id="f-1626" unitRef="eur">54000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-687" decimals="-6" id="f-1627" unitRef="eur">108000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-688" decimals="-6" id="f-1628" unitRef="eur">214000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-689" decimals="-6" id="f-1629" unitRef="eur">546000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-690" decimals="-6" id="f-1630" unitRef="eur">1891000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-691" decimals="-6" id="f-1631" unitRef="eur">610000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-692" decimals="-6" id="f-1632" unitRef="eur">3047000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-693" decimals="-6" id="f-1633" unitRef="eur">423000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-694" decimals="-6" id="f-1634" unitRef="eur">1204000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-695" decimals="-6" id="f-1635" unitRef="eur">473000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-696" decimals="-6" id="f-1636" unitRef="eur">2100000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:DisclosureOfOtherRevenueTextBlock contextRef="c-1" id="f-1637">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;VaxServe sales of non-Sanofi products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales to Opella &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Biopharma Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,168&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,246&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales / Revenues from Opella products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,452&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.&lt;/span&gt;&lt;/div&gt;(c)&#160;&#160;&#160;&#160;Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily</sny:DisclosureOfOtherRevenueTextBlock>
    <sny:RevenueFromVaxServeSalesOfNonSanofiProducts contextRef="c-74" decimals="-6" id="f-1638" unitRef="eur">746000000</sny:RevenueFromVaxServeSalesOfNonSanofiProducts>
    <sny:RevenueFromVaxServeSalesOfNonSanofiProducts contextRef="c-697" decimals="-6" id="f-1639" unitRef="eur">842000000</sny:RevenueFromVaxServeSalesOfNonSanofiProducts>
    <sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations contextRef="c-74" decimals="-6" id="f-1640" unitRef="eur">60000000</sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations>
    <sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations contextRef="c-697" decimals="-6" id="f-1641" unitRef="eur">61000000</sny:RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations>
    <ifrs-full:RevenueFromRoyalties contextRef="c-74" decimals="-6" id="f-1642" unitRef="eur">91000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="c-697" decimals="-6" id="f-1643" unitRef="eur">68000000</ifrs-full:RevenueFromRoyalties>
    <sny:MiscellaneousOtherRevenue contextRef="c-74" decimals="-6" id="f-1644" unitRef="eur">271000000</sny:MiscellaneousOtherRevenue>
    <sny:MiscellaneousOtherRevenue contextRef="c-697" decimals="-6" id="f-1645" unitRef="eur">275000000</sny:MiscellaneousOtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-74" decimals="-6" id="f-1646" unitRef="eur">1168000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-697" decimals="-6" id="f-1647" unitRef="eur">1246000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-698" decimals="-6" id="f-1648" unitRef="eur">270000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-699" decimals="-6" id="f-1649" unitRef="eur">206000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-6" id="f-1650" unitRef="eur">1438000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-4" decimals="-6" id="f-1651" unitRef="eur">1452000000</ifrs-full:OtherRevenue>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-1652">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="i467d65866f844e78b863815e9b5709f5"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.21. Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The segment information presented by Sanofi consists of a single operating segment: Biopharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines, and Vaccines franchises, plus support and corporate functions, for all geographical territories. It also includes revenues generated from the manufacture of Consumer Healthcare products invoiced to Opella Healthcare SAS (Opella), which constitutes a related party with effect from April 30, 2025, the deconsolidation date, corresponding to the closing of Sanofi's sale of a controlling stake of approximately 50% in Opella to Clayton, Dubilier &amp;amp; Rice (CD&amp;amp;R). Those revenues, which before the deconsolidation date represented intragroup transactions classified within continuing operations, are presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement. The Biopharma operating segment also includes the purchase price of Biopharma products manufactured by Opella.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other&#x201d; category comprises primarily, but not exclusively, Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i884faad2f1f94bc3832619db02e9fdaa"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.1. Segment results&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;letter-spacing:-0.025em;line-height:120%"&gt;Sanofi reports segment results on the basis of &#x201c;Business operating income&#x201d;. This indicator is used internally by Sanofi&#x2019;s chief operating decision maker to measure the performance of the operating segment and to allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Business operating income&#x201d; is derived from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, adjusted as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;amounts reported within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;other gains and losses (including gains and losses on major divestments), presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;other costs and provisions related to litigation, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates (i)&#160;to joint ventures or (ii) to associates with which Sanofi has entered into R&amp;amp;D agreements and/or whose operations are managed as an integral part of Sanofi&#x2019;s business activities, and;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;net income attributable to non-controlling interests related to continuing operations, and excluding the effects of the above reconciling items, is deducted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Segment results are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026 (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+11.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+15.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+11.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+15.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+31.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+31.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+9.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+72.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+76.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+10.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,230&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+16.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+22.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+75.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+68.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,258&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+16.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+22.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;28.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;28.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.924%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,347&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS 8, shows a reconciliation between &#x201c;Business operating income&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,258&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense arising from the impact of acquisitions on inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,168&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,759&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,840&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Mainly joint ventures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#x20ac;1,031&#160;million in the first half of 2026 mainly comprising a &#x20ac;952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly comprises impairment losses of &#x20ac;210  million linked to research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026 relate to the Blueprint Medicines and Dynavax acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;See Note B.16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt"&gt;See Note B.17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i17f4673892234e26865e7dfa66a30da2"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.2. Other segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method related (a) to joint ventures or (b) to associates with which Sanofi has entered into R&amp;amp;D agreements and/or whose operations are managed as an integral part of Sanofi&#x2019;s business activities; (ii) acquisitions of property, plant and equipment; and (iii) acquisitions of intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method mainly comprise MSP Vaccine Company and Infraserv GmbH &amp;amp; Co. H&#xf6;chst&#160;KG (see Note B.5.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="ic5ce3e905560415e91636d287653d938"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.3. Information by geographical region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The geographical information on net sales provided below is based on the geographical location of the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.137%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which China&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,364&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,359&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,052&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,261&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2025, goodwill is not allocated by geographical region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span id="i6ee48613616140ac9120c037d6917ecb"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;B.21.4. Disclosures about major customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented 42% of net sales in the first half of 2026. Sanofi&#x2019;s three largest customers respectively accounted for approximately 22%, 14% and 6% of consolidated net sales in the first half of 2026 (versus approximately 18%, 12% and 5% in the first half of 2025).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <sny:ProportionOfOwnershipInterestDisposedInSubsidiary
      contextRef="c-700"
      decimals="2"
      id="f-1653"
      unitRef="number">0.50</sny:ProportionOfOwnershipInterestDisposedInSubsidiary>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c-1" id="f-1654">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Segment results are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.583%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026 (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 on a reported basis (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%"&gt;Change vs. June 30, 2025 at constant exchange rates (non-IFRS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+11.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+15.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+11.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;+15.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+31.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+31.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;-1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+3.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+9.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+72.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+76.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+6.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;+10.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,230&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+16.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+22.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+75.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+68.8&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,258&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+16.7&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;+22.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;As % of net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;28.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;28.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.924%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025 (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,716)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,347&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-74" decimals="-6" id="f-1655" unitRef="eur">22106000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage contextRef="c-74" decimals="3" id="f-1656" unitRef="number">0.111</sny:IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage contextRef="c-74" decimals="3" id="f-1657" unitRef="number">0.157</sny:IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-701" decimals="-6" id="f-1658" unitRef="eur">22106000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1659"
      unitRef="number">0.111</sny:IncreaseDecreaseInRevenueOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1660"
      unitRef="number">0.157</sny:IncreaseDecreaseInRevenueAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:OtherRevenue contextRef="c-74" decimals="-6" id="f-1661" unitRef="eur">1168000000</ifrs-full:OtherRevenue>
    <sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage contextRef="c-74" decimals="3" id="f-1662" unitRef="number">-0.063</sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage contextRef="c-74" decimals="3" id="f-1663" unitRef="number">-0.020</sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:OtherRevenue contextRef="c-702" decimals="-6" id="f-1664" unitRef="eur">270000000</ifrs-full:OtherRevenue>
    <sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1665"
      unitRef="number">0.311</sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1666"
      unitRef="number">0.311</sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:OtherRevenue contextRef="c-701" decimals="-6" id="f-1667" unitRef="eur">1438000000</ifrs-full:OtherRevenue>
    <sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1668"
      unitRef="number">-0.010</sny:IncreaseDecreaseInOtherRevenueOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1669"
      unitRef="number">0.027</sny:IncreaseDecreaseInOtherRevenueAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:CostOfSales contextRef="c-74" decimals="-6" id="f-1670" unitRef="eur">5812000000</ifrs-full:CostOfSales>
    <sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage contextRef="c-74" decimals="3" id="f-1671" unitRef="number">0.010</sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS contextRef="c-74" decimals="3" id="f-1672" unitRef="number">0.038</sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS>
    <ifrs-full:CostOfSales contextRef="c-702" decimals="-6" id="f-1673" unitRef="eur">133000000</ifrs-full:CostOfSales>
    <sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1674"
      unitRef="number">0.039</sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS
      contextRef="c-702"
      decimals="3"
      id="f-1675"
      unitRef="number">0.031</sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS>
    <ifrs-full:CostOfSales contextRef="c-701" decimals="-6" id="f-1676" unitRef="eur">5945000000</ifrs-full:CostOfSales>
    <sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1677"
      unitRef="number">0.011</sny:IncreaseDecreaseInCostOfSalesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS
      contextRef="c-701"
      decimals="3"
      id="f-1678"
      unitRef="number">0.038</sny:IncreaseDecreaseInCostOfSalesAtConstantExchangeRatesPercentageNonIFRS>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-74" decimals="-6" id="f-1679" unitRef="eur">3979000000</ifrs-full:ResearchAndDevelopmentExpense>
    <sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage contextRef="c-74" decimals="3" id="f-1680" unitRef="number">0.071</sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage contextRef="c-74" decimals="3" id="f-1681" unitRef="number">0.099</sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-702" decimals="-6" id="f-1682" unitRef="eur">1000000</ifrs-full:ResearchAndDevelopmentExpense>
    <sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1683"
      unitRef="number">0</sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1684"
      unitRef="number">0</sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-701" decimals="-6" id="f-1685" unitRef="eur">3980000000</ifrs-full:ResearchAndDevelopmentExpense>
    <sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1686"
      unitRef="number">0.071</sny:IncreaseDecreaseInResearchAndDevelopmentExpensesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1687"
      unitRef="number">0.099</sny:IncreaseDecreaseInResearchAndDevelopmentExpensesAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-74" decimals="-6" id="f-1688" unitRef="eur">4690000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage contextRef="c-74" decimals="3" id="f-1689" unitRef="number">0.055</sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage contextRef="c-74" decimals="3" id="f-1690" unitRef="number">0.094</sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-702" decimals="-6" id="f-1691" unitRef="eur">102000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1692"
      unitRef="number">0.729</sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1693"
      unitRef="number">0.763</sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-701" decimals="-6" id="f-1694" unitRef="eur">4792000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1695"
      unitRef="number">0.063</sny:IncreaseDecreaseInSellingAndGeneralExpensesOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1696"
      unitRef="number">0.103</sny:IncreaseDecreaseInSellingAndGeneralExpensesAtConstantExchangeRatesNonIFRSPercentage>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-74" decimals="-6" id="f-1697" unitRef="eur">-2630000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-702" decimals="-6" id="f-1698" unitRef="eur">-6000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-701" decimals="-6" id="f-1699" unitRef="eur">-2636000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-74" decimals="-6" id="f-1700" unitRef="eur">74000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-702" id="f-1701" unitRef="eur" xsi:nil="true"/>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-701" decimals="-6" id="f-1702" unitRef="eur">74000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-74" decimals="-6" id="f-1703" unitRef="eur">-7000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-702" id="f-1704" unitRef="eur" xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-701" decimals="-6" id="f-1705" unitRef="eur">-7000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-74" decimals="-6" id="f-1706" unitRef="eur">6230000000</sny:BusinessOperatingIncome>
    <sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage contextRef="c-74" decimals="3" id="f-1707" unitRef="number">0.165</sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage contextRef="c-74" decimals="3" id="f-1708" unitRef="number">0.222</sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage>
    <sny:BusinessOperatingIncome contextRef="c-702" decimals="-6" id="f-1709" unitRef="eur">28000000</sny:BusinessOperatingIncome>
    <sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1710"
      unitRef="number">0.750</sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-702"
      decimals="3"
      id="f-1711"
      unitRef="number">0.688</sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage>
    <sny:BusinessOperatingIncome contextRef="c-701" decimals="-6" id="f-1712" unitRef="eur">6258000000</sny:BusinessOperatingIncome>
    <sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1713"
      unitRef="number">0.167</sny:IncreaseDecreaseInBusinessOperatingIncomeOnAReportedBasisIFRSPercentage>
    <sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage
      contextRef="c-701"
      decimals="3"
      id="f-1714"
      unitRef="number">0.223</sny:IncreaseDecreaseInBusinessOperatingIncomeAtConstantExchangeRatesNonIFRSPercentage>
    <sny:BusinessOperatingIncomeAsPercentOfNetSales contextRef="c-74" decimals="3" id="f-1715" unitRef="number">0.282</sny:BusinessOperatingIncomeAsPercentOfNetSales>
    <sny:BusinessOperatingIncomeAsPercentOfNetSales
      contextRef="c-701"
      decimals="3"
      id="f-1716"
      unitRef="number">0.283</sny:BusinessOperatingIncomeAsPercentOfNetSales>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-697" decimals="-6" id="f-1717" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-703" id="f-1718" unitRef="eur" xsi:nil="true"/>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-704" decimals="-6" id="f-1719" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-697" decimals="-6" id="f-1720" unitRef="eur">1246000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-703" decimals="-6" id="f-1721" unitRef="eur">206000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-704" decimals="-6" id="f-1722" unitRef="eur">1452000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-697" decimals="-6" id="f-1723" unitRef="eur">5753000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-703" decimals="-6" id="f-1724" unitRef="eur">128000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-704" decimals="-6" id="f-1725" unitRef="eur">5881000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-697" decimals="-6" id="f-1726" unitRef="eur">3716000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-703" decimals="-6" id="f-1727" unitRef="eur">1000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-704" decimals="-6" id="f-1728" unitRef="eur">3717000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-697" decimals="-6" id="f-1729" unitRef="eur">4447000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-703" decimals="-6" id="f-1730" unitRef="eur">59000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-704" decimals="-6" id="f-1731" unitRef="eur">4506000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-697" decimals="-6" id="f-1732" unitRef="eur">-1941000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-703" decimals="-6" id="f-1733" unitRef="eur">-2000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-704" decimals="-6" id="f-1734" unitRef="eur">-1943000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-697" decimals="-6" id="f-1735" unitRef="eur">77000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-703" decimals="-6" id="f-1736" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-704" decimals="-6" id="f-1737" unitRef="eur">77000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-697" decimals="-6" id="f-1738" unitRef="eur">-8000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-703" decimals="-6" id="f-1739" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-704" decimals="-6" id="f-1740" unitRef="eur">-8000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-697" decimals="-6" id="f-1741" unitRef="eur">5347000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-703" decimals="-6" id="f-1742" unitRef="eur">16000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-704" decimals="-6" id="f-1743" unitRef="eur">5363000000</sny:BusinessOperatingIncome>
    <sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock contextRef="c-1" id="f-1744">&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS 8, shows a reconciliation between &#x201c;Business operating income&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026            (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025           (6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,258&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,363&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense arising from the impact of acquisitions on inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,168&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,759&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,840&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,582&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt"&gt;Mainly joint ventures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt"&gt;The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of &#x20ac;1,031&#160;million in the first half of 2026 mainly comprising a &#x20ac;952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly comprises impairment losses of &#x20ac;210  million linked to research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt"&gt;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026 relate to the Blueprint Medicines and Dynavax acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt"&gt;See Note B.16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt"&gt;See Note B.17.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock>
    <sny:BusinessOperatingIncome contextRef="c-705" decimals="-6" id="f-1745" unitRef="eur">6258000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-706" decimals="-6" id="f-1746" unitRef="eur">5363000000</sny:BusinessOperatingIncome>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-707" decimals="-6" id="f-1747" unitRef="eur">-74000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-708" decimals="-6" id="f-1748" unitRef="eur">-77000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-707" decimals="-6" id="f-1749" unitRef="eur">7000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-708" decimals="-6" id="f-1750" unitRef="eur">8000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-707" decimals="-6" id="f-1751" unitRef="eur">1087000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-708" decimals="-6" id="f-1752" unitRef="eur">777000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-707" decimals="-6" id="f-1753" unitRef="eur">1031000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-708" decimals="-6" id="f-1754" unitRef="eur">210000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-707" decimals="-6" id="f-1755" unitRef="eur">37000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-708" decimals="-6" id="f-1756" unitRef="eur">61000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-707" decimals="-6" id="f-1757" unitRef="eur">210000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-708" decimals="-6" id="f-1758" unitRef="eur">0</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-707" decimals="-6" id="f-1759" unitRef="eur">563000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-708" decimals="-6" id="f-1760" unitRef="eur">430000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-707" decimals="-6" id="f-1761" unitRef="eur">-95000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-708" decimals="-6" id="f-1762" unitRef="eur">-57000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-1763" unitRef="eur">3168000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-6" id="f-1764" unitRef="eur">3759000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-1765" unitRef="eur">465000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-6" id="f-1766" unitRef="eur">361000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-1767" unitRef="eur">137000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-6" id="f-1768" unitRef="eur">184000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1769" unitRef="eur">2840000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-4" decimals="-6" id="f-1770" unitRef="eur">3582000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-1771" unitRef="eur">1031000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-116" decimals="-6" id="f-1772" unitRef="eur">952000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-6" id="f-1773" unitRef="eur">210000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock contextRef="c-1" id="f-1774">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Carrying amount at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-709" decimals="-6" id="f-1775" unitRef="eur">204000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-710" decimals="-6" id="f-1776" unitRef="eur">483000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-74" decimals="-6" id="f-1777" unitRef="eur">882000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-697" decimals="-6" id="f-1778" unitRef="eur">845000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-74" decimals="-6" id="f-1779" unitRef="eur">414000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-697" decimals="-6" id="f-1780" unitRef="eur">575000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c-1" id="f-1781">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The geographical information on net sales provided below is based on the geographical location of the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,106&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,889&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.137%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.302%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which China&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,364&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,359&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,052&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,261&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-547" decimals="-6" id="f-1782" unitRef="eur">4304000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-550" decimals="-6" id="f-1783" unitRef="eur">4144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-711" decimals="-6" id="f-1784" unitRef="eur">725000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-712" decimals="-6" id="f-1785" unitRef="eur">835000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-548" decimals="-6" id="f-1786" unitRef="eur">11633000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-551" decimals="-6" id="f-1787" unitRef="eur">9535000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-713" decimals="-6" id="f-1788" unitRef="eur">6169000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-714" decimals="-6" id="f-1789" unitRef="eur">6210000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-715" decimals="-6" id="f-1790" unitRef="eur">1325000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-716" decimals="-6" id="f-1791" unitRef="eur">1388000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-1792" unitRef="eur">22106000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-4" decimals="-6" id="f-1793" unitRef="eur">19889000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-717" decimals="-6" id="f-1794" unitRef="eur">5998000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-717" decimals="-6" id="f-1795" unitRef="eur">3951000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-718" decimals="-6" id="f-1796" unitRef="eur">5760000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-718" decimals="-6" id="f-1797" unitRef="eur">5094000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-719" decimals="-6" id="f-1798" unitRef="eur">3161000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-719" decimals="-6" id="f-1799" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-720" decimals="-6" id="f-1800" unitRef="eur">3123000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-720" decimals="-6" id="f-1801" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-721" decimals="-6" id="f-1802" unitRef="eur">2270000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-721" decimals="-6" id="f-1803" unitRef="eur">21972000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-722" decimals="-6" id="f-1804" unitRef="eur">2229000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-722" decimals="-6" id="f-1805" unitRef="eur">20694000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-723" decimals="-6" id="f-1806" unitRef="eur">2096000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-723" decimals="-6" id="f-1807" unitRef="eur">436000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-724" decimals="-6" id="f-1808" unitRef="eur">2063000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-724" decimals="-6" id="f-1809" unitRef="eur">473000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-725" decimals="-6" id="f-1810" unitRef="eur">167000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-725" decimals="-6" id="f-1811" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-726" decimals="-6" id="f-1812" unitRef="eur">122000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-726" decimals="-6" id="f-1813" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-6" id="f-1814" unitRef="eur">10364000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-6" id="f-1815" unitRef="eur">26359000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-6" id="f-1816" unitRef="eur">10052000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-6" id="f-1817" unitRef="eur">26261000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-727"
      decimals="2"
      id="f-1818"
      unitRef="number">0.42</ifrs-full:PercentageOfEntitysRevenue>
    <sny:NumberOfLargestCustomers
      contextRef="c-1"
      decimals="INF"
      id="f-1819"
      unitRef="customer">3</sny:NumberOfLargestCustomers>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-728"
      decimals="2"
      id="f-1820"
      unitRef="number">0.22</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-729"
      decimals="2"
      id="f-1821"
      unitRef="number">0.14</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-730"
      decimals="2"
      id="f-1822"
      unitRef="number">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-731"
      decimals="2"
      id="f-1823"
      unitRef="number">0.18</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-732"
      decimals="2"
      id="f-1824"
      unitRef="number">0.12</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-733"
      decimals="2"
      id="f-1825"
      unitRef="number">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory contextRef="c-1" id="f-1827">&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span id="ia9eff4859f124b0d914e6bab5e9a4ad8"&gt;&lt;/span&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.22. Information related to Opella, presented within discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 30, 2025, the Opella transaction was closed triggering loss of control, and resulting in the derecognition of all assets and liabilities of Opella subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the main items presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales and other revenues &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,736&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income from discontinued  operations (Opella)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,881&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) In 2025, this line includes an expense of &#x20ac;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock contextRef="c-1" id="f-1828">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the main items presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales and other revenues &lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,736&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income before tax and investments accounted for using the equity method, including gain on disposal of Opella before tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net income from discontinued  operations (Opella)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,881&lt;/span&gt;&lt;span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) In 2025, this line includes an expense of &#x20ac;88&#160;million related to the tax impact on the gain arising on the loss of control of Opella.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlockTextBlock>
    <sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations contextRef="c-734" decimals="-6" id="f-1829" unitRef="eur">0</sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations>
    <sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations contextRef="c-735" decimals="-6" id="f-1830" unitRef="eur">1736000000</sny:RevenueFromDisposalGroupIncludingDiscontinuedOperations>
    <sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations contextRef="c-734" decimals="-6" id="f-1831" unitRef="eur">0</sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations>
    <sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations contextRef="c-735" decimals="-6" id="f-1832" unitRef="eur">266000000</sny:OperatingRevenueDisposalGroupIncludingDiscontinuedOperations>
    <sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations contextRef="c-734" decimals="-6" id="f-1833" unitRef="eur">18000000</sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations>
    <sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations contextRef="c-735" decimals="-6" id="f-1834" unitRef="eur">2781000000</sny:GainOnDisposalOfOpellaDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations contextRef="c-734" decimals="-6" id="f-1835" unitRef="eur">22000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations contextRef="c-735" decimals="-6" id="f-1836" unitRef="eur">3039000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForUsingTheEquityMethodDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations contextRef="c-734" decimals="-6" id="f-1837" unitRef="eur">-4000000</sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations>
    <sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations contextRef="c-735" decimals="-6" id="f-1838" unitRef="eur">158000000</sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-734" decimals="-6" id="f-1839" unitRef="eur">26000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations contextRef="c-735" decimals="-6" id="f-1840" unitRef="eur">2881000000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations contextRef="c-736" decimals="-6" id="f-1841" unitRef="eur">88000000</sny:IncomeTaxExpenseBenefitDisposalGroupIncludingDiscontinuedOperations>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-331"
          xlink:label="f-331"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-342"
          xlink:label="f-342"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-332"
          xlink:label="f-332"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-327"
          xlink:label="f-327"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-329"
          xlink:label="f-329"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-264"
          xlink:label="f-264"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-208"
          xlink:label="f-208"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-326"
          xlink:label="f-326"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-339"
          xlink:label="f-339"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-209"
          xlink:label="f-209"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-341"
          xlink:label="f-341"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-328"
          xlink:label="f-328"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-263"
          xlink:label="f-263"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-344"
          xlink:label="f-344"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-265"
          xlink:label="f-265"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-210"
          xlink:label="f-210"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-325"
          xlink:label="f-325"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-330"
          xlink:label="f-330"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-340"
          xlink:label="f-340"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-343"
          xlink:label="f-343"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">See Note B.8.2 and B.8.3. (for amounts relating to 2025, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2025).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-331"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-342"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-332"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-327"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-329"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-264"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-208"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-326"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-339"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-209"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-341"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-328"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-263"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-344"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-265"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-210"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-325"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-330"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-340"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-343"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-216"
          xlink:label="f-216"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-217"
          xlink:label="f-217"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-335"
          xlink:label="f-335"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-333"
          xlink:label="f-333"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-272"
          xlink:label="f-272"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-334"
          xlink:label="f-334"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-274"
          xlink:label="f-274"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-273"
          xlink:label="f-273"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-218"
          xlink:label="f-218"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-216"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-217"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-335"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-333"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-272"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-334"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-274"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-273"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-218"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-351"
          xlink:label="f-351"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-233"
          xlink:label="f-233"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-234"
          xlink:label="f-234"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-235"
          xlink:label="f-235"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-353"
          xlink:label="f-353"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-352"
          xlink:label="f-352"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-351"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-233"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-234"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-235"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-353"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-352"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-236"
          xlink:label="f-236"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-286"
          xlink:label="f-286"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-285"
          xlink:label="f-285"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-237"
          xlink:label="f-237"
          xlink:type="locator"/>
        <link:footnote id="fn-4" xlink:label="fn-4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-236"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-286"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-285"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-237"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-373"
          xlink:label="f-373"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-374"
          xlink:label="f-374"
          xlink:type="locator"/>
        <link:footnote id="fn-5" xlink:label="fn-5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.98pt">Includes non-current financial assets and deferred taxes, amounting to zero as of June 30, 2026 and to &#x20ac;48&#160;million as of June 30, 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-373"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-374"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-377"
          xlink:label="f-377"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-378"
          xlink:label="f-378"
          xlink:type="locator"/>
        <link:footnote id="fn-6" xlink:label="fn-6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">This line item includes contributions paid to pension funds (see Note B.12.).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-377"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-378"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-383"
          xlink:label="f-383"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-384"
          xlink:label="f-384"
          xlink:type="locator"/>
        <link:footnote id="fn-7" xlink:label="fn-7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.36pt">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-383"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-384"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-400"
          xlink:label="f-400"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-399"
          xlink:label="f-399"
          xlink:type="locator"/>
        <link:footnote id="fn-8" xlink:label="fn-8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">Of which:</xhtml:span><xhtml:div style="margin-bottom:5pt;text-align:justify"><xhtml:table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><xhtml:tr><xhtml:td style="width:1.0%"/><xhtml:td style="width:70.240%"/><xhtml:td style="width:0.1%"/><xhtml:td style="width:1.0%"/><xhtml:td style="width:13.229%"/><xhtml:td style="width:0.1%"/><xhtml:td style="width:1.0%"/><xhtml:td style="width:13.231%"/><xhtml:td style="width:0.1%"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td colspan="3" style="padding:0 1pt"/><xhtml:td
              colspan="3"
              style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><xhtml:div style="text-align:right"><xhtml:span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2026        (6 months)</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="3"
              style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><xhtml:div style="text-align:right"><xhtml:span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2025        (6 months)</xhtml:span></xhtml:div></xhtml:td><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(925)</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="border-top:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,355)</xhtml:span></xhtml:td><xhtml:td style="border-top:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(260)</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(206)</xhtml:span></xhtml:td><xhtml:td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</xhtml:span></xhtml:td><xhtml:td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td
              colspan="2"
              style="border-bottom:0.5pt solid #23004c;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:middle"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</xhtml:span></xhtml:td><xhtml:td style="border-bottom:0.5pt solid #23004c;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:middle"/><xhtml:td colspan="3" style="display:none"/></xhtml:tr></xhtml:table></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-400"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-399"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-404"
          xlink:label="f-404"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-403"
          xlink:label="f-403"
          xlink:type="locator"/>
        <link:footnote id="fn-9" xlink:label="fn-9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.26pt">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2026, this line item includes the net cash outflow arising from the acquisition of Dynavax (see Note B.1.1.). For the six months ended June 30, 2025 it includes the net cash outflow arising from the acquisition of Dren-0201.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-404"
          xlink:to="fn-9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-403"
          xlink:to="fn-9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-407"
          xlink:label="f-407"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-408"
          xlink:label="f-408"
          xlink:type="locator"/>
        <link:footnote id="fn-10" xlink:label="fn-10" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.64pt">For the six months ended June 30, 2026 and June 30, 2025, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-407"
          xlink:to="fn-10"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-408"
          xlink:to="fn-10"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-418"
          xlink:label="f-418"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-417"
          xlink:label="f-417"
          xlink:type="locator"/>
        <link:footnote id="fn-11" xlink:label="fn-11" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.92pt">For the six months ended June 30, 2025, this amount includes &#x20ac;(667)&#160;million in respect of cash and cash equivalents held by Opella as of April 30, 2025.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-418"
          xlink:to="fn-11"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-417"
          xlink:to="fn-11"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-434"
          xlink:label="f-434"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-433"
          xlink:label="f-433"
          xlink:type="locator"/>
        <link:footnote id="fn-12" xlink:label="fn-12" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.11pt">For the six months ended June 30, 2026, this line item mainly comprises (i) a commercial paper program in the United States for &#x20ac;2,388 million and (ii) a cash outflow of &#x20ac;249 million arising from the settlement of the financial liabilities of Dynavax, acquired on February 10, 2026 (see Note B.1.1.). For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for &#x20ac;3,353&#160;million.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-434"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-433"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-449"
          xlink:label="f-449"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-450"
          xlink:label="f-450"
          xlink:type="locator"/>
        <link:footnote id="fn-13" xlink:label="fn-13" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.58pt">Includes the impact of the IFRS 9 amendment relating to the classification of financial instruments applicable from January 1, 2026.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-449"
          xlink:to="fn-13"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-450"
          xlink:to="fn-13"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
